PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Belyakov, IM; Hel, Z; Kelsall, B; Kuznetsov, VA; Ahlers, JD; Nacsa, J; Watkins, DI; Allen, TM; Sette, A; Altman, J; Woodward, R; Markham, PD; Clements, JD; Franchini, G; Strober, W; Berzofsky, JA				Belyakov, IM; Hel, Z; Kelsall, B; Kuznetsov, VA; Ahlers, JD; Nacsa, J; Watkins, DI; Allen, TM; Sette, A; Altman, J; Woodward, R; Markham, PD; Clements, JD; Franchini, G; Strober, W; Berzofsky, JA			Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; MAJOR HISTOCOMPATIBILITY COMPLEX; HIV-1 PEPTIDE VACCINE; RHESUS-MONKEYS; NEUTRALIZING ANTIBODY; ENVELOPE GLYCOPROTEIN; CELL RESPONSES; IN-VIVO; EPITOPE	Given the mucosal transmission of HIV-1, we compared whether a mucosal vaccine could Induce mucosal cytotoxic T lymphocytes (CTLs) and protect rhesus macaques against mucosal infection with simian/human immunodeficiency virus (SHIV) more effectively than the same vaccine given subcutaneously. Here we show that mucosal CTLs specific for simian immunodeficiency virus can be induced by intrarectal immunization of macaques with a synthetic-peptide vaccine incorporating the LT(R192G) adjuvant. This response correlated with the level of T-helper response. After intrarectal challenge with pathogenic SHIV-Ku2, viral titers were eliminated more completely (to undetectable levels) both in blood and intestine, a major reservoir for virus replication, in intrarectally immunized animals than in subcutaneously immunized or control macaques. Moreover, CD4(+) T cells were better preserved. Thus, induction of CTLs in the intestinal mucosa, a key site of virus replication, with a mucosal AIDS vaccine ameliorates infection by SHIV in non-human primates.	NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, Bethesda, MD 20892 USA; NCI, Anim Model & Retroviral Vaccines Sect, Basic Res Lab, Bethesda, MD 20892 USA; NIAID, Mucosal Immun Sect, Clin Invest Lab, Bethesda, MD 20892 USA; NICHHD, Sect Med Biophys, Lab Integrat & Med Biophys, Bethesda, MD 20892 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA; Epimmune, San Diego, CA USA; Emory Univ, Vaccine Ctr Yerkes, Atlanta, GA 30322 USA; Adv Biosci Labs, Kensington, MD USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, Program Mol Pathogenesis & Immun, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Wisconsin System; University of Wisconsin Madison; Emory University; Tulane University	Belyakov, IM (corresponding author), NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, Bethesda, MD 20892 USA.	belyakov@box-b.nih.gov; berzofsk@helix.nih.gov	Allen, Todd/F-5473-2011; Sette, Alessandro/AFO-8916-2022	Allen, Todd/0000-0002-6609-1318; Hel, Zdenek/0000-0002-4923-4794	NCRR NIH HHS [R24 RR 15731] Funding Source: Medline; NIAID NIH HHS [N01-AI-95362] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095362] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLERS JD, 1993, J IMMUNOL, V150, P5647; Ahlers JD, 1997, P NATL ACAD SCI USA, V94, P10856, DOI 10.1073/pnas.94.20.10856; Ahlers JD, 1996, AIDS RES HUM RETROV, V12, P259, DOI 10.1089/aid.1996.12.259; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Belyakov IM, 2000, J IMMUNOL, V165, P6454, DOI 10.4049/jimmunol.165.11.6454; Belyakov IM, 1998, J VIROL, V72, P8264, DOI 10.1128/JVI.72.10.8264-8272.1998; Belyakov IM, 1998, J CLIN INVEST, V102, P2072, DOI 10.1172/JCI5102; Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709; BERZOFSKY JA, 1991, J CLIN INVEST, V88, P876, DOI 10.1172/JCI115389; Berzofsky JA, 1999, IMMUNOL REV, V170, P151, DOI 10.1111/j.1600-065X.1999.tb01336.x; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Brunner E, 1999, J MULTIVARIATE ANAL, V70, P286, DOI 10.1006/jmva.1999.1821; Brunner E, 2001, STAT PAP, V42, P1, DOI 10.1007/s003620000039; BULL DM, 1977, J CLIN INVEST, V59, P966, DOI 10.1172/JCI108719; CRANAGE MP, 1992, LANCET, V339, P273, DOI 10.1016/0140-6736(92)91335-6; Czerkinsky C, 1999, IMMUNOL REV, V170, P197, DOI 10.1111/j.1600-065X.1999.tb01339.x; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; Egan MA, 1999, J VIROL, V73, P5466, DOI 10.1128/JVI.73.7.5466-5472.1999; HART MK, 1991, P NATL ACAD SCI USA, V88, P9448, DOI 10.1073/pnas.88.21.9448; HOSMALIN A, 1991, J IMMUNOL, V146, P1667; Joag SV, 1998, J MED PRIMATOL, V27, P59, DOI 10.1111/j.1600-0684.1998.tb00227.x; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602; Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x; Kuroda MJ, 1998, J EXP MED, V187, P1373, DOI 10.1084/jem.187.9.1373; Kuroda MJ, 1999, J IMMUNOL, V162, P5127; Lehner T, 1999, IMMUNOL REV, V170, P183, DOI 10.1111/j.1600-065X.1999.tb01338.x; MILLER MD, 1991, J IMMUNOL, V147, P320; Morris CB, 2000, VACCINE, V18, P1944, DOI 10.1016/S0264-410X(99)00447-8; Murphey-Corb M, 1999, J IMMUNOL, V162, P540; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; PALKER TJ, 1989, J IMMUNOL, V142, P3612; Romano JW, 2000, J VIROL METHODS, V86, P61, DOI 10.1016/S0166-0934(99)00184-6; Rose JR, 1998, J VIROL, V72, P726; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; SHIRAI M, 1994, J IMMUNOL, V152, P549; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; YASUTOMI Y, 1993, J IMMUNOL, V151, P5096	44	213	219	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1320	1326		10.1038/nm1201-1320	http://dx.doi.org/10.1038/nm1201-1320			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726972				2022-12-25	WOS:000172610300037
J	Priller, J; Flugel, A; Wehner, T; Boentert, M; Haas, CA; Prinz, M; Fernandez-Klett, F; Prass, K; Bechmann, I; de Boer, BA; Frotscher, M; Kreutzberg, GW; Persons, DA; Dirnagl, U				Priller, J; Flugel, A; Wehner, T; Boentert, M; Haas, CA; Prinz, M; Fernandez-Klett, F; Prass, K; Bechmann, I; de Boer, BA; Frotscher, M; Kreutzberg, GW; Persons, DA; Dirnagl, U			Targeting gene-modified hematopoietic cells to the central nervous system: Use of green fluorescent protein uncovers microglial engraftment	NATURE MEDICINE			English	Article							MARROW; BRAIN; MICE; TRANSPLANTATION; DIFFERENTIATE; ACTIVATION	Gene therapy in the central nervous system (CNS) is hindered by the presence of the blood-brain barrier, which restricts access of serum constituents and peripheral cells to the brain parenchyma. Expression of exogenously administered genes in the CNS has been achieved in vivo using highly invasive routes, or ex vivo relying on the direct implantation of genetically modified cells into the brain. Here we provide evidence for a novel, noninvasive approach for targeting potential therapeutic factors to the CNS. Genetically-modified hematopoietic cells enter the CNS and differentiate into microglia after bone-marrow transplantation. Up to a quarter of the regional microglial population is donor-derived by four months after transplantation. Microglial engraftment is enhanced by neuropathology, and gene-modified myeloid cells are specifically attracted to the sites of neuronal damage. Thus, microglia may serve as vehicles for gene delivery to the nervous system.	Humboldt Univ, Charite, Dept Neurol, Berlin, Germany; Max Planck Inst Neurobiol, Munich, Germany; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; Univ Freiburg, Inst Anat, Freiburg, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Humboldt Univ, Charite, Dept Anat, Berlin, Germany; FRFZ, D-10117 Berlin, Germany; St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; University of Munich; University of Freiburg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; St Jude Children's Research Hospital	Priller, J (corresponding author), Humboldt Univ, Charite, Dept Neurol, Berlin, Germany.	josef.priller@charite.de	Priller, Josef/ABW-3835-2022; Wehner, Tim/AAS-8045-2021; Wehner, Tim/AAE-1683-2021	Wehner, Tim/0000-0003-3319-2339; Priller, Josef/0000-0001-7596-0979; Dirnagl, Ulrich/0000-0003-0755-6119				Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Burt RK, 2000, J CLIN IMMUNOL, V20, P1, DOI 10.1023/A:1006673408343; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69; Goldman S, 2000, NAT MED, V6, P483, DOI 10.1038/74920; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hollerbach EH, 1998, J COMP NEUROL, V390, P481; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; KRALL WJ, 1994, BLOOD, V83, P2737; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Schluter D, 2001, BRAIN PATHOL, V11, P44, DOI 10.1111/j.1750-3639.2001.tb00380.x; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Wu YP, 2000, AM J PATHOL, V156, P1849, DOI 10.1016/S0002-9440(10)65058-4	25	490	511	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1356	1361		10.1038/nm1201-1356	http://dx.doi.org/10.1038/nm1201-1356			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726978				2022-12-25	WOS:000172610300043
J	Tartaglia, M; Mehler, EL; Goldberg, R; Zampino, G; Brunner, HG; Kremer, H; van der Burgt, I; Crosby, AH; Ion, A; Jeffery, S; Kalidas, K; Patton, MA; Kucherlapati, RS; Gelb, BD				Tartaglia, M; Mehler, EL; Goldberg, R; Zampino, G; Brunner, HG; Kremer, H; van der Burgt, I; Crosby, AH; Ion, A; Jeffery, S; Kalidas, K; Patton, MA; Kucherlapati, RS; Gelb, BD			Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome	NATURE GENETICS			English	Article							SH-PTP2; MUTANT; KINASE; MICE; CONFORMATIONS; ACTIVATION; CELL; SYP	Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy)(1,2). Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000-2,500 live births. it has been mapped to a 5-cM region (N-SH2) on chromosome 12q24.1, and genetic heterogeneity has also been documented(3-6). Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Ist Super Sanita, Lab Metab & Biochim Patol, I-00161 Rome, Italy; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Univ Cattolica Sacro Cuore, Ist Clin Pediat, Rome, Italy; Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Univ London St Georges Hosp, Sch Med, Dept Med Genet, London SW17 0RE, England	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Istituto Superiore di Sanita (ISS); Yeshiva University; Albert Einstein College of Medicine; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Radboud University Nijmegen; St Georges University London	Tartaglia, M (corresponding author), Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.	tartam02@doc.mssm.edu	Zampino, Giuseppe/AAC-2152-2019; Tartaglia, Marco/K-2955-2018; Brunner, Han/C-9928-2013; Kremer, Hannie/F-5126-2010; Crosby, Andrew H/E-2218-2015; Kucherlapati, Raju/ABC-8807-2021	Tartaglia, Marco/0000-0001-7736-9672; Kremer, Hannie/0000-0002-0841-8693; Crosby, Andrew H/0000-0003-3667-9054; 				ALLANSON JE, 1987, J MED GENET, V24, P9, DOI 10.1136/jmg.24.1.9; Allen MP., 1989, COMPUTER SIMULATION; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Bradford T, 1997, ART CRITICISM, V12, P5; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; DECHERT U, 1995, HUM GENET, V96, P609; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Hassan SA, 2000, J PHYS CHEM B, V104, P6478, DOI 10.1021/jp993895e; HASSAN SA, IN PRESS LECT NOTES; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; Legius E, 1998, EUR J HUM GENET, V6, P32, DOI 10.1038/sj.ejhg.5200150; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; NOGUTI T, 1985, BIOPOLYMERS, V24, P527, DOI 10.1002/bip.360240308; NOONAN JA, 1968, AM J DIS CHILD, V116, P373, DOI 10.1001/archpedi.1968.02100020377005; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHENKIN PS, 1994, J COMPUT CHEM, V15, P899, DOI 10.1002/jcc.540150811; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Steinberg DL, 1998, WORK EMPLOY SOC, V12, P559; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; van der Burgt I, 2000, AM J MED GENET, V94, P46, DOI 10.1002/1096-8628(20000904)94:1<46::AID-AJMG10>3.0.CO;2-I; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101	32	1173	1241	1	75	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2001	29	4					465	468		10.1038/ng772	http://dx.doi.org/10.1038/ng772			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11704759				2022-12-25	WOS:000172507500024
J	Rommel, C; Bodine, SC; Clarke, BA; Rossman, R; Nunez, L; Stitt, TN; Yancopoulos, GD; Glass, DJ				Rommel, C; Bodine, SC; Clarke, BA; Rossman, R; Nunez, L; Stitt, TN; Yancopoulos, GD; Glass, DJ			Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways	NATURE CELL BIOLOGY			English	Article							B-CELLS; AKT ACTIVATION; MUSCLE; GROWTH; CALCINEURIN; INSULIN; KINASE; SIZE; DIFFERENTIATION; PROLIFERATION	Skeletal muscle is composed of multinucleated fibres, formed after the differentiation and fusion of myoblast precursors'. Skeletal muscle atrophy and hypertrophy refer to changes in the diameter of these pre-existing muscle fibres. The prevention of atrophy would provide an obvious clinical benefit; insulin-like growth factor 1 (IGF-1) is a promising anti-atrophy agent(2-5) because of its ability to promote hypertrophy. However, the signalling pathways by which IGF-1 promotes hypertrophy remain unclear, with roles suggested for both the calcineurin/NFAT (nuclear factor of activated T cells) pathway(6,7) and the Ptdlns-3-OH kinase (PI(3)K)/Akt pathway(8). Here we employ a battery of approaches to examine these pathways during the hypertrophic response of cultured myotubes to IGF-1, We report that Akt promotes hypertrophy by activating downstream signalling pathways previously implicated in activating protein synthesis: the pathways downstream of mammalian target of rapamycin (mTOR) and the, pathway activated by phosphorylating and thereby inhibiting glycogen synthase kinase 3 (GSK3). In contrast, in addition to demonstrating that calcineurin does not mediate IGF-1-induced hypertrophy, we show that IGF-1 unexpectedly acts via Akt to antagonize calcineurin signalling during myotube hypertrophy.	Regeneron Pharmaceut, Tarrytown, NY 10591 USA	Regeneron	Glass, DJ (corresponding author), Regeneron Pharmaceut, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164; Bodine, Sue/0000-0002-5742-9145				Adams GR, 1996, J APPL PHYSIOL, V81, P2509, DOI 10.1152/jappl.1996.81.6.2509; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENGEL A, 1994, MYOLOGY, P1937; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; GLASS DJ, 1992, COLD SPRING HARB SYM, V57, P53, DOI 10.1101/SQB.1992.057.01.007; Goldspink G, 1999, J ANAT, V194, P323, DOI 10.1046/j.1469-7580.1999.19430323.x; Huang H, 1999, DEVELOPMENT, V126, P5365; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Renganathan M, 1997, FEBS LETT, V417, P13, DOI 10.1016/S0014-5793(97)01225-8; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Semsarian C, 1999, BIOCHEM J, V339, P443, DOI 10.1042/0264-6021:3390443; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Yu H, 1999, J La State Med Soc, V151, P218	26	1142	1180	4	98	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					1009	1013		10.1038/ncb1101-1009	http://dx.doi.org/10.1038/ncb1101-1009			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715022				2022-12-25	WOS:000172070300016
J	Bell, MP; Huntoon, CJ; Graham, D; McKean, DJ				Bell, MP; Huntoon, CJ; Graham, D; McKean, DJ			The analysis of costimulatory receptor signaling cascades in normal T lymphocytes using in vitro gene transfer and reporter gene analysis	NATURE MEDICINE			English	Article							TRANSIENT TRANSFECTION; CELLS; TRANSDUCTION	Ligation of the antigen receptor and costimulatory receptors on the surface of T lymphocytes initiates intracellular signals that regulate cell-cycle progression and cell differentiation. To effectively manipulate the activation of T cells for immunotherapeutic applications, it will be important to understand how these signaling pathways are integrated to control specific gene transcription events. Here we describe a novel transient transfection procedure that efficiently introduces DNA into non-dividing normal human and murine T lymphocytes while maintaining high cell viability. Using this technique, reporter genes can be introduced to characterize intracellular signaling pathways that regulate specific gene transcription events in normal T-lymphocyte populations. We show that the CD28 receptor can be differentially coupled to downstream signaling pathways in different T-lymphocyte populations. In addition, we demonstrate that a gene encoding a tagged constitutively active mitogen-activated kinase kinase-1 protein can be transfected and rapidly expressed to regulate the expression of Bcl-2 in normal thymocytes.	Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic	McKean, DJ (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.							CIBOTTI R, 1997, IMMUNITY, V6, P1; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; Huang H, 1998, J IMMUNOL METHODS, V215, P173, DOI 10.1016/S0022-1759(98)00088-X; Hughes CCW, 1996, J BIOL CHEM, V271, P5369, DOI 10.1074/jbc.271.10.5369; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McKean DJ, 2001, J IMMUNOL, V166, P3468, DOI 10.4049/jimmunol.166.5.3468; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x	11	26	26	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1155	1158		10.1038/nm1001-1155	http://dx.doi.org/10.1038/nm1001-1155			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590441				2022-12-25	WOS:000171524500039
J	Herceg, Z; Hulla, W; Gell, D; Cuenin, C; Lleonart, M; Jackson, S; Wang, ZQ				Herceg, Z; Hulla, W; Gell, D; Cuenin, C; Lleonart, M; Jackson, S; Wang, ZQ			Disruption of Trrap causes early embryonic lethality and defects in cell cycle progression	NATURE GENETICS			English	Article							HISTONE ACETYLTRANSFERASE; SPINDLE CHECKPOINT; ESSENTIAL COFACTOR; HUMAN CANCERS; C-MYC; COMPLEX; LACKING; EMBRYOGENESIS; APOPTOSIS; COMPONENT		Int Agcy Res Canc, F-69008 Lyon, France; Univ Cambridge, Inst Canc & Dev Biol, Wellcome Trust, Canc Res Campaign, Cambridge, England	World Health Organization; International Agency for Research on Cancer (IARC); CRUK Cambridge Institute; University of Cambridge; Wellcome Trust Sanger Institute	Wang, ZQ (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.		Jackson, Stephen Philip/R-4548-2019; LLeonart, Matilde E./Q-2662-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; LLeonart, Matilde E./0000-0002-6196-7405; Gell, David/0000-0003-0382-1181				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303	30	102	105	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					206	211		10.1038/ng725	http://dx.doi.org/10.1038/ng725			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11544477				2022-12-25	WOS:000171374100029
J	Jeffreys, AJ; Kauppi, L; Neumann, R				Jeffreys, AJ; Kauppi, L; Neumann, R			Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; DISEASE GENES; YEAST; HOTSPOTS; MEIOSIS; SITES; DNA; AMPLIFICATION	There is considerable interest in understanding patterns of linkage disequilibrium (LD) in the human genome, to aid investigations of human evolution and facilitate association studies in complex disease(1-5). The relative influences of meiotic crossover distribution and population history on LD remain unclear, however(5). In particular, it is uncertain to what extent crossovers are clustered into 'hot SpotS,(6-8) that might influence LID patterns. As a first step to investigating the relationship between LD and recombination, we have analyzed a 216-kb segment of the class II region of the major histocompatibility complex (MHC) already characterized for familial crossovers(9). High-resolution LD analysis shows the existence of extended domains of strong association interrupted by patchwork areas of LD breakdown. Sperm typing shows that these areas correspond precisely to meiotic crossover hot spots. All six hot spots defined share a remarkably similar symmetrical morphology but vary considerably in intensity, and are not obviously associated with any primary DNA sequence determinants of hot-spot activity. These hot spots occur in clusters and together account for almost all crossovers in this region of the MHC. These data show that, within the MHC at least, crossovers are far from randomly distributed at the molecular level and that recombination hot spots can profoundly affect LD patterns.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Leicester	Jeffreys, AJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	ajj@1e.ac.uk	Peng, Bo/A-6920-2009; Kauppi, Liisa/H-5845-2012	Peng, Bo/0000-0001-8225-2284; Kauppi, Liisa/0000-0002-6759-8997				Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; CULLEN M, 1995, AM J HUM GENET, V56, P1350; Cullen M, 1997, AM J HUM GENET, V60, P397; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Fan QQ, 1996, MOL CELL BIOL, V16, P2037; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEDRICK PW, 1988, HEREDITY, V60, P435, DOI 10.1038/hdy.1988.61; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; Jeffreys AJ, 1998, MOL CELL, V2, P267, DOI 10.1016/S1097-2765(00)80138-0; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Jorde LB, 2000, GENOME RES, V10, P1435, DOI 10.1101/gr.144500; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; LEWONTIN RC, 1964, GENETICS, V49, P49; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; Morton N. E., 1982, OUTLINE GENETIC EPID; OHTA K, 1994, EMBO J, V13, P5754, DOI 10.1002/j.1460-2075.1994.tb06913.x; Ott J, 2000, P NATL ACAD SCI USA, V97, P2, DOI 10.1073/pnas.97.1.2; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SHIROISHI T, 1995, ADV BIOPHYS, V31, P119, DOI 10.1016/0065-227X(95)99387-5; Snoek M, 1998, J IMMUNOL, V160, P266; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; Su XZ, 1996, NUCLEIC ACIDS RES, V24, P1574, DOI 10.1093/nar/24.8.1574; SVED J A, 1971, Theoretical Population Biology, V2, P125; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959	34	625	656	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2001	29	2					217	222		10.1038/ng1001-217	http://dx.doi.org/10.1038/ng1001-217			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586303				2022-12-25	WOS:000171374100031
J	MacDonald, TJ; Brown, KM; LaFleur, B; Peterson, K; Lawlor, C; Chen, YD; Packer, RJ; Cogen, P; Stephan, DA				MacDonald, TJ; Brown, KM; LaFleur, B; Peterson, K; Lawlor, C; Chen, YD; Packer, RJ; Cogen, P; Stephan, DA			Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease	NATURE GENETICS			English	Article							CHROMOSOME 17P DELETIONS; DNA-POLYMERASE-DELTA; GENE-EXPRESSION; GROWTH-FACTOR; CHILDHOOD MEDULLOBLASTOMA; MOLECULAR CLASSIFICATION; PROGNOSTIC-SIGNIFICANCE; BRAIN-TUMORS; RECEPTOR; CANCER	Little is known about the genetic regulation of medulloblastoma dissemination, but metastatic medulloblastoma is highly associated with poor outcome. We obtained expression profiles of 23 primary medulloblastomas clinically designated as either metastatic (M+) or non-metastatic (M0) and identified 85 genes whose expression differed significantly between classes. Using a class prediction algorithm based on these genes and a leave-one-out approach, we assigned sample class to these tumors (M+ or M0) with 72% accuracy and to four additional independent tumors with 100% accuracy. We also assigned the metastatic medulloblastoma cell line Daoy to the metastatic class. Notably, platelet-derived growth factor receptor alpha (PDGFRA) and members of the downstream RAS/mitogen-activated protein kinase (MAPK) signal transduction pathway are upregulated in M+ tumors. Immunohistochemical validation on an independent set of tumors shows significant overexpression of PDGFRA in M+ tumors compared to MO tumors. Using in vitro assays, we show that platelet-derived growth factor alpha (PDGFA) enhances medulloblastoma migration and increases downstream MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK1 (p42 MAPK) and MAPK3 (p44 MAPK) phosphorylation in a dose-dependent manner. Neutralizing antibodies to PDGFRA blocks MAP2K1, MAP2K2 and MAPK1/3 phosphorylation, whereas U0126, a highly specific inhibitor of MAP2K1 and MAP2K2, also blocks MAPK1/3. Both inhibit migration and prevent PDGFA-stimulated migration. These results provide the first insight into the genetic regulation of medulloblastoma metastasis and are the first to suggest a role for PDGFRA and the RAS/MAPK signaling pathway in medulloblastoma metastasis. Inhibitors of PDGFRA and RAS proteins should therefore be considered for investigation as possible novel therapeutic strategies against medulloblastoma.	Childrens Natl Med Ctr, Res Ctr Genet Med, Washington, DC 20010 USA; Childrens Natl Med Ctr, Ctr Canc & Transplantat Biol, Washington, DC 20010 USA; George Washington Univ, Dept Genet, Washington, DC USA; Vanderbilt Univ, Dept Prevent Med, Div Biostat, Nashville, TN USA; NHGRI, NIH, Bethesda, MD 20892 USA; Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Neurosurg, Washington, DC 20010 USA; Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA	Children's National Health System; Children's National Health System; George Washington University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Children's National Health System; Children's National Health System; Children's National Health System	MacDonald, TJ (corresponding author), Childrens Natl Med Ctr, Res Ctr Genet Med, 111 Michigan Ave NW, Washington, DC 20010 USA.		MacDonald, Tobey/D-4554-2013; LaFleur, Bonnie J/GPJ-9592-2022	LaFleur, Bonnie J/0000-0002-4939-9337				Adesina AM, 1999, J CHILD NEUROL, V14, P411, DOI 10.1177/088307389901400701; BATRA SK, 1995, J NEURO-ONCOL, V24, P39, DOI 10.1007/BF01052657; BENDOR A, 2000, AGL200012 AG LABS; Biegel JA, 1997, CLIN CANCER RES, V3, P473; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brown HG, 2000, J NEUROPATH EXP NEUR, V59, P857, DOI 10.1093/jnen/59.10.857; Cillo C, 1996, INT J CANCER, V66, P692, DOI 10.1002/(SICI)1097-0215(19960529)66:5<692::AID-IJC18>3.0.CO;2-6; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLISON JA, 1994, J NEUROSCI RES, V37, P116, DOI 10.1002/jnr.490370116; Emadian SM, 1996, CLIN CANCER RES, V2, P1559; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; GARSON JA, 1989, BRIT J CANCER, V59, P889, DOI 10.1038/bjc.1989.188; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; GILBERTSON RJ, 1995, BRIT J CANCER, V71, P473, DOI 10.1038/bjc.1995.96; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grotzer MA, 2000, J CLIN ONCOL, V18, P1027, DOI 10.1200/JCO.2000.18.5.1027; Herms J, 2000, INT J CANCER, V89, P395; Huang HT, 2000, CANCER RES, V60, P6868; Khan J, 1999, BIOCHIM BIOPHYS ACTA, V1423, P17; Kim JYH, 1999, CANCER RES, V59, P711; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; Packer RJ, 1999, J CLIN ONCOL, V17, P2127, DOI 10.1200/JCO.1999.17.7.2127; Packer RJ, 1999, ARCH NEUROL-CHICAGO, V56, P421, DOI 10.1001/archneur.56.4.421; Packer RJ, 1999, BRAIN DEV-JPN, V21, P75, DOI 10.1016/S0387-7604(98)00085-0; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Remacle A, 2000, INT J CANCER, V89, P118, DOI 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sunshine C, 2000, EXP CELL RES, V257, P1, DOI 10.1006/excr.2000.4855; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; ZEITZER PM, 1999, J CLIN ONCOL, V17, P832; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	38	349	370	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					143	152		10.1038/ng731	http://dx.doi.org/10.1038/ng731			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11544480				2022-12-25	WOS:000171374100019
J	Walley, AJ; Chavanas, S; Moffatt, ME; Esnouf, RM; Ubhi, B; Lawrence, R; Wong, K; Abecasis, GR; Jones, EY; Harper, JL; Hovnanian, A; Cookson, WOCM				Walley, AJ; Chavanas, S; Moffatt, ME; Esnouf, RM; Ubhi, B; Lawrence, R; Wong, K; Abecasis, GR; Jones, EY; Harper, JL; Hovnanian, A; Cookson, WOCM			Gene polymorphism in Netherton and common atopic disease	NATURE GENETICS			English	Article							PARTY DIAGNOSTIC-CRITERIA; GENOME-WIDE SEARCH; SERUM IGE LEVELS; UNDERLYING ASTHMA; LINKAGE; DERMATITIS; CHROMOSOME-11Q; ASSOCIATION; INHIBITOR; RECEPTOR	Atopic dermatitis (AD) and asthma are characterized by IgE-mediated atopic (allergic) responses to common proteins (allergens), many of which are proteinases. Loci influencing atopy have been localized to a number of chromosomal regions', including the chromosome 5q31 cytokine cluster(2-4). Netherton disease is a rare recessive skin disorder in which atopy is a universal accompaniment(5). The gene underlying Netherton disease (SPINK5)(6) encodes a 15-domain serine proteinase inhibitor (LEKTI) which is expressed in epithelial and mucosal surfaces and in the thymus(6,7). We have identified six coding polymorphisms in SPINK5 (Table 1) and found that a Glu420 --> Lys variant shows significant association with atopy and AD in two independent panels of families. Our results implicate a previously unrecognized pathway for the development of common allergic illnesses.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Great Ormond St Hosp Sick Children, Dept Paediat Dermatol, London WC1N 3JH, England	University of Oxford; Wellcome Centre for Human Genetics; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Cookson, WOCM (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	wocc@well.ox.ac.uk	Hovnanian, Alain/I-4711-2017; Jones, Yvonne/N-8111-2019; Abecasis, Goncalo R/B-7840-2010; Cookson, William/HHC-1790-2022; Walley, Andrew J/D-2573-2009; Chavanas, stephane/K-1183-2014; Jones, Yvonne/J-2293-2016	Hovnanian, Alain/0000-0003-3412-7512; Jones, Yvonne/0000-0002-3834-1893; Walley, Andrew J/0000-0001-7707-7549; Jones, Yvonne/0000-0002-3834-1893; chavanas, stephane/0000-0003-4323-2656; Abecasis, Goncalo/0000-0003-1509-1825				Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinati LC, 1996, AM J RESP CRIT CARE, V153, P1682, DOI 10.1164/ajrccm.153.5.8630620; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Rosenwasser LJ, 1997, INT ARCH ALLERGY IMM, V113, P61, DOI 10.1159/000237509; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; THOMAS WR, 1993, CLIN EXP ALLERGY, V23, P350, DOI 10.1111/j.1365-2222.1993.tb00338.x; Tobe VO, 1996, NUCLEIC ACIDS RES, V24, P3728, DOI 10.1093/nar/24.19.3728; Vorechovsky I, 1999, AM J HUM GENET, V64, P1096, DOI 10.1086/302326; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	31	283	298	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2001	29	2					175	178		10.1038/ng728	http://dx.doi.org/10.1038/ng728			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11544479				2022-12-25	WOS:000171374100023
J	Hong, S; Wilson, MT; Serizawa, I; Wu, L; Singh, N; Naidenko, OV; Miura, T; Haba, T; Scherer, DC; Wei, J; Kronenberg, M; Koezuka, Y; Van Kaer, L				Hong, S; Wilson, MT; Serizawa, I; Wu, L; Singh, N; Naidenko, OV; Miura, T; Haba, T; Scherer, DC; Wei, J; Kronenberg, M; Koezuka, Y; Van Kaer, L			The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice	NATURE MEDICINE			English	Article							NKT CELLS; CD1D TETRAMERS; ACTIVATION; RECOGNITION; THYMOCYTES; MELLITUS; MOUSE	Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells(1,2). V alpha 14-J alpha 15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3,4). We have previously shown that in vivo activation of V alpha 14 NKT cells by alpha -galactosylceramide (alpha -GalCer) and CD1d potentiates Th2-mediated adaptive immune responses Here we show that alpha -GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of alpha -GalCer to suppress interferon-gamma but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because alpha -GalCer recognition by NKT cells is conserved among mice and humans(7,8), these findings indicate that alpha -GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Nashville, TN 37212 USA; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma, Japan; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; La Jolla Inst Allergy & Immunol, San Diego, CA USA	Howard Hughes Medical Institute; Vanderbilt University; Kirin Brewery Company Limited; Vanderbilt University; La Jolla Institute for Immunology	Van Kaer, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Nashville, TN 37212 USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309				Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Burdin N, 1999, EUR J IMMUNOL, V29, P2014, DOI 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Falcone M, 1999, J EXP MED, V190, P963, DOI 10.1084/jem.190.7.963; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Laloux V, 2001, J IMMUNOL, V166, P3749, DOI 10.4049/jimmunol.166.6.3749; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Moodycliffe AM, 2000, NAT IMMUNOL, V1, P521, DOI 10.1038/82782; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; Osman Y, 2000, EUR J IMMUNOL, V30, P1919, DOI 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3; Pearson CI, 1999, CURR TOP MICROBIOL, V238, P79; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Shi FD, 2001, P NATL ACAD SCI USA, V98, P6777, DOI 10.1073/pnas.121169698; Singh N, 1999, J IMMUNOL, V163, P2373; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771	25	472	505	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1052	1056		10.1038/nm0901-1052	http://dx.doi.org/10.1038/nm0901-1052			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533710				2022-12-25	WOS:000170853300032
J	Cavallaro, U; Niedermeyer, J; Fuxa, M; Christofori, G				Cavallaro, U; Niedermeyer, J; Fuxa, M; Christofori, G			N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling	NATURE CELL BIOLOGY			English	Article							DEPENDENT NEURITE OUTGROWTH; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR-4; NERVOUS-SYSTEM; IMMUNOGLOBULIN SUPERFAMILY; EXTRACELLULAR-MATRIX; SYNTHETIC PEPTIDES; PANCREATIC-ISLETS; POLYSIALIC ACID; NEURONAL CELLS	Loss of expression of neural cell-adhesion molecule (N-CAM) is implicated in the progression of tumour metastasis. Here we show that N-CAM modulates neurite outgrowth and matrix adhesion of beta -cells from pancreatic tumours by assembling a fibroblast-growth-factor receptor-4 (FGFR-4) signalling complex, which consists of N-cadherin, FGFR-4, phospholipase C gamma (PLC-gamma), the adaptor protein FRS2, pp60(c-src), cortactin and growth-associated protein-43 (GAP-43), Dominant-negative FGFR-4, inhibitors of FGFR signalling and anti-beta (1)-integrin antibodies repress matrix adhesion induced by N-CAM, FGF ligands can replace N-CAM in promoting matrix adhesion but not neurite outgrowth. The results indicate that N-CAM stimulates beta (1)-integrin-mediated cell-matrix adhesion by activating FGFR signalling. This is a potential mechanism for preventing the dissemination of metastatic tumour cells.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Christofori, G (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Cavallaro, Ugo/J-9745-2012	Cavallaro, Ugo/0000-0002-0884-6460				BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Cavallaro U, 1998, FASEB J, V12, P1027, DOI 10.1096/fasebj.12.11.1027; CIRULLI V, 1994, J CELL SCI, V107, P1429; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Esni F, 1999, J CELL BIOL, V144, P325, DOI 10.1083/jcb.144.2.325; Fogar P, 1997, ANTICANCER RES, V17, P1227; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; Kaiser U, 1996, LEUKEMIA LYMPHOMA, V20, P389, DOI 10.3109/10428199609052420; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kolkova K, 2000, J NEUROSCI, V20, P2238; LANGLEY OK, 1989, J HISTOCHEM CYTOCHEM, V37, P781, DOI 10.1177/37.6.2723399; MATZNER Y, 1990, EXP CELL RES, V189, P233, DOI 10.1016/0014-4827(90)90241-2; Meiri KF, 1998, J NEUROSCI, V18, P10429; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; Olson DC, 1998, CELL GROWTH DIFFER, V9, P557; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PROBSTMEIER R, 1989, J NEUROCHEM, V53, P1794, DOI 10.1111/j.1471-4159.1989.tb09245.x; Rabinowitz JE, 1996, P NATL ACAD SCI USA, V93, P6421, DOI 10.1073/pnas.93.13.6421; Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.3.CO;2-T; Stork O, 1999, J NEUROBIOL, V40, P343, DOI 10.1002/(SICI)1097-4695(19990905)40:3<343::AID-NEU6>3.0.CO;2-S; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; ZHAN X, 1994, J BIOL CHEM, V269, P20221	49	244	261	0	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					650	657		10.1038/35083041	http://dx.doi.org/10.1038/35083041			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433297				2022-12-25	WOS:000169727000016
J	Kang, YK; Koo, DB; Park, JS; Choi, YH; Chung, AS; Lee, KK; Han, YM				Kang, YK; Koo, DB; Park, JS; Choi, YH; Chung, AS; Lee, KK; Han, YM			Aberrant methylation of donor genome in cloned bovine embryos	NATURE GENETICS			English	Letter							DNA METHYLTRANSFERASE; FETAL FIBROBLASTS; NUCLEAR TRANSFER; PATERNAL GENOME; GERM-CELLS; IN-VITRO; MOUSE; CALVES; DEMETHYLATION; CULTURE	Despite recent successes in cloning various animal species, the use of somatic cells as the source of donor nuclei has raised many practically relevant questions such as increased abortion rates, high birth weight and perinatal death(1-3). These anomalies may be caused by incomplete epigenetic reprogramming of donor DNA. Genome-wide demethylation occurs during early development, 'erasing' gamete-specific methylation patterns inherited from the parents(4-8). This process may be a prerequisite for the formation of pluripotent stem cells that are important for the later development(9), Here, we provide evidence that cloned bovine embryos may have impaired epigenetic reprogramming capabilities. We found highly aberrant methylation patterns in various genomic regions of cloned embryos. Cloned blastocysts closely resembled donor cells in their overall genomic methylation status, which was very different from that of normal blastocysts produced in vitro or in vivo. We found demethylation of the Bov-B long interspersed nuclear element sequence in normal embryos, hut not in cloned embryos, in which the donor-type methylation was simply maintained during preimplantation development. There were also significant variations in the degree of methylation among individual cloned blastocysts. Our findings indicate that the developmental anomalies of cloned embryos could be due to incomplete epigenetic reprogramming of donor genomic DNA.	KRIBB, Anim Dev Biotechnol Lab, Taejon 305600, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST)	Han, YM (corresponding author), KRIBB, Anim Dev Biotechnol Lab, POB 115, Taejon 305600, South Korea.		Han, Yong-Mahn/C-1652-2011					Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cardoso MC, 1999, J CELL BIOL, V147, P25, DOI 10.1083/jcb.147.1.25; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Gonzalgo ML, 1997, CANCER RES, V57, P594; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Mertineit C, 1998, DEVELOPMENT, V125, P889; MONK M, 1987, DEVELOPMENT, V99, P371; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; RELK W, 1997, GENOMIC INPRINTING; ROSENKRANS CF, 1993, BIOL REPROD, V49, P459, DOI 10.1095/biolreprod49.3.459; SANFORD J, 1984, NUCLEIC ACIDS RES, V12, P2823, DOI 10.1093/nar/12.6.2823; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Shiga K, 1999, THERIOGENOLOGY, V52, P527, DOI 10.1016/S0093-691X(99)00149-1; Thompson JG, 1998, THERIOGENOLOGY, V49, P1239, DOI 10.1016/S0093-691X(98)00071-5; TSUNODA Y, 1986, J EXP ZOOL, V240, P119, DOI 10.1002/jez.1402400115; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zakhartchenko V, 1999, MOL REPROD DEV, V54, P264, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;264::AID-MRD7&gt;3.0.CO;2-Y; Zakhartchenko V, 1999, J REPROD FERTIL, V115, P325, DOI 10.1530/jrf.0.1150325	24	423	466	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					173	177		10.1038/88903	http://dx.doi.org/10.1038/88903			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381267				2022-12-25	WOS:000169011800022
J	Kovalchuk, O; Titov, V; Hohn, B; Kovalchuk, I				Kovalchuk, O; Titov, V; Hohn, B; Kovalchuk, I			A sensitive transgenic plant system to detect toxic inorganic compounds in the environment	NATURE BIOTECHNOLOGY			English	Article							INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; METAL TOXICITY; WHOLE PLANTS; BIOASSAYS; ASSAY; GENE; GENOTOXICITY; INDUCTION; NICKEL; CELLS	We describe a transgenic plant-based assay to study the genetic effects of heavy metals. Arabidopsis thaliana plants carrying a beta -glucuronidase (GUS) marker gene either with a point mutation or as a recombination substrate were used to analyze the frequency of somatic point mutations and homologous recombination in whole plants. Transgenic test plants sown on media contaminated by the salts of the heavy metals Cd2+, Pb2+, Ni2+, Zn2+, Cu2+, and As2O3 exhibited a pronounced uptake-dependent increase in the frequencies of both somatic intrachromosomal recombination and point mutation. The test was applied to monitor the genotoxicity of soils sampled in sites contaminated with several heavy metals. Our results indicate that this is a highly sensitive system for monitoring metal contamination in soils and water.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Ivano Frankivsk State Med Acad, UA-284000 Ivano Frankivsk, Ukraine	Friedrich Miescher Institute for Biomedical Research; Ivano-Frankivsk National Medical University	Kovalchuk, I (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	igor@fmi.ch						Alloway B. J., 1993, CHEM PRINCIPLES ENV; BITTON G, 1994, ARCH ENVIRON CON TOX, V27, P25; BITTON G, 1992, REV ENVIRON CONTAM T, V125, P1; CODINA JC, 1993, ARCH ENVIRON CON TOX, V25, P250, DOI 10.1007/BF00212137; Dmitriev M. T., 1989, SANITARY CHEM ANAL P; FISKESJO G, 1988, MUTAT RES, V197, P243, DOI 10.1016/0027-5107(88)90096-6; Grant WF, 1999, MUTAT RES-FUND MOL M, V426, P107, DOI 10.1016/S0027-5107(99)00050-0; HARTMANN A, 1994, ENVIRON MOL MUTAGEN, V23, P299, DOI 10.1002/em.2850230407; HARTWIG A, 1995, BIOMETALS, V8, P3; Helleday T, 2000, ENVIRON MOL MUTAGEN, V35, P114, DOI 10.1002/(SICI)1098-2280(2000)35:2<114::AID-EM6>3.0.CO;2-Q; HORN N, 1984, METABOLISM TRACE MET, V2, P26; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JEFFERSON RA, 1987, BIOCHEM SOC T, V15, P17, DOI 10.1042/bst0150017; Knasmuller S, 1998, MUTAT RES-GEN TOX EN, V420, P37, DOI 10.1016/S1383-5718(98)00145-4; KONG IC, 1995, REV ENVIRON CONTAM T, V125, P1; Kovalchuk I, 2000, EMBO J, V19, P4431, DOI 10.1093/emboj/19.17.4431; Kovalchuk I, 1998, NAT BIOTECHNOL, V16, P1054, DOI 10.1038/3505; Lee YW, 1998, MUTAT RES-GEN TOX EN, V415, P213, DOI 10.1016/S1383-5718(98)00078-3; LEWIN DE, 1986, ENV MUTAGEN, V8, P9; Mass MJ, 1997, MUTAT RES-REV MUTAT, V386, P263, DOI 10.1016/S1383-5742(97)00008-2; Masson JE, 1997, P NATL ACAD SCI USA, V94, P11731, DOI 10.1073/pnas.94.21.11731; Mayer C, 1998, MUTAT RES-GEN TOX EN, V420, P85, DOI 10.1016/S1383-5718(98)00140-5; PETERHANS A, 1990, EMBO J, V9, P3437, DOI 10.1002/j.1460-2075.1990.tb07551.x; PUCHTA H, 1995, PLANT J, V7, P203, DOI 10.1046/j.1365-313X.1995.7020203.x; RANK J, 1994, MUTAT RES, V312, P17, DOI 10.1016/0165-1161(94)90004-3; RASMUSON A, 1985, MUTAT RES, V157, P157, DOI 10.1016/0165-1218(85)90111-9; ROSSMAN TG, 1991, MUTAT RES, V260, P349, DOI 10.1016/0165-1218(91)90021-D; Rossmann T, 1995, TOXICOLOGY METALS, P373; Sacco MG, 1997, NAT BIOTECHNOL, V15, P1392, DOI 10.1038/nbt1297-1392; SCHARNAGL C, 1991, J PHOTOCH PHOTOBIO B, V8, P129, DOI 10.1016/1011-1344(91)80053-K; SIVIKOVA K, 1995, MUTAT RES-FUND MOL M, V327, P17, DOI 10.1016/0027-5107(94)00061-9; Sokal RR, 1995, BIOMETRY; Steinkellner H, 1998, ENVIRON MOL MUTAGEN, V31, P183; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183	35	83	93	3	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					568	572		10.1038/89327	http://dx.doi.org/10.1038/89327			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385463				2022-12-25	WOS:000169081700032
J	Sagot, I; Klee, SK; Pellman, D				Sagot, I; Klee, SK; Pellman, D			Yeast formins regulate cell polarity by controlling the assembly of actin cables	NATURE CELL BIOLOGY			English	Article							MITOTIC SPINDLE; MICROTUBULE ORIENTATION; ARP2/3 COMPLEX; BUDDING YEAST; BUD SITE; CYTOSKELETON; PROTEIN; BNI1P; LOCALIZATION; ROLES	Formins are conserved Rho-GTPase effectors that communicate Rho-GTPase signals to the cytoskeleton. We found that formins were required for the assembly of one of the three budding yeast actin structures: polarized arrays of actin cables. A dominant-active formin induced the assembly of actin cables. The activation and localization of the formin Bni1p required components of the polarisome complex. These findings potentially define the cellular function of formins in budding yeast and explain their involvement in the generation of cell polarity. A requirement for formins in constructing specific actin structures might be the basis for the diverse activities of formins in development.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Stuttgart	Sagot, I (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.	david_pellman@dfci.harvard.edu			NIGMS NIH HHS [GM61345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Beach DL, 2000, CURR BIOL, V10, P1497, DOI 10.1016/S0960-9822(00)00837-X; Chang F, 1999, CURR BIOL, V9, P849, DOI 10.1016/S0960-9822(99)80372-8; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; Fujiwara T, 1999, MOL CELL BIOL, V19, P8016; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kamei T, 1998, J BIOL CHEM, V273, P28341, DOI 10.1074/jbc.273.43.28341; Karpova TS, 1998, J CELL BIOL, V142, P1501, DOI 10.1083/jcb.142.6.1501; Kato T, 2001, J CELL SCI, V114, P775; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne D, 2000, J CELL SCI, V113, P571; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Schuyler SC, 2001, J CELL SCI, V114, P247; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Tanaka K, 2000, BIOCHEM BIOPH RES CO, V267, P479, DOI 10.1006/bbrc.1999.1707; Theesfeld CL, 1999, J CELL BIOL, V146, P1019, DOI 10.1083/jcb.146.5.1019; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Vallen EA, 2000, MOL BIOL CELL, V11, P593, DOI 10.1091/mbc.11.2.593; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Yin HW, 2000, NATURE, V406, P1013, DOI 10.1038/35023024; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	48	329	332	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					42	50		10.1038/ncb719	http://dx.doi.org/10.1038/ncb719			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11740491				2022-12-25	WOS:000173381500015
J	Bamforth, SD; Braganca, J; Eloranta, JJ; Murdoch, JN; Marques, FIR; Kranc, KR; Farza, H; Henderson, DJ; Hurst, HC; Bhattacharya, S				Bamforth, SD; Braganca, J; Eloranta, JJ; Murdoch, JN; Marques, FIR; Kranc, KR; Farza, H; Henderson, DJ; Hurst, HC; Bhattacharya, S			Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR AP-2; RUBINSTEIN-TAYBI-SYNDROME; GENE-EXPRESSION; MOUSE EMBRYOGENESIS; BINDING-PROTEIN; MUTATIONS; ERBB3; MRG1; TUBE; CBP	The protein EP300 and its paralog CREBBP (CREB-binding protein) are ubiquitously expressed transcriptional co-activators and histone acetyl transferases'. The gene EP300 is essential for normal cardiac and neural development, whereas CREBBP is essential for neurulation, hematopoietic differentiation, angiogenesis and skeletal and cardiac development(2-5). Mutations in CREBBP cause Rubinstein-Taybi syndrome, which is characterized by mental retardation, skeletal abnormalities and congenital cardiac defects(6,7). The CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2) binds EP300 and CREBBP with high affinity(8) and regulates gene transcription(8-10). Here we show that Cited2(-/-) embryos die with cardiac malformations, adrenal agenesis, abnormal cranial ganglia and exencephaly. The cardiac defects include atrial and ventricular septal defects, overriding aorta, double-outlet right ventricle, persistent truncus arteriosus and right-sided aortic arches. We find increased apoptosis in the midbrain region and a marked reduction in ErbB3-expressing neural crest cells in mid-embryogenesis. We show that CITED2 interacts with and co-activates all isoforms of transcription factor AP-2 (TFAP2). Transactivation by TFAP2 isoforms is defective in Cited2(-/-) embryonic fibroblasts and is rescued by ectopically expressed CITED2. As certain Tfap2 isoforms are essential in neural crest, neural tube and cardiac development(11-13), we propose that abnormal embryogenesis in mice lacking Cited2 results, at least in part, from its role as a Tfap2 co-activator.	Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England; Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, London, England; Inst Child Hlth, Neural Dev Unit, London, England	University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Imperial College London; University of London; University College London	Bhattacharya, S (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Roosevelt Dr, Oxford OX3 7BN, England.		Braganca, Jose/F-4410-2012; Kranc, Kamil/B-3449-2009; Bamforth, Simon David/I-1277-2019; Bhattacharya, Shoumo/F-4127-2010	Braganca, Jose/0000-0001-9566-400X; Bamforth, Simon David/0000-0002-5666-4485; Bhattacharya, Shoumo/0000-0002-5571-0478; Henderson, Deborah/0000-0002-2705-5998				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bosher JM, 1996, ONCOGENE, V13, P1701; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Goodman RH, 2000, GENE DEV, V14, P1553; Haydar TF, 1999, CEREB CORTEX, V9, P621, DOI 10.1093/cercor/9.6.621; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; Kung AL, 2000, GENE DEV, V14, P272; Le Douarin NM, 1999, NEURAL CREST, V2; LOO DT, 1989, CELL GROWTH CELL DIV, P17; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; Oike Y, 1999, BLOOD, V93, P2771; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; SKINNER A, 1993, ONCOGENE, V8, P3393; STEVENS CA, 1995, AM J MED GENET, V59, P346, DOI 10.1002/ajmg.1320590313; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	30	253	268	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					469	474		10.1038/ng768	http://dx.doi.org/10.1038/ng768			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11694877				2022-12-25	WOS:000172507500025
J	Grand-Perret, T; Bouillot, A; Perrot, A; Commans, S; Walker, M; Issandou, M				Grand-Perret, T; Bouillot, A; Perrot, A; Commans, S; Walker, M; Issandou, M			SCAP ligands are potent new lipid-lowering drugs	NATURE MEDICINE			English	Article							STEROL REGULATORY ELEMENT; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; BINDING PROTEINS; CHOLESTEROL; SREBP; RECEPTOR; CLEAVAGE; PROMOTER; STATINS	Upregulation of low-density lipoprotein receptor (LDLr) is a key mechanism to control elevated plasma LDL-cholesterol levels. Here we identify a new class of compounds that directly binds to the sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP). We show that a C-14-labeled, photo-activatable analog specifically labeled both SCAP and a truncated form of SCAP containing the sterol-sensing domain. When administered to hyperlipidemic hamsters, SCAP ligands reduced both LDL cholesterol and triglycerides levels by up to 80% with a three-fold increase in LDLr mRNA in the livers. Using human hepatoma cells, we show that these compounds act through the sterol-responsive element of the LDLr promoter and activate the SCAP/SREBP pathway, leading to increased LDLr expression and activity, even in presence of excess of sterols. These findings have led to the identification of a class of compounds that represent a promising new class of hypolipidemic drugs.	GlaxoSmithKline, F-91951 Les Ulis, France	GlaxoSmithKline	Grand-Perret, T (corresponding author), GlaxoSmithKline, F-91951 Les Ulis, France.	tgp288760@gsk.com	Eckhardt, Erik/G-1567-2010					Aguilar-Salinas CA, 1998, ATHEROSCLEROSIS, V141, P203, DOI 10.1016/S0021-9150(98)00198-1; Ansell BJ, 1999, JAMA-J AM MED ASSOC, V282, P2051, DOI 10.1001/jama.282.21.2051; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; Blumenthal RS, 2000, AM HEART J, V139, P577, DOI 10.1016/S0002-8703(00)90033-4; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown WV, 2001, AM J CARDIOL, V87, p23B; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Chong PH, 2000, DRUGS, V60, P55, DOI 10.2165/00003495-200060010-00005; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; HAM J, 1991, EMBO J, V10, P2931, DOI 10.1002/j.1460-2075.1991.tb07843.x; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; KOVANEN PT, 1999, ADV VASC BIOL, V5, P165; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; Makar RSJ, 2000, J LIPID RES, V41, P762; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Natarajan R, 1998, BIOCHEM BIOPH RES CO, V243, P349, DOI 10.1006/bbrc.1997.8030; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Olsson AG, 2001, AM J CARDIOL, V87, p33B; Sakai J, 2001, CURR OPIN LIPIDOL, V12, P261, DOI 10.1097/00041433-200106000-00004; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Thompson GR, 2000, EXPERT OPIN INV DRUG, V9, P2619, DOI 10.1517/13543784.9.11.2619; Vaughan CJ, 2000, J AM COLL CARDIOL, V35, P1, DOI 10.1016/S0735-1097(99)00525-2; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200	36	59	73	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1332	1338		10.1038/nm1201-1332	http://dx.doi.org/10.1038/nm1201-1332			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726974				2022-12-25	WOS:000172610300039
J	Leegwater, PAJ; Vermeulen, G; Konst, AAM; Naidu, S; Mulders, J; Visser, A; Kersbergen, P; Mobach, D; Fonds, D; van Berkel, CGM; Lemmers, RJLF; Frants, RR; Oudejans, CBM; Schutgens, RBH; Pronk, JC; van der Knaap, MS				Leegwater, PAJ; Vermeulen, G; Konst, AAM; Naidu, S; Mulders, J; Visser, A; Kersbergen, P; Mobach, D; Fonds, D; van Berkel, CGM; Lemmers, RJLF; Frants, RR; Oudejans, CBM; Schutgens, RBH; Pronk, JC; van der Knaap, MS			Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter	NATURE GENETICS			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GLYCOGEN-SYNTHASE KINASE-3; SIGNAL-TRANSDUCTION; EPSILON-SUBUNIT; IDENTIFICATION; EIF2B-EPSILON; INACTIVATION; DOMAINS; INSULIN; YEAST	Leukoencephalopathy with vanishing white matter (VWM) is an inherited brain disease that occurs mainly in children. The course is chronic-progressive with additional episodes of rapid deterioration following febrile infection or minor head trauma. We have identified mutations in EIF2B5 and EIF2B2, encoding the epsilon- and beta -subunits of the translation initiation factor eIF2B and located on chromosomes 3q27 and 14q24, respectively, as causing VWM. We found 16 different mutations in EIF2B5 in 29 patients from 23 families. We also found two distantly related individuals who were homozygous with respect to a missense mutation in EIF2B2, affecting a conserved amino acid. Three other patients also had mutations in EIF2B2. As eIF2B has an essential role in the regulation of translation under different conditions, including stress, this may explain the rapid deterioration of people with VWM under stress. Mutant translation initiation factors have not previously been implicated in disease.	Free Univ Amsterdam, Med Ctr, Dept Human Genet, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Clin Chem, NL-1081 BT Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Child Neurol, NL-1081 BT Amsterdam, Netherlands; Kennedy Krieger Inst, Dept Neurogenet, Baltimore, MD USA; Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Kennedy Krieger Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Pronk, JC (corresponding author), Free Univ Amsterdam, Med Ctr, Dept Human Genet, Van Der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.			Leegwater, Peter/0000-0002-4100-015X; Oudejans, Cees/0000-0003-0717-4946				Anthony TG, 2000, BBA-GENE STRUCT EXPR, V1492, P56, DOI 10.1016/S0167-4781(00)00062-2; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; Delepine M, 2000, NAT GENET, V25, P406, DOI 10.1038/78085; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; HANEFELD F, 1993, NEUROPEDIATRICS, V24, P244, DOI 10.1055/s-2008-1071551; HINNEBUSCH AG, 1996, TRANSLATIONAL CONTRO, P194; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Leegwater PAJ, 1999, AM J HUM GENET, V65, P728, DOI 10.1086/302548; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Scheper GC, 1998, BIOCHEM J, V334, P463, DOI 10.1042/bj3340463; SCHIFFMANN R, 1994, ANN NEUROL, V35, P331, DOI 10.1002/ana.410350314; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; van der Knaap MS, 1998, NEUROLOGY, V51, P540, DOI 10.1212/WNL.51.2.540; vanderKnaap MS, 1997, NEUROLOGY, V48, P845, DOI 10.1212/WNL.48.4.845; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2	23	285	303	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					383	388		10.1038/ng764	http://dx.doi.org/10.1038/ng764			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11704758				2022-12-25	WOS:000172507500012
J	Zou, WP; Machelon, V; Coulomb-L'Hermin, A; Borvak, J; Nome, F; Isaeva, T; Wei, S; Krzysiek, R; Durand-Gasselin, I; Gordon, A; Pustilnik, T; Curiel, DT; Galanaud, P; Capron, F; Emilie, D; Curiel, TJ				Zou, WP; Machelon, V; Coulomb-L'Hermin, A; Borvak, J; Nome, F; Isaeva, T; Wei, S; Krzysiek, R; Durand-Gasselin, I; Gordon, A; Pustilnik, T; Curiel, DT; Galanaud, P; Capron, F; Emilie, D; Curiel, TJ			Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells	NATURE MEDICINE			English	Article							T-CELLS; CHEMOKINE RECEPTORS; GENE-EXPRESSION; BREAST; DIFFERENTIATION; VACCINATION; MATURATION; IMMATURE; ACTIVATION; MONOCYTES	Dendritic-cell (DQ trafficking and function in tumors is poorly characterized, with studies confined to myeloid DCs (DC1s). Tumors inhibit DC1 migration and function, likely hindering specific immunity. The role of plasmacytoid DCs (DC2s) in tumor immunity is unknown. We show here that malignant human ovarian epithelial tumor cells express very: high levels of stromal-derived factor-1, which induces DC2 precursor (preDC2) chemotaxis and adhesion/transmigration, upregulates preDC2 very late antigen (VLA)-5, and protects preDC2s from tumor macrophage interleukin-10-induced apoptosis, all through CXC chemokine receptor-4. The VLA-5 ligand vascular-cell adhesion molecule-1 mediated preDC2 adhesion/transmig ration. Tumor preDC2s induced significant T-cell interleukin-10 unrelated to preDC2 differentiation or activation state, and this contributed to poor T-cell activation. Myeloid precursor DCs (preDC1s) were not detected. Tumors may weaken immunity by attracting preDC2s and protecting them from the harsh microenvironment, and by altering preDC1 distribution.	Tulane Univ, Sch Med, Sect Hematol & Med Oncol, New Orleans, LA 70112 USA; Baylor Inst Immunol Res, Dallas, TX USA; Inst Paris Sud Cytokines, INSERM, U355, Clamart, France; Hop Antoine Beclere, Serv Anat Pathol, Clamart, France; Inst Paris Sud Cytokines, INSERM, U131, Clamart, France; Baylor Univ, Med Ctr, Dallas, TX USA; Univ Alabama Birmingham, Wallace Tumor Inst, Birmingham, AL USA	Tulane University; Baylor Scott & White Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Baylor University; Baylor University Medical Center; University of Alabama System; University of Alabama Birmingham	Zou, WP (corresponding author), Tulane Univ, Sch Med, Sect Hematol & Med Oncol, 1430 Tulane Ave, New Orleans, LA 70112 USA.	wzou@tulane.edu; tcuriel@tulane.edu						Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beatty P, 2001, CLIN CANCER RES, V7, p781S; Bell D, 1999, J EXP MED, V190, P1417, DOI 10.1084/jem.190.10.1417; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3; Foti M, 1999, INT IMMUNOL, V11, P979, DOI 10.1093/intimm/11.6.979; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gabrilovich DI, 1997, CLIN CANCER RES, V3, P483; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Groux H, 1998, J IMMUNOL, V160, P3188; Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Ito T, 1999, J IMMUNOL, V163, P1409; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kellermann SA, 1999, J IMMUNOL, V162, P3859; Kiertscher SM, 2000, J IMMUNOL, V164, P1269, DOI 10.4049/jimmunol.164.3.1269; Kohrgruber N, 1999, J IMMUNOL, V163, P3250; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nanki T, 2000, J IMMUNOL, V164, P5010, DOI 10.4049/jimmunol.164.10.5010; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Rabinowich H, 1996, INT J CANCER, V68, P276, DOI 10.1002/(SICI)1097-0215(19961104)68:3<276::AID-IJC2>3.3.CO;2-0; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROERS A, 1994, J INFECT DIS, V169, P807, DOI 10.1093/infdis/169.4.807; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rubbert A, 1998, J IMMUNOL, V160, P3933; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Tillman BW, 1999, J IMMUNOL, V162, P6378; Tilton B, 2000, J EXP MED, V192, P313, DOI 10.1084/jem.192.3.313; ZOU W, IN PRESS EUR J IMMUN; Zou W., 2001, DENDRITIC CELLS BIOL, P77; Zou WP, 2000, J IMMUNOL, V165, P4388, DOI 10.4049/jimmunol.165.8.4388; Zou WP, 1995, EUR CYTOKINE NETW, V6, P257	47	491	530	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1339	1346		10.1038/nm1201-1339	http://dx.doi.org/10.1038/nm1201-1339			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726975				2022-12-25	WOS:000172610300040
J	Gruenheid, S; DeVinney, R; Bladt, F; Goosney, D; Gelkop, S; Gish, GD; Pawson, T; Finlay, BB				Gruenheid, S; DeVinney, R; Bladt, F; Goosney, D; Gelkop, S; Gish, GD; Pawson, T; Finlay, BB			Enteropathogenic E-coli Tir binds Nck to initiate actin pedestal formation in host cells	NATURE CELL BIOLOGY			English	Article							TRANSLOCATED INTIMIN RECEPTOR; ADAPTER PROTEIN; POLYMERIZATION; COMPLEX; WASP	Enteropathogenic Escherichia coli (EPEC) is a bacterial pathogen that causes infantile diarrhea worldwide(1). EPEC injects a bacterial protein, translocated intimin receptor (Tir), into the host-cell plasma membrane where it acts as a receptor for the bacterial outer membrane protein, intimin(2). The interaction of Tir and intimin triggers a marked rearrangement of the host actin cytoskeleton into pedestals beneath adherent bacteria. On delivery into host cells, EPEC Tir is phosphorylated on tyrosine 474 of the intracellular carboxy-terminal domain, an event that is required for pedestal formation(3). Despite its essential role, the function of Tir tyrosine phosphorylation has not yet been elucidated. Here we show that tyrosine 474 of Tir directly binds the host-cell adaptor protein Nck, and that Nck is required for the recruitment of both neural Wiskott-Aldrich-syndrome protein (N-WASP) and the actin-related protein (Arp)2/3 complex to the EPEC pedestal, directly linking Tir to the cytoskeleton. Cells with null alleles of both mammalian Nick genes are resistant to the effects of EPEC on the actin cytoskeleton. These results implicate Nick adaptors as host-cell determinants of EPEC virulence.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1G3, Canada; Mt Sinai Hosp, Program Mol Biol & Canc, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of British Columbia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Finlay, BB (corresponding author), Univ British Columbia, Biotechnol Lab, 6174 Univ Blvd, Vancouver, BC V6T 1G3, Canada.	bfinlay@interchange.ubc.ca	Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Gruenheid, Samantha/0000-0002-0908-6715				Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Coutinho S, 2000, BLOOD, V96, P618; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DeVinney R, 1999, INFECT IMMUN, V67, P2389, DOI 10.1128/IAI.67.5.2389-2398.1999; FORTINEAU N, 1998, 98 ANN GEN M AM SOC; Freeman NL, 2000, CELL MOTIL CYTOSKEL, V47, P307, DOI 10.1002/1097-0169(200012)47:4<307::AID-CM5>3.0.CO;2-Q; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Goosney DL, 2000, CURR BIOL, V10, P735, DOI 10.1016/S0960-9822(00)00543-1; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; LEVIN RH, 1978, REACTIVE INTERMEDIAT, V1, P1; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Marches O, 2000, INFECT IMMUN, V68, P2171, DOI 10.1128/IAI.68.4.2171-2182.2000; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; Rockow S, 1996, ONCOGENE, V12, P2351; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Todd Ewen C. D., 1997, World Health Statistics Quarterly, V50, P30; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	279	292	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					856	859		10.1038/ncb0901-856	http://dx.doi.org/10.1038/ncb0901-856			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533668				2022-12-25	WOS:000170979600022
J	Ando, H; Furuta, T; Tsien, RY; Okamoto, H				Ando, H; Furuta, T; Tsien, RY; Okamoto, H			Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos	NATURE GENETICS			English	Article							TRANSGENIC ZEBRAFISH; EXPRESSION; BOUNDARY; BRAIN	We report a new and simple technique for photo-mediated temporal and spatial control of gene activation in zebrafish embryos as an alternative to the gene 'knockdown' approach using antisense, morpholino-modified oligonucleotides (morpholinos). The synthetic compound 6-bromo-4-diazomethyl-7-hydroxycoumarin (Bhc-diazo) forms a covalent bond with the phosphate moiety of the sugar-phosphate backbone of RNA, a process known as caging. The 6-bromo-7-hydroxycoumarin-4-ylmethyl (Bhc) group binds to approximately 30 sites on the phosphate moieties per 1 kb of RNA sequence. Bhc-caged mRNA undergoes photolysis (uncaging) when exposed to long-wave ultraviolet light (350 to 365 nm). We show that Bhc-caged green fluorescent protein (Gfp) mRNA has severely reduced translational activity in vitro, whereas illumination of Bhc-caged mRNA with ultraviolet light leads to partial recovery of translational activity. Bhc-caged mRNA is highly stable in zebrafish embryos. in embryos injected with Bhc-caged Gfp mRNA at the one-cell stage, GFP protein expression and fluorescence is specifically induced by ultraviolet light. We also show that, consistent with results obtained using other methods, uncaging eng2a (which encodes the, transcription factor Engrailed2a) in the head region during early development causes a severe reduction in the size of the eye and enhanced development of the midbrain and the midbrain-hindbrain boundary at the expense of the forebrain.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Dev Gene Regulat, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Chuo Ku, Tokyo 1030027, Japan; Toho Univ, Dept Biomol Sci, Chiba 2748510, Japan; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	RIKEN; Japan Science & Technology Agency (JST); Toho University; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Okamoto, H (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Lab Dev Gene Regulat, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hitoshi@brain.riken.go.jp	Furuta, Toshiaki/F-1363-2011; Okamoto, Hitoshi/P-9767-2015	Furuta, Toshiaki/0000-0001-8532-1775; Okamoto, Hitoshi/0000-0002-7512-8549	NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki I, 1999, DEVELOPMENT, V126, P5127; Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Cambridge SB, 1997, SCIENCE, V277, P825, DOI 10.1126/science.277.5327.825; Chaulk SG, 1998, NUCLEIC ACIDS RES, V26, P3173, DOI 10.1093/nar/26.13.3173; Cruz FG, 2000, J AM CHEM SOC, V122, P8777, DOI 10.1021/ja001804h; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; DRIEVER W, 1994, TRENDS GENET, V10, P152, DOI 10.1016/0168-9525(94)90091-4; EKKER M, 1992, DEVELOPMENT, V116, P1001; FJOSE A, 1992, MECH DEVELOP, V39, P51, DOI 10.1016/0925-4773(92)90025-F; Furuta T, 1998, Methods Enzymol, V291, P50; Furuta T, 1999, P NATL ACAD SCI USA, V96, P1193, DOI 10.1073/pnas.96.4.1193; Furuta T., 2000, USA Patent, Patent No. [0031588, WO/00/31588]; Higashijima S, 2000, J NEUROSCI, V20, P206, DOI 10.1523/JNEUROSCI.20-01-00206.2000; Higashijima S, 1997, DEV BIOL, V192, P289, DOI 10.1006/dbio.1997.8779; ITO K, 1983, CHEM PHARM BULL, V31, P3014; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; Kikuchi Y, 1997, NEURON, V18, P369, DOI 10.1016/S0896-6273(00)81239-8; KIMMEL CB, 1993, ANNU REV NEUROSCI, V16, P707, DOI 10.1146/annurev.ne.16.030193.003423; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; MARCH J, 1992, ADV ORG CHEM, P385; Miller JH., 1972, EXPT MOL GENETICS; Monroe WT, 1999, J BIOL CHEM, V274, P20895, DOI 10.1074/jbc.274.30.20895; MORI H, 1994, MOL BRAIN RES, V27, P221, DOI 10.1016/0169-328X(94)90004-3; MORITA T, 1995, NEUROSCI LETT, V198, P131, DOI 10.1016/0304-3940(95)11988-9; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Reifers F, 1998, DEVELOPMENT, V125, P2381; Ristoratore F, 1999, DEVELOPMENT, V126, P3769; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Scheer N, 1999, MECH DEVELOP, V80, P153, DOI 10.1016/S0925-4773(98)00209-3; SCHULTEMERKER S, 1995, ZEBRAFISH BOOK GUIDE; Segawa H, 2001, NEURON, V30, P423, DOI 10.1016/S0896-6273(01)00283-5; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; Wilson Stephen W., 1992, Current Opinion in Neurobiology, V2, P9, DOI 10.1016/0959-4388(92)90154-D; Wulfman D.S., 1978, CHEM ISTRY DIAZONIUM, P821	39	295	308	1	85	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					317	325		10.1038/ng583	http://dx.doi.org/10.1038/ng583			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479592				2022-12-25	WOS:000170174800011
J	Clarke, DJ; Segal, M; Jensen, S; Reed, SI				Clarke, DJ; Segal, M; Jensen, S; Reed, SI			Mec1p regulates Pds1p levels in S phase: complex coordination of DNA replication and mitosis	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID SEPARATION; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; ANAPHASE INHIBITOR; MITOTIC EXIT; CHECKPOINT PATHWAYS; DAMAGE CHECKPOINT; CYCLE CHECKPOINT; KINASE; SPINDLE	Genetic evidence suggests that the securin Pds1p is the target of a late-S-phase checkpoint control. Here we show that Pds1p becomes essential once two-thirds of the genome has been replicated and that the coupling of the completion of genome replication with mitosis relies on the regulation of Pds1p levels. Mec1p is needed to maintain Pds1p levels under S-phase checkpoint conditions. In contrast, Rad53p and Chk1p, needed for the stabilization of Pds1p in the context of the G2 DNA-damage checkpoint pathway, are dispensable. Thus, the Pds1p-dependent late-S-phase checkpoint pathway couples replication with mitosis but is mechanistically distinct from the G2 DNA-damage checkpoint. Finally, we show that the inhibition of spindle elongation in early S phase, controlled by the Mec1p/Rad53p branch, is not regulated via Pds1p/Esp1p. This can mechanistically explain the need for branched S-phase checkpoint controls.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Clarke, Duncan/0000-0002-7795-3294; Segal, Marisa/0000-0003-1848-9388				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Clarke DJ, 1999, CURR BIOL, V9, P365, DOI 10.1016/S0960-9822(99)80163-8; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Jensen S, 2001, J CELL BIOL, V152, P27, DOI 10.1083/jcb.152.1.27; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Mondesert G, 1997, GENETICS, V147, P421; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Segal M, 1998, J CELL BIOL, V143, P135, DOI 10.1083/jcb.143.1.135; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	36	38	39	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					619	627		10.1038/35083009	http://dx.doi.org/10.1038/35083009			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433293				2022-12-25	WOS:000169727000012
J	Turk, BE; Huang, LL; Piro, ET; Cantley, LC				Turk, BE; Huang, LL; Piro, ET; Cantley, LC			Determination of protease cleavage site motifs using mixture-based oriented peptide libraries	NATURE BIOTECHNOLOGY			English	Article							SUBSTRATE-SPECIFICITY; MATRIX METALLOPROTEINASES; CHONDROITIN SULFATE; ALPHA-1-PROTEINASE INHIBITOR; HUMAN FIBROBLAST; AMINO-ACIDS; COLLAGENASE; STROMELYSIN; GELATINASE; PROTEOGLYCANS	The number of known proteases is increasing at a tremendous rate as a consequence of genome sequencing projects. Although one can guess at the functions of these novel enzymes by considering sequence homology to known proteases, there is a need for new tools to rapidly provide functional information on large numbers of proteins. We describe a method for determining the cleavage site specificity of proteolytic enzymes that involves pooled sequencing of peptide library mixtures. The method was used to determine cleavage site motifs for six enzymes in the matrix metalloprotease (MMP) family. The results were validated by comparison with previous literature and by analyzing the cleavage of individually synthesized peptide substrates. The library data led us to identify the proteoglycan neurocan as a novel MMP-2 substrate. Our results indicate that a small set of libraries can be used to quickly profile an expanding protease family, providing information applicable to the design of inhibitors and to the identification of protein substrates.	Harvard Univ, Sch Med, Dept Cell Biol, Beth Israel Deaconess Med Ctr,Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Cantley, LC (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Beth Israel Deaconess Med Ctr,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	cantley@helix.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM056203, GM19895-01, GM56203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019895, R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold D, 1997, EUR J BIOCHEM, V249, P171, DOI 10.1111/j.1432-1033.1997.t01-1-00171.x; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BERMAN J, 1992, J BIOL CHEM, V267, P1434; BIRKETT AJ, 1991, ANAL BIOCHEM, V196, P137, DOI 10.1016/0003-2697(91)90129-H; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; Fernandez-Patron C, 1999, CIRC RES, V85, P906; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; Netzer R. H. B., 1993, IEEE Parallel & Distributed Technology: Systems & Applications, V1, P32, DOI 10.1109/88.260289; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; PETITHORY JR, 1991, P NATL ACAD SCI USA, V88, P11510, DOI 10.1073/pnas.88.24.11510; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ridky TW, 1996, J BIOL CHEM, V271, P4709, DOI 10.1074/jbc.271.9.4709; Sasaki T, 1997, J BIOL CHEM, V272, P9237; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TEAHAN J, 1989, BIOCHEMISTRY-US, V28, P8497, DOI 10.1021/bi00447a034; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Woessner J.F., 2000, PROTEIN PROFILE SER; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	39	449	495	5	112	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					661	667		10.1038/90273	http://dx.doi.org/10.1038/90273			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433279				2022-12-25	WOS:000169677200023
J	Shao, CS; Stambrook, PJ; Tischfield, JA				Shao, CS; Stambrook, PJ; Tischfield, JA			Mitotic recombination is suppressed by chromosomal divergence in hybrids of distantly related mouse strains	NATURE GENETICS			English	Letter							IN-VIVO LOSS; NEUROFIBROMATOSIS TYPE-1; HETEROZYGOUS MICE; ESCHERICHIA-COLI; CANCER; MAP; PREDISPOSITION; POLYMORPHISMS; DEPENDENCE; HOMOLOGY	Mitotic recombination occurs with high frequency in humans(1,2) and mice(3). It leads to loss of heterozygosity (LOH) at important gene loci and can cause disease(4-7). However, the genetic modulators of mitotic recombination are not well understood. As recombination depends on a high level of nucleotide sequence homology(8-12), we postulate that the frequency of somatic variants derived from mitotic recombination should be diminished in progeny from crosses between strains of mice in which nucleotide sequences have diverged. Here we report that mitotic recombination is suppressed, to various degrees in different tissues, in hybrids of distantly related mouse strains. Reintroduction of greater chromosomal homology by backcrossing restores mitotic recombination in offspring. Thus, chromosomal divergence inhibits mitotic recombination and, consequently, may act as a modifier of cancer susceptibility by limiting the rate of LOH. The suppression of mitotic recombination in some F-1 hybrids in which meiotic recombination persists indicates that these processes are differentially affected by chromosomal divergence.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; University System of Ohio; University of Cincinnati	Shao, CS (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.		Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005652] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK38185] Funding Source: Medline; NIEHS NIH HHS [P01ES05652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chen WL, 1999, GENETICS, V151, P1299; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Gupta PK, 1997, CANCER RES, V57, P1188; Hagstrom SA, 1999, P NATL ACAD SCI USA, V96, P2952, DOI 10.1073/pnas.96.6.2952; Holt D, 1999, AM J HUM GENET, V65, P1423, DOI 10.1086/302614; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Liang L, 2000, ENVIRON MOL MUTAGEN, V35, P150, DOI 10.1002/(SICI)1098-2280(2000)35:2<150::AID-EM10>3.3.CO;2-S; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Qian F, 1997, AM J HUM GENET, V61, P1000, DOI 10.1086/301618; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; SHEN P, 1986, GENETICS, V112, P441; Van Sloun PPH, 1998, NUCLEIC ACIDS RES, V26, P4888, DOI 10.1093/nar/26.21.4888; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350	24	54	55	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					169	172		10.1038/88897	http://dx.doi.org/10.1038/88897			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381266				2022-12-25	WOS:000169011800021
J	Wallace, RH; Marini, C; Petrou, S; Harkin, LA; Bowser, DN; Panchal, RG; Williams, DA; Sutherland, GR; Mulley, JC; Scheffer, IE; Berkovic, SF				Wallace, RH; Marini, C; Petrou, S; Harkin, LA; Bowser, DN; Panchal, RG; Williams, DA; Sutherland, GR; Mulley, JC; Scheffer, IE; Berkovic, SF			Mutant GABA(A) receptor gamma 2-subunit in childhood absence epilepsy and febrile seizures	NATURE GENETICS			English	Article							IDIOPATHIC GENERALIZED EPILEPSIES; POTASSIUM CHANNEL GENE; SUBUNIT; LINKAGE; MUTATION; ASSOCIATION; CLUSTER	Epilepsies affect at least 2% of the population at some time in life, and many forms have genetic determinants(1,2). We have found a mutation in a gene encoding a GABA, receptor subunit in a large family with epilepsy. The two main phenotypes were childhood absence epilepsy (CAE) and febrile seizures (FS), There is a recognized genetic: relationship between FS and CAE, yet the two syndromes have different ages of onset, and the physiology of absences and convulsions is distinct. This suggests the mutation has age-dependent effects on different neuronal networks that influence the expression of these clinically distinct, but genetically related, epilepsy phenotypes. We found that the mutation in GABRG2 (encoding the gamma2-subunit) abolished in vitro sensitivity to diazepam, raising the possibility that endozepines do in fact exist and have a physiological role in preventing seizures.	Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, Adelaide, SA, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA, Australia; Univ Adelaide, Dept Genet, Adelaide, SA, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Epilepsy Res Inst, Heidelberg, Vic, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med Neurol, Heidelberg, Vic, Australia; Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Dept Neurol, Parkville, Vic 3052, Australia	Womens & Childrens Hospital Australia; University of Adelaide; University of Adelaide; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne	Wallace, RH (corresponding author), Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, Adelaide, SA, Australia.	rwallace@wch.bionomics.com.au	Scheffer, Ingrid E/G-1668-2013; jiang, yu/HGU-0029-2022; Sutherland, Grant Robert/D-2606-2012; Marini, Carla/AAC-2413-2022; Petrou, Steven/M-8332-2013; Panchal, Rekha/None	Scheffer, Ingrid E/0000-0002-2311-2174; Marini, Carla/0000-0002-9212-2691; Berkovic, Samuel/0000-0003-4580-841X; Petrou, Steven/0000-0002-4960-6375; Bowser, David/0000-0002-8974-9442; Wallace, Robyn/0000-0001-6141-3317; Panchal, Rekha/0000-0001-8621-9078				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BIANCHI A, 1993, EPILEPSIA, V34, P819; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROOKSKAYAL AR, 1993, ANN NEUROL, V34, P687, DOI 10.1002/ana.410340511; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; De Fusco M, 2000, NAT GENET, V26, P275; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; Feucht M, 1999, BIOL PSYCHIAT, V46, P997, DOI 10.1016/S0006-3223(99)00039-6; Fong GCY, 1998, AM J HUM GENET, V63, P1117, DOI 10.1086/302066; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Knudsen FU, 2000, EPILEPSIA, V41, P2, DOI 10.1111/j.1528-1157.2000.tb01497.x; Kucken AM, 2000, MOL PHARMACOL, V57, P932; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Olsen RW, 1997, EPILEPSIA, V38, P399, DOI 10.1111/j.1528-1157.1997.tb01728.x; Sander T, 1999, AM J MED GENET, V88, P305, DOI 10.1002/(SICI)1096-8628(19990820)88:4<305::AID-AJMG5>3.0.CO;2-X; Sander T, 1997, ACTA NEUROL SCAND, V96, P1; Sander T, 1996, EPILEPSY RES, V23, P235, DOI 10.1016/0920-1211(95)00098-4; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Scheffer IE, 2000, CURR OPIN PEDIATR, V12, P536, DOI 10.1097/00008480-200012000-00004; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Snead O C 3rd, 1999, Adv Neurol, V79, P253; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252	27	622	664	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					49	52		10.1038/ng0501-49	http://dx.doi.org/10.1038/ng0501-49			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326275				2022-12-25	WOS:000168413300015
J	Jonkers, J; Meuwissen, R; van der Gulden, H; Peterse, H; van der Valk, M; Berns, A				Jonkers, J; Meuwissen, R; van der Gulden, H; Peterse, H; van der Valk, M; Berns, A			Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer	NATURE GENETICS			English	Article							SUSCEPTIBILITY GENE; P53-DEFICIENT MICE; TRANSGENIC MICE; DNA-REPAIR; STEM-CELLS; MUTATION; RAD51; SPECTRUM; DELETION; TUMORIGENESIS	Inheritance of one defective BRCA2 allele predisposes humans to breast cancer, To establish a mouse model for BRCA2-associated breast cancer, we generated mouse conditional mutants with BRCA2 and/or p53 inactivated in various epithelial tissues, including mammary-gland epithelium. Although no tumors arose in mice carrying conditional Brca2 alleles, mammary and skin tumors developed frequently in females carrying conditional Brca2 and Trp53 alleles. The presence of one wildtype Brca2 allele resulted in a markedly delayed tumor formation; loss of the wildtype Brca2 allele occurred in a subset of these tumors. Our results show that inactivation of BRCA2 and of p53 combine to mediate mammary tumorigenesis, and indicate that disruption of the p53 pathway is pivotal in BRCA2-associated breast cancer.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792				Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bogliolo M, 2000, ONCOGENE, V19, P5781, DOI 10.1038/sj.onc.1203951; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Friedman LS, 1998, CANCER RES, V58, P1338; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hogan B, 1994, MANIPULATING MOUSE E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PURDIE CA, 1994, ONCOGENE, V9, P603; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Ramus SJ, 1999, GENE CHROMOSOME CANC, V25, P91, DOI 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Sambrook J., 2002, MOL CLONING LAB MANU; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Venkitaraman AR, 2000, PHILOS T R SOC B, V355, P191, DOI 10.1098/rstb.2000.0558; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yu VPCC, 2000, GENE DEV, V14, P1400; 1999, J NATL CANC I, V91, P1310	50	779	798	1	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					418	425		10.1038/ng747	http://dx.doi.org/10.1038/ng747			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11694875				2022-12-25	WOS:000172507500017
J	Waters, VL				Waters, VL			Conjugation between bacterial and mammalian cells	NATURE GENETICS			English	Article							DNA TRANSFER; AGROBACTERIUM-TUMEFACIENS; TI PLASMIDS; INCP; YEAST; TRANSFORMATION	Bacterial conjugation, in which DNA is transferred from one bacterium to another, was first reported in 1946 and found to be mediated by the F factor(1). Although the F and RK2/RP4 prototypic plasmids can mediate the transfer of DNA from bacteria to yeast(2), there has been no evidence of classical bacterial conjugation to higher eukaryotes. Here, I present evidence of such transfer, using Escherichia coli, the RK2 plasmid system and Chinese hamster ovary CHO K1 cells.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Waters, VL (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA.	vwaters@ucsd.edu						BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; Haase J, 1997, J BACTERIOL, V179, P5728, DOI 10.1128/jb.179.18.5728-5735.1997; HEINEMANN JA, 1993, MOL MICROBIOL, V10, P57, DOI 10.1111/j.1365-2958.1993.tb00903.x; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; INOMATA K, 1994, J BACTERIOL, V176, P4770, DOI 10.1128/JB.176.15.4770-4773.1994; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEDERBERG J, 1946, NATURE, V158, P558, DOI 10.1038/158558a0; Piers KL, 1996, P NATL ACAD SCI USA, V93, P1613, DOI 10.1073/pnas.93.4.1613; Schubbert R, 1998, MOL GEN GENET, V259, P569, DOI 10.1007/s004380050850; SIA EA, 1995, J BACTERIOL, V177, P2789, DOI 10.1128/jb.177.10.2789-2797.1995; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; WATERS VL, 1992, J BACTERIOL, V174, P6666, DOI 10.1128/JB.174.20.6666-6673.1992; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456	15	117	136	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					375	376		10.1038/ng779	http://dx.doi.org/10.1038/ng779			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726922				2022-12-25	WOS:000172507500008
J	Rovio, AT; Marchington, DR; Donat, S; Schuppe, HC; Abe, J; Fritsche, E; Elliott, DJ; Laippala, P; Ahola, AL; McNay, D; Harrison, RF; Hughes, B; Barrett, T; Bailey, DMD; Mehmet, D; Jequier, AM; Hargreave, TB; Kao, SH; Cummins, JM; Barton, DE; Cooke, HJ; Wei, YH; Wichmann, L; Poulton, J; Jacobs, HT				Rovio, AT; Marchington, DR; Donat, S; Schuppe, HC; Abe, J; Fritsche, E; Elliott, DJ; Laippala, P; Ahola, AL; McNay, D; Harrison, RF; Hughes, B; Barrett, T; Bailey, DMD; Mehmet, D; Jequier, AM; Hargreave, TB; Kao, SH; Cummins, JM; Barton, DE; Cooke, HJ; Wei, YH; Wichmann, L; Poulton, J; Jacobs, HT			Mutations at the mitochondrial DNA polymerase (POLG) locus associated with male infertility	NATURE GENETICS			English	Article							MOTILITY; SPERMATOZOA; CELLS	Human mitochondrial DNA polymerase, encoded by POLG, contains a polyglutamine tract encoded by a CAG microsatellite repeat(1,2). Analysis of POLG genotypes in different populations identified an association between absence of the common, ten-repeat allele and male infertility typified by a range of sperm quality defects but excluding azoospermia.	Ancobio Ltd, Glasgow, Lanark, Scotland; Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Tampere Univ, Dept Anat, FIN-33101 Tampere, Finland; Tampere Univ, Sch Publ Hlth, Biometry Unit, FIN-33101 Tampere, Finland; Univ Oxford, Dept Paediat, Oxford OX1 2JD, England; Univ Dusseldorf, Med Inst Environm Hyg, Dept Expt Toxicol, D-4000 Dusseldorf, Germany; Univ Giessen, Ctr Dermatol & Androl, Giessen, Germany; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; Rotunda Hosp, Human Assisted Reprod Ireland, Dublin, Ireland; Univ Coll Dublin, Natl Ctr Med Genet, Dublin 2, Ireland; Murdoch Univ, Div Vet & Biomed Sci, Murdoch, WA 6150, Australia; Joondalup Hlth Campus, Perth, WA, Australia; Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland; Natl Yang Ming Univ, Dept Biochem, Taipei 112, Taiwan; Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University; University of Oxford; Heinrich Heine University Dusseldorf; Justus Liebig University Giessen; University of Edinburgh; University College Dublin; Murdoch University; University of Edinburgh; National Yang Ming Chiao Tung University; University of Glasgow	Jacobs, HT (corresponding author), Ancobio Ltd, Glasgow, Lanark, Scotland.	howy.jacobs@uta.fi	Poulton, Joanna/AAB-4828-2021; Barton, David E/I-1795-2019; Barton, David E/B-9460-2008; Wei, Yau-Huei/ABA-6841-2021; Jacobs, Howard T/G-2434-2011	Barton, David E/0000-0002-2031-9719; Wei, Yau-Huei/0000-0002-6429-2546; Jacobs, Howard/0000-0003-1895-6003; Kao, Shu-Huei/0000-0003-4618-0898; Poulton, Joanna/0000-0002-2460-5587; Elliott, David/0000-0002-6930-0699; McNay, David/0000-0002-4747-0136				CUMMINS JM, 1994, MOL REPROD DEV, V37, P345, DOI 10.1002/mrd.1080370314; Hargreave TB, 2000, BRIT MED BULL, V56, P650, DOI 10.1258/0007142001903454; John JCS, 1997, NAT MED, V3, P124, DOI 10.1038/nm0297-124c; Kao SH, 1998, MOL HUM REPROD, V4, P657, DOI 10.1093/molehr/4.7.657; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Lestienne P, 1997, MOL HUM REPROD, V3, P811, DOI 10.1093/molehr/3.9.811; Mifsud A, 2001, FERTIL STERIL, V75, P275, DOI 10.1016/S0015-0282(00)01693-9; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Rovio A, 1999, EUR J HUM GENET, V7, P140, DOI 10.1038/sj.ejhg.5200244; Ruiz-Pesini E, 2000, CLIN CHIM ACTA, V300, P97, DOI 10.1016/S0009-8981(00)00305-3; Ruiz-Pesini E, 1998, CLIN CHEM, V44, P1616; Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040; SOKOL RZ, 1995, CURR OPIN OBSTET GYN, V7, P177, DOI 10.1097/00001703-199506000-00004; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Troiano L, 1998, EXP CELL RES, V241, P384, DOI 10.1006/excr.1998.4064	15	142	147	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					261	262		10.1038/ng759	http://dx.doi.org/10.1038/ng759			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687794				2022-12-25	WOS:000171911000009
J	Snijders, AM; Nowak, N; Segraves, R; Blackwood, S; Brown, N; Conroy, J; Hamilton, G; Hindle, AK; Huey, B; Kimura, K; Law, S; Myambo, K; Palmer, J; Ylstra, B; Yue, JP; Gray, JW; Jain, AN; Pinkel, D; Albertson, DG				Snijders, AM; Nowak, N; Segraves, R; Blackwood, S; Brown, N; Conroy, J; Hamilton, G; Hindle, AK; Huey, B; Kimura, K; Law, S; Myambo, K; Palmer, J; Ylstra, B; Yue, JP; Gray, JW; Jain, AN; Pinkel, D; Albertson, DG			Assembly of microarrays for genome-wide measurement of DNA copy number.	NATURE GENETICS			English	Article							HYBRIDIZATION; CELLS	We have assembled arrays of approximately 2,400 BAC clones for measurement of DNA copy number across the human genome. The arrays provide precise measurement (s.d. of log(2) ratios=0.05-0.10) in cell lines and clinical material, so that we can reliably detect and quantify high-level amplifications and single-copy alterations in diploid, polyploid and heterogeneous backgrounds.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roswell Park Cancer Institute	Albertson, DG (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.		Ylstra, Bauke/D-2906-2012	Ylstra, Bauke/0000-0001-9479-3010	NCI NIH HHS [CA58207, CA84118, CA83040, CA80314] Funding Source: Medline; NICHD NIH HHS [HD17665] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017665] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA083040, R01CA080314, U01CA084118, P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Geschwind DH, 1998, DEV GENET, V23, P215, DOI 10.1002/(SICI)1520-6408(1998)23:3<215::AID-DVG7>3.0.CO;2-X; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Knight SJL, 2000, AM J HUM GENET, V67, P320, DOI 10.1086/302998; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524	7	691	791	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2001	29	3					263	264		10.1038/ng754	http://dx.doi.org/10.1038/ng754			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687795				2022-12-25	WOS:000171911000010
J	Tanaka, K; Russell, P				Tanaka, K; Russell, P			Mrc1 channels the DNA replication arrest signal to checkpoint kinase Cds1	NATURE CELL BIOLOGY			English	Article							FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; DAMAGE CHECKPOINT; S-PHASE; CELL-CYCLE; PROTEIN-KINASES; CHK1; MITOSIS; PHOSPHORYLATION; ACTIVATION	Checkpoint responses change as cells proceed through the cell cycle. Here we describe a novel checkpoint gene in fission yeast, mrc1 (mediator of replication checkpoint), that confers activation of the checkpoint kinase Cds1 to DNA synthesis (S) phase. Mrc1 associates with Cds1 and is required for regulation of Cds1 by the checkpoint kinase Rad3. Mrc1 is regulated by the cell cycle, with the appearance of Mrc1 mRNA and protein coinciding with S phase. We propose that coordinated expression of Mrc1 with replication control proteins helps to ensure activation of the appropriate checkpoint response during DNA replication.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	prussell@scripps.edu	Tanaka, Katsunori/F-8086-2010	Tanaka, Katsunori/0000-0001-9692-0968				Baber-Furnari BA, 2000, MOL BIOL CELL, V11, P1; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; Chua G, 2000, Nucleic Acids Res, V28, pE53, DOI 10.1093/nar/28.11.e53; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopez JB, 1999, INT J BIOL MARKER, V14, P172, DOI 10.1177/172460089901400309; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; OCHMAN H, 1988, GENETICS, V120, P621; Rhind N, 1998, GENETICS, V149, P1729; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	43	194	201	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					966	972		10.1038/ncb1101-966	http://dx.doi.org/10.1038/ncb1101-966			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715017				2022-12-25	WOS:000172070300011
J	Chung, KKK; Zhang, Y; Lim, KL; Tanaka, Y; Huang, H; Gao, J; Ross, CA; Dawson, VL; Dawson, TM				Chung, KKK; Zhang, Y; Lim, KL; Tanaka, Y; Huang, H; Gao, J; Ross, CA; Dawson, VL; Dawson, TM			Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease	NATURE MEDICINE			English	Article							RECESSIVE JUVENILE PARKINSONISM; OXIDATIVE STRESS; NEURODEGENERATIVE DISORDERS; NACP/ALPHA-SYNUCLEIN; 2 PARTS; BODIES; DEMENTIA; MUTATION; LIGASE; AGGREGATION	Parkinson disease is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons and the presence of intracytoplasmic-ubiquitinated inclusions (Lewy bodies). Mutations in alpha -synuclein (A53T, A30P) and parkin cause familial Parkinson disease, Both these proteins are found in Lewy bodies. The absence of Lewy bodies in patients with parkin mutations suggests that parkin might be required for the formation of Lewy bodies. Here we show that parkin interacts with and ubiquitinates the alpha -synuclein-interacting protein, synphilin-1. Coexpression of alpha -synuclein, synphilin-1 and parkin result in the formation of Lewy-body-like ubiquitin-positive cytosolic inclusions. We further show that familial-linked mutations in parkin disrupt the ubiquitination of synphilin-1 and the formation of the ubiquitin-positive inclusions. These results provide a molecular basis for the ubiquitination of Lewy-body-associated proteins and link parkin and alpha -synuclein in a common pathogenic mechanism through their interaction with synphilin-1.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Dawson, TM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	tdawson@jhmi.edu	Lim, Kah-Leong/AAY-3308-2020; Lim, Kah/L-5426-2019; Dawson, Valina/Y-9757-2019; Ross, Christopher A/H-8395-2013	Lim, Kah-Leong/0000-0002-5440-2588; Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38377] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Bayer TA, 1999, NEUROSCI LETT, V266, P213, DOI 10.1016/S0304-3940(99)00311-0; CHUNG KKK, IN PRESS TRENDS NEUR; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galvin J E, 1999, Adv Neurol, V80, P313; Gomez-Tortosa E, 2000, ACTA NEUROPATHOL, V99, P352, DOI 10.1007/s004010051135; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Ishikawa A, 1998, J NEUROL, V245, pP4, DOI 10.1007/PL00007745; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhang Y, 2000, NEUROBIOL DIS, V7, P240, DOI 10.1006/nbdi.2000.0319	45	588	611	2	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1144	1150		10.1038/nm1001-1144	http://dx.doi.org/10.1038/nm1001-1144			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590439				2022-12-25	WOS:000171524500037
J	Johnson, GCL; Esposito, L; Barratt, BJ; Smith, AN; Heward, J; Di Genova, G; Ueda, H; Cordell, HJ; Eaves, IA; Dudbridge, F; Twells, RCJ; Payne, F; Hughes, W; Nutland, S; Stevens, H; Carr, P; Tuomilehto-Wolf, E; Tuomilehto, J; Gough, SCL; Clayton, DG; Todd, JA				Johnson, GCL; Esposito, L; Barratt, BJ; Smith, AN; Heward, J; Di Genova, G; Ueda, H; Cordell, HJ; Eaves, IA; Dudbridge, F; Twells, RCJ; Payne, F; Hughes, W; Nutland, S; Stevens, H; Carr, P; Tuomilehto-Wolf, E; Tuomilehto, J; Gough, SCL; Clayton, DG; Todd, JA			Haplotype tagging for the identification of common disease genes	NATURE GENETICS			English	Article							HUMAN LIPOPROTEIN-LIPASE; DEPENDENT DIABETES-MELLITUS; LINKAGE DISEQUILIBRIUM; SEQUENCE VARIATION; DIVERSITY; REGION; SUSCEPTIBILITY; POLYMORPHISM; LOCUS	Genome-wide linkage disequilibrium (LD) mapping of common disease genes could be more powerful than linkage analysis if the appropriate density of polymorphic markers were known and if the genotyping effort and cost of producing such an LD map could be reduced. Although different metrics that measure the extent of LD have been evaluated(1-3), even the most recent studies(2,4) have not placed significant emphasis on the most informative and cost-effective method of LD mapping-that based on haplotypes. We have scanned 135 kb of DNA from nine genes, genotyped 122 single-nucleotide polymorphisms (SNPs; approximately 184,000 genotypes) and determined the common haplotypes in a minimum of 384 European individuals for each gene. Here we show how knowledge of the common haplotypes and the SNPs that tag them can be used to (i) explain the often complex patterns of LD between adjacent markers, (ii) reduce genotyping significantly (in this case from 122 to 34 SNPs), (iii) scan the common variation of a gene sensitively and comprehensively and (iv) provide key fine-mapping data within regions of strong LD. Our results also indicate that, at least for the genes studied here, the current version of dbSNP would have been of limited utility for LD mapping because many common haplotypes could not be defined. A directed re-sequencing effort of the approximately 10% of the genome in or near genes in the major ethnic groups would aid the systematic evaluation of the common variant model of common disease.	Univ Cambridge, Cambridge Inst Med Res, JDRF WT Diabet & Inflammat Lab, Cambridge, England; Univ Birmingham, Dept Med, Birmingham, W Midlands, England; Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England; Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	University of Cambridge; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; University of Birmingham; Finland National Institute for Health & Welfare; University of Helsinki	Todd, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, JDRF WT Diabet & Inflammat Lab, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge, England.		Payne, Felicity/GKF-2573-2022; Todd, John A/A-3542-2010	Payne, Felicity/0000-0003-4228-581X; Todd, John A/0000-0003-2740-8148; Dudbridge, Frank/0000-0002-8817-8908; Barratt, Bryan/0000-0002-5598-2422; Cordell, Heather/0000-0002-1879-5572				Bonnen PE, 2000, AM J HUM GENET, V67, P1437, DOI 10.1086/316908; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DEGLIESPOSTI MA, 1992, IMMUNOGENETICS, V36, P345; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Farrall M, 1999, NAT GENET, V23, P270, DOI 10.1038/15449; Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070; Harding RM, 2000, AM J HUM GENET, V66, P1351, DOI 10.1086/302863; Hollox EJ, 2001, AM J HUM GENET, V68, P160, DOI 10.1086/316924; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Joosten PHLJ, 2001, NAT GENET, V27, P215, DOI 10.1038/84867; Kidd KK, 1998, HUM GENET, V103, P211, DOI 10.1007/s004390050809; Longmate JA, 2001, AM J HUM GENET, V68, P1229, DOI 10.1086/320106; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; Marth G, 2001, NAT GENET, V27, P371, DOI 10.1038/86864; Martin ER, 2000, AM J HUM GENET, V67, P383, DOI 10.1086/303003; Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330; Morton NE, 2001, P NATL ACAD SCI USA, V98, P5217, DOI 10.1073/pnas.091062198; Mummidi S, 2000, J BIOL CHEM, V275, P18946, DOI 10.1074/jbc.M000169200; Nickerson DA, 2000, GENOME RES, V10, P1532, DOI 10.1101/gr.146900; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Rieder MJ, 1999, NAT GENET, V22, P59, DOI 10.1038/8760; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Templeton AR, 2000, GENETICS, V156, P1259; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; TODD JA, 1989, NATURE, V338, P587, DOI 10.1038/338587a0	32	918	982	1	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					233	237		10.1038/ng1001-233	http://dx.doi.org/10.1038/ng1001-233			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586306				2022-12-25	WOS:000171374100034
J	Snapper, SB; Takeshima, F; Anton, I; Liu, CH; Thomas, SM; Nguyen, D; Dudley, D; Fraser, H; Purich, D; Lopez-Ilasaca, M; Klein, C; Davidson, L; Bronson, R; Mulligan, RC; Southwick, F; Geha, R; Goldberg, MB; Rosen, FS; Hartwig, JH; Alt, FW				Snapper, SB; Takeshima, F; Anton, I; Liu, CH; Thomas, SM; Nguyen, D; Dudley, D; Fraser, H; Purich, D; Lopez-Ilasaca, M; Klein, C; Davidson, L; Bronson, R; Mulligan, RC; Southwick, F; Geha, R; Goldberg, MB; Rosen, FS; Hartwig, JH; Alt, FW			N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility	NATURE CELL BIOLOGY			English	Article							WISKOTT-ALDRICH-SYNDROME; ARP2/3 COMPLEX; SYNDROME PROTEIN; SHIGELLA-FLEXNERI; LISTERIA-MONOCYTOGENES; DEPOLYMERIZING PROTEIN; FILOPODIUM FORMATION; WASP/SCAR PROTEINS; FAMILY PROTEIN; POLYMERIZATION	The Wiskott-Aldrich syndrome protein (WASP) family of molecules integrates upstream signalling events with changes in the actin cytoskeleton. N-WASP has been implicated both in the formation of cell-surface projections (filopodia) required for cell movement and in the actin-based motility of intracellular pathogens. To examine N-WASP function we have used homologous recombination to inactivate the gene encoding murine N-WASP. Whereas N-WASP-deficient embryos survive beyond gastrulation and initiate organogenesis, they have marked developmental delay and die before embryonic day 12. N-WASP is not required for the actin-based movement of the intracellular pathogen Listeria but is absolutely required for the motility of Shigella and vaccinia virus. Despite these distinct defects in bacterial and viral motility, N-WASP-deficient fibroblasts spread by using lamellipodia and can protrude filopodia. These results imply a crucial and non-redundant role for N-WASP in murine embryogenesis and in the actin-based motility of certain pathogens but not in the general formation of actin-containing structures.	Ctr Blood Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Gastrointestinal Unit, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Beth Israel Deaconess Hosp, Div Hematol, Boston, MA 02215 USA; Univ Florida, Coll Med, Dept Infect Dis, Gainesville, FL 32601 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Beth Israel Deaconess Medical Center; State University System of Florida; University of Florida; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Snapper, SB (corresponding author), Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.		Goldberg, Marcia/U-8604-2019; Anton, Ines M/G-6090-2015	Anton, Ines M/0000-0002-2935-5919	NIAID NIH HHS [R01 AI034276, R01 AI023262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262, R01AI034276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hed J, 1986, Methods Enzymol, V132, P198; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LASKO M, 1996, P NATL ACAD SCI USA, V93, P5860; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottger S, 1999, J VIROL, V73, P2863; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; TAKAYAMA H, 1986, J CELL PHYSIOL, V128, P271, DOI 10.1002/jcp.1041280219; Takenawa T, 2001, J CELL SCI, V114, P1801; ULRICH RG, 1983, CELL MOTIL CYTOSKEL, V3, P553, DOI 10.1002/cm.970030522; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	50	261	263	1	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					897	904		10.1038/ncb1001-897	http://dx.doi.org/10.1038/ncb1001-897			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584271				2022-12-25	WOS:000171396400014
J	Wu, GH; Datar, RH; Hansen, KM; Thundat, T; Cote, RJ; Majumdar, A				Wu, GH; Datar, RH; Hansen, KM; Thundat, T; Cote, RJ; Majumdar, A			Bioassay of prostate-specific antigen (PSA) using microcantilevers	NATURE BIOTECHNOLOGY			English	Article							PROTEIN; IMMUNOSENSOR; IMMUNOASSAYS; ASSAY	Diagnosis and monitoring of complex diseases such as cancer require quantitative detection of multiple proteins. Recent work has shown that when specific biomolecular binding occurs on one surface of a microcantilever beam, intermolecular nanomechanics bend the cantilever, which can be optically detected. Although this label-free technique readily lends itself to formation of microcantilever arrays, what has remained unclear is the technologically critical issue of whether it is sufficiently specific and sensitive to detect disease-related proteins at clinically relevant conditions and concentrations. As an example, we report here that microcantilevers of different geometries have been used to detect two forms of prostate-specific antigen (PSA) over a wide range of concentrations from 0.2 ng/ml to 60 mug/ml in a background of human serum albumin (HSA) and human plasminogen (HP) at 1 mg/ml, making this a clinically relevant diagnostic technique for prostate cancer. Because cantilever motion originates from the free-energy change induced by specific biomolecular binding, this technique may offer a common platform for high-throughput label-free analysis of protein-protein binding, DNA hybridization, and DNA-protein interactions, as well as drug discovery.	Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA	University of California System; University of California Berkeley; University of Southern California; United States Department of Energy (DOE); Oak Ridge National Laboratory	Majumdar, A (corresponding author), Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.	majumdar@me.berkeley.edu		Majumdar, Arunava/0000-0003-4226-9705; Thundat, Thomas/0000-0003-1721-1181	NATIONAL CANCER INSTITUTE [R21CA086132] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA86132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blonder R, 1996, ANAL CHEM, V68, P3151, DOI 10.1021/ac960290v; Bock JL, 2000, AM J CLIN PATHOL, V113, P628, DOI 10.1309/DUDM-3Y6L-3R1L-QP15; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; Dahint R, 1999, ANAL CHEM, V71, P3150, DOI 10.1021/ac990119u; Davies H, 1999, BIOTECHNIQUES, V27, P1258; DEVINE PJ, 1995, ANAL BIOCHEM, V227, P216, DOI 10.1006/abio.1995.1273; Emmert-Buck MR, 2000, AM J PATHOL, V156, P1109, DOI 10.1016/S0002-9440(10)64979-6; Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316; Hansen KM, 2001, ANAL CHEM, V73, P1567, DOI 10.1021/ac0012748; Heegaard NHH, 1999, ELECTROPHORESIS, V20, P3122, DOI 10.1002/(SICI)1522-2683(19991001)20:15/16<3122::AID-ELPS3122>3.3.CO;2-D; Ji HF, 2000, CHEM COMMUN, P457, DOI 10.1039/a908143g; Jones VW, 1998, ANAL CHEM, V70, P1233, DOI 10.1021/ac971125y; KATZ EY, 1990, J ELECTROANAL CHEM, V291, P257, DOI 10.1016/0022-0728(90)87193-N; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; Lavrik NV, 2001, CHEM PHYS LETT, V336, P371, DOI 10.1016/S0009-2614(01)00155-5; LILJA H, 1993, UROL CLIN N AM, V20, P681; Madou M., 1997, FUNDAMENTALS MICROFA; Moulin AM, 2000, ULTRAMICROSCOPY, V82, P23, DOI 10.1016/S0304-3991(99)00145-X; Mullett W, 1998, ANAL BIOCHEM, V258, P161, DOI 10.1006/abio.1998.2616; Nicholson S, 1999, LANCET, V353, P808, DOI 10.1016/S0140-6736(98)04907-1; Ostroff RM, 1998, CLIN CHEM, V44, P2031; Piehler J, 1997, ANAL BIOCHEM, V249, P94, DOI 10.1006/abio.1997.2160; Polascik TJ, 1999, J UROLOGY, V162, P293, DOI 10.1016/S0022-5347(05)68543-6; Raiteri R, 1999, SENSOR ACTUAT B-CHEM, V61, P213; Rubio I, 1997, BIOTECHNIQUES, V22, P269, DOI 10.2144/97222bm15; Sander C, 2000, SCIENCE, V287, P1977, DOI 10.1126/science.287.5460.1977; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WHELAN JP, 1993, ANAL CHEM, V65, P3561, DOI 10.1021/ac00072a005; Wu GH, 2001, P NATL ACAD SCI USA, V98, P1560, DOI 10.1073/pnas.031362498; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576	31	845	923	7	212	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					856	860		10.1038/nbt0901-856	http://dx.doi.org/10.1038/nbt0901-856			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533645				2022-12-25	WOS:000170774000025
J	Storici, F; Lewis, LK; Resnick, MA				Storici, F; Lewis, LK; Resnick, MA			In vivo site-directed mutagenesis using oligonucleotides	NATURE BIOTECHNOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; SYNTHETIC OLIGONUCLEOTIDES; ARTIFICIAL CHROMOSOMES; DNA-REPAIR; YEAST; RECOMBINATION; GENE; TRANSFORMATION; REPLACEMENT; DISRUPTION	Functional characterization of the genes of higher eukaryotes has been aided by their expression in model organisms and by analyzing site-specific changes in homologous genes in model systems such as the yeast Saccharomyces cerevisiae(1), Modifying sequences in yeast or other organisms such that no heterologous material is retained requires in vitro mutagenesis together with subcloning(2,3). PCR-based procedures that do not involve cloning are inefficient or require multistep reactions that increase the risk of additional mutations(4,5). An alternative approach, demonstrated in yeast, relies on transformation with an oligonucleotide(6), but the method is restricted to the generation of mutants with a selectable phenotype. Oligonucleoticles, when combined with gap repair, have also been used to modify plasmids in yeast(7); however, this approach is limited by restriction-site availability. We have developed a mutagenesis approach in yeast based on transformation by unpurified oligonucleotides that allows the rapid creation of site-specific DNA mutations in vivo. A two-step, cloning-free process, referred to as delitto perfetto, generates products having only the desired mutation, such as a single or multiple base change, an insertion, a small or a large deletion, or even random mutations. The system provides for multiple rounds of mutation in a window up to 200 base pairs. The process is RAD52 dependent, is not constrained by the distribution of naturally occurring restriction sites, and requires minimal DNA sequencing. Because yeast is commonly used for random and selective cloning of genomic DNA from higher eukaryotes(8) such as yeast artificial chromosomes, the delitto perfetto strategy also provides an efficient way to create precise changes in mammalian or other DNA sequences.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		resnick, Michael/F-1668-2019	resnick, Michael/0000-0002-8473-7506	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065073, Z01ES065072, ZIAES065073] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BARTON MC, 1990, NUCLEIC ACIDS RES, V18, P7349, DOI 10.1093/nar/18.24.7349; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Brachmann CB, 1998, YEAST, V14, P115; Delneri D, 1999, YEAST, V15, P1681, DOI 10.1002/(SICI)1097-0061(199911)15:15<1681::AID-YEA486>3.0.CO;2-A; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Duno M, 1999, Nucleic Acids Res, V27, pe1, DOI 10.1093/nar/27.8.e1; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; LANGLEROUAULT F, 1995, NUCLEIC ACIDS RES, V23, P3079, DOI 10.1093/nar/23.15.3079; Larionov V, 1997, P NATL ACAD SCI USA, V94, P7384, DOI 10.1073/pnas.94.14.7384; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; MOERSCHELL RP, 1988, P NATL ACAD SCI USA, V85, P524, DOI 10.1073/pnas.85.2.524; Muyrers JPP, 2000, EMBO REP, V1, P239, DOI 10.1093/embo-reports/kvd049; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; Resnick MA, 2000, MUTAT RES-FUND MOL M, V451, P1, DOI 10.1016/S0027-5107(00)00036-1; Schaefer DG, 1997, PLANT J, V11, P1195, DOI 10.1046/j.1365-313X.1997.11061195.x; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Tucker RM, 1996, NUCLEIC ACIDS RES, V24, P3467, DOI 10.1093/nar/24.17.3467; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104	22	262	294	1	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					773	776		10.1038/90837	http://dx.doi.org/10.1038/90837			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479573				2022-12-25	WOS:000170188600031
J	Xu, Y; Hortsman, H; Seet, L; Wong, SH; Hong, W				Xu, Y; Hortsman, H; Seet, L; Wong, SH; Hong, W			SNX3 regulates endosomal function through its PX-domain-mediated interaction with Ptdlns(3)P	NATURE CELL BIOLOGY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASES; SACCHAROMYCES-CEREVISIAE; TRANSFERRIN RECEPTOR; MEMBRANE-PROTEINS; SORTING NEXIN; LATE-GOLGI; TRANSPORT; BINDING; PATHWAY	The sorting nexin (SNX) protein family is implicated in regulating membrane traffic, but the mechanism is still unknown, We show that SNX3 is associated with the early endosome through a novel motif (PX domain) capable of interaction with phosphatidylinositol-3-phosphate (Ptdlns(3)P), Overexpression of SNX3 alters endosomal morphology and delays transport to the lysosome, Transport from the early to the recycling endosome is affected upon microinjection of SNX3 antibodies, Our results highlight a novel mechanism by which SNX proteins regulate traffic and uncover a novel class of effecters for Ptdlns(3)P.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, W (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; EKENA K, 1995, MOL CELL BIOL, V15, P1671; FAINES P, 2000, CURR OPIN CELL BIOL, V12, P407; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MELLMAN I, 1996, CELL DEV BIOL, V12, P575; MIARA S, 1999, CELL, V97, P657; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SATO FT, 1998, J BIOL CHEM, V18, P5309; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; UMEDA M, 1989, J IMMUNOL, V143, P2273; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VOLINIA S, 1995, EMBO J, V14, P3319; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	47	239	245	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					658	666		10.1038/35083051	http://dx.doi.org/10.1038/35083051			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433298				2022-12-25	WOS:000169727000017
J	Thompson, DA; Li, Y; McHenry, CL; Carlson, TJ; Ding, X; Sieving, PA; Apfelstedt-Sylla, E; Gal, A				Thompson, DA; Li, Y; McHenry, CL; Carlson, TJ; Ding, X; Sieving, PA; Apfelstedt-Sylla, E; Gal, A			Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy	NATURE GENETICS			English	Article							VITAMIN-A; RPE65; PIGMENT; MOUSE	The chromophore of the visual pigments, 11-cis retinal, is derived from vitamin A tall-trans retinol) through a series of reactions that take place in retinal pigment epithelium (RPE); (ref. 1), The first of these reactions is catalyzed by lecithin retinol acyltransferase (LRAT): (ref. 2). We screened 267 retinal dystrophy patients for mutations in LRAT and identified disease-associated mutations (S175R and 396delAA) in three individuals with severe, early-onset disease. We showed that the S175R mutant has no acyltransferase activity in transfected COS-7 cells. Our findings highlight the importance of genetic defects in vitamin A metabolism as causes of retinal dystrophies and extend prospects for retinoid replacement therapy in this group of diseases.	Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI USA; Univ Hamburg, Hosp Eppendorf, Inst Human Genet, D-20246 Hamburg, Germany; Dupont Exptl Stn, Wilmington, DE USA; Univ Tubingen, Hosp Eye, Dept 2, Tubingen, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Hamburg; Eberhard Karls University of Tubingen	Thompson, DA (corresponding author), Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.	dathom@umich.edu		Thompson, Debra/0000-0003-3485-0794	NATIONAL EYE INSTITUTE [R01EY012298] Funding Source: NIH RePORTER; NEI NIH HHS [EY06094, EY07003, EY12298] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BUNGE S, 1996, METH MOL G, V8, P26; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P5215, DOI 10.1021/bi9929554; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ruiz A, 2001, INVEST OPHTH VIS SCI, V42, P31; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SHI YQ, 1993, BIOCHEMISTRY-US, V32, P1257, DOI 10.1021/bi00056a009; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Zolfaghari R, 2000, J LIPID RES, V41, P2024	15	146	158	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					123	124		10.1038/88828	http://dx.doi.org/10.1038/88828			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381255				2022-12-25	WOS:000169011800010
J	Acland, GM; Aguirre, GD; Ray, J; Zhang, Q; Aleman, TS; Cideciyan, AV; Pearce-Kelling, SE; Anand, V; Zeng, Y; Maguire, AM; Jacobson, SG; Hauswirth, WW; Bennett, J				Acland, GM; Aguirre, GD; Ray, J; Zhang, Q; Aleman, TS; Cideciyan, AV; Pearce-Kelling, SE; Anand, V; Zeng, Y; Maguire, AM; Jacobson, SG; Hauswirth, WW; Bennett, J			Gene therapy restores vision in a canine model of childhood blindness	NATURE GENETICS			English	Article							VISUAL PIGMENT; RPE65; EXPRESSION; MUTATIONS	The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor(1) and RPE diseases(2-4) that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases(5,6), but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA. type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65(-/-) dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.	Univ Penn, Scheie Eye Inst, FM Kirby Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL USA; Univ Florida, Powell Gene Therapy Ctr, Gainesville, FL USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Bennett, J (corresponding author), Univ Penn, Scheie Eye Inst, FM Kirby Ctr, Philadelphia, PA 19104 USA.	jebennet@mail.med.upenn.edu	Cideciyan, Artur V/A-1075-2007	Cideciyan, Artur V/0000-0002-2018-0905; Jacobson, Samuel/0000-0003-2122-169X	NATIONAL EYE INSTITUTE [U01EY006855, R01EY011123, R01EY006855, R01EY010820, R01EY013132, R01EY011142] Funding Source: NIH RePORTER; NEI NIH HHS [EY11142, EY13132, EY06855, EY10820, EY11123] Funding Source: Medline; NINDS NIH HHS [NS36202] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguirre G D, 1998, Mol Vis, V4, P23; Banin E, 1999, NEURON, V23, P549, DOI 10.1016/S0896-6273(00)80807-7; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; Bennett J, 2000, MOL THER, V1, P501, DOI 10.1006/mthe.2000.0080; Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920; Dudus L, 1999, VISION RES, V39, P2545, DOI 10.1016/S0042-6989(98)00308-3; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Hauswirth WW, 2000, INVEST OPHTH VIS SCI, V41, P2821; Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Phelan JK, 2000, MOL VIS, V6, P116; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Wrigstad A, 1994, THESIS LINKOPING U	20	914	985	3	104	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					92	95		10.1038/88327	http://dx.doi.org/10.1038/88327			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326284				2022-12-25	WOS:000168413300024
J	Caldwell, MA; He, XL; Wilkie, N; Pollack, S; Marshall, G; Wafford, KA; Svendsen, CN				Caldwell, MA; He, XL; Wilkie, N; Pollack, S; Marshall, G; Wafford, KA; Svendsen, CN			Growth factors regulate the survival and fate of cells derived from human neurospheres	NATURE BIOTECHNOLOGY			English	Article							NEURAL STEM-CELLS; PRECURSOR CELLS; NEURONAL DIFFERENTIATION; HUMAN CNS; IN-VITRO; TRANSPLANTATION; POPULATION; PHENOTYPE; FETAL; GENE	Cells isolated from the embryonic, neonatal, acid adult rodent central nervous system divide in response to epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF-2), while retaining the ability to differentiate into neurons and glia(1,2). These cultures can be grown in aggregates termed neurospheres, which contain a heterogeneous mix of both multipotent stem cells and more restricted progenitor populations(3,4). Neurospheres can also be generated from the embryonic human brain(5-7) and in some cases have been expanded for extended periods of time in culture(8-10). However, the mechanisms controlling the number of neurons generated from human neurospheres are poorly understood. Here we show that maintaining cell-cell contact during the differentiation stage, in combination with growth factor administration, can increase the number of neurons generated under serum-free conditions from 8% to > 60%. Neurotrophic factors 3 and 4 (NT3, NT4) and platelet-derived growth factor (PDGF) were the most potent, and acted by increasing neuronal survival rather than inducing neuronal phenotype. Following differentiation, the neurons could survive dissociation and either replating or transplantation into the adult rat brain. This experimental system provides a practically limitless supply of enriched, non-genetically transformed neurons. These should be useful for both neuroactive drug screening in vitro and possibly cell therapy for neurodegenerative diseases.	Univ Cambridge, MRC, Ctr Brain Repair, Cambridge CB2 2PY, England; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Harlow CN20 2QR, Essex, England; Univ Wisconsin, Dept Anat, Waisman Ctr Stem Cell Res Program, Madison, WI 53705 USA; Univ Wisconsin, Dept Neurol, Waisman Ctr Stem Cell Res Program, Madison, WI 53705 USA	University of Cambridge; Merck & Company; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Caldwell, MA (corresponding author), Univ Cambridge, MRC, Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 2PY, England.	mac28@hermes.cam.ac.uk	Caldwell, Maeve/HHN-1986-2022	Caldwell, Maeve/0000-0001-7442-711X; Wafford, Keith/0000-0003-4537-4690				Bjorklund A, 2000, NATURE, V405, P892, DOI 10.1038/35016175; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Emerich DF, 1996, J NEUROSCI, V16, P5168; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2000, DEV NEUROSCI-BASEL, V22, P86, DOI 10.1159/000017430; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; IP NY, 1991, J NEUROSCI, V11, P3124; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KORNACK DR, 1995, NEURON, V15, P311, DOI 10.1016/0896-6273(95)90036-5; Larkfors L, 1996, J NEUROCHEM, V66, P1362; Lindvall O, 1997, NEUROREPORT, V8, pR3, DOI 10.1097/00001756-199709290-00036; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; Piper DR, 2000, J NEUROPHYSIOL, V84, P534, DOI 10.1152/jn.2000.84.1.534; Quinn SM, 1999, J NEUROSCI RES, V57, P590, DOI 10.1002/(SICI)1097-4547(19990901)57:5<590::AID-JNR2>3.0.CO;2-X; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Svendsen C N, 2000, Prog Brain Res, V127, P13; Svendsen CN, 1997, DEV BRAIN RES, V99, P253, DOI 10.1016/S0165-3806(97)00002-3; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Williams BP, 1997, NEURON, V18, P553, DOI 10.1016/S0896-6273(00)80297-4; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	33	273	299	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					475	479		10.1038/88158	http://dx.doi.org/10.1038/88158			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329020				2022-12-25	WOS:000168394800028
J	Golovan, SP; Hayes, MA; Phillips, JP; Forsberg, CW				Golovan, SP; Hayes, MA; Phillips, JP; Forsberg, CW			Transgenic mice expressing bacterial phytase as a model for phosphorus pollution control	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI PHYTASE; SALIVARY-GLANDS; POLYACRYLAMIDE GELS; MAMMALIAN-CELLS; DIETS; PIGS; DIGESTIBILITY; PURIFICATION; EFFICACY; PROTEINS	We have developed transgenic mouse models to determine whether endogenous expression of phytase transgenes in the digestive tract of monogastric animals can increase the bioavailability of dietary phytate, a major but indigestible form of dietary phosphorus. We constructed phytase transgenes composed of the appA phytase gene from Escherichia coli regulated for expression in salivary glands by the rat R15 proline-rich protein promoter or by the mouse parotid secretory protein promoter. Transgenic phytase is highly expressed in the parotid salivary glands and secreted in saliva as an enzymatically active 55 kDa glycosylated protein. Expression of salivary phytase reduces fecal phosphorus by 11%. These results suggest that the introduction of salivary phytase transgenes into monogastric farm animals offers a promising biological approach to relieving the requirement for dietary phosphate supplements and to reducing phosphorus pollution from animal agriculture.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Guelph; University of Guelph	Phillips, JP (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.		Golovan, Serguei/A-6564-2014	Golovan, Serguei/0000-0001-5327-8522				*ASS OFF AN CHEM, 1984, OFF METH AN ASS OFF; BROWNGRANT K, 1961, NATURE, V191, P1076, DOI 10.1038/1911076a0; Canadian Council on Animal Care, 1980, GUID CAR US EXP AN, V1; Chi TH, 2000, SCIENCE, V287, P1937, DOI 10.1126/science.287.5460.1937; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORRING T, 1980, CURRENT CONCEPTS DIG, P136; Delgado C. L., 1999, Choices. The Magazine of Food, Farm, and Resources Issues, P40; EBINO KY, 1988, LAB ANIM, V22, P1, DOI 10.1258/002367788780746548; ENGELEN AJ, 1994, J AOAC INT, V77, P760; Golovan S, 2000, CAN J MICROBIOL, V46, P59, DOI 10.1139/cjm-46-1-59; Harlow E., 1988, ANTIBODIES LAB MANUA; HOGAN B, 1986, MANIPULATING MOUSE E; HU YF, 1992, AM J PHYSIOL, V263, pE607, DOI 10.1152/ajpendo.1992.263.4.E607; Hudson JJ, 2000, NATURE, V406, P54, DOI 10.1038/35017531; Jia ZC, 1998, ACTA CRYSTALLOGR D, V54, P647, DOI 10.1107/S0907444997016156; Jongbloed AW, 1998, J ANIM SCI, V76, P2641; Kemme PA, 1997, J ANIM SCI, V75, P2139; Kerr DE, 2001, NAT BIOTECHNOL, V19, P66, DOI 10.1038/83540; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Laursen J, 1997, GENE, V198, P367, DOI 10.1016/S0378-1119(97)00339-9; Leeson S, 2000, CAN J ANIM SCI, V80, P527, DOI 10.4141/A99-123; Lim D, 2000, NAT STRUCT BIOL, V7, P108; Mallin MA, 2000, AM SCI, V88, P26, DOI 10.1511/2000.15.762; MIKKELSEN TR, 1992, NUCLEIC ACIDS RES, V20, P2249, DOI 10.1093/nar/20.9.2249; Murray JD, 1999, THERIOGENOLOGY, V51, P149, DOI 10.1016/S0093-691X(98)00238-6; Murry AC, 1997, J ANIM SCI, V75, P1284; Naqvi SWA, 2000, NATURE, V408, P346, DOI 10.1038/35042551; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; OQuinn PR, 1997, J ANIM SCI, V75, P1299; REDDY NR, 1982, ADV FOOD RES, V28, P1; RUSHMORE TH, 1988, CANCER RES, V48, P2805; SCHEIFFELE P, 2000, MOL TRAFFICKUNG, P27; Smith LC, 2000, CAN VET J, V41, P919; Tilman D, 1999, P NATL ACAD SCI USA, V96, P5995, DOI 10.1073/pnas.96.11.5995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tu Zheng-Jin, 1993, Gene Expression, V3, P289; Ward KA, 2000, TRENDS BIOTECHNOL, V18, P99, DOI 10.1016/S0167-7799(99)01417-1; Westhusin M, 2000, NAT BIOTECHNOL, V18, P1144, DOI 10.1038/81119; Zhang JX, 1999, ARCH BIOCHEM BIOPHYS, V367, P317, DOI 10.1006/abbi.1999.1243; Zhang JX, 1997, BBA-MOL CELL RES, V1357, P215, DOI 10.1016/S0167-4889(97)00030-X	40	74	89	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					429	433		10.1038/88091	http://dx.doi.org/10.1038/88091			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329011				2022-12-25	WOS:000168394800019
J	Pelkmans, L; Kartenbeck, J; Helenius, A				Pelkmans, L; Kartenbeck, J; Helenius, A			Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; MONOPINOCYTOTIC VESICLES; MEMBRANE DOMAINS; GOLGI-NETWORK; EARLY EVENTS; CELLS; ENTRY; CHOLESTEROL; POLYOMAVIRUS; SIMIAN-VIRUS-40	Simian virus 40 (SV40) is unusual among animal Viruses in that it enters cells through caveolae, and the internalized virus accumulates in a smooth endoplasmic reticulum (ER) compartment. Using video-enhanced, dual-colour, live fluorescence microscopy, we show the uptake of individual virus particles in CV-1 cells. After associating with caveolae, SV40 leaves the plasma membrane in small, caveolin-1-containing vesicles. It then enters larger, peripheral organelles with a non-acidic pH. Although rich in caveolin-1, these organelles do not contain markers for endosomes, lysosomes, ER or Golgi, nor do they acquire ligands of clathrin-coated vesicle endocytosis. After several hours in these organelles, SV40 is sorted into tubular, caveolin-free membrane vesicles that move rapidly along microtubules, and is deposited in perinuclear, syntaxin 17-positive, smooth ER organelles. The microtubule-disrupting agent nocodazole inhibits formation and transport of these tubular carriers, and blocks viral infection. Our results demonstrate the existence of a two-step transport pathway from plasma-membrane caveolae, through an intermediate organelle (termed the caveosome), to the ER. This pathway bypasses endosomes and the Golgi complex, and is part of the productive infectious route used by SV40.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; German Canc Res Ctr, D-69120 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Pelkmans, L (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	ari.helenius@bc.biol.ethz.ch		Pelkmans, Lucas/0000-0002-6754-9730				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BREAU WC, 1992, J VIROL, V66, P2037, DOI 10.1128/JVI.66.4.2037-2045.1992; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding CJ, 1997, J LIPID RES, V38, P1503; Gilbert JM, 2000, J VIROL, V74, P8582, DOI 10.1128/JVI.74.18.8582-8588.2000; Greber UF, 1996, TRENDS CELL BIOL, V6, P189, DOI 10.1016/0962-8924(96)10016-7; GRIFFITH GR, 1988, VIRUS RES, V10, P41, DOI 10.1016/0168-1702(88)90056-1; GRIFFITH GR, 1984, J VIROL, V50, P77, DOI 10.1128/JVI.50.1.77-85.1984; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; HUMMELER K, 1970, J VIROL, V6, P87, DOI 10.1128/JVI.6.1.87-93.1970; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; Khoury G, 1979, Methods Enzymol, V58, P404; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lange Y, 1999, J LIPID RES, V40, P2264; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; MACKAY RL, 1976, J VIROL, V19, P620, DOI 10.1128/JVI.19.2.620-636.1976; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MAUL GG, 1978, J VIROL, V28, P936, DOI 10.1128/JVI.28.3.936-944.1978; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MAXFIELD FR, 1985, ACIDIFICATION ENDOCY, P235; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Nakano MY, 2000, J STRUCT BIOL, V129, P57, DOI 10.1006/jsbi.1999.4201; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 1999, J BIOL CHEM, V274, P14495, DOI 10.1074/jbc.274.20.14495; Ponnambalam S, 1996, J CELL SCI, V109, P675; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SAHLI R, 1994, CELL BIOL LAB HDB, P471; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Steegmaier M, 2000, MOL BIOL CELL, V11, P2719, DOI 10.1091/mbc.11.8.2719; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993	47	1004	1028	1	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					473	483		10.1038/35074539	http://dx.doi.org/10.1038/35074539			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331875				2022-12-25	WOS:000168592500017
J	Hughes, JF; Coffin, JM				Hughes, JF; Coffin, JM			Evidence for genomic rearrangements mediated by human endogenous retroviruses during primate evolution	NATURE GENETICS			English	Article							INTRACHROMOSOMAL RECOMBINATION; GENES; SEQUENCES	Human endogenous retroviruses (HERVs), which are remnants of past retroviral infections of the germline cells of our ancestors(1), make up as much as 8% of the human genome and may even outnumber genes(2,3). Most HERVs seem to have entered the genome between 10 and 50 million years ago, and they comprise over 200 distinct groups and subgroups(1,4). Although repeated sequence elements such as HERVs have the potential to lead to chromosomal rearrangement through homologous recombination between distant loci, evidence for the generality of this process is lacking. To gain insight into the expansion of these elements in the genome during the course of primate evolution, we have identified 23 new members of the HERV-K (HML-2) group, which is thought to contain the most recently active members. Here we show, by phylogenetic and sequence analysis, that at least 16% of these elements have undergone apparent rearrangements that may have resulted in large-scale deletions, duplications and chromosome reshuffling during the evolution of the human genome.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA	Tufts University; Tufts University	Coffin, JM (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.	jcoffin_par@opal.tufts.edu			NCI NIH HHS [CA5441, R01 CA 89441, R35 CA 44385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089441, R35CA044385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Blanco P, 2000, J MED GENET, V37, P752, DOI 10.1136/jmg.37.10.752; Boeke J. D., 1997, P343; Costas J, 2001, J MOL EVOL, V53, P237, DOI 10.1007/s002390010213; Johnson WE, 1999, P NATL ACAD SCI USA, V96, P10254, DOI 10.1073/pnas.96.18.10254; Jurka J, 2000, TRENDS GENET, V16, P418, DOI 10.1016/S0168-9525(00)02093-X; Kamp C, 2000, HUM MOL GENET, V9, P2563, DOI 10.1093/hmg/9.17.2563; Kulski JK, 1999, J MOL EVOL, V49, P84, DOI 10.1007/PL00006537; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; ONO M, 1986, J VIROL, V58, P937, DOI 10.1128/JVI.58.3.937-944.1986; REARDEN A, 1993, J BIOL CHEM, V268, P2260; Reus K, 2001, J VIROL, V75, P8917, DOI 10.1128/JVI.75.19.8917-8926.2001; Schwartz A, 1998, HUM MOL GENET, V7, P1, DOI 10.1093/hmg/7.1.1; Sugimoto J, 2001, GENOMICS, V72, P137, DOI 10.1006/geno.2001.6473; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yoder AD, 2000, MOL BIOL EVOL, V17, P1081, DOI 10.1093/oxfordjournals.molbev.a026389	16	162	167	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					487	489		10.1038/ng775	http://dx.doi.org/10.1038/ng775			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11704760				2022-12-25	WOS:000172507500028
J	Zaheer, A; Lenkinski, RE; Mahmood, A; Jones, AG; Cantley, LC; Frangioni, JV				Zaheer, A; Lenkinski, RE; Mahmood, A; Jones, AG; Cantley, LC; Frangioni, JV			In vivo near-infrared fluorescence imaging of osteoblastic activity	NATURE BIOTECHNOLOGY			English	Article							OSTEOTROPIC DRUG-DELIVERY; BISPHOSPHONIC PRODRUG; INDOCYANINE GREEN; TARGETING CHARACTERISTICS; BONE; CARBOXYFLUORESCEIN; CALCIFICATION; DISPOSITION; ESTRADIOL; BIOLOGY	In vertebrates, the development and integrity of the skeleton requires hydroxyapatite (HA) deposition by osteoblasts. HA deposition is also a marker of, or a participant in, processes as diverse as cancer and atherosclerosis. At present, sites of osteoblastic activity can only be imaged in vivo using gamma -emitting radioisotopes. The scan times required are long, and the resultant radioscintigraphic images suffer from relatively low resolution. We have synthesized a near-infrared (NIR) fluorescent bisphosphonate derivative that exhibits rapid and specific binding to HA in vitro and in vivo. We demonstrate NIR light-based detection of osteoblastic activity in the living animal, and discuss how this technology can be used to study skeletal development, osteoblastic metastasis, coronary atherosclerosis, and other human diseases.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Frangioni, JV (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.		Lenkinski, Robert/F-9045-2014; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Lenkinski, Robert/0000-0001-7371-5048	NCI NIH HHS [R01CA/34970, R21CA88245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034970, R21CA088245] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abels C, 2000, ARCH DERMATOL RES, V292, P404, DOI 10.1007/s004030000147; Altkorn D, 2001, JAMA-J AM MED ASSOC, V285, P1415, DOI 10.1001/jama.285.11.1415; BACHMAN CH, 1965, NATURE, V206, P1328, DOI 10.1038/2061328a0; Chance B, 1998, ANN NY ACAD SCI, V838, P29, DOI 10.1111/j.1749-6632.1998.tb08185.x; CLEYNHENS B, 1999, TECHNETIUM RHENIUM O, P611; Drake WM, 2001, CLIN THER, V23, P620, DOI 10.1016/S0149-2918(01)80065-5; DUPOUY P, 1993, AM HEART J, V126, P76, DOI 10.1016/S0002-8703(07)80012-3; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Farkas DL, 1998, COMPUT MED IMAG GRAP, V22, P89, DOI 10.1016/S0895-6111(98)00011-1; FLEISCH H, 1987, BONE S, V8, P23; Fujisaki J, 1996, J DRUG TARGET, V4, P117, DOI 10.3109/10611869609046270; Fujisaki J, 1996, J PHARM PHARMACOL, V48, P798, DOI 10.1111/j.2042-7158.1996.tb03976.x; Fujisaki J, 1995, J DRUG TARGET, V3, P273, DOI 10.3109/10611869509015956; Fujisaki J, 1997, BIOL PHARM BULL, V20, P1183; Fujisaki J, 1998, J DRUG TARGET, V5, P129, DOI 10.3109/10611869808995866; Gunther T, 2000, TRENDS ENDOCRIN MET, V11, P189, DOI 10.1016/S1043-2760(00)00256-3; Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168-3659(00)00355-2; Ikehira H, 1999, J Nucl Med Technol, V27, P41; Jakoby MG, 2000, CURR OPIN NEPHROL HY, V9, P11, DOI 10.1097/00041552-200001000-00003; JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227; Karrer S, 1997, DEUT MED WOCHENSCHR, V122, P1111, DOI 10.1055/s-2008-1047735; KLENNER T, 1990, J CANCER RES CLIN, V116, P341, DOI 10.1007/BF01612916; LIM DJ, 1977, ANN OTO RHINOL LARYN, V86, P525, DOI 10.1177/000348947708600413; LIN JH, 1991, DRUG METAB DISPOS, V19, P926; Mahmood U, 1999, RADIOLOGY, V213, P866, DOI 10.1148/radiology.213.3.r99dc14866; MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; MCKERN NM, 1982, GROWTH, V46, P53; MIWA N, 2000, Patent No. 0016810; Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; PRENTICE AI, 1967, J CLIN PATHOL, V20, P717, DOI 10.1136/jcp.20.5.717; Quaresima V, 1998, PHOTOCHEM PHOTOBIOL, V67, P4, DOI 10.1111/j.1751-1097.1998.tb05159.x; REILLY DT, 1975, J BIOMECH, V8, P393, DOI 10.1016/0021-9290(75)90075-5; Rockson SG, 2000, CIRCULATION, V102, P2322, DOI 10.1161/01.CIR.102.19.2322; Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Watson KE, 2000, J CARDIOVASC RISK, V7, P93	39	299	332	1	89	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1148	1154		10.1038/nbt1201-1148	http://dx.doi.org/10.1038/nbt1201-1148			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731784				2022-12-25	WOS:000172524400028
J	Ligon, LA; Karki, S; Tokito, M; Holzbaur, ELF				Ligon, LA; Karki, S; Tokito, M; Holzbaur, ELF			Dynein binds to beta-catenin and may tether microtubules at adherens junctions	NATURE CELL BIOLOGY			English	Article							CYTOPLASMIC DYNEIN; CELL-ADHESION; DYNACTIN	Interactions between microtubule and actin networks are thought to be crucial for mechanical and signalling events at the cell cortex. Cytoplasmic dynein has been proposed to mediate many of these interactions(1-3). Here, we report that dynein is localized to the cortex at adherens junctions in cultured epithelial cells and that this localization is sensitive to drugs that disrupt the actin cytoskeleton. Dynein is recruited to developing contacts between cells, where it localizes with the junctional proteins beta -catenin and E-cadherin. Microtubules project towards these early contacts and we hypothesize that dynein captures and tethers microtubules at these sites. Dynein immunoprecipitates with beta -catenin, and biochemical analysis shows that dynein binds directly to beta -catenin. Overexpression of beta -catenin disrupts the cellular localization of dynein and also dramatically perturbs the organization of the cellular microtubule array. In cells overexpressing beta -catenin, the centrosome becomes disorganized and microtubules no longer appear to be anchored at the cortex. These results identify a novel role for cytoplasmic dynein in capturing and tethering microtubules at adherens junctions, thus mediating cross-talk between actin and microtubule networks at the cell cortex.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Holzbaur, ELF (corresponding author), Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA.			Ligon, Lee/0000-0002-5735-3654				Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; Tokito MK, 1996, MOL BIOL CELL, V7, P1167, DOI 10.1091/mbc.7.8.1167; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Waterman-Storer CM, 2000, MOL BIOL CELL, V11, P2471, DOI 10.1091/mbc.11.7.2471	14	226	228	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					913	917		10.1038/ncb1001-913	http://dx.doi.org/10.1038/ncb1001-913			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584273				2022-12-25	WOS:000171396400016
J	Keyoung, HM; Roy, NS; Benraiss, A; Louissaint, A; Suzuki, A; Hashimoto, M; Rashbaum, WK; Okano, H; Goldman, SA				Keyoung, HM; Roy, NS; Benraiss, A; Louissaint, A; Suzuki, A; Hashimoto, M; Rashbaum, WK; Okano, H; Goldman, SA			High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain	NATURE BIOTECHNOLOGY			English	Article							CNS PROGENITOR CELLS; ADULT MAMMALIAN FOREBRAIN; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; SUBEPENDYMAL CELLS; GENE-EXPRESSION; ALPHA-TUBULIN; SUBVENTRICULAR ZONE; GROWTH-FACTOR; DIFFERENTIATION	Neural stem and precursor cells reside in the ventricular lining of the fetal forebrain, and may provide a cellular substrate for brain repair. To selectively identify and extract these cells, we infected dissociated fetal human brain cells with adenoviruses bearing the gene for green fluorescence protein (GFP), placed under the control of enhancer/promoters for two genes (nestin and musashi1) that are expressed in uncommitted neuroepithelial cells. The cells were then sorted by fluorescence-activated cell sorting (FACS) on the basis of E/nestin- or P/musashi1-driven GFP expression. Both P/musashi1:hGFP- and E/nestin:EGFP-sorted cells were multipotent: limiting dilution with clonal expansion as neurospheres, in tandem with retroviral lineage analysis and xenograft to E17 and P0-2 rat forebrain, revealed that each phenotype was able to both self-renew and co-generate neurons and glia. Thus, fluorescent genes placed under the control of early neural promoters allow neural stem cells to be specifically targeted, isolated, and substantially enriched from the fetal human brain.	Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Obstet & Gynecol, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY 10021 USA; Osaka Univ, Sch Med, Dept Neuroanat, Osaka 5660871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan; RIKEN BSI, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan	Cornell University; Cornell University; NewYork-Presbyterian Hospital; Osaka University; Japan Science & Technology Agency (JST); RIKEN; Keio University	Goldman, SA (corresponding author), Cornell Univ, Coll Med, Dept Neurol & Neurosci, New York, NY 10021 USA.		Benraiss, Abdellatif/AAI-8584-2021; Okano, Hideyuki/I-7584-2019; Hashimoto, Mitsuhiro/G-1981-2010	Benraiss, Abdellatif/0000-0002-0325-6234; Hashimoto, Mitsuhiro/0000-0002-8751-4068; Goldman, Steven/0000-0002-5498-4303				BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Good P, 1998, GENOMICS, V52, P382, DOI 10.1006/geno.1998.5456; Graham FL, 1991, METHOD MOL BIOL, P109; Gritti A, 1996, J NEUROSCI, V16, P1091; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925; KIRSCHENBAUM B, 1994, CEREB CORTEX, V4, P576, DOI 10.1093/cercor/4.6.576; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Luskin MB, 1997, MOL CELL NEUROSCI, V8, P351, DOI 10.1006/mcne.1996.0592; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; MILLER FD, 1987, J CELL BIOL, V105, P3065, DOI 10.1083/jcb.105.6.3065; MILLER FD, 1989, J NEUROSCI, V9, P1452; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505; Pincus DW, 1998, NEUROSURGERY, V42, P858, DOI 10.1097/00006123-199804000-00103; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Roy NS, 2000, NAT MED, V6, P271; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang S, 2000, DEV NEUROSCI-BASEL, V22, P167, DOI 10.1159/000017437	46	135	154	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					843	850		10.1038/nbt0901-843	http://dx.doi.org/10.1038/nbt0901-843			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533643				2022-12-25	WOS:000170774000023
J	Zhang, ZQ; Wang, Y; Vikis, HG; Johnson, L; Liu, GJ; Li, J; Anderson, MW; Sills, RC; Hong, HL; Devereux, TR; Jacks, T; Guan, KL; You, M				Zhang, ZQ; Wang, Y; Vikis, HG; Johnson, L; Liu, GJ; Li, J; Anderson, MW; Sills, RC; Hong, HL; Devereux, TR; Jacks, T; Guan, KL; You, M			Wildtype Kras2 can inhibit lung carcinogenesis in mice	NATURE GENETICS			English	Article							NEGATIVE RAS MUTANT; C-KI-RAS; GENE AMPLIFICATION; MALIGNANT TRANSFORMATION; PHEOCHROMOCYTOMA CELLS; TUMOR PROGRESSION; SARCOMA-VIRUSES; POINT MUTATION; N-RAS; MOUSE	Although the ras genes have long been established as proto-oncogenes, the dominant role of activated ras in cell transformation has been questioned. Previous studies have shown frequent loss of the wildtype Kras2 allele in both mouse and human lung adenocarcinomas. To address the possible tumor suppressor role of wildtype Kras2 in lung tumorigenesis, we have carried out a lung tumor bioassay in heterozygous Kras2-deficient mice. Mice with a heterozygous Kras2 deficiency were highly susceptible to the chemical induction of lung tumors when compared to wildtype mice. Activating Kras2 mutations were detected in all chemically induced lung tumors obtained from both wildtype and heterozygous Kras2-deficient mice. Furthermore, wildtype Kras2 inhibited colony formation and tumor development by transformed NIH/3T3 cells and a mouse lung tumor cell line containing an activated Kras2 allele. Allelic loss of wildtype Kras2 was found in 67% to 100% of chemically induced mouse lung adenocarcinomas that harbor a mutant Kras2 allele. Finally, an inverse correlation between the level of wildtype Kras2 expression and extracellular signal-regulated kinase (ERK) activity was observed in these cells. These data strongly suggest that wildtype Kras2 has tumor suppressor activity and is frequently lost during lung tumor progression.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; MIT, Dept Biol, Cambridge, MA USA; MIT, Howard Hughes Med Inst, Cambridge, MA USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wang, Y (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, 420 W 12th Ave, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021219, Z01ES023006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062694] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, R01CA78797] Funding Source: Medline; NIGMS NIH HHS [R01GM62694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON M, 1992, ENV HLTH PERSPECT, V98, P12; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORASIO GD, 1989, NEURON, V2, P1087; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BUCHMANN A, 1991, CANCER RES, V51, P4097; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CICHUTEK K, 1989, J VIROL, V63, P1377, DOI 10.1128/JVI.63.3.1377-1383.1989; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; COROMINAS M, 1991, CANCER RES, V51, P5129; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Esteller M, 1997, EUR J CANCER, V33, P1572, DOI 10.1016/S0959-8049(97)00154-8; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD JK, 1990, ANTICANCER RES, V10, P1; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HEGI ME, 1994, CANCER RES, V54, P6257; HEIGHWAY J, 1986, BRIT J CANCER, V53, P285, DOI 10.1038/bjc.1986.47; HERRICK CL, 1995, MINN GEOL NAT HIST S, V2, P1; Heumann Rolf, 1994, Current Opinion in Neurobiology, V4, P668, DOI 10.1016/0959-4388(94)90008-6; Hua VY, 1997, P NATL ACAD SCI USA, V94, P9614, DOI 10.1073/pnas.94.18.9614; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Manenti G, 1999, GENOME RES, V9, P639; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; McDoniels-Silvers AL, 2001, EXP LUNG RES, V27, P297, DOI 10.1080/019021401300054064; National Toxicology Program, 1996, NIH PUBL; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; Shichinohe T, 1996, J SURG RES, V66, P125, DOI 10.1006/jsre.1996.0383; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; SHIRAISHI M, 1989, CANCER RES, V49, P6474; Sills RC, 1999, CARCINOGENESIS, V20, P657, DOI 10.1093/carcin/20.4.657; SLEBOS RJC, 1989, BRIT J CANCER, V59, P76, DOI 10.1038/bjc.1989.14; SORRENTINO V, 1988, ONCOGENE RES, V2, P189; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Takeuchi S, 1996, CANCER RES, V56, P738; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070	50	239	240	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					25	33		10.1038/ng721	http://dx.doi.org/10.1038/ng721			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528387				2022-12-25	WOS:000170781300012
J	Mitchell, P				Mitchell, P			Microfluidics - downsizing large-scale biology	NATURE BIOTECHNOLOGY			English	Article																		Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; Prins MWJ, 2001, SCIENCE, V291, P277, DOI 10.1126/science.291.5502.277; Quake SR, 2000, SCIENCE, V290, P1536, DOI 10.1126/science.290.5496.1536; *UBS WARB, 2001, LAB CHIPS MEANS MAN; Zhao B, 2001, SCIENCE, V291, P1023, DOI 10.1126/science.291.5506.1023	5	230	233	0	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					717	721		10.1038/90754	http://dx.doi.org/10.1038/90754			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479557				2022-12-25	WOS:000170188600016
J	Sisodiya, SM; Free, SL; Williamson, KA; Mitchell, TN; Willis, C; Stevens, JM; Kendall, BE; Shorvon, SD; Hanson, IM; Moore, AT; van Heyningen, V				Sisodiya, SM; Free, SL; Williamson, KA; Mitchell, TN; Willis, C; Stevens, JM; Kendall, BE; Shorvon, SD; Hanson, IM; Moore, AT; van Heyningen, V			PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans	NATURE GENETICS			English	Article							SMALL-EYE SEY; GENE DOSAGE; DEFECTS; DIFFERENTIATION; FOREBRAIN; ANIRIDIA; CORTEX; MOUSE; MICE	PAX6 is widely expressed in the central nervous system. Heterozygous PAX6 mutations in human aniridia cause defects that would seem to be confined to the eye(1). Magnetic resonance imaging (MRI) and smell testing reveal the absence or hypoplasia of the anterior commissure and reduced olfaction in a large proportion of aniridia cases, which shows that PAX6 haploinsuffiency causes more widespread human neuro developmental anomalies.	UCL, Inst Neurol, Dept Clin Neurol, Epilepsy Res Grp, London WC1N 3BG, England; Natl Soc Epilepsy, Gerrards Cross SL9 0RJ, Bucks, England; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Moorfields Eye Hosp, London EC1V 2PD, England; Addenbrookes Hosp, Cambridge CB2 2QQ, England	University of London; University College London; University of Edinburgh; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Sisodiya, SM (corresponding author), UCL, Inst Neurol, Dept Clin Neurol, Epilepsy Res Grp, Queen Sq, London WC1N 3BG, England.	sisodiya@ion.ucl.ac.uk	VAN HEYNINGEN, Veronica/GYE-0531-2022; van Heyningen, Veronica/B-8039-2008; Shorvon, Simon D/A-2019-2009	van Heyningen, Veronica/0000-0003-0359-0141; Hanson, Isabel/0000-0002-1878-0530	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Dellovade TL, 1998, J COMP NEUROL, V402, P402; Di Virgilio G, 1999, EXP BRAIN RES, V124, P1, DOI 10.1007/s002210050593; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Gotz M, 1998, NEURON, V21, P1031, DOI 10.1016/S0896-6273(00)80621-2; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; MARTHA A, 1995, HUM MUTAT, V6, P44, DOI 10.1002/humu.1380060109; Mastick GS, 1997, DEVELOPMENT, V124, P1985; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; Sisodiya S, 1996, J ANAT, V188, P425; Stoykova A, 1996, DEVELOPMENT, V122, P3453; Warren N, 1999, CEREB CORTEX, V9, P627, DOI 10.1093/cercor/9.6.627	14	179	185	2	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					214	216		10.1038/90042	http://dx.doi.org/10.1038/90042			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431688				2022-12-25	WOS:000169656400010
J	Fodde, R; Kuipers, J; Rosenberg, C; Smits, R; Kielman, M; Gaspar, C; van Es, JH; Bruekel, C; Wiegant, J; Giles, RH; Clevers, H				Fodde, R; Kuipers, J; Rosenberg, C; Smits, R; Kielman, M; Gaspar, C; van Es, JH; Bruekel, C; Wiegant, J; Giles, RH; Clevers, H			Mutations in the APC tumour suppressor gene cause chromosomal instability	NATURE CELL BIOLOGY			English	Article							POLYPOSIS-COLI APC; BETA-CATENIN; BINDING PROTEIN; YEAST HOMOLOG; RAS ONCOGENE; EB1; IDENTIFICATION; MICROTUBULES; CENTROSOME; ACTIVATION	Two forms of genetic instability have been described in colorectal cancer(1): microsatellite instability and chromosomal instability. Microsatellite instability results from mutations in mismatch repair genes; chromosomal instability is the hallmark of many colorectal cancers, although it is not completely understood at the molecular level. As truncations of the Adenomatous Polyposis Coli (APC) gene are found in most colorectal tumours, we thought that mutations in APC might be responsible for chromosomal instability. To test this hypothesis, we examined mouse embryonic stem (ES) cells homozygous for Min (multiple intestinal neoplasia) or Apc1638T alleles, Here we show that Ape mutant ES cells display extensive chromosome and spindle aberrations, providing genetic evidence for a role of APC in chromosome segregation. Consistent with this, APC accumulates at the kinetochore during mitosis, Ape mutant cells form mitotic spindles with an abundance of microtubules that inefficiently connect with kinetochores. This phenotype is recapitulated by the induced expression of a 253-amino-acid carboxy-terminal fragment of APC in microsatellite unstable colorectal cancer cells, We conclude that loss of APC sequences that lie C-terminal to the beta -catenin regulatory domain contributes to chromosomal instability in colorectal cancer.	Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Med Ctr, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 GA Utrecht, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Fodde, R (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, POB 9503, NL-2300 RA Leiden, Netherlands.	r.fodde@lumc.nl; h.clevers@lab.azu.nl	van+Es, Johan/ABD-5411-2021; Fodde, Riccardo/AAW-9394-2021; rosenberg, carla/N-4148-2015; Gaspar, Claudia/I-6402-2013	Fodde, Riccardo/0000-0001-9839-4324; rosenberg, carla/0000-0003-3253-4448; Gaspar, Claudia/0000-0003-1051-0998; Giles, Rachel/0000-0001-9133-2008				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakagawa H, 1998, CANCER RES, V58, P5176; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Samowitz WS, 1999, CANCER RES, V59, P1442; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1995, CANCER RES, V55, P2972; Tanke HJ, 1999, EUR J HUM GENET, V7, P2, DOI 10.1038/sj.ejhg.5200265; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	42	540	555	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					433	438		10.1038/35070129	http://dx.doi.org/10.1038/35070129			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283620				2022-12-25	WOS:000168043900025
J	Kaplan, KB; Burds, AA; Swedlow, JR; Bekir, SS; Sorger, PK; Nathke, IS				Kaplan, KB; Burds, AA; Swedlow, JR; Bekir, SS; Sorger, PK; Nathke, IS			A role for the Adenomatous Polyposis Coli protein in chromosome segregation	NATURE CELL BIOLOGY			English	Article							CHECKPOINT PROTEIN; HOMOLOG	Mutations in the Adenomatous Polyposis Coli (APC) gene are responsible for familial colon cancer and also occur in the early stages of sporadic colon cancer(1). APC functions in the Wnt signalling pathway to regulate the degradation of beta -catenin (reviewed in refs 1-3). APC also binds to and stabilizes microtubules in viva and in vitro(4), localizes to clusters at the ends of microtubules near the plasma membrane of interphase cells(5,6), and is an important regulator of cytoskeletal function(7,8). Here we show that cells carrying a truncated APC gene (Min)(9) are defective in chromosome segregation. Moreover during mitosis, APC localizes to the ends of microtubules embedded in kinetochores and forms a complex with the checkpoint proteins Bub1 and Bub3, In vitro, APC is a high-affinity substrate for Pub kinases. Our data are consistent with a role for APC in kinetochore-microtubule attachment and suggest that truncations in APC that eliminate microtubule binding may contribute to chromosomal instability in cancer cells(10).	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	Massachusetts Institute of Technology (MIT); University of Dundee	Nathke, IS (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	i.s.nathke@dundee.ac.uk		Nathke, Inke/0000-0003-2420-4385; Connor, Aurora/0000-0003-2705-5100; Swedlow, Jason/0000-0002-2198-1958; Sorger, Peter/0000-0002-3364-1838				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	18	444	461	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					429	432		10.1038/35070123	http://dx.doi.org/10.1038/35070123			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283619				2022-12-25	WOS:000168043900024
J	Cheung, A; Dantzig, JA; Hollingworth, S; Baylor, SM; Goldman, YE; Mitchison, TJ; Straight, AF				Cheung, A; Dantzig, JA; Hollingworth, S; Baylor, SM; Goldman, YE; Mitchison, TJ; Straight, AF			A small-molecule inhibitor of skeletal muscle myosin II	NATURE CELL BIOLOGY			English	Article							LIGHT CHAIN KINASE; BUTANEDIONE MONOXIME; MITOTIC SPINDLE; FIBERS; FAMILY; ACTIN; GENERATION; TRANSIENTS; NEURONS; CELLS	We screened a small-molecule library for inhibitors of rabbit muscle myosin II subfragment 1 (S1) actin-stimulated ATPase activity. The best inhibitor, N-benzyl-p-toluene sulphonamide (BTS), an aryl sulphonamide, inhibited the Ca2+-stimulated S1 ATPase, and reversibly blocked gliding motility. Although BTS does not compete for the nucleotide-binding site of myosin, it weakens myosin's interaction with F-actin. BTS reversibly suppressed force production in skinned skeletal muscle fibres from rabbit and frog skin at micromolar concentrations. BTS suppressed twitch production of intact frog fibres with minimum alteration of Ca2+ metabolism. BTS is remarkably specific, as it was much less effective in suppressing contraction in rat myocardial or rabbit slow-twitch muscle, and did not inhibit platelet myosin II. The isolation of BTS and the recently discovered Eg5 kinesin inhibitor, monastrol(1), suggests that motor proteins may be potential targets for therapeutic applications.	Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	Harvard University; Harvard Medical School; University of Pennsylvania; University of Pennsylvania	Cheung, A (corresponding author), Harvard Univ, Sch Med, Inst Chem & Cell Biol, 250 Longwood Ave, Boston, MA 02115 USA.			Straight, Aaron/0000-0001-5885-7881	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL015835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023928, P01GM062566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017620] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL15835] Funding Source: Medline; NIGMS NIH HHS [GM23928, GM62566] Funding Source: Medline; NINDS NIH HHS [NS17620] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bevan D R, 1995, Acta Anaesthesiol Scand Suppl, V106, P2; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; EDMAN KA, 1978, INT S CURR PROBL SLI, P347; FRYER MW, 1988, PFLUG ARCH EUR J PHY, V411, P76, DOI 10.1007/BF00581649; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V350, P497, DOI 10.1113/jphysiol.1984.sp015215; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Hasson T, 1997, CURR OPIN NEUROBIOL, V7, P615, DOI 10.1016/S0959-4388(97)80080-3; HIGUCHI H, 1989, J BIOCHEM-TOKYO, V105, P638, DOI 10.1093/oxfordjournals.jbchem.a122717; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hodge T, 2000, J CELL SCI, V113, P3353; HORI M, 1993, FEBS LETT, V322, P151, DOI 10.1016/0014-5793(93)81557-G; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO;2-T; KONISHI M, 1991, J GEN PHYSIOL, V97, P271, DOI 10.1085/jgp.97.2.271; LANG RJ, 1991, J PHYSIOL-LONDON, V433, P1; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Patocka J, 1999, Acta Medica (Hradec Kralove), V42, P3; Saito S, 1996, CLIN EXP PHARMACOL P, V23, P743, DOI 10.1111/j.1440-1681.1996.tb01770.x; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sellers J. R., 1999, MYOSINS; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; WILSON L, 1975, LIFE SCI, V17, P303, DOI 10.1016/0024-3205(75)90476-2	28	219	226	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					83	88		10.1038/ncb734	http://dx.doi.org/10.1038/ncb734			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11744924				2022-12-25	WOS:000173381500021
J	Sugihara, K; Asano, S; Tanaka, K; Iwamatsu, A; Okawa, K; Ohta, Y				Sugihara, K; Asano, S; Tanaka, K; Iwamatsu, A; Okawa, K; Ohta, Y			The exocyst complex binds the small GTPase RaIA to mediate filopodia formation	NATURE CELL BIOLOGY			English	Article							RAL-GTPASE; SACCHAROMYCES-CEREVISIAE; BREFELDIN-A; PROTEIN; IDENTIFICATION; EXOCYTOSIS; TARGET; ACTIVATION; SECRETION; POLARITY	The Ras-related small GTPase RalA is involved in controlling actin cytoskeletal remodelling and vesicle transport in mammalian cells(1,2). We identified the mammalian homologue of Sec5, a subunit of the exocyst complex determining yeast cell polarity, as a specific binding partner for GTP-ligated RalA. Inhibition of RalA binding to Sec5 prevents filopod production by tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and by activated forms of RalA and Cdc42, signalling intermediates downstream of these inflammatory cytokines. We propose that the RalA-exocyst complex interaction integrates the secretory and cytoskeletal pathways.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA; Kirin Brewery Co Ltd, Cent Labs Key Technol, Sect Prot Chem, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Kirin Brewery Company Limited	Sugihara, K (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19429] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; ORCI L, 1991, CELL, V64, P1183; Park SH, 1995, ONCOGENE, V11, P2349; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; Puls A, 1999, J CELL SCI, V112, P2983; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; Vaidyanathan VV, 2001, J BIOL CHEM, V276, P25101, DOI 10.1074/jbc.M103536200; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	30	191	194	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					73	78		10.1038/ncb720	http://dx.doi.org/10.1038/ncb720			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11744922				2022-12-25	WOS:000173381500019
J	Lawrence, T; Gilroy, DW; Colville-Nash, PR; Willoughby, DA				Lawrence, T; Gilroy, DW; Colville-Nash, PR; Willoughby, DA			Possible new role for NF-kappa B in the resolution of inflammation	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; TRANSCRIPTIONAL ACTIVATION; CYCLOOXYGENASE-2 GENE; P53 PROMOTER; MICE LACKING; APOPTOSIS; PHOSPHORYLATION; EXPRESSION	Inflammation involves the sequential activation of signaling pathways leading to the production of both pro- and anti-inflammatory mediators. Although much attention has focused on pro-inflammatory pathways that initiate inflammation, relatively little is known about the mechanisms that switch off inflammation and resolve the inflammatory response. The transcription factor NF-kappaB is thought to have a central role in the induction of pro-inflammatory gene expression and has attracted interest as a new target for the treatment of inflammatory disease. We, show here that NF-kappaB activation in leukocytes recruited during the onset of inflammation is associated with pro-inflammatory gene expression, whereas such activation during the resolution of inflammation is associated with the expression of anti-inflammatory genes and the induction of apoptosis. Inhibition of NF-kappaB during the resolution of inflammation protracts the inflammatory response and prevents apoptosis. This:suggests that NF-kappaB has an anti-inflammatory role in vivo involving the regulation of inflammatory resolution.	William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England	University of London; Queen Mary University London	Lawrence, T (corresponding author), William Harvey Res Inst, Dept Expt Pathol, Charterhouse Sq, London EC1M 6BQ, England.	t.lawrence@mds.qmw.ac.uk	Gilroy, Derek/AAP-7227-2020; Gilroy, Derek W/C-2588-2009; Lawrence, Toby/GLU-3895-2022	Gilroy, Derek/0000-0003-3476-0844; Lawrence, Toby/0000-0003-0967-6122				Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Haslett C, 1997, BRIT MED BULL, V53, P669; HOBBS AJ, 1999, PROG INFLAM RES, P31; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Liu L, 1999, CIRCULATION, V100, P1; Lotem J, 1997, P NATL ACAD SCI USA, V94, P9349, DOI 10.1073/pnas.94.17.9349; MCDONALD DG, 1964, PSYCHOPHYSIOLOGY, V1, P163, DOI 10.1111/j.1469-8986.1964.tb03231.x; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; TOMLINSON A, 1999, PROG INFLAM RES, P187; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WU HY, 1994, J BIOL CHEM, V269, P20067; Xaus J, 2000, BLOOD, V95, P3823; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	45	623	653	2	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1291	1297		10.1038/nm1201-1291	http://dx.doi.org/10.1038/nm1201-1291			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726968				2022-12-25	WOS:000172610300033
J	Trockenbacher, A; Suckow, V; Foerster, J; Winter, J; Krauss, S; Ropers, HH; Schneider, R; Schweiger, S				Trockenbacher, A; Suckow, V; Foerster, J; Winter, J; Krauss, S; Ropers, HH; Schneider, R; Schweiger, S			MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation	NATURE GENETICS			English	Article							SYNDROME GENE-PRODUCT; CELL-CYCLE; PROTEIN PHOSPHATASE-2A; G/BBB SYNDROME; FG-SYNDROME; IN-VIVO; PHOSPHORYLATION; MICROTUBULES; EXPRESSION; XP22	The gene MID1, the mutation of which causes X-linked Opitz G/BBB syndrome (OS, MIM 300000), encodes a microtubule-associated protein (MAP). We show that mutation of MID1 leads to a marked accumulation of the catalytic subunit of protein phosphatase 2A (PP2Ac), a central cellular regulator. PP2Ac accumulation is caused by an impairment of a newly identified E3 ubiquitin ligase activity of the MID1 protein that normally targets PP2Ac for degradation through binding to its alpha4 regulatory subunit in an embryonic fibroblast line derived from a fetus with OS. Elevated PP2Ac causes hypophosphorylation of MAPs, a pathological mechanism that is consistent with the OS phenotype.	Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Inst Biochem, A-6020 Innsbruck, Austria; Charite, Dept Dermatol, D-10117 Berlin, Germany	Max Planck Society; University of Innsbruck; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schweiger, S (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.	schweiger@molgen.mpg.de	Krauss, Sybille/L-5328-2016	Krauss, Sybille/0000-0002-5653-9289				AVILA J, 1994, INT J DEV BIOL, V38, P13; Baharians Z, 1999, MOL CARCINOGEN, V24, P246, DOI 10.1002/(SICI)1098-2744(199904)24:4<246::AID-MC2>3.0.CO;2-H; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Briault S, 1997, AM J MED GENET, V73, P87; Buchner G, 1999, HUM MOL GENET, V8, P1397, DOI 10.1093/hmg/8.8.1397; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gong CX, 2000, BRAIN RES, V853, P299, DOI 10.1016/S0006-8993(99)02294-5; Graham JM, 1998, AM J MED GENET, V80, P145; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; INUI S, 1995, J IMMUNOL, V154, P2714; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Kobayashi N, 2001, HISTOCHEM CELL BIOL, V115, P255; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; MAIER GD, 1995, INT J CANCER, V61, P54, DOI 10.1002/ijc.2910610110; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; OPITZ JM, 1974, Z KINDERHEILKD, V117, P1, DOI 10.1007/BF00439020; Price NE, 1999, MOL BRAIN RES, V73, P68, DOI 10.1016/S0169-328X(99)00237-5; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Robin NH, 1996, AM J MED GENET, V62, P305, DOI 10.1002/(SICI)1096-8628(19960329)62:3<305::AID-AJMG20>3.0.CO;2-N; ROBIN NH, 1995, NAT GENET, V11, P459, DOI 10.1038/ng1295-459; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Sapir T, 1999, EUR J BIOCHEM, V265, P181, DOI 10.1046/j.1432-1327.1999.00711.x; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Trojanowski JQ, 1995, FASEB J, V9, P1570, DOI 10.1096/fasebj.9.15.8529836; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; ZOINIEROWSICZ S, 2000, BIOCHEM PHARMACOL, V60, P1225	48	235	240	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					287	294		10.1038/ng762	http://dx.doi.org/10.1038/ng762			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11685209				2022-12-25	WOS:000171911000014
J	Verpy, E; Masmoudi, S; Zwaenepoel, I; Leibovici, M; Hutchin, TP; Del Castillo, I; Nouaille, S; Blanchard, S; Laine, S; Popot, JL; Moreno, F; Mueller, RF; Petit, C				Verpy, E; Masmoudi, S; Zwaenepoel, I; Leibovici, M; Hutchin, TP; Del Castillo, I; Nouaille, S; Blanchard, S; Laine, S; Popot, JL; Moreno, F; Mueller, RF; Petit, C			Mutations in a new gene encoding a protein of the hair bundle cause non-syndromic deafness at the DFNB16 locus	NATURE GENETICS			English	Article							INNER-EAR; ACELLULAR MEMBRANES; MYOSIN-VIIA; SEQUENCES; OTOGELIN; INSIGHTS; CELLS; CDNA	Hearing impairment affects about 1 in 1,000 children at birth. Approximately 70 loci implicated in non-syndromic forms of deafness have been reported in humans and 24 causative genes have been identified(1) (see also http://www.uia.ac.be/dnalab/hhh). We report a mouse transcript, isolated by a candidate deafness gene approach, that is expressed almost exclusively in the inner ear. Genomic analysis shows that the human ortholog STRC (so called owing to the name we have given its protein-stereocilin), which is located on chromosome 15q15, contains 29 exons encompassing approximately 19 kb. STRC is tandemly duplicated, with the coding sequence of the second copy interrupted by a stop codon in exon 20. We have identified two frameshift mutations and a large deletion in the copy containing 29 coding exons in two families affected by autosomal recessive non-syndromal sensorineural deafness linked to the DFNB16 locus. Stereocilin is made up of 1,809 amino acids, and contains a putative signal petide and several hydrophobic segments. Using immunohistolabeling, we demonstrate that, in the mouse inner ear,stereocilin is expressed only in the sensory hair cells and is associated with the stereocilia, the stiff microvilli forming the structure for mechanoreception of sound stimulation.	Inst Pasteur, CNRS URA 1968, Unite Genet Deficits Sensoriels, F-75724 Paris 15, France; Fac Med Sfax, Lab Genet Mol Humaine, Sfax, Tunisia; St James Hosp, Dept Mol Med, Leeds LS9 7TF, W Yorkshire, England; St James Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Hosp Ramon y Cajal, Unidad Genet Mol, E-28034 Madrid, Spain; Inst Biol Physicochim, CNRS UPR9052, Unite Physico Chim Mol Membranes Biol, F-75005 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Sfax; Saint James's University Hospital; Saint James's University Hospital; Hospital Universitario Ramon y Cajal	Petit, C (corresponding author), Inst Pasteur, CNRS URA 1968, Unite Genet Deficits Sensoriels, 25 Rue Dr Roux, F-75724 Paris 15, France.		Masmoudi, Saber/W-1478-2019; del Castillo, Ignacio/B-4314-2013; Leibovici, Michel/ABB-6745-2020	del Castillo, Ignacio/0000-0003-1188-3665; Saber, Masmoudi/0000-0002-1076-5256; Petit, Christine/0000-0002-9069-002X	RNID [G6] Funding Source: Medline	RNID		Campbell DA, 1997, J MED GENET, V34, P1015, DOI 10.1136/jmg.34.12.1015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; ElAmraoui A, 1996, HUM MOL GENET, V5, P1171, DOI 10.1093/hmg/5.8.1171; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; PETIT C, IN PRESS ANN REV GEN; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; Simmler MC, 2000, MAMM GENOME, V11, P961, DOI 10.1007/s003350010197; Simmler MC, 2000, NAT GENET, V24, P139, DOI 10.1038/72793; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; Villamar M, 1999, AM J HUM GENET, V64, P1238, DOI 10.1086/302321; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693; Zine A, 1996, BRAIN RES, V721, P49, DOI 10.1016/0006-8993(96)00147-3	19	114	123	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2001	29	3					345	349		10.1038/ng726	http://dx.doi.org/10.1038/ng726			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687802				2022-12-25	WOS:000171911000025
J	Baum, B; Perrimon, N				Baum, B; Perrimon, N			Spatial control of the actin cytoskeleton in Drosophila epithelial cells	NATURE CELL BIOLOGY			English	Article							ABL TYROSINE KINASE; PROFILIN; POLYMERIZATION; MUTATIONS; POLARITY; PROTEINS; GROWTH; IDENTIFICATION; SUBSTRATE; MOTILITY	The actin cytoskeleton orders cellular space and transduces many of the forces required for morphogenesis. Here we combine genetics and cell biology to identify genes that control the polarized distribution of actin filaments within the Drosophila follicular epithelium. We find that profilin and cofilin regulate actin-filament formation throughout the cell cortex. In contrast, CAP-a Drosophila homologue of Adenylyl Cyclase Associated Proteins-functions specifically to limit actin-filament formation catalysed by Ena at apical cell junctions. The Abl tyrosine kinase also collaborates in this process. We therefore propose that CAP, Ena and Abl act in concert to modulate the subcellular distribution of actin filaments in Drosophila.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Baum, B (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	bbaum@rascal.med.harvard.edu		Perrimon, Norbert/0000-0001-7542-472X				Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Baum B, 2000, CURR BIOL, V10, P964, DOI 10.1016/S0960-9822(00)00640-0; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Benlali A, 2000, CELL, V101, P271, DOI 10.1016/S0092-8674(00)80837-5; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chou TB, 1996, GENETICS, V144, P1673; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; Duffy JB, 1998, DEVELOPMENT, V125, P2263; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Gottwald U, 1996, MOL BIOL CELL, V7, P261, DOI 10.1091/mbc.7.2.261; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Muller HAJ, 2000, DEV DYNAM, V218, P52; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pollard TD, 2001, J CELL SCI, V114, P3; Pruyne D, 2000, J CELL SCI, V113, P571; Reinking D., 1992, Journal of Educational Multimedia and Hypermedia, V1, P11; Spradling Allan C., 1993, P1; Sutherland JD, 1999, CURR OPIN CELL BIOL, V11, P142, DOI 10.1016/S0955-0674(99)80018-0; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001	41	103	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					883	890		10.1038/ncb1001-883	http://dx.doi.org/10.1038/ncb1001-883			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584269				2022-12-25	WOS:000171396400012
J	De Vries, TJ; Shaham, Y; Homberg, JR; Crombag, H; Schuurman, K; Dieben, J; Vanderschuren, LJMJ; Schoffelmeer, ANM				De Vries, TJ; Shaham, Y; Homberg, JR; Crombag, H; Schuurman, K; Dieben, J; Vanderschuren, LJMJ; Schoffelmeer, ANM			A cannabinoid mechanism in relapse to cocaine seeking	NATURE MEDICINE			English	Article							EXTRACELLULAR DOPAMINE LEVELS; STRESS-INDUCED RELAPSE; NUCLEUS-ACCUMBENS; CB1 RECEPTOR; BEHAVIOR; RATS; AMYGDALA; HEROIN; WITHDRAWAL; ACTIVATION	Treatment of cocaine addiction is hampered by high rates of relapse even after prolonged drug abstinence. This relapse to compulsive cocaine use can be triggered by re-exposure to cocaine(1), by re-exposure to stimuli previously associated with cocaine(2) or by exposure to stress(3). In laboratory rats, similar events reinstate cocaine seeking after prolonged withdrawal periods', thus providing a model to study neuronal mechanisms underlying the relapse to cocaine. The endocannabinoid system has been implicated in a number of neuropsychiatric conditions, including drug addiction(7,8). The active ingredient of marijuana, Delta9-tetrahydrocannabinol, activates the mesolimbic dopamine (DA) reward system(9,10) and has rewarding effects in preclinical models of drug abuse(8,11,12). We report here that the synthetic cannabinoid agonist, HU210 (ref. 13), provokes relapse to cocaine seeking after prolonged withdrawal periods. Furthermore, the selective CB1 receptor antagonist, SR141716A (ref. 14), attenuates relapse induced by re-exposure to cocaine-associated cues or cocaine itself, but not relapse induced by exposure to stress. These data reveal an important role of the cannabinoid system in the neuronal processes underlying relapse to cocaine seeking, and provide a rationale for the use of cannabinoid receptor antagonists for the prevention of relapse to cocaine use.	Vrije Univ Amsterdam, Neurosci Res Inst, Dept Med Pharmacol, Med Ctr, Amsterdam, Netherlands; NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, Baltimore, MD USA	Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	De Vries, TJ (corresponding author), Vrije Univ Amsterdam, Neurosci Res Inst, Dept Med Pharmacol, Med Ctr, Amsterdam, Netherlands.		Homberg, J.R./N-4172-2019; De Vries, Taco J/B-2831-2014; Homberg, Judith R/D-2473-2010; Vanderschuren, Louk/AAS-4391-2020; shaham, yavin/G-1306-2014	Vanderschuren, Louk/0000-0002-5379-0363; De Vries, Taco/0000-0002-0340-4946				Ameri A, 1999, PROG NEUROBIOL, V58, P315, DOI 10.1016/S0301-0082(98)00087-2; Chaperon F, 1999, CRIT REV NEUROBIOL, V13, P243, DOI 10.1615/CritRevNeurobiol.v13.i3.20; CHEN JP, 1991, NEUROSCI LETT, V129, P136, DOI 10.1016/0304-3940(91)90739-G; Childress AR, 1992, SUBSTANCE ABUSE COMP, P56; COMER SD, 1993, J PHARMACOL EXP THER, V267, P1470; Cossu G, 2001, BEHAV BRAIN RES, V118, P61, DOI 10.1016/S0166-4328(00)00311-9; De Vries TJ, 1999, PSYCHOPHARMACOLOGY, V143, P254, DOI 10.1007/s002130050944; deWit H, 1996, EXP CLIN PSYCHOPHARM, V4, P5, DOI 10.1037/1064-1297.4.1.5; Di Marzo V, 2000, J NEUROCHEM, V74, P1627, DOI 10.1046/j.1471-4159.2000.0741627.x; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Grimm JW, 2000, NEUROPSYCHOPHARMACOL, V22, P473, DOI 10.1016/S0893-133X(99)00157-8; Huestis MA, 2001, ARCH GEN PSYCHIAT, V58, P322, DOI 10.1001/archpsyc.58.4.322; Khroyan TV, 2000, J PHARMACOL EXP THER, V294, P680; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Mascia MS, 1999, EUR J PHARMACOL, V383, pR1, DOI 10.1016/S0014-2999(99)00656-1; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2; Sinha R, 1999, PSYCHOPHARMACOLOGY, V142, P343, DOI 10.1007/s002130050898; Stewart J, 2000, J PSYCHIATR NEUROSCI, V25, P125; Tanda G, 2000, NAT NEUROSCI, V3, P1073, DOI 10.1038/80577; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; Tran-Nguyen LTL, 1998, NEUROPSYCHOPHARMACOL, V19, P48; Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321	28	348	359	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1151	1154		10.1038/nm1001-1151	http://dx.doi.org/10.1038/nm1001-1151			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590440	Bronze			2022-12-25	WOS:000171524500038
J	Janis, MD; Kesan, JP				Janis, MD; Kesan, JP			Designing an optimal intellectual property system for plants: a US Supreme Court debate	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Iowa, Coll Law, Iowa City, IA 52242 USA	University of Iowa	Janis, MD (corresponding author), Univ Iowa, Coll Law, Iowa City, IA 52242 USA.							*G, 2000, 000198 G NOVARTIS; *G NOVARTIS EPOR, 2000, 303 G NOVARTIS EPOR; HIBBARD EP, 1985, Patent No. 227; JANIS MD, IN PRESS INT J GLOBA; Kesan JP, 2000, AM BEHAV SCI, V44, P464, DOI 10.1177/00027640021956288; 1996, Patent No. 5567861; 1996, Patent No. 5491295; 1996, Patent No. 5506397	8	13	13	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					981	983		10.1038/nbt1001-981	http://dx.doi.org/10.1038/nbt1001-981			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581668				2022-12-25	WOS:000171417600030
J	Moreira, MC; Barbot, C; Tachi, N; Kozuka, N; Uchida, E; Gibson, T; Mendonca, P; Costa, M; Barros, J; Yanagisawa, T; Watanabe, M; Ikeda, Y; Aoki, M; Nagata, T; Coutinho, P; Sequeiros, J; Koenig, M				Moreira, MC; Barbot, C; Tachi, N; Kozuka, N; Uchida, E; Gibson, T; Mendonca, P; Costa, M; Barros, J; Yanagisawa, T; Watanabe, M; Ikeda, Y; Aoki, M; Nagata, T; Coutinho, P; Sequeiros, J; Koenig, M			The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin	NATURE GENETICS			English	Article							CEREBELLAR ATROPHY HMSNCA; DNA STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE; HEREDITARY MOTOR; LIGASE-III; NEUROPATHY; TELANGIECTASIA; KINASE; ATM	The newly recognized ataxia-ocular apraxia 1 (AOA1; MIM 208920)(1-4) is the most frequent cause of autosomal recessive ataxia in Japan(2,4-9) and is second only to Friedreich ataxia in Portugal(10). It shares several neurological features with ataxia-telanglectasia, including early onset ataxia, oculomotor apraxia and cerebellar atrophy, but does not share its extraneurological features (immune deficiency, chromosomal instability and hypersensitivity to X-rays). AOA1 is also characterized by axonal motor neuropathy(3,5,9) and the later decrease of serum albumin levels and elevation of total cholesterol(2,4,5,9). We have identified the gene causing AOA1 and the major Portuguese and Japanese mutations. This gene encodes a new, ubiquitously expressed protein that we named aprataxin. This protein is composed of three domains that share distant homology with the amino-terminal domain of polynucleotide kinase 3'-phosphatase (PNKP), with histidine-triad (HIT) proteins and with DNA-binding C2H2 zinc-finger proteins, respectively. PNKP is involved in DNA single-strand break repair (SSBR)(11) following exposure to ionizing radiation and reactive oxygen species. Fragile-HIT proteins (FHIT) cleave diadenosine tetraphosphate, which is potentially produced during activation of the SSBR complex(12). The results suggest that aprataxin is a nuclear protein with a role in DNA repair reminiscent of the function of the protein defective in ataxia-telangiectasia, but that would cause a phenotype restricted to neurological signs when mutant.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Univ Porto, IBMC, UnIGENe, Oporto, Portugal; Univ Porto, ICBAS, Oporto, Portugal; Hosp Maria Pia, Dept Neurol, Oporto, Portugal; Sapporo Med Univ, Sch Hlth Sci, Sapporo, Hokkaido, Japan; European Mol Biol Lab, Heidelberg, Germany; Hosp Divino Espirito Santo, Dept Hematol, Azores, Portugal; Hosp Pedro Hispano, Dept Neurol, Matosinhos, Portugal; Hosp Geral Sto Antonio, Dept Neurol, Oporto, Portugal; Isesaki Fukushima Hosp, Dept Neurol, Iseaki, Japan; Gunma Univ, Sch Med, Dept Neurol, Maebashi, Gumma, Japan; Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 980, Japan; Hosp S Sebastiao, Div Neurol, Santa Maria da Feira, Portugal	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universidade do Porto; Universidade do Porto; Sapporo Medical University; European Molecular Biology Laboratory (EMBL); Gunma University; Tohoku University	Koenig, M (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, CU Strasbourg, Illkirch Graffenstaden, France.		Barbot, Clara/K-6378-2013; Coutinho, Paula/K-6053-2013	Barbot, Clara/0000-0002-5597-107X; Sequeiros, Jorge/0000-0002-9846-1037; Barros, Jose/0000-0001-6183-5050; Franco Mendonca, Pedro/0000-0002-3850-2909; Gibson, Toby James/0000-0003-0657-5166; Coutinho, Paula/0000-0002-3461-230X				AICARDI J, 1988, ANN NEUROL, V24, P497, DOI 10.1002/ana.410240404; Barbot C, 2001, ARCH NEUROL-CHICAGO, V58, P201, DOI 10.1001/archneur.58.2.201; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; FUKUHARA N, 1995, J NEUROL SCI, V133, P140, DOI 10.1016/0022-510X(95)00176-3; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; Hanihara T, 1995, Rinsho Shinkeigaku, V35, P83; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kubota H, 1995, No To Shinkei, V47, P289; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; MOREIRA MC, 1999, ARQ MED, V13, P39; Moreira MD, 2001, AM J HUM GENET, V68, P501, DOI 10.1086/318191; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sekijima Y, 1998, J NEUROL SCI, V158, P30, DOI 10.1016/S0022-510X(98)00103-8; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tachi N, 2000, EUR NEUROL, V43, P82, DOI 10.1159/000008140; UEKAWA K, 1992, CLIN NEUROL, V32, P1067; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; YOSHIHARA K, 1981, J BIOL CHEM, V256, P6756	26	317	329	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					189	193		10.1038/ng1001-189	http://dx.doi.org/10.1038/ng1001-189			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586300				2022-12-25	WOS:000171374100026
J	Sozen, MA; Suzuki, K; Tolarova, MM; Bustos, T; Iglesias, JEF; Spritz, RA				Sozen, MA; Suzuki, K; Tolarova, MM; Bustos, T; Iglesias, JEF; Spritz, RA			Mutation of PVRL1 is associated with sporadic, non-syndromic cleft lip/palate in northern Venezuela	NATURE GENETICS			English	Article							ECTODERMAL DYSPLASIA; PALATE; LIP; GENE	Non-syndromic cleft lip with or without cleft palate (CL/P, MIM 119530) is among the most common of major birth defects. Homozygosity for a nonsense mutation of PVRL1, W185X, results in an autosomal recessive CL/P syndrome on Margarita Island, CLPED1 (ref. 1). Here we demonstrate highly significant association between heterozygosity for this mutation and sporadic, non-syndromic CL/P in northern Venezuela.	Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Pacific, Dept Orthodont, San Francisco, CA USA; Cent Univ Venezuela, Ctr Nacl Genet Humana & Expt, Caracas, Venezuela; Ctr Diagnost Odontol, Porlamar, Isla Margarita, Venezuela	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of the Pacific; University of Central Venezuela	Spritz, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA.	richard.spritz@uchsc.edu			NIDCR NIH HHS [DE13571] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013571] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Braybrook C, 2001, NAT GENET, V29, P179, DOI 10.1038/ng730; BUSTOS T, 1991, AM J MED GENET, V41, P398, DOI 10.1002/ajmg.1320410403; Juriloff DM, 2001, MAMM GENOME, V12, P426, DOI 10.1007/s003350010284; MELNICK M, 1980, AM J MED GENET, V6, P83, DOI 10.1002/ajmg.1320060108; Mitchell LE, 1997, EPIDEMIOL REV, V19, P61, DOI 10.1093/oxfordjournals.epirev.a017947; MITCHELL LE, 1992, AM J HUM GENET, V51, P323; Schutte BC, 1999, HUM MOL GENET, V8, P1853, DOI 10.1093/hmg/8.10.1853; SPRITZ RA, 2001, IN PRESS CURRENT OPI, V13; Suzuki K, 1998, AM J HUM GENET, V63, P1102, DOI 10.1086/302072; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; Tolarova MM, 1998, AM J MED GENET, V75, P126; Young DL, 2000, CRIT REV ORAL BIOL M, V11, P304, DOI 10.1177/10454411000110030201	13	146	150	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2001	29	2					141	142		10.1038/ng740	http://dx.doi.org/10.1038/ng740			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11559849				2022-12-25	WOS:000171374100018
J	Sprecher, E; Bergman, R; Richard, G; Lurie, R; Shalev, S; Petronius, D; Shalata, A; Anbinder, Y; Leibu, R; Perlman, I; Cohen, N; Szargel, R				Sprecher, E; Bergman, R; Richard, G; Lurie, R; Shalev, S; Petronius, D; Shalata, A; Anbinder, Y; Leibu, R; Perlman, I; Cohen, N; Szargel, R			Hypotrichosis with juvenile macular dystrophy is caused by a mutation in CDH3, encoding P-cadherin	NATURE GENETICS			English	Article							HAIR FOLLICLE MORPHOGENESIS; BETA-CATENIN; IN-VITRO; EXPRESSION; MICE	Congenital hypotrichosis associated with juvenile macular dystrophy (HJMD; MIM601553) is an autosomal recessive disorder of unknown etiology, characterized by hair loss heralding progressive macular degeneration and early blindness(1,2). We used homozygosity mapping in four consanguineous families to localize the gene defective in HJMD to 16q22.1. This region contains CDH3, encoding P-cadherin, which is expressed in the retinal pigment epithelium and hair follicles. Mutation analysis shows in all families a common homozygous deletion in exon 8 of CDH3. These results establish the molecular etiology of HJMD and implicate for the first time a cadherin molecule in the pathogenesis of a human hair and retinal disorder.	Rambam Med Ctr, Dept Dermatol, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Pediat Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Human Genet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Physiol & Biophys, IL-31096 Haifa, Israel; Thomas Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA USA; Thomas Jefferson Med Coll, Thomas Jefferson Inst Mol Med, Philadelphia, PA USA; Schneider Childrens Hosp, Pediat Dermatol Unit, Petah Tiqwa, Israel; Haemek Med Ctr, Inst Human Genet, Afula, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Jefferson University; Jefferson University; Emek Medical Center	Sprecher, E (corresponding author), Rambam Med Ctr, Dept Dermatol, IL-31096 Haifa, Israel.							Ahmed ZM, 2001, AM J HUM GENET, V69, P25, DOI 10.1086/321277; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Burke JM, 1999, INVEST OPHTH VIS SCI, V40, P2963; Chen GTC, 1998, ENDOCRINE, V9, P263, DOI 10.1385/ENDO:9:3:263; Da Cruz L, 2001, BRIT J OPHTHALMOL, V85, P239; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; KRUGLYAK L, 1995, AM J HUM GENET, V56, P519; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; Muller-Rover S, 1999, EXP DERMATOL, V8, P237; QUMSIYEH MB, 1997, GENETIC DISORDERS AR, P232; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Riehl R, 1996, NEURON, V17, P837, DOI 10.1016/S0896-6273(00)80216-0; SOUIED E, 1995, OPHTHALMIC GENET, V16, P11, DOI 10.3109/13816819509057848; Yagi T, 2000, GENE DEV, V14, P1169	15	126	132	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					134	136		10.1038/ng716	http://dx.doi.org/10.1038/ng716			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11544476				2022-12-25	WOS:000171374100015
J	Moghadaszadeh, B; Petit, N; Jaillard, C; Brockington, M; Roy, SQ; Merlini, L; Romero, N; Estournet, B; Desguerre, I; Chaigne, D; Muntoni, F; Topaloglu, H; Guicheney, P				Moghadaszadeh, B; Petit, N; Jaillard, C; Brockington, M; Roy, SQ; Merlini, L; Romero, N; Estournet, B; Desguerre, I; Chaigne, D; Muntoni, F; Topaloglu, H; Guicheney, P			Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome	NATURE GENETICS			English	Article							RNA STRUCTURAL MOTIF; SELENOCYSTEINE INSERTION; SECIS ELEMENTS; SELENOPROTEINS; SELENIUM; SEQUENCE	One form of congenital muscular dystrophy, rigid spine syndrome (MIM 602771), is a rare neuromuscular disorder characterized by early rigidity of the spine and respiratory insufficiency. A locus on 1p35-36 (RSMD1) was recently found to segregate with rigid spine muscular dystrophy 1 (ref. 1). Here we refine the locus and find evidence of linkage disequilibrium associated with SEPN1, which encodes the recently described selenoprotein N (ref. 2). Our identification and analysis of mutations in SEPN1 is the first description of a selenoprotein implicated in a human disease.	Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U523, F-75651 Paris 13, France; Hammersmith Hosp, Imperial Coll Sch Med, Dept Paediat & Neonatal Med, London, England; Hop Ray Poincare, Garches, France; Rizzoli Orthoped Inst, Bologna, Italy; Hop St Vincent de Paul, Serv Neuropediat, F-75674 Paris, France; Clin St Odile, Strasbourg, France; Hacettepe Childrens Hosp Med Ctr, Dept Paediat Neurol, Ankara, Turkey	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; IRCCS Istituto Ortopedico Rizzoli; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Hacettepe University	Guicheney, P (corresponding author), Grp Hosp Pitie Salpetriere, Inst Myol, INSERM, U523, 47 Blvd Hop, F-75651 Paris 13, France.		Merlini, Luciano/N-6478-2019; Guicheney, Pascale/D-1034-2017; TOPALOGLU, HALUK AYDIN/I-9318-2013	Merlini, Luciano/0000-0002-1108-1198; Guicheney, Pascale/0000-0002-7663-2050; Moghadaszadeh, Behzad/0000-0001-9787-0106				BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Flanigan KM, 2000, ANN NEUROL, V47, P152, DOI 10.1002/1531-8249(200002)47:2<152::AID-ANA4>3.3.CO;2-L; Flohe L, 2000, IUBMB LIFE, V49, P411; GE KY, 1983, VIRCHOWS ARCH A, V401, P1, DOI 10.1007/BF00644785; Gu QP, 1997, GENE, V193, P187, DOI 10.1016/S0378-1119(97)00113-3; Holben DH, 1999, J AM DIET ASSOC, V99, P836, DOI 10.1016/S0002-8223(99)00198-4; LAMAND MCR, 1970, ACAD SCI HEBD SCI D, V270, P417; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; MERLINI L, 1989, J CHILD NEUROL, V4, P274, DOI 10.1177/088307388900400405; Moghadaszadeh B, 1998, AM J HUM GENET, V62, P1439, DOI 10.1086/301882; Moghadaszadeh B, 1999, NEUROMUSCULAR DISORD, V9, P376, DOI 10.1016/S0960-8966(99)00051-6; OLDFIELD JE, 1989, BIOL TRACE ELEM RES, V20, P23, DOI 10.1007/BF02919095; TOME FMS, 1998, NEUROMUSCULAR DISORD, P21; Walczak R, 1996, RNA, V2, P367; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	15	236	242	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					17	18		10.1038/ng713	http://dx.doi.org/10.1038/ng713			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528383				2022-12-25	WOS:000170781300007
J	Ryo, A; Nakamura, M; Wulf, G; Liou, YC; Lu, KP				Ryo, A; Nakamura, M; Wulf, G; Liou, YC; Lu, KP			Pin 1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; DEPENDENT PROLINE ISOMERIZATION; HUMAN BREAST-CANCER; CELL-CYCLE; PROLYL ISOMERIZATION; XENOPUS EMBRYOS; COLON-CARCINOMA; COMPLEX; IDENTIFICATION; ASSOCIATION	Phosphorylation on a serine or threonine residue preceding proline (Ser/Thr-Pro) is a key regulatory mechanism, and the conformation of certain phosphorylated Ser/Thr-Pro bonds is regulated specifically by the prolyl isomerase Pin1. Whereas the inhibition of Pin1 induces apoptosis, Pin1 is strikingly overexpressed in a subset of human tumours. Here we show that Pin1 regulates beta -catenin turnover and subcellular localization by interfering with its interaction with adenomatous polyposis coli protein (APC). A differential-display screen reveals that Pin1 increases the transcription of several beta -catenin target genes, including those encoding cyclin D1 and c-Myc. Manipulation of Pin1 levels affects the stability of beta -catenin in vitro. Furthermore, beta -catenin levels are decreased in Pin1-deficient mice but are increased and correlated with Pin1 overexpression in human breast cancer. Pin1 directly binds a phosphorylated Ser-Pro motif next to the APC-binding site in beta -catenin, inhibits its interaction with APC and increases its translocation into the nucleus. Thus, Pin1 is a novel regulator of beta -catenin signalling and its overexpression might contribute to the upregulation of beta -catenin in tumours such as breast cancer, in which APC or beta -catenin mutations are not common.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, 330 Brookline Ave, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021					Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kondoh N, 1999, ANAL BIOCHEM, V269, P427, DOI 10.1006/abio.1999.4046; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Polakis P, 2000, GENE DEV, V14, P1837; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	50	411	428	0	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					793	801		10.1038/ncb0901-793	http://dx.doi.org/10.1038/ncb0901-793			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533658				2022-12-25	WOS:000170979600012
J	Filippova, GN; Thienes, CP; Penn, BH; Cho, DH; Hu, YJ; Moore, JM; Klesert, T; Lobanenkov, VV; Tapscott, SJ				Filippova, GN; Thienes, CP; Penn, BH; Cho, DH; Hu, YJ; Moore, JM; Klesert, T; Lobanenkov, VV; Tapscott, SJ			CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus	NATURE GENETICS			English	Article							C-MYC GENE; ENHANCER-BLOCKING ACTIVITY; MYOTONIC-DYSTROPHY GENE; CTG REPEAT; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; REDUCES EXPRESSION; TRIPLET REPEATS; DNA-SEQUENCE; PROTEIN CTCF	An expansion of a CTG repeat at the DM1 locus causes myotonic dystrophy (DM) by altering the expression of the two adjacent genes, DMPK and SIX5, and through a toxic effect of the repeat-containing RNA. Here we identify two CTCF-binding sites that flank the CTG repeat and form an insulator element between DMPK and SIX5. Methylation of these sites prevents binding of CTCF, indicating that the DM1 locus methylation in congenital DM would disrupt insulator function. Furthermore, CTCF-binding sites are associated with CTG/CAG repeats at several other loci. We suggest a general role for CTG/CAG repeats as components of insulator elements at multiple sites in the human genome.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98109 USA; NIAID, Mol Pathol Sect, Immunopathol Lab, NIH, Bethesda, MD 20892 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Washington; University of Washington Seattle	Lobanenkov, VV (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA.		Lobanenkov, Victor/ABD-5710-2021; Lobanenkov, Victor V./AGQ-8903-2022	Tapscott, Stephen/0000-0002-0319-0968; Thienes, Cortlandt/0000-0002-1715-7835; Lobanenkov, Victor/0000-0001-6665-3635	NATIONAL CANCER INSTITUTE [R01CA068360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045203] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA68360] Funding Source: Medline; NIAMS NIH HHS [R01-AR45203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alwazzan M, 1998, MAMM GENOME, V9, P485, DOI 10.1007/s003359900804; Awad TA, 1999, J BIOL CHEM, V274, P27092, DOI 10.1074/jbc.274.38.27092; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Berul CI, 1999, J CLIN INVEST, V103, pR1, DOI 10.1172/JCI5346; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LOBANENKOV VV, 1986, EUR J BIOCHEM, V159, P181, DOI 10.1111/j.1432-1033.1986.tb09850.x; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NOVELLI G, 1993, BIOCHEM MOL BIOL INT, V29, P291; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; Reik W, 2000, NATURE, V405, P408, DOI 10.1038/35013178; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sarkar PS, 2000, NAT GENET, V25, P110, DOI 10.1038/75500; Steinbach P, 1998, AM J HUM GENET, V62, P278, DOI 10.1086/301711; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; Tapscott SJ, 2000, SCIENCE, V289, P1701, DOI 10.1126/science.289.5485.1701; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Wolffe AP, 2000, CURR BIOL, V10, pR463, DOI 10.1016/S0960-9822(00)00534-0	45	245	256	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					335	343		10.1038/ng570	http://dx.doi.org/10.1038/ng570			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479593				2022-12-25	WOS:000170174800013
J	Golovan, SP; Meidinger, RG; Ajakaiye, A; Cottrill, M; Wiederkehr, MZ; Barney, DJ; Plante, C; Pollard, JW; Fan, MZ; Hayes, MA; Laursen, J; Hjorth, JP; Hacker, RR; Phillips, JR; Forsberg, CW				Golovan, SP; Meidinger, RG; Ajakaiye, A; Cottrill, M; Wiederkehr, MZ; Barney, DJ; Plante, C; Pollard, JW; Fan, MZ; Hayes, MA; Laursen, J; Hjorth, JP; Hacker, RR; Phillips, JR; Forsberg, CW			Pigs expressing salivary phytase produce low-phosphorus manure	NATURE BIOTECHNOLOGY			English	Article							BACTERIAL PHYTASE; MICROBIAL PHYTASE; ESCHERICHIA-COLI; TRANSGENIC MICE; DIGESTIBILITY; AVAILABILITY; FEEDSTUFFS; ENVIRONMENT; ENZYME; MOUSE	To address the problem of manure-based environmental pollution in the pork industry, we have developed the phytase transgenic pig. The saliva of these pigs contains the enzyme phytase, which allows the pigs to digest the phosphorus in phytate, the most abundant source of phosphorus in the pig diet. Without this enzyme, phytate phosphorus passes undigested into manure to become the single most important manure pollutant of pork production. We show here that salivary phytase provides essentially complete digestion of dietary phytate phosphorus, relieves the requirement for inorganic phosphate supplements, and reduces fecal phosphorus output by up to 75%. These pigs offer a unique biological approach to the management of phosphorus nutrition and environmental pollution in the pork industry.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Populat Med, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; Aarhus C Univ, Inst Mol & Struct Biol, DK-800 Aarhus C, Denmark	University of Guelph; University of Guelph; University of Guelph; University of Guelph; University of Guelph	Forsberg, CW (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	jphillip@uoguelph.ca; cforsber@uoguelph.ca	Golovan, Serguei/A-6564-2014	Golovan, Serguei/0000-0001-5327-8522				Abelson PH, 1999, SCIENCE, V283, P2015, DOI 10.1126/science.283.5410.2015; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; ALSHAWI R, 1990, MOL CELL BIOL, V10, P1192, DOI 10.1128/MCB.10.3.1192; *AM SOC AGR ENG, 1999, ASAE STAND STAND ENG, P663; BALL WD, 1993, BIOL SALIVARY GLANDS, P355; Chi TH, 2000, SCIENCE, V287, P1937, DOI 10.1126/science.287.5460.1937; Correll DL, 1999, POULTRY SCI, V78, P674, DOI 10.1093/ps/78.5.674; CORRING T, 1980, CURRENT CONCEPTS DIG, P136; DRACKLEY JK, 2000, SOY ANIMAL NUTR; Driver J, 1999, ENVIRON TECHNOL, V20, P651, DOI 10.1080/09593332008616861; EECKHOUT W, 1994, ANIM FEED SCI TECH, V47, P19, DOI 10.1016/0377-8401(94)90156-2; Fan MZ, 1997, J SCI FOOD AGR, V73, P189, DOI 10.1002/(SICI)1097-0010(199702)73:2&lt;189::AID-JSFA702&gt;3.0.CO;2-N; FAN MZ, 2001, J NUTR, V131; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Golovan S, 2000, CAN J MICROBIOL, V46, P59, DOI 10.1139/cjm-46-1-59; Golovan SP, 2001, NAT BIOTECHNOL, V19, P429, DOI 10.1038/88091; Greiner R, 2000, J BIOTECHNOL, V84, P53, DOI 10.1016/S0168-1656(00)00331-X; Jongbloed AW, 1998, J ANIM SCI, V76, P2641; JONGBLOED AW, 1990, NETH J AGR SCI, V38, P567; JONGBLOED AW, 1990, ANIM FEED SCI TECH, V28, P233, DOI 10.1016/0377-8401(90)90155-2; KETAREN PP, 1993, BRIT J NUTR, V70, P289, DOI 10.1079/BJN19930123; Kornegay E. T., 2001, Enzymes in farm animal nutrition, P237, DOI 10.1079/9780851993935.0237; LAM SJ, 1994, METHODS GEN MOL BACT, P104; Leeson S, 2000, CAN J ANIM SCI, V80, P527, DOI 10.4141/A99-123; Mallin MA, 2000, AM SCI, V88, P26, DOI 10.1511/2000.15.762; Mirels L, 1998, BIOCHEM J, V330, P437, DOI 10.1042/bj3300437; MROZ Z, 1994, J ANIM SCI, V72, P126, DOI 10.2527/1994.721126x; Naqvi SWA, 2000, NATURE, V408, P346, DOI 10.1038/35042551; NRC, 1998, NUTR REQ SWIN, DOI [10.17226/6016, DOI 10.17226/6016]; Poulsen HA, 2000, J ENVIRON QUAL, V29, P24, DOI 10.2134/jeq2000.00472425002900010004x; Ridley RM, 1999, VET QUART, V21, P86, DOI 10.1080/01652176.1999.9695000; Robertson G, 1996, NUCLEIC ACIDS RES, V24, P1465, DOI 10.1093/nar/24.8.1465; Ryder SJ, 2000, J COMP PATHOL, V122, P131, DOI 10.1053/jcpa.1999.0349; SAKAMOTO K, 1993, J NUTR, V123, P713, DOI 10.1093/jn/123.4.713; SIMONS PCM, 1990, BRIT J NUTR, V64, P525, DOI 10.1079/BJN19900052; Smil V, 2000, ANNU REV ENERG ENV, V25, P53, DOI 10.1146/annurev.energy.25.1.53; SOUFFRANT WB, 1991, EAAP PUBLIC, V54, P147; Spencer JD, 2000, J ANIM SCI, V78, P675; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; WALL RJ, 1985, BIOL REPROD, V32, P645, DOI 10.1095/biolreprod32.3.645; Wodzinski RJ, 1996, ADV APPL MICROBIOL, V42, P263, DOI 10.1016/S0065-2164(08)70375-7; Zhang ZB, 2000, J ANIM SCI, V78, P2868	42	263	304	0	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					741	745		10.1038/90788	http://dx.doi.org/10.1038/90788			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479566				2022-12-25	WOS:000170188600024
J	Tong, AK; Li, ZM; Jones, GS; Russo, JJ; Ju, JY				Tong, AK; Li, ZM; Jones, GS; Russo, JJ; Ju, JY			Combinatorial fluorescence energy transfer tags for multiplex biological assays	NATURE BIOTECHNOLOGY			English	Article							HUMAN-CHROMOSOMES; DNA; PRIMERS; LIGASE; GENE	We report an approach for developing combinatorial fluorescence energy transfer (CFET) tags by tuning the tags' fluorescence emission signatures. The tags can all be excited at a single wavelength and analyzed by a simple optical system. We constructed eight CFET tags with unique fluorescence signatures, detected by a three-color capillary array electrophoresis (CAE) system with 488 nm excitation, using only three fluorescent dyes. A 1',2'-dideoxyribose phosphate spacer was used to separate the donor and acceptor to tune the energy transfer efficiency, generating unique fluorescence signatures. The spacer also served as an electrophoretic mobility tag to tune the mobility of CFET-labeled DNA for multiplex detection of single-nucleotide polymorphisms (SNPs). Six nucleotide variations were identified simultaneously using six CFET tags on synthetic DNA templates and on a PCR product from the retinoblastoma tumor suppressor gene.	Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, Lab DNA Sequencing & Chem Biol, New York, NY 10032 USA; Columbia Univ, Dept Chem Engn & Appl Chem, New York, NY 10027 USA	Columbia University; Columbia University	Ju, JY (corresponding author), Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, Lab DNA Sequencing & Chem Biol, 701 W 168th St, New York, NY 10032 USA.							BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chen CT, 1998, SCIENCE, V279, P851, DOI 10.1126/science.279.5352.851; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Fairclough R H, 1978, Methods Enzymol, V48, P347; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; Ju JY, 1996, NUCLEIC ACIDS RES, V24, P1144, DOI 10.1093/nar/24.6.1144; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; Kheterpal I, 1999, ANAL CHEM, V71, p31A, DOI 10.1021/ac990099w; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Rosenblum BB, 1997, NUCLEIC ACIDS RES, V25, P4500, DOI 10.1093/nar/25.22.4500; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHUBERT EL, 1994, ANN MED, V26, P177, DOI 10.3109/07853899409147887; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303	18	77	93	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					756	759		10.1038/90810	http://dx.doi.org/10.1038/90810			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479569				2022-12-25	WOS:000170188600027
J	Flattmann, GJ; Kaplan, JM				Flattmann, GJ; Kaplan, JM			Patenting expressed sequence tags and single nucleotide polymorphisms	NATURE BIOTECHNOLOGY			English	Editorial Material									Fish & Neave, New York, NY 10020 USA		Flattmann, GJ (corresponding author), Fish & Neave, 1251 Ave Amer, New York, NY 10020 USA.							Auth DR, 1997, NAT BIOTECHNOL, V15, P911, DOI 10.1038/nbt0997-911; Dastgheib-Vinarov Sara, 2000, MARQ INTELL PROP L R, V4, P143; Eisenberg R S, 2000, Emory Law J, V49, P783; HARNETT CJ, 1994, RISK ISSUES HLTH SAF; HOLMAN MA, 2000, IOWA LAW REV, V735, P753; Kowalski TJ, 2000, NAT BIOTECHNOL, V18, P349, DOI 10.1038/73820; 2001, FED REG, V66, P1092	7	2	2	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					683	684		10.1038/90309	http://dx.doi.org/10.1038/90309			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433286				2022-12-25	WOS:000169677200030
J	Heeschen, C; Jang, JJ; Weis, M; Pathak, A; Kaji, S; Hu, RS; Tsao, PS; Johnson, FL; Cooke, JP				Heeschen, C; Jang, JJ; Weis, M; Pathak, A; Kaji, S; Hu, RS; Tsao, PS; Johnson, FL; Cooke, JP			Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis	NATURE MEDICINE			English	Article							HUMAN-ENDOTHELIAL-CELLS; ARTERIAL SMOOTH-MUSCLE; DNA-SYNTHESIS; NITRIC-OXIDE; MATRIX METALLOPROTEINASES; TRANSDERMAL NICOTINE; CIGARETTE-SMOKING; ACETYLCHOLINE; PROSTACYCLIN; MODULATION	We provide anatomic and functional evidence that nicotine induces angiogenesis. We also show that nicotine accelerates the growth of tumor and atheroma in association with increased neovascularization. Nicotine increased endothelial-cell growth and tube formation in vitro, and accelerated fibrovascular growth in vivo. In a mouse model of hind-limb ischemia, nicotine increased capillary and collateral growth, and enhanced tissue perfusion. In mouse models of lung cancer and atherosclerosis, we found that nicotine enhanced lesion growth in association with an increase in lesion vascularity. These effects of nicotine were mediated through nicotinic acetylcholine receptors at nicotine concentrations that are pathophysiologically relevant. The endothelial production of nitric oxide, prostacyclin and vascular endothelial growth factor might have a role in these effects.	Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA	Stanford University	Cooke, JP (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA.		Guba, Markus/M-4309-2019	Cooke, John/0000-0003-0033-9138; Heeschen, Christopher/0000-0002-1158-8554	NHLBI NIH HHS [R01 HL-58638] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADIO B, 1994, MOL PHARMACOL, V45, P563; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BOUTHERINFALSON O, 1990, NOUV REV FR HEMATOL, V32, P253; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carty CS, 1996, J VASC SURG, V24, P927, DOI 10.1016/S0741-5214(96)70038-1; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Clouse WD, 2000, J APPL PHYSIOL, V89, P1213, DOI 10.1152/jappl.2000.89.3.1213; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Cucina A, 1999, BIOCHEM BIOPH RES CO, V257, P306, DOI 10.1006/bbrc.1999.0478; Cucina A, 2000, SURGERY, V127, P316, DOI 10.1067/msy.2000.104249; FOLTS JD, 1990, ADV EXP MED BIOL, V273, P339; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GULLINO PM, 1978, JNCI-J NATL CANCER I, V61, P639; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hecht SS, 2000, P NATL ACAD SCI USA, V97, P12493, DOI 10.1073/pnas.220207697; HILL P, 1983, J CHRON DIS, V36, P439, DOI 10.1016/0021-9681(83)90136-4; Jang JJ, 2000, CIRCULATION, V102, P1414, DOI 10.1161/01.CIR.102.12.1414; Jones MK, 1999, NAT MED, V5, P1418; Joseph AM, 1996, NEW ENGL J MED, V335, P1792, DOI 10.1056/NEJM199612123352402; KAWASHIMA K, 1990, NEUROSCI LETT, V119, P156, DOI 10.1016/0304-3940(90)90822-Q; KAWASHIMA K, 1989, NEUROSCI LETT, V104, P336, DOI 10.1016/0304-3940(89)90599-5; Krupski W C, 1991, Ann Vasc Surg, V5, P291, DOI 10.1007/BF02329389; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lee WO, 1999, METABOLISM, V48, P845, DOI 10.1016/S0026-0495(99)90216-0; LI Z, 1994, J PHARMACOL EXP THER, V271, P1135; Macklin KD, 1998, J PHARMACOL EXP THER, V287, P435; MAGERS T, 1995, REPROD TOXICOL, V9, P513, DOI 10.1016/0890-6238(95)02002-0; Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Payne JB, 1996, J PERIODONTAL RES, V31, P99, DOI 10.1111/j.1600-0765.1996.tb00470.x; PITTILO RM, 1990, INT J EXP PATHOL, V71, P573; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Powell J T, 1998, Vasc Med, V3, P21, DOI 10.1191/135886398670269973; Pratico D, 2001, P NATL ACAD SCI USA, V98, P3358, DOI 10.1073/pnas.061607398; Schaper W, 1999, CARDIOVASC RES, V43, P835, DOI 10.1016/S0008-6363(99)00191-1; Sopori ML, 1998, ADV EXP MED BIOL, V437, P279; St Croix B, 2000, SCIENCE, V289, P1197; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; THYBERG J, 1986, VIRCHOWS ARCH B, V52, P25, DOI 10.1007/BF02889947; Tonnessen BH, 2000, J PHARMACOL EXP THER, V295, P601; Villablanca AC, 1998, J APPL PHYSIOL, V84, P2089, DOI 10.1152/jappl.1998.84.6.2089; Waldum HL, 1996, LIFE SCI, V58, P1339, DOI 10.1016/0024-3205(96)00100-2; Wilke N, 1997, RADIOLOGY, V204, P373, DOI 10.1148/radiology.204.2.9240523; Zhang SL, 2001, ATHEROSCLEROSIS, V154, P277, DOI 10.1016/S0021-9150(00)00475-5	46	596	680	1	44	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					833	839		10.1038/89961	http://dx.doi.org/10.1038/89961			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433349				2022-12-25	WOS:000169808600036
J	Mitchell, KJ; Pinson, KI; Kelly, OG; Brennan, J; Zupicich, L; Scherz, P; Leighton, PA; Goodrich, LV; Lu, XW; Avery, BJ; Tate, P; Dill, K; Pangilinan, E; Wakenight, P; Tessier-Lavigne, M; Skarnes, WC				Mitchell, KJ; Pinson, KI; Kelly, OG; Brennan, J; Zupicich, L; Scherz, P; Leighton, PA; Goodrich, LV; Lu, XW; Avery, BJ; Tate, P; Dill, K; Pangilinan, E; Wakenight, P; Tessier-Lavigne, M; Skarnes, WC			Functional analysis of secreted and transmembrane proteins critical to mouse development	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; GENE TRAP INTEGRATIONS; INSERTIONAL MUTATIONS; REGULATED GENES; GROWTH-FACTOR; MUTANT MICE; GENOME-WIDE; TOUT-VELU; DISRUPTION; IDENTIFICATION	We describe the successful application of a modified gene-trap approach, the secretory trap, to systematically analyze the functions in vivo of large numbers of genes encoding secreted and membrane proteins. Secretory-trap insertions in embryonic stem cells can be transmitted to the germ line of mice with high efficiency and effectively mutate the target gene. Of 60 insertions analyzed in mice, one-third cause recessive lethal phenotypes affecting various stages of embryonic and postnatal development. Thus, secretory-trap mutagenesis can be used for a genome-wide functional analysis of cell signaling pathways that are critical for normal mammalian development and physiology.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Skarnes, WC (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	skarnes@socrates.berkeley.edu	Schick, Joel/ABA-3728-2021	Schick, Joel/0000-0002-8623-4910; Mitchell, Kevin/0000-0002-3433-4530; Brennan, Jane/0000-0003-3222-5485				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Brennan J, 1999, METH MOL B, V97, P123, DOI 10.1385/1-59259-270-8:123; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Burgess RW, 2000, J CELL BIOL, V151, P41, DOI 10.1083/jcb.151.1.41; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; CHEN CC, 1993, ASIA PAC J PHARMACOL, V8, P1; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CORMICK C, 1998, NAT GENET, V19, P158; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; Forrester LM, 1996, P NATL ACAD SCI USA, V93, P1677, DOI 10.1073/pnas.93.4.1677; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Friedrich GA, 1997, DEV BIOL, V192, P364, DOI 10.1006/dbio.1997.8727; GASCA S, 1995, DEV GENET, V17, P141, DOI 10.1002/dvg.1020170206; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; McClive P, 1998, DEV DYNAM, V212, P267, DOI 10.1002/(SICI)1097-0177(199806)212:2<267::AID-AJA11>3.0.CO;2-1; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Sagane K, 1999, GENE, V236, P79, DOI 10.1016/S0378-1119(99)00253-X; Sam M, 1998, DEV DYNAM, V212, P304, DOI 10.1002/(SICI)1097-0177(199806)212:2<304::AID-AJA15>3.0.CO;2-3; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Skarnes WC, 2000, METHOD ENZYMOL, V328, P592, DOI 10.1016/S0076-6879(00)28420-6; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Tate P, 1998, J CELL SCI, V111, P2575; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; Voss AK, 1998, DEV DYNAM, V212, P258; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WURST W, 1995, GENETICS, V139, P889; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	55	329	344	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					241	249		10.1038/90074	http://dx.doi.org/10.1038/90074			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431694				2022-12-25	WOS:000169656400016
J	Moellenbeck, DJ; Peters, ML; Bing, JW; Rouse, JR; Higgins, LS; Sims, L; Nevshemal, T; Marshall, L; Ellis, RT; Bystrak, PG; Lang, BA; Stewart, JL; Kouba, K; Sondag, V; Gustafson, V; Nour, K; Xu, DP; Swenson, J; Zhang, J; Czapla, T; Schwab, G; Jayne, S; Stockhoff, BA; Narva, K; Schnepf, HE; Stelman, SJ; Poutre, C; Koziel, M; Duck, N				Moellenbeck, DJ; Peters, ML; Bing, JW; Rouse, JR; Higgins, LS; Sims, L; Nevshemal, T; Marshall, L; Ellis, RT; Bystrak, PG; Lang, BA; Stewart, JL; Kouba, K; Sondag, V; Gustafson, V; Nour, K; Xu, DP; Swenson, J; Zhang, J; Czapla, T; Schwab, G; Jayne, S; Stockhoff, BA; Narva, K; Schnepf, HE; Stelman, SJ; Poutre, C; Koziel, M; Duck, N			Insecticidal proteins from Bacillus thuringiensis protect corn from corn rootworms	NATURE BIOTECHNOLOGY			English	Article							CHRYSOMELIDAE; COLEOPTERA; PLANTS; GENES; RICE	Field tests of corn co-expressing two new delta-endotoxins from Bacillus thuringiensis (Bt) have demonstrated protection from root damage by western corn rootworm (Diabrotica virgifera virgifera LeConte). The level of protection exceeds that provided by chemical insecticides. In the bacterium, these proteins form crystals during the sporulation phase of the growth cycle, are encoded by a single operon, and have molecular masses of 14 kDa and 44 kDa. Corn rootworm larvae fed on corn roots expressing the proteins showed histopathological symptoms in the midgut epithelium.	Pioneer HiBred Int Inc, Johnston, IA 50131 USA; Dow AgroSci LLC, Huxley, IA 50124 USA; Dow AgroSci LLC, San Diego, CA 92121 USA	DuPont; Dow Chemical Company; Dow Chemical Company	Moellenbeck, DJ (corresponding author), Pioneer HiBred Int Inc, 7250 NW 62nd Ave,POB 552, Johnston, IA 50131 USA.	DAN.MOLLENBECK@pioneer.com		Narva, Kenneth/0000-0001-8094-6418; Moellenbeck, Daniel/0000-0002-0646-8806				Armstrong C. L., 1991, Maize Genetics Cooperation News Letter, P92; BAUMANN L, 1988, J BACTERIOL, V170, P2045, DOI 10.1128/jb.170.5.2045-2050.1988; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; CHU CC, 1975, SCI SINICA, V18, P659; Estruch JJ, 1996, P NATL ACAD SCI USA, V93, P5389, DOI 10.1073/pnas.93.11.5389; FUJIMOTO H, 1993, BIO-TECHNOL, V11, P1151, DOI 10.1038/nbt1093-1151; HILLS TM, 1971, J ECON ENTOMOL, V64, P764, DOI 10.1093/jee/64.3.764; KLEIN TM, 1988, BIO-TECHNOL, V6, P559, DOI 10.1038/nbt0588-559; KOZIEL MG, 1993, BIO-TECHNOL, V11, P194, DOI 10.1038/nbt0293-194; Levine E, 1996, J ECON ENTOMOL, V89, P1010, DOI 10.1093/jee/89.4.1010; MARRONE PG, 1985, J ECON ENTOMOL, V78, P290, DOI 10.1093/jee/78.1.290; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PERLAK FJ, 1993, PLANT MOL BIOL, V22, P313, DOI 10.1007/BF00014938; PERLAK FJ, 1990, BIO-TECHNOL, V8, P939, DOI 10.1038/nbt1090-939; RUSSELL R M, 1977, Bulletin of the Entomological Society of America, V23, P209; RYERSE JS, 1994, TISSUE CELL, V26, P431, DOI 10.1016/0040-8166(94)90026-4; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Tukey JW., 1953, PROBLEM MULTIPLE COM; Warren G.W., 1997, ADV INSECT CONTROL R, P109, DOI DOI 10.1201/9780203211731.CH7; [No title captured]	20	152	220	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					668	672		10.1038/90282	http://dx.doi.org/10.1038/90282			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433280				2022-12-25	WOS:000169677200024
J	O'Rahilly, S				O'Rahilly, S			Uncoupling protein 2: Adiposity angel and diabetes devil?	NATURE MEDICINE			English	Editorial Material							SKELETAL-MUSCLE; BROWN FAT; GENE; MICE; OVEREXPRESSION; ISLETS	The discovery of a family of proteins with strong homology to the uncoupling protein of brown fat has generated great interest as these molecules might represent therapeutic targets for human obesity. Two recent studies have used genetics to explore the role of one of these proteins, UCP2, in the control of mammalian metabolism and come to rather different conclusions.	Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England.		O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	12	15	15	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					770	772		10.1038/89877	http://dx.doi.org/10.1038/89877			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433333				2022-12-25	WOS:000169808600016
J	Serra, E; Rosenbaum, T; Nadal, M; Winner, U; Ars, E; Estivill, X; Lazaro, C				Serra, E; Rosenbaum, T; Nadal, M; Winner, U; Ars, E; Estivill, X; Lazaro, C			Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas	NATURE GENETICS			English	Letter							BENIGN NEUROFIBROMAS; GENE; HETEROZYGOSITY; TYPE-1; CELLS; TUMORS; DNA	Pure populations of neurofibroma-derived Schwann cells bearing both NF1 mutated alleles (NF1(-/-)) have been isolated from different neurofibromas' showing loss of heterozygosity of nearly the entire 17q chromosome. By comparing molecular and fluorescent in site hybridization analysis of these cells, we demonstrate mitotic recombination is the mechanism underlying this type of loss of heterozygosity leading to reduction to homozygosity of NF1 germline mutation.	Hosp Duran & Reynals, IRO, Med & Mol Genet Ctr, Barcelona 08907, Spain; Univ Dusseldorf, Childrens Hosp, Dept Neuropediat, D-40225 Dusseldorf, Germany	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Heinrich Heine University Dusseldorf	Lazaro, C (corresponding author), Hosp Duran & Reynals, IRO, Med & Mol Genet Ctr, Autovia Castelldefels Km 2-7, Barcelona 08907, Spain.	clazaro@iro.es	GARCIA, CONXI LAZARO/Q-2410-2016; Ars, Elisabet/AAM-8454-2021; Serra, Eduard/K-1332-2013; Estivill, Xavier/E-2957-2012; Estivill, Xavier/A-3125-2013	GARCIA, CONXI LAZARO/0000-0002-7198-5906; Ars, Elisabet/0000-0002-4118-4358; Serra, Eduard/0000-0003-2895-9857; Estivill, Xavier/0000-0002-0723-2256; Nadal, Marga/0000-0002-5739-1693				Ars E, 2000, HUM MOL GENET, V9, P237, DOI 10.1093/hmg/9.2.237; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; Cooper LJN, 2000, BLOOD, V96, P2310; Correa CL, 2000, AM J HUM GENET, V66, P1969, DOI 10.1086/302920; Daschner K, 1997, BIOCHEM BIOPH RES CO, V234, P346, DOI 10.1006/bbrc.1997.6645; Dorschner MO, 2000, HUM MOL GENET, V9, P35, DOI 10.1093/hmg/9.1.35; EASTGATE AR, 1993, J ANAL ATOM SPECTROM, V8, P305, DOI 10.1039/ja9930800305; Eisenbarth I, 2000, AM J HUM GENET, V66, P393, DOI 10.1086/302747; Gupta PK, 1997, CANCER RES, V57, P1188; Holt D, 1999, AM J HUM GENET, V65, P1423, DOI 10.1086/302614; John AM, 2000, J MED GENET, V37, P44, DOI 10.1136/jmg.37.1.44; Kluwe L, 1999, CANCER GENET CYTOGEN, V113, P65, DOI 10.1016/S0165-4608(99)00006-0; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nadal M, 1997, J MED GENET, V34, P50, DOI 10.1136/jmg.34.1.50; Rasmussen SA, 2000, GENE CHROMOSOME CANC, V28, P425, DOI 10.1002/1098-2264(200008)28:4<425::AID-GCC8>3.0.CO;2-E; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; Serra E, 1997, AM J HUM GENET, V61, P512, DOI 10.1086/515504; Serra E, 2001, HUM GENET, V108, P416; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; STEPHENS K, 1998, AM J HUM GENET, V63, pA39; Tischfield JA, 1997, AM J HUM GENET, V61, P995, DOI 10.1086/301617; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087	25	55	57	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					294	296		10.1038/90148	http://dx.doi.org/10.1038/90148			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431704				2022-12-25	WOS:000169656400026
J	Coller, HA; Khrapko, K; Bodyak, ND; Nekhaeva, E; Herrero-Jimenez, P; Thilly, WG				Coller, HA; Khrapko, K; Bodyak, ND; Nekhaeva, E; Herrero-Jimenez, P; Thilly, WG			High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection	NATURE GENETICS			English	Letter							MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; POINT MUTATIONS; CONTROL REGION; UNITED-STATES; COLON-CANCER; GENOME; SEGREGATION; ADVANTAGE; SEQUENCE	Researchers in several laboratories have reported a high frequency of homoplasmic mitochondrial DNA (mtDNA) mutations in human tumors(1-6). This observation has been interpreted to reflect a replicative advantage for mutated mtDNA copies(1,2,6), a growth advantage for a cell containing certain mtDNA mutations(1,6), and/or tumorigenic properties of mtDNA mutations(2). We consider another possibility-that the observed homoplasmy arose entirely by chance in tumor progenitor cells, without any physiological advantage or tumorigenic requirement. Through extensive computer modeling, we demonstrate that there is sufficient opportunity for a tumor progenitor cell to achieve homoplasmy through unbiased mtDNA replication and sorting during cell division. To test our model in vivo, we analyzed mtDNA homoplasmy in healthy human epithelial tissues and discovered that the model correctly predicts the considerable observed frequency of homoplasmic cells. Based on the available data on mitochondrial mutant fractions and cell division kinetics, we show that the predicted frequency of homoplasmy in tumor progenitor cells in the absence of selection is similar to the reported frequency of homoplasmic mutations in tumors. Although a role for other mechanisms is not excluded, random processes are sufficient to explain the incidence of homoplasmic mtDNA mutations in human tumors.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98119 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; MIT, Div Bioengn & Environm Hlth, Environm Hlth Sci Ctr, Cambridge, MA 02139 USA	Fred Hutchinson Cancer Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Coller, HA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98119 USA.		Khrapko, Konstantin/A-3244-2009		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES007168, P30ES002109, P42ES004675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000251, R03AG018536] Funding Source: NIH RePORTER; NIA NIH HHS [R03-AG18536, T32-AG18388, T32-AG00251] Funding Source: Medline; NIEHS NIH HHS [P01-ES07168, P30 ES002109, P42-ES04675, P30-ES02109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2; AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.es.18.110187.002421; BODENTEICH A, 1991, GENE, V108, P305, DOI 10.1016/0378-1119(91)90451-G; Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17; Cavelier L, 2000, EXP CELL RES, V259, P79, DOI 10.1006/excr.2000.4949; Coller HA, 1998, CANCER RES, V58, P1268; COOK PJ, 1969, INT J CANCER, V4, P93, DOI 10.1002/ijc.2910040113; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; HEERDT BG, 1994, CANCER RES, V54, P3912; Herrero-Jimenez P, 2000, MUTAT RES-FUND MOL M, V447, P73, DOI 10.1016/S0027-5107(99)00201-8; Herrero-Jimenez P, 1998, MUTAT RES-FUND MOL M, V400, P553, DOI 10.1016/S0027-5107(98)00067-0; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MONNAT RJ, 1985, P NATL ACAD SCI USA, V82, P2895, DOI 10.1073/pnas.82.9.2895; Pallotti F, 1996, AM J HUM GENET, V59, P591; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Richard SM, 2000, CANCER RES, V60, P4231; SHAY JW, 1990, ANTICANCER RES, V10, P279; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Shibata D, 1996, NAT MED, V2, P676, DOI 10.1038/nm0696-676; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	25	222	232	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					147	150		10.1038/88859	http://dx.doi.org/10.1038/88859			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381261				2022-12-25	WOS:000169011800016
J	Duckers, HJ; Boehm, M; True, AL; Yet, SF; San, H; Park, JL; Webb, RC; Lee, ME; Nabel, GJ; Nabel, EG				Duckers, HJ; Boehm, M; True, AL; Yet, SF; San, H; Park, JL; Webb, RC; Lee, ME; Nabel, GJ; Nabel, EG			Heme oxygenase-1 protects against vascular constriction and proliferation	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; CARBON-MONOXIDE; NITRIC-OXIDE; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; GENE-EXPRESSION; P21; ACTIVATION; INHIBITORS; INDUCTION	Heme oxygenase (HO-1, encoded by Hmox1) is an inducible protein activated in systemic inflammatory conditions by oxidant stress. Vascular injury is characterized by a local reparative process with inflammatory components, indicating a potential protective role for HO-1 in arterial wound repair. Here we report that HO-1 directly reduces vasoconstriction and inhibits cell proliferation during vascular injury. Expression of HO-1 in arteries stimulated vascular relaxation, mediated by guanylate cyclase and cGMP, independent of nitric oxide. The unexpected effects of HO-1 on vascular smooth muscle cell growth were mediated by cell-cycle arrest involving p21(Cip1). HO-1 reduced the proliferative response to vascular injury in vivo; expression of HO-1 in pig arteries inhibited lesion formation and Hmox1(-/-) mice produced hyperplastic arteries compared with controls. Induction of the HO-1 pathway moderates the severity of vascular injury by at least two adaptive mechanisms independent of nitric oxide, and is a potential therapeutic target for diseases of the vasculature.	NHLBI, Vasc Biol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Georgia; Augusta University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Nabel, EG (corresponding author), NHLBI, Vasc Biol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	enabel@nih.gov	Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; OTTERBEIN LE, 1999, AM J PHYSIOL, V276, P688; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; Wang LJ, 1998, AM J PATHOL, V152, P711; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	36	454	485	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					693	698		10.1038/89068	http://dx.doi.org/10.1038/89068			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385506				2022-12-25	WOS:000169081500037
J	Moroni, MC; Hickman, ES; Denchi, EL; Caprara, G; Colli, E; Cecconi, F; Muller, H; Helin, K				Moroni, MC; Hickman, ES; Denchi, EL; Caprara, G; Colli, E; Cecconi, F; Muller, H; Helin, K			Apaf-1 is a transcriptional target for E2F and p53	NATURE CELL BIOLOGY			English	Article							S-PHASE ENTRY; CELL-DEATH; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; APOPTOSIS; INHIBITION; CASPASE-9; PATHWAYS; HOMOLOG; P73	Loss of function of the retinoblastoma protein, pRB, leads to lack of differentiation, hyperproliferation and apoptosis. Inactivation of pRB results in deregulated E2F activity, which in turn induces entry to S-phase and apoptosis. Induction of apoptosis by either the loss of pRB or the deregulation of E2F activity occurs via both p53-dependent and p53-independent mechanisms. The mechanism by which E2F induces apoptosis is still unclear. Here we show that E2F1 directly regulates the expression of Apaf-1, the gene for apoptosis protease-activating factor 1. These results provide a direct link between the deregulation of the pRB pathway and apoptosis. Furthermore, because the pRB pathway is functionally inactivated in most cancers, the identification of Apaf-1 as a transcriptional target for E2F might explain the increased sensitivity of tumour cells to chemotherapy. We also show that, independently of the pRB pathway, Apaf-1 is a direct transcriptional target of p53, suggesting that p53 might sensitize cells to apoptosis by increasing Apaf-1 levels.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany	IRCCS European Institute of Oncology (IEO); Max Planck Society	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Moroni, Maria Cristina/H-7044-2018; Denchi, Eros Lazzerini/AAD-8208-2020; Cecconi, Francesco/K-3969-2016; Caprara, Greta/AAM-8110-2020; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022; lazzerini denchi, eros/F-7913-2010	Moroni, Maria Cristina/0000-0003-2409-5764; Cecconi, Francesco/0000-0002-5614-4359; Caprara, Greta/0000-0001-9975-4395; Helin, Kristian/0000-0003-1975-6097; lazzerini denchi, eros/0000-0001-5378-4644; Muller, Heiko/0000-0001-9873-3146				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holme IB, 1998, PLANT CELL TISS ORG, V53, P143, DOI 10.1023/A:1006001419989; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Pelton R., 1990, DEVELOPMENT, V110, P600; Perkins C, 1998, CANCER RES, V58, P4561; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8	38	498	511	0	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					552	558		10.1038/35078527	http://dx.doi.org/10.1038/35078527			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389439				2022-12-25	WOS:000169194400010
J	Takahashi, N; Kakinuma, H; Liu, LD; Nishi, Y; Fujii, I				Takahashi, N; Kakinuma, H; Liu, LD; Nishi, Y; Fujii, I			In vitro abzyme evolution to optimize antibody recognition for catalysis	NATURE BIOTECHNOLOGY			English	Article							CATALYTIC ANTIBODIES; SPECIFICITY; GENERATION; RESIDUES	Enzymes have evolved their ability to use binding energies for catalysis by increasing the affinity for the transition state of a reaction and decreasing the affinity for the ground state. To evolve abzymes toward higher catalytic activity, we have reconstructed an enzyme-evolutionary process in vitro. Thus, a phage-displayed combinatorial library from a hydrolytic abzyme, 6D9, generated by the conventional in vivo method with immunization of the transition-state analog (TSA), was screened against a newly devised TSA to optimize the differential affinity for the transition state relative to the ground state. The library format successfully afforded evolved variants with 6- to 20-fold increases in activity (k(cat)) as compared with 6D9. Structural analysis revealed an advantage of the in vitro evolution over the in vivo evolution: an induced catalytic residue in the evolved abzyme arises from double mutations in one codon, which rarely occur in somatic hypermutation in the immune response.	Biomol Engn Res Inst, Suita, Osaka 5650784, Japan; Japan Tobacco Inc, Lab Life Sci & Biomed Engn, Aoba Ku, Yokohama, Kanagawa 2278512, Japan	Japan Tobacco Inc.	Fujii, I (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 5650784, Japan.	fujii@bioorg.beri.co.jp		Takahashi-Ando, Naoko/0000-0001-8997-0772				ANGELES TS, 1993, BIOCHEMISTRY-US, V32, P12128, DOI 10.1021/bi00096a025; Arkin MR, 1998, J MOL BIOL, V284, P1083, DOI 10.1006/jmbi.1998.2234; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; CAGNON C, 1991, PROTEIN ENG, V4, P843, DOI 10.1093/protein/4.7.843; CORBET S, 1987, J IMMUNOL, V138, P932; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FUJII I, 1995, J AM CHEM SOC, V117, P6199, DOI 10.1021/ja00128a006; Fujii I, 1998, NAT BIOTECHNOL, V16, P463, DOI 10.1038/nbt0598-463; Gao CS, 1998, J AM CHEM SOC, V120, P2211, DOI 10.1021/ja9720220; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Janda KD, 1997, SCIENCE, V275, P945, DOI 10.1126/science.275.5302.945; Kabat EA, 1991, SEQUENCES PROTEINS I; Kristensen O, 1998, J MOL BIOL, V281, P501, DOI 10.1006/jmbi.1998.1940; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LIENHARD GE, 1973, SCIENCE, V180, P149, DOI 10.1126/science.180.4082.149; MIYASHITA H, 1993, P NATL ACAD SCI USA, V90, P5337, DOI 10.1073/pnas.90.11.5337; MIYASHITA H, 1994, P NATL ACAD SCI USA, V91, P6045, DOI 10.1073/pnas.91.13.6045; Miyashita H, 1997, J MOL BIOL, V267, P1247, DOI 10.1006/jmbi.1997.0938; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; PAULING L, 1948, Am Sci, V36, P51; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Takahashi N, 1999, EUR J BIOCHEM, V261, P108, DOI 10.1046/j.1432-1327.1999.00235.x; Tanaka F, 2000, J AM CHEM SOC, V122, P4835, DOI 10.1021/ja0005441; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Wentworth P, 1998, P NATL ACAD SCI USA, V95, P5971, DOI 10.1073/pnas.95.11.5971; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775	30	60	63	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					563	567		10.1038/89320	http://dx.doi.org/10.1038/89320			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385462				2022-12-25	WOS:000169081700031
J	Wicks, SR; Yeh, RT; Gish, WR; Waterston, RH; Plasterk, RHA				Wicks, SR; Yeh, RT; Gish, WR; Waterston, RH; Plasterk, RHA			Rapid gene mapping in Caenorhabditis elegans using a high density polymorphism map	NATURE GENETICS			English	Letter							SINGLE-NUCLEOTIDE POLYMORPHISMS; BULKED SEGREGANT ANALYSIS; NATURAL VARIATION; RESISTANCE GENES; C-ELEGANS; MARKERS; GENOME; IDENTIFICATION; PATTERNS; NEURONS	Single nucleotide polymorphisms (SNPs) are valuable genetic markers of human disease(1-3). They also comprise the highest potential density marker set available for mapping experimentally derived mutations in model organisms such as Caenorhabditis elegans. To facilitate the positional cloning of mutations we have identified polymorphisms in CB4856, an isolate from a Hawaiian island that shows a uniformly high density of polymorphisms compared with the reference Bristol N2 strain. Based on 5.4 Mbp of aligned sequences, we predicted 6.222 polymorphisms. Furthermore, 3,457 of these markers modify restriction enzyme recognition sites ('snip-SNPs') and are therefore easily detected as RFLPs. Of these, 493 were experimentally confirmed by restriction digest to produce a snip-SNP map of the worm genome. A mapping strategy using snip-SNPs and bulked segregant analysis(4) (BSA) is outlined. CB4856 is crossed into a mutant strain, and exclusion of CB4856 alleles of a subset of snip-SNPs in mutant progeny is assesed with BSA. The proximity of a linked marker to the mutation is estimated by the relative proportion of each form of the biallelic marker in populations of wildtype and mutant genomes. The usefulness of this approach is illustrated by the rapid mapping of the dyf-5 gene.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Netherlands Inst Dev Biol, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Washington Univ, Dept Genet, St Louis, MO 63108 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Washington University (WUSTL); Washington University (WUSTL)	Plasterk, RHA (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Gish, Warren/C-8123-2012; Wicks, Stephen/AAJ-7470-2020	Wicks, Stephen/0000-0003-3908-1891				ARRATIA R, 1991, GENOMICS, V11, P806, DOI 10.1016/0888-7543(91)90004-X; Bedell JA, 2000, BIOINFORMATICS, V16, P1040, DOI 10.1093/bioinformatics/16.11.1040; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; De Tomaso AW, 1998, GENETICS, V149, P277; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gilles PN, 1999, NAT BIOTECHNOL, V17, P365, DOI 10.1038/7921; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Hodgkin J, 1997, GENETICS, V146, P149; Jakubowski J, 1999, GENETICS, V153, P743; Koch R, 2000, GENOME RES, V10, P1690, DOI 10.1101/gr.GR-1471R; Kolchinsky A, 1997, MOL GEN GENET, V254, P29, DOI 10.1007/s004380050387; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Kurian KM, 1999, J PATHOL, V187, P267; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Petrov DA, 1999, P NATL ACAD SCI USA, V96, P1475, DOI 10.1073/pnas.96.4.1475; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Severson DW, 1999, GENET RES, V73, P217, DOI 10.1017/S0016672399003791; STARICH TA, 1995, GENETICS, V139, P171; Villar M, 1996, GENETICS, V143, P531; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	27	488	497	1	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					160	164		10.1038/88878	http://dx.doi.org/10.1038/88878			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381264				2022-12-25	WOS:000169011800019
J	Bermak, JC; Li, M; Bullock, C; Zhou, QY				Bermak, JC; Li, M; Bullock, C; Zhou, QY			Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein	NATURE CELL BIOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; COUPLED RECEPTOR; SECRETORY PATHWAY; CYTOPLASMIC TAIL; BINDING; EXPORT; GLYCOPROTEIN; LOCALIZATION	Many structural determinants for G protein-coupled receptor (GPCR) functions have been defined, but little is known concerning the regulation of their transport from the endoplasmic reticulum (ER) to the cell surface. Here we show that a carboxy-terminal hydrophobic motif, FxxxFxxxF, which is highly conserved among GPCRs, functions independently as an ER-export signal for the dopamine D1 receptor. A newly identified ER-membrane-associated protein, DRiP78, binds to this motif. Overexpression or sequestration of DRiP78 leads to retention of D1 receptors in the ER, reduced ligand binding, and a slowdown in the kinetics of receptor glycosylation. Our results indicate that DRiP78 may regulate the transport of a GPCR by binding to a specific ER-export signal.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Bermak, JC (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.							BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Bohm SK, 1997, BIOCHEM J, V322, P1; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Fiedler K, 1997, J BIOL CHEM, V272, P24739, DOI 10.1074/jbc.272.40.24739; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kuznetsov G, 1998, NEW ENGL J MED, V339, P1688, DOI 10.1056/NEJM199812033392307; Lane D., 1988, ANTIBODIES LAB MANUA, P579; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	37	218	224	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					492	498		10.1038/35074561	http://dx.doi.org/10.1038/35074561			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331877				2022-12-25	WOS:000168592500019
J	Chen, RY; Kim, O; Li, M; Xiong, XS; Guan, JL; Kung, HJ; Chen, HG; Shimizu, Y; Qiu, Y				Chen, RY; Kim, O; Li, M; Xiong, XS; Guan, JL; Kung, HJ; Chen, HG; Shimizu, Y; Qiu, Y			Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain	NATURE CELL BIOLOGY			English	Article							PROMOTED CELL-MIGRATION; PROSTATE-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; FAMILY; BTK; SRC; ASSOCIATION; ACTIVATION; PHOSPHORYLATION; PROTEINS	Etk/BMX, a member of the Btk family of tyrosine kinases, is highly expressed in cells with great migratory potential, including endothelial cells and metastatic carcinoma cell lines. Here, we present evidence that Etk is involved in integrin signalling and promotes cell migration. The activation of Etk by extracellular matrix proteins is regulated by FAK through an interaction between the PH domain of Etk and the FERM domain of FAK. The lack of Etk activation by extracellular matrix in FAK-null cells could be restored by co-transfection with wild-type FAK, Disrupting the interaction between Etk and FAK diminished the cell migration promoted by either kinase. Furthermore, inhibiting Etk expression in metastatic carcinoma cell lines with an antisense oligonucleotide blocks integrin-mediated migration of these cells. Taken together, our data indicate the essential role of the interaction of the PH domain of Etk and the FERM domain of FAK in integrin signalling.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cornell University; University of California System; University of California Davis; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Chen, RY (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.		Kung, Hsing-Jien/C-7651-2013	Shimizu, Yoji/0000-0001-9760-0288	NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SIGE DJ, 2000, NATURE CELL BIOL, V2, P249; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	28	120	126	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					439	444		10.1038/35074500	http://dx.doi.org/10.1038/35074500			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331870				2022-12-25	WOS:000168592500012
J	Fujita, T; Toda, K; Karimova, A; Yan, SF; Naka, Y; Yet, SF; Pinsky, DJ				Fujita, T; Toda, K; Karimova, A; Yan, SF; Naka, Y; Yet, SF; Pinsky, DJ			Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis	NATURE MEDICINE			English	Article							HUMAN SKIN FIBROBLASTS; SMOOTH-MUSCLE CELLS; HEME OXYGENASE-1; NITRIC-OXIDE; OXIDATIVE STRESS; ISCHEMIA/REPERFUSION INJURY; PROVIDES PROTECTION; UP-REGULATION; NULL MICE; GENE	Carbon monoxide (CO) can arrest cellular respiration, but paradoxically, it is synthesized endogenously by heme oxygenase type 1 (Ho-1) in response to ischemic stress. Ho-1-deficient (Hmox1(-/-)) mice exhibited lethal ischemic lung injury, but were rescued from death by inhaled CO. CO drove ischemic protection by activating soluble guanylate cyclase and thereby suppressed hypoxic induction of the gene encoding plasminogen activator inhibitor-1 (PAI-1) in mononuclear phagocytes, which reduced accrual of microvascular fibrin. GO-mediated ischemic protection observed in wild-type mice was lost in mice null for the gene encoding PAI-1 (Serpine1). These data establish a fundamental link between CO and prevention of ischemic injury based on the ability of CO to derepress the fibrinolytic axis. These data also point to a potential therapeutic use for inhaled CO.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Columbia University; Harvard University; Brigham & Women's Hospital	Pinsky, DJ (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.		Yet, Shaw-Fang/B-1067-2010; Tomoyuki, Fujita/AAC-7464-2020; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [R01 HL60900, R01 HL55397, R01 HL59488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL060900, R01HL055397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Bouchie JL, 1998, ARTERIOSCL THROM VAS, V18, P1771, DOI 10.1161/01.ATV.18.11.1771; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; GETTLER AO, 1940, AM J CLIN PATHOL, V11, P603; Goda N, 1998, J CLIN INVEST, V101, P604, DOI 10.1172/JCI1324; GOLDBAUM LR, 1975, AVIAT SPACE ENVIR MD, V46, P1289; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maines MD, 1999, J PHARMACOL EXP THER, V291, P911; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Naka Y, 1997, P NATL ACAD SCI USA, V94, P757, DOI 10.1073/pnas.94.2.757; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; Okada K, 2000, J BIOL CHEM, V275, P21468, DOI 10.1074/jbc.M002682200; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Panahian N, 1999, J NEUROCHEM, V72, P1187; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; PINSKY DJ, 1994, P NATL ACAD SCI USA, V91, P12086, DOI 10.1073/pnas.91.25.12086; Polte T, 2000, ARTERIOSCL THROM VAS, V20, P1209, DOI 10.1161/01.ATV.20.5.1209; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; SOKAL JA, 1975, ARCH TOXICOL, V34, P331, DOI 10.1007/BF00353853; Taylor JL, 1998, AM J PHYSIOL-LUNG C, V274, pL582, DOI 10.1152/ajplung.1998.274.4.L582; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; Weng YH, 2000, AM J PHYSIOL-LUNG C, V278, pL1273, DOI 10.1152/ajplung.2000.278.6.L1273; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; Zingarelli B, 1999, CRIT CARE MED, V27, P1701, DOI 10.1097/00003246-199909000-00001	45	357	391	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					598	604		10.1038/87929	http://dx.doi.org/10.1038/87929			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329062				2022-12-25	WOS:000169961100040
J	Jungnickel, MK; Marrero, H; Birnbaumer, L; Lemos, JR; Florman, HM				Jungnickel, MK; Marrero, H; Birnbaumer, L; Lemos, JR; Florman, HM			Trp2 regulates entry of Ca2(+) into mouse sperm triggered by egg ZP3	NATURE CELL BIOLOGY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CA2+ ENTRY; ACROSOME REACTION; STORE DEPLETION; CALCIUM; CHANNELS; INFLUX; ACTIVATION; EXPRESSION; HOMOLOG	In many cells, receptor activation initiates sustained Ca2+ entry which is critical in signal transduction(1). Mammalian transient receptor potential (Trp) proteins, which are homologous to the Drosophila photoreceptor-cell Trp protein, have emerged as candidate subunits of the ion channels that mediate this influx. As a consequence of over-expression, these proteins produce cation currents that open either after depletion of internal Ca2+ stoves or through receptor activation(2). However, determining the role of endogenous Trp proteins in signal transduction is complicated by the absence of selective antagonists. Here we examine Trp function during sperm-egg interaction, The sperm acrosome reaction is a Ca2+-dependent secretary event that must be completed before fertilization. in mammals, exocytosis is triggered during gamete contact by ZP3, a glycoprotein constituent of the egg's extracellular matrix, or zona pellucida (ZP). ZP3 activates trimeric G proteins and phospholipase C and causes a transient Ca2+ influx into sperm through T-type Ca2+ channels(3). These early responses promote a second Ca2+-entry pathway, thereby producing sustained increases in intracellular Ca2+ concentration ([Ca2+](i)) that drive acrosome reactions(4). Our results show that Trp2 is essential for the activation of sustained Ca2+ influx into sperm by ZP3.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Jungnickel, MK (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	harvey.florman@umassmed.edu						Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; BLACKMORE PF, 1993, CELL CALCIUM, V14, P53, DOI 10.1016/0143-4160(93)90018-2; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; Dragileva E, 1999, BIOL REPROD, V61, P1226, DOI 10.1095/biolreprod61.5.1226; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Jan CR, 1999, N-S ARCH PHARMACOL, V359, P92, DOI 10.1007/PL00005336; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Litscher ES, 1999, ADV MOLEC BIOL, P10; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MEIZEL S, 1993, J EXP ZOOL, V267, P350, DOI 10.1002/jez.1402670312; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Publicover SJ, 1999, HUM REPROD, V14, P873, DOI 10.1093/humrep/14.4.873; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Rockwell PL, 1999, MOL REPROD DEV, V54, P418, DOI 10.1002/(SICI)1098-2795(199912)54:4&lt;418::AID-MRD13&gt;3.0.CO;2-I; Santi CM, 1998, J GEN PHYSIOL, V112, P33, DOI 10.1085/jgp.112.1.33; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Wissenbach U, 1998, FEBS LETT, V429, P61, DOI 10.1016/S0014-5793(98)00561-4; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5	30	254	268	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					499	502		10.1038/35074570	http://dx.doi.org/10.1038/35074570			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331878				2022-12-25	WOS:000168592500020
J	Martinez-Quiles, N; Rohatgi, R; Anton, IM; Medina, M; Saville, SP; Miki, H; Yamaguchi, H; Takenawa, T; Hartwig, JH; Geha, RS; Ramesh, N				Martinez-Quiles, N; Rohatgi, R; Anton, IM; Medina, M; Saville, SP; Miki, H; Yamaguchi, H; Takenawa, T; Hartwig, JH; Geha, RS; Ramesh, N			WIP regulates N-WASP-mediated actin polymerization and filopodium formation	NATURE CELL BIOLOGY			English	Article							WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN; ARP2/3 COMPLEX; DEPOLYMERIZING PROTEIN; INTERACTING PROTEIN; MYOSIN-I; F-ACTIN; FILAMENTS; CYTOSKELETON; ACTIVATION	Induction of filopodia is dependent on activation of the small GTPase Cdc42 and on neural Wiskott-Aldrich-syndrome protein (N-WASP). Here we show that WASP-interacting protein (WIP) interacts directly with N-WASP and actin. WIP retards N-WASP/Cdc42-activated actin polymerization mediated by the Arp2/3 complex, and stabilizes actin filaments. Microinjection of WIP into NIH 3T3 fibroblasts induces filopodial this is inhibited by microinjection of anti-N-WASP antibody. Microinjection of anti-WIP antibody inhibits induction of filopodia by bradykinin, by an active Cdc42 mutant (Cdc42(V12)) and by N-WASP. Our results indicate that WIP and N-WASP may act as a functional unit in filopodium formation, which is consistent with their role in actin-tail formation in cells infected with vaccinia virus or Shigella.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 108, Japan	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Tokyo	Martinez-Quiles, N (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.		Martinez-Quiles, Narcisa/G-8514-2013; Medina, Miguel/I-7135-2019; Saville, Stephen/F-7668-2010; Medina, Miguel/J-1642-2019; Yamaguchi, Hideki/AAP-1767-2021; Anton, Ines M/G-6090-2015; Medina, Miguel/H-5676-2012	Yamaguchi, Hideki/0000-0003-2125-9655; Anton, Ines M/0000-0002-2935-5919; Martinez Quiles, Narcisa/0000-0002-0366-6591; Medina, Miguel/0000-0002-7016-5340	NHLBI NIH HHS [P01 HL059561] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; CASELLA JF, 1995, CELL MOTIL CYTOSKEL, V30, P164, DOI 10.1002/cm.970300208; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Geli MI, 2000, EMBO J, V19, P4281, DOI 10.1093/emboj/19.16.4281; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Haddad E, 1999, BLOOD, V94, P509, DOI 10.1182/blood.V94.2.509.414k09_509_518; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lehman W, 1997, J MOL BIOL, V274, P310, DOI 10.1006/jmbi.1997.1422; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Vaduva G, 1997, J CELL BIOL, V139, P1821, DOI 10.1083/jcb.139.7.1821; Vaduva G, 1999, J BIOL CHEM, V274, P17103, DOI 10.1074/jbc.274.24.17103; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001	36	225	227	1	28	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					484	491		10.1038/35074551	http://dx.doi.org/10.1038/35074551			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331876				2022-12-25	WOS:000168592500018
J	Petit, A; Bihel, F; da Costa, CA; Pourquie, O; Checler, F; Kraus, JL				Petit, A; Bihel, F; da Costa, CA; Pourquie, O; Checler, F; Kraus, JL			New protease inhibitors prevent gamma-secretase-mediated production of A beta 40/42 without affecting Notch cleavage	NATURE CELL BIOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; PRESENILIN-1; MATURATION; CELLS; SITE; ENDOPROTEOLYSIS; PROTEOLYSIS; ASPARTATES	We have designed new non-peptidic potential inhibitors of gamma -secretase and examined their ability to prevent production of amyloid-beta 40 (A beta 40) and A beta 42 by human cells expressing wild-type and Swedish-mutant beta -amyloid precursor protein (beta APP). Here we identify three such agents that markedly reduce recovery of both A beta 40 and A beta 42 produced by both cell lines, and increase that of C99 and C83, the carboxy-terminal fragments of beta APP that are derived from beta -and alpha -secretase, respectively, Furthermore, we show that these inhibitors do not affect endoproteolysis of endogenous or overexpressed presenilins. These inhibitors are totally unable to affect the m Delta Enotch-1 cleavage that leads to generation of the Notch intracellular domain (NICD). These represent the first non-peptidic inhibitors that are able to prevent gamma -secretase cleavage of beta APP without affecting processing of m Delta Enotch-1 or endoproteolysis of presenilins. The distinction between these two proteolytic events, which are both prevented by disruption of presenilin genes, indicates that although they are intimately linked with beta APP and Notch maturation, presenilins are probably involved in the control of maturation processes upstream of enzymes that cleave gamma -secretase and Notch.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, F-06560 Valbonne, France; Univ Mediterranee, Fac Sci Luminy, Lab Chim Biomol, Marseille, France; LGPD, Unite Mixte Rech 6545, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Aix-Marseille Universite	Petit, A (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, 660 Route Lucioles, F-06560 Valbonne, France.		Pourquié, Olivier/CAJ-5443-2022; Checler, Frederic/C-1241-2009; BIHEL, Frederic/B-2895-2008; Alves da Costa, Cristine/G-8075-2011	Pourquié, Olivier/0000-0001-5189-1227; Checler, Frederic/0000-0003-2098-1750; BIHEL, Frederic/0000-0002-4122-0929; Petit-Paitel, Agnes/0000-0003-1138-9966; Alves da Costa, Cristine/0000-0002-7777-005X				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Checler F, 1999, MOL NEUROBIOL, V19, P255, DOI 10.1007/BF02821716; Christie G, 1999, J NEUROCHEM, V73, P195, DOI 10.1046/j.1471-4159.1999.0730195.x; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, J BIOL CHEM, V275, P27348; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	30	173	187	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					507	511		10.1038/35074581	http://dx.doi.org/10.1038/35074581			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331880				2022-12-25	WOS:000168592500022
J	Stubbs, AC; Martin, KS; Coeshott, C; Skaates, SV; Kuritzkes, DR; Bellgrau, D; Franzusoff, A; Duke, RC; Wilson, CC				Stubbs, AC; Martin, KS; Coeshott, C; Skaates, SV; Kuritzkes, DR; Bellgrau, D; Franzusoff, A; Duke, RC; Wilson, CC			Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity	NATURE MEDICINE			English	Article							CLASS-II; IN-VIVO; MANNOSE RECEPTOR; IL-12 PRODUCTION; DOWN-REGULATION; T-HELPER; ANTIGEN; RESPONSES; LIPOPOLYSACCHARIDE; MOLECULES	There is currently a need for vaccines that stimulate cell-mediated immunity-particularly that mediated by CD8(+) cytotoxic T lymphocytes (CTLs)-against viral and tumor antigens. The optimal induction of cell-mediated immunity requires the presentation of antigens by specialized cells of the immune system called dendritic cells(1) (DCs). DCs are unique in their ability to process exogenous antigens via the major histocompatibility complex (MHC) class I pathway(2) as well as in their ability to activate naive, antigen-specific CD8(+) and CD4(+) T cells(1,3). Vaccine strategies that target or activate DCs in order to elicit potent CTL-mediated immunity are the subject of intense research. We report here that whole recombinant Saccharomyces cerevisiae yeast expressing tumor or HIV-1 antigens potently induced antigen-specific, CTL responses, including those mediating tumor protection, in vaccinated animals. Interactions between yeast and DCs led to DC maturation, IL-12 production and the efficient priming of MHC class I- and class II-restricted, antigen-specific T-cell responses. Yeast exerted a strong adjuvant effect, augmenting DC presentation of exogenous whole-protein antigen to MHC class I- and class II-restricted T cells. Recombinant yeast represent a novel vaccine strategy for the induction of broad-based cellular immune responses.	Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; CERES Pharmaceut, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Duke, RC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Immunol, 4200 E 9th Ave, Denver, CO 80206 USA.				NCI NIH HHS [CA-46934] Funding Source: Medline; NIAID NIH HHS [AI-42704, AI-01459, AI-33299, AI-34747, AI-42688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042688, R01AI034747, R21AI034747, R29AI033299, R21AI042704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brossart P, 1997, J IMMUNOL, V158, P3270; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; FRANZUSOFF A, 1995, J BIOL CHEM, V270, P3154, DOI 10.1074/jbc.270.7.3154; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Mayordomo JI, 1996, J EXP MED, V183, P1357, DOI 10.1084/jem.183.4.1357; MCCABE BJ, 1995, CANCER RES, V55, P1741; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; O'Hagan DT, 1998, J PHARM PHARMACOL, V50, P1, DOI 10.1111/j.2042-7158.1998.tb03298.x; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rios-Hernandez M, 1994, Arch Med Res, V25, P179; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Schreuder MP, 1996, VACCINE, V14, P383, DOI 10.1016/0264-410X(95)00206-G; Shibata Y, 1997, J IMMUNOL, V159, P2462; Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x; WILLIAMS DL, 1992, CARBOHYD RES, V235, P247, DOI 10.1016/0008-6215(92)80093-G; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	24	177	220	2	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					625	629		10.1038/87974	http://dx.doi.org/10.1038/87974			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329066				2022-12-25	WOS:000169961100044
J	Ravi, R; Bedi, GC; Engstrom, LW; Zeng, QW; Mookerjee, B; Gelinas, C; Fuchs, EJ; Bedi, A				Ravi, R; Bedi, GC; Engstrom, LW; Zeng, QW; Mookerjee, B; Gelinas, C; Fuchs, EJ; Bedi, A			Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappa B	NATURE CELL BIOLOGY			English	Article							ALPHA-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; DNA-DAMAGE; MICE LACKING; LIGAND TRAIL; FAMILY; MEMBER; BCL-2; ACTIVATION; BLOCKS	TRAIL (tumour-necrosis factor-related apoptosis ligand or Apo2L) triggers apoptosis through engagement of the death receptors TRAIL-R1 (also known as DR4) and TRAIL-R2 (DR5). Here we show that the c-Rel subunit of the transcription factor NF-kappaB induces expression of TRAIL-R1 and TRAIL-R2 conversely, a transdominant mutant of the inhibitory protein I kappaB alpha or a transactivation-deficient mutant of c-Rel reduces expression of either death receptor. Whereas NF-kappaB promotes death receptor expression, cytokine-mediated activation of the RelA subunit of NF-kappaB also increases expression of the apoptosis inhibitor, Bcl-x(L), and protects cells from TRAIL. Inhibition of NF-kappaB by blocking activation of the I kappaB kinase complex reduces Bcl-x(L) expression and sensitizes tumour cells to TRAIL-induced apoptosis, The ability to induce death receptors or Bcl-x(L) may explain the dual roles of NF-kappaB as a mediator or inhibitor of cell death during immune and stress responses.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Bedi, A (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Bunting Blaustein Canc Res Bldg,1650 Orleans St, Baltimore, MD 21231 USA.							ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Ibrado AM, 1997, CANCER RES, V57, P1109; Kastan M, 1997, NAT GENET, V17, P130, DOI 10.1038/ng1097-130; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ravi R, 1998, CANCER RES, V58, P4531; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	50	287	301	1	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					409	416		10.1038/35070096	http://dx.doi.org/10.1038/35070096			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283615				2022-12-25	WOS:000168043900020
J	Zhang, ZJ; Butler, JD; Levin, SW; Wisniewski, KE; Brooks, SS; Mukherjee, AB				Zhang, ZJ; Butler, JD; Levin, SW; Wisniewski, KE; Brooks, SS; Mukherjee, AB			Lysosomal ceroid depletion by drugs: Therapeutic implications for a hereditary neurodegenerative disease of childhood	NATURE MEDICINE			English	Article							PALMITOYL-PROTEIN THIOESTERASE; NEUROBLASTOMA-CELLS; LIPID MODIFICATIONS; MOLECULAR-GENETICS; FATTY ACYLATION; RAT-BRAIN; LIPOFUSCINOSIS; EXPRESSION; IDENTIFICATION; ENZYME	Neuronal ceroid lipofuscinoses (NCLs) are the most common hereditary neurodegenerative diseases of childhood. The infantile form, INCL, is caused by lysosomal palmitoyl-protein thioesterase (PPT) deficiency, which impairs the cleavage of thioester linkages in palmitoylated proteins, preventing their hydrolysis by lysosomal proteinases. Consequent accumulation of these lipid-modified proteins (constituents of ceroid) in lysosomes leads to INCL. Because thioester linkages are susceptible to nucleophilic attack, drugs with this property may have therapeutic potential for INCL. We report here that two such drugs, phosphocysteamine and N-acetylcystelne, disrupt thioester linkages in a model thioester compound, [C-14]palmitoyl-CoA. Most importantly, in lymphoblasts derived from INCL patients, phosphocysteamine, a known lysosomotrophic drug, mediates the depletion of lysosomal ceroids, prevents their re-accumulation and inhibits apoptosis. Our results define a novel pharmacological approach to lysosomal ceroid depletion and raise the possibility that nucleophilic drugs such as phosphocysteamine hold therapeutic potential for INCL.	NICHHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Inst Basic Res Dev Disabilities, Staten Isl, NY USA; New York State Inst Basic Res Dev Disabil, Dept Pathol Neurobiol, Staten Isl, NY 10314 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Institute for Basic Research in Developmental Disabilities	Mukherjee, AB (corresponding author), NICHHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038988] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS389 88-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong D, 1982, CEROID LIPOFUSCINOSI; Assadi FK, 1998, TERATOLOGY, V58, P88, DOI 10.1002/(SICI)1096-9926(199809/10)58:3/4<88::AID-TERA4>3.0.CO;2-5; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; Bizzozero OA, 1997, NEUROPEDIATRICS, V28, P23, DOI 10.1055/s-2007-973660; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; Broyer M, 1996, J INHERIT METAB DIS, V19, P65, DOI 10.1007/BF01799350; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Cho SG, 2000, J NEUROCHEM, V74, P1478, DOI 10.1046/j.1471-4159.2000.0741478.x; Cho SG, 2000, J NEUROSCI RES, V62, P234, DOI 10.1002/1097-4547(20001015)62:2<234::AID-JNR8>3.0.CO;2-8; Das AK, 1998, J CLIN INVEST, V102, P361, DOI 10.1172/JCI3112; GAHL WA, 1995, METABOLIC MOL BASES, V3, P3763; GOEBEL HH, 1999, BIOMEDICAL HLTH RES, P211; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HOEG JM, 1986, J BIOL CHEM, V261, P3911; Hofmann SL, 1997, NEUROPEDIATRICS, V28, P27, DOI 10.1055/s-2007-973661; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; Isosomppi J, 1999, DEV BRAIN RES, V118, P1, DOI 10.1016/S0165-3806(99)00115-7; JARVELA I, 1991, GENOMICS, V9, P170, DOI 10.1016/0888-7543(91)90235-7; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JOCELYN PC, 1972, BIOCH SH GROUP, P63; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; RANDALL WR, 1994, J BIOL CHEM, V269, P12367; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; Riikonen R, 2000, NEUROLOGY, V54, P1828, DOI 10.1212/WNL.54.9.1828; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; SCHLESINGER MJ, 1972, PALMITOYLATION CELLU, P1; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; Suopanki J, 1999, NEUROSCI LETT, V265, P53, DOI 10.1016/S0304-3940(99)00207-4; TYYNELA J, 1993, FEBS LETT, V330, P8, DOI 10.1016/0014-5793(93)80908-D; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Waliany S, 2000, Hum Mutat, V15, P206, DOI 10.1002/(SICI)1098-1004(200002)15:2<206::AID-HUMU14>3.0.CO;2-L; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WISNIEWSKI KE, 1992, AM J MED GENET, V42, P525, DOI 10.1002/ajmg.1320420420; Wisniewski KE, 1998, PEDIATR NEUROL, V18, P119, DOI 10.1016/S0887-8994(97)00173-2; Yalovsky S, 1999, TRENDS PLANT SCI, V4, P439, DOI 10.1016/S1360-1385(99)01492-2; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zhang ZJ, 1999, GENE, V231, P203, DOI 10.1016/S0378-1119(99)00050-5; Zheng F, 1999, NAT MED, V5, P1018, DOI 10.1038/12458	47	70	71	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					478	484		10.1038/86554	http://dx.doi.org/10.1038/86554			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283676				2022-12-25	WOS:000167960500044
J	Baxter, RV; Ben Othmane, K; Rochelle, JM; Stajich, JE; Hulette, C; Dew-Knight, S; Hentati, F; Ben Hamida, M; Bel, S; Stenger, JE; Gilbert, JR; Pericak-Vance, MA; Vance, JM				Baxter, RV; Ben Othmane, K; Rochelle, JM; Stajich, JE; Hulette, C; Dew-Knight, S; Hentati, F; Ben Hamida, M; Bel, S; Stenger, JE; Gilbert, JR; Pericak-Vance, MA; Vance, JM			Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21	NATURE GENETICS			English	Article								We previously localized and fine-mapped Charcot Marie Tooth 4A (CMT4A), the autosoma[ recessive, demyelinating peripheral neuropathy, to chromosome 8. Through additional positional cloning, we have identified a good candidate gene, encoding ganglioside-induced differentiation-associated protein-1 (GDAP1). We found three different mutations in four different Tunisian families-two nonsense and one missense mutation. How mutations in GDAP1 lead to CMT4A remains to be understood.	Duke Univ, Med Ctr, Inst Genom Sci & Policy, Ctr Human Genet, Durham, NC 27710 USA; Inst Natl Neurol, Tunis 1007, Tunisia	Duke University; Universite de Tunis-El-Manar; Institut National de Neurologie	Vance, JM (corresponding author), Duke Univ, Med Ctr, Inst Genom Sci & Policy, Ctr Human Genet, Res Pk Bldg 11 Room 105,Box 2903, Durham, NC 27710 USA.	jeff@chg.mc.duke.edu	Stajich, Jason Eric/C-7297-2008	Stajich, Jason Eric/0000-0002-7591-0020; Vance, Jeffery/0000-0003-3815-8199				Barhoumi C, 2001, NEUROMUSCULAR DISORD, V11, P27, DOI 10.1016/S0960-8966(00)00162-0; Ben Othmane K, 1998, NEUROGENETICS, V2, P18, DOI 10.1007/s100480050047; Cuesta A, 2002, NAT GENET, V30, P22, DOI 10.1038/ng798; De Jonghe P, 1997, J Peripher Nerv Syst, V2, P370; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P619, DOI 10.1001/archneur.1968.00470360041003; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P603, DOI 10.1001/archneur.1968.00470360025002; Martinotti Alessia, 1992, Human Molecular Genetics, V1, P331, DOI 10.1093/hmg/1.5.331; OTHMANE KB, 1993, HUM MOL GENET, V2, P1625, DOI 10.1093/hmg/2.10.1625; Vance JM, 2000, ARCH NEUROL-CHICAGO, V57, P638, DOI 10.1001/archneur.57.5.638	9	276	285	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2002	30	1					21	22		10.1038/ng796	http://dx.doi.org/10.1038/ng796			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743579				2022-12-25	WOS:000173105600006
J	Dyer, RB; McMurray, CT				Dyer, RB; McMurray, CT			Mutant protein in Huntington disease is resistant to proteolysis in affected brain	NATURE GENETICS			English	Article							INTRANUCLEAR NEURONAL INCLUSIONS; N-TERMINAL HUNTINGTIN; POLYGLUTAMINE TRACT; NUCLEAR-LOCALIZATION; GLUTAMINE REPEATS; STRIATAL NEURONS; CASPASE CLEAVAGE; TRANSGENIC MICE; IN-VITRO; EXPRESSION	The cause of Huntington disease pathophysiology is unknown, but a major hypothesis suggests that toxicity arises from the cleavage and accumulation of amino-terminal fragments containing an expanded polyglutamine region. In evaluating huntingtin protein (HD) from human brain, transgenic animals and cells, we observed, unexpectedly, that mutant HD is more resistant to proteolysis than normal HD. The N-terminal cleavage fragments we observed arise from the processing of normal HD and are sequestered by full-length mutant HD. Our results support a model in which inhibition of proteolysis of mutant HD leads to aggregation and toxicity through the sequestering of important targets, including normal HD.	Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.	mcmurray.cynthia@mayo.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040738] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43694] Funding Source: Medline; NIMH NIH HHS [MH/NS 31862] Funding Source: Medline; NINDS NIH HHS [NS40738] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; de Cristofaro T, 2000, BIOCHEM BIOPH RES CO, V272, P816, DOI 10.1006/bbrc.2000.2843; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Goellner GM, 1997, AM J HUM GENET, V60, P879; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Hazeki N, 2000, BIOCHEM BIOPH RES CO, V277, P386, DOI 10.1006/bbrc.2000.3682; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Kim M, 1999, J NEUROSCI, V19, P964; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; MCMURRAY CT, 1989, ENDOCRINOLOGY, V124, P49, DOI 10.1210/endo-124-1-49; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schilling G, 1999, HUM MOL GENET, V8, P943; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Sieradzan KA, 1999, EXP NEUROL, V156, P92, DOI 10.1006/exnr.1998.7005; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	48	70	72	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					270	278		10.1038/ng745	http://dx.doi.org/10.1038/ng745			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11600884				2022-12-25	WOS:000171911000012
J	Petroff, MGV; Kim, SH; Pepe, S; Dessy, C; Marban, E; Balligand, JL; Sollott, SJ				Petroff, MGV; Kim, SH; Pepe, S; Dessy, C; Marban, E; Balligand, JL; Sollott, SJ			Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes	NATURE CELL BIOLOGY			English	Article							PIG VENTRICULAR MYOCYTES; SMOOTH-MUSCLE CELLS; CARDIAC MYOCYTES; ANGIOTENSIN-II; PHOSPHOINOSITIDE 3-KINASE; ENDOTHELIAL-CELLS; CALCIUM SPARKS; IN-VITRO; ACTIVATION; HEART	Stretching of cardiac muscle modulates contraction through the enhancement of the Ca2+ transient, but how this occurs is still not known. We found that stretching of myocytes modulates the elementary Ca2+ release process from ryanodine-receptor Ca2+-release channels (RyRCs), Ca2+ sparks and the electrically stimulated Ca2+ transient. Stretching induces PtdIns-3-OH kinase (PI(3)K)-dependent phosphorylation of both Akt and the endothelial isoform of nitric oxide synthase (NOS), nitric oxide (NO) production, and a proportionate increase in Ca2+-spark frequency that is abolished by inhibiting NOS and PI(3)K. Exogenously generated NO reversibly increases Ca2+-spark frequency without cell stretching. We propose that myocyte NO produced by activation of the PI(3)K-Akt-endothelial NOS axis acts as a second messenger of stretch by enhancing RyRC activity, contributing to myocardial contractile activation.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, Intramural Res Program, Baltimore, MD 21224 USA; Univ Catholique Louvain, Sch Med, Dept Med, Unit Pharmacol & Therapeut,FATH 5349, B-1200 Brussels, Belgium; Johns Hopkins Med Inst, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Johns Hopkins University; Johns Hopkins Medicine	Sollott, SJ (corresponding author), NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156	NATIONAL INSTITUTE ON AGING [Z01AG000261] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN DG, 1982, J PHYSIOL-LONDON, V327, P79, DOI 10.1113/jphysiol.1982.sp014221; Alvarez BV, 1999, CIRC RES, V85, P716, DOI 10.1161/01.RES.85.8.716; Balligand J. L., 2000, NITRIC OXIDE BIOL PA, P585; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; BERS DM, 1989, J PHYSIOL-LONDON, V417, P537, DOI 10.1113/jphysiol.1989.sp017817; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Chen Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1790, DOI 10.1152/ajpcell.1996.270.6.C1790; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Clerk A, 1999, AM J CARDIOL, V83, p64H; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Doyle DD, 2000, CIRC RES, V87, P480; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Haendeler J, 2000, CIRC RES, V86, P729, DOI 10.1161/01.RES.86.7.729; HAN S, 1994, J PHYSIOL-LONDON, V480, P411, DOI 10.1113/jphysiol.1994.sp020371; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hongo K, 1996, J PHYSIOL-LONDON, V491, P609, DOI 10.1113/jphysiol.1996.sp021243; Kentish JC, 1999, CIRC RES, V85, P658, DOI 10.1161/01.RES.85.8.658; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; LAKATTA EG, 1993, PHYSIOL REV, V73, P413, DOI 10.1152/physrev.1993.73.2.413; LEVIN KR, 1980, CIRC RES, V46, P244, DOI 10.1161/01.RES.46.2.244; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moniotte S, 2001, CIRCULATION, V103, P1649, DOI 10.1161/01.CIR.103.12.1649; PARMLEY WW, 1973, AM J PHYSIOL, V224, P1195, DOI 10.1152/ajplegacy.1973.224.5.1195; Perez NG, 2001, CIRC RES, V88, P376; Pinsky DJ, 1997, CIRC RES, V81, P372, DOI 10.1161/01.RES.81.3.372; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prendergast BD, 1997, CIRCULATION, V96, P1320, DOI 10.1161/01.CIR.96.4.1320; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Satoh H, 1997, AM J PHYSIOL-HEART C, V272, pH657, DOI 10.1152/ajpheart.1997.272.2.H657; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; Shah AM, 2000, PHARMACOL THERAPEUT, V86, P49, DOI 10.1016/S0163-7258(99)00072-8; SOLLOTT SJ, 1994, AM J PHYSIOL-HEART C, V267, pH1619, DOI 10.1152/ajpheart.1994.267.4.H1619; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Wilson HL, 1998, BIOCHEM J, V331, P837, DOI 10.1042/bj3310837; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	49	236	245	0	21	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					867	873		10.1038/ncb1001-867	http://dx.doi.org/10.1038/ncb1001-867			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584267				2022-12-25	WOS:000171396400010
J	Goto, S; Taniguchi, M; Muraoka, M; Toyoda, H; Sado, Y; Kawakita, M; Hayashi, S				Goto, S; Taniguchi, M; Muraoka, M; Toyoda, H; Sado, Y; Kawakita, M; Hayashi, S			UDP-sugar transporter implicated in glycosylation and processing of Notch	NATURE CELL BIOLOGY			English	Article							POLAR COORDINATE SYSTEM; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; GOLGI-APPARATUS; FRINGE; DELTA; GLYCOSYLTRANSFERASE; WINGLESS; RECEPTOR; DORSAL	Glycosylation modifies protein activities in various biological processes. Here, we report the functions of a novel UDP-sugar transporter (UST74C, an alternative name for Fringe connection (Frc)) localized to the Golgi apparatus in cellular signalling of Drosophila. Mutants in the frc gene exhibit phenotypes resembling wingless and Notch mutants. Both Fringe-dependent and Fringe-independent Notch pathways are affected, and both glycosylation and proteolytic maturation of Notch are defective in mutant larvae. The results suggest that changes in nucleotide-sugar levels can differently affect Wingless and two distinct aspects of Notch signalling.	Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4118540, Japan; Tokyo Metropolitan Inst Med Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1138613, Japan; Chiba Univ, Fac Pharmaceut Sci, Div Analyt Sci, Chiba 2638522, Japan; RIKEN, Ctr Dev Biol, Mishima, Shizuoka 4118540, Japan; Natl Inst Genet, Genet Strain Res Ctr, Mishima, Shizuoka 4118540, Japan	Graduate University for Advanced Studies - Japan; Tokyo Metropolitan Institute of Medical Science; Chiba University; RIKEN; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Goto, S (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	sgoto@mrc-lmb.cam.ac.uk	Hayashi, Shigeo/N-5128-2015; Hayashi, Shigeo/J-9628-2019	Hayashi, Shigeo/0000-0001-7785-1290; Hayashi, Shigeo/0000-0001-7785-1290				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ARIAS AM, 1988, DEVELOPMENT, V103, P157; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; de Celis JF, 1998, DEVELOPMENT, V125, P4617; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Goto S, 1997, DEVELOPMENT, V124, P125; GOTO S, 1995, ROUX ARCH DEV BIOL, V204, P378, DOI 10.1007/BF00360483; Guillen E, 1999, J BIOL CHEM, V274, P6641, DOI 10.1074/jbc.274.10.6641; Harlow E., 1988, ANTIBODIES LAB MANUA; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Ito K, 1997, DEVELOPMENT, V124, P761; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; Kawakita M, 1998, J BIOCHEM, V123, P777; Lindsley D. L., 1968, GENOME DROSOPHILA ME; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; MOHLER J, 1988, GENETICS, V120, P1061; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Parks AL, 2000, DEVELOPMENT, V127, P1373; PARODY TR, 1993, GENETICS, V135, P527; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Selva EM, 2001, NAT CELL BIOL, V3, P809, DOI 10.1038/ncb0901-809; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Webel R, 2000, J BIOL CHEM, V275, P24752, DOI 10.1074/jbc.M002668200; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; XU T, 1993, DEVELOPMENT, V117, P1223	51	104	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					816	822		10.1038/ncb0901-816	http://dx.doi.org/10.1038/ncb0901-816			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533661				2022-12-25	WOS:000170979600015
J	Krebs, S; Seichter, D; Forster, M				Krebs, S; Seichter, D; Forster, M			Genotyping of dinucleotide tandem repeats by MALDI mass spectrometry of ribozyme-cleaved RNA transcripts	NATURE BIOTECHNOLOGY			English	Article							NUCLEIC-ACIDS; ION STABILITY; DNA; POLYMERASE; BANDS	We describe a method for high-throughput typing of short tandem repeat (STR) polymorphisms. Current gel electrophoresis techniques allow only moderate throughput with long hands-on and analysis time, and the output is on a relative scale of electrophoretic mobility, prone to artifacts. Matrix-assisted laser-desorption/ionization mass spectrometry (MALDI-MS) enables an automated high throughput and delivers accurate data directly depicting the molecular nature of the analyte(1). Analysis of large DNA fragments, however, is limited by adduct formation and fragmentation(2,3), which result in peak broadening and low signal intensity. MALDI typing of polymorphic STRs has been reported for tri- and tetranucleotide repeats(1,4-6) with sufficient resolution to distinguish alleles. For dinucleotide repeats, essential in animal genome studies, an enhanced resolution is necessary, Increased mass resolution was reported for RNA (ref. 7) and modified DNA (refs 8-10) due to substituents that disfavor intramolecular reactions leading to fragmentation. RNA transcripts can be synthesized enzymatically from PCR products containing a promoter sequence, requiring no specialty reagents or primer labels. Furthermore, RNA transcripts are single-stranded, a prerequisite for high-resolution mass spectrometry of nucleic acids. The 3' heterogeneities produced by viral RNA polymerases, however, impede exact sizing of RNA runoff transcripts. Non-templated multiple-base extensions as well as premature termination have been reported(7,11). PCR of dinucleotide repeats tends toward the deletion of repeat unit(12,13), generating a complex pattern of interleaved extensions (from RNA polymerase) and deletions (from PCR) that obscure the true allele size. We overcome this obstacle by adding a 3' sequence encoding a catalytic RNA sequence, the so-called hammerhead ribozyme(14), that cleaves itself co-transcriptionally, creating a homogeneous 3' end.	Univ Munich, Inst Anim Breeding, D-80713 Munich, Germany; Tierzuchtforsch EV Munchen, D-85586 Grub, Germany	University of Munich	Krebs, S (corresponding author), Univ Munich, Inst Anim Breeding, Vet Str 13, D-80713 Munich, Germany.	Stefan.Krebs@gen.vetmed.uni-muenchen.de		Seichter, Doris/0000-0002-0325-1134				BISHOP MD, 1994, GENETICS, V136, P619; Bovo D, 1999, J CLIN PATHOL-MOL PA, V52, P50, DOI 10.1136/mp.52.1.50; Braun A, 1997, GENOMICS, V46, P18, DOI 10.1006/geno.1997.5011; Butler JM, 1998, INT J LEGAL MED, V112, P45, DOI 10.1007/s004140050197; FITZGERALD MC, 1993, RAPID COMMUN MASS SP, V7, P895, DOI 10.1002/rcm.1290071008; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; KIRPEKAR F, 1994, NUCLEIC ACIDS RES, V22, P3866, DOI 10.1093/nar/22.19.3866; KIRPEKAR F, 1995, RAPID COMMUN MASS SP, V9, P525, DOI 10.1002/rcm.1290090611; KOSSAREK LM, 1993, J ANIM SCI, V71, P3178, DOI 10.2527/1993.71113178x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MURRAY V, 1993, NUCLEIC ACIDS RES, V21, P2395, DOI 10.1093/nar/21.10.2395; NORDHOFF E, 1994, NUCLEIC ACIDS RES, V22, P2460, DOI 10.1093/nar/22.13.2460; NORDHOFF E, 1993, NUCLEIC ACIDS RES, V21, P3347, DOI 10.1093/nar/21.15.3347; Ono T, 1997, NUCLEIC ACIDS RES, V25, P4581, DOI 10.1093/nar/25.22.4581; Ross PL, 1997, ANAL CHEM, V69, P3966, DOI 10.1021/ac970312t; Ross PL, 1998, ANAL CHEM, V70, P2067, DOI 10.1021/ac971256z; Sauer S, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e100; SWARBRICK PA, 1992, ANIM GENET, V23, P187, DOI 10.1111/j.1365-2052.1992.tb00045.x; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641	20	15	18	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					877	880		10.1038/nbt0901-877	http://dx.doi.org/10.1038/nbt0901-877			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533649				2022-12-25	WOS:000170774000029
J	Blower, MD; Karpen, GH				Blower, MD; Karpen, GH			The role of Drosophila CID in kinetochore formation, cell-cycle progression and heterochromatin interactions	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID COHESION; PROTEIN CENP-A; CHROMOSOME SEGREGATION; FISSION YEAST; CENTROMERE; MEI-S332; SPINDLE; MITOSIS; LOCALIZATION; COMPONENT	Centromere function requires the coordination of many processes including kinetochore assembly, sister chromatid cohesion, spindle attachment and chromosome movement. Here we show that CID, the Drosophila homologue of the CENP-A centromere-specific H3-like proteins, colocalizes with molecular-genetically defined functional centromeres in minichromosomes. Injection of CID antibodies into early embryos, as well as RNA interference in tissue-culture cells, showed that CID is required for several mitotic processes. Deconvolution fluorescence microscopy showed that CID chromatin is physically separate from proteins involved in sister cohesion (MEI-S332), centric condensation (PROD), kinetochore function (ROD, ZW10 and BUB1) and heterochromatin structure (HP1). CID localization is unaffected by mutations in mei-S332, Su(var)2-5 (HP1), prod or polo. Furthermore, the localization of POLO, CENP-meta, ROD, BUB1 and MEI-S332, but not PROD or HP1, depends on the presence of functional CID. We conclude that the centromere and flanking heterochromatin are physically and functionally separable protein domains that are required for different inheritance functions, and that CID is required for normal kinetochore formation and function, as well as cell-cycle progression.	Salk Inst Biol Studies, Mol & Cell Biol Labs, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92037 USA	Salk Institute; University of California System; University of California San Diego	Karpen, GH (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Labs, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Blower, Michael/0000-0002-5037-1972	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066272] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM066272, R01 GM066272-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Bonaccorsi S, 2000, NAT CELL BIOL, V2, P54, DOI 10.1038/71378; Buchwitz BJ, 1999, NATURE, V401, P547, DOI 10.1038/44062; Casso D, 1999, MECH DEVELOP, V88, P229, DOI 10.1016/S0925-4773(99)00174-4; Casso David, 2000, Mechanisms of Development, V91, P451, DOI 10.1016/S0925-4773(00)00248-3; Clarkson M, 1999, DNA CELL BIOL, V18, P457, DOI 10.1089/104454999315178; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; Figueroa J, 1998, CHROMOSOMA, V107, P397, DOI 10.1007/s004120050323; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P206; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Karaiskou A, 1999, J CELL SCI, V112, P3747; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; LeBlanc HN, 1999, CHROMOSOMA, V108, P401, DOI 10.1007/s004120050392; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lopez JM, 2000, CURR BIOL, V10, P997, DOI 10.1016/S0960-9822(00)00650-3; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; Partridge JF, 2000, GENE DEV, V14, P783; Platero JS, 1998, J CELL BIOL, V140, P1297; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; Rieder CL, 1999, J CELL SCI, V112, P2607; Saffery R, 2000, HUM MOL GENET, V9, P175, DOI 10.1093/hmg/9.2.175; Scaerou F, 1999, J CELL SCI, V112, P3757; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Shelby RD, 2000, J CELL BIOL, V151, P1113, DOI 10.1083/jcb.151.5.1113; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; SULLIVAN BA, IN PRESS J CELL BIOL; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; THEURKAUF WE, 1994, METHOD CELL BIOL, V44, P489, DOI 10.1016/S0091-679X(08)60928-0; Torok T, 1997, GENE DEV, V11, P213, DOI 10.1101/gad.11.2.213; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Williams BC, 1998, NAT GENET, V18, P30, DOI 10.1038/ng0198-30; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; Yucel JK, 2000, J CELL BIOL, V150, P1, DOI 10.1083/jcb.150.1.1; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	54	287	298	0	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					730	739		10.1038/35087045	http://dx.doi.org/10.1038/35087045			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483958	Green Accepted			2022-12-25	WOS:000170393200018
J	Douglas, JA; Boehnke, M; Gillanders, E; Trent, JA; Gruber, SB				Douglas, JA; Boehnke, M; Gillanders, E; Trent, JA; Gruber, SB			Experimentally-derived haplotypes substantially increase the efficiency of linkage disequilibrium studies	NATURE GENETICS			English	Article							FREQUENCIES; INDIVIDUALS; PHENOTYPES	The study of complex genetic traits in humans is limited by the expense and difficulty of ascertaining populations of sufficient sample size to detect subtle genetic contributions to disease. Here we introduce an application of a somatic cell hybrid construction strategy called conversion(1-4) that maximizes the genotypic information from each sampled individual. The approach permits direct observation of individual haplotypes, thereby eliminating the need for collecting and genotyping DNA from family members for haplotype-based analyses. We describe experimental data that validate the use of conversion as a whole-genome haplotyping too[ and evaluate the theoretical efficiency of using conversion-derived haplotypes instead of conventional genotypes in the context of haplotype-frequency estimation. We show that, particularly when phenotyping is expensive, conversion-based haplotyping can be more efficient and cost-effective than standard genotyping.	Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA; NHGRI, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Boehnke, M (corresponding author), Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.	boehnke@umich.edu			NATIONAL CANCER INSTITUTE [R01CA081488] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000376] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81488] Funding Source: Medline; NHGRI NIH HHS [R01-HG00376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; HAWLEY ME, 1995, J HERED, V86, P409, DOI 10.1093/oxfordjournals.jhered.a111613; HILL WG, 1974, HEREDITY, V33, P229, DOI 10.1038/hdy.1974.89; Hodge SE, 1999, NAT GENET, V21, P360, DOI 10.1038/7687; Laken SJ, 1999, P NATL ACAD SCI USA, V96, P2322, DOI 10.1073/pnas.96.5.2322; LONG JC, 1995, AM J HUM GENET, V56, P799; MACLEAN C J, 1985, Genetic Epidemiology, V2, P263, DOI 10.1002/gepi.1370020304; McKeigue PM, 2000, AM J HUM GENET, V67, P1626, DOI 10.1086/316912; MichalatosBeloin S, 1996, NUCLEIC ACIDS RES, V24, P4841, DOI 10.1093/nar/24.23.4841; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; PAPADOPOULOS N, 1995, NAT GENET, V11, P99, DOI 10.1038/ng0995-99; Tishkoff SA, 2000, AM J HUM GENET, V67, P518, DOI 10.1086/303000; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; WEISS MC, 1967, P NATL ACAD SCI USA, V58, P1104, DOI 10.1073/pnas.58.3.1104; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; Yen H, 2000, SCIENCE, V289, P1890	17	126	143	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					361	364		10.1038/ng582	http://dx.doi.org/10.1038/ng582			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11443299				2022-12-25	WOS:000170174800017
J	Gehring, NH; Frede, U; Neu-Yilik, G; Hundsdoerfer, P; Vetter, B; Hentze, MW; Kulozik, AE				Gehring, NH; Frede, U; Neu-Yilik, G; Hundsdoerfer, P; Vetter, B; Hentze, MW; Kulozik, AE			Increased efficiency of mRNA 3 ' end formation: a new genetic mechanism contributing to hereditary thrombophilia	NATURE GENETICS			English	Article							PROTHROMBIN GENE; G20210A MUTATION; HUMAN-BETA; POLYADENYLATION; DEGRADATION; THROMBOSIS	The G-->A mutation at position 20210 of the prothrombin or coagulation factor II gene (F2) represents a common genetic risk factor for the occurrence of thromboembolic events(1-3). This mutation affects the T-terminal nucleotide of the 3' untranslated region (UTR) of the mRNA and causes elevated prothrombin plasma concentrations(1-4) by an unknown mechanism. Here, we show that the mutation does not affect the amount of pre-mRNA, the site of 3' end cleavage or the length of the poly(A) tail of the mature mRNA. Rather, we demonstrate that the physiological F2 3' end cleavage signal is inefficient and that F2 20210 G-->A represents a gain-of-function mutation, causing increased cleavage site recognition, increased Tend processing and increased mRNA accumulation and protein synthesis. Enhanced mRNA 3' end formation efficiency emerges as a novel principle causing a genetic disorder and explains the role of the F2 20210 G-->A mutation in the pathogenesis of thrombophilia. This work also illustrates the pathophysiologic importance of quantitatively minor aberrations of RNA metabolism.	EMBL, Gene Express Programme, Heidelberg, Germany; Humboldt Univ, Charite, Dept Pediat, Berlin, Germany	European Molecular Biology Laboratory (EMBL); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kulozik, AE (corresponding author), Humboldt Univ, Charite, Dept Pediat, Berlin, Germany.	andreas.kulozik@charite.de	Hentze, Matthias W/V-3980-2017; Kulozik, Andreas/AAO-2432-2020	Hentze, Matthias W/0000-0002-4023-7876; 				BATT DB, 1994, NUCLEIC ACIDS RES, V22, P2811, DOI 10.1093/nar/22.14.2811; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; Cattaneo M, 1999, THROMB RES, V93, P1, DOI 10.1016/S0049-3848(98)00136-4; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; CHOU ZF, 1994, NUCLEIC ACIDS RES, V22, P2525, DOI 10.1093/nar/22.13.2525; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; KUGLER W, 1995, NUCLEIC ACIDS RES, V23, P413, DOI 10.1093/nar/23.3.413; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; Makris M, 1997, THROMB HAEMOSTASIS, V78, P1426; Muhlrad D, 1999, RNA, V5, P1299, DOI 10.1017/S1355838299990829; Neu-Yilik G, 2001, EMBO J, V20, P532, DOI 10.1093/emboj/20.3.532; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; ROSS J, 1983, J MOL BIOL, V167, P607, DOI 10.1016/S0022-2836(83)80101-6; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Tosetto A, 1999, THROMB HAEMOSTASIS, V82, P1395; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	19	197	204	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					389	392		10.1038/ng578	http://dx.doi.org/10.1038/ng578			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11443298				2022-12-25	WOS:000170174800023
J	Prieto, I; Suja, JA; Pezzi, N; Kremer, L; Martinez, C; Rufas, JS; Barbero, JL				Prieto, I; Suja, JA; Pezzi, N; Kremer, L; Martinez, C; Rufas, JS; Barbero, JL			Mammalian STAG3 is a cohesin specific to sister chromatid arms in meiosis I	NATURE CELL BIOLOGY			English	Article							FISSION YEAST; SYNAPTONEMAL COMPLEXES; CHROMOSOME SEGREGATION; MOLECULAR-CLONING; MEIOTIC PROPHASE; PROTEIN; RECOMBINATION; SEPARATION; FAMILY; MOUSE	Cohesins, which have been characterized in budding yeast(1,2) and Xenopus(3), are multisubunit protein complexes involved in sister chromatid cohesion. Regulation of the interactions among different cohesin subunits and the assembly/disassembly of the cohesin complex to chromatin are key steps in chromosome segregation. We previously characterized the mammalian STAG3 protein as a component of the synaptonemal complex that is specifically expressed in germinal cells(4), although its function in meiosis remains unknown. Here we show that STAG3 has a role in sister chromatid arm cohesion during mammalian meiosis I. Immunofluorescence results in prophase I cells suggest that STAG3 is a component of the axial/lateral element of the synaptonemal complex. In metaphase I, STAG3 is located at the interchromatid domain and is absent from the chiasma region. In late anaphase I and the later stages of meiosis, STAG3 is not detected. STAG3 interacts with the structural maintenance chromosome proteins SMC1 and SMC3, which have been reported to be subunits of the mitotic cohesin complex(2,3). We propose that STAG3 is a sister chromatid arm cohesin that is specific to mammalian meiosis I.	Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Unidad Biol Celular, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid	Barbero, JL (corresponding author), Ctr Nacl Biotecnol, Dept Immunol & Oncol, UAM Campus Cantoblanco, E-28049 Madrid, Spain.		Suja, José A/L-4548-2014; Barbero, Jose Luis/J-9833-2014; Rufas, Julio S/L-5174-2014; Kremer, Leonor/L-5445-2015	Suja, José A/0000-0002-4266-795X; Rufas, Julio S/0000-0002-7516-809X; Kremer, Leonor/0000-0002-2235-2010; BARBERO, JOSE LUIS/0000-0002-1226-0323				Alsheimer M, 1996, EXP CELL RES, V228, P181, DOI 10.1006/excr.1996.0315; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Carramolino L, 1997, GENE, V195, P151, DOI 10.1016/S0378-1119(97)00121-2; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; DELMAZO J, 1986, CYTOGENET CELL GENET, V43, P201, DOI 10.1159/000132321; Eijpe M, 2000, J CELL SCI, V113, P673; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Krawchuk MD, 1999, GENETICS, V153, P57; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOENS PB, 1995, CHROMOSOMA, V104, P175, DOI 10.1007/BF00352182; Page J, 1998, CHROMOSOME RES, V6, P639, DOI 10.1023/A:1009209628300; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pezzi N, 2000, FASEB J, V14, P581, DOI 10.1096/fasebj.14.3.581; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Suja JA, 1999, J CELL SCI, V112, P2957; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Valdeolmillos A, 1998, DNA CELL BIOL, V17, P699, DOI 10.1089/dna.1998.17.699; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Zetka MC, 1999, GENE DEV, V13, P2258, DOI 10.1101/gad.13.17.2258	30	197	207	2	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					761	766		10.1038/35087082	http://dx.doi.org/10.1038/35087082			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483963				2022-12-25	WOS:000170393200023
J	Jiang, XC; Qin, SC; Qiao, CP; Kawano, K; Lin, M; Skold, A; Xiao, X; Tall, AR				Jiang, XC; Qin, SC; Qiao, CP; Kawano, K; Lin, M; Skold, A; Xiao, X; Tall, AR			Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency	NATURE MEDICINE			English	Article							CONTAINING LIPOPROTEINS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; RECEPTOR; SITE; RNA	Increased secretion and levels of ApoB-containing lipoproteins (BLp) commonly occur in familiar hyperlipidemia, obesity and diabetes. The plasma phospholipid-transfer protein (PLTP) is known to mediate transfer of phospholipids between BLp and HDL during their intravascular metabolism. To address a possible role of PLTP in dyslipidemia and atherogenesis, we bred mice deficient in the gene encoding PLTP (PLTP-deficient mice) using different hyperlipidemic mouse strains. In ApoB-transgenic and ApoE-deficient backgrounds, PLTP deficiency resulted in reduced production and levels of BLp and markedly decreased atherosclerosis. BLp secretion was diminished in hepatocytes from ApoB-transgenic PLTP-deficient mice, a defect that was corrected when PLTP was reintroduced in adenovirus. The studies reveal a major, unexpected role of PLTP in regulating the secretion of BLp and identify PLTP as a therapeutic target.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10027 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10027 USA.	art1@columbia.edu	Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; BRUNZELL JD, 1983, J LIPID RES, V24, P147; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Duvillard L, 2000, EUR J CLIN INVEST, V30, P685, DOI 10.1046/j.1365-2362.2000.00702.x; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Hamilton RL, 1998, J LIPID RES, V39, P1543; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Huuskonen J, 1999, J LIPID RES, V40, P1123; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; Li J, 1999, GENE THER, V6, P74, DOI 10.1038/sj.gt.3300830; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Riches FM, 1998, INT J OBESITY, V22, P414, DOI 10.1038/sj.ijo.0800602; Rinninger F, 1999, ARTERIOSCL THROM VAS, V19, P1325, DOI 10.1161/01.ATV.19.5.1325; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1983, J BIOL CHEM, V258, P2174; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Veniant MM, 1999, J NUTR, V129, p451S, DOI 10.1093/jn/129.2.451S; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	223	234	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					847	852		10.1038/89977	http://dx.doi.org/10.1038/89977			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433351				2022-12-25	WOS:000169808600038
J	Xu, XL; Qiao, WH; Linke, SP; Cao, L; Li, WM; Furth, PA; Harris, CC; Deng, CX				Xu, XL; Qiao, WH; Linke, SP; Cao, L; Li, WM; Furth, PA; Harris, CC; Deng, CX			Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis	NATURE GENETICS			English	Letter							DAMAGE-INDUCED PHOSPHORYLATION; ATM-DEPENDENT PHOSPHORYLATION; DOUBLE-STRAND BREAKS; DNA-DAMAGE; GAMMA-IRRADIATION; MOUSE; MICE; PROTEIN; MDM2; MORPHOGENESIS	Breast cancer is a chief cause of cancer-related mortality that affects women worldwide. About 8% of cases are hereditary. and approximately half of these are associated with germline mutations of the breast tumor suppressor gene BRCA1 (refs. 1,2). We have previously reported a mouse model in which Brca1 exon 11 is eliminated in mammary epithelial cells through Cre-mediated excision(3). This mutation is often accompanied by alterations in transformation-related protein 53 (Trp53, encoding p53), which substantially accelerates mammary tumor formation. Here. we sought to elucidate the underlying mechanism(s) using mice deficient in the Brca1 exon 11 isoform (Brca1(Delta 11/Delta 11)). Brca1(Delta 11/Delta 11) embryos died late in gestation because of widespread apoptosis. Unexpectedly. elimination of one Trp53 allele completely rescues this embryonic lethality and restores normal mammary gland development. However, most female Brca1(Delta 11/Delta 11)Trp53(+/-) mice develop mammary tumors with loss of the remaining Trp53 allele within 6-12 months. Lymphoma and ovarian tumors also occurr at lower frequencies. Heterozygous mutation of Trp53 decreases p53 and results in attenuated apoptosis and G(1)-S checkpoint control, allowing Brca1(Delta 11/Delta 11) cells to proliferate. The p53 protein regulates Brca1 transcription both in vitro and in vivo, and Brca1 participates in p53 accumulation after gamma -irradiation through regulation of its phosphorylation and Mdm2 expression. These findings provide a mechanism for BRCA1-associated breast carcinogenesis.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Med, Inst Human Virol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016	Linke, Steven/0000-0001-8584-4947	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Deng CX, 2000, BIOESSAYS, V22, P728; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hill ADK, 1997, BRIT J SURG, V84, P1334; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Linke SP, 1997, CANCER RES, V57, P1171; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schuyer M, 1999, MOL CELL ENDOCRINOL, V155, P143, DOI 10.1016/S0303-7207(99)00117-3; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	30	289	297	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					266	271		10.1038/90108	http://dx.doi.org/10.1038/90108			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431698				2022-12-25	WOS:000169656400020
J	Umana, P; Gerdes, CA; Stone, D; Davis, JRE; Ward, D; Castro, MG; Lowenstein, PR				Umana, P; Gerdes, CA; Stone, D; Davis, JRE; Ward, D; Castro, MG; Lowenstein, PR			Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination	NATURE BIOTECHNOLOGY			English	Article							VIRAL CODING SEQUENCES; IN-VIVO; HIGH-CAPACITY; DNA; EXPRESSION; SYSTEM; CONSTRUCTION; PURIFICATION; TRANSGENE; DELIVERY	Helper-dependent (HD), high-capacity adenoviruses are one of the most efficient and safe gene therapy vectors, capable of mediating long-term expression(1-12). Currently, the most widely used system for HD vector production avoids significant contamination with helper virus by using producer cells stably expressing a nuclear-targeted Cre recombinase and an engineered first-generation helper virus with parallel loxP sites flanking its packaging signal(1,3-12). The system requires a final, density-based separation of HD and residual helper viruses by ultracentrifugation to reduce contaminating helper virus to low levels. This separation step hinders large-scale production of clinical-grade HD virus(13), By using a very efficient recombinase, in vitro-evolved FLPe (ref. 14), to excise the helper virus packaging signal in the producer cells, we have developed a scalable HD vector production method. FLP has previously been shown to mediate maximum levels of excision close to 100% compared to 80% for Cre (ref. 15). Utilizing a common HD plasmid backbone(1,7,8,10-12), the FLPe-based system reproducibly yielded HD virus with the same low levels of helper virus contamination before any density-based separation by ultracentrifugation. This should allow large-scale production of HD vectors using column chromatography-based virus purification(13).	Univ Manchester, Sch Med, Mol Med & Gene Therapy Unit, Manchester M13 9PT, Lancs, England; Univ Manchester, Endocrine Sci Res Grp, Manchester M13 9PT, Lancs, England; Univ Manchester, ARC Epidemiol Unit, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Lowenstein, PR (corresponding author), Univ Manchester, Sch Med, Mol Med & Gene Therapy Unit, Room 1-302,Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Castro, Maria/ABC-5182-2021; Davis, Julian R/G-8943-2014	Castro, Maria/0000-0003-2237-2756; Davis, Julian R/0000-0003-0838-0557; Stone, Daniel/0000-0003-1619-7541				BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Blanche F, 2000, GENE THER, V7, P1055, DOI 10.1038/sj.gt.3301190; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Chen HH, 1997, P NATL ACAD SCI USA, V94, P1645, DOI 10.1073/pnas.94.5.1645; Gerdes CA, 2000, MOL THER, V2, P330, DOI 10.1006/mthe.2000.0140; GRABLE M, 1992, J VIROL, V66, P723; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Maione D, 2000, HUM GENE THER, V11, P859, DOI 10.1089/10430340050015473; MITANI K, 1995, P NATL ACAD SCI USA, V92, P3854, DOI 10.1073/pnas.92.9.3854; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; Sandig V, 2000, P NATL ACAD SCI USA, V97, P1002, DOI 10.1073/pnas.97.3.1002; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; SOUTHGATE T, 2000, CURRENT PROTOCOLS NE; Thomas CE, 2000, P NATL ACAD SCI USA, V97, P7482, DOI 10.1073/pnas.120474397; THOMAS CE, 2001, IN PRESS HUM GENE TH; Umana P, 1999, BIOTECHNOL BIOENG, V65, P542, DOI 10.1002/(SICI)1097-0290(19991205)65:5<542::AID-BIT7>3.3.CO;2-Q	20	112	122	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					582	585		10.1038/89349	http://dx.doi.org/10.1038/89349			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385466				2022-12-25	WOS:000169081700035
J	Hsu, SY; Hsueh, AJW				Hsu, SY; Hsueh, AJW			Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor	NATURE MEDICINE			English	Article							MICE LACKING; RAT-BRAIN; UROCORTIN; CLONING; EXPRESSION; ANXIETY; BEHAVIOR; INJURY; FAMILY; CELLS	Adaptive stress responses mediated by the endocrine, autonomic, cardiovascular and immune systems are essential for the survival of the individual. Initial stress-induced responses provide a vital short-term metabolic lift, but prolonged or inappropriate exposure to stress can compromise homeostasis thereby leading to disease. This 'fight-or-flight' response is characterized by the activation of the corticotropin-releasing hormone (CRH)-adrenocorticotropin-glucocorticoid axis, mediated by the type 1 CRH receptor. In contrast, the type 2 CRH receptor mediates the stress-coping responses during the recovery phase of stress. We identified human stresscopin (SCP) and stresscopin-related peptide (SRP) as specific ligands for the type 2 CRH receptor. The genes encoding these peptides were expressed in diverse peripheral tissues as well as in the central nervous system. Treatment with SCP or SRP suppressed food intake, delayed gastric emptying and decreased heat-induced edema. Thus SCP and SRP might represent endogenous ligands for maintaining homeostasis after stress, and could allow the design of drugs to ameliorate stress-related diseases.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.							Asakawa A, 1999, GASTROENTEROLOGY, V116, P1287, DOI 10.1016/S0016-5085(99)70491-9; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Bittencourt JC, 1999, J COMP NEUROL, V415, P285; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brunner B, 2000, CHROMOSOME RES, V8, P465, DOI 10.1023/A:1009263504671; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Hauger RL, 1997, J NEUROCHEM, V68, P2308; Heinrichs SC, 1999, NEUROPEPTIDES, V33, P350, DOI 10.1054/npep.1999.0047; Hsu SY, 1999, MOL ENDOCRINOL, V13, P2163, DOI 10.1210/me.13.12.2163; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; HSUEH AJW, 1978, NATURE, V273, P57, DOI 10.1038/273057a0; Kageyama K, 2000, ENDOCRINOLOGY, V141, P2285, DOI 10.1210/en.141.7.2285; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; LAU SH, 1983, P NATL ACAD SCI-BIOL, V80, P7070, DOI 10.1073/pnas.80.23.7070; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Nozu T, 1999, AM J PHYSIOL-GASTR L, V276, pG867, DOI 10.1152/ajpgi.1999.276.4.G867; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; SELYE H, 1946, J CLIN ENDOCR METAB, V6, P117, DOI 10.1210/jcem-6-2-117; SEYLE H, 1955, SCIENCE, V122, P625; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; SPIESS J, 1981, P NATL ACAD SCI-BIOL, V78, P6517, DOI 10.1073/pnas.78.10.6517; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Turnbull AV, 1996, EUR J PHARMACOL, V303, P213, DOI 10.1016/0014-2999(96)00141-0; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; Weninger SC, 1999, P NATL ACAD SCI USA, V96, P8283, DOI 10.1073/pnas.96.14.8283	29	566	587	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					605	611		10.1038/87936	http://dx.doi.org/10.1038/87936			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329063				2022-12-25	WOS:000169961100041
J	Pashmforoush, M; Pomies, P; Peterson, KL; Kubalak, S; Ross, JR; Hefti, A; Aebi, U; Beckerle, MC; Chien, KR				Pashmforoush, M; Pomies, P; Peterson, KL; Kubalak, S; Ross, JR; Hefti, A; Aebi, U; Beckerle, MC; Chien, KR			Adult mice deficient in actinin-associated LIM-domain protein reveal a developmental pathway for right ventricular cardiomyopathy	NATURE MEDICINE			English	Article							ALPHA-ACTININ; HEART-FAILURE; DILATED CARDIOMYOPATHY; MUSCLE DIFFERENTIATION; CARDIAC-HYPERTROPHY; PLAKOGLOBIN; DISEASE; PDZ; IDENTIFICATION; DISRUPTION	Although cytoskeletal mutations are known causes of genetically based forms of dilated cardiomyopathy, the pathways that link these defects with cardiomyopathy are unclear. Here we report that the alpha -actinin-associated LIM protein (ALP; Alp in mice) has an essential role in the embryonic development of the right ventricular (RV) chamber during its exposure to high biomechanical workloads in utero. Disruption of the gene encoding Alp (Alp) is associated with RV chamber dilation and dysfunction, directly implicating alpha -actinin-associated proteins in the onset of cardiomyopathy. In vitro assays showed that Alp directly enhances the capacity of a-actinin to cross-link actin filaments, indicating that the loss of Alp function contributes to destabilization of actin anchorage sites in cardiac muscle. Alp also colocalizes at the intercalated disc with alpha -actinin and gamma -catenin, the latter being a known disease gene for human RV dysplasia. Taken together, these studies point to a novel developmental pathway for RV dilated cardiomyopathy via instability of alpha -actinin complexes.	Univ Calif San Diego, Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; Univ Basel, Biozentrum, Basel, Switzerland; Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29425 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Basel; Medical University of South Carolina	Chien, KR (corresponding author), Univ Calif San Diego, Salk Program Mol Med, La Jolla, CA 92093 USA.		Pomiès, Pascal/AAC-8037-2020	Pomiès, Pascal/0000-0002-5301-6087				Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Basso C, 1996, CIRCULATION, V94, P983, DOI 10.1161/01.CIR.94.5.983; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Corrado D, 2000, CIRCULATION, V101, pE101, DOI 10.1161/01.CIR.101.11.e101; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Fontaine G, 1999, ANNU REV MED, V50, P17, DOI 10.1146/annurev.med.50.1.17; Fontaine G, 1998, CIRCULATION, V97, P1532, DOI 10.1161/01.CIR.97.16.1532; Fontaine G, 1999, ACTA CARDIOL, V54, P189; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; KIESS M, 1995, ONCOGENE, V10, P61; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Murata K, 1997, CARDIOVASC RES, V33, P359, DOI 10.1016/S0008-6363(96)00218-0; Nieset JE, 1997, J CELL SCI, V110, P1013; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pomies P, 1999, J BIOL CHEM, V274, P29242, DOI 10.1074/jbc.274.41.29242; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SUTTON MS, 1991, BRIT HEART J, V66, P285; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Towbin J A, 2000, Curr Cardiol Rep, V2, P475, DOI 10.1007/s11886-000-0063-9; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; WANG HC, 1995, GENE, V165, P267, DOI 10.1016/0378-1119(95)00542-E; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507	34	149	151	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					591	597		10.1038/87920	http://dx.doi.org/10.1038/87920			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329061				2022-12-25	WOS:000169961100039
J	Yoshikawa, H; Matsubara, K; Qian, GS; Jackson, P; Groopman, JD; Manning, JE; Harris, CC; Herman, JG				Yoshikawa, H; Matsubara, K; Qian, GS; Jackson, P; Groopman, JD; Manning, JE; Harris, CC; Herman, JG			SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity	NATURE GENETICS			English	Article							CONSTITUTIVE ACTIVATION; PROMOTER HYPERMETHYLATION; SIGNAL-TRANSDUCTION; LIVER-REGENERATION; DNA METHYLATION; GENE; PROTEIN; CELLS; INACTIVATION; LEUKEMIA	Hepatocellular carcinoma (HCC) is a major cause of cancer death, but the molecular mechanism for its development beyond its initiation has not been well characterized. Suppressor of cytokine signaling (SOCS-1; also known as JAB and SSI-1) switches cytokine signaling 'off' by means of its direct interaction with Janus kinase (JAK). We identified aberrant methylation in the CpG island of SOCS-1 that correlated with its transcription silencing in HCC cell lines. The incidence of aberrant methylation was 65% in the 26 human primary HCC tumor samples analyzed. Moreover, the restoration of SOCS-1 suppressed both growth rate and anchorage-independent growth of cells in which SOCS-1 was methylation-silenced and JAK2 was constitutively activated. This growth suppression was caused by apoptosis and was reproduced by AG490. a specific, chemical JAK2 inhibitor that reversed constitutive phosphorylation of STAT3 in SOCS-1 inactivated cells. The high prevalence of the aberrant SOCS-1 methylation and its growth suppression activity demonstrated the importance of the constitutive activation of the JAK/STAT pathway in the development of HCC. Our results also indicate therapeutic strategies for the treatment of HCC including use of SOCS-1 in gene therapy and inhibition of JAK2 by small molecules, such as AG490.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Nara Inst Sci & Technol, Nara, Japan; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Shanghai Canc Inst, Shanghai, Peoples R China; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Nara Institute of Science & Technology; Johns Hopkins University; Shanghai Jiao Tong University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Herman, JG (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA.		/X-4205-2019	/0000-0003-4690-2133; Manning, Jr., Jasper E./0000-0002-2376-8288	NCI NIH HHS [P50 CA58184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Esteller M, 1999, CANCER RES, V59, P793; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GRAFF JR, 1995, CANCER RES, V55, P5195; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kramer JA, 1997, BIOTECHNIQUES, V22, P826, DOI 10.2144/97225bm07; Kramer JA, 1998, J EXP ZOOL, V282, P245, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2<245::AID-JEZ26>3.0.CO;2-R; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Losman JA, 1999, J IMMUNOL, V162, P3770; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; NAGAI H, 1994, CANCER RES, V54, P1545; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; WeberNordt RM, 1996, BLOOD, V88, P809; Yoshikawa H, 1997, GENE, V197, P129, DOI 10.1016/S0378-1119(97)00251-5; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; ZLATANOVA J S, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P211	44	625	666	0	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					29	35		10.1038/88225	http://dx.doi.org/10.1038/88225			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326271				2022-12-25	WOS:000168413300011
J	Gribkoff, VK; Starrett, JE; Dworetzky, SI; Hewawasam, P; Boissard, CG; Cook, DA; Frantz, SW; Heman, K; Hibbard, JR; Huston, K; Johnson, G; Krishnan, BS; Kinney, GG; Lombardo, LA; Meanwell, NA; Molinoff, PB; Myers, RA; Moon, SL; Ortiz, A; Pajor, L; Pieschl, RL; Post-Munson, DJ; Signor, LJ; Srinivas, N; Taber, MT; Thalody, G; Trojnacki, JT; Wiener, H; Yeleswaram, K; Yeola, SW				Gribkoff, VK; Starrett, JE; Dworetzky, SI; Hewawasam, P; Boissard, CG; Cook, DA; Frantz, SW; Heman, K; Hibbard, JR; Huston, K; Johnson, G; Krishnan, BS; Kinney, GG; Lombardo, LA; Meanwell, NA; Molinoff, PB; Myers, RA; Moon, SL; Ortiz, A; Pajor, L; Pieschl, RL; Post-Munson, DJ; Signor, LJ; Srinivas, N; Taber, MT; Thalody, G; Trojnacki, JT; Wiener, H; Yeleswaram, K; Yeola, SW			Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels	NATURE MEDICINE			English	Article							LARGE-CONDUCTANCE; CEREBRAL-ISCHEMIA; BK CHANNELS; CELL-DEATH; RAT; CLONING; BRAIN; EXPRESSION; MODULATION; OCCLUSION	During ischemic stroke, neurons at risk are exposed to pathologically high levels of intracellular calcium (Ca++), initiating a fatal biochemical cascade. To protect these neurons, we have developed openers of large-conductance, Ca++-activated (maxi-K or BK) potassium channels, thereby augmenting an endogenous mechanism for regulating Ca++ entry and membrane potential. The novel fluoro-oxindoles BMS-204352 and racemic compound 1 are potent, effective and uniquely Ca++-sensitive openers of maxi-K channels. In rat models of permanent large-vessel stroke, BMS-204352 provided significant levels of cortical neuroprotection when administered two hours after the onset of occlusion, but had no effects on blood pressure or cerebral blood flow. This novel approach may restrict Ca++ entry in neurons at risk while having minimal side effects.	Bristol Myers Squibb Pharmaceut Res Inst, Neurosci Drug Discovery Div, Wallingford, CT 06492 USA; Bristol Myers Squibb Pharmaceut Res Inst, Neurosci Chem Div, Wallingford, CT USA; Bristol Myers Squibb Pharmaceut Res Inst, Drug Safety Evaluat Div, Wallingford, CT USA; Bristol Myers Squibb Pharmaceut Res Inst, Metab & Pharmacokinet Div, Wallingford, CT USA; Bristol Myers Squibb Pharmaceut Res Inst, Analyt Sci Div, Wallingford, CT USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Gribkoff, VK (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Neurosci Drug Discovery Div, Wallingford, CT 06492 USA.			Meanwell, Nicholas/0000-0002-8857-1515				Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P90, DOI 10.1136/jnnp.64.1.90; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 1999, J THROMB THROMBOLYS, V7, P165, DOI 10.1023/A:1008889605137; Gillard JH, 1997, AM J NEURORADIOL, V18, P343; Gribkoff V K, 1997, Adv Pharmacol, V37, P319; Gribkoff V K, 1999, Expert Opin Pharmacother, V1, P61, DOI 10.1517/14656566.1.1.61; Gribkoff V.K., 1997, 3-substituted oxindole derivatives as potassium channel modulators,, Patent No. [US5602169A, 5602169, US5602169]; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; HEWAWASAM P, 1996, Patent No. 5565483; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P695, DOI 10.1517/13543784.9.4.695; Joiner WJ, 1998, NAT NEUROSCI, V1, P462, DOI 10.1038/2176; Juhng KN, 1999, EPILEPSY RES, V34, P177, DOI 10.1016/S0920-1211(98)00111-9; Knaus HG, 1996, J NEUROSCI, V16, P955; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li FH, 2000, NEUROLOGY, V54, P689, DOI 10.1212/WNL.54.3.689; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MCKAY MC, 1994, J NEUROPHYSIOL, V71, P1873, DOI 10.1152/jn.1994.71.5.1873; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Penner Reinhold, 1995, P3; Schlaug G, 1999, NEUROLOGY, V53, P1528, DOI 10.1212/WNL.53.7.1528; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; Starrett JE, 1996, CURR PHARM DESIGN, V2, P413; Strobaek D, 1996, NEUROPHARMACOLOGY, V35, P903, DOI 10.1016/0028-3908(96)00096-2; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vang C, 1999, STROKE, V30, P2119, DOI 10.1161/01.STR.30.10.2119; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; WILLETTE RN, 1990, STROKE, V21, P451, DOI 10.1161/01.STR.21.3.451; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523	39	253	262	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					471	477		10.1038/86546	http://dx.doi.org/10.1038/86546			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283675				2022-12-25	WOS:000167960500043
J	Liu, PT; Jenkins, NA; Copeland, NG				Liu, PT; Jenkins, NA; Copeland, NG			Efficient Cre-IoxP-induced mitotic recombination in mouse embryonic stem cells	NATURE GENETICS			English	Article							GENETIC MOSAICS; PRADER-WILLI; DROSOPHILA; MICE; SEGREGATION; CHROMOSOMES; REGION; MODEL	FLP/FRT-induced mitotic recombination provides a powerful method for creating genetic mosaics in Drosophila and for discerning the function of recessive genes in a heterozygous individual. Here we show that mitotic recombination can be reproducibly induced in mouse embryonic stem (ES) cells, by Cre/loxP technology, at frequencies ranging from 4.2 x 10(-5) (Snrpn) to 7.0 x 10(-3) (D7Mit178) for single allelic loxP sites, and to 5.0 x 10(-2) (D7Mit178) for multiple allelic lox sites, after transient Cre expression. Notably, much of the recombination occurs in G2 and is followed by X segregation, where the recombinant chromatids segregate away from each other during mitosis. It is X segregation that is useful for genetic mosaic analysis because it produces clones of homozygous mutant daughter cells from heterozygous mothers. Our studies confirm the predictions made from studies in Drosophila(1) that suggest that X segregation will not be limited to organisms with strong mitotic pairing, because the forces (sister-chromatid cohesion) responsible for X segregation are an elemental feature of mitosis in all eukaryotes. Our studies also show that genetic mosaic analysis in mice is feasible, at least for certain chromosomal regions.	NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Copeland, NG (corresponding author), NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA.							Araki K, 1997, NUCLEIC ACIDS RES, V25, P868, DOI 10.1093/nar/25.4.868; BATEMAN AJ, 1967, GENET RES, V9, P375, DOI 10.1017/S001667230001065X; BAUBONIS W, 1993, NUCLEIC ACIDS RES, V21, P2025, DOI 10.1093/nar/21.9.2025; Beumer KJ, 1998, GENETICS, V150, P173; CATTANACH BM, 1994, J INHERIT METAB DIS, V17, P403, DOI 10.1007/BF00711356; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FAVOR J, 1994, ANNU REV GENET, V28, P27, DOI 10.1146/annurev.ge.28.120194.000331; FISHER G, 1986, MUTAT RES, V164, P381, DOI 10.1016/0165-1161(86)90031-2; Gabriel JM, 1999, P NATL ACAD SCI USA, V96, P9258, DOI 10.1073/pnas.96.16.9258; GERMAN J, 1964, SCIENCE, V144, P298, DOI 10.1126/science.144.3616.298; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; PANTHIER JJ, 1990, GENETICS, V125, P175; PIMPINELLI S, 1986, P NATL ACAD SCI USA, V83, P3900, DOI 10.1073/pnas.83.11.3900; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Riesselmann L, 1999, CYTOGENET CELL GENET, V86, P39, DOI 10.1159/000015426; Rossant J, 1998, TRENDS GENET, V14, P358, DOI 10.1016/S0168-9525(98)01552-2; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Stevens N. M., 1908, Journal of Experimental Zoology Philadelphia, V5, DOI 10.1002/jez.1400050304; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000	31	71	76	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					66	72		10.1038/ng788	http://dx.doi.org/10.1038/ng788			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11740496				2022-12-25	WOS:000173105600015
J	Bennett, CB; Lewis, LK; Karthikeyan, G; Lobachev, KS; Jin, YH; Sterling, JF; Snipe, JR; Resnick, MA				Bennett, CB; Lewis, LK; Karthikeyan, G; Lobachev, KS; Jin, YH; Sterling, JF; Snipe, JR; Resnick, MA			Genes required for ionizing radiation resistance in yeast	NATURE GENETICS			English	Article							PUTATIVE RNA HELICASE; SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; CELL-CYCLE; REPAIR; EXPRESSION; PROTEIN; CHECKPOINT; END; RECOMBINATION	The ability of Saccharomyces cerevisiae to tolerate ionizing radiation damage requires many DNA-repair and checkpoint genes, most having human orthologs. A genome-wide screen of diploid mutants homozygous with respect to deletions of 3,670 nonessential genes revealed 107 new loci that influence gamma -ray sensitivity. Many affect replication, recombination and checkpoint functions. Nearly 90% were sensitive to other agents, and most new genes could be assigned to the following functional groups: chromatin remodeling, chromosome segregation, nuclear pore formation, transcription, Golgi/vacuolar activities, ubiquitin-mediated protein degradation, cytokinesis, mitochondrial activity and cell wall maintenance. Over 50% share homology with human genes, including 17 implicated in cancer, indicating that a large set of newly identified human genes may have related roles in the toleration of radiation damage.	NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), NIEHS, Mol Genet Lab, POB 12233, Res Triangle Pk, NC 27709 USA.		resnick, Michael/F-1668-2019	resnick, Michael/0000-0002-8473-7506	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGUILERA A, 1988, GENETICS, V119, P779; Alper T, 1977, Adv Exp Med Biol, V84, P139; ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Bartsch S, 2000, MOL CELL BIOL, V20, P1194, DOI 10.1128/MCB.20.4.1194-1205.2000; BENNETT CB, 1989, RADIAT RES, V120, P102, DOI 10.2307/3577637; Bennett CB, 2001, MOL CELL BIOL, V21, P5359, DOI 10.1128/MCB.21.16.5359-5373.2001; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; COSS RA, 1981, RADIAT RES, V85, P99, DOI 10.2307/3575441; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Fasullo M, 1998, MOL CELL BIOL, V18, P1190, DOI 10.1128/MCB.18.3.1190; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Game JC, 2000, MUTAT RES-FUND MOL M, V451, P277, DOI 10.1016/S0027-5107(00)00055-5; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Hata H, 1998, GENETICS, V148, P571; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HEUDE M, 1993, GENETICS, V133, P489; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Kerscher O, 2001, GENETICS, V157, P1543; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; LOVETT ST, 1987, GENETICS, V116, P547; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; MOORE CW, 1982, CANCER RES, V42, P929; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nakao K, 2000, INTERNAL MED, V39, P412, DOI 10.2169/internalmedicine.39.412; Negritto MC, 2001, MOL CELL BIOL, V21, P2349, DOI 10.1128/MCB.21.7.2349-2358.2001; Paglin S, 2001, CANCER RES, V61, P439; Perkins EL, 1999, P NATL ACAD SCI USA, V96, P2204, DOI 10.1073/pnas.96.5.2204; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Resnick MA, 2000, MUTAT RES-FUND MOL M, V451, P1, DOI 10.1016/S0027-5107(00)00036-1; Stevenson LF, 2001, P NATL ACAD SCI USA, V98, P3946, DOI 10.1073/pnas.051013498; THOMAS JH, 1985, GENETICS, V111, P715; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang XQ, 1996, NUCLEIC ACIDS RES, V24, P4791, DOI 10.1093/nar/24.23.4791; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WELCH MD, 1994, MOL BIOL CELL, V5, P617, DOI 10.1091/mbc.5.6.617; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yu Z, 1999, ENVIRON MOL MUTAGEN, V33, P3, DOI 10.1002/(SICI)1098-2280(1999)33:1<3::AID-EM2>3.0.CO;2-L	50	257	264	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					426	434		10.1038/ng778	http://dx.doi.org/10.1038/ng778			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726929				2022-12-25	WOS:000172507500018
J	Davuluri, RV; Grosse, I; Zhang, MQ				Davuluri, RV; Grosse, I; Zhang, MQ			Computational identification of promoters and first exons in the human genome	NATURE GENETICS			English	Article							CPG ISLANDS; DISCRIMINANT-ANALYSIS; DNA-SEQUENCE; BIOLOGY; REGIONS; GENES	The identification of promoters and first exons has been one of the most difficult problems in gene-finding. We present a set of discriminant functions that can recognize structural and compositional features such as CpG islands, promoter regions and first splice-donor sites. We explain the implementation of the discriminant functions into a decision tree that constitutes a new program called FirstEF. By using different models to predict CpG-related and non-CpG-related first exons, we showed by cross-validation that the program could predict 86% of the first exons with 17% false positives. We also demonstrated the prediction accuracy of FirstEF at the genome level by applying it to the finished sequences of human chromosomes 21 and 22 as well as by comparing the predictions with the locations of the experimentally verified first exons. Finally, we present the analysis of the predicted first exons for all of the 24 chromosomes of the human genome.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Zhang, MQ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	mzhang@cshl.org	Davuluri, Ramana/D-7348-2011					Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Claverie JM, 2000, GENOME RES, V10, P1277, DOI 10.1101/gr.155500; CLEVERIE JM, 1997, HUM MOL GENET, V6, P1735; CROSS S, 1991, NUCLEIC ACIDS RES, V19, P1469, DOI 10.1093/nar/19.7.1469; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Galas DJ, 2001, SCIENCE, V291, P1257, DOI 10.1126/science.291.5507.1257; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Hong SJ, 2001, PATTERN RECOGN LETT, V22, P55, DOI 10.1016/S0167-8655(00)00099-4; Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Maroni G, 1996, EVOL BIOL, V29, P1; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Stormo GD, 2000, GENOME RES, V10, P394, DOI 10.1101/gr.10.4.394; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zhang MQ, 1998, GENOME RES, V8, P319, DOI 10.1101/gr.8.3.319; Zhang MQ, 1997, P NATL ACAD SCI USA, V94, P565, DOI 10.1073/pnas.94.2.565; [No title captured]	24	301	327	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					412	417		10.1038/ng780	http://dx.doi.org/10.1038/ng780			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726928				2022-12-25	WOS:000172507500016
J	Avner, P; Bruls, T; Poras, I; Eley, L; Gas, S; Ruiz, P; Wiles, MV; Sousa-Nunes, R; Kettleborough, R; Rana, A; Morissette, J; Bentley, L; Goldsworthy, M; Haynes, A; Herbert, E; Southam, L; Lehrach, H; Weissenbach, J; Manenti, G; Rodriguez-Tome, P; Beddington, R; Dunwoodie, S; Cox, RD				Avner, P; Bruls, T; Poras, I; Eley, L; Gas, S; Ruiz, P; Wiles, MV; Sousa-Nunes, R; Kettleborough, R; Rana, A; Morissette, J; Bentley, L; Goldsworthy, M; Haynes, A; Herbert, E; Southam, L; Lehrach, H; Weissenbach, J; Manenti, G; Rodriguez-Tome, P; Beddington, R; Dunwoodie, S; Cox, RD			A radiation hybrid transcript map of the mouse genome	NATURE GENETICS			English	Article							DELTA-HOMOLOG; PHYSICAL MAP; DLL3; WIDE; GENE	Expressed-sequence tag (EST) maps are an adjunct to sequence-based analytical methods of gene detection and localization for those species for which such data are available, and provide anchors for high-density homology and orthology mapping in species for which large-scale sequencing has yet to be done(1). Species for which radiation hybrid-based transcript maps have been established include human(2), rat(3-5), mouse(6), dog(7), cat(8) and zebrafish(9,10). We have established a comprehensive first-generation-placement radiation hybrid map of the mouse consisting of 5,904 mapped markers (3,993 ESTs and 1,911 sequence-tagged sites (STSs)). The mapped ESTs, which often originate from small-EST clusters, are enriched for genes expressed during early mouse embryogenesis and are probably different from those localized in humans. We have confirmed by in situ hybridization that even singleton ESTs, which are usually not retained for mapping studies, may represent bona fide transcribed sequences. Our studies on mouse chromosomes 12 and 14 orthologous to human chromosome 14 show the power of our radiation hybrid map as a predictive tool for orthology mapping in humans.	Ctr Natl Sequencage, F-91057 Evry, France; CNRS, UMR 8030, F-91057 Evry, France; Inst Pasteur, Unite Genet Mol Murine, Paris, France; MRC, Mammalian Genet Unit, Harwell, Berks, England; Max Planck Inst Mol Genet, Berlin, Germany; CHUL, Ctr Rech, Laval, PQ, Canada; Natl Inst Med Res, Lab Mammalian Dev, London NW7 1AA, England; Inst Nazl Tumori, Div Oncol, Milan, Italy; European Bioinformat Inst, European Mol Biol Lab Outstn, Cambridge, England; Victor Chang Cardiac Res Inst, Sydney, NSW, Australia	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society; Laval University; MRC National Institute for Medical Research; Fondazione IRCCS Istituto Nazionale Tumori Milan; European Molecular Biology Laboratory (EMBL); Victor Chang Cardiac Research Institute	Avner, P (corresponding author), Ctr Natl Sequencage, CP 5706, F-91057 Evry, France.	pavner@pasteur.fr	Sousa-Nunes, Rita/AAE-4628-2020; Ruiz Noppinger, Patricia/D-6418-2014; Dunwoodie, Sally L/M-4019-2018; Noppinger, Patricia Ruiz/AAH-1753-2019; Manenti, Giacomo/J-3339-2017	Ruiz Noppinger, Patricia/0000-0001-5617-8965; Dunwoodie, Sally L/0000-0002-2069-7349; Noppinger, Patricia Ruiz/0000-0001-5617-8965; Manenti, Giacomo/0000-0002-4887-4482; Goldsworthy, Michelle/0000-0003-1354-7737; Sousa-Nunes, Rita/0000-0002-7401-8081; Cox, Roger/0000-0001-7170-5014; wiles, michael/0000-0002-3620-8386				Agarwala R, 2000, GENOME RES, V10, P350, DOI 10.1101/gr.10.3.350; Applegate D. L., 1998, DOCUMENTA MATH, P645; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; Bruls T, 2001, NATURE, V409, P947, DOI 10.1038/35057177; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Elliott RW, 1999, GENOMICS, V57, P365, DOI 10.1006/geno.1998.5205; Geisler R, 1999, NAT GENET, V23, P86, DOI 10.1038/12692; Gusfield D., 1997, ALGORITHMS STRINGS T; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HARRISON SM, 1995, DEVELOPMENT, V121, P2479; HUDSON TJ, NATURE GENET, V27, P201; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Mellersh CS, 2000, MAMM GENOME, V11, P120, DOI 10.1007/s003350010024; Murphy WJ, 2000, GENOME RES, V10, P691, DOI 10.1101/gr.10.5.691; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Parsons JD, 2000, BIOINFORMATICS, V16, P313, DOI 10.1093/bioinformatics/16.4.313; Rodriguez-Tome P, 2000, NUCLEIC ACIDS RES, V28, P146, DOI 10.1093/nar/28.1.146; Sabile A, 1997, MAMM GENOME, V8, P81, DOI 10.1007/s003359900362; Scheetz TE, 2001, GENOME RES, V11, P497, DOI 10.1101/gr.GR-1516R; Steen RG, 1999, GENOME RES, V9, pAP1; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Yang YP, 1998, GENOME RES, V8, P731, DOI 10.1101/gr.8.7.731	31	21	21	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2001	29	2					194	200		10.1038/ng1001-194	http://dx.doi.org/10.1038/ng1001-194			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586301				2022-12-25	WOS:000171374100027
J	Hadano, S; Hand, CK; Osuga, H; Yanagisawa, Y; Otomo, A; Devon, RS; Miyamoto, N; Showguchi-Miyata, J; Okada, Y; Singaraja, R; Figlewicz, DA; Kwiatkowski, T; Hosler, BA; Sagie, T; Skaug, J; Nasir, J; Brown, RH; Scherer, SW; Rouleau, GA; Hayden, MR; Ikeda, JE				Hadano, S; Hand, CK; Osuga, H; Yanagisawa, Y; Otomo, A; Devon, RS; Miyamoto, N; Showguchi-Miyata, J; Okada, Y; Singaraja, R; Figlewicz, DA; Kwiatkowski, T; Hosler, BA; Sagie, T; Skaug, J; Nasir, J; Brown, RH; Scherer, SW; Rouleau, GA; Hayden, MR; Ikeda, JE			A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2	NATURE GENETICS			English	Article							NUCLEOTIDE EXCHANGE FACTOR; CHROMOSOME CONDENSATION; CRYSTAL-STRUCTURE; AXONAL-TRANSPORT; RHO GTPASES; PROTEIN; LINKAGE; RCC1; GENERATION; INTERACTS	Amyotrophic lateral sclerosis 2 (ALS2) is an autosomal recessive form of juvenile ALS and has been mapped to human chromosome 2q33. Here we report the identification of two independent deletion mutations linked to ALS2 in the coding exons of the new gene ALS2. These deletion mutations result in frameshifts that generate premature stop codons. ALS2 is expressed in various tissues and cells, including neurons throughout the brain and spinal cord, and encodes a protein containing multiple domains that have homology to RanGEF as well as RhoGEF. Deletion mutations are predicted to cause a loss of protein function, providing strong evidence that ALS2 is the causative gene underlying this form of ALS.	Tokai Univ, Sch Med, Japan Sci & Technol Corp, Int Cooperat Res Project, Kanagawa 2591193, Japan; Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Kanagawa 2591193, Japan; McGill Univ, Ctr Res Neurosci, Montreal, PQ H3A 2T5, Canada; Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC, Canada; Womens & Childrens Hosp, Vancouver, BC, Canada; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurobiol & Anat, Rochester, NY 14642 USA; Day Neuromuscular Res Lab, Charlestown, MA USA; E Wolfson Med Ctr, Pediat Neurol & Metab Neurogenet Clin, Holon, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Univ Ottawa, Fac Med, Dept Paediat, Ottawa, ON, Canada	Japan Science & Technology Agency (JST); Tokai University; Tokai University; McGill University; McGill University; University of British Columbia; University of British Columbia; University of Rochester; University of Rochester; Tel Aviv University; Sackler Faculty of Medicine; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Sheffield; University of Ottawa	Hayden, MR (corresponding author), Tokai Univ, Sch Med, Japan Sci & Technol Corp, Int Cooperat Res Project, Kanagawa 2591193, Japan.		Otomo, Asako/AAA-6374-2019; Hand, Collette/GRY-7269-2022; Hadano, Shinji/ABA-5052-2021; Lerman-Sagie, Tally/AAY-7598-2021; Hayden, Michael R/D-8581-2011; Scherer, Stephen W./B-3785-2013	Otomo, Asako/0000-0002-7849-4309; Hadano, Shinji/0000-0002-4997-3968; Lerman-Sagie, Tally/0000-0001-6641-6875; Hayden, Michael R/0000-0001-5159-1419; Scherer, Stephen W./0000-0002-8326-1999; Hand, Collette/0000-0003-2348-5058; Singaraja, Roshni/0000-0002-3418-3867; Nasir, Jamal/0000-0001-6378-5616				Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; BENHAMIDA M, 1990, BRAIN, V113, P347; Blair IP, 2000, NEUROGENETICS, V3, P1; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Chance PF, 1998, AM J HUM GENET, V62, P633, DOI 10.1086/301769; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Hadano S, 1999, GENOMICS, V55, P106, DOI 10.1006/geno.1998.5637; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Hentati A, 1998, NEUROGENETICS, V2, P55, DOI 10.1007/s100480050052; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Hosler BA, 1998, NEUROGENETICS, V2, P34, DOI 10.1007/s100480050049; Hosler BA, 2000, JAMA-J AM MED ASSOC, V284, P1664, DOI 10.1001/jama.284.13.1664; LermanSagie T, 1996, J CHILD NEUROL, V11, P54, DOI 10.1177/088307389601100114; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; MARTIJN FBG, 1997, J CELL BIOL, V137, P1603; Matsumoto K, 1999, MOL REPROD DEV, V54, P103, DOI 10.1002/(SICI)1098-2795(199910)54:2&lt;103::AID-MRD1&gt;3.0.CO;2-V; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Nagase T, 2000, DNA RES, V7, P273; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Roepman R, 2000, HUM MOL GENET, V9, P2095, DOI 10.1093/hmg/9.14.2095; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SIDDIQUE T, 1996, NEUROLOGY S2, V47, P27; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553	34	506	541	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					166	173		10.1038/ng1001-166	http://dx.doi.org/10.1038/ng1001-166			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586298				2022-12-25	WOS:000171374100022
J	Han, DK; Eng, J; Zhou, HL; Aebersold, R				Han, DK; Eng, J; Zhou, HL; Aebersold, R			Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry	NATURE BIOTECHNOLOGY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; HEPATIC SQUALENE SYNTHASE; MEMBRANE-PROTEINS; KINASE-C; PROTEOMIC ANALYSIS; HL-60 CELLS; IDENTIFICATION; SOLUBILIZATION; ACTIVATION; DATABASE	An approach to the systematic identification and quantification of the proteins contained in the microsomal fraction of cells is described. It consists of three steps: (1) preparation of microsomal fractions from cells or tissues representing different states; (2) covalent tagging of the proteins with isotope-coded affinity tag (ICAT) reagents followed by proteolysis of the combined labeled protein samples; and (3) isolation, identification, and quantification of the tagged peptides by multidimensional chromatography, automated tandem mass spectrometry, and computational analysis of the obtained data. The method was used to identify and determine the ratios of abundance of each of 491 proteins contained in the microsomal fractions of naive and in vitro-differentiated human myeloid leukemia (HL-60) cells. The method and the new software tools to support it are well suited to the large-scale, quantitative analysis of membrane proteins and other classes of proteins that have been refractory to standard proteomics technology.	Inst Syst Biol, Seattle, WA 98105 USA; Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA	Institute for Systems Biology (ISB); University of Connecticut	Aebersold, R (corresponding author), Inst Syst Biol, 4225 Roosevelt Way NE, Seattle, WA 98105 USA.	raebersold@systemsbiology.org	Eng, Jimmy K/I-4202-2012	Eng, Jimmy K/0000-0001-6352-6737; Zhou, Huilin/0000-0002-1350-4430	NCI NIH HHS [1R33CA84698] Funding Source: Medline; NHLBI NIH HHS [R01 HL067569-02, HL67569, R01 HL067569, R01 HL067569-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA084698] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aebersold R, 2000, NAT BIOTECHNOL, V18, P359, DOI 10.1038/74325; Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; BIRNIE GD, 1988, BRIT J CANCER, V58, P41; Chen HT, 1999, ARCH BIOCHEM BIOPHYS, V364, P203, DOI 10.1006/abbi.1999.1131; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Drews J, 1999, NAT BIOTECHNOL, V17, P406, DOI 10.1038/8531; Eccles SA, 2001, BREAST CANCER RES, V3, P86, DOI 10.1186/bcr276; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gu PD, 1998, J BIOL CHEM, V273, P12515, DOI 10.1074/jbc.273.20.12515; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; KISS Z, 1988, FEBS LETT, V231, P41, DOI 10.1016/0014-5793(88)80698-7; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; LIU E, 1992, ONCOGENE, V7, P1027; Memon RA, 1997, J LIPID RES, V38, P1620; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Molloy MP, 1998, ELECTROPHORESIS, V19, P837, DOI 10.1002/elps.1150190539; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OSEROFF AR, 1973, ANNU REV BIOCHEM, V42, P647, DOI 10.1146/annurev.bi.42.070173.003243; Rabilloud T, 1999, ELECTROPHORESIS, V20, P3603, DOI 10.1002/(SICI)1522-2683(19991201)20:18&lt;3603::AID-ELPS3603&gt;3.0.CO;2-V; Santoni V, 1999, BIOCHIMIE, V81, P655, DOI 10.1016/S0300-9084(99)80122-9; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; SEIBENHENER ML, 1993, EXP CELL RES, V207, P183, DOI 10.1006/excr.1993.1178; Shak S, 1999, SEMIN ONCOL, V26, P71; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; Simpson RJ, 2000, ELECTROPHORESIS, V21, P1707, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1707::AID-ELPS1707>3.0.CO;2-Q; STAMELLOS KD, 1993, J BIOL CHEM, V268, P12825; Szkopinska A, 2000, BIOCHEM BIOPH RES CO, V267, P473, DOI 10.1006/bbrc.1999.1981; Tansey TR, 2001, PROG NUCLEIC ACID RE, V65, P157; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wooten Marie W., 1993, Cytobios, V76, P19; YOKOYAMA K, 1992, BIOCHEM SOC T, V20, P489, DOI 10.1042/bst0200489; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	34	770	823	2	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					946	951		10.1038/nbt1001-946	http://dx.doi.org/10.1038/nbt1001-946			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581660	Green Accepted			2022-12-25	WOS:000171417600022
J	Hudson, TJ; Church, DM; Greenaway, S; Nguyen, H; Cook, A; Steen, RG; Van Etten, WJ; Castle, AB; Strivens, MA; Trickett, P; Heuston, C; Davison, C; Southwell, A; Hardisty, R; Varela-Carver, A; Haynes, AR; Rodriguez-Tome, P; Doi, H; Ko, MSH; Pontius, J; Schriml, L; Wagner, L; Maglott, D; Brown, SDM; Lander, ES; Schuler, G; Denny, P				Hudson, TJ; Church, DM; Greenaway, S; Nguyen, H; Cook, A; Steen, RG; Van Etten, WJ; Castle, AB; Strivens, MA; Trickett, P; Heuston, C; Davison, C; Southwell, A; Hardisty, R; Varela-Carver, A; Haynes, AR; Rodriguez-Tome, P; Doi, H; Ko, MSH; Pontius, J; Schriml, L; Wagner, L; Maglott, D; Brown, SDM; Lander, ES; Schuler, G; Denny, P			A radiation hybrid map of mouse genes	NATURE GENETICS			English	Article							HUMAN GENOME	A comprehensive gene-based map of a genome is a powerful tool for genetic studies and is especially useful for the positional cloning and positional candidate approaches. The availability of gene maps for multiple organisms provides the foundation for detailed conserved-orthology maps showing the correspondence between conserved genomic segments, These maps make it possible to use cross-species information in gene hunts and shed light on the evolutionary forces that shape the genome. Here we report a radiation hybrid map of mouse genes, a combined project of the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research, the Medical Research Council UK Mouse Genome Centre, and the National Center for Biotechnology Information. The map contains 11,109 genes, screened against the T31 RH panel(1) and positioned relative to a reference map containing 2,280 mouse genetic markers(2). It includes 3,658 genes homologous to the human genome sequence(3) and provides a framework for overlaying the human genome sequence to the mouse and for sequencing the mouse genome.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, England; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ, Canada; NIH, Natl Ctr Biotechnol Informat, Bethesda, MD USA; MRC, UK Mouse Genome Ctr, Oxford, England; Mammalian Genet Unit, Oxford, England; European Mol Biol Lab, European Bioinformat INst, Cambridge, England; Japan Sci & Technol Corp, ERATO, Doi Bioasymmetry Project, Chiba 2617112, Japan; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; MIT, Dept Biol, Cambridge, MA USA	McGill University; National Institutes of Health (NIH) - USA; European Molecular Biology Laboratory (EMBL); Japan Science & Technology Agency (JST); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Massachusetts Institute of Technology (MIT)	Hudson, TJ (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, Cambridge, England.	tjhudson@med.mcgill.ca	Ko, Minoru S. H./B-7969-2009; Schriml, Lynn/AFO-9472-2022	Ko, Minoru S. H./0000-0002-3530-3015; Hudson, Thomas/0000-0002-1376-4849; Denny, Paul/0000-0003-4659-6893; Schriml, Lynn/0000-0001-8910-9851	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001806] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01806] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Arkel RM, 2001, MAMM GENOME, V12, P687, DOI 10.1007/s00335-001-2066-2; Chen XN, 1999, GENOME RES, V9, P492; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; EVANS EP, 1989, GENETIC VARIANTS STR, P576; Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115; FLURY B, 1997, 1 COURSE MULTIVARIAT, P656; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Ko MSH, 1998, HUM MOL GENET, V7, P1967, DOI 10.1093/hmg/7.12.1967; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Slonim D, 1997, J COMPUT BIOL, V4, P487, DOI 10.1089/cmb.1997.4.487; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962	18	48	50	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					201	205		10.1038/ng1001-201	http://dx.doi.org/10.1038/ng1001-201			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586302				2022-12-25	WOS:000171374100028
J	Jo, DW; Nashabi, A; Doxsee, C; Lin, Q; Unutmaz, D; Chen, J; Ruley, HE				Jo, DW; Nashabi, A; Doxsee, C; Lin, Q; Unutmaz, D; Chen, J; Ruley, HE			Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase	NATURE BIOTECHNOLOGY			English	Article							SITE-SPECIFIC RECOMBINATION; PROTEIN TRANSDUCTION; RETROVIRAL VECTORS; MICE; DELIVERY; PEPTIDE; TRANSLOCATION; MUTAGENESIS; EXPRESSION; ACTIVATION	Studies of mammalian gene function are hampered by temporal limitations in which phenotypes occurring at one stage of development interfere with analysis at later stages. Moreover, phenotypes resulting from altered gene activity include both direct and indirect effects that may be difficult to distinguish. In the present study, recombinant fusion proteins bearing the 12 amino acid membrane translocation sequence (MTS) from the Kaposi fibroblast growth factor (FGF-4) were used to transduce enzymatically active Cre proteins directly into mammalian cells. High levels of recombination were observed in a variety of cultured cell types and in all tissues examined in mice following intraperitoneal administration. This represents the first use of protein transduction to induce the enzymatic conversion of a substrate in living cells and animals and provides a rapid and efficient means to manipulate mammalian gene structure and function.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Ruley, HE (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 1161 21 Ave S,SS4210, Nashville, TN 37232 USA.			Chen, Jin/0000-0002-5557-2079	NCI NIH HHS [P30CA42014] Funding Source: Medline; NCRR NIH HHS [R01RR13166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Beddington R. S. P., 1990, POSTIMPLANTATION MAM, P267; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Justice MJ, 1997, METHODS, V13, P423, DOI 10.1006/meth.1997.0548; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; Kolb AF, 1996, GENE, V183, P53, DOI 10.1016/S0378-1119(96)00470-2; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu XY, 2000, J BIOL CHEM, V275, P16774; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEREZ F, 1992, J CELL SCI, V102, P717; Rohlmann A, 1996, NAT BIOTECHNOL, V14, P1562, DOI 10.1038/nbt1196-1562; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Russ AP, 1996, P NATL ACAD SCI USA, V93, P15279, DOI 10.1073/pnas.93.26.15279; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SAUER B, 1990, New Biologist, V2, P441; Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Su H, 2000, NAT GENET, V24, P92, DOI 10.1038/71756; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949; ZOU YR, 1994, CURR BIOL, V4, P1099, DOI 10.1016/S0960-9822(00)00248-7	33	115	138	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					929	933		10.1038/nbt1001-929	http://dx.doi.org/10.1038/nbt1001-929			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581657				2022-12-25	WOS:000171417600019
J	Joberty, G; Perlungher, RR; Sheffield, PJ; Kinoshita, M; Noda, M; Haystead, T; Macara, IG				Joberty, G; Perlungher, RR; Sheffield, PJ; Kinoshita, M; Noda, M; Haystead, T; Macara, IG			Borg proteins control septin organization and are negatively regulated by Cdc42	NATURE CELL BIOLOGY			English	Article							ALDRICH-SYNDROME PROTEIN; ACUTE MYELOID-LEUKEMIA; GTPASE-BINDING DOMAIN; N-WASP; PLASMA-MEMBRANE; CELL-POLARITY; YEAST; COMPLEX; GENE; REGION	The Cdc42 GTPase binds to numerous effector proteins that control cell polarity, cytoskeletal remodelling and vesicle transport. In many cases the signalling pathways downstream of these effectors are not known. Here we show that the Cdc42 effectors Borg1 to Borg3 bind to septin GTPases. Endogenous septin Cdc10 and Borg3 proteins can be immunoprecipitated together by an anti-Borg3 antibody. The ectopic expression of Borgs disrupts normal septin organization. Cdc42 negatively regulates this effect and inhibits the binding of Borg3 to septins. Borgs are therefore the first known regulators of mammalian septin organization and provide an unexpected link between the septin and Cdc42 GTPases.	Univ Virginia, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto, Japan; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Virginia; University of Virginia; Kyoto University; Duke University; Harvard University; Harvard Medical School	Macara, IG (corresponding author), Univ Virginia, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA.							Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Barral Y, 2000, MOL CELL, V5, P841, DOI 10.1016/S1097-2765(00)80324-X; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Field CM, 1996, J CELL BIOL, V133, P605, DOI 10.1083/jcb.133.3.605; Frazier JA, 1998, J CELL BIOL, V143, P737, DOI 10.1083/jcb.143.3.737; Fung ET, 1999, FEBS LETT, V451, P203, DOI 10.1016/S0014-5793(99)00559-1; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kinoshita A, 2000, J COMP NEUROL, V428, P223, DOI 10.1002/1096-9861(20001211)428:2<223::AID-CNE3>3.0.CO;2-M; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; McKie JM, 1997, HUM GENET, V101, P6, DOI 10.1007/s004390050576; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Richman TJ, 1999, J BIOL CHEM, V274, P16861, DOI 10.1074/jbc.274.24.16861; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; TIANDRA H, 1998, CURR BIOL, V8, P991; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	36	140	149	3	14	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					861	866		10.1038/ncb1001-861	http://dx.doi.org/10.1038/ncb1001-861			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584266				2022-12-25	WOS:000171396400009
J	Runswick, SK; O'Hare, MJ; Jones, L; Streuli, CH; Garrod, DR				Runswick, SK; O'Hare, MJ; Jones, L; Streuli, CH; Garrod, DR			Desmosomal adhesion regulates epithelial morphogenesis and cell positioning	NATURE CELL BIOLOGY			English	Article							PEMPHIGUS-VULGARIS ANTIGEN; EMBRYONIC HEART; N-CADHERIN; EXPRESSION; MOUSE; PLAKOGLOBIN; DESMOCOLLIN; GENE; DIFFERENTIATION; DESMOGLEIN	Desmosomes are intercellular junctions of epithelia and are of widespread importance in the maintenance of tissue architecture. We provide evidence that desmosomal adhesion has a function in epithelial morphogenesis and cell-type-specific positioning. Blocking peptides corresponding to the cell adhesion recognition (CAR) sites of desmosomal cadherins block alveolar morphogenesis by epithelial cells from mammary lumen. Desmosomal CAR-site peptides also disrupt positional sorting of luminal and myoepithelial cells in aggregates formed by the reassociation of isolated cells. We demonstrate that desmosomal cadherins and E-cadherin are comparably involved in epithelial morphoregulation. The results indicate a wider role for desmosomal adhesion in morphogenesis than has previously been considered.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; UCL, LICR, Breast Canc Lab, London W1W 4EJ, England; Univ Leicester, Dept Pathol, Leicester LE2 7LX, Leics, England	University of Manchester; University of London; University College London; University of Leicester	Garrod, DR (corresponding author), Univ Manchester, Sch Biol Sci, 3-239 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							AGGELER J, 1991, J CELL SCI, V99, P407; Amagai M, 2000, NAT MED, V6, P1275, DOI 10.1038/81385; AMAGAI M, 1994, J INVEST DERMATOL, V102, P402, DOI 10.1111/1523-1747.ep12372164; ARNEMANN J, 1993, J CELL SCI, V104, P741; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Chidgey MAJ, 1997, HISTOL HISTOPATHOL, V12, P1159; Chidgey MAJ, 1996, J INVEST DERMATOL, V106, P689, DOI 10.1111/1523-1747.ep12345525; Chitaev NA, 1997, J CELL BIOL, V138, P193, DOI 10.1083/jcb.138.1.193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EALEY PA, 1988, J MOL ENDOCRINOL, V1, pR1, DOI 10.1677/jme.0.001R001; Edwards GM, 1999, METH MOL B, V129, P135; FLEMING TP, 1991, DEVELOPMENT, V112, P527; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; King IA, 1996, J INVEST DERMATOL, V107, P531, DOI 10.1111/1523-1747.ep12582790; KITTRELL FS, 1992, CANCER RES, V52, P1924; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P12; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kowalczyk AP, 1996, J INVEST DERMATOL, V107, P293, DOI 10.1111/1523-1747.ep12363000; LEGAN PK, 1994, J CELL BIOL, V126, P507, DOI 10.1083/jcb.126.2.507; LORIMER JE, 1994, MOL MEMBR BIOL, V11, P229, DOI 10.3109/09687689409160432; Marcozzi C, 1998, J CELL SCI, V111, P495; MBALAVIELE G, 1995, J CLIN INVEST, V95, P2757, DOI 10.1172/JCI117979; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; MEGE RM, 1992, J CELL SCI, V103, P897; Noe V, 1999, J CELL SCI, V112, P127; North AJ, 1996, P NATL ACAD SCI USA, V93, P7701, DOI 10.1073/pnas.93.15.7701; NUBER UA, 1995, EUR J CELL BIOL, V66, P69; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; PARRISH EP, 1990, J CELL SCI, V96, P239; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SCHAFER S, 1994, EXP CELL RES, V211, P391, DOI 10.1006/excr.1994.1103; Steinberg MS., 1964, CELLULAR MEMBRANES D, P321; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; VILELA MJ, 1995, J CELL SCI, V108, P1743; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; WILLEMS J, 1995, FEBS LETT, V363, P289, DOI 10.1016/0014-5793(95)00334-6; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007	44	186	187	0	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					823	830		10.1038/ncb0901-823	http://dx.doi.org/10.1038/ncb0901-823			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533662				2022-12-25	WOS:000170979600016
J	Telling, G				Telling, G			Protein-based PCR for prion diseases?	NATURE MEDICINE			English	Editorial Material							SCRAPIE INFECTIVITY; PROPAGATION	The development of a sensitive in vitro method to amplify the pathological form of the prion protein might provide a tool for the pre-clinical diagnosis of prion diseases.	Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Telling, G (corresponding author), Univ Kentucky, Dept Microbiol & Immunol, Lexington, KY 40536 USA.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805				BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riesner D, 1996, J VIROL, V70, P1714, DOI 10.1128/JVI.70.3.1714-1722.1996; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8	8	1	1	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					778	779		10.1038/89895	http://dx.doi.org/10.1038/89895			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433339				2022-12-25	WOS:000169808600022
J	Vergnolle, N; Bunnett, NW; Sharkey, KA; Brussee, V; Compton, SJ; Grady, EF; Cirino, G; Gerard, N; Basbaum, AI; Andrade-Gordon, P; Hollenberg, MD; Wallace, JL				Vergnolle, N; Bunnett, NW; Sharkey, KA; Brussee, V; Compton, SJ; Grady, EF; Cirino, G; Gerard, N; Basbaum, AI; Andrade-Gordon, P; Hollenberg, MD; Wallace, JL			Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway	NATURE MEDICINE			English	Article							GENE-RELATED PEPTIDE; MUCOSAL MAST-CELLS; SUBSTANCE-P; (PAR(2))-ACTIVATING PEPTIDES; MICE LACKING; DORSAL-HORN; SPINAL-CORD; INFLAMMATION; ANTAGONISTS; EXPRESSION	Using a combined pharmacological and gene-deletion approach, we have delineated a novel mechanism of neurokinin-1 (NK-1) receptor-dependent hyperalgesia induced by proteinase-activated receptor-2 (PAR2), a G-protein-coupled receptor expressed on nociceptive primary afferent neurons. Injections into the paw of sub-inflammatory doses of PAR2 agonists in rats and mice induced a prolonged thermal and mechanical hyperalgesia and elevated spinal Fos protein expression. This hyperalgesia was markedly diminished or absent in mice lacking the NK-1 receptor, preprotachykinin-A or PAR2 genes, or in rats treated with a centrally acting cyclooxygenase inhibitor or treated by spinal cord injection of NK-1 antagonists. Here we identify a previously unrecognized nociceptive pathway with important therapeutic implications, and our results point to a direct role for proteinases and their receptors in pain transmission.	Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; RW Johnson Pharmaceut Res Inst, Spring House, PA 19477 USA	University of Calgary; University of Calgary; University of Calgary; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Naples Federico II; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johnson & Johnson; Johnson & Johnson USA	Wallace, JL (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada.	wallacej@ucalgary.ca	Hollenberg, Morley/AFV-6966-2022; Vergnolle, Nathalie/C-7677-2018; Wallace, John/AAL-3763-2021	Vergnolle, Nathalie/0000-0003-1825-6015; Bunnett, Nigel W./0000-0003-3367-0644; Cirino, Giuseppe/0000-0003-3954-4083; Sharkey, Keith/0000-0001-9560-1711	NHLBI NIH HHS [HL 41587] Funding Source: Medline; NIDDK NIH HHS [DK 43207, DK 39957, DK 57840, DK 52388] Funding Source: Medline; NINDS NIH HHS [NS 14627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK043207, R01DK039957, R01DK057840, R01DK043207, R01DK052388, R37DK039957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014627, R37NS014627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMANN R, 1995, N-S ARCH PHARMACOL, V352, P201; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cao T, 1999, AM J PHYSIOL-REG I, V277, pR476, DOI 10.1152/ajpregu.1999.277.2.R476; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 1998, J IMMUNOL, V161, P1939; Coudore-Civiale MA, 1998, EUR J PHARMACOL, V361, P175, DOI 10.1016/S0014-2999(98)00722-5; Couture R, 1999, LIFE SCI, V66, P51; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Dickinson T, 1998, Trends Pharmacol Sci, V19, P346, DOI 10.1016/S0165-6147(98)01237-1; FERRAZ JGP, 1995, GASTROENTEROLOGY, V108, P1183, DOI 10.1016/0016-5085(95)90218-X; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; FERREIRA SH, 1978, EUR J PHARMACOL, V53, P39, DOI 10.1016/0014-2999(78)90265-0; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Hill R, 2000, TRENDS PHARMACOL SCI, V21, P244, DOI 10.1016/S0165-6147(00)01502-9; Hollenberg MD, 1999, TRENDS PHARMACOL SCI, V20, P271, DOI 10.1016/S0165-6147(99)01333-4; Hua XY, 1998, J NEUROCHEM, V70, P688; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; LEGREVES P, 1985, EUR J PHARMACOL, V115, P309, DOI 10.1016/0014-2999(85)90706-X; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; MCCARSON KE, 1991, BRAIN RES, V568, P109, DOI 10.1016/0006-8993(91)91385-E; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miampamba M, 1999, J AUTONOM NERV SYST, V77, P140, DOI 10.1016/S0165-1838(99)00048-X; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NAKAMURACRAIG M, 1991, NEUROSCI LETT, V124, P49, DOI 10.1016/0304-3940(91)90819-F; OHKUBO T, 1990, J PHARMACOL EXP THER, V252, P1261; OKU R, 1987, BRAIN RES, V403, P350, DOI 10.1016/0006-8993(87)90074-6; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Takasaki I, 2001, J PHARMACOL EXP THER, V296, P270; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vergnolle N, 1998, P NATL ACAD SCI USA, V95, P7766, DOI 10.1073/pnas.95.13.7766; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Xu GY, 2000, J PHYSIOL-LONDON, V528, P339, DOI 10.1111/j.1469-7793.2000.00339.x	43	372	386	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					821	826		10.1038/89945	http://dx.doi.org/10.1038/89945			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433347				2022-12-25	WOS:000169808600034
J	Esterbauer, H; Schneitler, C; Oberkofler, H; Ebenbichler, C; Paulweber, B; Sandhofer, F; Ladurner, G; Hell, E; Strosberg, AD; Patsch, JR; Krempler, F; Patsch, W				Esterbauer, H; Schneitler, C; Oberkofler, H; Ebenbichler, C; Paulweber, B; Sandhofer, F; Ladurner, G; Hell, E; Strosberg, AD; Patsch, JR; Krempler, F; Patsch, W			A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans	NATURE GENETICS			English	Letter							UNCOUPLING PROTEIN-3 GENE; MESSENGER-RNA EXPRESSION; BODY-MASS INDEX; ENERGY-METABOLISM; PIMA-INDIANS; WEIGHT; REGION; TISSUE; DIET	Obesity is the most common nutritional disorder in Western society. Uncoupling protein-2 (UCP2) is a recently identified member of the mitochondrial transporter superfamily that is expressed in many tissues, including adipose tissue(1,2). Like its close relatives UCP1 and UCP3. UCP2 uncouples proton entry in the mitochondrial matrix from ATP synthesis(1,3) and is therefore a candidate gene for obesity(4-6). We show here that a common G/A polymorphism in the UCP2 promoter region is associated with enhanced adipose tissue mRNA expression in vivo and results in increased transcription of a reporter gene in the human adipocyte cell line PAZ-6. In analyzing 340 obese and 256 never-obese middle-aged subjects, we found a modest but significant reduction in obesity prevalence associated with the less-common allele. We confirmed this association in a population-based sample of 791 middle-aged subjects from the same geographic area. Despite its modest effect, but because of its high frequency (similar to 63%). the more-common risk allele conferred a relatively large population-attributable risk accounting for 15% of the obesity in the population studied.	Landskliniken Salzburg, Dept Lab Med, Salzburg, Austria; Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria; Landskliniken Salzburg, Dept Internal Med, Salzburg, Austria; Landskliniken Salzburg, Dept Neurol, Salzburg, Austria; Inst Cochin Genet Mol, F-75014 Paris, France	University of Innsbruck; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Patsch, W (corresponding author), Landskliniken Salzburg, Dept Lab Med, Salzburg, Austria.	w.patsch@lks.at		Ebenbichler, Christoph/0000-0001-5025-7929; Esterbauer, Harald/0000-0001-7343-7455				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; BRADBURN MJ, 1998, STATA TECHNICAL B, V44, P4; Cassell PG, 2000, DIABETOLOGIA, V43, P1558, DOI 10.1007/s001250051569; Chiano MN, 1998, ANN HUM GENET, V62, P55, DOI 10.1046/j.1469-1809.1998.6210055.x; Dalgaard LT, 1999, DIABETOLOGIA, V42, P1413, DOI 10.1007/s001250051312; Esterbauer H, 2000, J BIOL CHEM, V275, P36394, DOI 10.1074/jbc.M005713200; Esterbauer H, 1999, DIABETOLOGIA, V42, P302, DOI 10.1007/s001250051155; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Kiefer I, 1998, ACTA MED AUST, V25, P126; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kozak LP, 2000, NAT MED, V6, P1092, DOI 10.1038/80412; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; MANDER AP, 2000, STAT TECH B, V55, P10; Oberkofler H, 1998, DIABETOLOGIA, V41, P940, DOI 10.1007/s001250051011; Otabe S, 2000, DIABETOLOGIA, V43, P245, DOI 10.1007/s001250050037; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Schrauwen P, 1999, INT J OBESITY, V23, P1242, DOI 10.1038/sj.ijo.0801057; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Walder K, 1998, HUM MOL GENET, V7, P1431, DOI 10.1093/hmg/7.9.1431; Zilberfarb V, 1997, J CELL SCI, V110, P801	30	307	321	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					178	183		10.1038/88911	http://dx.doi.org/10.1038/88911			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381268				2022-12-25	WOS:000169011800023
J	Lin, SX; Grant, B; Hirsh, D; Maxfield, FR				Lin, SX; Grant, B; Hirsh, D; Maxfield, FR			Rme-1 regulates the distribution and function of the endocytic recycling compartment in mammalian cells	NATURE CELL BIOLOGY			English	Article							HAMSTER OVARY CELLS; TRANS-GOLGI NETWORK; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; SORTING ENDOSOMES; PROTEIN; RAB11; TRAFFICKING; EXPRESSION	RME-1 is an Epsl5-homology (EH)-domain protein that was identified in a genetic screen for endocytosis genes in Caenorhabditis elegans. When expressed in a CHO cell line the worm RME-1 protein and a mouse homologue are both associated with the endocytic recycling compartment. Here we show that expression of a dominant-negative construct with a point mutation near the EH domain results in redistribution of the endocytic recycling compartment and slowing down of transferrin receptor recycling. The delivery of a TGN38 chimaeric protein to the trans-Golgi network is also slowed down. The function of Rme-1 in endocytic recycling is evolutionarily conserved in metazoans as shown by the protein's properties in C. elegans.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Cornell University; Columbia University	Maxfield, FR (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.		Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; Grant, Barth/0000-0002-5943-8336	NIGMS NIH HHS [F32 GM019167-02, F32 GM019167, F32 GM019167-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GRANT B, 2001, NATURE CELL BIOL, V3; Green EG, 1997, BIOCHEM BIOPH RES CO, V239, P612, DOI 10.1006/bbrc.1997.7520; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Haider NB, 1999, GENE, V240, P227, DOI 10.1016/S0378-1119(99)00395-9; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; IACOPETTA BJ, 1983, J BIOL CHEM, V258, P9108; Johannes L, 1997, J BIOL CHEM, V272, P19554, DOI 10.1074/jbc.272.31.19554; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; McDaniel JP, 1999, INT J PARASITOL, V29, P723, DOI 10.1016/S0020-7519(99)00024-7; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zeng JB, 1999, P NATL ACAD SCI USA, V96, P2840, DOI 10.1073/pnas.96.6.2840; Zuk PA, 2000, J BIOL CHEM, V275, P26754	37	204	208	1	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					567	572		10.1038/35078543	http://dx.doi.org/10.1038/35078543			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389441				2022-12-25	WOS:000169194400012
J	Rudolph, KL; Millard, M; Bosenberg, MW; DePinho, RA				Rudolph, KL; Millard, M; Bosenberg, MW; DePinho, RA			Telomere dysfunction and evolution of intestinal carcinoma in mice and humans	NATURE GENETICS			English	Letter							COMPARATIVE GENOMIC HYBRIDIZATION; COLORECTAL-CANCER; CHROMOSOMAL GAINS; DEFICIENT MICE; MOUSE; NEOPLASIA; TUMORIGENESIS; PROGRESSION; MUTATION; CELLS	Telomerase activation is a common feature of advanced human cancers' and facilitates the malignant transformation of cultured human cells(2) and in mice(3,4). These experimental observations are in accord with the presence of robust telomerase activity in more advanced stages of human colorectal carcinogenesis(5-7). However, the occurrence of colon carcinomas in telomerase RNA (Terc)-null, p53-mutant mice(8) has revealed complex interactions between telomere dynamics, checkpoint responses and carcinogenesis9. We therefore sought to determine whether telomere dysfunction exerts differential effects on cancer initiation versus progression of mouse and human intestinal neoplasia. In successive generations of Apc(Min) Terc(-/-) mice(10,11). progressive telomere dysfunction led to an increase in initiated lesions (microscopic adenomas), yet a significant decline in the multiplicity and size of macroscopic adenomas. That telomere dysfunction also contributes to human colorectal carcinogenesis is supported by the appearance of anaphase bridges (a correlate of telomere dysfunction) at the adenomaearly carcinoma transition, a transition recognized for marked chromosomal instability(12-15). Together. these data are consistent with a model in which telomere dysfunction promotes the chromosomal instability that drives early carcinogenesis, while telomerase activation restores genomic stability to a level permissive for tumor progression. We propose that early and transient telomere dysfunction is a major mechanism underlying chromosomal instability of human cancer.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30623 Hannover, Germany	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Hannover Medical School	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.			Rudolph, Karl Lenhard/0000-0002-4839-2862; DePinho, Ronald/0000-0002-5625-577X				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Engelhardt M, 1997, CLIN CANCER RES, V3, P1931; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hanahan D, 2000, NATURE, V406, P573, DOI 10.1038/35020662; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; McClintock B, 1941, GENETICS, V26, P234; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tang RP, 1998, CANCER RES, V58, P4052; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	31	421	441	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					155	159		10.1038/88871	http://dx.doi.org/10.1038/88871			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381263				2022-12-25	WOS:000169011800018
J	Balaban, NQ; Schwarz, US; Riveline, D; Goichberg, P; Tzur, G; Sabanay, I; Mahalu, D; Safran, S; Bershadsky, A; Addadi, L; Geiger, B				Balaban, NQ; Schwarz, US; Riveline, D; Goichberg, P; Tzur, G; Sabanay, I; Mahalu, D; Safran, S; Bershadsky, A; Addadi, L; Geiger, B			Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates	NATURE CELL BIOLOGY			English	Article							CELL-MATRIX ADHESIONS; TRACTION FORCES; MOLECULAR-INTERACTIONS; PROTEIN; CONTRACTILITY; LOCOMOTION; INTEGRINS; STRESSES	Mechanical forces play a major role in the regulation of cell adhesion and cytoskeletal organization. In order to explore the molecular mechanism underlying this regulation, we have investigated the relationship between local force applied by the cell to the substrate and the assembly of focal adhesions. A novel approach was developed for real-time, high-resolution measurements of forces applied by cells at single adhesion sites. This method combines micropatterning of elastomer substrates and fluorescence imaging of focal adhesions in live cells expressing GFP-tagged vinculin, Local forces are correlated with the orientation, total fluorescence intensity and area of the focal adhesions, indicating a constant stress of 5.5 +/- 2 nN mum-2. The dynamics of the force-dependent modulation of focal adhesions were characterized by blocking actomyosin contractility and were found to be on a time scale of seconds. The results put clear constraints on the possible molecular mechanisms for the mechanosensory response of focal adhesions to applied force.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel; Univ Grenoble 1, Spectrometrie Phys Lab, Grenoble, France; Weizmann Inst Sci, Braun Ctr Submicron Semicond Res, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Weizmann Institute of Science; Weizmann Institute of Science	Balaban, NQ (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	benny.geiger@weizmann.ac.il	Balaban, Nathalie/AGI-1487-2022; Balaban, Nathalie/AAH-1004-2019; Ladoux, Benoit/A-9879-2013; Schwarz, Ulrich S/K-4111-2014; Riveline, Daniel/GXV-6609-2022; Schwarz, Ulrich/ABB-5642-2020; Safran, Samuel/K-1504-2012	Balaban, Nathalie/0000-0001-8018-0766; Balaban, Nathalie/0000-0001-8018-0766; Schwarz, Ulrich S/0000-0003-1483-640X; Schwarz, Ulrich/0000-0003-1483-640X; Safran, Samuel/0000-0002-0798-1492; Bershadsky, Alexander/0000-0002-9571-7375				ABERCROMBIE M, 1975, EXP CELL RES, V92, P57, DOI 10.1016/0014-4827(75)90636-9; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BENIGO KA, 2000, MOL BIOL CELL, V11, P4; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; BERSHADSKY A, 1999, GUIDEBOOK EXTRACELLU, P3; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Burton K, 1999, MOL BIOL CELL, V10, P3745, DOI 10.1091/mbc.10.11.3745; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; Dembo M, 1996, BIOPHYS J, V70, P2008, DOI 10.1016/S0006-3495(96)79767-9; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; DOW JAT, 1987, J CELL SCI, P55; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FINER JT, 1995, BIOPHYS J, V68, pS291; Galbraith CG, 1997, P NATL ACAD SCI USA, V94, P9114, DOI 10.1073/pnas.94.17.9114; Geiger B, 1995, ACTA ANAT, V154, P46; Harder BA, 1998, J STRUCT BIOL, V122, P162, DOI 10.1006/jsbi.1998.3981; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; Landau L. D., 1970, Theory of elasticity; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; Levenberg S, 1998, J CELL SCI, V111, P347; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Press W., 1992, NUMERICAL RECIPES FO; RIVELINE D, IN PRESS J CELL BIOL; Rossiter H, 1997, MOL MED TODAY, V3, P214, DOI 10.1016/S1357-4310(97)01040-X; Shaub A, 1999, NAT CELL BIOL, V1, pE173, DOI 10.1038/15608; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Tibshirani R.J., 1993, MONOGRAPHS STAT APPL, VVolume 57, P1; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YANG JT, 1995, DEVELOPMENT, V121, P549; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	44	1635	1672	6	364	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					466	472		10.1038/35074532	http://dx.doi.org/10.1038/35074532			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331874				2022-12-25	WOS:000168592500016
J	Fares, H; Greenwald, I				Fares, H; Greenwald, I			Regulation of endocytosis by CUP-5, the Caenorhabditis elegans mucolipin-1 homolog	NATURE GENETICS			English	Article							ABNORMAL TRANSPORT; MEMBRANE-PROTEIN; GENE; IV; MUTATIONS; IDENTIFICATION; ALIGNMENT; TOOL	Loss of the human 1mucolipin-l gene underlies mucolipidosis type IV (MLIV), a lysosomal storage disease that results in severe developmental neuropathology(1-3). Unlike other lysosomal storage diseases, MLIV is not associated with a lack of lysosomal hydrolases(4); instead, MLIV cells display abnormal endocytosis of lipids and accumulate large vesicles, indicating that a defect in endocytosis may underlie the disease(4-6). Here we report the identification of a loss-of-function mutation in the Caenorhabditis elegans mucolipin-1 homolog, cup-5, and show that this mutation results in an enhanced rate of uptake of fluid-phase markers, decreased degradation of endocytosed protein and accumulation of large vacuoles. Overexpression of cup-5(+) causes the opposite phenotype, indicating that cup-5 activity controls aspects of endocytosis. Studies in model organisms such as C. elegans have helped illuminate fundamental mechanisms involved in normal cellular function and human disease; thus the C. elegans cup-5 mutant may be a useful model for studying conserved aspects of mucolipin-1 structure and function and for assessing the effects of potential therapeutic compounds.	Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY USA	Columbia University; Howard Hughes Medical Institute	Fares, H (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Life Sci S Room 531, Tucson, AZ 85721 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; Bargal R, 1997, J INHERIT METAB DIS, V20, P625, DOI 10.1023/A:1005362123443; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HOSONO R, 1982, J EXP ZOOL, V235, P409; Jakubowski J, 1999, GENETICS, V153, P743; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MERIN S, 1975, INVEST OPHTH VISUAL, V14, P437; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZEIGLER M, 1992, PRENATAL DIAG, V12, P1037, DOI 10.1002/pd.1970121209; ZHANG Y, IN PRESS MOL BIOL CE	22	179	183	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					64	68		10.1038/ng0501-64	http://dx.doi.org/10.1038/ng0501-64			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326278				2022-12-25	WOS:000168413300018
J	Christova, R; Oelgeschlager, T				Christova, R; Oelgeschlager, T			Association of human TFIID-promoter complexes with silenced mitotic chromatin in vivo	NATURE CELL BIOLOGY			English	Article							RNA-POLYMERASE-II; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; IN-VIVO; BINDING; TBP; REPRESSION; ACTIVATOR; PHOSPHORYLATION; INHIBITION	When eukaryotic cells enter mitosis, transcription is abruptly silenced. Earlier studies indicated that most transcription factors and RNA polymerase II (RNAP II) are displaced when chromatin is condensed into mitotic chromosomes(1,2). A more recent study suggested that hitherto unidentified factors might 'bookmark' previously active genes for rapid reactivation after cell division(3). Here we used chromatin immunoprecipitation (ChIP) assays to examine the association of TFIID, TFIIB, NC2 and RNAP II with various gene promoters in asynchronous and mitotic human cell populations. We show that TFIID and TFIIB can remain associated with active gene promoters during mitosis whereas RNA polymerase II is displaced, and also that NC2, originally identified as ubiquitous repressor of transcription 4,5, is associated with active gene promoters in asynchronous cell populations and is displaced from some, but not all, genes in mitotic cells. Consistent with the remarkable stability of TFIID-promoter complexes observed in vitro(6-8), our data suggest that these complexes can withstand condensation of chromatin into transcriptionally silent chromosomes. Stable TFIID-promoter complexes are therefore implicated in the propagation of cell-type-specific gene expression patterns through cell division.	Marie Curie Res Inst, Eukaryot Gene Regulat Lab, Surrey RH8 0TL, England		Christova, R (corresponding author), Marie Curie Res Inst, Eukaryot Gene Regulat Lab, Surrey RH8 0TL, England.			Oelgeschlager, Thomas/0000-0002-4086-719X				Akoulitchev S, 1998, GENE DEV, V12, P3541, DOI 10.1101/gad.12.22.3541; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Parsons GG, 1997, MOL CELL BIOL, V17, P5791, DOI 10.1128/MCB.17.10.5791; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	28	128	132	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					79	82		10.1038/ncb733	http://dx.doi.org/10.1038/ncb733			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11744923				2022-12-25	WOS:000173381500020
J	Liang, JS; Distler, O; Cooper, DA; Jamil, H; Deckelbaum, RJ; Ginsberg, HN; Sturley, SL				Liang, JS; Distler, O; Cooper, DA; Jamil, H; Deckelbaum, RJ; Ginsberg, HN; Sturley, SL			HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia	NATURE MEDICINE			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; INSULIN-RESISTANCE; PERIPHERAL LIPODYSTROPHY; CONTAINING LIPOPROTEINS; SECRETION; CELLS; B100; ATHEROSCLEROSIS; TRANSLOCATION; PATHOGENESIS	Highly active anti-retroviral therapies, which incorporate HIV protease inhibitors, resolve many AIDS-defining illnesses. However, patients receiving protease inhibitors develop a marked lipodystrophy and hyperlipidemia. Using cultured human and rat hepatoma cells and primary hepatocytes from transgenic mice we demonstrate that protease inhibitor treatment inhibits proteasomal degradation of nascent apolipoprotein B, the principal protein component of triglyceride and cholesterol-rich plasma lipoproteins. Unexpectedly, protease inhibitors also inhibited the secretion of apolipoprotein B. This was associated with inhibition of cholesteryl-ester synthesis and microsomal triglyceride transfer-protein activity. However, in the presence of oleic acid, which stimulates neutral-lipid biosynthesis, protease-inhibitor treatment increased secretion of apolipoprotein B-lipoproteins above controls. These findings suggest a molecular basis for protease-inhibitor-associated hyperlipidemia, a serious adverse effect of an otherwise efficacious treatment for HIV infection.	Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Bristol Myers Squibb Co, Princeton, NJ USA	Columbia University; Columbia University; Columbia University; University of New South Wales Sydney; Kirby Institute; Bristol-Myers Squibb	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, 630 W 168th St, New York, NY 10032 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, R01HL040404, R01HL065954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55638, HL65954, HL40404] Funding Source: Medline; NIAID NIH HHS [P30 AI42848] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; BILLHEIMER JT, 1991, 9TH INT S ATH ROS, V184, pA94; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CARR TP, 1995, J LIPID RES, V36, P25; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Flynn TE, 1999, ANN INTERN MED, V131, P548, DOI 10.7326/0003-4819-131-7-199910050-00032; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Moyle GJ, 1999, DRUG SAFETY, V20, P299, DOI 10.2165/00002018-199920040-00002; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Purnell JQ, 2000, AIDS, V14, P51, DOI 10.1097/00002030-200001070-00006; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	34	177	185	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1327	1331		10.1038/nm1201-1327	http://dx.doi.org/10.1038/nm1201-1327			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726973				2022-12-25	WOS:000172610300038
J	Martin-Serrano, J; Zang, T; Bieniasz, PD				Martin-Serrano, J; Zang, T; Bieniasz, PD			HIV-I and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress	NATURE MEDICINE			English	Article							ROUS-SARCOMA VIRUS; VESICULAR STOMATITIS-VIRUS; PROLINE-RICH MOTIF; GAG POLYPROTEIN; MATRIX PROTEIN; UBIQUITIN LIGASE; TYPE-1; DOMAIN; RELEASE; REPLICATION	Retroviral Gag proteins encode sequences, termed late domains, which facilitate the final stages of particle budding from the plasma membrane. We report here that interactions between Tsg101, a factor involved in endosomal protein sorting, and short peptide motifs in the HIV-1 Gag late domain and Ebola virus matrix (EbVp40) proteins are essential for efficient egress of HIV-1 virions and Ebola virus-like particles. EbVp40 recruits Tsg101 to sites of particle assembly and a short, EbVp40-derived Tsg101-binding peptide sequence can functionally substitute for the HIV-1 Gag late domain. Notably, recruitment of Tsg101 to assembling virions restores budding competence to a late-domain-defective HIV-1 in the complete absence of viral late domain. These studies define an essential virus-host interaction that is conserved in two unrelated viruses. Because the Tsg101 is recruited by small, conserved viral sequence motifs, agents that mimic these structures are potential inhibitors of the replication of these lethal human pathogens.	Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Bieniasz, PD (corresponding author), Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.			Martin-Serrano, Juan/0000-0002-8183-3914	NIAID NIH HHS [AI50111] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050111] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bieniasz PD, 2000, J VIROL, V74, P9868, DOI 10.1128/JVI.74.21.9868-9877.2000; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; Craven RC, 1999, J VIROL, V73, P3359, DOI 10.1128/JVI.73.4.3359-3365.1999; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Jasenosky LD, 2001, J VIROL, V75, P5205, DOI 10.1128/JVI.75.11.5205-5214.2001; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kikonyogo A, 2001, P NATL ACAD SCI USA, V98, P11199, DOI 10.1073/pnas.201268998; LEE PP, 1994, J VIROL, V68, P6644, DOI 10.1128/JVI.68.10.6644-6654.1994; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Puffer BA, 1997, J VIROL, V71, P6541, DOI 10.1128/JVI.71.9.6541-6546.1997; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Timmins J, 2001, VIROLOGY, V283, P1, DOI 10.1006/viro.2001.0860; Tritel M, 2000, J VIROL, V74, P5845, DOI 10.1128/JVI.74.13.5845-5855.2000; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; Xiang Y, 1996, J VIROL, V70, P5695, DOI 10.1128/JVI.70.8.5695-5700.1996; Yasuda J, 1998, J VIROL, V72, P4095, DOI 10.1128/JVI.72.5.4095-4103.1998; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993	31	593	616	1	275	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1313	1319		10.1038/nm1201-1313	http://dx.doi.org/10.1038/nm1201-1313			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726971				2022-12-25	WOS:000172610300036
J	Thomas, NA; Choong, DYH; Jokubaitis, VJ; Neville, PJ; Campbell, IG				Thomas, NA; Choong, DYH; Jokubaitis, VJ; Neville, PJ; Campbell, IG			Mutation of the ST7 tumor suppressor gene on 7q31.1 is rare in breast, ovarian and colorectal cancers	NATURE GENETICS			English	Article							SQUAMOUS-CELL; FREQUENT LOSS; CARCINOMAS; IDENTIFICATION; HETEROZYGOSITY; REGION	The gene ST7 has recently been implicated as the broad-range tumor suppressor on human chromosome 7q31.1. We did not detect somatic mutations in ST7 in any of 149 primary ovarian, breast or colon carcinomas. These data suggest that epigenetic downregulation or haploinsufficiency, rather than somatic genetic alterations, may be the primary mechanism of abrogation of ST7 function in these tumor types.	Peter MacCallum Canc Inst, Victorian Breast Canc Res Consortium, Canc Genet Lab, Melbourne, Vic 3002, Australia; Princess Anne Hosp, Dept Obstet & Gynecol, Southampton S016 5YA, Hants, England	Peter Maccallum Cancer Center	Campbell, IG (corresponding author), Peter MacCallum Canc Inst, Victorian Breast Canc Res Consortium, Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Miyamoto S, 1991, Hum Cell, V4, P38; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Vincent JB, 2000, AM J HUM GENET, V67, P510, DOI 10.1086/303005; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488	11	16	17	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					379	380		10.1038/ng784	http://dx.doi.org/10.1038/ng784			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726923				2022-12-25	WOS:000172507500010
J	Chen, XN; Scala, G; Quinto, I; Liu, WM; Chun, TW; Justement, JS; Cohen, OJ; vanCott, TC; Iwanicki, M; Lewis, MG; Greenhouse, J; Barry, T; Venzon, D; Fauci, AS				Chen, XN; Scala, G; Quinto, I; Liu, WM; Chun, TW; Justement, JS; Cohen, OJ; vanCott, TC; Iwanicki, M; Lewis, MG; Greenhouse, J; Barry, T; Venzon, D; Fauci, AS			Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; RANDOM PEPTIDE LIBRARIES; FILAMENTOUS BACTERIOPHAGE; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODY; CHIMERIC VIRUS; VIRAL LOAD; IN-VIVO; TYPE-1	The antigenic polymorphism of HIV-1 is a major obstacle in developing an effective vaccine. Accordingly, we screened random peptide libraries (RPLs) displayed on phage with antibodies from HIV-infected individuals and identified an array of HIV-specific epitopes that behave as antigenic mimics of conformational epitopes of gp120 and gp41 proteins. We report that the selected epitopes are shared by a collection of HIV-1 isolates of clades A-F. The phage-borne epitopes are immunogenic in rhesus macaques, where they elicit envelope-specific antibody responses. Upon intravenous challenge with 60 MID50 of pathogenic SHIV-89.6PD, all monkeys became infected; however, in contrast to the naive and mock-immunized monkeys, four of five mimotope-immunized monkeys experienced lower levels of peak viremia, followed by viral set points of undetectable or transient levels of viremia and a mild decline of CD4(+) T cells, and were protected from progression to AIDS-like illness. These results provide a new approach to the design of broadly protective HIV-1 vaccines.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Univ Catanzaro, Sch Med, Dept Clin & Expt Med, Catanzaro, Italy; Univ Naples Federico II, Sch Med, Dept Biochem & Biomed Technol, Naples, Italy; HM Jackson Fdn, Rockville, MD USA; So Res Inst, Frederick, MD USA; NCI, Hematopathol Sect, NIH, Bethesda, MD 20892 USA; NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Magna Graecia University of Catanzaro; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Scala, G (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		SCALA, GIUSEPPE/A-3280-2009; Chun, Tae-Wook/W-9187-2019; Chun, Tae-Wook/AAC-3101-2020; Venzon, David J/B-3078-2008	Chun, Tae-Wook/0000-0001-5153-7340; QUINTO, Ileana/0000-0001-8212-8515	Telethon [A.045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000778, Z01AI000886, ZIAAI000886] Funding Source: NIH RePORTER	Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Beyrer C, 1998, AIDS RES HUM RETROV, V14, P1687, DOI 10.1089/aid.1998.14.1687; Bures R, 2000, AIDS RES HUM RETROV, V16, P2019, DOI 10.1089/088922200750054756; Cho MW, 2001, J VIROL, V75, P2224, DOI 10.1128/JVI.75.5.2224-2234.2001; Chun TW, 2001, P NATL ACAD SCI USA, V98, P253, DOI 10.1073/pnas.98.1.253; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Cortese R, 1996, CURR OPIN BIOTECH, V7, P616, DOI 10.1016/S0958-1669(96)80072-3; Cotropia J, 1996, J ACQ IMMUN DEF SYND, V12, P221, DOI 10.1097/00042560-199607000-00002; De Berardinis P, 2000, NAT BIOTECHNOL, V18, P873, DOI 10.1038/78490; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Fogelman I, 2000, J INFECT DIS, V182, P435, DOI 10.1086/315739; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; Karlsson GB, 1997, J VIROL, V71, P4218, DOI 10.1128/JVI.71.6.4218-4225.1997; KUIKEN C, 1999, THEORETICAL BIOL BIO, P1; Kumar A, 2000, VIROLOGY, V274, P149, DOI 10.1006/viro.2000.0444; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LETWIN NL, 2001, J VIROL, V75, P4165; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Nabel GJ, 2000, NEW ENGL J MED, V343, P1263, DOI 10.1056/NEJM200010263431711; Parren PWHI, 1999, AIDS, V13, pS137; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Reimann KA, 1996, J VIROL, V70, P3198, DOI 10.1128/JVI.70.5.3198-3206.1996; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Scala G, 1999, J IMMUNOL, V162, P6155; SHAPSHAK P, 1995, ADV EXP MED BIOL, V373, P225; Shibata R, 1999, NAT MED, V5, P204, DOI 10.1038/5568; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Stamatos NM, 1998, J VIROL, V72, P9656, DOI 10.1128/JVI.72.12.9656-9667.1998; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994; VERONESE FDM, 1994, J MOL BIOL, V243, P167, DOI 10.1006/jmbi.1994.1643; Wasserstein AG, 1997, J AM SOC NEPHROL, V8, P664; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; ZHU TF, 1995, J VIROL, V69, P1324, DOI 10.1128/JVI.69.2.1324-1327.1995; Zolla-Pazner S, 1999, J VIROL, V73, P4042, DOI 10.1128/JVI.73.5.4042-4051.1999	44	69	84	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2001	7	11					1225	1231		10.1038/nm1101-1225	http://dx.doi.org/10.1038/nm1101-1225			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689887				2022-12-25	WOS:000172054100030
J	Zhao, XP; Alvarado, D; Rainier, S; Lemons, R; Hedera, P; Weber, CH; Tukel, T; Apak, M; Heiman-Patterson, T; Ming, L; Bui, M; Fink, JK				Zhao, XP; Alvarado, D; Rainier, S; Lemons, R; Hedera, P; Weber, CH; Tukel, T; Apak, M; Heiman-Patterson, T; Ming, L; Bui, M; Fink, JK			Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia	NATURE GENETICS			English	Article							GUANYLATE-BINDING PROTEIN-1; DYNAMIN; RECEPTOR; ENDOCYTOSIS; IMPAIRMENT; DATABASE; PROGRAMS; FAMILY	The hereditary spastic paraplegias (HSPs; Strumpell-Lorrain syndrome, MIM number 18260) are a diverse class of disorders characterized by insidiously progressive lower-extremity spastic weakness (reviewed in refs. 1-3). Eight autosomal dominant HSP (ADHSP) loci have been identified, the most frequent of which is that linked to the SPG4 locus on chromosome 2p22 (found in -42%)(1), followed by that linked to the SPG3A locus on chromosome 14q11-q21 (in similar to9%)(1). Only SPG4 has been identified(4) as a causative gene in ADHSP. Its protein (spastin) is predicted to participate in the assembly or function of nuclear protein complexes(4). Here we report the identification of mutations in a newly identified GTPase gene, SPG3A, in ADHSP affected individuals.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Istanbul, Inst Child Hlth, Div Med Genet, Istanbul, Turkey; Med Coll Penn & Hahnemann Univ, Sch Med, Dept Neurol, Philadelphia, PA USA; Ann Arbor Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Istanbul University; Drexel University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Fink, JK (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.			Hedera, Peter/0000-0003-2699-4085	NINDS NIH HHS [R01NS33645, R01NS36177, R01NS38713] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036177, R01NS033645, R01NS038713] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Fink JK, 1996, NEUROLOGY, V46, P1507, DOI 10.1212/WNL.46.6.1507; Fink JK, 1999, SEMIN NEUROL, V19, P301, DOI 10.1055/s-2008-1040846; FINK JK, 2001, IN PRESS EMERY RIMOI, V4; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hedera P, 2000, NEUROLOGY, V55, P1591, DOI 10.1212/WNL.55.10.1591; Hedera P, 2001, PRENATAL DIAG, V21, P202, DOI 10.1002/1097-0223(200103)21:3<202::AID-PD4>3.0.CO;2-U; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Nicoziani P, 2000, MOL BIOL CELL, V11, P481, DOI 10.1091/mbc.11.2.481; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Prakash B, 2000, EMBO J, V19, P4555, DOI 10.1093/emboj/19.17.4555; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; RAINER S, 2001, IN PRESS J MED GENET; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	30	259	280	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2001	29	3					326	331		10.1038/ng758	http://dx.doi.org/10.1038/ng758			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11685207				2022-12-25	WOS:000171911000021
J	Cottingham, IR; Millar, A; Emslie, E; Colman, A; Schnieke, AE; McKee, C				Cottingham, IR; Millar, A; Emslie, E; Colman, A; Schnieke, AE; McKee, C			A method for the amidation of recombinant peptides expressed as intein fusion proteins in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article							SALMON-CALCITONIN; AMINO	The increasing use of peptides as pharmaceutical agents, especially in the antiviral and anti-infective therapeutic areas, requires cost-effective production on a large scale(1). Many peptides need carboxy amidation for full activity or prolonged bioavailability(2). However, this modification is not possible in prokaryotes and must be done using recombinant enzymes(3) or by expression in transgenic milk(4). Methods employing recombinant enzymes are appropriate for small-scale production, whereas transgenic milk expression is suitable for making complex disulfide-containing peptides required in large quantity. Here we describe a method for making amidated peptides using a modified self-cleaving vacuolar membrane ATPase (VMA) intein expression systems. This system is suitable for making amidated peptides at a laboratory scale using readily available constructs and reagents. Further improvements are possible, such as reducing the size of the intein to improve the peptide yields (the VMA intein comprises 454 amino acids) and, if necessary, secreting the fusion protein to ensure correct N-terminal processing to the peptide. With such developments, this method could form the basis of a large-scale cost-effective system for the bulk production of amidated peptides without the use of recombinant enzymes or the need to cleave fusion proteins.	PPL Therapeut Scotland Ltd, Roslin Bioctr, Edinburgh EH25 9PP, Midlothian, Scotland		Cottingham, IR (corresponding author), PPL Therapeut Scotland Ltd, Roslin Bioctr, Edinburgh EH25 9PP, Midlothian, Scotland.		Wood, David W/B-2992-2012	Schnieke, Angelika/0000-0002-5761-9635				CHONG S, 1998, J BIOL CHEM, V24, P10587; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Latham PW, 1999, NAT BIOTECHNOL, V17, P755, DOI 10.1038/11686; McKee C, 1998, NAT BIOTECHNOL, V16, P647, DOI 10.1038/nbt0798-647; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; RAY MVL, 1993, BIO-TECHNOL, V11, P64, DOI 10.1038/nbt0193-64; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; Wood DW, 1999, NAT BIOTECHNOL, V17, P889, DOI 10.1038/12879	8	36	44	1	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					974	977		10.1038/nbt1001-974	http://dx.doi.org/10.1038/nbt1001-974			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581666				2022-12-25	WOS:000171417600028
J	Ready, T				Ready, T			Pfizer in "unethical" trial suit	NATURE MEDICINE			English	News Item																			0	4	4	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1077	1077		10.1038/nm1001-1077c	http://dx.doi.org/10.1038/nm1001-1077c			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590414	Bronze			2022-12-25	WOS:000171524500009
J	Grenon, M; Gilbert, C; Lowndes, NF				Grenon, M; Gilbert, C; Lowndes, NF			Checkpoint activation in response to double-strand breaks requires the Mre11/Rad50/Xrs2 complex	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE CHECKPOINT; LYMPHOBLASTOID CELL-LINES; BUDDING YEAST; MEC1-DEPENDENT PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; PROTEIN COMPLEX; CYCLE; REPAIR; RAD53; INTERACTS	Studies of human Nijmegen breakage syndrome (NBS) cells have led to the proposal that the Mre11/Rad50/NBS1 complex, which is involved in the repair of DNA double-strand breaks (DSBs), might also function in activating the DNA damage checkpoint pathways after DSBs occur(1,2). We have studied the role of the homologous budding yeast complex, Mre11/Rad50/Xrs2, in checkpoint activation in response to DSB-inducing agents. Here we show that this complex is required for phosphorylation and activation of the Rad53 and Chk1 checkpoint kinases specifically in response to DSBs. Consistent with defective Rad53 activation, we observed defective cell-cycle delays after induction of DSBs in the absence of Mrell. Furthermore, after gamma -irradiation phosphorylation of Rad9, which is an early event in checkpoint activation, is also dependent on Mre11. All three components of the Mre11/Rad50/Xrs2 complex are required for activation of Rad53, however, the Ku80, Rad51 or Rad52 proteins, which are also involved in DSB repair, are not. Thus, the integrity of the Mre11/Rad50/Xrs2 complex is specifically required for checkpoint activation after the formation of DSBs.	Imperial Canc Res Fund, Clare Hall Labs, CDC Lab, Potters Bar EN6 3LD, Herts, England; Natl Univ Ireland Univ Coll Galway, Dept Biochem, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway	Lowndes, NF (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, CDC Lab, Blanche Lane, Potters Bar EN6 3LD, Herts, England.		Grenon, Muriel/D-5228-2011; Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427; Grenon, Muriel/0000-0002-9910-5974				Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; Antoccia A, 1997, INT J RADIAT BIOL, V71, P41, DOI 10.1080/095530097144409; Antoccia A, 1999, INT J RADIAT BIOL, V75, P583; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Girard PM, 2000, CANCER RES, V60, P4881; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paciotti V, 2000, GENE DEV, V14, P2046; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; Pincheira J, 1998, CLIN GENET, V53, P262; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamazaki V, 1998, CANCER RES, V58, P2316; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	30	147	153	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					844	847		10.1038/ncb0901-844	http://dx.doi.org/10.1038/ncb0901-844			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533665				2022-12-25	WOS:000170979600019
J	Spelbrink, JN; Li, FY; Tiranti, V; Nikali, K; Yuan, QP; Tariq, M; Wanrooij, S; Garrido, N; Comi, G; Morandi, L; Santoro, L; Toscano, A; Fabrizi, GM; Somer, H; Croxen, R; Beeson, D; Poulton, L; Suomalainen, A; Jacobs, HT; Zeviani, M; Larsson, C				Spelbrink, JN; Li, FY; Tiranti, V; Nikali, K; Yuan, QP; Tariq, M; Wanrooij, S; Garrido, N; Comi, G; Morandi, L; Santoro, L; Toscano, A; Fabrizi, GM; Somer, H; Croxen, R; Beeson, D; Poulton, L; Suomalainen, A; Jacobs, HT; Zeviani, M; Larsson, C			Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene LF-like protein localized in mitochondria	NATURE GENETICS			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MULTIPLE DELETIONS; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; HELICASE DOMAIN; BACTERIOPHAGE-T7; MTDNA; POLYMERASE; PRIMASE; YEAST	The gene products involved in mammalian mitochondrial DNA (mtDNA) maintenance and organization remain largely unknown. We report here a novel mitochondrial protein. Twinkle, with structural similarity to phage T7 gene 4 primase/helicase and other hexameric ring helicases. Twinkle colocalizes with mtDNA in mitochondrial nucleoids. Screening of the gene encoding Twinkle in individuals with autosomal dominant progressive external ophthalmoplegia (adPEO). associated with multiple mtDNA deletions, identified 11 different coding-region mutations co-segregating with the disorder in 12 adPEO pedigrees of various ethnic origins. The mutations duster in a region of the protein proposed to be involved in subunit interactions. The function of Twinkle is inferred to be critical for lifetime maintenance of human mtDNA integrity.	Karolinska Hosp, Dept Mol Med, S-17176 Stockholm, Sweden; Tampere Univ Hosp, Tampere, Finland; Inst Med Technol, Tampere, Finland; Natl Neurol Inst C Besta, Div Biochem & Genet, Milan, Italy; Natl Publ Hlth Inst, Dept Human Mol Genet, Helsinki, Finland; Pakistan Inst Med Sci, Dept Neurol, Islamabad, Pakistan; Univ Milan, Sch Med, Inst Clin Neurol, Dino Ferrari Ctr, Milan, Italy; Natl Neurol Inst C Besta, Dept Neuromuscular Disorders, Milan, Italy; Univ Naples Federico II, Dept Neurol Sci, Naples, Italy; Univ Messina, Inst Clin Neurol, Messina, Italy; Univ Verona, Inst Clin Neurol, I-37100 Verona, Italy; Univ Helsinki, Dept Neurol, Helsinki, Finland; John Radcliffe Hosp, Neurosci Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DS, England; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Karolinska Institutet; Karolinska University Hospital; Tampere University; Tampere University Hospital; IRCCS Istituto Neurologico Besta; Finland National Institute for Health & Welfare; Pakistan Institute of Medical Sciences; University of Milan; IRCCS Istituto Neurologico Besta; University of Naples Federico II; University of Messina; University of Verona; University of Helsinki; University of Oxford; University of Oxford; McGill University; University of Glasgow	Spelbrink, JN (corresponding author), Inst Med Technol, Tampere, Finland.		Comi, Giacomo P/K-5702-2016; Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021; Spelbrink, Johannes N/L-4661-2015; Wanrooij, Sjoerd/J-1367-2019; Tiranti, Valeria/J-8233-2016; Jacobs, Howard T/G-2434-2011; Tiranti, Valeria/AFN-5783-2022	Comi, Giacomo P/0000-0002-1383-5248; Zeviani, Massimo/0000-0002-9067-5508; Spelbrink, Johannes N/0000-0002-9756-2602; Tiranti, Valeria/0000-0002-3584-7338; Tiranti, Valeria/0000-0002-3584-7338; Jacobs, Howard/0000-0003-1895-6003; Santoro, Lucio/0000-0001-9507-2303; Wanrooij, Sjoerd/0000-0001-6126-4382; Poulton, Joanna/0000-0002-2460-5587; Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195	Telethon [1180] Funding Source: Medline	Telethon(Fondazione Telethon)		Battey, 1986, BASIC METHODS MOL BI; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FOURY F, 1989, J BIOL CHEM, V264, P20552; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HEHMAN GL, 1992, P NATL ACAD SCI USA, V89, P8562, DOI 10.1073/pnas.89.18.8562; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Iyengar B, 1999, GENETICS, V153, P1809; Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445; Kornberg A., 1992, DNA REPLICATION; Kuroiwa T, 1998, INT REV CYTOL, V181, P1, DOI 10.1016/S0074-7696(08)60415-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Leipe DD, 2000, GENOME RES, V10, P5; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5; Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Melberg A, 1996, MUSCLE NERVE, V19, P751; MIYAKAWA I, 1987, J CELL SCI, V88, P431; Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; PATEL SS, 1993, J BIOL CHEM, V268, P10668; ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316; Santorelli FM, 2000, J INHERIT METAB DIS, V23, P155, DOI 10.1023/A:1005617916260; SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244; SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZEVIANI M, 1990, AM J HUM GENET, V47, P904; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; ZHANG PL, 1994, MOL CARCINOGEN, V9, P46, DOI 10.1002/mc.2940090109	49	628	643	1	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					223	231		10.1038/90058	http://dx.doi.org/10.1038/90058			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431692				2022-12-25	WOS:000169656400014
J	Yuhanna, IS; Zhu, Y; Cox, BE; Hahner, LD; Osborne-Lawrence, S; Marcel, YL; Anderson, RGW; Mendelsohn, ME; Hobbs, HH; Shaul, PW				Yuhanna, IS; Zhu, Y; Cox, BE; Hahner, LD; Osborne-Lawrence, S; Marcel, YL; Anderson, RGW; Mendelsohn, ME; Hobbs, HH; Shaul, PW			High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase	NATURE MEDICINE			English	Article							A-I; ARTERY ENDOTHELIUM; SR-BI; ATHEROSCLEROSIS; CHOLESTEROL; EXPRESSION; CAVEOLAE; HDL; IDENTIFICATION; INHIBITION	Atherosclerosis is the primary cause of cardiovascular disease, and the risk for atherosclerosis is inversely proportional to circulating levels of high-density lipoprotein (HDL) cholesterol. However, the mechanisms by which HDL is atheroprotective are complex and not well understood(1,2), Here we show that HDL stimulates endothelial nitric oxide synthase (eNOS) in cultured endothelial cells. In contrast, eNOS is not activated by purified forms of the major HDL apolipoproteins ApoA-I and ApoA-II or by low-density lipoprotein. Heterologous expression experiments in Chinese hamster ovary cells reveal that scavenger receptor-BI (SR-BI) mediates the effects of HDL on the enzyme. HDL activation of eNOS is demonstrable in isolated endothelial-cell caveolae where SR-BI and eNOS are colocalized, and the response in isolated plasma membranes is blocked by antibodies to ApoA-I and SR-BI, but not by antibody to ApoA-II. HDL also enhances endothelium- and nitric-oxide-dependent relaxation in aortae from wild-type mice, but not in aortae from homozygous null SR-BI knockout mice. Thus, HDL activates eNOS via SR-BI through a process that requires ApoA-I binding. The resulting increase in nitric-oxide production might be critical to the atheroprotective properties of HDL and ApoA-I.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON, Canada	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tufts Medical Center; Tufts University; University of Ottawa; University of Ottawa Heart Institute	Shaul, PW (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA.		Eckhardt, Erik/G-1567-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030276] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058888, R01HL053546, R01HL059953, R01HL056069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53546, HL58888, HL59953, HL56069] Funding Source: Medline; NICHD NIH HHS [HD30276] Funding Source: Medline; NIGMS NIH HHS [GM52016] Funding Source: Medline; PHS HHS [NL20948] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BABBITT J, 1997, J BIOL CHEM, V272, P13242; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; Fidge NH, 1999, J LIPID RES, V40, P187; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Jolley CD, 1998, J LIPID RES, V39, P2143; Jun SS, 1998, J CLIN INVEST, V102, P176, DOI 10.1172/JCI2034; Kellner-Weibel G, 2000, BIOCHEMISTRY-US, V39, P221, DOI 10.1021/bi991666c; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Krieger M, 1998, P NATL ACAD SCI USA, V95, P4077, DOI 10.1073/pnas.95.8.4077; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Pace MC, 1999, AM J PHYSIOL-LUNG C, V277, pL106, DOI 10.1152/ajplung.1999.277.1.L106; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHAUL PW, 1992, AM J PHYSIOL, V262, pH355, DOI 10.1152/ajpheart.1992.262.2.H355; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; ZHU Y, 1999, CIRCULATION, V100, P1	35	588	609	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					853	857		10.1038/89986	http://dx.doi.org/10.1038/89986			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433352				2022-12-25	WOS:000169808600039
J	Weitz-Schmidt, G; Welzenbach, K; Brinkmann, V; Kamata, T; Kallen, J; Bruns, C; Cottens, S; Takada, Y; Hommel, U				Weitz-Schmidt, G; Welzenbach, K; Brinkmann, V; Kamata, T; Kallen, J; Bruns, C; Cottens, S; Takada, Y; Hommel, U			Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site	NATURE MEDICINE			English	Article							HMG-COA-REDUCTASE; INTERCELLULAR-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; TRANSPLANTATION; RECEPTOR; DOMAIN; ICAM-1; CD11A; LFA-1	The beta2 integrin leukocyte function antigen-1 (LFA-1) has an important role in the pathophysiology of inflammatory and autoimmune diseases. Here we report that statin compounds commonly used for the treatment of hypercholesterolemia selectively blocked LFA-1-mediated adhesion and costimulation of lymphocytes. This effect was unrelated to the statins' inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A reductase; instead it occurred via binding to a novel allosteric site within LFA-1. Subsequent optimization of the statins for LFA-1 binding resulted in potent, selective and orally active LFA-1 inhibitors that suppress the inflammatory response in a murine model of peritonitis. Targeting of the statin-binding site of LFA-1 could be used to treat diseases such as psoriasis, rheumatoid arthritis, ischemia/reperfusion injury and transplant rejection.	Novartis Pharma AG, Preclin Res, Basel, Switzerland; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA USA	Novartis; Scripps Research Institute	Weitz-Schmidt, G (corresponding author), Novartis Pharma AG, Preclin Res, Basel, Switzerland.	gabriele.weitz@pharma.novartis.com		takada, yoshikazu/0000-0001-5481-9589				Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CARLOS TM, 1994, BLOOD, V84, P2068; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUGGAN DE, 1990, DRUG METAB REV, V22, P333, DOI 10.3109/03602539009041088; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; FISCHER A, 1991, BLOOD, V77, P249; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; HUTCH JR, 2000, P NATL ACAD SCI USA, V97, P5231; Issekutz AC, 1998, INFLAMM RES, V47, pS123; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KATZNELSON S, 1995, KIDNEY INT, V48, pS112; Kelly TA, 1999, J IMMUNOL, V163, P5173; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Krueger J, 2000, J INVEST DERMATOL, V115, P333, DOI 10.1046/j.1523-1747.2000.00abs-8.x; Kurakata S, 1996, IMMUNOPHARMACOLOGY, V34, P51, DOI 10.1016/0162-3109(96)00108-7; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Liu G, 2000, J MED CHEM, V43, P4025, DOI 10.1021/jm0002782; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Martin X, 2000, TRANSPLANT P, V32, P481, DOI 10.1016/S0041-1345(00)00849-6; Mousa SA, 1997, DRUG DISCOV TODAY, V2, P187, DOI 10.1016/S1359-6446(97)01027-1; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nakakura EK, 1996, TRANSPLANTATION, V62, P547, DOI 10.1097/00007890-199609150-00001; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Poston RS, 2000, TRANSPLANTATION, V69, P2005, DOI 10.1097/00007890-200005270-00006; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115; Scheynius A, 1996, J IMMUNOL, V156, P1804; Shum YY, 1998, THER DRUG MONIT, V20, P41, DOI 10.1097/00007691-199802000-00008; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398	40	845	906	2	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					687	692		10.1038/89058	http://dx.doi.org/10.1038/89058			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385505				2022-12-25	WOS:000169081500036
J	Baulac, S; Huberfeld, G; Gourfinkel-An, I; Mitropoulou, G; Beranger, A; Prud'homme, JF; Baulac, M; Brice, A; Bruzzone, R; LeGuern, E				Baulac, S; Huberfeld, G; Gourfinkel-An, I; Mitropoulou, G; Beranger, A; Prud'homme, JF; Baulac, M; Brice, A; Bruzzone, R; LeGuern, E			First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma 2-subunit gene	NATURE GENETICS			English	Article							FEBRILE SEIZURES PLUS; POTASSIUM CHANNEL GENE; GENERALIZED EPILEPSY; SUBUNIT; FAMILY; LOCUS; IDENTIFICATION; DISEASE; MAPS	Major advances in the identification of genes implicated in idiopathic epilepsy have been made. Generalized epilepsy with febrile seizures plus (GEFS+), benign familiar neonatal convulsions and nocturnal frontal lobe epilepsy, three autosomal dominant idiopathic epilepsies, result from mutations affecting voltage-gated sodium and potassium channels, and nicotinic acetylcholine receptors, respectively(1-6), Disruption of GABAergic neurotransmission mediated by gamma -aminobutyric acid (GABA) has been implicated in epilepsy for many decades(7). We now report a K289M mutation in the GABA(A) receptor gamma2-subunit gene (GABRG2) that segregates in a family with a phenotype closely related to GEFS+ (ref. 8), an autosomal dominant disorder associating febrile seizures and generalized epilepsy previously linked to mutations in sodium channel genes(1,2). The K289M mutation affects a highly conserved residue located in the extracellular loop between transmembrane segments M2 and M3. Analysis of the mutated and wild-type alleles in Xenopus laevis oocytes confirmed the predicted effect of the mutation, a decrease in the amplitude of GABA-activated currents. We thus provide the first genetic evidence that a GABA(A) receptor is directly involved in human idiopathic epilepsy.	Hop La Pitie Salpetriere, INSERM, U289, Paris, France; Hop La Pitie Salpetriere, Ctr Epileptol, Paris, France; Hop La Pitie Salpetriere, Dept Genet Cytogenet & Embryol, Paris, France; Genethon, Evry, France; Inst Pasteur, NRSN, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LeGuern, E (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, Paris, France.		brice, alexis/AAE-8275-2019; Baulac, Stéphanie/O-2099-2016; Bruzzone, Roberto/G-9355-2017; Bruzzone, Roberto/C-4719-2009; Brice, Alexis/A-2170-2009	brice, alexis/0000-0002-0941-3990; Baulac, Stéphanie/0000-0001-6430-4693; Bruzzone, Roberto/0000-0003-4373-1447; Bruzzone, Roberto/0000-0003-4373-1447; 				Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Baulac S, 1999, AM J HUM GENET, V65, P1078, DOI 10.1086/302593; Boileau AJ, 1999, J NEUROSCI, V19, P10213; CASTRO RAMIREZ L.C., 2010, NAT GENET, VXXXI, P33; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Elmslie FV, 1996, J MED GENET, V33, P435, DOI 10.1136/jmg.33.5.435; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; Kostrzewa M, 1996, EUR J HUM GENET, V4, P199; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lopes-Cendes I, 2000, AM J HUM GENET, V66, P698, DOI 10.1086/302768; Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165-0173(98)00052-6; Moulard B, 1999, AM J HUM GENET, V65, P1396, DOI 10.1086/302621; Olsen R W, 1999, Adv Neurol, V79, P499; Ressot C, 1998, J NEUROSCI, V18, P4063; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WILCOX AS, 1992, P NATL ACAD SCI USA, V89, P5857, DOI 10.1073/pnas.89.13.5857	21	612	649	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					46	48		10.1038/88254	http://dx.doi.org/10.1038/88254			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326274				2022-12-25	WOS:000168413300014
J	Bergsten, E; Uutela, M; Li, XR; Pietras, K; Ostman, A; Heldin, CH; Alitalo, K; Eriksson, U				Bergsten, E; Uutela, M; Li, XR; Pietras, K; Ostman, A; Heldin, CH; Alitalo, K; Eriksson, U			PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR; MICE	The term 'platelet-derived growth factor' (PDGF) refers to a family of disulphide-bonded dimeric isoforms that are important for growth, survival and function in several types of connective tissue cell. So far, three different PDGF chains have been identified - the classical PDGF-A and PDGF-B-1,B-2 and the recently identified PDGF-C-3. PDGF isoforms (PDGF-AA, AB, BB and CC) exert their cellular effects by differential binding to two receptor tyrosine kinases. The PDGF alpha -receptor (PDGFR-alpha) binds to all three PDGF chains, whereas the beta -receptor (PDGFR-beta) binds only to PDGF-B-1. Gene-targeting studies using mice have shown that the genes for PDGF-A and PDGF-B, as well as the two PDGFR genes, are essential for normal development(4). Furthermore, overexpression of PDGFs is linked to different pathological conditions, including malignancies, atherosclerosis and fibroproliferative diseases(1). Here we have identify and characterize a fourth member of the PDGF family, PDGF-D. PDGF-D has a two-domain structure similar to PDGF-C-3 and is secreted as a disulphide-linked homodimer, PDGF-DD, Upon limited proteolysis, PDGF-DD is activated and becomes a specific agonistic ligand for PDGFR-beta. PDGF-DD is the first known PDGFR-beta -specific ligand, and its unique receptor specificity indicates that it may be important for development and pathophysiology in several organs.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland; Ludwig Inst Canc Res, Uppsala Branch, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; University of Helsinki; Ludwig Institute for Cancer Research	Bergsten, E (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, POB 240, S-17177 Stockholm, Sweden.		Alitalo, Kari K/J-5013-2014; Pietras, Kristian/ABG-2097-2021; Pietras, Kristian/ABE-8727-2020	Alitalo, Kari K/0000-0002-7331-0902; Pietras, Kristian/0000-0001-6738-4705; 				Aase K, 1999, DEV DYNAM, V215, P12, DOI 10.1002/(SICI)1097-0177(199905)215:1<12::AID-DVDY3>3.0.CO;2-N; ARAT M, 2000, J BIOL CHEM, V275, P9527; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1999, CURR TOPICS PATHOL, V93, P27; Lindahl P, 1998, DEVELOPMENT, V125, P3313; RAINES EW, 1990, PEPTIDE GROWTH FACTO, V1, P173; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	16	425	477	3	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					512	516		10.1038/35074588	http://dx.doi.org/10.1038/35074588			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331881				2022-12-25	WOS:000168592500023
J	Kocher, AA; Schuster, MD; Szabolcs, MJ; Takuma, S; Burkhoff, D; Wang, J; Homma, S; Edwards, NM; Itescu, S				Kocher, AA; Schuster, MD; Szabolcs, MJ; Takuma, S; Burkhoff, D; Wang, J; Homma, S; Edwards, NM; Itescu, S			Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function	NATURE MEDICINE			English	Article							ENDOTHELIAL PROGENITOR CELLS; ANGIOTENSIN-II; PLASMINOGEN-ACTIVATOR; THERAPEUTIC ANGIOGENESIS; HEMATOPOIETIC-CELLS; COMMON PRECURSOR; CORONARY-ARTERY; INFARCTION; HEART; TRANSPLANTATION	Left ventricular remodeling is a major cause of progressive heart failure and death after myocardial infarction. Although neoangiogenesis within the infarcted tissue is an integral component of the remodeling process, the capillary network is unable to support the greater demands of the hypertrophied myocardium, resulting in progressive loss of viable tissue, infarct extension and fibrous replacement. Here we show that bone marrow from adult humans contains endothelial precursors with phenotypic and functional characteristics of embryonic hemangioblasts, and that these can be used to directly induce new blood vessel formation in the infarct-bed (vasculogenesis) and proliferation of preexisting vasculature (angiogenesis) after experimental myocardial infarction. The neoangiogenesis resulted in decreased apoptosis of hypertrophied myocytes in the peri-infarct region, long-term salvage and survival of viable myocardium, reduction in collagen deposition and sustained improvement in cardiac function. The use of cytokine-mobilized autologous human bone-marrow-derived angioblasts for revascularization of infarcted myocardium (alone or in conjunction with currently used therapies) has the potential to significantly reduce morbidity and mortality associated with left ventricular remodeling.	Columbia Univ, Dept Surg, New York, NY 10027 USA; Columbia Univ, Dept Med, New York, NY USA; Columbia Univ, Dept Pathol, New York, NY USA	Columbia University; Columbia University; Columbia University	Itescu, S (corresponding author), Columbia Univ, Dept Surg, New York, NY 10027 USA.	si5@columbia.edu	Burkhoff, Daniel/D-7674-2011					Agocha A, 1997, J MOL CELL CARDIOL, V29, P2233, DOI 10.1006/jmcc.1997.0462; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Choi K, 1998, DEVELOPMENT, V125, P725; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; HART PH, 1991, BLOOD, V77, P841; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; Jaffredo T, 1998, DEVELOPMENT, V125, P4575; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kalkman EAJ, 1997, J MOL CELL CARDIOL, V29, P1487, DOI 10.1006/jmcc.1997.0388; Kalkman EAJ, 1996, CARDIOVASC RES, V32, P1088, DOI 10.1016/S0008-6363(96)00166-6; Kawano H, 2000, CIRCULATION, V101, P1130, DOI 10.1161/01.CIR.101.10.1130; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Mahon NG, 1999, HEART, V81, P478, DOI 10.1136/hrt.81.5.478; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; McEwan PE, 1998, CIRCULATION, V98, P2765, DOI 10.1161/01.CIR.98.24.2765; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NelissenVrancken HJMG, 1996, CIRCULATION, V93, P349; NIDORF SM, 1992, J AM COLL CARDIOL, V20, P307; Ogawa M, 1999, BLOOD, V93, P1168, DOI 10.1182/blood.V93.4.1168.404k12_1168_1177; OLIVETTI G, 1991, CIRC RES, V68, P856, DOI 10.1161/01.RES.68.3.856; Pei XH, 1998, CLIN EXP METASTAS, V16, P551, DOI 10.1023/A:1006546402703; Pelchev M., 2000, BLOOD, V95, P952; PFEFFER JM, 1991, AM J PHYSIOL, V260, pH1406, DOI 10.1152/ajpheart.1991.260.5.H1406; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RAFII S, 1994, BLOOD, V84, P10; RAVICHANDRAN LV, 1991, BIOCHEM INT, V24, P405; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WHITE HD, 1994, CIRCULATION, V89, P61, DOI 10.1161/01.CIR.89.1.61; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	48	1985	2351	5	144	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					430	436		10.1038/86498	http://dx.doi.org/10.1038/86498			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283669				2022-12-25	WOS:000167960500037
J	Ge, H; Liu, ZH; Church, GM; Vidal, M				Ge, H; Liu, ZH; Church, GM; Vidal, M			Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae	NATURE GENETICS			English	Article							EXPRESSION; GENOMES; YEAST	Genomic and proteomic approaches can provide hypotheses concerning function for the large number of genes predicted from genome sequences(1-5). Because of the artificial nature of the assays, however, the information from these high-throughput approaches should be considered with caution. Although it is possible that more meaningful hypotheses could be formulated by integrating the data from various functional genomic and proteomic projects(6), it has yet to be seen to what extent the data can be correlated and how such integration can be achieved. We developed a 'transcriptome-interactome correlation mapping' strategy to compare the interactions between proteins encoded by genes that belong to common expression-profiling clusters with those between proteins encoded by genes that belong to different clusters. Using this strategy with currently available data sets for Saccharomyces cerevisiae, we provide the first global evidence that genes with similar expression profiles are more likely to encode interacting proteins. We show how this correlation between transcriptome and interactome data can be used to improve the quality of hypotheses based on the information from both approaches. The strategy described here may help to integrate other functional genomic and proteomic data, both in yeast and in higher organisms.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol, Boston, MA USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA USA; Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Vidal, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.			church, george/0000-0001-6232-9969	NHGRI NIH HHS [1 RO1 HG01715-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hartigan J., 1975, CLUSTERING ALGORITHM; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Kumar A, 2001, NAT REV GENET, V2, P302, DOI 10.1038/35066084; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Sternberg PW, 2001, CELL, V105, P173, DOI 10.1016/S0092-8674(01)00308-7; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107	18	445	468	2	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					482	486		10.1038/ng776	http://dx.doi.org/10.1038/ng776			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11694880				2022-12-25	WOS:000172507500027
J	Kasinathan, P; Knott, JG; Wang, ZD; Jerry, DJ; Robl, JM				Kasinathan, P; Knott, JG; Wang, ZD; Jerry, DJ; Robl, JM			Production of calves from G1 fibroblasts	NATURE BIOTECHNOLOGY			English	Article							PARTHENOGENETIC DEVELOPMENT; NUCLEAR TRANSFER; BOVINE OOCYTES; FETAL	Since the landmark study of Wilmut et al.(1) describing the birth of a cloned lamb derived from a somatic cell nucleus, there has been debate about the donor nucleus cell cycle stage required for somatic cell nuclear transfer (NT). Wilmut et al.(1) suggested that induction of quiescence by serum starvation was critical in allowing donor somatic cells to support development of cloned embryos. In a subsequent report, Cibelli et al.(2) proposed that G0 was unnecessary and that calves could be produced from actively dividing fibroblasts. Neither study conclusively documented the importance of donor cell cycle stage for development to term. Other laboratories have had success with NT in several species(1-7), and most have used a serum starvation treatment. Here we evaluate methods for producing G0 and G1 cell populations and compare development following NT. High confluence was more effective than serum starvation for arresting cells in G0. Pure G1 cell populations could be obtained using a "shake-off" procedure. No differences in in vitro development were observed between cells derived from the high-confluence treatment and from the "shake-off" treatment. However, when embryos from each treatment were transferred to 50 recipients, five calves were obtained from embryos derived from "shake-off" cells, whereas no embryos from confluent cells survived beyond 180 days of gestation. These results indicate that donor cell cycle stage is important for NT, particularly during late fetal development, and that actively dividing G1 cells support higher development rates than cells in G0.	Hematech LLC, Worcester, MA 01605 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Hematech LLC, Manhattan, KS 66502 USA	University of Massachusetts System; University of Massachusetts Amherst	Robl, JM (corresponding author), Hematech LLC, 4 Biotech Pk,377 Plantat Dr, Worcester, MA 01605 USA.	jrobl@hematech.com						Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Freshney I., 1994, CULTURE ANIMAL CELLS; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; Kasinathan P, 2001, BIOL REPROD, V64, P1487, DOI 10.1095/biolreprod64.5.1487; KUBOTAC, 2000, P NATL ACAD SCI USA, V973, P990; Liu L, 1998, MOL REPROD DEV, V49, P298, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;298::AID-MRD10&gt;3.0.CO;2-T; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; PRESICCE GA, 1994, MOL REPROD DEV, V38, P380, DOI 10.1002/mrd.1080380405; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	12	84	95	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1176	1178		10.1038/nbt1201-1176	http://dx.doi.org/10.1038/nbt1201-1176			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731789				2022-12-25	WOS:000172524400033
J	Giordano, RJ; Cardo-Vila, M; Lahdenranta, J; Pasqualini, R; Arap, W				Giordano, RJ; Cardo-Vila, M; Lahdenranta, J; Pasqualini, R; Arap, W			Biopanning and rapid analysis of selective interactive ligands	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HEMATOPOIETIC-CELLS; TRYPANOSOMA-CRUZI; PEPTIDES; BINDING; NEUROPILIN-1; RECEPTORS; LIBRARIES	Here we introduce a new approach for the screening, selection and sorting of cell-surface-binding peptides from phage libraries. Biopanning and rapid analysis of selective interactive ligands (termed BRASIL) is based on differential centrifugation in which a cell suspension incubated with phage in an aqueous upper phase is centrifuged through a non-miscible organic lower phase. This single-step organic phase separation is faster, more sensitive and more specific than current methods that rely on washing steps or limiting dilution. As a proof-of-principle, we screened human endothelial cells stimulated with vascular endothelial growth factor (VEGF) and constructed a peptide-based ligand-receptor map of the VEGF family. Next, we validated the motif PQPRPL as a novel chimeric ligand mimic that binds specifically to VEGF receptor-1 and to neuropilin-1. BRASIL may prove itself a superior method for probing target cell surfaces with a broad range of potential applications.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Pasqualini, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rpasqual@notes.mdacc.tmc.edu; warap@notes.mdacc.tmc.edu	Giordano, Ricardo/A-2074-2010	Giordano, Ricardo/0000-0001-8116-6771	NCI NIH HHS [CA9081001, CA90270, CA8297601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA090810, P50CA090270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Brown KC, 2000, CURR OPIN CHEM BIOL, V4, P16, DOI 10.1016/S1367-5931(99)00045-9; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1; HATZFELD JA, 1982, P NATL ACAD SCI-BIOL, V79, P6280, DOI 10.1073/pnas.79.20.6280; Koivunen E, 1999, METH MOL B, V129, P3; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; LEVESQUE JP, 1985, EXP CELL RES, V156, P558, DOI 10.1016/0014-4827(85)90563-4; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; OUAISSI MA, 1984, NATURE, V308, P380, DOI 10.1038/308380a0; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PASQUALINI R, 2000, PHAGE DISPLAY LAB MA, P1; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6	16	215	244	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1249	1253		10.1038/nm1101-1249	http://dx.doi.org/10.1038/nm1101-1249			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689892				2022-12-25	WOS:000172054100035
J	Koppen, M; Simske, JS; Sims, PA; Firestein, BL; Hall, DH; Radice, AD; Rongo, C; Hardin, JD				Koppen, M; Simske, JS; Sims, PA; Firestein, BL; Hall, DH; Radice, AD; Rongo, C; Hardin, JD			Cooperative regulation of AJM-1 controls junctional integrity in Caenorhabditis elegans epithelia	NATURE CELL BIOLOGY			English	Article							MUSCLE-CELL ATTACHMENT; BODY-WALL MUSCLE; SEPTATE JUNCTIONS; TIGHT JUNCTION; C-ELEGANS; DROSOPHILA-CORACLE; PROTEIN; MORPHOGENESIS; LOCALIZATION; ZO-1	The function of epithelial cell sheets depends on the integrity of specialized cell-cell junctions that connect neighbouring cells. We have characterized the novel coiled-coil protein AJM-1, which localizes to an apical junctional domain of Caenorhabditis elegans epithelia basal to the HMR-HMP (cadherin-catenin) complex. In the absence of AJM-1, the integrity of this domain is compromised. Proper AJM-1 localization requires LET-413 and DLG-1, homologues of the Drosophila tumour suppressors Scribble and Discs large, respectively. DLG-1 physically interacts with AJM-1 and is required for its normal apical distribution, and LET-413 mediates the rapid accumulation of both DLG-1 and AJM-1 in the apical domain. In the absence of both dlg-1 and let-413 function AJM-1 is almost completely lost from apical junctions in embryos, whereas HMP-1 (alpha -catenin) localization is only mildly affected. We conclude that LET-413 and DLG-1 cooperatively control AJM-1 localization and that AJM-1 controls the integrity of a distinct apical junctional domain in C. elegans.	Univ Wisconsin, Program Cellular & Mol Biol, Madison, WI 53706 USA; Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Ctr C Elegans Anat, Bronx, NY 10461 USA; New York Blood Ctr, Lindsley F Kimball Res Inst, Dept Stem Cell Biol, New York, NY 10021 USA; Rutgers State Univ, Waksman Inst, Dept Genet, Piscataway, NJ 08854 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Rutgers State University New Brunswick; Yeshiva University; Albert Einstein College of Medicine; New York Blood Center; Rutgers State University New Brunswick	Hardin, JD (corresponding author), Univ Wisconsin, Program Cellular & Mol Biol, 1117 W Johnson St, Madison, WI 53706 USA.			Firestein, Bonnie/0000-0002-1679-3565	NCRR NIH HHS [R24 RR012596] Funding Source: Medline; NIGMS NIH HHS [GM58038] Funding Source: Medline; NIH HHS [R24 OD010943] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR012596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058038] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel P. L., 1997, YEAST 2 HYBRID SYSTE; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bossinger O, 2001, DEV BIOL, V230, P29, DOI 10.1006/dbio.2000.0113; BRENNER S, 1974, GENETICS, V77, P71; Cordenonsi M, 1999, EUR J BIOCHEM, V264, P374, DOI 10.1046/j.1432-1327.1999.00616.x; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Gatewood BK, 1997, GENETICS, V146, P165; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall DH, 1995, METHOD CELL BIOL, V48, P395; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; HRESKO MC, 1994, J CELL BIOL, V124, P491, DOI 10.1083/jcb.124.4.491; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KAGAWA H, 1988, NUCL ACIDS RES S SER, V19, P81; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Lamb RS, 1998, MOL BIOL CELL, V9, P3505, DOI 10.1091/mbc.9.12.3505; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Mello C, 1995, METHOD CELL BIOL, V48, P451; Mohler WA, 1998, CURR BIOL, V8, P1087, DOI 10.1016/S0960-9822(98)70447-6; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; Raich WB, 1999, CURR BIOL, V9, P1139, DOI 10.1016/S0960-9822(00)80015-9; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sambrook J., 2002, MOL CLONING LAB MANU; SELKIRK ME, 1990, MOL BIOCHEM PARASIT, V42, P31, DOI 10.1016/0166-6851(90)90110-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Ward RE, 1998, J CELL BIOL, V140, P1463, DOI 10.1083/jcb.140.6.1463; WATERSTON RH, 1989, EMBO J, V8, P3429, DOI 10.1002/j.1460-2075.1989.tb08507.x; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YAMADA I, 1993, NTT REVIEW, V5, P70	44	233	240	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					983	991		10.1038/ncb1101-983	http://dx.doi.org/10.1038/ncb1101-983			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715019				2022-12-25	WOS:000172070300013
J	Partida-Sanchez, S; Cockayne, DA; Monard, S; Jacobson, EL; Oppenheimer, N; Garvy, B; Kusser, K; Goodrich, S; Howard, M; Harmsen, A; Randall, TD; Lund, FE				Partida-Sanchez, S; Cockayne, DA; Monard, S; Jacobson, EL; Oppenheimer, N; Garvy, B; Kusser, K; Goodrich, S; Howard, M; Harmsen, A; Randall, TD; Lund, FE			Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo	NATURE MEDICINE			English	Article							CA2+ INFLUX; RECEPTOR; MICE; CYCLASE; 2ND-MESSENGER; LYMPHOCYTES; METABOLITE; ACTIVATION; TISSUES; ENZYMES	Cyclic ADP-ribose is believed to be an important calcium-mobilizing second messenger in invertebrate, mammalian and plant cells. CD38, the best-characterized mammalian ADP-ribosyl cyclase, is postulated to be an important source of cyclic ADP-ribose in vivo. Using CD38-deficient mice, we demonstrate that the loss of CD38 renders mice susceptible to bacterial infections due to an inability of CD38-deficient neutrophils to directionally migrate to the site of infection. Furthermore, we show that cyclic ADP-ribose can directly induce intracellular Cal release in neutrophils and is required for sustained extracellular Ca++ influx in neutrophils that have been stimulated by the bacterial chemoattractant, formyl-methionyl-leucyl-phenylalanine (fMLP). Finally, we demonstrate that neutrophil chemotaxis to fMLP is dependent on Cal mobilization mediated by cyclic ADP-ribose. Thus, CD38 controls neutrophil chemotaxis to bacterial chemoattractants through its production of cyclic ADP-ribose, and acts as a critical regulator of inflammation and innate immune responses.	Trudeau Inst Inc, Saranac Lake, NY 12983 USA; Roche Biosci, Neurobiol Unit, Palo Alto, CA USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Kentucky, Dept Internal Med, Lexington, KY USA; Chemocentryx, San Carlos, CA USA; Montana State Univ, Dept Vet Mol Biol, Bozeman, MT 59717 USA	Trudeau Institute; Roche Holding; University of Arizona; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Francisco; University of Kentucky; Montana State University System; Montana State University Bozeman	Lund, FE (corresponding author), Trudeau Inst Inc, POB 59, Saranac Lake, NY 12983 USA.		Partida-Sanchez, Santiago/B-7523-2008	Partida-Sanchez, Santiago/0000-0003-2996-9440				ABDALLAH MA, 1975, EUR J BIOCHEM, V50, P475, DOI 10.1111/j.1432-1033.1975.tb09885.x; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; Fernandez JE, 1998, J BIOL REG HOMEOS AG, V12, P81; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Garvy BA, 1996, INFLAMMATION, V20, P499, DOI 10.1007/BF01487042; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; Guse AH, 1999, CELL SIGNAL, V11, P309, DOI 10.1016/S0898-6568(99)00004-2; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872; Higashida H, 2001, J NEUROCHEM, V76, P321, DOI 10.1046/j.1471-4159.2001.00082.x; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUB E, 1996, CHEMOATTRACTANT LIGA, P301; KRAUSE KH, 1989, CELL CALCIUM, V10, P351, DOI 10.1016/0143-4160(89)90061-4; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lentsch AB, 2000, J PATHOL, V190, P343; LEW DP, 1989, EUR J CLIN INVEST, V19, P338, DOI 10.1111/j.1365-2362.1989.tb00240.x; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MERRITT JE, 1991, CELL SIGNAL, V3, P73, DOI 10.1016/0898-6568(91)90010-R; MESZAROS L, 1993, NATURE, V354, P76; Murphy P.M., 1996, CHEMOATTRACTANT LIGA, P269; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; Schorr W, 1999, EUR J IMMUNOL, V29, P897, DOI 10.1002/(SICI)1521-4141(199903)29:03<897::AID-IMMU897>3.3.CO;2-X; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Vu CQ, 1997, BIOCHEM BIOPH RES CO, V236, P723, DOI 10.1006/bbrc.1997.7038; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	41	358	371	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2001	7	11					1209	1216		10.1038/nm1101-1209	http://dx.doi.org/10.1038/nm1101-1209			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689885				2022-12-25	WOS:000172054100028
J	Hussain, NK; Jenna, S; Glogauer, M; Quinn, CC; Wasiak, S; Guipponi, M; Antonarakis, SE; Kay, BK; Stossel, TP; Lamarche-Vane, N; McPherson, PS				Hussain, NK; Jenna, S; Glogauer, M; Quinn, CC; Wasiak, S; Guipponi, M; Antonarakis, SE; Kay, BK; Stossel, TP; Lamarche-Vane, N; McPherson, PS			Endocytic protein intersectin-I regulates actin assembly via Cdc42 and N-WASP	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCHANGE ACTIVITY; DEPOLYMERIZING PROTEIN; EPS15 HOMOLOGY; RAC; RHO; GTPASES; DOMAIN; DOWNSTREAM; MACHINERY; COMPLEXES	Intersectin-s is a modular scaffolding protein regulating the formation of clathrin-coated vesicles(1,2). In addition to the Eps15 homology (EH) and Src homology 3 (SH3) domains of intersectin-s, the neuronal variant (intersectin-I) also has Dbl homology (DH), pleckstrin homology (PH) and C2 domains(1,3-7). We now show that intersectin-I functions through its DH domain as a guanine nucleotide exchange factor (GEF) for Cdc42. In cultured cells, expression of DH-domain-containing constructs cause actin rearrangements specific for Cdc42 activation. Moreover, in vivo studies reveal that stimulation of Cdc42 by intersectin-I accelerates actin assembly via N-WASP and the Arp2/3 complex. N-WASP binds directly to intersectin-I and upregulates its GEF activity, thereby generating GTP-bound Cdc42, a critical activator of N-WASP. These studies reveal a role for intersectin-I in a novel mechanism of N-WASP activation and in regulation of the actin cytoskeleton.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Univ Geneva, Sch Med, Div Med Genet, CH-1211 Geneva 4, Switzerland; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	McGill University; McGill University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University; University of Geneva; University of Wisconsin System; University of Wisconsin Madison	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.	peter.mcpherson@mcgill.ca	Glogauer, Michael/D-2504-2011; Antonarakis, Stylianos E/N-8866-2014	Antonarakis, Stylianos E/0000-0001-8907-5823; Glogauer, Michael/0000-0002-6248-5977				BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; De Camilli P, 2001, SYNAPSES, P217; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; MAVCOX PR, 1992, J CELL BIOL, V118, P1379; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Pucharcos C, 2000, FEBS LETT, V478, P43, DOI 10.1016/S0014-5793(00)01793-2; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Roos J, 1999, CURR BIOL, V9, P1411, DOI 10.1016/S0960-9822(00)80087-1; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	40	283	295	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					927	932		10.1038/ncb1001-927	http://dx.doi.org/10.1038/ncb1001-927			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584276				2022-12-25	WOS:000171396400019
J	Pilpel, Y; Sudarsanam, P; Church, GM				Pilpel, Y; Sudarsanam, P; Church, GM			Identifying regulatory networks by combinatorial analysis of promoter elements	NATURE GENETICS			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CELL-CYCLE; COMPUTATIONAL ANALYSIS; EXCISION-REPAIR; GENOMIC SCALE; IDENTIFICATION; SEQUENCES; DATABASE	Several computational methods based on microarray data are currently used to study genome-wide transcriptional regulation. Few studies, however, address the combinatorial nature of transcription, a well-established phenomenon in eukaryotes. Here we describe a new approach using microarray data to uncover novel functional motif combinations in the promoters of Saccharomyces cerevisiae. In addition to identifying novel motif combinations that affect expression patterns during the cell cycle, sporulation and various stress responses, we observed regulatory cross-talk among several of these processes. We have also generated motif-association maps that provide a global view of transcription networks. The maps are highly connected, suggesting that a small number of transcription factors are responsible for a complex set of expression patterns in diverse conditions. This approach may be useful for modeling transcriptional regulatory networks in more complex eukaryotes.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Church, GM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			church, george/0000-0001-6232-9969				Aach J, 2000, GENOME RES, V10, P431, DOI 10.1101/gr.10.4.431; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; Brazma A, 1998, GENOME RES, V8, P1202, DOI 10.1101/gr.8.11.1202; BULYK ML, 2001, P NATL ACAD SCI US, V12; Bussemaker HJ, 2001, NAT GENET, V27, P167, DOI 10.1038/84792; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fickett JW, 2000, CURR OPIN BIOTECH, V11, P19, DOI 10.1016/S0958-1669(99)00049-X; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; KEI OV, 1995, NUCLEIC ACIDS RES, V23, P4097; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Leem SH, 1998, NUCLEIC ACIDS RES, V26, P3154, DOI 10.1093/nar/26.13.3154; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Quandt K, 1996, GENOMICS, V33, P301, DOI 10.1006/geno.1996.0197; Reed SH, 1999, GENE DEV, V13, P3052, DOI 10.1101/gad.13.23.3052; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Umemura K, 1997, EUR J BIOCHEM, V243, P748, DOI 10.1111/j.1432-1033.1997.00748.x; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Wagner A, 1999, BIOINFORMATICS, V15, P776, DOI 10.1093/bioinformatics/15.10.776; Wang J, 1999, J MOL BIOL, V286, P315, DOI 10.1006/jmbi.1998.2489; Werner T, 1999, MAMM GENOME, V10, P168, DOI 10.1007/s003359900963; Wolfsberg TG, 1999, GENOME RES, V9, P775; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	39	472	497	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					153	159		10.1038/ng724	http://dx.doi.org/10.1038/ng724			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11547334				2022-12-25	WOS:000171374100020
J	Zhang, PJ; Hinshaw, JE				Zhang, PJ; Hinshaw, JE			Three-dimensional reconstruction of dynamin in the constricted state	NATURE CELL BIOLOGY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RECEPTOR-MEDIATED ENDOCYTOSIS; ACETYLCHOLINE-RECEPTOR; CRYSTAL-STRUCTURE; VESICLE FORMATION; NERVE-TERMINALS; GTPASE; UNDERGOES; ASSEMBLES; DIVISION	Members of the dynamin family of GTPases have unique structural properties that might reveal a general mechanochemical basis for membrane constriction. Receptor-mediated endocytosis, caveolae internalization and certain trafficking events in the Golgi all require dynamin for vesiculation(1). The dynamin-related protein Drp1 (Dlp1) has been implicated in mitochondria fission(2) and a plant dynamin-like protein phragmoplastin is involved in the vesicular events leading to cell wall formation(3). A common theme among these proteins is their ability to self-assemble into spirals and their localization to areas of membrane fission. Here we present the first three-dimensional structure of dynamin at a resolution of similar to 20 Angstrom, determined from cryo-electron micrographs of tubular crystals in the constricted state. The map reveals a T-shaped dimer consisting of three prominent densities: leg, stalk and head. The structure suggests that the dense stalk and head regions rearrange when GTP is added, a rearrangement that generates a force on the underlying lipid bilayer and thereby leads to membrane constriction. These results indicate that dynamin is a force-generating 'contrictase'.	NIDDKD, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hinshaw, JE (corresponding author), NIDDKD, Lab Cell Biochem & Biol, NIH, Bldg 8,Room 419,MSC 0851,8 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK060100, Z01DK060100] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Beroukhim R, 1997, ULTRAMICROSCOPY, V70, P57, DOI 10.1016/S0304-3991(97)00070-3; Binns DD, 1999, J PROTEIN CHEM, V18, P277, DOI 10.1023/A:1021083211267; Burger KNJ, 2000, BIOCHEMISTRY-US, V39, P12485, DOI 10.1021/bi000971r; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Carragher B, 1996, J STRUCT BIOL, V116, P107, DOI 10.1006/jsbi.1996.0018; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Erickson HP, 2000, J CELL BIOL, V148, P1103, DOI 10.1083/jcb.148.6.1103; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; Gilbert A, 1997, J CELL SCI, V110, P3105; Gu XJ, 1997, PLANT CELL, V9, P157, DOI 10.1105/tpc.9.2.157; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sever S, 2000, J CELL BIOL, V150, P1137, DOI 10.1083/jcb.150.5.1137; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553	33	189	191	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					922	926		10.1038/ncb1001-922	http://dx.doi.org/10.1038/ncb1001-922			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584275				2022-12-25	WOS:000171396400018
J	Lin, SY; Makino, K; Xia, WY; Matin, A; Wen, Y; Kwong, KY; Bourguignon, L; Hung, MC				Lin, SY; Makino, K; Xia, WY; Matin, A; Wen, Y; Kwong, KY; Bourguignon, L; Hung, MC			Nuclear localization of EGF receptor and its potential new role as a transcription factor	NATURE CELL BIOLOGY			English	Article							EPIDERMAL GROWTH-FACTOR; EXPRESSION; CELLS; BINDING; CHROMATIN; COMPLEX; PROTOONCOGENE; TRANSLOCATION; CARCINOMA; C-ERBB-2	Epidermal growth factor receptor (EGFR) has been detected in the nucleus in many tissues and cell lines. However, the potential functions of nuclear EGFR have largely been overlooked. Here we demonstrate that nuclear EGFR is strongly correlated with highly proliferating activities of tissues. When EGFR was fused to the GAL4 DNA-binding domain, we found that the carboxy terminus of EGFR contained a strong transactivation domain. Moreover, the receptor complex bound and activated AT rich consensus-sequence-dependent transcription, including the consensus site in cyclin Dl promoter. By using chromatin immunoprecipitation assays, we further demonstrated that nuclear EGFR associated with promoter region of cyclin D1 in vivo. EGFR might therefore function as a transcription factor to activate genes required for highly proliferating activities.	Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Calif San Francisco, Endocrine Unit 111N, Vet Adm Med Ctr, San Francisco, CA 94121 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; COHEN S, 1982, J BIOL CHEM, V257, P1523; CURTIS BM, 1990, J IMMUNOL, V144, P1295; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; GUSTERSON B, 1985, INT J CANCER, V36, P689; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KNAUER DJ, 1984, J BIOL CHEM, V259, P5623; LIPPONEN P, 1994, BRIT J CANCER, V69, P1120, DOI 10.1038/bjc.1994.220; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PILCH PF, 1979, J BIOL CHEM, V254, P3375; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAKOWICZSZULCZYNSKA EM, 1988, CANCER RES, V48, P7200; Srinivasan R, 2000, CANCER RES, V60, P1483; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P234, DOI 10.1097/00004347-199407000-00007; VIGNERI R, 1978, J BIOL CHEM, V253, P2098; WAKSHULL EM, 1985, P NATL ACAD SCI USA, V82, P8513, DOI 10.1073/pnas.82.24.8513; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; ZIMMERMANN H, 1995, J HEPATOL, V23, P459, DOI 10.1016/0168-8278(95)80205-3	31	823	855	0	46	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					802	808		10.1038/ncb0901-802	http://dx.doi.org/10.1038/ncb0901-802			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533659				2022-12-25	WOS:000170979600013
J	Pasqualetti, M; Neun, R; Davenne, M; Rijli, FM				Pasqualetti, M; Neun, R; Davenne, M; Rijli, FM			Retinoic acid rescues inner ear defects in Hoxa1 deficient mice	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR; SEGMENTATION MUTANT; MOUSE HINDBRAIN; 2 RHOMBOMERES; EXPRESSION; PROTEIN; GENES; TRANSFORMATION; BOUNDARIES; INDUCTION	Little is known about the genetic pathways involved in the early steps of inner ear morphogenesis. Hoxa1 is transiently expressed in the developing hindbrain; its targeted inactivation in mice results in severe abnormalities of the otic capsule and membranous labyrinth(1). Here we show that a single maternal administration of a low dose of the vitamin A metabolite retinoic acid is sufficient to compensate the requirement for Hoxa1 function. It rescues cochlear and vestibular defects in mutant fetuses without affecting the development of the wildtype fetuses. These results identify a temporal window of susceptibility to retinoids that is critical for mammalian inner ear specification, and provide the first evidence that a subteratogenic dose of vitamin A derivative can be effective in rescuing a congenital defect in the mammalian embryo.	Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rijli, FM (corresponding author), Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	rijli@igbmc.u-strasbg.fr	Pasqualetti, Massimo/F-8682-2012; RIJLI, Filippo/AAP-2516-2020	RIJLI, Filippo/0000-0003-0515-0182; Pasqualetti, Massimo/0000-0002-0844-8139				Brigande JV, 2000, DEV BIOL, V227, P256, DOI 10.1006/dbio.2000.9914; Brigande JV, 2000, P NATL ACAD SCI USA, V97, P11700, DOI 10.1073/pnas.97.22.11700; Cantos R, 2000, P NATL ACAD SCI USA, V97, P11707, DOI 10.1073/pnas.97.22.11707; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; Choo D, 1998, DEV BIOL, V204, P136, DOI 10.1006/dbio.1998.9095; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; CONLON RA, 1992, DEVELOPMENT, V116, P357; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Dupe V, 1999, DEVELOPMENT, V126, P5051; Dupe V, 1997, DEVELOPMENT, V124, P399; Fekete DM, 1999, TRENDS NEUROSCI, V22, P263, DOI 10.1016/S0166-2236(98)01366-6; Frenz DA, 1996, TERATOLOGY, V53, P292; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; Gale E, 1999, MECH DEVELOP, V89, P43, DOI 10.1016/S0925-4773(99)00202-6; Gavalas A, 1998, DEVELOPMENT, V125, P1123; Groves AK, 2000, DEVELOPMENT, V127, P3489; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kiernan AE, 2001, P NATL ACAD SCI USA, V98, P3873, DOI 10.1073/pnas.071496998; Ladher RK, 2000, SCIENCE, V290, P1965, DOI 10.1126/science.290.5498.1965; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARK M, 1993, DEVELOPMENT, V119, P319; Marshall H, 1996, FASEB J, V10, P969, DOI 10.1096/fasebj.10.9.8801179; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; McKay IJ, 1996, DEV BIOL, V174, P370, DOI 10.1006/dbio.1996.0081; Morrison A, 1999, MECH DEVELOP, V84, P169, DOI 10.1016/S0925-4773(99)00066-0; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; Morsli H, 1998, J NEUROSCI, V18, P3327; Murakami A, 1999, J BIOL CHEM, V274, P17242, DOI 10.1074/jbc.274.24.17242; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Pasqualetti M, 2000, DEVELOPMENT, V127, P5367; Pirvola U, 2000, J NEUROSCI, V20, P6125, DOI 10.1523/JNEUROSCI.20-16-06125.2000; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Rossel M, 1999, DEVELOPMENT, V126, P5027; SIMEONE A, 1995, MECH DEVELOP, V51, P83, DOI 10.1016/0925-4773(95)96241-M; SOPRANO DR, 1994, MECH DEVELOP, V45, P243, DOI 10.1016/0925-4773(94)90011-6; Studer M, 1998, DEVELOPMENT, V125, P1025; SULIK KK, 1988, DEVELOPMENT, V103, P213; SULIK KK, 1995, TERATOLOGY, V51, P398, DOI 10.1002/tera.1420510605; Torres M, 1998, MECH DEVELOP, V71, P5, DOI 10.1016/S0925-4773(97)00155-X; Torres MA, 1996, DEVELOPMENT, V122, P3381; Trainor P, 2000, NAT CELL BIOL, V2, P96, DOI 10.1038/35000051; VANDEWATER TR, 1982, ANAT REC, pA195; Vendrell V, 2000, DEVELOPMENT, V127, P2011; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YNTEMA CL, 1950, J EXP ZOOL, V113, P211, DOI 10.1002/jez.1401130110; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	49	55	60	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2001	29	1					34	39		10.1038/ng702	http://dx.doi.org/10.1038/ng702			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528388				2022-12-25	WOS:000170781300013
J	Homann, D; Teyton, L; Oldstone, MBA				Homann, D; Teyton, L; Oldstone, MBA			Differential regulation of antiviral T-cell immunity results in stable CD8(+) but declining CD4(+) T-cell memory	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; QUANTITATIVE-ANALYSIS; VIRAL-INFECTION; DEFICIENT MICE; B-CELLS; RESPONSES; IMMUNOTHERAPY; PERSISTENCE; ACTIVATION; EXPRESSION	Emerging evidence indicates that CD8(+) and CD4(+) T-cell immunity is differentially regulated. Here we have delineated differences and commonalities among antiviral T-cell responses by enumeration and functional profiling of eight specific CD8(+) and CD4(+) T-cell populations during primary, memory and recall responses. A high degree of coordinate regulation among all specific T-cell populations stood out against an approximately 20-fold lower peak expansion and prolonged contraction phase of specific CD4(+) T-cell populations. Surprisingly, although CD8(+) T-cell memory was stably maintained for life, levels of specific CD4(+) memory T cells gradually declined. However, this decay, which seemed to result from less efficient rescue from apoptosis, did not affect functionality of surviving virus-specific CD4(+) T cells. Our results indicate that CD4(+) T-cell memory might become limiting under physiological conditions and that conditions precipitating CD4(+) T-cell loss might compromise protective immunity even in the presence of unimpaired CD8+ T-cell responses.	Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute	Homann, D (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA.	dhomann@scripps.edu		Homann, Dirk/0000-0002-7622-5754	NIAID NIH HHS [AI-09484] Funding Source: Medline; NIA NIH HHS [AG-00080, AG-04342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Belz GT, 1998, P NATL ACAD SCI USA, V95, P13812, DOI 10.1073/pnas.95.23.13812; Berger DP, 2000, VIROLOGY, V266, P257, DOI 10.1006/viro.1999.0074; Beverley PCL, 2000, PHILOS T R SOC B, V355, P401, DOI 10.1098/rstb.2000.0580; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Christensen JP, 1999, J VIROL, V73, P4279, DOI 10.1128/JVI.73.5.4279-4283.1999; Ciurea A, 1999, P NATL ACAD SCI USA, V96, P11964, DOI 10.1073/pnas.96.21.11964; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferlin W, 2000, CURR OPIN IMMUNOL, V12, P670, DOI 10.1016/S0952-7915(00)00161-8; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Guidotti LG, 1999, CURR OPIN MICROBIOL, V2, P388; HOBBS MV, 1993, J IMMUNOL, V150, P3602; Homann D, 1998, J VIROL, V72, P9208, DOI 10.1128/JVI.72.11.9208-9216.1998; HOMANN D, IN PRESS CURR TOP MI; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kamperschroer C, 1999, CELL IMMUNOL, V193, P134, DOI 10.1006/cimm.1999.1458; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Maini MK, 1999, IMMUNOL TODAY, V20, P262, DOI 10.1016/S0167-5699(99)01472-3; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mehal WZ, 1999, J IMMUNOL, V163, P3202; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; OLDSTONE MBA, 1987, CURR TOP MICROBIOL, V134, P211; Opferman JT, 1999, SCIENCE, V283, P1745, DOI 10.1126/science.283.5408.1745; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Rentenaar RJ, 2000, J CLIN INVEST, V105, P541, DOI 10.1172/JCI8229; Slifka MK, 2000, J IMMUNOL, V164, P208, DOI 10.4049/jimmunol.164.1.208; Stratmann T, 2000, J IMMUNOL, V165, P3214, DOI 10.4049/jimmunol.165.6.3214; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Topham DJ, 1996, J IMMUNOL, V157, P2947; Topham DJ, 1998, J IMMUNOL, V161, P4530; van Essen D, 2000, PHILOS T ROY SOC B, V355, P351, DOI 10.1098/rstb.2000.0572; Varga SM, 2000, J VIROL, V74, P4429, DOI 10.1128/JVI.74.9.4429-4432.2000; Varga SM, 1998, J IMMUNOL, V161, P367; Welsh RM, 2001, J EXP MED, V193, pF19, DOI 10.1084/jem.193.5.F19; Whitmire JK, 2000, CURR OPIN IMMUNOL, V12, P448, DOI 10.1016/S0952-7915(00)00119-9; Whitmire JK, 1998, J VIROL, V72, P8281, DOI 10.1128/JVI.72.10.8281-8288.1998; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	45	464	470	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					913	919		10.1038/90950	http://dx.doi.org/10.1038/90950			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479623				2022-12-25	WOS:000171740400028
J	Matikainen, T; Perez, GI; Jurisicova, A; Pru, JK; Schlezinger, JJ; Ryu, HY; Laine, J; Sakai, T; Korsmeyer, SJ; Casper, RF; Sherr, DH; Tilly, JL				Matikainen, T; Perez, GI; Jurisicova, A; Pru, JK; Schlezinger, JJ; Ryu, HY; Laine, J; Sakai, T; Korsmeyer, SJ; Casper, RF; Sherr, DH; Tilly, JL			Aromatic hydrocarbon receptor-driven Bax gene expression is required for premature ovarian failure caused by biohazardous environmental chemicals	NATURE GENETICS			English	Article							DIOXIN-RESPONSIVE ENHANCER; PROTEIN-DNA INTERACTIONS; LIGANDED AH RECEPTOR; OOCYTE APOPTOSIS; CELL-DEATH; MOUSE OOCYTES; IN-VITRO; BCL-2; DESTRUCTION; FOLLICLES	Polycyclic aromatic hydrocarbons (PAHs) are toxic chemicals released into the environment by fossil fuel combustion. Moreover, a primary route of human exposure to PAHs is tobacco smoke(1,2). Oocyte destruction and ovarian failure occur in PAH-treated mice(1,2), and cigarette smoking causes early menopause in women(1,3). In many cells, PAHs activate the aromatic hydrocarbon receptor (Ahr), a member of the Per-Arnt-Sim family of transcription factors(4,5). The Ahr is also activated by dioxin, one of the most intensively studied environmental contaminants. Here we show that an exposure of mice to PAHs induces the expression of Bax in oocytes(6), followed by apoptosis. Ovarian damage caused by PAHs is prevented by Ahr or Bax inactivation. Oocytes microinjected with a Bax promoter-reporter construct show Ahr-dependent transcriptional activation after PAH, but not dioxin, treatment, consistent with findings that dioxin is not cytotoxic to oocytes. This difference in the action of PAHs versus dioxin is conveyed by a single base pair flanking each Ahr response element in the Bax promoter. Oocytes in human ovarian biopsies grafted into immunodeficient mice also accumulate Bax and undergo apoptosis after PAH exposure in vivo. Thus, Ahr-driven Bax transcription is a novel and evolutionarily conserved cell-death signaling pathway responsible for environmental toxicant-induced ovarian failure.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Publ Hlth, Boston, MA 02118 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA 02115 USA; Kyoto Prefectural Univ, Sch Med, Dept Prevent Med, Kyoto 6028566, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Kyoto Prefectural University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Tilly, JL (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Vincent Ctr Reprod Biol, Boston, MA 02114 USA.	jtilly@partners.org	Casper, Robert F./E-3775-2013; Jurisicova, Andrea/E-4580-2013; Perez, Gloria I/GMX-1286-2022	Casper, Robert F./0000-0002-6249-462X; Sherr, David/0000-0003-3353-0553; Schlezinger, Jennifer/0000-0001-6834-4369	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008430] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES08430] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLANK JA, 1987, MOL PHARMACOL, V32, P168; Eppig JJ, 1996, BIOL REPROD, V54, P197, DOI 10.1095/biolreprod54.1.197; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Heidel SM, 1998, MOL PHARMACOL, V54, P1000, DOI 10.1124/mol.54.6.1000; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; JICK H, 1977, LANCET, V1, P1354; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Mann KK, 1999, TOXICOL APPL PHARM, V161, P10, DOI 10.1006/taap.1999.8778; MATTISON DR, 1980, TOXICOL APPL PHARM, V56, P399, DOI 10.1016/0041-008X(80)90074-5; MATTISON DR, 1989, SEMIN REPROD ENDOCR, V7, P291, DOI 10.1055/s-2007-1021411; MATTISON DR, 1979, CANCER RES, V39, P3471; Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344; Morita Y, 1999, MOL ENDOCRINOL, V13, P841, DOI 10.1210/me.13.6.841; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perez GI, 1999, NAT GENET, V21, P200, DOI 10.1038/5985; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Pru JK, 2001, BIOL REPROD, V64, P965, DOI 10.1095/biolreprod64.3.965; Pru JK, 2001, MOL ENDOCRINOL, V15, P845, DOI 10.1210/me.15.6.845; QVIST R, 1990, J REPROD FERTIL, V89, P169, DOI 10.1530/jrf.0.0890169; Robles R, 2000, ENDOCRINOLOGY, V141, P450, DOI 10.1210/en.141.1.450; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Shi SR, 1997, J HISTOCHEM CYTOCHEM, V45, P327, DOI 10.1177/002215549704500301; SILBERGELD EK, 1987, AM J IND MED, V11, P131, DOI 10.1002/ajim.4700110203; Sussman NB, 1999, J WOMENS HEALTH, V8, P217, DOI 10.1089/jwh.1999.8.217; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Weissman A, 1999, BIOL REPROD, V60, P1462, DOI 10.1095/biolreprod60.6.1462; Wilson CL, 1998, TOXICOL PATHOL, V26, P657, DOI 10.1177/019262339802600510	30	352	368	1	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					355	360		10.1038/ng575	http://dx.doi.org/10.1038/ng575			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11455387				2022-12-25	WOS:000170174800016
J	Batkai, S; Jarat, Z; Wagner, JA; Goparaju, SK; Varga, K; Liu, J; Wang, L; Mirshahi, F; Khanolkar, AD; Makriyannis, A; Urbaschek, R; Garcia, N; Sanyal, AJ; Kunos, G				Batkai, S; Jarat, Z; Wagner, JA; Goparaju, SK; Varga, K; Liu, J; Wang, L; Mirshahi, F; Khanolkar, AD; Makriyannis, A; Urbaschek, R; Garcia, N; Sanyal, AJ; Kunos, G			Endocannabinoids acting at vascular CB, receptors mediate the vasodilated state in advanced liver cirrhosis	NATURE MEDICINE			English	Article							NITRIC-OXIDE SYNTHASE; HYPERDYNAMIC CIRCULATION; CANNABINOID RECEPTORS; PORTAL-HYPERTENSION; ENDOTOXIN LEVELS; WATER-RETENTION; RATS; ANTAGONIST; RESISTANCE; SODIUM	Advanced cirrhosis is associated with generalized vasodilation of unknown origin, which contributes to mortality. Cirrhotic patients are endotoxemic, and activation of Vascular cannabinoid CB1 receptors has been implicated in endotoxin-induced hypotension. Here we show that rats with biliary cirrhosis have low blood pressure, which is elevated by the CB1 receptor antagonist SR141716A. The low blood pressure of rats with CCl4-induced cirrhosis was similarly reversed by SR141716A, which also reduced the elevated mesenteric blood flow and portal pressure. Monocytes from cirrhotic but not control patients or rats elicited SR141716A-sensitive hypotension in normal recipient rats and showed significantly elevated levels of anandamide. Compared with non-cirrhotic controls, in cirrhotic human livers there was a three-fold increase in CB1 receptors on isolated vascular endothelial cells. These results implicate anandamide and vascular CB1 receptors in the vasodilated state in advanced cirrhosis and indicate a novel approach for its management.	NIAAA, NIH, Bethesda, MD USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA; Univ Connecticut, Sch Pharm, Dept Pharmaceut Sci, Storrs, CT USA; Heidelberg Univ, Klinikum Mannheim, Inst Med Microbiol & Hyg, Mannheim, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Virginia Commonwealth University; University of Connecticut; Ruprecht Karls University Heidelberg	Kunos, G (corresponding author), NIAAA, NIH, Bethesda, MD USA.	gkunos@mail.nih.gov	Goparaju, Sravan/H-3422-2011; Batkai, Sandor/H-7983-2014; Batkai, Sandor/G-3889-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000065] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000351] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-00065-38] Funding Source: Medline; NHLBI NIH HHS [HL-59257] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARROYO V, 1993, J HEPATOL, V17, pS24, DOI 10.1016/S0168-8278(05)80451-9; BILLINGER TV, 1998, INT J CARDIOL S1, V64, pS15; Bosch Jaume, 1994, P1343; CAHILL PA, 1995, HEPATOLOGY, V22, P598, DOI 10.1016/0270-9139(95)90585-5; Chan CC, 1997, SCAND J GASTROENTERO, V32, P942, DOI 10.3109/00365529709011206; Chu CJ, 1997, CLIN SCI, V93, P219, DOI 10.1042/cs0930219; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; FERNANDEZ M, 1995, GASTROENTEROLOGY, V108, P1487, DOI 10.1016/0016-5085(95)90698-3; Garcia N, 2001, AM J PHYSIOL-GASTR L, V280, pG14, DOI 10.1152/ajpgi.2001.280.1.G14; Gatley SJ, 1997, LIFE SCI, V61, pPL191, DOI 10.1016/S0024-3205(97)00690-5; Gebremedhin D, 1999, AM J PHYSIOL-HEART C, V276, pH2085, DOI 10.1152/ajpheart.1999.276.6.H2085; Genecin Paul, 1994, P1327; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Heller S, 1999, CRIT CARE MED, V27, P756, DOI 10.1097/00003246-199904000-00031; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KROEGER RJ, 1985, HEPATOLOGY, V5, P97, DOI 10.1002/hep.1840050120; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; LIN RS, 1995, J HEPATOL, V22, P165, DOI 10.1016/0168-8278(95)80424-2; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; Martin PY, 1998, NEW ENGL J MED, V339, P533, DOI 10.1056/NEJM199808203390807; Martin PY, 1996, AM J PHYSIOL-RENAL, V270, pF494, DOI 10.1152/ajprenal.1996.270.3.F494; Mathie RT, 1996, HEPATOLOGY, V23, P130; McCuskey RS, 1996, CARDIOVASC RES, V32, P752, DOI 10.1016/S0008-6363(96)00113-7; Pilette C, 1996, J GASTROEN HEPATOL, V11, P1, DOI 10.1111/j.1440-1746.1996.tb00002.x; Piscaglia F, 1997, EUR J GASTROEN HEPAT, V9, P799, DOI 10.1097/00042737-199708000-00012; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROEY G, 1997, CLIN SCI, V93, P549; Ryan J, 1996, CLIN SCI, V91, P23, DOI 10.1042/cs0910023; Sanyal AJ, 1998, LAB INVEST, V78, P1469; Sarela AI, 1999, GUT, V44, P749, DOI 10.1136/gut.44.5.749; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SIEBER CC, 1993, GASTROENTEROLOGY, V104, P1750, DOI 10.1016/0016-5085(93)90655-V; SIKULER E, 1986, AM J PHYSIOL, V250, pG205, DOI 10.1152/ajpgi.1986.250.2.G205; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Wiest R, 1999, J CLIN INVEST, V104, P1223, DOI 10.1172/JCI7458	43	277	289	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					827	832		10.1038/89953	http://dx.doi.org/10.1038/89953			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433348				2022-12-25	WOS:000169808600035
J	Griffin, E; Re, A; Hamel, N; Fu, CZ; Bush, H; McCaffrey, T; Asch, AS				Griffin, E; Re, A; Hamel, N; Fu, CZ; Bush, H; McCaffrey, T; Asch, AS			A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; SCAVENGER RECEPTOR CD36; GLYCATION END-PRODUCTS; OPEN READING FRAMES; PPAR-GAMMA; MESSENGER-RNA; FATTY-ACID; SECONDARY STRUCTURE; INSULIN-RESISTANCE; OXIDIZED LDL	Both the risk and the rate of development of atherosclerosis are increased in diabetics, but the mechanisms involved are unknown. Here we report a glucose-mediated increase in CD36 mRNA translation efficiency that results in increased expression of the macrophage scavenger receptor CD36. Expression of CD36 was increased in endarterectomy lesions from patients with a history of hyperglycemia. Macrophages that were differentiated from human peripheral blood monocytes in the presence of high glucose concentrations showed increased expression of cell-surface CD36 secondary to an increase in translational efficiency of CD36 mRNA. We obtained similar data from primary cells isolated from human vascular lesions, and we found that glucose sensitivity is a function of ribosomal reinitiation following translation of an upstream open reading frame (uORF). Increased translation of macrophage CD36 transcript under high glucose conditions provides a mechanism for accelerated atherosclerosis in diabetics.	Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Asch, AS (corresponding author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.	asasch@med.cornell.edu		Re, Alessandro/0000-0003-1156-6395	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048698] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48698] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huh HY, 1996, BLOOD, V87, P2020; HUNT JV, 1994, BIOCHEM J, V300, P243, DOI 10.1042/bj3000243; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Laakso M, 1996, ANN MED, V28, P415, DOI 10.3109/07853899608999101; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACH M, 1986, J BIOL CHEM, V261, P1697; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; SCHMIDT AM, 1996, DIABETES, V45, P77; SEMENKOVICH CF, 1995, J LIPID RES, V36, P1507; Semenkovich CF, 1997, DIABETES, V46, P327, DOI 10.2337/diabetes.46.3.327; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VLASSARA H, 1997, DIABETES S2, V46, P19; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	44	201	221	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					840	846		10.1038/89969	http://dx.doi.org/10.1038/89969			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433350				2022-12-25	WOS:000169808600037
J	Springall, T; Sheerin, NS; Abe, K; Holers, VM; Wan, H; Sacks, SH				Springall, T; Sheerin, NS; Abe, K; Holers, VM; Wan, H; Sacks, SH			Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli	NATURE MEDICINE			English	Article							COMPLEMENT COMPONENT C3; EXPERIMENTAL PYELONEPHRITIS; MEDIATES STIMULATION; HUMAN-KIDNEY; CELLS; EXPRESSION; MICE; INFECTION; GLOMERULONEPHRITIS; BIOSYNTHESIS	To assess the role of complement in renal infection, we studied a model of Escherichia coli-induced pyelonephritis in mice deficient in complement components C3 and C4. Renal infection occurred less frequently in C3- and C4-deficient mice compared with wild-type mice. In vitro, renal epithelial cells internalized fewer bacteria in the absence of C3 or in the presence of blockade of C3 bound to the bacteria. Moreover, upregulation of epithelial C3 production by stimulation with lipopolysaccharide enhanced bacterial internalization. Here we provide evidence that uropathogenic E, coli might use host C3 to invade the renal epithelium and that local complement production is sufficient for the bacteria to achieve this effect.	Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, GKT, London WC2R 2LS, England; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Kings Coll London, Dept Cell & Mol Pathol, St Thomas Hosp, GKT,St Johns Inst Dermatol, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sheerin, NS (corresponding author), Kings Coll London, Dept Nephrol & Transplantat, Guys Hosp, GKT, London WC2R 2LS, England.	neil.sheerin@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095				ANDREWS PA, 1995, EUR J IMMUNOL, V25, P1087, DOI 10.1002/eji.1830250434; AULT BH, 1994, IMMUNOLOGY, V81, P655; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; BOTTO M, 1992, J IMMUNOL, V149, P1348; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Connell H, 1997, Adv Dent Res, V11, P50; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DASILVA RP, 1989, J IMMUNOL, V143, P617; DETRISAC CJ, 1984, KIDNEY INT, V25, P383, DOI 10.1038/ki.1984.28; Ernst JD, 1998, INFECT IMMUN, V66, P1277, DOI 10.1128/IAI.66.4.1277-1281.1998; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALKOW S, 1987, REV INFECT DIS, V9, pS450; Fischer MB, 1996, J IMMUNOL, V157, P549; GLAUSER MP, 1978, J CLIN INVEST, V61, P403, DOI 10.1172/JCI108951; HAGBERG L, 1983, INFECT IMMUN, V40, P273, DOI 10.1128/IAI.40.1.273-283.1983; Hori Y, 1999, KIDNEY INT, V56, P2096, DOI 10.1046/j.1523-1755.1999.00765.x; Ichinose H, 1996, CLIN EXP IMMUNOL, V103, P125; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; IVANYI B, 1985, VIRCHOWS ARCH B, V50, P59; KUNIN CM, 1968, NEW ENGL J MED, V278, P635, DOI 10.1056/NEJM196803212781201; Kunin CM, 1994, CLIN INFECT DIS, V18, P11; Li WX, 1999, MICROBIOL IMMUNOL, V43, P585, DOI 10.1111/j.1348-0421.1999.tb02445.x; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MILLER TE, 1978, CLIN EXP IMMUNOL, V33, P115; Morita Y, 1997, J AM SOC NEPHROL, V8, P1363; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; Palmer LM, 1997, INFECT IMMUN, V65, P2570, DOI 10.1128/IAI.65.7.2570-2575.1997; Quigg RJ, 1998, J IMMUNOL, V160, P4553; QUIGG RJ, 1997, KIDNEY INT, V53, P1124; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; ROBERTS JA, 1983, J UROLOGY, V129, P193, DOI 10.1016/S0022-5347(17)51981-3; SEELEN MAJ, 1993, KIDNEY INT, V44, P50, DOI 10.1038/ki.1993.212; Sheerin NS, 1997, CLIN EXP IMMUNOL, V110, P403, DOI 10.1046/j.1365-2249.1997.4261438.x; SHIMAMURA T, 1981, EXP MOL PATHOL, V34, P34, DOI 10.1016/0014-4800(81)90033-2; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; Tang S, 1999, J IMMUNOL, V162, P4336; TAUB M, 1980, J CELL PHYSIOL, V105, P369, DOI 10.1002/jcp.1041050220; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; VANDERBIEST I, 1994, KIDNEY INT, V45, P85, DOI 10.1038/ki.1994.10; WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407; WELCH TR, 1993, J CLIN INVEST, V92, P1451, DOI 10.1172/JCI116722; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490	42	68	70	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					801	806		10.1038/89923	http://dx.doi.org/10.1038/89923			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433344				2022-12-25	WOS:000169808600031
J	Noensie, EN; Dietz, HC				Noensie, EN; Dietz, HC			A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition	NATURE BIOTECHNOLOGY			English	Article							MESSENGER-RNA INSTABILITY; MAMMALIAN-CELLS; MUTATIONS; PROTEIN; CANCER; POLYRIBOSOMES; SURVEILLANCE; SUPPRESSION; EXPRESSION; STABILITY	Premature termination codons (PTCs) have been shown to initiate degradation of mutant transcripts through the nonsense-mediated messenger RNA (mRNA) decay (NMD) pathway. We report a strategy, termed gene identification by NMD inhibition (GINI), to identify genes harboring nonsense codons that underlie human diseases. In this strategy, the NMD pathway is pharmacologically inhibited in cultured patient cells, resulting in stabilization of nonsense transcripts. To distinguish stabilized nonsense transcripts from background transcripts upregulated by drug treatment, drug-induced expression changes are measured in control and disease cell lines with complementary DNA (cDNA) microarrays. Transcripts are ranked by a nonsense enrichment index (NEI), which relates expression changes for a given transcript in NMD-inhibited control and patient cell lines. The most promising candidates can be selected using information such as map location or biological function; however, an important advantage of the GINI strategy is that a priori information is not essential for disease gene identification. GINI was tested on colon cancer and Sandhoff disease cell lines, which contained previously characterized nonsense mutations in the MutL homolog 1 (MLH1) and hexosaminidase B (HEXB) genes, respectively. A list of genes was produced in which the MLH1 and HEXB genes were among the top 1% of candidates, thus validating the strategy.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Dietz, HC (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM55239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkin AL, 1997, J BIOL CHEM, V272, P22163, DOI 10.1074/jbc.272.35.22163; ATKIN AL, 1995, MOL BIOL CELL, V6, P611; Bateman JF, 1999, HUM MUTAT, V13, P311, DOI 10.1002/(SICI)1098-1004(1999)13:4<311::AID-HUMU8>3.3.CO;2-G; BURKE JF, 1985, NUCLEIC ACIDS RES, V13, P6265, DOI 10.1093/nar/13.17.6265; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Freddi S, 2000, AM J MED GENET, V90, P398, DOI 10.1002/(SICI)1096-8628(20000228)90:5<398::AID-AJMG10>3.3.CO;2-Z; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GILBERT F, 1975, P NATL ACAD SCI USA, V72, P263, DOI 10.1073/pnas.72.1.263; ISAACS WB, 1991, CANCER RES, V51, P4716; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; Medghalchi SM, 2001, HUM MOL GENET, V10, P99, DOI 10.1093/hmg/10.2.99; Nagy E, 1998, TRENDS BIOCHEM SCI, V23, P198, DOI 10.1016/S0968-0004(98)01208-0; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; Perlick HA, 1996, P NATL ACAD SCI USA, V93, P10928, DOI 10.1073/pnas.93.20.10928; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009	21	155	162	1	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					434	439		10.1038/88099	http://dx.doi.org/10.1038/88099			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329012				2022-12-25	WOS:000168394800020
J	Wyss-Coray, T; Lin, C; Yan, FR; Yu, GQ; Rohde, M; McConlogue, L; Masliah, E; Mucke, L				Wyss-Coray, T; Lin, C; Yan, FR; Yu, GQ; Rohde, M; McConlogue, L; Masliah, E; Mucke, L			TGF-beta 1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; DISEASE-LIKE PATHOLOGY; E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; MOUSE MODEL; TRANSFORMING GROWTH-FACTOR-BETA-1; CELL BIOLOGY; HEAD-INJURY	Abnormal accumulation of the amyloid-beta peptide (A beta) in the brain appears crucial to pathogenesis in all forms of Alzheimer disease (AD), but the underlying mechanisms in the sporadic forms of AD remain unknown. Transforming growth factor beta1 (TGF-beta1), a key regulator of the brain's responses to injury and inflammation, has been implicated in A beta Delta deposition in vivo. Here we demonstrate that a modest increase in astroglial TGF-beta1 production in aged transgenic mice expressing the human beta -amyloid precursor protein (hAPP) results in a three-fold reduction in the number of parenchymal amyloid plaques, a 50% reduction in the overall A beta load in the hippocampus and neocortex, and a decrease in the number of dystrophic neurites. In mice expressing hAPP and TGF-beta1, A beta accumulated substantially in cerebral blood vessels, but not in parenchymal plaques. In human cases of AD, A beta immunoreactivity associated with parenchymal plaques was inversely correlated with A beta in blood vessels and cortical TGF-beta1 mRNA levels. The reduction of parenchymal plaques in hAPP/TGF-beta1 mice was associated with a strong activation of microglia and an increase in inflammatory mediators. Recombinant TGF-beta1 stimulated A beta clearance in microglial cell cultures. These results demonstrate that TGF-beta1 is an important modifier of amyloid deposition in vivo and indicate that TGF-beta1 might promote microglial processes that inhibit the accumulation of A beta in the brain parenchyma.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Elan Pharmaceut, S San Francisco, CA USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego	Wyss-Coray, T (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94143 USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831	NIA NIH HHS [AG-11385, AG-51131, AG-15871, AG-10689] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011385, R01AG015871, R01AG010689, R01AG011385] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; GALBREATH E, 1995, J NEUROPATH EXP NEUR, V54, P339, DOI 10.1097/00005072-199505000-00007; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KISILEVSKY R, 1994, MOL NEUROBIOL, V9, P23, DOI 10.1007/BF02816101; KUO YM, IN PRESS J BIOL CHEM; Mann DMA, 1996, AM J PATHOL, V148, P1257; Masliah E, 1996, J NEUROSCI, V16, P5795; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Paxinos G, 1995, RAT NERVOUS SYSTEM, V2nd; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; TERRY R, 1999, ALZHEIMER DIS; Verbeek MM, 1998, ACTA NEUROPATHOL, V96, P628, DOI 10.1007/s004010050944; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; WyssCoray T, 1997, J NEUROIMMUNOL, V77, P45, DOI 10.1016/S0165-5728(97)00049-0; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106; Zlokovic BV, 1996, LIFE SCI, V59, P1483, DOI 10.1016/0024-3205(96)00310-4	44	478	500	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					612	618		10.1038/87945	http://dx.doi.org/10.1038/87945			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329064				2022-12-25	WOS:000169961100042
J	Gerlich, D; Beaudouin, J; Gebhard, M; Ellenberg, J; Eils, R				Gerlich, D; Beaudouin, J; Gebhard, M; Ellenberg, J; Eils, R			Four-dimensional imaging and quantitative reconstruction to analyse complex spatiotemporal processes in live cells	NATURE CELL BIOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; NUCLEAR-ENVELOPE; DYNAMIC PROCESSES; LIVING CELLS; INTERPHASE; RECRUITMENT; MOBILITY; END	Live-cell imaging technology using fluorescent proteins (green fluorescent protein and its homologues) has revolutionized the study of cellular dynamics(1,2). But tools that can quantitatively analyse complex spatiotemporal processes in live cells remain lacking. Here we describe a new technique - fast mufti-colour four-dimensional imaging combined with automated and quantitative time-space reconstruction - to fill this gap. As a proof of principle, we apply this method to study the re-formation of the nuclear envelope in live cells(3-6). Four-dimensional imaging of three spectrally distinct fluorescent proteins is used to simultaneously visualize three different cellular compartments at high speed and with high spatial resolution. The highly complex data, comprising several thousand images from a single cell, were quantitatively reconstructed in time-space by software developed in-house. This analysis reveals quantitative and qualitative insights into the highly ordered topology of nuclear envelope formation, in correlation with chromatin expansion - results that would have been impossible to achieve by manual inspection alone. Our new technique will greatly facilitate study of the highly ordered dynamic architecture of eukaryotic cells.	German Canc Res Ctr, Intelligent Bioinformat Syst Dept, D-69120 Heidelberg, Germany; European Mol Biol Lab, Gene Express & Cell Biol Biophys Programme, D-69117 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)	Eils, R (corresponding author), German Canc Res Ctr, Intelligent Bioinformat Syst Dept, D-69120 Heidelberg, Germany.	r.eils@dkfz.de	Ellenberg, Jan/I-4688-2014; Eils, Roland/B-6121-2009; Gerlich, Daniel Wolfram W/A-6991-2016	Ellenberg, Jan/0000-0001-5909-701X; Eils, Roland/0000-0002-0034-4036; Gerlich, Daniel Wolfram W/0000-0003-1637-3365				AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1016/S0022-2836(95)80050-6; Belmont AS, 1999, CURR OPIN CELL BIOL, V11, P307, DOI 10.1016/S0955-0674(99)80041-6; BESL PJ, 1992, IEEE T PATTERN ANAL, V14, P239, DOI 10.1109/34.121791; Black MJ, 1998, IEEE T IMAGE PROCESS, V7, P421, DOI 10.1109/83.661192; Bodoor K, 1999, J CELL SCI, V112, P2253; Broers JLV, 1999, J CELL SCI, V112, P3463; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; Collas P, 2000, TRENDS CELL BIOL, V10, P5, DOI 10.1016/S0962-8924(99)01697-9; Eils R, 2000, MOL BIOL CELL, V11, P413, DOI 10.1091/mbc.11.2.413; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Ellenberg J, 1999, METHODS, V19, P362, DOI 10.1006/meth.1999.0872; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Haraguchi T, 2000, J CELL SCI, V113, P779; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lippincott-Schwartz J, 1999, METHOD CELL BIOL, V58, P261; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Matz MV, 1999, NAT BIOTECHNOL, V17, P1227; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Rustom A, 2000, BIOTECHNIQUES, V28, P722, DOI 10.2144/00284rr01; Terasaki M, 2000, MOL BIOL CELL, V11, P897, DOI 10.1091/mbc.11.3.897; Thomas CF, 1998, TRENDS BIOTECHNOL, V16, P175, DOI 10.1016/S0167-7799(97)01169-4; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tvarusko W, 1999, P NATL ACAD SCI USA, V96, P7950, DOI 10.1073/pnas.96.14.7950; Watt A.H., 1992, ADV ANIMATION RENDER	27	89	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					852	855		10.1038/ncb0901-852	http://dx.doi.org/10.1038/ncb0901-852			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533667				2022-12-25	WOS:000170979600021
J	Muthuswamy, SK; Li, DM; Lelievre, S; Bissell, MJ; Brugge, JS				Muthuswamy, SK; Li, DM; Lelievre, S; Bissell, MJ; Brugge, JS			ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini	NATURE CELL BIOLOGY			English	Article							C-HA-RAS; GROWTH-FACTOR; SIGNALING NETWORK; RECEPTOR FAMILY; PROTEIN CAUSES; CELL POLARITY; EGF RECEPTOR; IN-VITRO; EXPRESSION; DIFFERENTIATION	Both ErbB1 and ErbB2 are overexpressed or amplified in breast tumours. To examine the effects of activating ErbB receptors in a context that mimics polarized epithelial cells in vivo, we activated ErbB1 and ErbB2 homodimers in preformed, growth-arrested mammary acini cultured in three-dimensional basement membrane gels. Activation of ErbB2, but not that of ErbB1, led to a reinitiation of cell proliferation and altered the properties of mammary acinar structures. These altered structures share several properties with early-stage tumours, including a loss of proliferative suppression, an absence of lumen, retention of the basement membrane and a lack of invasive properties. ErbB2 activation also disrupted tight junctions and the cell polarity of polarized epithelia, whereas ErbB1 activation did not have any effect. Our results indicate that ErbB receptors differ in their ability to induce early stages of mammary carcinogenesis in vitro and this three-dimensional model system can reveal biological activities of oncogenes that cannot be examined in vitro in standard transformation assays.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Harvard University; Harvard Medical School; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Brugge, JS (corresponding author), Cold Spring Harbor Labs, Cold Spring Harbor, NY 11724 USA.	joan_brugge@hms.harvard.edu	Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634; LELIEVRE, Sophie/0000-0001-6606-2501	NCI NIH HHS [U54 CA112970-01, R01 CA064786-05, U54 CA126552, U54 CA143836-01, U54 CA112970, U54 CA126552-01, R01 CA057621, U01 CA143233, R01 CA064786, R01 CA057621-07, U54 CA143836, U01 CA143233-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA112970, U54CA143836, U01CA143233, U54CA126552, R01CA064786, R01CA057621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Baeckstrom D, 2000, INT J ONCOL, V16, P1081; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Chausovsky A, 2000, ONCOGENE, V19, P878, DOI 10.1038/sj.onc.1203410; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harris J, 1999, DIS BREAST; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; HOWLETT AR, 1995, J CELL SCI, V108, P1945; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; LUCASSEN E, 1994, J CELL SCI, V107, P2919; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PETERSEN OW, 1993, P NATL ACAD SCI USA, V90, P2556; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PIERCE JH, 1991, ONCOGENE, V6, P1189; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SOULE HD, 1990, CANCER RES, V50, P6075; Spancake KM, 1999, CANCER RES, V59, P6042; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8	48	456	473	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					785	792		10.1038/ncb0901-785	http://dx.doi.org/10.1038/ncb0901-785			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533657	Green Submitted, Green Accepted			2022-12-25	WOS:000170979600011
J	Oota, H; Settheetham-Ishida, W; Tiwawech, D; Ishida, T; Stoneking, M				Oota, H; Settheetham-Ishida, W; Tiwawech, D; Ishida, T; Stoneking, M			Human mtDNA and Y-chromosome variation is correlated with matrilocal versus patrilocal residence	NATURE GENETICS			English	Article							MITOCHONDRIAL	Genetic differences among human populations are usually larger for the Y chromosome than for mtDNA(1-3). one possible explanation is the higher rate of female versus male migration due to the widespread phenomenon of patrilocality, in which the woman moves to her mate's residence after marriage. To test this hypothesis, we compare mtDNA and Y-chromosome variation in three matrilocal (in which the man moves to his mate's residence after marriage) and three patrilocal groups among the hill tribes of northern Thailand. Genetic diversity in these groups shows a striking correlation with residence pattern, supporting the role of sex-specific migration in influencing human genetic variation.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Khon Kaen Univ, Khon Kaen, Thailand; Natl Canc Inst, Bangkok, Thailand; Univ Tokyo, Sch Sci, Dept Biol Sci, Tokyo, Japan	Max Planck Society; Khon Kaen University; National Cancer Institute - Thailand; University of Tokyo	Stoneking, M (corresponding author), Max Planck Inst Evolutionary Anthropol, Inselstr 22, D-04103 Leipzig, Germany.			Tiwawech, Danai/0000-0002-5023-7888				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Bamshad M, 2001, GENOME RES, V11, P994, DOI 10.1101/gr.GR-1733RR; Bamshad MJ, 1998, NATURE, V395, P651, DOI 10.1038/27103; Burckhardt F, 1999, NUCLEIC ACIDS RES, V27, P138, DOI 10.1093/nar/27.1.138; Burton ML, 1996, CURR ANTHROPOL, V37, P87, DOI 10.1086/204474; Jorde LB, 2000, AM J HUM GENET, V66, P979, DOI 10.1086/302825; Kimura M, 1998, HUM BIOL, V70, P993; Nei M., 1987, MOL EVOLUTIONARY GEN; Perez-Lezaun A, 1999, AM J HUM GENET, V65, P208, DOI 10.1086/302451; Salem AH, 1996, AM J HUM GENET, V59, P741; Seielstad MT, 1998, NAT GENET, V20, P278, DOI 10.1038/3088; SLATKIN M, 1995, GENETICS, V139, P457	12	223	229	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					20	21		10.1038/ng711	http://dx.doi.org/10.1038/ng711			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528385				2022-12-25	WOS:000170781300009
J	Sullivan, M; Lehane, C; Uhlmann, F				Sullivan, M; Lehane, C; Uhlmann, F			Orchestrating anaphase and mitotic exit: separase cleavage and localization of Slk19	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID SEPARATION; COHESIN SUBUNIT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME; SPINDLE; METAPHASE; GENES; PROTEOLYSIS; PROTEIN; CYCLE	Anaphase in budding yeast is triggered by cleavage of the central subunit, Sccl, of the chromosomal cohesin complex by the protease separase. Here we show that separase also cleaves the kinetochore-associated protein Slk19 at anaphase onset. Separase activity is also required for the proper localization of a stable Slk19 cleavage product to the spindle midzone in anaphase. The cleavage and localization of Slk19 are necessary to stabilize the anaphase spindle, and we show that a stable spindle is a prerequisite for timely exit from mitosis This demonstrates the cleavage of targets other than cohesin by separase in the orchestration of high-fidelity anaphase.	Imperial Canc Res Fund, Chromosome Segregat Lab, London WC2A 3PX, England	Cancer Research UK	Uhlmann, F (corresponding author), Imperial Canc Res Fund, Chromosome Segregat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	f.uhlmann@icrf.icnet.uk		Uhlmann, Frank/0000-0002-3527-6619	Cancer Research UK [A3592] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Jensen S, 2001, J CELL BIOL, V152, P27, DOI 10.1083/jcb.152.1.27; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rose M, 1990, LAB COURSE MANUAL ME; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2001, EMBO REP, V2, P487, DOI 10.1093/embo-reports/kve113; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; Winey M, 2001, NAT CELL BIOL, V3, pE23, DOI 10.1038/35050663; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415	36	120	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					771	777		10.1038/ncb0901-771	http://dx.doi.org/10.1038/ncb0901-771			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533655	Green Accepted			2022-12-25	WOS:000170979600009
J	Fradelizi, J; Noireaux, V; Plastino, J; Menichi, B; Louvard, D; Sykes, C; Golsteyn, RM; Friederich, E				Fradelizi, J; Noireaux, V; Plastino, J; Menichi, B; Louvard, D; Sykes, C; Golsteyn, RM; Friederich, E			ActA and human zyxin harbour Arp2/3-independent actin-polymerization activity	NATURE CELL BIOLOGY			English	Article							PROLINE-RICH REGION; LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; STIMULATED PHOSPHOPROTEIN; WASP/SCAR PROTEINS; ENA/VASP FAMILY; CELL MOTILITY; FILAMENTS; DOMAIN; ORGANIZATION	The actin cytoskeleton is a dynamic network that is composed of a variety of F-actin structures. To understand how these structures are produced, we tested the capacity of proteins to direct actin polymerization in a bead assay in vitro and in a mitochondrial-targeting assay in cells. We found that human zyxin and the related protein ActA of Listeria monocytogenes can generate new actin structures in a vasodilator-stimulated phosphoprotein-dependent (VASP) manner, but independently of the Arp2/3 complex. These results are consistent with the concept that there are multiple actin-polymerization machines in cells. With these simple tests it is possible to probe the specific function of proteins or identify novel molecules that act upon cellular actin polymerization.	Inst Curie, Lab Morphogenese & Signalisat Cellulaires, CNRS, UMR 144, F-75248 Paris 05, France; Inst Curie, Lab Physicochim Curie, CNRS, UMR 168, F-75248 Paris, France; Ctr Univ, CRP Sante, CNRS, Lab Franco Luxembourgeois Rech Biomed, L-1511 Luxembourg, Luxembourg	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Luxembourg Institute of Health; University of Luxembourg	Golsteyn, RM (corresponding author), Inst Curie, Lab Morphogenese & Signalisat Cellulaires, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Sykes, Cécile/B-1271-2016	Sykes, Cécile/0000-0003-3057-2600; noireaux, vincent/0000-0002-5213-273X; Plastino, Julie/0000-0002-7808-5927				Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fradelizi J, 1999, BIOTECHNIQUES, V26, P484; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; Golsteyn RM, 1997, J CELL SCI, V110, P1893; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KREIS TE, 1982, CELL, V29, P835, DOI 10.1016/0092-8674(82)90445-7; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Laurent V, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P359; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Machesky LM, 1997, BIOCHEM J, V328, P105; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; May RC, 1999, CURR BIOL, V9, P759, DOI 10.1016/S0960-9822(99)80337-6; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Noireaux V, 2000, BIOPHYS J, V78, P1643, DOI 10.1016/S0006-3495(00)76716-6; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sechi AS, 1997, J CELL BIOL, V137, P155, DOI 10.1083/jcb.137.1.155; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; van Oudenaarden A, 1999, NAT CELL BIOL, V1, P493, DOI 10.1038/70281; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; ZHUKAREV V, 1995, CELL MOTIL CYTOSKEL, V30, P229, DOI 10.1002/cm.970300307; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	45	95	99	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					699	707		10.1038/35087009	http://dx.doi.org/10.1038/35087009			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483954				2022-12-25	WOS:000170393200014
J	Shimizu, Y; Inoue, A; Tomari, Y; Suzuki, T; Yokogawa, T; Nishikawa, K; Ueda, T				Shimizu, Y; Inoue, A; Tomari, Y; Suzuki, T; Yokogawa, T; Nishikawa, K; Ueda, T			Cell-free translation reconstituted with purified components	NATURE BIOTECHNOLOGY			English	Article							UNNATURAL AMINO-ACIDS; ESCHERICHIA-COLI; MESSENGER-RNA; FREE SYSTEM; PROTEIN; INVITRO; GENE; SITE	We have developed a protein-synthesizing system reconstituted from recombinant tagged protein factors purified to homogeneity. The system was able to produce protein at a rate of about 160 mug/ml/h in a batch mode without the need for any supplementary apparatus. The protein products were easily purified within 1 h using affinity chromatography to remove the tagged protein factors. Moreover, omission of a release factor allowed efficient incorporation of an unnatural amino acid using suppressor transfer RNA (tRNA).	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan	University of Tokyo; University of Tokyo; Gifu University	Ueda, T (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bldg FSB401,5-1-5 Kasiwanoha, Kashiwa, Chiba 2778562, Japan.		Shimizu, Yoshihiro/A-6472-2016; Tomari, Yukihide/A-8009-2009; Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Shimizu, Yoshihiro/0000-0003-3499-1394; Tomari, Yukihide/0000-0001-8442-0851; Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731				ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BENNE R, 1972, BIOCHIM BIOPHYS ACTA, V269, P304, DOI 10.1016/0005-2787(72)90440-6; GANOZA MC, 1985, P NATL ACAD SCI USA, V82, P1648, DOI 10.1073/pnas.82.6.1648; GLICK BR, 1975, P NATL ACAD SCI USA, V72, P4257, DOI 10.1073/pnas.72.11.4257; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jermutus L, 1998, CURR OPIN BIOTECH, V9, P534, DOI 10.1016/S0958-1669(98)80042-6; Kim DM, 1996, EUR J BIOCHEM, V239, P881, DOI 10.1111/j.1432-1033.1996.0881u.x; Kim DM, 1996, BIOTECHNOL PROGR, V12, P645, DOI 10.1021/bp960052l; Kitaoka Y, 1996, J BIOTECHNOL, V48, P1, DOI 10.1016/0168-1656(96)01389-2; KOSSEL H, 1970, BIOCHIM BIOPHYS ACTA, V204, P191, DOI 10.1016/0005-2787(70)90502-2; KUNG H, 1977, J BIOL CHEM, V252, P6889; Lu J, 1999, INT J BIOCHEM CELL B, V31, P215, DOI 10.1016/S1357-2725(98)00142-3; Matveev SV, 1996, BBA-PROTEIN STRUCT M, V1293, P207, DOI 10.1016/0167-4838(95)00244-8; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OLINS PO, 1989, J BIOL CHEM, V264, P16973; Pavlov MY, 1996, ARCH BIOCHEM BIOPHYS, V328, P9, DOI 10.1006/abbi.1996.0136; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; POE M, 1972, BIOCHEMISTRY-US, V11, P1023, DOI 10.1021/bi00756a012; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHLEIF RF, 1971, J MOL BIOL, V61, P275, DOI 10.1016/0022-2836(71)90226-9; Short GF, 1999, BIOCHEMISTRY-US, V38, P8808, DOI 10.1021/bi990281r; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; STIEGE W, 1995, J BIOTECHNOL, V41, P81, DOI 10.1016/0168-1656(95)00005-B; WAGNER EGH, 1982, EUR J BIOCHEM, V122, P193, DOI 10.1111/j.1432-1033.1982.tb05866.x	26	1219	1312	5	195	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					751	755		10.1038/90802	http://dx.doi.org/10.1038/90802			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479568				2022-12-25	WOS:000170188600026
J	Ono, T; Isobe, K; Nakada, K; Hayashi, JI				Ono, T; Isobe, K; Nakada, K; Hayashi, JI			Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria	NATURE GENETICS			English	Letter							DEGENERATIVE DISEASES; MOUSE MTDNA; HUMAN BRAIN; MUTATIONS; RECOMBINATION; EMBRYOGENESIS; ELIMINATION; ORGANELLES; DELETIONS; GENETICS	Extensive complementation between fused mitochondria is indicated by recombination of 'parental' mitochondrial (mt) DNA (refs, 1,2) of yeast and plant cells. It has been difficult, however, to demonstrate the occurrence of complementation between fused mitochondria in mammalian species through the presence of recombinant mtDNA molecules(3), because sequence of mtDNA throughout an individual tends to be uniform(4) owing to its strictly maternal inheritance(5-7). We isolated two types of respiration-deficient cell lines, with pathogenic mutations in mitochondrial tRNA(lle) or tRNA(Leu(UUR)) genes from patients with mitochondrial diseases. The coexistence of their mitochondria within hybrids restored their normal morphology and respiratory enzyme activity by 10-14 days after fusion, indicating the presence of an extensive and continuous exchange of genetic contents between the mitochondria. This complementation between fused mitochondria may represent a defence of highly oxidative organelles against mitochondrial dysfunction caused by the accumulation of mtDNA lesions with age.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.							BELLIARD G, 1979, NATURE, V281, P401, DOI 10.1038/281401a0; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DUJON B, 1974, GENETICS, V78, P415; Enriquez JA, 2000, J BIOL CHEM, V275, P11207, DOI 10.1074/jbc.275.15.11207; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1985, EXP CELL RES, V160, P387, DOI 10.1016/0014-4827(85)90185-5; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446; Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Lightowlers RH, 1999, TRENDS GENET, V15, P91, DOI 10.1016/S0168-9525(98)01684-9; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MONNAT RJ, 1986, GENE, V43, P205, DOI 10.1016/0378-1119(86)90208-8; Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7; NAKADA K, IN PRESS NATURE MED; NONAKA I, 1989, J NEUROL SCI, V92, P193, DOI 10.1016/0022-510X(89)90136-6; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shitara H, 2000, GENETICS, V156, P1277; Shitara H, 1998, GENETICS, V148, P851; SOONG NW, 1992, NAT GENET, V2, P318; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	29	316	322	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					272	275		10.1038/90116	http://dx.doi.org/10.1038/90116			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431699				2022-12-25	WOS:000169656400021
J	Xie, MT; He, YH; Gan, SS				Xie, MT; He, YH; Gan, SS			Bidirectionalization of polar promoters in plants	NATURE BIOTECHNOLOGY			English	Article							ARABIDOPSIS-THALIANA; TRANSGENIC PLANTS; EXPRESSION; TRANSFORMATION; TRANSCRIPTION; VECTORS; INVITRO; RNA	A typical eukaryotic promoter consists of a minimal promoter and other upstream cis elements(1-3). The minimal promoter is essentially a TATA box region where RNA polymerase II, TATA-binding protein (TBP), and TBP-associated factors (TAFs) bind to initiate transcription(4), but minimal promoters alone have no transcriptional activity(1). The cis elements, to which tissue-specific or development-specific transcription factors bind, individually or in combination, determine the spatio-temporal expression pattern of a promoter at the transcriptional level(1). The arrangement of upstream cis elements followed by a minimal promoter sets the polarity of the promoter. Promoters in plants that have been cloned and widely used for both basic research and biotechnological application are generally unidirectional, directing only one gene that has been fused at its 3' end (downstream). It is often necessary to introduce multiple genes into plants for metabolic engineering and trait stacking(5). It is also desirable to minimize or avoid repeated use of a single promoter that may cause transcriptional gene silencing(6). Here we describe a strategy to make polar promoters bidirectional so that one promoter can direct the expression of two genes, one on each end of the promoter.	Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA; Univ Kentucky, Tobacco & Hlth Res Inst, Lexington, KY 40546 USA	University of Kentucky; University of Kentucky	Gan, SS (corresponding author), Univ Kentucky, Dept Agron, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA.		HE, Yuehui/H-9795-2012; HE, Yuehui/Y-8792-2018	HE, Yuehui/0000-0003-3304-4555; HE, Yuehui/0000-0003-3304-4555; Xie, Mingtang/0000-0002-2797-0598				AN G, 1987, METHOD ENZYMOL, V153, P292; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Biesgen C, 1999, PLANTA, V208, P155, DOI 10.1007/s004250050545; Dasgupta S, 1998, PLANT J, V16, P107, DOI 10.1046/j.1365-313x.1998.00255.x; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; De Wilde C, 2000, PLANT MOL BIOL, V43, P347, DOI 10.1023/A:1006464304199; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257, DOI 10.1093/nar/15.8.3257; GAN S, 1995, THESIS U WISCONSIN M; GAN SS, 1995, SCIENCE, V270, P1986, DOI 10.1126/science.270.5244.1986; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Holtorf S, 1995, PLANT MOL BIOL, V29, P637, DOI 10.1007/BF00041155; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; Lewin B, 1997, GENES; Maiti IB, 1998, BIOCHEM BIOPH RES CO, V244, P440, DOI 10.1006/bbrc.1998.8287; Sambrook J., 2002, MOL CLONING LAB MANU; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	20	56	81	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					677	679		10.1038/90296	http://dx.doi.org/10.1038/90296			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433282				2022-12-25	WOS:000169677200026
J	Altucci, L; Rossin, A; Raffelsberger, W; Reitmair, A; Chomienne, C; Gronemeyer, H				Altucci, L; Rossin, A; Raffelsberger, W; Reitmair, A; Chomienne, C; Gronemeyer, H			Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NF-KAPPA-B; 13-CIS-RETINOIC ACID; INTERFERON ALPHA-2A; RECEPTOR; CASPASE-8; DIFFERENTIATION; MATURATION; ACTIVATION; INDUCTION	The therapeutic and preventive activities of retinoids in cancer are due to their ability to modulate the growth, differentiation, and survival or apoptosis of cancer cells. Here we show that in NB4 acute promyelocyeic leukemia cells, retinoids selective for retinoic-acid receptor-alpha induced an autoregulatory circuitry of survival programs followed by expression of the membrane-bound tumor-selective death ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand, also called Apo-2L). In a paracrine mode of action, TRAIL killed NB4 as well as heterologous and retinoic-acid-resistant cells. In the leukemic blasts of freshly diagnosed acute promyelocytic leukemia patients, retinoic-acid-induced expression of TRAIL most likely caused blast apoptosis. Thus, induction of TRAIL-mediated death signaling appears to contribute to the therapeutic value of retinoids.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, CU de Strasbourg, France; Hop St Louis, LBCH, Inst Hematol, Paris, France; Univ Naples 2, Ist Patol Gen & Oncol, Naples, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Universita della Campania Vanvitelli	Gronemeyer, H (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, CU de Strasbourg, France.		Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Altucci, Lucia/S-8031-2019; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; altucci, lucia/0000-0002-7312-5387; CHOMIENNE, Christine/0000-0001-5513-5752; Rossin, Aurelie/0000-0002-6110-1249				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BONHOMME L, 1991, ANN ONCOL, V2, P234, DOI 10.1093/oxfordjournals.annonc.a057916; BRUEL A, 1995, LEUKEMIA, V9, P1173; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOMIENNE C, 1990, BLOOD, V76, P1710; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; Gehin M, 1999, CHEM BIOL, V6, P519, DOI 10.1016/S1074-5521(99)80084-2; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; *INT AG RES CANC, 1999, IARC HDB CANC PREV, V4; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LANOTTE M, 1991, BLOOD, V77, P1080; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Moreb JS, 1997, LEUKEMIA, V11, P998, DOI 10.1038/sj.leu.2400719; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Slack JL, 1999, CANC TREAT, V99, P75; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 2000, CANCER RES, V60, P7149; TUCKER KA, 1987, BLOOD, V70, P372; VERMA AK, 1987, CANCER RES, V47, P5097; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zamai L, 2000, BLOOD, V95, P3716; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	294	307	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					680	686		10.1038/89050	http://dx.doi.org/10.1038/89050			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385504				2022-12-25	WOS:000169081500035
J	Makowski, L; Boord, JB; Maeda, K; Babaev, VR; Uysal, KT; Morgan, MA; Parker, RA; Suttles, J; Fazio, S; Hotamisligil, GS; Linton, MF				Makowski, L; Boord, JB; Maeda, K; Babaev, VR; Uysal, KT; Morgan, MA; Parker, RA; Suttles, J; Fazio, S; Hotamisligil, GS; Linton, MF			Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis	NATURE MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; BONE-MARROW TRANSPLANTATION; ACTIVATED RECEPTOR-GAMMA; FOAM CELL-FORMATION; PPAR-GAMMA; INSULIN-RESISTANCE; GENE-EXPRESSION; CHOLESTEROL ACYLTRANSFERASE; HUMAN MONOCYTES; OXIDIZED LDL	The adipocyte fatty-acid-binding protein, aP2, has an important role in regulating systemic insulin resistance and lipid metabolism. Here we demonstrate that aP2 is also expressed in macrophages, has a significant role in their biological responses and contributes to the development of atherosclerosis. Apolipoprotein E (ApoE)-deficient mice also deficient for aP2 showed protection from atherosclerosis in the absence of significant differences in serum lipids or insulin sensitivity. aP2-deficient macrophages showed alterations in inflammatory cytokine production and a reduced ability to accumulate cholesterol esters when exposed to modified lipoproteins. Apoe(-/-) mice with Ap2(+/+) adipocytes and Ap2(-/-) macrophages generated by bone-marrow transplantation showed a comparable reduction in atherosclerotic lesions to those with total aP2 deficiency, indicating an independent role for macrophage aP2 in atherogenesis. Through its distinct actions in adipocytes and macrophages, aP2 provides a link between features of the metabolic syndrome and could be a new therapeutic target for the prevention of atherosclerosis.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37240 USA; Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Bristol Myers Squibb PRI, Dept Metab Res, Princeton, NJ USA; Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA	Vanderbilt University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University; Vanderbilt University; Bristol-Myers Squibb; University of Louisville	Linton, MF (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37240 USA.			Makowski, Liza/0000-0002-5337-8037	NHLBI NIH HHS [R01 HL065405, F32 HL075970, HL65405-01] Funding Source: Medline; NIDDK NIH HHS [T32 DK7061, T32 DK007061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL075970, R01HL065405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007061] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1991, J LIPID RES, V32, P1449; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Babaev VR, 2000, J BIOL CHEM, V275, P26293, DOI 10.1074/jbc.M002423200; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BROWN WJ, 1988, ARCH PATHOL LAB MED, V112, P295; Coe NR, 1999, J LIPID RES, V40, P967; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; DAVIS PJ, 1992, BIOCHEM CELL BIOL, V70, P1313, DOI 10.1139/o92-178; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Fazio S, 1997, J LIPID RES, V38, P391; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Fu YC, 2000, J LIPID RES, V41, P2017; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KIENER PA, 1995, J IMMUNOL, V155, P4917; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Linton MF, 1999, J BIOL CHEM, V274, P19204, DOI 10.1074/jbc.274.27.19204; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RUMSEY SC, 1995, J BIOL CHEM, V270, P10008, DOI 10.1074/jbc.270.17.10008; Scheja L, 1999, DIABETES, V48, P1987, DOI 10.2337/diabetes.48.10.1987; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Uysal KT, 1998, ENDOCRINOLOGY, V139, P4832, DOI 10.1210/en.139.12.4832; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	539	571	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					699	705		10.1038/89076	http://dx.doi.org/10.1038/89076			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385507	Green Accepted			2022-12-25	WOS:000169081500038
J	Pola, R; Ling, LE; Silver, M; Corbley, MJ; Kearney, M; Pepinsky, RB; Shapiro, R; Taylor, FR; Baker, DP; Asahara, T; Isner, JM				Pola, R; Ling, LE; Silver, M; Corbley, MJ; Kearney, M; Pepinsky, RB; Shapiro, R; Taylor, FR; Baker, DP; Asahara, T; Isner, JM			The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors	NATURE MEDICINE			English	Article							KINESIN-RELATED PROTEIN; SIGNALING PATHWAY; REGULATES PROLIFERATION; NEGATIVE REGULATOR; LIMB DEVELOPMENT; HAIR DEVELOPMENT; GENE-EXPRESSION; COUP-TFII; SUPPRESSOR; VEGF	Sonic hedgehog (Shh) is a prototypical morphogen known to regulate epithelial/mesenchymal interactions during embryonic development. We found that the hedgehog-signaling pathway is present in adult cardiovascular tissues and can be activated in vivo. Shh was able to induce robust angiogenesis, characterized by distinct large-diameter vessels. Shh also augmented blood-flow recovery and limb salvage following operatively induced hind-limb ischemia in aged mice. In vitro, Shh had no effect on endothelial-cell migration or proliferation; instead, it induced expression of two families of angiogenic cytokines, including all three vascular endothelial growth factor-1 isoforms and angiopoietins-1 and -2 from interstitial mesenchymal cells. These findings reveal a novel role for Shh as an indirect angiogenic factor regulating expression of multiple angiogenic cytokines and indicate that Shh might have potential therapeutic use for ischemic disorders.	Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr, Boston, MA 02111 USA; Biogen Inc, Cambridge, MA 02142 USA	St. Elizabeth's Medical Center; Tufts University; Biogen	Isner, JM (corresponding author), Tufts Univ, Sch Med, Dept Med, St Elizabeths Med Ctr, Boston, MA 02111 USA.			Pola, Roberto/0000-0001-5224-2931				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cho CS, 2000, J IMMUNOL, V164, P5055, DOI 10.4049/jimmunol.164.10.5055; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KALDERON D, 1997, CURR BIOL, V7, P759; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Mecklenburg L, 2000, J INVEST DERMATOL, V114, P909, DOI 10.1046/j.1523-1747.2000.00954.x; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Parmantier E, 1999, NEURON, V23, P713, DOI 10.1016/S0896-6273(01)80030-1; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Scheid A, 2000, PEDIATR SURG INT, V16, P232, DOI 10.1007/s003830050735; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stone DM, 1999, J CELL SCI, V112, P4437; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164; VOLPERT OV, 1997, ONCOGENE, V14, P1492; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; Williams KP, 1999, J CELL SCI, V112, P4405; Zardoya R, 1996, TRENDS GENET, V12, P496, DOI 10.1016/S0168-9525(96)20014-9; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	45	494	532	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					706	711		10.1038/89083	http://dx.doi.org/10.1038/89083			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385508				2022-12-25	WOS:000169081500039
J	Sasaki, S; Amara, RR; Oran, AE; Smith, JM; Robinson, HL				Sasaki, S; Amara, RR; Oran, AE; Smith, JM; Robinson, HL			Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases	NATURE BIOTECHNOLOGY			English	Article							INFLUENZA-VIRUS; DENDRITIC CELLS; HEMAGGLUTININ; PRECURSOR; PRODOMAIN; VACCINES; REQUIRES; ANTIBODY; ANTIGEN; GENE	Apoptotic bodies can be used to target delivery of DNA-expressed immunogens into professional antigen-presenting cells (APCs). Here we show that antigen-laden apoptotic bodies created by vectors co-expressing influenza virus hemagglutinin (HA) or nucleoprotein (NP) genes and mutant caspase genes markedly increased T-cell responses. Both CD8 and CD4 T-cell responses were affected. The adjuvant activity was restricted to partially inactivated caspases that allowed immunogen expression before the generation of apoptotic bodies. Active-site mutants of murine caspase 2 and an autocatalytic chimera of murine caspase 2 prodomain and human caspase 3 induced apoptosis that did not interfere with immunogen expression. The adjuvant activity also enhanced B-cell responses, but to a lesser extent than T-cell responses. The large increases in T-cell responses represent one of the strongest effects to date of a DNA adjuvant on cellular immunity.	Emory Univ, Yerkes Reg Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30329 USA	Emory University	Robinson, HL (corresponding author), Emory Univ, Yerkes Reg Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30329 USA.	hrobins@rmy.emory.edu	Amara, Rama/AAO-8136-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034946] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00165] Funding Source: Medline; NIAID NIH HHS [R01AI34946] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chattergoon MA, 2000, NAT BIOTECHNOL, V18, P974, DOI 10.1038/79470; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; GAO XM, 1989, J IMMUNOL, V143, P3007; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Holmgren L, 1999, BLOOD, V93, P3956, DOI 10.1182/blood.V93.11.3956.411k05_3956_3963; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pertmer TM, 2000, J VIROL, V74, P7787, DOI 10.1128/JVI.74.17.7787-7793.2000; Robinson Harriet L., 1997, Journal of Infectious Diseases, V176, pS50, DOI 10.1086/514176; Robinson HL, 2000, ADV VIRUS RES, V55, P1, DOI 10.1016/S0065-3527(00)55001-5; Ross TM, 2000, NAT IMMUNOL, V1, P127, DOI 10.1038/77802; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Spetz AL, 1999, J IMMUNOL, V163, P736; Torres CAT, 1999, VACCINE, V18, P805, DOI 10.1016/S0264-410X(99)00345-X; Waldrop SL, 1998, J IMMUNOL, V161, P5284; WINTER G, 1981, NATURE, V292, P72, DOI 10.1038/292072a0	22	106	120	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					543	547		10.1038/89289	http://dx.doi.org/10.1038/89289			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385458				2022-12-25	WOS:000169081700027
J	Yarema, KJ; Goon, S; Bertozzi, CR				Yarema, KJ; Goon, S; Bertozzi, CR			Metabolic selection of glycosylation defects in human cells	NATURE BIOTECHNOLOGY			English	Article							POLYMERASE CHAIN-REACTION; ACID STORAGE DISEASE; ADHESION MOLECULE; POLYSIALIC ACID; PROTEIN GLYCOSYLATION; SIALIC ACIDS; EXPRESSION; CANCER; BIOSYNTHESIS; SURFACE	Changes in glycosylation are often associated with disease progression, but the genetic and metabolic basis of these events is rarely understood in detail at a molecular level. We describe a metabolism-based approach to the selection of mutants in glycoconjugate biosynthesis that provides insight into regulatory mechanisms for oligosaccharide expression and metabolic flux. Unnatural intermediates are used to challenge a specific pathway, and cell surface expression of their metabolic products provides a readout of flux in that pathway and a basis for selecting genetic mutants. The approach was applied to the sialic acid metabolic pathway in human cells, yielding novel mutants with phenotypes related to the inborn metabolic defect sialuria and metastatic tumor cells.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Ctr Adv Mat, Div Mat Sci, Berkeley, CA 94720 USA; Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Howard Hughes Medical Institute	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Yarema, Kevin/A-3329-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM058867, R01GM058867] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58867-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axford JS, 1999, BBA-MOL BASIS DIS, V1455, P219, DOI 10.1016/S0925-4439(99)00057-5; Bellgard MI, 1999, ANN NY ACAD SCI, V870, P293, DOI 10.1111/j.1749-6632.1999.tb08891.x; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Durand G, 2000, CLIN CHEM, V46, P795; Fabb SA, 1997, BIOTECHNIQUES, V22, P814, DOI 10.2144/97225bm05; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; HALE LP, 1995, PEDIATR PATHOL LAB M, V15, P443, DOI 10.3109/15513819509026980; Halford WP, 1999, ANAL BIOCHEM, V266, P181, DOI 10.1006/abio.1998.2913; Hang HC, 2001, J AM CHEM SOC, V123, P1242, DOI 10.1021/ja002962b; JALANKO A, 1988, BIOCHIM BIOPHYS ACTA, V949, P206, DOI 10.1016/0167-4781(88)90084-X; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kameda K, 1999, CANCER LETT, V137, P201, DOI 10.1016/S0304-3835(98)00359-0; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Kukuruzinska MA, 1998, CRIT REV ORAL BIOL M, V9, P415, DOI 10.1177/10454411980090040301; Lemyre E, 1999, AM J MED GENET, V82, P385, DOI 10.1002/(SICI)1096-8628(19990219)82:5<385::AID-AJMG6>3.3.CO;2-V; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; MACKIEWICZ A, 1995, GLYCOCONJUGATE J, V12, P241, DOI 10.1007/BF00731326; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Nakayama J, 1998, PATHOL INT, V48, P665, DOI 10.1111/j.1440-1827.1998.tb03967.x; Orntoft TF, 1999, ELECTROPHORESIS, V20, P362, DOI 10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.3.CO;2-M; PERERA AD, 1993, ENDOCRINOLOGY, V133, P2729, DOI 10.1210/en.133.6.2729; Ronn LCB, 2000, INT J DEV NEUROSCI, V18, P193, DOI 10.1016/S0736-5748(99)00088-X; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; SELL S, 1990, HUM PATHOL, V21, P1003, DOI 10.1016/0046-8177(90)90250-9; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; Sillanaukee P, 1999, EUR J CLIN INVEST, V29, P413; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; TAATJES DJ, 1988, HISTOCHEM J, V20, P478, DOI 10.1007/BF01002646; THOMAS GH, 1989, CLIN GENET, V36, P242; WANG WC, 1988, J BIOL CHEM, V263, P4576; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168; Zimmermann K, 1996, BIOTECHNIQUES, V21, P268	34	56	59	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					553	558		10.1038/89305	http://dx.doi.org/10.1038/89305			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385460				2022-12-25	WOS:000169081700029
J	Ferrigno, O; Virolle, T; Djabari, Z; Ortonne, JP; White, RJ; Aberdam, D				Ferrigno, O; Virolle, T; Djabari, Z; Ortonne, JP; White, RJ; Aberdam, D			Transposable B2SINE elements can provide mobile RNA polymerase II promoters	NATURE GENETICS			English	Article							HUMAN GENOME; TRANSCRIPTION; GENE; INITIATOR; SEQUENCE; DNA; ALU; USF; FAMILIES; REPEAT	Short interspersed elements (SINEs) are highly abundant components of mammalian genomes that are propagated by retrotransposition. SINEs are recognized as a causal agent of human disease and must also have had a profound influence in shaping eukaryotic genomes(1). The B2 SINE family constitutes approximately 0.7% of total mouse genomic DNA(ref, 2) and is also found at low abundance in humans(3) It resembles the Alufamily in several respects, such as its mechanism of propagation. BZ SINEs are derived from tRNA and are transcribed by RNA polymerase (pol) III to generate short transcripts that are not translated(4,5). We find here, however, that one B2 SINE also carries an active pol II promoter located outside the tRNA region. Indeed, a B2 element is responsible for the production of a mouse Lama3 transcript. The B2 pol Il promoters can be bound and stimulated by the transcription factor USF (for upstream stimulatory factor), as shown by transient transfection experiments. Moreover, this pol II activity does not preclude the pol III transcription necessary for retrotransposition(6). Dispersal of BZ SINEs by retrotransposition may therefore have provided numerous opportunities for creating regulated pol II transcription at novel genomic sites. This mechanism may have allowed the evolution of new transcription units and new genes.	Fac Med, INSERM, U385, Nice, France; Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Glasgow	Aberdam, D (corresponding author), Fac Med, INSERM, U385, Nice, France.		Virolle, Thierry/E-5838-2016; ferrigno, olivier/GSN-8581-2022; Aberdam, Daniel/G-3299-2013	ferrigno, olivier/0000-0001-7544-4384; Aberdam, Daniel/0000-0002-4019-5418				ABERDAM D, 2000, LAMININS, P228; BENNETT KL, 1984, MOL CELL BIOL, V4, P1561, DOI 10.1128/MCB.4.8.1561; BRINI AT, 1993, J BIOL CHEM, V268, P1355; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; CHANDRASEKARAN B, 1992, IEEE EXPERT, V7, P2; Chen YL, 1998, T NONFERR METAL SOC, V8, P5; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FEHLING HJ, 1995, IMMUNOGENETICS, V42, P275, DOI 10.1007/BF00176445; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; Makalowski W., 1995, IMPACT SHORT INTERSP, P81; Marinoni JC, 1997, METHODS, V12, P235, DOI 10.1006/meth.1997.0476; Mayorov VI, 2000, MAMM GENOME, V11, P177, DOI 10.1007/s003350010033; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; REHN M, 1994, J BIOL CHEM, V269, P13929; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAKAMOTO K, 1985, J MOL EVOL, V22, P134, DOI 10.1007/BF02101691; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; Vailly J, 1998, GENE THER, V5, P1322, DOI 10.1038/sj.gt.3300730; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	24	91	94	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					77	81		10.1038/ng0501-77	http://dx.doi.org/10.1038/ng0501-77			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326281				2022-12-25	WOS:000168413300021
J	Bulte, JWM; Douglas, T; Witwer, B; Zhang, SC; Strable, E; Lewis, BK; Zywicke, H; Miller, B; van Gelderen, P; Moskowitz, BM; Duncan, ID; Frank, JA				Bulte, JWM; Douglas, T; Witwer, B; Zhang, SC; Strable, E; Lewis, BK; Zywicke, H; Miller, B; van Gelderen, P; Moskowitz, BM; Duncan, ID; Frank, JA			Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells	NATURE BIOTECHNOLOGY			English	Article							MR CONTRAST AGENT; POLYAMIDOAMINE DENDRIMERS; MAMMALIAN-CELLS; GENE DELIVERY; IN-VIVO; RAT; RELAXOMETRY; GENERATION; PEPTIDE; BRAIN	Magnetic resonance (MR) tracking of magnetically labeled stem and progenitor cells is an emerging technology, leading to an urgent need for magnetic probes that can make cells highly magnetic during their normal expansion in culture. We have developed magnetodendrimers as a versatile class of magnetic tags that can efficiently label mammalian cells, including human neural stem cells (NSCs) and mesenchymal stem cells (MSCs), through a nonspecific membrane adsorption process with subsequent intracellular (non-nuclear) localization in endosomes. The superparamagnetic iron oxide nanocomposites have been optimized to exhibit superior magnetic properties and to induce sufficient MR cell contrast at incubated doses as low as 1 mug iron/ml culture medium. When containing between 9 and 14 pg iron/cell, labeled cells exhibit an ex vivo nuclear magnetic resonance (NMR) relaxation rate (1/T2) as high as 24-39 s(-1)/mM iron. Labeled cells are unaffected in their viability and proliferating capacity, and labeled human NSCs differentiate normally into neurons. Furthermore, we show here that NSC-derived (and LacZ-transfected), magnetically labeled oligodendroglial progenitors can be readily detected in vivo at least as long as six weeks after transplantation, with an excellent correlation between the obtained MR contrast and staining for beta -galactosidase expression. The availability of magnetodendrimers opens up the possibility of MR tracking of a wide variety of (stem) cell transplants.	NIH, Lab Diagnost Radiol Res CC, Bethesda, MD 20892 USA; Temple Univ, Dept Chem, Philadelphia, PA 19122 USA; Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53705 USA; NINCDS, Adv Magnet Resonance Imaging, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Geol & Geophys, Inst Rock Magnetism, Minneapolis, MN 55455 USA	National Institutes of Health (NIH) - USA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Minnesota System; University of Minnesota Twin Cities	Bulte, JWM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA.		Douglas, Trevor/GRS-0012-2022; Miller, Bradley/G-7426-2014; van Gelderen, Peter/U-4535-2019; Bulte, Jeff W.M./A-3240-2008; Frank, Joseph/W-2021-2019; Douglas, Trevor/F-2748-2011	Douglas, Trevor/0000-0002-7882-2704; Bulte, Jeff W.M./0000-0003-1202-1610; 	CLINICAL CENTER [Z01CL090005, Z01CL090004, ZIACL090004] Funding Source: NIH RePORTER	CLINICAL CENTER		ADAM G, 1994, JMRI-J MAGN RESON IM, V4, P462, DOI 10.1002/jmri.1880040336; Balogh L, 1998, J AM CHEM SOC, V120, P7355, DOI 10.1021/ja980861w; Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d; Bourne MW, 1996, JMRI-J MAGN RESON IM, V6, P305, DOI 10.1002/jmri.1880060209; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Bryant LH, 1999, JMRI-J MAGN RESON IM, V9, P348, DOI 10.1002/(SICI)1522-2586(199902)9:2<348::AID-JMRI30>3.0.CO;2-J; Bulte JWM, 1998, INVEST RADIOL, V33, P841, DOI 10.1097/00004424-199811000-00008; Bulte JWM, 1997, MAGN RESON MED, V37, P530, DOI 10.1002/mrm.1910370409; BULTE JWM, 1993, J NEURO-ONCOL, V16, P11, DOI 10.1007/BF01324829; Bulte JWM, 2001, FOCUS BIOTECHNOL, V7, P197; Bulte JWM, 1999, MAGN RESON MED, V42, P379, DOI 10.1002/(SICI)1522-2594(199908)42:2<379::AID-MRM20>3.0.CO;2-L; Bulte JWM, 1997, SCIENTIFIC AND CLINICAL APPLICATIONS OF MAGNETIC CARRIERS, P527; Bulte JWM, 1999, P NATL ACAD SCI USA, V96, P15256, DOI 10.1073/pnas.96.26.15256; DeLong R, 1997, J PHARM SCI, V86, P762, DOI 10.1021/js960409f; Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Krause W, 2000, TOP CURR CHEM, V210, P261; KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; O'Connor LT, 1999, J NEUROSCI, V19, P3404; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; SCHWICKERT HC, 1995, EUR J RADIOL, V20, P144, DOI 10.1016/0720-048X(95)00645-7; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SHEN T, 1993, MAGN RESON MED, V29, P599, DOI 10.1002/mrm.1910290504; Strable E, 2001, CHEM MATER, V13, P2201, DOI 10.1021/cm010125i; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WIENER EC, 1994, MAGNET RESON MED, V31, P1, DOI 10.1002/mrm.1910310102; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zhang SC, 1998, J NEUROCYTOL, V27, P475, DOI 10.1023/A:1006953023845; Zhang ZY, 2000, BIOCONJUGATE CHEM, V11, P805, DOI 10.1021/bc000018z; Zhao MQ, 1998, J AM CHEM SOC, V120, P4877, DOI 10.1021/ja980438n; Zhao MQ, 1999, ANGEW CHEM INT EDIT, V38, P364, DOI 10.1002/(SICI)1521-3773(19990201)38:3<364::AID-ANIE364>3.0.CO;2-L	38	880	940	4	147	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1141	1147		10.1038/nbt1201-1141	http://dx.doi.org/10.1038/nbt1201-1141			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731783				2022-12-25	WOS:000172524400027
J	Holmes, SE; O'Hearn, E; Rosenblatt, A; Callahan, C; Hwang, HS; Ingersoll-Ashworth, RG; Fleisher, A; Stevanin, G; Brice, A; Potter, NT; Ross, CA; Margolis, RL				Holmes, SE; O'Hearn, E; Rosenblatt, A; Callahan, C; Hwang, HS; Ingersoll-Ashworth, RG; Fleisher, A; Stevanin, G; Brice, A; Potter, NT; Ross, CA; Margolis, RL			A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2	NATURE GENETICS			English	Article							TRINUCLEOTIDE REPEAT; GENOMIC DNA	We recently described a disorder termed Huntington disease-like 2 (HDL2) that completely segregates with an unidentified CAG/CTG expansion in a large pedigree (W)(1). We now report the cloning of this expansion and its localization to a variably spliced exon of JPH3 (encoding junctophilin-3), a gene involved in the formation of junctional membrane structures.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Hop La Pitie Salpetriere, INSERM U289, Paris, France; Univ Tennessee, Med Ctr, Dept Med Genet, Knoxville, TN USA; Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University	Margolis, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA.	rmargoli@jhmi.edu	brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009; Ross, Christopher A/H-8395-2013; Stevanin, Giovanni/E-5038-2016	brice, alexis/0000-0002-0941-3990; Stevanin, Giovanni/0000-0001-9368-8657; , Roxann/0000-0002-4266-613X; Hwang, Hyon Sung/0000-0001-8117-0199	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038054, P50NS016375, P01NS016375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16375, NS38054] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Margolis RL, 2001, ANN NEUROL, V50, P373, DOI 10.1002/ana.1124; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Nishi M, 2000, BIOCHEM BIOPH RES CO, V273, P920, DOI 10.1006/bbrc.2000.3011; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	10	193	203	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2001	29	4					377	378		10.1038/ng760	http://dx.doi.org/10.1038/ng760			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11694876				2022-12-25	WOS:000172507500009
J	Morris, MC; Depollier, J; Mery, J; Heitz, F; Divita, G				Morris, MC; Depollier, J; Mery, J; Heitz, F; Divita, G			A peptide carrier for the delivery of biologically active proteins into mammalian cells	NATURE BIOTECHNOLOGY			English	Article							HIV-1 TAT PROTEIN; TRANSDUCTION; DOMAIN; DNA	The development of peptide drugs and therapeutic proteins is limited by the poor permeability and the selectivity of the cell membrane. There is a growing effort to circumvent these problems by designing strategies to deliver full-length proteins into a large number of cells(1-3). A series of small protein domains, termed protein transduction domains (PTDs), have been shown to cross biological membranes efficiently and independently of transporters or specific receptors, and to promote the delivery of peptides and proteins into cells. TAT protein from human immunodeficiency virus (HIV-1) is able to deliver biologically active proteins in vivo and has been shown to be of considerable interest for protein therapeutics(4-9). Similarly, the third alpha -helix of Antennapedia homeodomain(10-12), and VP22 protein from herpes simplex virus(13,14) promote the delivery of covalently linked peptides or proteins into cells. However, these PTD vectors display a certain number of limitations in that they all require crosslinking to the target peptide or protein. Moreover, protein transduction using PTD-TAT fusion protein systems may require denaturation of the protein before delivery to increase the accessibility of the TAT-PTD domain. This requirement introduces an additional delay between the time of delivery and intracellular activation of the protein(1). In this report, we propose a new strategy for protein delivery based on a short amphipathic peptide carrier, Pep-1. This peptide carrier is able to efficiently deliver a variety of peptides and proteins into several cell lines in a fully biologically active form, without the need for prior chemical covalent coupling or denaturation steps. In addition, this peptide carrier presents several advantages or protein therapy, including stability in physiological buffer, lack of toxicity, and lack of sensitivity to serum. Pep-1 technology should be extremely useful for targeting specific protein-protein interactions in living cells and for screening novel therapeutic proteins.	CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Divita, G (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		DIVITA, GILLES/AAV-9214-2021; MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728				Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Morris MC, 1999, J BIOL CHEM, V274, P24941, DOI 10.1074/jbc.274.35.24941; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	20	828	1005	5	181	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1173	1176		10.1038/nbt1201-1173	http://dx.doi.org/10.1038/nbt1201-1173			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731788				2022-12-25	WOS:000172524400032
J	Evans, MJ				Evans, MJ			The cultural mouse	NATURE MEDICINE			English	Editorial Material									Cardiff Univ, Cardiff, S Glam, Wales	Cardiff University	Evans, MJ (corresponding author), Cardiff Univ, Biomed Sci Bldg,Museum Ave, Cardiff, S Glam, Wales.								0	32	41	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1081	1083		10.1038/nm1001-1081	http://dx.doi.org/10.1038/nm1001-1081			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590418				2022-12-25	WOS:000171524500013
J	Zhou, S; Schuetz, JD; Bunting, KD; Colapietro, AM; Sampath, J; Morris, JJ; Lagutina, I; Grosveld, GC; Osawa, M; Nakauchi, H; Sorrentino, BP				Zhou, S; Schuetz, JD; Bunting, KD; Colapietro, AM; Sampath, J; Morris, JJ; Lagutina, I; Grosveld, GC; Osawa, M; Nakauchi, H; Sorrentino, BP			The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype	NATURE MEDICINE			English	Article							BONE-MARROW-CELLS; HEMATOPOIETIC STEM; P-GLYCOPROTEIN; IN-VITRO; GENE-TRANSFER; EFFLUX PUMP; DYE EFFLUX; VIVO; RESISTANCE; PROGENITOR	Stem cells from bone marrow, skeletal muscle and possibly other tissues can be identified by the 'side-population' (SP) phenotype. Although it has been assumed that expression of ABC transporters is responsible for this phenotype, the specific molecules involved have not been defined. Here we show that expression of the Bcrp1 (also known as Abcg2 murine/ABCG2 human) gene is a conserved feature of stem cells from a wide variety of sources. Bcrp1 mRNA was expressed at high levels in primitive murine hematopoietic stem cells, and was sharply downregulated with differentiation. Enforced expression of the ABCG2 cDNA directly conferred the SP phenotype to bone-marrow cells and caused a reduction in maturing progeny both in vitro and in transplantation-based assays. These results show that expression of the Bcrp1/ABCG2 gene is an important determinant of the SP phenotype, and that it might serve as a marker for stem cells from various sources.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; Univ Tsukuba, Inst Basic Med Sci, Dept Immunol, Tsukuba, Ibaraki, Japan	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; University of Tsukuba	Sorrentino, BP (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Div Expt Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.	brian.sorrentino@stjude.org	Schuetz, John D/N-2692-2018	Zhou, Sheng/0000-0001-5902-5868	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749, R01HL067366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R29ES005851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060904, R56GM060904] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL 53749, R01 HL67366-01] Funding Source: Medline; NIEHS NIH HHS [ES05851] Funding Source: Medline; NIGMS NIH HHS [GM60904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allay JA, 1997, BLOOD, V90, P3546, DOI 10.1182/blood.V90.9.3546; Allay JA, 1998, NAT MED, V4, P1136, DOI 10.1038/2632; Bodine DM, 1996, BLOOD, V88, P89; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; DHondt V, 1997, HUM GENE THER, V8, P1745, DOI 10.1089/hum.1997.8.15-1745; Doyle LA, 1999, P NATL ACAD SCI USA, V96, P2569; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Good JR, 2000, DEV BIOL, V220, P53, DOI 10.1006/dbio.2000.9611; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hulspas R, 2000, CYTOMETRY, V40, P245, DOI 10.1002/1097-0320(20000701)40:3<245::AID-CYTO10>3.3.CO;2-X; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; KLIMECKI WT, 1995, J CLIN IMMUNOL, V15, P152, DOI 10.1007/BF01543107; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Maliepaard M, 1999, CANCER RES, V59, P4559; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Miyake K, 1999, CANCER RES, V59, P8; Nakamura Y, 1999, BLOOD, V94, P4053, DOI 10.1182/blood.V94.12.4053.424k41_4053_4059; Orkin SH, 2000, NAT MED, V6, P1212, DOI 10.1038/81303; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Sato T, 1999, BLOOD, V94, P2548, DOI 10.1182/blood.V94.8.2548.420k38_2548_2554; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; SORRENTINO BP, 1995, BLOOD, V86, P491, DOI 10.1182/blood.V86.2.491.bloodjournal862491; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; Storms RW, 2000, BLOOD, V96, P2125; WOLF NS, 1993, EXP HEMATOL, V21, P614; Zeng H, 2000, CANCER RES, V60, P4779	37	1713	1890	3	108	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1028	1034		10.1038/nm0901-1028	http://dx.doi.org/10.1038/nm0901-1028			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533706				2022-12-25	WOS:000170853300028
J	Chapman, KL; Mortier, GR; Chapman, K; Loughlin, J; Grant, ME; Briggs, MD				Chapman, KL; Mortier, GR; Chapman, K; Loughlin, J; Grant, ME; Briggs, MD			Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia	NATURE GENETICS			English	Article							OLIGOMERIC MATRIX PROTEIN; IX COLLAGEN; PSEUDOACHONDROPLASIA; GENE; IDENTIFICATION; CHAIN; COMP; STATURE; COL9A2; FAMILY	Multiple epiphyseal dysplasia (MED) is a relatively mild and clinically variable osteochondrodysplasia, primarily characterized by delayed and irregular ossification of the epiphyses and early-onset osteoarthritis(1-3). Mutations in the genes encoding cartilage oligomeric matrix protein (COMP) and type IX collagen (COL9A2 and COL9A3) have previously been shown to cause different forms of MED (refs. 4-13). These dominant forms of MED (EDM1-3) are caused by mutations in the genes encoding structural proteins of the cartilage extracellular matrix (ECM); these proteins interact with high affinity in vitro(14,15). A recessive form of MED (EDM4) has also been reported; it is caused by a mutation in the diastrophic dysplasia sulfate transporter gene(16) (SLC26A). A genomewide screen of family with autosomal-dominant MED not linked to the EDM1-3 genes(17) provides significant genetic evidence for a MED locus on the short arm of chromosome 2 (2p24-p23), and a search for candidate genes identified MATN3 (ref. 18), encoding matrilin-3, within the critical region. Matrilin-3 is an oligomeric protein that is present in the cartilage ECM. We have identified two different missense mutations in the exon encoding the von Willebrand factor A (vWFA) domain of matrilin-3 in two unrelated families with MED (EDM5). These are the first mutations to be identified in any of the genes encoding the matrilin family of proteins and confirm a role for matrilin-3 in the development and homeostasis of cartilage and bone.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England; Ghent Univ Hosp, Dept Med Genet, B-9000 Ghent, Belgium; Univ Oxford, Inst Mol Med, Oxford, England	University of Manchester; Ghent University; Ghent University Hospital; University of Oxford	Briggs, MD (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England.	mike.briggs@man.ac.uk	Mortier, Geert/D-2542-2012	Mortier, Geert/0000-0001-9871-4578; Loughlin, John/0000-0003-2018-3361				Aszodi A, 1999, MOL CELL BIOL, V19, P7841; Belluoccio D, 1998, GENOMICS, V53, P391, DOI 10.1006/geno.1998.5519; Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; Briggs MD, 2000, METH MOL B, V139, P133; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; Haga N, 1998, J PEDIATR ORTHOPED, V18, P394, DOI 10.1097/00004694-199805000-00023; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; Holden P, 1999, AM J HUM GENET, V65, P31, DOI 10.1086/302440; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; Lohiniva J, 2000, AM J MED GENET, V90, P216, DOI 10.1002/(SICI)1096-8628(20000131)90:3<216::AID-AJMG6>3.0.CO;2-1; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; MORTIER GR, IN PRESS EUR J HUM G; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; Rimoin DL, 1998, AM J MED GENET, V79, P376; Sasaki T, 2000, FASEB J, V14, P761, DOI 10.1096/fasebj.14.5.761; Spayde EC, 2000, MATRIX BIOL, V19, P121, DOI 10.1016/S0945-053X(00)00055-X; Superti-Furga A, 1999, J MED GENET, V36, P621; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; TREBLE NJ, 1990, J BONE JOINT SURG BR, V72, P1061, DOI 10.1302/0301-620X.72B6.2246289; Unger SL, 2001, PEDIATR RADIOL, V31, P10, DOI 10.1007/s002470000362; Wagener R, 2000, MAMM GENOME, V11, P85, DOI 10.1007/s003350010018	28	147	150	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					393	396		10.1038/ng573	http://dx.doi.org/10.1038/ng573			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479597				2022-12-25	WOS:000170174800024
J	Flattmann, GJ; Kaplan, JM				Flattmann, GJ; Kaplan, JM			Patenting expressed sequence tags and single nucleotide polymorphisms	NATURE BIOTECHNOLOGY			English	Article									Fish & Neave, New York, NY 10020 USA		Flattmann, GJ (corresponding author), Fish & Neave, 1251 Ave Amer, New York, NY 10020 USA.							Flattmann GJ, 2001, NAT BIOTECHNOL, V19, P683, DOI 10.1038/90309; Written Description Guidelines, 2001, FED REG, V66, P1099	2	2	2	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					777	779		10.1038/90843	http://dx.doi.org/10.1038/90843			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479574				2022-12-25	WOS:000170188600032
J	Lieb, JD; Liu, XL; Botstein, D; Brown, PO				Lieb, JD; Liu, XL; Botstein, D; Brown, PO			Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; YEAST TELOMERES; SIR4 PROTEINS; COMPLEX; SEQUENCES; TRANSCRIPTION; INTERACTS; DATABASE; TERMINI	We determined the distribution of repressor-activator protein 1 (Rap1) and the accessory silencing proteins Sir2, Sir3 and Sir4 in vivo on the entire yeast genome, at a resolution of 2 kb. Rap1 is central to the cellular economy during rapid growth, targeting 294 loci, about 5% of yeast genes, and participating in the activation of 37% of all RNA polymerase II initiation events in exponentially growing cells. Although the DNA sequence recognized by Rap1 is found in both coding and intergenic sequences, the binding of Rap1 to the genome was highly specific to intergenic regions with the potential to act as promoters. This global phenomenon, which may be a general characteristic of sequence-specific transcriptional factors, indicates the existence of a genome-wide molecular mechanism for marking promoter regions.	Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Stanford Med Informat, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Brown, PO (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu		Lieb, Jason/0000-0001-7601-8061				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHERRY JM, 2000, SACCHAROMYCES GENOME; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; FREEMAN K, 1995, GENETICS, V141, P1253; Goncalves PM, 1996, MOL MICROBIOL, V19, P535, DOI 10.1046/j.1365-2958.1996.404939.x; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; Graham IR, 1999, MOL CELL BIOL, V19, P7481; Guarente L, 2000, GENE DEV, V14, P1021; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Idrissi FZ, 1999, BIOCHEM J, V341, P477, DOI 10.1042/0264-6021:3410477; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Leblanc BP, 2000, P NATL ACAD SCI USA, V97, P10745, DOI 10.1073/pnas.200365097; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu X, 2001, Pac Symp Biocomput, P127; Lopez N, 1999, J BACTERIOL, V181, P3136, DOI 10.1128/JB.181.10.3136-3143.1999; Mewes HW, 1999, NUCLEIC ACIDS RES, V27, P44, DOI 10.1093/nar/27.1.44; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	36	535	546	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					327	334		10.1038/ng569	http://dx.doi.org/10.1038/ng569			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11455386				2022-12-25	WOS:000170174800012
J	Yung, E; Sorin, M; Pal, A; Craig, E; Morozov, A; Delattre, O; Kappes, J; Oti, D; Kalpana, GV				Yung, E; Sorin, M; Pal, A; Craig, E; Morozov, A; Delattre, O; Kappes, J; Oti, D; Kalpana, GV			Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FINGER-LIKE DOMAIN; TYPE-1 INTEGRASE; VIRAL REPLICATION; MUTATIONS; DNA; COMPLEX; BINDING; PROTEIN; CELLS	Integase Interactor 1(INI), also known as hSNF5, is a protein that interacts with HIV-1 integrase. We report here that a cytoplasmically localized fragment of INI (S6; aa183-294) containing the minimal integrase-interaction domain potently inhibits HIV-1 particle production and replication. Mutations in 56 or integrase that disrupt integrase-INI1 interaction abrogated the inhibitory effect. An integrase-deficient HIV-1 transcomplemented with integrase fused to Vpr was not affected by S6. INI1 was specifically incorporated into virions and was required for efficient HIV-1 particle production. These results indicate that INI1 is required for late events in the viral life cycle, and that ectopic expression of S6 inhibits HIV-1 replication in a transdominant manner via its specific interaction with integrase within the context of Gag-Pol, providing a novel strategy to control HIV-1 replication.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; NCI, AIDS Vaccine Program, SAIC Frederick, Frederick, MD 21701 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Inst Curie, Lab Pathol Mol Canc, Paris, France	Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Alabama System; University of Alabama Birmingham; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Kalpana, GV (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA.	kalpana@aecom.yu.edu		delattre, olivier/0000-0002-8730-2276; Kalpana, Ganjam/0000-0003-4111-0604; Yung, Eric/0000-0002-7328-7204	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007501] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NIAID NIH HHS [AI/GM 399951, T32-AI07501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1991, ARCH VIROL, V117, P45, DOI 10.1007/BF01310491; ANSARILARI MA, 1995, VIROLOGY, V211, P332, DOI 10.1006/viro.1995.1412; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Biegel JA, 1999, CANCER RES, V59, P74; Brown P. O., 1997, P161; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; Bukovsky A, 1996, J VIROL, V70, P6820, DOI 10.1128/JVI.70.10.6820-6825.1996; CANNON PM, 1994, J VIROL, V68, P4768, DOI 10.1128/JVI.68.8.4768-4775.1994; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Desrosiers RC, 1999, NAT MED, V5, P723, DOI 10.1038/10439; ENGELMAN A, 1995, J VIROL, V69, P2729, DOI 10.1128/JVI.69.5.2729-2736.1995; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Leung DW, 1989, TECHNIQUE, V1, P11; MASUDA T, 1995, J VIROL, V69, P6687, DOI 10.1128/JVI.69.11.6687-6696.1995; Mathe' C, 1999, NUCLEOS NUCLEOT, V18, P681, DOI 10.1080/15257779908041539; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V239, P715, DOI 10.1006/bbrc.1997.7541; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Pani A, 2000, CURR PHARM DESIGN, V6, P569, DOI 10.2174/1381612003400759; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Swanstrom R., 1997, P263; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999	33	110	120	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					920	926		10.1038/90959	http://dx.doi.org/10.1038/90959			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479624				2022-12-25	WOS:000171740400029
J	Kanai, F; Liu, H; Field, SJ; Akbary, H; Matsuo, T; Brown, GE; Cantley, LC; Yaffe, MB				Kanai, F; Liu, H; Field, SJ; Akbary, H; Matsuo, T; Brown, GE; Cantley, LC; Yaffe, MB			The PX domains of p47phox and p40phox bind to lipid products of Pl(3)K	NATURE CELL BIOLOGY			English	Article							PHOSPHOINOSITIDE-BINDING; SORTING NEXIN; NADPH OXIDASE; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; IDENTIFICATION; PLECKSTRIN; LOCALIZATION; 3-PHOSPHATE; NEUTROPHILS; WORTMANNIN	PX domains are found in a variety of proteins that associate with cell membranes, but their molecular function has remained obscure. We show here that the PX domains in p47phox and p40phox subunits of the phagocyte NADPH oxidase bind to phosphatidylinositol-3,4-bisphosphate (Ptdlns(3,4)P-2) and phosphatidylinositol-3-phosphate (Ptdlns(3)P), respectively. We also show that an Arg-to-Gln mutation in the PX domain of p47phox, which is found in patients with chronic granulomatous disease, eliminates phosphoinositide binding, as does the analogous mutation in the PX domain of p40phox, The PX domain of p40phox localizes specifically to Ptdlns(B)P-enriched early endosomes, and this localization is disrupted by inhibition of phosphoinositide-3-OH kinase (PI(3)K) or by the Arg-to-Gln point mutation. These findings provide a molecular foundation to understand the role of PI(3)K in regulating neutrophil function and inflammation, and to identify PX domains as specific phosphoinositide-binding modules involved in signal transduction events in eukaryotic cells.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Massachusetts Gen Hosp, Div Endocrinol, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center	Yaffe, MB (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	myaffe@mit.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Field, Seth/0000-0002-8893-4806	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Goldblatt D, 2000, CLIN EXP IMMUNOL, V122, P1, DOI 10.1046/j.1365-2249.2000.01314.x; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; OKADA T, 1994, J BIOL CHEM, V269, P3563; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; Wientjes FB, 1997, J LEUKOCYTE BIOL, V61, P303, DOI 10.1002/jlb.61.3.303; Yaffe MB, 2001, STRUCTURE, V9, pR33, DOI 10.1016/S0969-2126(01)00580-9	31	496	502	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					675	678		10.1038/35083070	http://dx.doi.org/10.1038/35083070			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433300				2022-12-25	WOS:000169727000019
J	Lin, K; Hsin, H; Libina, N; Kenyon, C				Lin, K; Hsin, H; Libina, N; Kenyon, C			Regulation of the Caenorhabditis elegans longevity protein DAF-16 by insulin/IGF-1 and germline signaling	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR FKHR; AGE-1 PI3 KINASE; LIFE-SPAN; GENETIC-ANALYSIS; DAUER FORMATION; FACTOR AFX; DIAPAUSE; HOMOLOG; PHOSPHORYLATION; PATHWAY	The lifespan of Caenorhabditis elegans is regulated by the insulin/insulin-like growth factor (IGF)-1 receptor homolog DAF-2, which signals through a conserved phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway(1-7) Mutants in this pathway remain youthful and active much longer than normal animals and can live more than twice as long, This lifespan extension requires DAF-16, a forkhead/winged-helix transcription factor(8,9). DAF-16 is thought to be the main target of the DAF-2 pathway. Insulin/IGF-1 signaling is thought to lead to phosphorylation of DAF-16 by AKT activity, which in turn shortens lifespan. Here, we show that the DAF-2 pathway prevents DAF-16 accumulation in nuclei. Disrupting Akt-consensus phosphorylation sites in DAF-16 causes nuclear accumulation in wild-type animals, but, surprisingly, has little effect on lifespan. Thus the DAF-2 pathway must have additional outputs. Lifespan in C. elegans can be extended by perturbing sensory neurons or germ cells(10,11). In both cases, lifespan extension requires DAF-16. We find that both sensory neurons and germline activity regulate DAF-16 accumulation in nuclei, but the nuclear localization patterns are different. Together these findings reveal unexpected complexity in the DAF-16-dependent pathways that regulate aging.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Genentech Inc, Dept Cell Biol & Technol, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; Roche Holding; Genentech	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	ckenyon@biochem.ucsf.edu		Hsin, Honor/0000-0002-0510-7494				Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; DORMAN JB, 1995, GENETICS, V141, P1399; Gems D, 2000, J GERONTOL A-BIOL, V55, pB215, DOI 10.1093/gerona/55.5.B215; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; GOTTLIEB S, 1994, GENETICS, V137, P107; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lin SY, 1997, QUAL RELIAB ENG INT, V13, P9, DOI 10.1002/(SICI)1099-1638(199701)13:1<9::AID-QRE58>3.0.CO;2-W; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Malone EA, 1996, GENETICS, V143, P1193; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Riddle DL, 1997, C ELEGANS, P739; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; VOWELS JJ, 1992, GENETICS, V130, P105; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147	31	716	751	6	116	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					139	145		10.1038/88850	http://dx.doi.org/10.1038/88850			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381260				2022-12-25	WOS:000169011800015
J	Bernard, P; Maure, JF; Javerzat, JP				Bernard, P; Maure, JF; Javerzat, JP			Fission yeast Bub1 is essential in setting up the meiotic pattern of chromosome segregation	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID COHESION; SPINDLE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; DROSOPHILA-MELANOGASTER; MEIOSIS; CENTROMERE; GENE; RECOMBINATION; ORIENTATION; MUTATIONS	In meiosis, sister-chromatids move to the same spindle pole during the first division (MI) and to opposite poles during the second division (MII). This requires that MI sister kinetochores are co-orientated and form an apparent single functional unit that only interacts with microtubules from one pole, and that sister-chromatids remain associated through their centromeres until anaphase II. Here we investigate the function of Bub1 and Mad2, which are components of the mitotic-spindle checkpoint, on chromosome segregation during meiosis. Both proteins are required to prevent the occurrence of non-disjunction events in MI, which is consistent with recent findings that components of the mitotic-spindle checkpoint also operate during meiosis(1). However, Bub1 has several functions that are not shared with Mad2. When the bub1 gene is deleted, sister chromatids often move to opposite spindle poles during MI, indicating that sister kinetochores are disunited. Furthermore, the cohesin Rec8 is never retained at centromeres at anaphase I and sister-chromatid cohesion is lost. Our results show that Bub1, besides its functions in monitoring chromosome attachment, is essential for two other significant aspects of MI - unification of sister kinetochores and retention of centromeric cohesion.	Inst Biochim & Genet Cellulaires, CNRS, Unite Mixte Rech 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS)	Bernard, P (corresponding author), Inst Biochim & Genet Cellulaires, CNRS, Unite Mixte Rech 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jpaul.javerzat@igbc.u-bordeaux2.fr	Bernard, Pascal/I-1859-2015	Bernard, Pascal/0000-0003-2732-9685				Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Dobie KW, 1999, CURR OPIN GENET DEV, V9, P206, DOI 10.1016/S0959-437X(99)80031-8; Ekwall K, 1996, J CELL SCI, V109, P2637; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HUGERAT Y, 1993, GENETICS, V135, P297; Kamieniecki RJ, 2000, CURR BIOL, V10, P1182, DOI 10.1016/S0960-9822(00)00723-5; KERREBROCK AW, 1992, GENETICS, V130, P827; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; LIN HP, 1982, GENETICS, V102, P751; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MULLER W, 1972, CHROMOSOMA, V38, P139, DOI 10.1007/BF00326191; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Paliulis LV, 2000, J CELL BIOL, V150, P1223, DOI 10.1083/jcb.150.6.1223; SHIMODA C, 1985, MOL GEN GENET, V200, P252, DOI 10.1007/BF00425432; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; UZAWA S, 1992, J CELL SCI, V101, P267; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; WOODS A, 1989, J CELL SCI, V93, P491	27	86	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					522	526		10.1038/35074598	http://dx.doi.org/10.1038/35074598			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331883				2022-12-25	WOS:000168592500025
J	Sieber, V; Martinez, CA; Arnold, FH				Sieber, V; Martinez, CA; Arnold, FH			Libraries of hybrid proteins from distantly related sequences	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO RECOMBINATION; CIRCULAR PERMUTATION; P450; CONSTRUCTION; EVOLUTION	We introduce a method for sequence homology-independent protein recombination (SHIPREC) that can create libraries of single-crossover hybrids of unrelated or distantly related proteins. The method maintains the proper sequence alignment between the parents and introduces crossovers mainly at structurally related sites distributed over the aligned sequences. We used SHIPREC to create a library of interspecies hybrids of a membrane-associated human cytochrome P450 (1A2) and the heme domain of a soluble bacterial P450 (BM3). By fusing the hybrid gene library to the gene for chloramphenicol acetyl transferase (CAT), we were able to select for soluble and properly folded protein variants. Screening for 1A2 activity (deethylation of 7-ethoxyresorufin) identified two functional P450 hybrids that were more soluble in the bacterial cytoplasm than the wild-type 1A2 enzyme.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91105 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, 210-41, Pasadena, CA 91105 USA.	frances@cheme.caltech.edu	Sieber, Volker/D-2006-2013	Sieber, Volker/0000-0001-5458-9330; Arnold, Frances H./0000-0002-4027-364X				Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; BELLAMINE A, 1994, EUR J BIOCHEM, V225, P1005, DOI 10.1111/j.1432-1033.1994.1005b.x; Bogarad LD, 1999, P NATL ACAD SCI USA, V96, P2591, DOI 10.1073/pnas.96.6.2591; Chang T K, 1998, Methods Mol Biol, V107, P95; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; Jenkins C M, 1998, Methods Mol Biol, V107, P181; Maxwell KL, 1999, PROTEIN SCI, V8, P1908, DOI 10.1110/ps.8.9.1908; MITRA B, 1993, BIOCHEMISTRY-US, V32, P12959, DOI 10.1021/bi00211a003; NARHI LO, 1983, BIOCHEM BIOPH RES CO, V116, P851, DOI 10.1016/S0006-291X(83)80220-4; Ostermeier M, 2001, ADV PROTEIN CHEM, V55, P29, DOI 10.1016/S0065-3233(01)55002-0; Ostermeier M, 1999, NAT BIOTECHNOL, V17, P1205, DOI 10.1038/70754; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; QUATTROCHI LC, 1985, DNA-J MOLEC CELL BIO, V4, P395, DOI 10.1089/dna.1985.4.395; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schenkman John B., 1998, V107, P25; Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; Shimoji M, 1998, BIOCHEMISTRY-US, V37, P8848, DOI 10.1021/bi972775z; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Volkov AA, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.18.e18; WOODARD SI, 1995, ARCH BIOCHEM BIOPHYS, V316, P110, DOI 10.1006/abbi.1995.1016; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	24	168	289	2	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					456	460		10.1038/88129	http://dx.doi.org/10.1038/88129			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329016				2022-12-25	WOS:000168394800024
J	Brett, D; Pospisil, H; Valcarcel, J; Reich, J; Bork, P				Brett, D; Pospisil, H; Valcarcel, J; Reich, J; Bork, P			Alternative splicing and genome complexity	NATURE GENETICS			English	Article							GENES	Alternative splicing of mRNA allows many gene products with different functions to be produced from a single coding sequence. It has recently been proposed as a mechanism by which higher-order diversity is generated. Here we show, using large-scale expressed sequence tag (EST) analysis, that among seven different eukaryotes the amount of alternative splicing is comparable, with no large differences between humans and other animals.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; European Molecular Biology Laboratory (EMBL)	Brett, D (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Pospisil, Heike/G-7377-2016; Valcarcel, Juan/O-9814-2014; Bork, Peer/F-1813-2013	Valcarcel, Juan/0000-0001-5398-3571; Bork, Peer/0000-0002-2627-833X				Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Brett D, 2001, ONCOGENE, V20, P4581, DOI 10.1038/sj.onc.1204610; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	12	365	385	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2002	30	1					29	30		10.1038/ng803	http://dx.doi.org/10.1038/ng803			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743582				2022-12-25	WOS:000173105600010
J	Berger, J; Suzuki, T; Senti, KA; Stubbs, J; Schaffner, G; Dickson, BJ				Berger, J; Suzuki, T; Senti, KA; Stubbs, J; Schaffner, G; Dickson, BJ			Genetic mapping with SNP markers in Drosophila	NATURE GENETICS			English	Article							GENOME; MELANOGASTER; MOSAICS; DISCOVERY; SEQUENCE; KINASE	Map-based positional cloning of Drosophila melanogaster genes is hampered by both the time-consuming, error-prone nature of traditional methods for genetic mapping and the difficulties in aligning the genetic and cytological maps with the genome sequence. The identification of sequence polymorphisms in the Drosophila genome will make it possible to map mutations directly to the genome sequence with high accuracy and resolution. Here we report the identification of 7,223 single-nucleotide polymorphisms (SNPs) and 1,392 insertions/deletions (InDels) in common laboratory strains of Drosophila. These sequence polymorphisms define a map of 787 autosomal marker loci with a resolution of 114 kb. We have established PCR product-length polymorphism (PLP) or restriction fragment-length polymorphism (RFLP) assays for 215 of these markers. We demonstrate the use of this map by delimiting two mutations to intervals of 169 kb and 307 kb, respectively. Using a local high-density SNP map, we also mapped a third mutation to a resolution of approximately 2 kb, sufficient to localize the mutation within a single gene. These methods should accelerate the rate of positional cloning in Drosophila.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Dickson, BJ (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Suzuki, Takashi/D-3651-2019; Dickson, Barry/AAE-7632-2019; Senti, Kirsten-Andre/AAB-3036-2020	Suzuki, Takashi/0000-0001-9093-2562; Dickson, Barry/0000-0003-0715-892X; Senti, Kirsten-Andre/0000-0002-7208-7593				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; Benlali A, 2000, CELL, V101, P271, DOI 10.1016/S0092-8674(00)80837-5; Cho RJ, 1999, NAT GENET, V23, P203, DOI 10.1038/13833; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Hoskins RA, 2001, GENOME RES, V11, P1100, DOI 10.1101/gr.GR-1780R; Kimmerly W, 1996, GENOME RES, V6, P414, DOI 10.1101/gr.6.5.414; Kwok PY, 2001, ANNU REV GENOM HUM G, V2, P235, DOI 10.1146/annurev.genom.2.1.235; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Liu YR, 1999, DEVELOPMENT, V126, P1869; Marth GT, 1999, NAT GENET, V23, P452, DOI 10.1038/70570; Newsome TP, 2000, DEVELOPMENT, V127, P851; Petrov DA, 1999, P NATL ACAD SCI USA, V96, P1475, DOI 10.1073/pnas.96.4.1475; Pichaud F, 2001, DEVELOPMENT, V128, P815; Rorth P, 1998, DEVELOPMENT, V125, P1049; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; Teeter K, 2000, J EXP ZOOL, V288, P63, DOI 10.1002/(SICI)1097-010X(20000415)288:1&lt;63::AID-JEZ7&gt;3.0.CO;2-1; Wicks SR, 2001, NAT GENET, V28, P160, DOI 10.1038/88878; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053	23	126	132	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					475	481		10.1038/ng773	http://dx.doi.org/10.1038/ng773			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726933				2022-12-25	WOS:000172507500026
J	Chen, WS; Calvo, PA; Malide, D; Gibbs, J; Schubert, U; Bacik, I; Basta, S; O'Neill, R; Schickli, J; Palese, P; Henklein, P; Bennink, JR; Yewdell, JW				Chen, WS; Calvo, PA; Malide, D; Gibbs, J; Schubert, U; Bacik, I; Basta, S; O'Neill, R; Schickli, J; Palese, P; Henklein, P; Bennink, JR; Yewdell, JW			A novel influenza A virus mitochondrial protein that induces cell death	NATURE MEDICINE			English	Article							A VIRUS; MESSENGER-RNA; EPITOPES; GENE	While searching for alternative reading-frame peptides encoded by influenza A virus that are recognized by CD8(+)T cells, we found an abundant immunogenic peptide encoded by the +1 reading frame of PB1. This peptide derives from a novel conserved 87-residue protein, PB1-F2, which has several unusual features compared with other influenza gene products in addition to its mode of translation. These include its absence from some animal (particularly swine) influenza virus Isolates, variable expression in individual infected cells, rapid proteasome-dependent degradation and mitochondrial localization. Exposure of cells to a synthetic version of PB1-F2 induces apoptosis, and influenza viruses with targeted mutations that interfere with PB1-F2 expression Induce less extensive apoptosis in human monocytic cells than those with intact PB1-F2. We propose that PB1-F2 functions to kill host immune cells responding to influenza virus infection.	NIAID, Viral Dis Lab, Bethesda, MD 20892 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; Humboldt Univ, Inst Biochem, Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai; Heinrich Pette Institute; University of Hamburg; Humboldt University of Berlin	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, Bethesda, MD 20892 USA.	jyewdell@nih.gov	Chen, Weisan/E-7828-2012; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Chen, Weisan/0000-0002-5221-9771; Palese, Peter/0000-0002-0337-5823	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000658, ZIAAI000658] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECERRA SP, 1988, J VIROL, V62, P2745, DOI 10.1128/JVI.62.8.2745-2754.1988; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chen WS, 1999, J EXP MED, V189, P1757, DOI 10.1084/jem.189.11.1757; Chen WS, 2000, IMMUNITY, V12, P83, DOI 10.1016/S1074-7613(00)80161-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; KAWAOKA Y, 1989, J VIROL, V63, P4603, DOI 10.1128/JVI.63.11.4603-4608.1989; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb R. A, 1983, GENETICS INFLUENZA V, P26; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Mayrand SM, 1998, IMMUNOL TODAY, V19, P551, DOI 10.1016/S0167-5699(98)01342-5; Pleschka S, 1996, J VIROL, V70, P4188, DOI 10.1128/JVI.70.6.4188-4192.1996; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Schultz-Cherry S, 2001, J VIROL, V75, P7875, DOI 10.1128/JVI.75.17.7875-7881.2001; Schultz-Cherry S, 1998, SEMIN VIROL, V8, P491, DOI 10.1006/smvy.1998.0153; Taubenberger JK, 2000, VIROLOGY, V274, P241, DOI 10.1006/viro.2000.0495; VANCAMPEN H, 1989, J GEN VIROL, V70, P467, DOI 10.1099/0022-1317-70-2-467; Vitiello A, 1996, J IMMUNOL, V157, P5555; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Webster RG, 1997, ARCH VIROL, P105; WILLIAMS MA, 1989, J VIROL, V63, P28, DOI 10.1128/JVI.63.1.28-35.1989	25	752	820	4	113	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1306	1312		10.1038/nm1201-1306	http://dx.doi.org/10.1038/nm1201-1306			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726970				2022-12-25	WOS:000172610300035
J	Zhang, SC; Wernig, M; Duncan, ID; Brustle, O; Thomson, JA				Zhang, SC; Wernig, M; Duncan, ID; Brustle, O; Thomson, JA			In vitro differentiation of transplantable neural precursors from human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO; PROGENITOR CELLS; HUMAN BLASTOCYSTS; SPINAL-CORD; ES CELLS; LINES; BRAIN; EXPRESS; RAT; CNS	The remarkable developmental potential and replicative capacity of human embryonic stem (ES) cells promise an almost unlimited supply of specific cell types for transplantation therapies. Here we describe the in vitro differentiation, enrichment, and transplantation of neural precursor cells from human ES cells. Upon aggregation to embryoid bodies, differentiating ES cells formed large numbers of neural tube-like structures in the presence of fibroblast growth factor 2 (FGF-2). Neural precursors within these formations were isolated by selective enzymatic digestion and further purified on the basis of differential adhesion. Following withdrawal of FGF-2, they differentiated into neurons, astrocytes, and oligodendrocytes. After transplantation into the neonatal mouse brain human ES cell-derived neural precursors were incorporated into a variety of brain regions, where they differentiated into both neurons and astrocytes. No teratoma formation was observed in the transplant recipients. These results depict human ES cells as a source of transplantable neural precursors for possible nervous system repair.	Univ Wisconsin, Waisman Ctr, Dept Anat, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Dept Neurol, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Dept Med Sci, Madison, WI 53705 USA; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Bonn	Zhang, SC (corresponding author), Univ Wisconsin, Waisman Ctr, Dept Anat, 1500 Highland Ave, Madison, WI 53705 USA.	zhang@waisman.wiscl.edu; brustle@uni-bonn.de						Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Kalyani A, 1997, DEV BIOL, V186, P202, DOI 10.1006/dbio.1997.8592; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mujtaba T, 1999, DEV BIOL, V214, P113, DOI 10.1006/dbio.1999.9418; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Svendsen CN, 1996, EXP NEUROL, V137, P376, DOI 10.1006/exnr.1996.0039; Thomson JA, 2000, TRENDS BIOTECHNOL, V18, P53, DOI 10.1016/S0167-7799(99)01410-9; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; WILES MV, 1991, DEVELOPMENT, V111, P259; Zhang SC, 1999, P NATL ACAD SCI USA, V96, P4089, DOI 10.1073/pnas.96.7.4089; Zhang SC, 2000, J NEUROSCI RES, V59, P421, DOI 10.1002/(SICI)1097-4547(20000201)59:3<421::AID-JNR17>3.3.CO;2-3	26	1397	1557	3	158	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1129	1133		10.1038/nbt1201-1129	http://dx.doi.org/10.1038/nbt1201-1129			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731781				2022-12-25	WOS:000172524400025
J	Birkenhager, R; Otto, E; Schurmann, MJ; Vollmer, M; Ruf, EM; Maier-Lutz, I; Beekmann, F; Fekete, A; Omran, H; Feldmann, D; Milford, DV; Jeck, N; Konrad, M; Landau, D; Knoers, NVAM; Antignac, C; Sudbrak, R; Kispert, A; Hildebrandt, F				Birkenhager, R; Otto, E; Schurmann, MJ; Vollmer, M; Ruf, EM; Maier-Lutz, I; Beekmann, F; Fekete, A; Omran, H; Feldmann, D; Milford, DV; Jeck, N; Konrad, M; Landau, D; Knoers, NVAM; Antignac, C; Sudbrak, R; Kispert, A; Hildebrandt, F			Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure	NATURE GENETICS			English	Article							LANGE-NIELSEN-SYNDROME; CHLORIDE CHANNEL GENE; POTASSIUM CHANNEL; CAUSE JERVELL; HUMAN GENOME; COTRANSPORTER; LOCALIZATION; MAP; HETEROGENEITY; PROTEIN	Antenatal Bartter syndrome (aBS) comprises a heterogeneous group of autosomal recessive salt-losing nephropathies'. identification of three genes that code for renal transporters and channels as responsible for aBS(2-7) has resulted in new insights into renal salt handling, diuretic action and blood-pressure regulations. A gene locus of a fourth variant of aBS called BSND, which in contrast to the other forms is associated with sensorineural deafness (SND) and renal failure, has been mapped to chromosome 1p(9). We report here the identification by positional cloning, in a region not covered by the human genome sequencing projects, of a new gene, BSND, as the cause of BSND. We examined ten families with BSND and detected seven different mutations in BSND that probably result in loss of function. In accordance with the phenotype, BSND is expressed in the thin limb and the thick ascending limb of the loop of Henle in the kidney and in the dark cells of the inner ear. The gene encodes a hitherto unknown protein with two putative transmembrane a-helices and thus might function as a regulator for ion-transport proteins involved in aBS, or else as a new transporter or channel itself.	Univ Freiburg, Childrens Hosp, D-79106 Freiburg, Germany; Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary; Armand Trousseau Hosp, Dept Biochem, Paris, France; Birmingham Childrens Hosp, Birmingham, W Midlands, England; Univ Marburg, Childrens Hosp, Marburg, Germany; Soroka Med Ctr, Dept Pediat, IL-84101 Beer Sheva, Israel; Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Hop Necker Enfants Malad, INSERM U423, Paris, France; Max Planck Inst Mol Genet, Berlin, Germany; Hannover Med Sch, Inst Mol Biol, Hannover, Germany	University of Freiburg; Semmelweis University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Birmingham; Philipps University Marburg; Ben Gurion University; Soroka Medical Center; Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society; Hannover Medical School	Hildebrandt, F (corresponding author), Univ Freiburg, Childrens Hosp, Hugstetter Str 55, D-79106 Freiburg, Germany.	hildebra@kikli.ukl.uni-freiburg.de	ANTIGNAC, Corinne/H-8945-2017; Sudbrak, Ralf/HHZ-8821-2022	ANTIGNAC, Corinne/0000-0002-9934-4940; Otto, Edgar/0000-0002-2387-9973	NIDDK NIH HHS [R01 DK088767] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088767] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brennan TMH, 1998, AM J HUM GENET, V62, P355, DOI 10.1086/301708; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jeck N, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.1.e5; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Karolyi L, 1997, HUM MOL GENET, V6, P17; Kobayashi K, 2001, J AM SOC NEPHROL, V12, P1327, DOI 10.1681/ASN.V1271327; Kockerling A, 1996, J PEDIATR-US, V129, P519, DOI 10.1016/S0022-3476(96)70116-6; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Nicolas MT, 2001, HEARING RES, V153, P132, DOI 10.1016/S0378-5955(00)00268-9; Nothwang HG, 1998, GENOMICS, V47, P276, DOI 10.1006/geno.1997.5102; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Rodriguez-Soriano J, 1998, PEDIATR NEPHROL, V12, P315, DOI 10.1007/s004670050461; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Steel KP, 2001, NAT GENET, V27, P143, DOI 10.1038/84758; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; TYSON KP, 1997, HUM MOL GENET, V6, P2179; Vargas-Poussou R, 1998, AM J HUM GENET, V62, P1332, DOI 10.1086/301872; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vollmer M, 2000, NEPHROL DIAL TRANSPL, V15, P970, DOI 10.1093/ndt/15.7.970; Yoshikawa M, 1999, AM J PHYSIOL-RENAL, V276, pF552, DOI 10.1152/ajprenal.1999.276.4.F552	31	369	382	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2001	29	3					310	314		10.1038/ng752	http://dx.doi.org/10.1038/ng752			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687798				2022-12-25	WOS:000171911000018
J	Gurjar, RS; Backman, V; Perelman, LT; Georgakoudi, I; Badizadegan, K; Itzkan, I; Dasari, RR; Feld, MS				Gurjar, RS; Backman, V; Perelman, LT; Georgakoudi, I; Badizadegan, K; Itzkan, I; Dasari, RR; Feld, MS			Imaging human epithelial properties with polarized light-scattering spectroscopy	NATURE MEDICINE			English	Article							TISSUES; CANCER; MEDIA	Biomedical imaging with light-scattering spectroscopy (LSS) is a novel optical technology developed to probe the structure of living epithelial cells in situ without need for tissue removal. LSS makes it possible to distinguish between single backscattering from epithelial-cell nuclei and multiply scattered light. The spectrum of the single backscattering component is further analyzed to provide quantitative information about the epithelial-cell nuclei such as nuclear size, degree of pleomorphism, degree of hyperchromasia and amount of chromatin. LSS imaging allows mapping these histological properties over wide areas of epithelial lining. Because nuclear enlargement, pleomorphism and hyperchromasia are principal features of nuclear atypia associated with precancerous and cancerous changes in virtually all epithelia, LSS imaging can be used to detect precancerous lesions in optically accessible organs.	Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA; MIT, GR Harrison Spect Lab, Cambridge, MA 02139 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Northwestern University; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard Medical School	Backman, V (corresponding author), Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.	v-backman@northwestern.edu	Backman, Vadim/B-6689-2009		NATIONAL CANCER INSTITUTE [R01CA053717] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002594] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA53717] Funding Source: Medline; NCRR NIH HHS [P41 RR02594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON RR, 1991, ARCH DERMATOL, V127, P1000, DOI 10.1001/archderm.127.7.1000; Backman V, 1999, IEEE J SEL TOP QUANT, V5, P1019, DOI 10.1109/2944.796325; Backman V, 2000, NATURE, V406, P35, DOI 10.1038/35017638; Bartel S, 2000, APPL OPTICS, V39, P1580, DOI 10.1364/AO.39.001580; Boone CW, 2000, CANCER EPIDEM BIOMAR, V9, P495; BROWN GL, 1955, NATURE, V176, P161, DOI 10.1038/176161a0; Crawford J.M., 1994, ROBBINS PATHOLOGIC B, V5th, P910; DAVIES H. G., 1957, EXPTL CELL RES SUPPL, V4, P136; DAVIES HG, 1958, GEN CYTOCHEMICAL MET, V1; Demos SG, 1997, APPL OPTICS, V36, P150, DOI 10.1364/AO.36.000150; Hulst H.C., 1957, LIGHT SCATTERING SMA; Jacques SL, 2000, LASER SURG MED, V26, P119, DOI 10.1002/(SICI)1096-9101(2000)26:2<119::AID-LSM3>3.0.CO;2-Y; LEE LH, 1973, ACTA CYTOL, V17, P214; Mourant JR, 1995, LASER SURG MED, V17, P350, DOI 10.1002/lsm.1900170403; Perelman LT, 1999, PROC SPIE, V3597, P474, DOI 10.1117/12.356844; Perelman LT, 1998, PHYS REV LETT, V80, P627, DOI 10.1103/PhysRevLett.80.627; Russ J.C, 1992, IMAGE PROCESSING HDB; Sankaran V, 1999, APPL OPTICS, V38, P4252, DOI 10.1364/AO.38.004252; Sokolov K, 1999, OPT EXPRESS, V5, P302, DOI 10.1364/OE.5.000302; Wallace MB, 2000, GASTROENTEROLOGY, V119, P677, DOI 10.1053/gast.2000.16511	20	332	351	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1245	1248		10.1038/nm1101-1245	http://dx.doi.org/10.1038/nm1101-1245			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689891				2022-12-25	WOS:000172054100034
J	Cheever, ML; Sato, TK; de Beer, T; Kutateladze, TG; Emr, SD; Overduin, M				Cheever, ML; Sato, TK; de Beer, T; Kutateladze, TG; Emr, SD; Overduin, M			Phox domain interaction with Ptdlns(S)P targets the Vam7 t-SNARE to vacuole membranes	NATURE CELL BIOLOGY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PROTEIN-KINASE; CRYSTAL-STRUCTURE; PHOSPHOLIPASE D1; YEAST; COMPLEX; IDENTIFICATION; TRANSPORT; BINDING	Specific recognition of phosphoinositides is crucial for protein sorting and membrane trafficking, Protein transport to the yeast vacuole depends on the Vam7 t-SNARE and its phox homology (PX) domain. Here, we show that the PX domain of Vam7 targets to vacuoles in vivo in a manner dependent on phosphatidylinositol 3-phosphate generation. A novel phosphatidylinositol-3-phosphate-binding motif and an exposed loop that interacts with the lipid bilayer are identified by nuclear magnetic resonance spectroscopy. Conservation of key structural and binding site residues across the diverse PX family indicates a shared fold and phosphoinositide recognition function.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Overduin, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.		Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Kutateladze, Tatiana/0000-0001-7375-6990				Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Hoer A, 2000, BBA-PROTEIN STRUCT M, V1481, P189, DOI 10.1016/S0167-4838(00)00108-4; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kay LE, 1995, PROG BIOPHYS MOL BIO, V63, P277, DOI 10.1016/0079-6107(95)00007-0; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kurten RC, 2001, J CELL SCI, V114, P1743; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Lukin JA, 1997, J BIOMOL NMR, V9, P151, DOI 10.1023/A:1018602220061; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yokozeki T, 1996, J NEUROCHEM, V66, P1234	39	313	324	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					613	618		10.1038/35083000	http://dx.doi.org/10.1038/35083000			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433291				2022-12-25	WOS:000169727000011
J	Avota, E; Avots, A; Niewiesk, S; Kane, LP; Bommhardt, U; ter Meulen, V; Schneider-Schaulies, S				Avota, E; Avots, A; Niewiesk, S; Kane, LP; Bommhardt, U; ter Meulen, V; Schneider-Schaulies, S			Disruption of Akt kinase activation is important for immunosuppression induced by measles virus	NATURE MEDICINE			English	Article							CELL-CYCLE ARREST; INTEGRIN-LINKED KINASE; RECEPTOR-BETA-CHAIN; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VITRO; INTERLEUKIN-2 RECEPTOR; VIRAL GLYCOPROTEINS; B ACTIVATION; KAPPA-B	Surface-contact-mediated signaling induced by the measles virus (MV) fusion and hemagglutinin glycoproteins is necessary and sufficient to induce T-cell unresponsiveness in vitro and in vivo. To define the intracellular pathways involved, we analyzed interleukin (IL)-2R signaling in primary human T cells and in Kit-225 cells. Unlike IL-2-dependent activation of JAK/STAT pathways, activation of Akt kinase was impaired after MV contact both in vitro and in vivo. MV interference with Akt activation was important for immunosuppression, as expression of a catalytically active Akt prevented negative signaling by the MV glycoproteins. Thus, we show here that MV exploits a novel strategy to interfere with T-cell activation during immunosuppression.	Univ Wurzburg, Inst Virol & Immunobiol, D-8700 Wurzburg, Germany; Univ Wurzburg, Inst Med Radiat & Cell Res, D-8700 Wurzburg, Germany; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of Wurzburg; University of Wurzburg; University of California System; University of California San Francisco	Schneider-Schaulies, S (corresponding author), Univ Wurzburg, Inst Virol & Immunobiol, Versbacher Str 7, D-8700 Wurzburg, Germany.	s-s-s@vim.uni-wuerzburg.de		Kane, Lawrence/0000-0001-5198-516X				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Bell AF, 1997, VIROLOGY, V232, P241, DOI 10.1006/viro.1997.8577; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; BORROW P, 1995, CURR TOP MICROBIOL, V191, P85; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Bright JJ, 1997, J IMMUNOL, V159, P175; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Engelking O, 1999, J GEN VIROL, V80, P1599, DOI 10.1099/0022-1317-80-7-1599; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRIFFIN DE, 1995, CURR TOP MICROBIOL, V191, P117; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Lord JD, 1998, J IMMUNOL, V161, P4627; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; Naniche D, 1999, J VIROL, V73, P1894, DOI 10.1128/JVI.73.3.1894-1901.1999; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Niewiesk S, 1999, J GEN VIROL, V80, P2023, DOI 10.1099/0022-1317-80-8-2023; Niewiesk S, 1997, J VIROL, V71, P7214, DOI 10.1128/JVI.71.10.7214-7219.1997; Niewiesk S, 2000, P NATL ACAD SCI USA, V97, P4251, DOI 10.1073/pnas.060012097; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Rusterholz C, 1999, MOL CELL BIOL, V19, P2681; Schlender J, 1996, P NATL ACAD SCI USA, V93, P13194, DOI 10.1073/pnas.93.23.13194; Schneider-Schaulies S, 1999, ARCH VIROL, P139; Schnorr JJ, 1997, J GEN VIROL, V78, P3217, DOI 10.1099/0022-1317-78-12-3217; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Van Dooren S, 1998, J GEN VIROL, V79, P2695, DOI 10.1099/0022-1317-79-11-2695; Weidmann A, 2000, J VIROL, V74, P1985, DOI 10.1128/JVI.74.4.1985-1993.2000; Weidmann A, 2000, J VIROL, V74, P7548, DOI 10.1128/JVI.74.16.7548-7553.2000; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	93	94	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					725	731		10.1038/89106	http://dx.doi.org/10.1038/89106			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385511				2022-12-25	WOS:000169081500042
J	Rampoldi, L; Dobson-Stone, C; Rubio, JP; Danek, A; Chalmers, RM; Wood, NW; Verellen, C; Ferrer, X; Malandrini, A; Fabrizi, GM; Brown, R; Vance, J; Pericak-Vance, M; Rudolf, G; Carre, S; Alonso, E; Manfredi, M; Nemeth, AH; Monaco, AP				Rampoldi, L; Dobson-Stone, C; Rubio, JP; Danek, A; Chalmers, RM; Wood, NW; Verellen, C; Ferrer, X; Malandrini, A; Fabrizi, GM; Brown, R; Vance, J; Pericak-Vance, M; Rudolf, G; Carre, S; Alonso, E; Manfredi, M; Nemeth, AH; Monaco, AP			A conserved sorting-associated protein is mutant in chorea-acanthocytosis	NATURE GENETICS			English	Article							NEUROACANTHOCYTOSIS; LOCALIZATION; KEX2P; GENES	Chorea-acanthocytosis (CHAC. MIM 200150) is an autosomal recessive neurodegenerative disorder characterized by the gradual onset of hyperkinetic movements and abnormal erythrocyte morphology(1,2) (acanthocytosis). Neurological findings closely resemble those observed in Huntington disease(3-8). We identified a gene in the CHAC critical region(9) and found 16 different mutations in individuals with chorea-acanthocytosis. CHAC encodes an evolutionarily conserved protein that is probably involved in protein sorting.	Wellcome Trust Ctr Human Genet, Oxford, England; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Munich, Neurol Klin, Munich, Germany; Neurol Inst, Dept Clin Neurol, London, England; Unite Genet Med, Brussels, Belgium; Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France; Ist Sci Neurol, Siena, Italy; Univ Verona, Dept Neurol & Visual Sci, Sect Clin Neurol, I-37100 Verona, Italy; Cecil B Day Lab Muscle Res, Charlestown, MA USA; Duke Univ, Med Ctr, Durham, NC USA; Hop Univ Strasbourg, Strasbourg, France; Natl Inst Neurol & Neurosurg Manuel Velasco Suarez, Dept Genet, Mexico City, DF, Mexico; Casa Cura Poliambulanza Neurol, Brescia, Italy; Churchill Hosp, Dept Clin Genet, Oxford, England	University of Oxford; Wellcome Centre for Human Genetics; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Munich; University of London; University College London; CHU Bordeaux; University of Verona; Duke University; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Oxford	Monaco, AP (corresponding author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford, England.		Monaco, Anthony P/A-4495-2010; Rampoldi, Luca/AAN-6228-2020; Wood, Nicholas W/C-2505-2009; Rampoldi, Luca/L-3639-2018; Danek, Adrian/G-7339-2011	Monaco, Anthony P/0000-0001-7480-3197; Rampoldi, Luca/0000-0002-0544-7042; Wood, Nicholas W/0000-0002-9500-3348; Rampoldi, Luca/0000-0002-0544-7042; Danek, Adrian/0000-0001-8857-5383; Rudolf, Gabrielle/0000-0002-2050-3911; Nemeth, Andrea/0000-0002-2941-7657; Vance, Jeffery/0000-0003-3815-8199; RUBIO, JUSTIN/0000-0003-3750-917X; Dobson-Stone, Carol/0000-0002-2211-0257	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630] Funding Source: NIH RePORTER; NINDS NIH HHS [2P01 NS26630] Funding Source: Medline; Telethon [359/B] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		ALONSO ME, 1989, CAN J NEUROL SCI, V16, P426, DOI 10.1017/S0317167100029516; Bostantjopoulou S, 2000, MOVEMENT DISORD, V15, P1271, DOI 10.1002/1531-8257(200011)15:6<1271::AID-MDS1037>3.0.CO;2-T; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; CRITCHLEY EM, 1968, ARCH NEUROL-CHICAGO, V18, P134, DOI 10.1001/archneur.1968.00470320036004; HARDIE RJ, 1991, BRAIN, V114, P13; Kutcher JS, 1999, J NEUROIMAGING, V9, P187, DOI 10.1111/jon199993187; LEVINE IM, 1968, ARCH NEUROL-CHICAGO, V19, P403, DOI 10.1001/archneur.1968.00480040069007; Redding K, 1996, MOL CELL BIOL, V16, P6208; RINNE JO, 1994, MOVEMENT DISORD, V9, P297, DOI 10.1002/mds.870090303; Rubio JP, 1997, AM J HUM GENET, V61, P899, DOI 10.1086/514876; Rubio JP, 1999, GENOMICS, V57, P84, DOI 10.1006/geno.1999.5758; SHIBASAKI H, 1982, ANN NEUROL, V12, P311, DOI 10.1002/ana.410120319	12	217	222	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					119	120		10.1038/88821	http://dx.doi.org/10.1038/88821			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381253				2022-12-25	WOS:000169011800008
J	van den Hoogen, BG; de Jong, J; Groen, J; Kuiken, T; de Groot, R; Fouchier, RAM; Osterhaus, ADME				van den Hoogen, BG; de Jong, J; Groen, J; Kuiken, T; de Groot, R; Fouchier, RAM; Osterhaus, ADME			A newly discovered human pneumovirus isolated from young children with respiratory tract disease	NATURE MEDICINE			English	Article							TURKEY RHINOTRACHEITIS VIRUS; GENE ORDER DIFFERENT; AVIAN PNEUMOVIRUS; SYNCYTIAL VIRUS; INFECTION; REVEAL; PCR	From 28 young children in the Netherlands, we isolated a paramyxovirus that was identified as a tentative new member of the Metapneumovirus genus based on virological data, sequence homology and gene constellation. Previously, avian pneumovirus was the sole member of this recently assigned genus, hence the provisional name for the newly discovered virus: human metapneumovirus. The clinical symptoms of the children from whom the virus was isolated were similar to those caused by human respiratory syncytial virus infection, ranging from upper respiratory tract disease to severe bronchiolitis and pneumonia. Serological studies showed that by the age of five years, virtually all children in the Netherlands have been exposed to human metapneumovirus and that the virus has been circulating in humans for at least 50 years.	Erasmus Sch Ctr, Dept Virol, Rotterdam, Netherlands; Erasmus Sch Ctr, Dept Pediat, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	Osterhaus, ADME (corresponding author), Erasmus Sch Ctr, Dept Virol, Rotterdam, Netherlands.	osterhaus@viro.fgg.eur.nl	Fouchier, Ron A/A-1911-2014; van den Hoogen, Bernadette/J-5461-2013	Fouchier, Ron A/0000-0001-8095-2869; 				Bayon-Auboyer MH, 2000, J GEN VIROL, V81, P2723, DOI 10.1099/0022-1317-81-11-2723; Brandenburg AH, 1997, J MED VIROL, V52, P97, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;97::AID-JMV16&gt;3.0.CO;2-Y; Cook JKA, 1999, AVIAN PATHOL, V28, P607, DOI 10.1080/03079459994407; Cool JKA, 2000, REV SCI TECH OIE, V19, P602, DOI 10.20506/rst.19.2.1233; DORNACHOWSKE JB, 1999, CLIN MICROBIOL REV, V12, P298; EVANS AS, 1989, VIRAL INFECT HUMANS, P22; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fields B. N, 1996, FIELDS VIROLOGY, V1, P1177; GIRAUD P, 1986, VET REC, V119, P606; LENNETTE DA, 1995, DIAGNOSTIC PROCEDURE; LING R, 1992, J GEN VIROL, V73, P1709, DOI 10.1099/0022-1317-73-7-1709; Madeley C.R., 1988, VIRUS MORPHOLOGY; MASUREL N, 1969, LANCET, V1, P907; MULDER J, 1958, LANCET, V1, P810; OSTERHAUS ADME, 1985, ARCH VIROL, V86, P239, DOI 10.1007/BF01309828; PRINGLE CR, 1986, J GEN VIROL, V67, P975, DOI 10.1099/0022-1317-67-6-975; PRINGLE CR, 1991, PARAMYXOVIRUSES, P1; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; Randhawa JS, 1997, J VIROL, V71, P9849, DOI 10.1128/JVI.71.12.9849-9854.1997; REGENMORTEL MH, 2000, VIRUS TAXONOMY, P551; Rothbarth PH, 1999, J VIROL METHODS, V78, P163, DOI 10.1016/S0166-0934(98)00174-8; SELWYN BJ, 1990, REV INFECT DIS, V12, pS870; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; YU Q, 1992, VIROLOGY, V186, P426, DOI 10.1016/0042-6822(92)90007-C	24	1472	1573	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					719	724		10.1038/89098	http://dx.doi.org/10.1038/89098			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385510	Green Published, Bronze			2022-12-25	WOS:000169081500041
J	Harada, T; Morooka, T; Ogawa, S; Nishida, E				Harada, T; Morooka, T; Ogawa, S; Nishida, E			ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1	NATURE CELL BIOLOGY			English	Article							NERVE GROWTH-FACTOR; CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; MAP KINASE; PC12 CELLS; NEURITE OUTGROWTH; REGULATORY SUBUNIT; PC-12 CELLS; DIFFERENTIATION; SIGNAL	The classical mitogen-activated protein kinase (MAPK; also known as extracellular-signal-regulated kinase), ERK cascade has been shown to have a crucial role in cell proliferation and differentiation. In PC12 cells, sustained activation of ERK induced by nerve-growth factor (NGF) is essential for neuronal differentiation. However downstream targets of ERK that are essential for neuronal differentiation have not been defined. Here we show that NGF induces strong, sustained expression of p35, the neuron-specific activator of cyclin-dependent kinase 5 (Cdk5), through activation of the ERK pathway. The induced kinase activity of Cdk5 is required for NGF-induced neurite outgrowth. Our results indicate that sustained activation of ERK is necessary and sufficient for strong induction of p35. Furthermore, the transcription factor Egr1, is induced by NGF through the ERK pathway and mediates induction of p35 by ERK. Our results thus define an essential signalling pathway, downstream of ERK/MAPK, that leads to neuronal differentiation.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University; Kyoto University	Harada, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.							Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hayashi T, 1999, NEUROSCI LETT, V265, P37, DOI 10.1016/S0304-3940(99)00201-3; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; KARIN M, 1995, J BIOL CHEM, V270, P4730; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ohshima T, 1996, GENOMICS, V35, P372, DOI 10.1006/geno.1996.0370; Paglini G, 1998, J NEUROSCI, V18, P9858; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Papanikolaou NA, 2000, J BIOL CHEM, V275, P26683; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Tokuoka H, 2000, J CELL SCI, V113, P1059; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; YAN GZ, 1995, J NEUROSCI, V15, P6200	49	268	280	0	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					453	459		10.1038/35074516	http://dx.doi.org/10.1038/35074516			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331872				2022-12-25	WOS:000168592500014
J	Ibbotson, GC; Doig, C; Kaur, J; Gill, V; Ostrovsky, L; Fairhead, T; Kubes, P				Ibbotson, GC; Doig, C; Kaur, J; Gill, V; Ostrovsky, L; Fairhead, T; Kubes, P			Functional alpha(4)-integrin: A newly identified pathway of neutrophil recruitment in critically ill septic patients	NATURE MEDICINE			English	Article							P-SELECTIN; LEUKOCYTE EMIGRATION; ADHESION; MECHANISM; FLOW; PERITONEUM; ACTIVATION; EXPRESSION; PLATELETS; ADHERENCE	Using a novel flow chamber assay system and whole blood, we show that leukocytes from septic individuals have a four-fold elevation of adhesion, but not rolling, on a P-seIectin/beta (2)-integrin substrate. Most leukocytes from septic patients (but not healthy controls) that bound vascular cell adhesion molecule 1 (VCAM-1) were neutrophils. All adhesion was inhibited with an antibody specific for the VCAM-1 ligand alpha (4)-integrin. The alpha (4)-integrin was present on neutrophils from septic patients but not on neutrophils from patients with localized bacterial infections. The plasma milieu of septic patients was sufficient to induce neutrophils from healthy subjects to bind VCAM-1 under flow conditions. This is the first description of alpha (4)-integrin/VCAM-1 pathway of neutrophil recruitment in human disease. This pathway may provide a new therapeutic target to reduce inappropriate neutrophil adhesion without altering the normal yet critical beta (2)-integrin-mediated adhesive function of neutrophils.	Univ Calgary, Med Ctr, Dept Physiol & Biophys, Calgary, AB, Canada; Univ Calgary, Med Ctr, Dept Surg, Calgary, AB, Canada; Univ Calgary, Med Ctr, Dept Med, Calgary, AB, Canada; Univ Calgary, Med Ctr, Immunol Res Grp, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Kubes, P (corresponding author), Univ Calgary, Med Ctr, Dept Physiol & Biophys, Calgary, AB, Canada.	pkubes@ucalgary.ca	Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; ASTIZ ME, 1995, CRIT CARE MED, V23, P265, DOI 10.1097/00003246-199502000-00011; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTTRUM SM, 1993, BLOOD, V82, P1165; Center of Disease Control and Prevention, 1993, MONTHLY VITAL STAT R, V41, P5; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Diacovo TG, 1996, BLOOD, V88, P146; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; FEIN AM, 1991, CHEST, V99, P1456, DOI 10.1378/chest.99.6.1456; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Horan TC, 1997, AM J INFECT CONTROL, V25, P112, DOI 10.1016/S0196-6553(97)90037-7; Jaeschke H, 1996, SHOCK, V6, P345; Kanwar S, 1999, J IMMUNOL, V162, P2709; Kirveskari J, 2000, J LEUKOCYTE BIOL, V68, P243; KUBES P, 1995, FASEB J, V9, P1103; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; McGill SN, 1996, ARCH SURG-CHICAGO, V131, P1141; MercerJones MA, 1997, SHOCK, V8, P193, DOI 10.1097/00024382-199709000-00007; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Ostrovsky L, 1998, BLOOD, V91, P3028, DOI 10.1182/blood.V91.8.3028.3028_3028_3036; Patel KD, 1998, BLOOD, V92, P3904, DOI 10.1182/blood.V92.10.3904.422k41_3904_3911; Reinhardt PH, 1997, BLOOD, V89, P3837, DOI 10.1182/blood.V89.10.3837.3837_3837_3846; Reinhardt PH, 1998, BLOOD, V92, P4691, DOI 10.1182/blood.V92.12.4691.424k18_4691_4699; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; Rosenbloom AJ, 1999, J LEUKOCYTE BIOL, V66, P83, DOI 10.1002/jlb.66.1.83; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Terregino CA, 1997, ANN EMERG MED, V29, P400, DOI 10.1016/S0196-0644(97)70353-6; VENEZIO FR, 1982, J INFECT DIS, V145, P351, DOI 10.1093/infdis/145.3.351; WINN RK, 1993, J CLIN INVEST, V92, P1168, DOI 10.1172/JCI116686; Yodice PC, 1997, AM J RESP CRIT CARE, V155, P38, DOI 10.1164/ajrccm.155.1.9001286	38	113	115	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					465	470		10.1038/86539	http://dx.doi.org/10.1038/86539			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283674	Bronze			2022-12-25	WOS:000167960500042
J	Arya, R; Duggirala, R; Almasy, L; Rainwater, DL; Mahaney, MC; Cole, S; Dyer, TD; Williams, K; Leach, RJ; Hixson, JE; MacCluer, JW; O'Connell, P; Stern, MP; Blangero, J				Arya, R; Duggirala, R; Almasy, L; Rainwater, DL; Mahaney, MC; Cole, S; Dyer, TD; Williams, K; Leach, RJ; Hixson, JE; MacCluer, JW; O'Connell, P; Stern, MP; Blangero, J			Linkage of high-density lipoprotein-cholesterol concentrations to a locus on chromosome 9p in Mexican Americans	NATURE GENETICS			English	Article							COMPLEX TRAITS; SUSCEPTIBILITY LOCUS; RISK-FACTORS; GENE; ATHEROSCLEROSIS; DISEASE; LOCALIZATION; REPLICATION; MUTATIONS; LOCATION	High-density lipoproteins (HDLs) are anti-atherogenic lipoproteins that have a major role in transporting cholesterol from peripheral tissues to the liver, where it is removed(1,2). Epidemiologic studies have shown that low levels of high-density lipoprotein-cholesterol (HDL-C) are associated with an increased incidence of coronary heart disease and an increased mortality rate(3,4), indicating a protective role of high concentrations of HDL-C against atherogenesis and the development of coronary heart disease. HDL-C level is influenced by several genetic and nongenetic factors(3,5). Nongenetic factors include smoking, which has been shown to decrease the HDL-C level. Exercise and alcohol have been shown to increase HDL-C levels(6,7). Decreased HDL-C is often associated with other coronary heart disease risk factors such as obesity, hyperinsulinemia and insulin resistance, hyper-triglyceridemia and hypertension(3). Although several genes have been identified for rare forms of dyslipidemia, the genes accounting for major variation in HDL-C levels have yet to be identified(8). Using a multipoint variance components linkage approach, we found strong evidence of linkage (lod score=3.4; P=0.00004) of a quantitative trait locus (QTL) for HDL-C level to a genetic location between markers D9S925 and D9S741 on chromosome 9p in Mexican Americans. A replication study in an independent set of Mexican American families confirmed the existence of a QTL on chromosome 9p.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Cell & Struct Biol, San Antonio, TX 78284 USA; SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA; Baylor Coll Med, Baylor Breast Ctr, Houston, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Texas Biomedical Research Institute; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	Arya, R (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78284 USA.		Almasy, Laura/V-3156-2019; Blangero, John/ABA-7175-2021	Leach, Robin/0000-0002-3201-5579; Hixson, James/0000-0002-0849-9315				Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Blangero J, 1997, GENET EPIDEMIOL, V14, P959, DOI 10.1002/(SICI)1098-2272(1997)14:6<959::AID-GEPI66>3.0.CO;2-K; Calabresi L, 1997, CURR OPIN LIPIDOL, V8, P219, DOI 10.1097/00041433-199708000-00005; Duggirala R, 2000, AM J HUM GENET, V66, P1237, DOI 10.1086/302849; Duggirala R, 1999, AM J HUM GENET, V64, P1127, DOI 10.1086/302316; Dupuis J, 1999, GENETICS, V151, P373; FERNANDEZRUIZ E, 1993, GENOMICS, V17, P759, DOI 10.1006/geno.1993.1401; Fong IW, 2000, CAN MED ASSOC J, V163, P49; Gordon DJ, 1998, ENDOCRIN METAB CLIN, V27, P699, DOI 10.1016/S0889-8529(05)70034-7; Hauser ER, 1997, AM J HUM GENET, V61, pA278; Hegele RA, 2001, AM J HUM GENET, V69, P1161, DOI 10.1086/324647; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; Imperatore G, 2000, ARTERIOSCL THROM VAS, V20, P2651, DOI 10.1161/01.ATV.20.12.2651; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; KLINGER KW, 1987, P NATL ACAD SCI USA, V84, P8548, DOI 10.1073/pnas.84.23.8548; KRUGLYAK L, 1995, AM J HUM GENET, V56, P1212; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Luoma PV, 1997, PHARMACOL TOXICOL, V81, P57, DOI 10.1111/j.1600-0773.1997.tb00032.x; MacCluer JW, 1999, NUTR REV, V57, pS59, DOI 10.1111/j.1753-4887.1999.tb01790.x; Mitchell BD, 1996, CIRCULATION, V94, P2159, DOI 10.1161/01.CIR.94.9.2159; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; OWERBACH D, 1981, P NATL ACAD SCI-BIOL, V78, P3123, DOI 10.1073/pnas.78.5.3123; Roberts SB, 1999, AM J HUM GENET, V65, P876, DOI 10.1086/302528; Rosenson RS, 1996, ARCH INTERN MED, V156, P1278, DOI 10.1001/archinte.156.12.1278; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SELF SG, 1987, J AM STAT ASSOC, V82, P605, DOI 10.2307/2289471; THOMPSON PD, 1991, CIRCULATION, V84, P140, DOI 10.1161/01.CIR.84.1.140; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; WEIDNER G, 1991, CIRCULATION, V83, P176, DOI 10.1161/01.CIR.83.1.176; WHITMORE TE, 1995, GENOMICS, V28, P599, DOI 10.1006/geno.1995.1198; WILT VM, 1996, ANN PHARMACOTHER, V31, P89	31	75	76	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					102	105		10.1038/ng810	http://dx.doi.org/10.1038/ng810			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743583				2022-12-25	WOS:000173105600022
J	Backman, SA; Stambolic, V; Suzuki, A; Haight, J; Elia, A; Pretorius, J; Tsao, MS; Shannon, P; Bolon, B; Ivy, GO; Mak, TW				Backman, SA; Stambolic, V; Suzuki, A; Haight, J; Elia, A; Pretorius, J; Tsao, MS; Shannon, P; Bolon, B; Ivy, GO; Mak, TW			Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR PTEN; SIGNALING PATHWAY; COWDEN-SYNDROME; CELL-SURVIVAL; GERMLINE MUTATIONS; PROTEUS SYNDROME; CANCER; GENE; CEREBELLUM; MICE	Initially identified in high-grade gliomas, mutations in the PTEN tumor-suppressor are also found in many sporadic cancers and a few related autosomal dominant hamartoma syndromes. PTEN is a 3'-specific phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P-3) phosphatase and functions as a negative regulator of PI3K signaling. We generated a tissue-specific deletion of the mouse homolog Pten to address its role in brain function. Mice homozygous for this deletion (Pten(loxP/loxP);Gfap-cre), developed seizures and ataxia by 9 wk and died by 29 wk. Histological analysis showed brain enlargement in Pten(loxP/loxP);Gfap-cre mice as a consequence of primary granule-cell dysplasia in the cerebellum and dentate gyrus. Pten mutant cells showed a cell-autonomous increase in soma size and elevated phosphorylation of Akt. These data represent the first evidence for the role of Pten and Akt in cell size regulation in mammals and provide an animal model for a human phakomatosis condition, Lhermitte-Duclos disease (LDD).	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Amgen Res Inst, Toronto, ON M5G 2C1, Canada; Osaka Univ, Dept Mol Cell Biol, Microbial Dis Res Inst, Suita, Osaka 5650874, Japan; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Univ Hlth Network, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Toronto Western Hosp, Div Neuropathol, Toronto, ON M5T 2S8, Canada; Univ Hlth Care Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Psychol, Scarborough, ON M1C 1A4, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Osaka University; Amgen; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Scarborough	Mak, TW (corresponding author), Univ Toronto, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	tmak@oci.utoronto.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017; Suzuki, Akira/GYD-6697-2022	Tsao, Ming Sound/0000-0002-9160-5405; Suzuki, Akira/0000-0002-5950-8808; Stambolic, Vuk/0000-0001-8853-3239				Biesecker LG, 1999, AM J MED GENET, V84, P389, DOI 10.1002/(SICI)1096-8628(19990611)84:5<389::AID-AJMG1>3.0.CO;2-O; Brown W., 1987, SURGICAL TREATMENT E, P511; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Ding H, 2001, CANCER RES, V61, P3826; Dorland W. A. N., 2000, DORLANDS ILLUSTRATED; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; GRIFFITHS PD, 1994, NEUROPEDIATRICS, V25, P140, DOI 10.1055/s-2008-1073012; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hampe CS, 2001, J NEUROIMMUNOL, V113, P63, DOI 10.1016/S0165-5728(00)00423-9; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Huang H, 1999, DEVELOPMENT, V126, P5365; Iida S, 1998, INT J MOL MED, V1, P925; Karle J, 2001, NEUROL RES, V23, P39, DOI 10.1179/016164101101198262; KHURGEL M, 1995, NEUROBIOL DIS, V2, P23, DOI 10.1006/nbdi.1995.0003; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Morrison ME, 1998, J NEUROSCI, V18, P3563; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nishio S, 2000, NEUROSURG REV, V23, P84; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; PRIVAT A, 1976, J COMP NEUROL, V166, P201, DOI 10.1002/cne.901660207; RAKIC P, 1975, ADV NEUROL, V12, P117; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; ROESSMANN U, 1984, J NEUROSURG, V60, P845, DOI 10.3171/jns.1984.60.4.0845; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; SOTELO C, 1976, BRAIN RES, V111, P389, DOI 10.1016/0006-8993(76)90782-4; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEWARD O, 1992, EPILEPSY RES, P197; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; VINCHON M, 1994, J NEUROL NEUROSUR PS, V57, P699, DOI 10.1136/jnnp.57.6.699; Voogd J, 1998, TRENDS NEUROSCI, V21, P370, DOI 10.1016/S0166-2236(98)01318-6; WIESTLER OD, 2000, PATHOLOGY GENETICS T, P235; WUENSCHELL CW, 1986, P NATL ACAD SCI USA, V83, P6193, DOI 10.1073/pnas.83.16.6193; Zhou XP, 2000, HUM MOL GENET, V9, P765, DOI 10.1093/hmg/9.5.765; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5	53	373	392	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2001	29	4					396	403		10.1038/ng782	http://dx.doi.org/10.1038/ng782			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726926				2022-12-25	WOS:000172507500014
J	Hughes, KA; Hurlstone, AFL; Tobias, ES; McFarlane, R; Black, DM				Hughes, KA; Hurlstone, AFL; Tobias, ES; McFarlane, R; Black, DM			Absence of ST7 mutations in tumor-derived cell lines and tumors	NATURE GENETICS			English	Article							GENE; IDENTIFICATION; SUPPRESSOR	The gene ST7 has been proposed as the multi-tissue tumor-suppressor gene (TSG) at chromosome 7q31.1. However, we have sought and failed to detect the truncating mutations reported to exist in this gene.	Beatson Inst Canc Res, Canc Res Campaign Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Black, DM (corresponding author), Beatson Inst Canc Res, Canc Res Campaign Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Tobias, Edward/D-4246-2009	Tobias, Edward/0000-0003-2649-7695; Hurlstone, Adam/0000-0001-5260-9457				Black DM, 1999, BRIT J CANCER, V80, P42; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; HURLSTONE AFL, 1998, THESIS U GLASGOW; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Vincent JB, 2000, AM J HUM GENET, V67, P510, DOI 10.1086/303005; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	9	15	15	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					380	381		10.1038/ng783	http://dx.doi.org/10.1038/ng783			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726924				2022-12-25	WOS:000172507500011
J	Armogida, M; Petit, A; Vincent, B; Scarzello, S; da Costa, CA; Checler, F				Armogida, M; Petit, A; Vincent, B; Scarzello, S; da Costa, CA; Checler, F			Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts	NATURE CELL BIOLOGY			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; DEFECTS; CELLS; MICE; ENDOPROTEOLYSIS; INHIBITORS; MUTATION; PEPTIDES	Genetic and biochemical evidence have led to the suggestion that presenilins could be the long-searched-for gamma -secretase, the proteolytic activity that generates the carboxy terminus of amyloid beta -peptides. This activity is also thought to be responsible for the release of the Notch intracellular domain (NICD) from Notch. Here, we report the production of endogenous secreted and intracellular 40- and 42-amino-acid A beta peptides in mouse fibroblasts deficient in presenilin 1, presenilin 2 or both. We show that the endogenous production of A beta 40 and A beta 42 was not altered by presenilin deficiency. By contrast, inactivating presenilin genes fully abolished NICD production. These data indicate that A beta and NICD production are distinct catabolic events. Also, even though NICD formation is indeed presenilin dependent, endogenous secreted and intracellular beta -amyloid peptides are still generated in absence of presenilins, indicating that there is a gamma -secretase activity distinct from presenilins, at least in murine fibroblasts.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.		Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011	Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X; Petit-Paitel, Agnes/0000-0003-1138-9966; Vincent, Bruno/0000-0003-3876-2118				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BURDICK D, 1992, J BIOL CHEM, V267, P546; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Checler F, 2001, J NEUROCHEM, V76, P1621, DOI 10.1046/j.1471-4159.2001.00244.x; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chui DH, 2001, J ALZHEIMERS DIS, V3, P231; Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Refolo LM, 1999, J NEUROCHEM, V73, P2383, DOI 10.1046/j.1471-4159.1999.0732383.x; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Wolfe MS, 2001, J NEUROCHEM, V76, P1615, DOI 10.1046/j.1471-4159.2001.00245.x; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	29	89	90	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					1030	1033		10.1038/ncb1101-1030	http://dx.doi.org/10.1038/ncb1101-1030			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715026				2022-12-25	WOS:000172070300020
J	Hoffman, HM; Mueller, JL; Broide, DH; Wanderer, AA; Kolodner, RD				Hoffman, HM; Mueller, JL; Broide, DH; Wanderer, AA; Kolodner, RD			Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome	NATURE GENETICS			English	Article							PERIODIC FEVER SYNDROME; MEDITERRANEAN FEVER; MEVALONATE KINASE; CHROMOSOME 1Q44; URTICARIA; MEFV	Familial cold autoinflammatory syndrome (FCAS, MIM 120100), commonly known as familial cold urticaria (FCU), is an autosomal-dominant systemic inflammatory disease characterized by intermittent episodes of rash, arthralgia, fever and conjunctivitis after generalized exposure to cold(1-4). FCAS was previously mapped to a 10-cM region on chromosome 1q44 (refs. 5,6). Muckle-Wells syndrome (MWS; MIM 191900), which also maps to chromosome 1q44, is an autosomal-dominant periodic fever syndrome with a similar phenotype except that symptoms are not precipitated by cold exposure and that sensorineural hearing loss is frequently also present(6-8). To identify the genes for FCAS and MWS, we screened exons in the 1q44 region for mutations by direct sequencing of genomic DNA from affected individuals and controls. This resulted in the identification of four distinct mutations in a gene that segregated with the disorder in three families with FCAS and one family with MWS. This gene, called CIAS1, is expressed in peripheral blood leukocytes and encodes a protein with a pyrin domain(9-11), a nucleotide-binding site (NBS, NACHT subfamily(12)) domain and a leucine-rich repeat (LRR) motif region(13), suggesting a role in the regulation of inflammation and apoptosis.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Ctr Canc, San Diego, CA 92103 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat & Allergy, Denver, CO USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hoffman, HM (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, San Diego, CA 92103 USA.	hahoffman@ucsd.edu		Broide, David/0000-0001-8405-9090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001508] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI001508, 5-K08-AI01508] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Centola M, 2000, BLOOD, V95, P3223, DOI 10.1182/blood.V95.10.3223; Cuisset L, 1999, AM J HUM GENET, V65, P1054, DOI 10.1086/302589; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Hoffman HM, 2000, AM J HUM GENET, V66, P1693, DOI 10.1086/302874; HOFFMAN HM, IN PRESS J ALLERGY C; Houten SM, 1999, NAT GENET, V22, P175, DOI 10.1038/9691; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jung M., 1996, American Journal of Human Genetics, V59, pA223; Kile RL., 1940, J AM MED ASS, V114, P1067, DOI [10.1001/jama.1940.62810120003010b, DOI 10.1001/JAMA.1940.62810120003010B]; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kolodner RD, 1999, CANCER RES, V59, P5068; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Mansfield E, 2001, BLOOD, V98, P851, DOI 10.1182/blood.V98.3.851; Martin Seamus J., 2001, Trends in Cell Biology, V11, P188, DOI 10.1016/S0962-8924(01)01971-7; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; McDermott MF, 2000, ARTHRITIS RHEUM-US, V43, P2034, DOI 10.1002/1529-0131(200009)43:9<2034::AID-ANR14>3.0.CO;2-J; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; MUCKLE TJ, 1979, BRIT J DERMATOL, V100, P87, DOI 10.1111/j.1365-2133.1979.tb03572.x; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; ORMEROD AD, 1993, ARCH DERMATOL, V129, P343, DOI 10.1001/archderm.129.3.343; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Tidow N, 2000, BLOOD, V95, P1451, DOI 10.1182/blood.V95.4.1451.004k52_1451_1455; TINDALL JP, 1969, ARCH INTERN MED, V124, P129, DOI 10.1001/archinte.124.2.129; ZIP CM, 1993, CLIN EXP DERMATOL, V18, P338, DOI 10.1111/j.1365-2230.1993.tb02212.x	29	1164	1227	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					301	305		10.1038/ng756	http://dx.doi.org/10.1038/ng756			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687797	Green Accepted			2022-12-25	WOS:000171911000016
J	Welsh, CF; Roovers, K; Villanueva, J; Liu, YQ; Schwartz, MA; Assoian, RK				Welsh, CF; Roovers, K; Villanueva, J; Liu, YQ; Schwartz, MA; Assoian, RK			Timing of cyclin D1 expression within G1 phase is controlled by Rho	NATURE CELL BIOLOGY			English	Article							ACTIN STRESS FIBERS; ACTIVATED PROTEIN-KINASE; CELL-CYCLE; GENE-PRODUCT; RETINOBLASTOMA PROTEIN; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; GROWTH-FACTORS; G(1) PHASE; RAC	The expression of cyclin D1 in mid-G1 phase is associated with sustained ERK activity, and we show here that Rho is required for the sustained ERK signal. However, we also re port that Rho inhibits an alternative Rac/Cdc42-dependent pathway, which results in a strikingly early GI-phase expression of cyclin D1. Thus, cyclin D1 is induced in mid-G1 phase because a Rho switch couples its expression to sustained ERK activity rather than Rac and Cdc42. Our results show that Rho is crucial for maintaining the correct timing of cyclin D1 expression in G1 phase and describe a new role for cytoskeletal integrity in the regulation of cell cycle progression.	Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of Miami; University of Miami; University of Pennsylvania; Scripps Research Institute	Welsh, CF (corresponding author), Univ Miami, Sch Med, Dept Med, 1475 NW 12th Ave, Miami, FL 33136 USA.			schwartz, martin/0000-0002-2071-1243	NATIONAL CANCER INSTITUTE [R01CA072639] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900] Funding Source: NIH RePORTER; NCI NIH HHS [CA72639, R01 CA072639] Funding Source: Medline; NHLBI NIH HHS [P01 HL057900, HL57900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; APLIN AE, J BIOL CHEM, V272, P8849; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Hansen LK, 1999, J CELL SCI, V112, P2971; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	44	258	262	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					950	957		10.1038/ncb1101-950	http://dx.doi.org/10.1038/ncb1101-950			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715015				2022-12-25	WOS:000172070300009
J	Tsukiyama-Kohara, K; Poulin, F; Kohara, M; DeMaria, CT; Cheng, A; Wu, ZD; Gingras, AC; Katsume, A; Elchebly, M; Spiegelman, BM; Harper, ME; Tremblay, ML; Sonenberg, N				Tsukiyama-Kohara, K; Poulin, F; Kohara, M; DeMaria, CT; Cheng, A; Wu, ZD; Gingras, AC; Katsume, A; Elchebly, M; Spiegelman, BM; Harper, ME; Tremblay, ML; Sonenberg, N			Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1	NATURE MEDICINE			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; WHITE FAT; PHAS-I; GENE; EXPRESSION; OBESITY; PHOSPHORYLATION; COACTIVATOR; SELECTION; INSULIN	All nuclear-encoded mRNAs contain a 5' cap structure (m(7)GpppN, where N is any nucleotide), which is recognized by the eukaryotic translation initiation factor 4E (eIF4E) subunit of the eIF4F complex. The elF4E-binding proteins constitute a family of three polypeptides that reversibly repress cap-dependent translation by binding to eIF4E, thus preventing the formation of the eIF4F complex. We investigated the biological function of 4E-BP1 by disrupting its gene (Eif4ebp1) in the mouse. Eif4ebp1(-/-) mice manifest markedly smaller white fat pads than wild-type animals, and knockout males display an increase in metabolic rate. The males' white adipose tissue contains cells that exhibit the distinctive multilocular appearance of brown adipocytes, and expresses the uncoupling protein 1 (UCP1), a specific marker of brown fat. Consistent with these observations, translation of the peroxisome proliferator-activated receptor-gamma co-activator 1 (PGC1), a transcriptional co-activator implicated in mitochondrial biogenesis and adaptive thermogenesis, is increased in white adipose tissue of Eif4ebp1(-/-) mice. These findings demonstrate that 4E-BP1 is a novel regulator of adipogenesis and metabolism in mammals.	McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; Tokyo Metropolitan Inst Med Sci, Dept Microbiol & Cell Biol, Tokyo 113, Japan; Dana Farber Canc Inst, Boston, MA 02115 USA; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka, Japan; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Tokyo, Inst Med Sci, Tokyo, Japan	McGill University; McGill University; Tokyo Metropolitan Institute of Medical Science; Harvard University; Dana-Farber Cancer Institute; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Ottawa; University of Tokyo	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	nsonen@med.mcgill.ca	Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010; Cheng, Alan/M-9319-2013	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Cheng, Alan/0000-0001-7897-4751; Wu, Zhidan/0000-0001-7289-9420; Harper, Mary-Ellen/0000-0003-3864-5886				BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; Blackshear PJ, 1997, J BIOL CHEM, V272, P31510, DOI 10.1074/jbc.272.50.31510; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Ewart-Toland A, 1999, ENDOCRINOLOGY, V140, P732, DOI 10.1210/en.140.2.732; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; SHIBATA H, 1987, J APPL PHYSIOL, V63, P465, DOI 10.1152/jappl.1987.63.2.465; Soukas A, 2000, GENE DEV, V14, P963; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; TsukiyamaKohara K, 1996, GENOMICS, V38, P353, DOI 10.1006/geno.1996.0638; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	29	296	309	0	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1128	1132		10.1038/nm1001-1128	http://dx.doi.org/10.1038/nm1001-1128			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590436				2022-12-25	WOS:000171524500034
J	de Lonlay, P; Valnot, I; Barrientos, A; Gorbatyuk, M; Tzagoloff, A; Taanman, JW; Benayoun, E; Chretien, D; Kadhom, N; Lombes, A; de Baulny, HO; Niaudet, P; Munnich, M; Rustin, P; Rotig, A				de Lonlay, P; Valnot, I; Barrientos, A; Gorbatyuk, M; Tzagoloff, A; Taanman, JW; Benayoun, E; Chretien, D; Kadhom, N; Lombes, A; de Baulny, HO; Niaudet, P; Munnich, M; Rustin, P; Rotig, A			A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure	NATURE GENETICS			English	Article							CYTOCHROME-C-OXIDASE; B GENE; SACCHAROMYCES-CEREVISIAE; EXERCISE INTOLERANCE; LEIGH-SYNDROME; BC(1) COMPLEX; MUTATIONS; EXPRESSION; REDUCTASE; SURF1	Complex III (CIII; ubiquinol cytochrome c reductase of the mitochondrial respiratory chain) catalyzes electron transfer from succinate and nicotinamide adenine dinucleotide-linked dehydrogenases to cytochrome c. CIII is made up of 11 subunits, of which all but one (cytochrome b) are encoded by nuclear DNA. CIII deficiencies are rare and manifest heterogeneous clinical presentations(1,2). Although pathogenic mutations in the gene encoding mitochondrial cytochrome b have been described(3-7), mutations in the nuclear-DNA-encoded subunits have not been reported. Involvement of various genes has been indicated in assembly of yeast CIII (refs. 8-11). So far only one such gene, BCS1L, has been identified in human(12). BCS1L represents, therefore, an obvious candidate gene in CIII deficiency. Here,we report BCS1L mutations in six patients, from four unrelated families and presenting neonatal proximal tubulopathy, hepatic involvement and encephalopathy. Complementation study in yeast confirmed the deleterious effect of these mutations. Mutation of BCS1L would seem to be a frequent cause of CIII deficiency, as one-third of our patients have BCS1L mutations.	Hop Necker Enfants Malad, INSERM, U393, F-75015 Paris, France; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; UCL Royal Free & Univ Coll Med Sch, Dept Clin Neurosci, London NW3 2PF, England; Inst Myol, INSERM, U523, F-75013 Paris, France; Hop Robert Debre, Serv Neuropediat, F-75019 Paris, France; Hop Necker Enfants Malad, Dept Pediat, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Columbia University; University of London; University College London; UCL Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Rotig, A (corresponding author), Hop Necker Enfants Malad, INSERM, U393, 149 Rue Sevres, F-75015 Paris, France.	roetig@necker.fr	Taanman, Jan W/A-5379-2011; Rötig, Agnès/G-9592-2017; Lombes, Anne/G-4684-2014	Taanman, Jan W/0000-0002-5476-9785; Rötig, Agnès/0000-0003-0589-0703; Lombes, Anne/0000-0002-9064-0399; Gorbatyuk, Marina/0000-0001-9060-856X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022174, R56HL022174, R01HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL022174, HL22174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; CRIVELLONE MD, 1994, J BIOL CHEM, V269, P21284; Cruciat CM, 1999, EMBO J, V18, P5226, DOI 10.1093/emboj/18.19.5226; De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.3.CO;2-Q; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900; Kuklin A, 1997, GENET TEST, V1, P201, DOI 10.1089/gte.1997.1.201; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; Mourmans J, 1997, J NEUROL SCI, V149, P111, DOI 10.1016/S0022-510X(97)05379-3; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; Papadopoulou LC, 1999, NAT GENET, V23, P333; Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580; Rahman S, 2001, ANN NEUROL, V49, P797, DOI 10.1002/ana.1060; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; Valnot I, 1999, HUM GENET, V104, P460, DOI 10.1007/s004390050988; von Kleist-Retzow JC, 1999, BBA-MOL BASIS DIS, V1455, P35, DOI 10.1016/S0925-4439(99)00050-2; von Kleist-Retzow JC, 1998, AM J HUM GENET, V63, P428, DOI 10.1086/301957; Von Kleist-Retzow JC, 2001, J MED GENET, V38, P109, DOI 10.1136/jmg.38.2.109; WU M, 1989, J BIOL CHEM, V264, P11122; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	25	226	227	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2001	29	1					57	60		10.1038/ng706	http://dx.doi.org/10.1038/ng706			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528392				2022-12-25	WOS:000170781300017
J	Dormond, O; Foletti, A; Paroz, C; Ruegg, C				Dormond, O; Foletti, A; Paroz, C; Ruegg, C			NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis	NATURE MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; GROWTH-FACTOR; CYCLOOXYGENASE-2 INHIBITORS; THROMBOXANE A(2); IN-VITRO; ACTIVATION; CANCER; ALPHA(V)BETA(3); SULINDAC	Cyclooxygenase-2 (COX-2), a key enzyme in arachidonic acid metabolism, is overexpressed in many cancers. Inhibition of COX-2 by nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of cancer development in humans and suppresses tumor growth in animal models. The anticancer effect of NSAIDs seems to involve suppression of tumor angiogenesis, but the underlying mechanism is not completely understood. Integrin alphaV beta3 is an adhesion receptor critically involved in mediating tumor angiogenesis. Here we show that inhibition of endothelial-cell COX-2 by NSAIDs suppresses alphaV beta3-dependent activation of the small GTPases Cdc42 and Rac, resulting in inhibition of endothelial-cell spreading and migration in vitro and suppression of fibroblast growth factor-2-induced angiogenesis in vivo. These results establish a novel functional link between COX-2, integrin alphaV beta3 and Cdc42-/Rac-dependent endothelial-cell migration. Moreover, they provide a rationale to the understanding of the anti-angiogenic activity of NSAIDs.	Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland	University of Lausanne	Ruegg, C (corresponding author), Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland.		Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782				BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; Daniel TO, 1999, CANCER RES, V59, P4574; Dominguez-Jimenez C, 1999, FEBS LETT, V446, P318, DOI 10.1016/S0014-5793(99)00236-7; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GarciaVicuna R, 1997, ARTHRITIS RHEUM-US, V40, P143, DOI 10.1002/art.1780400119; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Honda S, 2001, BLOOD, V97, P175, DOI 10.1182/blood.V97.1.175; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Jones MK, 1999, NAT MED, V5, P1418; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Masferrer JL, 2000, CANCER RES, V60, P1306; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SANO H, 1995, CANCER RES, V55, P3785; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Skopinska-Rozewska E, 1998, INT J TISSUE REACT, V20, P85; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	44	244	255	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1041	1047		10.1038/nm0901-1041	http://dx.doi.org/10.1038/nm0901-1041			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533708				2022-12-25	WOS:000170853300030
J	Robertson, MP; Ellington, AD				Robertson, MP; Ellington, AD			In vitro selection of nucleoprotein enzymes	NATURE BIOTECHNOLOGY			English	Article							GROUP-I INTRON; RIBONUCLEASE-P; CATALYTIC CORE; TRANSFER-RNA; RIBONUCLEOPROTEIN ENZYME; MOLECULAR SWITCHES; PROTEIN-COMPONENT; RIBOZYME; CHAPERONES; DESIGN	Natural nucleic acids frequently rely on proteins for stabilization or catalytic activity. In contrast, nucleic acids selected in vitro can catalyze a wide range of reactions even in the absence of proteins. To augment selected nucleic acids with protein functionalities, we have developed a technique for the selection of protein-dependent ribozyme ligases. After randomizing a previously selected ribozyme ligase, L1, we selected variants that required one of two protein cofactors, a tyrosyl transfer RNA (tRNA) synthetase (Cyt18) or hen egg white lysozyme. The resulting nucleoprotein enzymes were activated several thousand fold by their cognate protein effecters, and could specifically recognize the structures of the native proteins. Protein-dependent ribozymes can potentially be adapted to novel assays for detecting target proteins. and the selection method's generality may allow the high-through identification of ribozymes capable of recognizing a sizable fraction of a proteome.	Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Robertson, MP (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA.	andy.ellington@utexas.edu						Ackers GK, 1998, ADV PROTEIN CHEM, V51, P185; AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; Biswas R, 2000, J MOL BIOL, V296, P19, DOI 10.1006/jmbi.1999.3443; Borrebaeck CAK, 2000, IMMUNOL TODAY, V21, P379, DOI 10.1016/S0167-5699(00)01683-2; Caprara MG, 1996, J MOL BIOL, V257, P512, DOI 10.1006/jmbi.1996.0182; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; Cox JC, 1998, BIOTECHNOL PROGR, V14, P845, DOI 10.1021/bp980097h; COX JC, IN PRESS BIOORG MED; FISCHER B, 1992, ARCH BIOCHEM BIOPHYS, V298, P361, DOI 10.1016/0003-9861(92)90422-S; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; Hesselberth J, 2000, J Biotechnol, V74, P15, DOI 10.1016/S1389-0352(99)00005-7; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; Holt L J, 2000, Nucleic Acids Res, V28, pE72, DOI 10.1093/nar/28.15.e72; JHAVERI SD, 2000, CURRENT PROTOCOLS NU; Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062; Kumar S, 1999, CELL BIOCHEM BIOPHYS, V31, P141, DOI 10.1007/BF02738169; Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9; Kurz JC, 1998, BIOCHEMISTRY-US, V37, P2393, DOI 10.1021/bi972530m; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Loria A, 1998, BIOCHEMISTRY-US, V37, P15466, DOI 10.1021/bi9816507; Mendoza LG, 1999, BIOTECHNIQUES, V27, P778, DOI 10.2144/99274rr01; Myers CA, 1996, J MOL BIOL, V262, P87, DOI 10.1006/jmbi.1996.0501; Niranjanakumari S, 1998, P NATL ACAD SCI USA, V95, P15212, DOI 10.1073/pnas.95.26.15212; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; Robertson MP, 2000, NUCLEIC ACIDS RES, V28, P1751, DOI 10.1093/nar/28.8.1751; Robertson MP, 1999, NAT BIOTECHNOL, V17, P62, DOI 10.1038/5236; Robertson MP, 2001, RNA, V7, P513, DOI 10.1017/S1355838201002199; Saldanha R, 1996, J MOL BIOL, V261, P23, DOI 10.1006/jmbi.1996.0439; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; Schon A, 1999, FEMS MICROBIOL REV, V23, P391, DOI 10.1016/S0168-6445(99)00014-5; Soukup GA, 1999, TRENDS BIOTECHNOL, V17, P469, DOI 10.1016/S0167-7799(99)01383-9; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; Weeks KM, 1997, CURR OPIN STRUC BIOL, V7, P336, DOI 10.1016/S0959-440X(97)80048-6; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7	38	65	73	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					650	655		10.1038/90256	http://dx.doi.org/10.1038/90256			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433277				2022-12-25	WOS:000169677200021
J	Vidal, VPI; Chaboissier, MC; de Rooij, DG; Schedl, A				Vidal, VPI; Chaboissier, MC; de Rooij, DG; Schedl, A			Sox9 induces testis development in XX transgenic mice	NATURE GENETICS			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CAMPOMELIC DYSPLASIA; MOUSE; EXPRESSION; MUTATIONS; UPSTREAM	Mutations in SOX9 are associated with male-to-female sex reversal in humans(1,2). To analyze Sox9 function during sex determination, we ectopically expressed this gene in XX gonads. Here, we show that Sox9 is sufficient to induce testis formation in mice, indicating that it can substitute for the sex-determining gene Sry.	MDC Mol Med, D-13092 Berlin, Germany; Univ Utrecht, Med Ctr, Dept Cell Biol, Utrecht, Netherlands	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Utrecht University	Schedl, A (corresponding author), MDC Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	andreas.schedl@ncl.ac.uk	de Rooij, D.G./AAW-1195-2021; vidal, valerie/S-2597-2019; CHABOISSIER, Marie-Christine/AAZ-5905-2021; Schedl, Andreas/F-8823-2015; Schedl, Andreas/GOP-3427-2022; Vidal, Valerie/M-1477-2018; CHABOISSIER, Marie-Christine/F-6166-2019	CHABOISSIER, Marie-Christine/0000-0003-0934-8217; Schedl, Andreas/0000-0001-9380-7396; CHABOISSIER, Marie-Christine/0000-0003-0934-8217; de Rooij, Dirk/0000-0003-3932-4419				Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Bergstrom DE, 2000, GENESIS, V28, P111, DOI 10.1002/1526-968X(200011/12)28:3/4<111::AID-GENE40>3.0.CO;2-5; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Huang B, 1999, AM J MED GENET, V87, P349, DOI 10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N; Hunt PA, 1998, MOL REPROD DEV, V49, P101, DOI 10.1002/(SICI)1098-2795(199802)49:2&lt;101::AID-MRD1&gt;3.0.CO;2-T; Kent J, 1996, DEVELOPMENT, V122, P2813; Moore AW, 1998, MECH DEVELOP, V79, P169, DOI 10.1016/S0925-4773(98)00188-9; Pask A, 1999, CELL MOL LIFE SCI, V55, P864, DOI 10.1007/s000180050340; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; Scholz H, 1997, J BIOL CHEM, V272, P32836, DOI 10.1074/jbc.272.52.32836; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8	15	510	531	2	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					216	217		10.1038/90046	http://dx.doi.org/10.1038/90046			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431689				2022-12-25	WOS:000169656400011
J	Hsu, T; McRackan, D; Vincent, TS; de Couet, HG				Hsu, T; McRackan, D; Vincent, TS; de Couet, HG			Drosophila Pin1 prolyl isomerase Dodo is a MAP kinase signal responder during oogenesis	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTION FACTOR CF2; EGF RECEPTOR; X-CHROMOSOME; CELL-CYCLE; BODY AXES; GENE; ESS1; ENCODES; PROTEIN; POLARIZATION	The mammalian cis-trans prolyl isomerase Pin1 and its yeast orthologue Ess1/Ptf1 have been implicated in cell cycle control but a correlation between biochemical and physiological functions has not been established conclusively. Pin1 targets the proline residue carboxy-terminal to the phosphorylated threonine or serine residue, which constitutes part of the phosphorylated mitogen-activated protein kinase (MAPK) site PXpT/SP. Here we show that the Drosophila Pin1 homologue, the Dodo protein, is involved in dorsoventral patterning of the follicular epithelium in the egg chamber. Its function is to facilitate the degradation of transcription factor CF2, which requires, a priori, activated epidermal growth factor receptor-MAPK signalling.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Univ Hawaii, Dept Zool, Honolulu, HI 96822 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University of Hawaii System	Hsu, T (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	hsut@musc.edu	de Couet, Heinz/J-9522-2012	de Couet, Heinz/0000-0002-0307-2881; Hsu, Tien/0000-0003-2308-4297				Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Hsu T, 1996, GENE DEV, V10, P1411, DOI 10.1101/gad.10.11.1411; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Maleszka R, 1997, GENE, V203, P89, DOI 10.1016/S0378-1119(97)00522-2; Maleszka R, 1998, P NATL ACAD SCI USA, V95, P3731, DOI 10.1073/pnas.95.7.3731; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; Mantrova EY, 1998, GENE DEV, V12, P1166; MIKLOS GLG, 1990, J NEUROGENET, V6, P133, DOI 10.3109/01677069009107106; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PERRIMON N, 1989, GENETICS, V121, P313; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rorth P, 2000, MOL CELL, V6, P23; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Sapir A, 1998, DEVELOPMENT, V125, P191; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Spradling Allan C., 1993, P1; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	30	75	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					538	543		10.1038/35078508	http://dx.doi.org/10.1038/35078508			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389437				2022-12-25	WOS:000169194400008
J	Sklar, P; Schwab, SG; Williams, NM; Daly, M; Schaffner, S; Maier, W; Albus, M; Trixler, M; Eichhammer, P; Lerer, B; Hallmayer, J; Norton, N; Williams, H; Zammit, S; Cardno, AG; Jones, S; McCarthy, G; Milanova, V; Kirov, G; O'Donovan, MC; Lander, ES; Owen, MJ; Wildenauer, DB				Sklar, P; Schwab, SG; Williams, NM; Daly, M; Schaffner, S; Maier, W; Albus, M; Trixler, M; Eichhammer, P; Lerer, B; Hallmayer, J; Norton, N; Williams, H; Zammit, S; Cardno, AG; Jones, S; McCarthy, G; Milanova, V; Kirov, G; O'Donovan, MC; Lander, ES; Owen, MJ; Wildenauer, DB			Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls	NATURE GENETICS			English	Article							SUSCEPTIBILITY	A genetic association between NOTCH4 and schizophrenia has previously been proposed(1). Unsing all markers previously shown to be associated, we found no evidence for such in three independent family-based samples (n=519 parent-offspring trios), and a case-control sample derived from the same ethnic background as the original observaton, These data strongly suggest that NOTCH4 is not a significant susceptibility allele for schizophrenia.	Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Univ Bonn, Dept Psychiat, Genet Mol Lab, D-53111 Bonn, Germany; Cardiff Univ, Dept Psychol Med, Cardiff CF4 4XN, S Glam, Wales; Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany; Mental State Hosp, D-85529 Haar, Germany; Univ Pecs, Sch Med, Dept Psychiat, H-7623 Pecs, Hungary; Univ Regensburg, Dept Psychiat, D-93042 Regensburg, Germany; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Psychiat, IL-91120 Jerusalem, Israel; Univ Western Australia, Graylands Hosp, Ctr Clin Res Neuropscyhiat, Mtr Claremont, WA 6010, Australia; Med Univ Sofia, Dept Psychiat, Sofia 1431, Bulgaria	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Bonn; Cardiff University; University of Bonn; University of Pecs; University of Regensburg; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Western Australia; Medical University Sofia	Sklar, P (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.	sklar@genome.wi.mit.edu	Williams, Hywel/AAL-2440-2021; Daly, Mark J/B-2453-2017; O'Donovan, Michael C/P-7005-2018; McCarthy, Geraldine/AAU-9549-2021; Schaffner, Stephen F/D-1189-2011	Williams, Hywel/0000-0001-7758-0312; Daly, Mark J/0000-0002-0949-8752; O'Donovan, Michael C/0000-0001-7073-2379; Kirov, George/0000-0002-3427-3950; Zammit, Stanley/0000-0002-2647-9211; Schaffner, Stephen/0000-0001-6699-3568; McCarthy, Geraldine/0000-0002-1312-0998				Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; SCHWAB SG, 1995, NAT GENET, V11, P325, DOI 10.1038/ng1195-325; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Wei J, 2000, NAT GENET, V25, P376, DOI 10.1038/78044; 1999, NATURE GENET, V22, P1	5	57	59	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					126	128		10.1038/88836	http://dx.doi.org/10.1038/88836			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381257				2022-12-25	WOS:000169011800012
J	Lubke, T; Marquardt, T; Etzioni, A; Hartmann, E; von Figura, K; Korner, C				Lubke, T; Marquardt, T; Etzioni, A; Hartmann, E; von Figura, K; Korner, C			Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency	NATURE GENETICS			English	Article								Congenital disorders of glycosylation (CDG) comprise a rapidly growing group of inherited disorders in which glycosylation of glycoproteins is defective due to mutations in genes required for the assembly of lipid-linked oligosaccharides, their transfer to nascent glycoproteins (CDG-I) or the processing of protein-bound glycansl(1,2) (CDG-II). Previously' a defect in the GDP-fucose import into the lumen of the Golgi was identified in a person with CDG (A.C.) with a general deficiency of fucosyl residues in glycoproteins(3). This patient presents the clinical features of leukocyte adhesion deficiency type II (LAD II) including mental retardation, short stature, facial stigmata, and recurrent bacterial peripheral infections with persistently elevated peripheral leukocytes(4-7). Using a fucose-specific. lectin-staining procedure for detection of fucosylated glycoproteins and a retroviral cDNA library, we isolated a cDNA complementing the fucosylation defect in the patient's fibroblasts. The cDNA encodes a highly hydrophobic protein of 364 amino acids with multiple putative transmembrane domains. Restoration of CDP-fucose import activity in Golgi-enriched vesicles from the patient's fibroblasts verified the GDP-fucose transporter activity of this protein. We identified two missense mutations in the GDP-fucose transporter cDNA of patient A.C. and of two other people with LAD II. Thus complementation cloning allowed us to identify the human GDP-fucose transporter cDNA and GDP-fucose transporter deficiency as a cause for a new type of CDG. Following the recent recommendations(2,8) for the nomenclature for CDG, this new type is classified as CDG-IIc (formerly LAD II).	Univ Gottingen, Biochem Abt 2, Gottingen, Germany; Klin & Poliklin Kinderheilkunde, Munster, Germany; Rambam Med Ctr, B Rappaport Sch Med, Dept Pediat & Immunol, Haifa, Israel	University of Gottingen; University of Munster; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Korner, C (corresponding author), Univ Gottingen, Biochem Abt 2, Heinrich Duker Weg 12, Gottingen, Germany.	ckoerne@gwdg.de	Lübke, Torben/B-6019-2012; Hartmann, Enno/C-5687-2013	Lubke, Torben/0000-0002-3342-0090				Aebi M, 2000, GLYCOBIOLOGY, V10, pIII; Etzioni A, 1998, J ALLERGY CLIN IMMUN, V102, P323, DOI 10.1016/S0091-6749(98)70104-6; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRYDMAN M, 1992, AM J MED GENET, V44, P297, DOI 10.1002/ajmg.1320440307; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Krasnewich D, 1997, Adv Pediatr, V44, P109; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; MANIATIS NT, 1989, MOL CLONING LAB MANU; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; 1999, GLYCOCONJ J, V16, P669	14	239	254	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					73	76		10.1038/ng0501-73	http://dx.doi.org/10.1038/ng0501-73			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326280	Green Published			2022-12-25	WOS:000168413300020
J	Celletti, FL; Waugh, JM; Amabile, PG; Brendolan, A; Hilfiker, PR; Dake, MD				Celletti, FL; Waugh, JM; Amabile, PG; Brendolan, A; Hilfiker, PR; Dake, MD			Vascular endothelial growth factor enhances atherosclerotic plaque progression	NATURE MEDICINE			English	Article							PERMEABILITY FACTOR; INTIMAL NEOVASCULARIZATION; GENE-TRANSFER; VEGF; MACROPHAGES; EXPRESSION; CELLS; MICROVESSELS; PATHOGENESIS; RECEPTORS	Vascular endothelial growth factor (VEGF) can promote angiogenesis but may also exert certain effects to alter the rate of atherosclerotic plaque development. To evaluate this potential impact on plaque progression, we treated cholesterol-fed mice doubly deficient in apolipoprotein E/apolipoprotein B100 with low doses of VEGF (2 mug/kg) or albumin. VEGF significantly increased macrophage levels in bone marrow and peripheral blood and increased plaque area 5-, 14- and 4-fold compared with controls at weeks 1, 2 and 3, respectively. Plaque macrophage and endothelial cell content also increased disproportionately over controls. In order to confirm that the VEGF-mediated plaque progression was not species-specific, the experiment was repeated in cholesterol-fed rabbits at the three-week timepoint, which showed comparable increases in plaque progression.	Stanford Univ, Med Ctr, Stanford, CA 94305 USA; WHO, CH-1211 Geneva, Switzerland	Stanford University; World Health Organization	Dake, MD (corresponding author), Stanford Univ, Med Ctr, Stanford, CA 94305 USA.	mddake@stanford.edu		Brendolan, Andrea/0000-0003-0109-6879				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BHARDWAY R, 1994, J LEUKOCYTE BIOL, V57, P747; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; GOWN AM, 1986, AM J PATHOL, V125, P191; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kaartinen M, 1996, ATHEROSCLEROSIS, V123, P123, DOI 10.1016/0021-9150(95)05794-3; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kolodgie FD, 1996, ARTERIOSCL THROM VAS, V16, P1454, DOI 10.1161/01.ATV.16.12.1454; KRATKY RG, 1993, ATHEROSCLEROSIS, V99, P121, DOI 10.1016/0021-9150(93)90057-2; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6; LIBBY P, 1986, AM J PATHOL, V124, P179; Lopez JJ, 1998, CARDIOVASC RES, V40, P272, DOI 10.1016/S0008-6363(98)00136-9; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Paterson JC, 1938, ARCH PATHOL, V25, P474; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; Pujol BF, 2000, DIFFERENTIATION, V65, P287, DOI 10.1046/j.1432-0436.2000.6550287.x; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHEN H, 1993, BLOOD, V81, P2767; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Sueishi K, 1997, ANN NY ACAD SCI, V811, P311, DOI 10.1111/j.1749-6632.1997.tb52011.x; Tenaglia AN, 1998, AM HEART J, V135, P10, DOI 10.1016/S0002-8703(98)70336-9; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Yonemitsu Y, 1996, LAB INVEST, V75, P313	31	574	616	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					425	429		10.1038/86490	http://dx.doi.org/10.1038/86490			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283668				2022-12-25	WOS:000167960500036
J	Zhou, BHP; Liao, Y; Xia, WY; Zou, YY; Spohn, B; Hung, MC				Zhou, BHP; Liao, Y; Xia, WY; Zou, YY; Spohn, B; Hung, MC			HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation	NATURE CELL BIOLOGY			English	Article							NUCLEAR EXPORT; BREAST-CANCER; TUMOR; SURVIVAL; LOCALIZATION; DEGRADATION; CHECKPOINTS; ACTIVATION; P19(ARF); PATHWAY	HER-2/neu amplification or overexpression can make cancer cells resistant to apoptosis and promotes their growth. p53 is crucial in regulating cell growth and apoptosis, and is often mutated or deleted in many types of tumour. Moreover, many turnours with a wild-type gene for p53 do not have normal p53 function, suggesting that some oncogenic signals suppress the function of p53. In this study, we show that HER-2/neu-mediated resistance to DNA-damaging agents requires the activation of Akt, which enhances MDM2-mediated ubiquitination and degradation of p53. Akt physically associates with MDM2 and phosphorylates it at Ser166 and Ser186. Phosphorylation of MDM2 enhances its nuclear localization and its interaction with p300, and inhibits its interaction with P19(ARF), thus increasing p53 degradation. Our study indicates that blocking the Akt pathway mediated by HER-2/neu would increase the cytotoxic effect of DNA-damaging drugs in tumour cells with wild-type p53.	Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Breast Canc Basic Res Program, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@notes.mdacc.tmc.edu	Hung, Mien-Chie/ABD-5911-2021; 高, 雨莉/HGU-8187-2022	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R01CA077858, P50CA083639, R01CA078633, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA77858, CA 83639, CA 78633, CA 58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Ozes ON, 1999, NATURE, V401, P82; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; YU D, 2000, DNA ALTERATIONS CANC, pCH21; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	36	746	778	4	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					973	982		10.1038/ncb1101-973	http://dx.doi.org/10.1038/ncb1101-973			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715018				2022-12-25	WOS:000172070300012
J	Hwang, PM; Bunz, F; Yu, J; Rago, C; Chan, TA; Murphy, MP; Kelso, GF; Smith, RAJ; Kinzler, KW; Vogelstein, B				Hwang, PM; Bunz, F; Yu, J; Rago, C; Chan, TA; Murphy, MP; Kelso, GF; Smith, RAJ; Kinzler, KW; Vogelstein, B			Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells	NATURE MEDICINE			English	Article							REACTIVE OXYGEN; ADRENODOXIN REDUCTASE; ANTICANCER AGENTS; ELECTRON LEAKAGE; GENE-EXPRESSION; DNA-DAMAGE; P53; MITOCHONDRIA; P21; PROTEIN	Loss of p53 gene function, which occurs in most colon cancer cells, has been shown to abolish the apoptotic response to 5-fluorouracil (54U). To identify genes downstream of p53 that might mediate these effects, we assessed global patterns of gene expression following 5-FU treatment of isogenic cells differing only in their p53 status. The gene encoding mitochondrial ferredoxin reductase (protein, FR; gene, FDXR) was one of the few genes significantly induced by p53 after 5-FU treatment. The FR protein was localized to mitochondria and suppressed the growth of colon cancer cells when over-expressed. Targeted disruption of the FDXR gene in human colon cancer cells showed that it was essential for viability, and partial disruption of the gene resulted in decreased sensitivity to 5-FU-induced apoptosis. These data, coupled with the effects of pharmacologic inhibitors of reactive oxygen species, indicate that FIR contributes to p53-mediated apoptosis through the generation of oxidative stress in mitochondria.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; Wellcome Trust Res Labs, Cambridge, England; Univ Otago, Dept Chem, Dunedin, New Zealand	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wellcome Trust Sanger Institute; University of Otago	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Murphy, Michael P/C-2120-2009; Chan, Timothy A/ABD-5850-2021; Yu, Jian/A-8301-2009	Murphy, Michael P/0000-0003-1115-9618; Yu, Jian/0000-0002-4021-1000	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043460, CA 43460] Funding Source: Medline; NIGMS NIH HHS [GM 07184, T32 GM007184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANUKOGLU I, 1993, ARCH BIOCHEM BIOPHYS, V305, P489, DOI 10.1006/abbi.1993.1452; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LIN D, 1990, P NATL ACAD SCI USA, V87, P8516, DOI 10.1073/pnas.87.21.8516; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Masramon L, 2000, CANCER GENET CYTOGEN, V121, P17, DOI 10.1016/S0165-4608(00)00219-3; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; OConnor PM, 1997, CANCER RES, V57, P4285; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pham NA, 2000, CYTOMETRY, V41, P245, DOI 10.1002/1097-0320(20001201)41:4<245::AID-CYTO2>3.0.CO;2-#; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; RAPOPORT R, 1995, ARCH BIOCHEM BIOPHYS, V317, P412, DOI 10.1006/abbi.1995.1182; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807	39	346	357	2	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1111	1117		10.1038/nm1001-1111	http://dx.doi.org/10.1038/nm1001-1111			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590433	Green Accepted			2022-12-25	WOS:000171524500031
J	Rioux, JD; Daly, MJ; Silverberg, MS; Lindblad, K; Steinhart, H; Cohen, Z; Delmonte, T; Kocher, K; Miller, K; Guschwan, S; Kulbokas, EJ; O'Leary, S; Winchester, E; Dewar, K; Green, T; Stone, V; Chow, C; Cohen, A; Langelier, D; Lapointe, G; Gaudet, D; Faith, J; Branco, N; Bull, SB; McLeod, RS; Griffiths, AM; Bitton, A; Greenberg, GR; Lander, ES; Siminovitch, KA; Hudson, TJ				Rioux, JD; Daly, MJ; Silverberg, MS; Lindblad, K; Steinhart, H; Cohen, Z; Delmonte, T; Kocher, K; Miller, K; Guschwan, S; Kulbokas, EJ; O'Leary, S; Winchester, E; Dewar, K; Green, T; Stone, V; Chow, C; Cohen, A; Langelier, D; Lapointe, G; Gaudet, D; Faith, J; Branco, N; Bull, SB; McLeod, RS; Griffiths, AM; Bitton, A; Greenberg, GR; Lander, ES; Siminovitch, KA; Hudson, TJ			Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease	NATURE GENETICS			English	Article							INFLAMMATORY-BOWEL-DISEASE; ASSOCIATION; REGION	Linkage disequilibrium (LD) mapping provides a powerful method for fine-structure localization of rare disease genes, but has not yet been widely applied to common disease(1). We sought to design a systematic approach for LD mapping and apply it to the localization of a gene (IBD5) conferring susceptibility to Crohn disease. The key issues are: (i) to detect a significant LD signal (ii) to rigorously bound the critical region and (iii) to identify the causal genetic variant within this region. We previously mapped the IBD5 locus to a large region spanning 18 cM of chromosome 5q31 (P<10(-4)). Using dense genetic maps of microsatellite markers and single-nucleotide polymorphisms (SNPs) across the entire region, we found strong evidence of LD. We bound the region to a common haplotype spanning 250 kb that shows strong association with the disease (P<2x10(-7)) and contains the cytokine gene cluster, This finding provides overwhelming evidence that a specific common haplotype of the cytokine region in 5q31 confers susceptibility to Crohn disease. However, genetic evidence alone is not sufficient to identify the causal mutation within this region, as strong LD across the region results in multiple SNPs having equivalent genetic evidence-each consistent with the expected properties of the 1BD5 locus. These results have important implications for Crohn disease in particular and LID mapping in general.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Immunol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; McGill Univ, Ctr Hlth, Dept Gastroenterol, Montreal, PQ, Canada; McGill Univ, Montreal Genome Ctr, Montreal, PQ, Canada; Ctr Hosp Sherbrooke, Sherbrooke, PQ, Canada; Ctr Hosp Sagamie, Chicoutimi, PQ, Canada; MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; McGill University; Massachusetts Institute of Technology (MIT)	Rioux, JD (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	rioux@genome.wi.mit.edu; lander@wi.mit.edu; ksiminovitch@mtsinai.on.ca; tjhudson@med.mcgill.ca	Greenberg, Gordon/C-4620-2015; McLeod, Robin/K-1476-2013; Bull, Shelley B/A-1920-2013; Silverberg, Mark/B-4183-2008; Rioux, John D/A-9599-2015; Siminovitch, Katherine/K-1475-2013; Daly, Mark J/B-2453-2017	Rioux, John D/0000-0001-7560-8326; Daly, Mark J/0000-0002-0949-8752				Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Clavell M, 2000, J PEDIATR GASTR NUTR, V30, P43, DOI 10.1097/00005176-200001000-00016; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; FARTHING MJG, 1978, GUT, V19, P743, DOI 10.1136/gut.19.8.743; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Rioux JD, 2000, AM J HUM GENET, V66, P1863, DOI 10.1086/302913; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; Spielman RS, 1996, AM J HUM GENET, V59, P983; Zhu YW, 2000, P NATL ACAD SCI USA, V97, P1137, DOI 10.1073/pnas.97.3.1137	15	632	655	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					223	228		10.1038/ng1001-223	http://dx.doi.org/10.1038/ng1001-223			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586304				2022-12-25	WOS:000171374100032
J	Eisenberg, I; Avidan, N; Potikha, T; Hochner, H; Chen, M; Olender, T; Barash, M; Shemesh, M; Sadeh, M; Grabov-Nardini, G; Shmilevich, I; Friedmann, A; Karpati, G; Bradley, WG; Baumbach, L; Lancet, D; Ben Asher, E; Beckmann, JS; Argov, Z; Mitrani-Rosenbaum, S				Eisenberg, I; Avidan, N; Potikha, T; Hochner, H; Chen, M; Olender, T; Barash, M; Shemesh, M; Sadeh, M; Grabov-Nardini, G; Shmilevich, I; Friedmann, A; Karpati, G; Bradley, WG; Baumbach, L; Lancet, D; Ben Asher, E; Beckmann, JS; Argov, Z; Mitrani-Rosenbaum, S			The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy	NATURE GENETICS			English	Article							ACETYLNEURAMINIC ACID BIOSYNTHESIS; BIFUNCTIONAL ENZYME CATALYZES; 1ST 2 STEPS; SEQUENCE ALIGNMENTS; DISTAL MYOPATHY; RIMMED VACUOLE; RAT-LIVER; LOCUS; 2-EPIMERASE; MAPS	Hereditary inclusion body myopathy (HIBM; OMIM 600737) is a unique group of neuromuscular disorders characterized by adult onset, slowly progressive distal and proximal weakness and a typical muscle pathology including rimmed vacuoles and filamentous inclusions'. The autosomal recessive form described in Jews of Persian descent(2) is the HIBM prototype. This myopathy affects mainly leg muscles, but with an unusual distribution that spares the quadriceps(3). This particular pattern of weakness distribution, termed quadriceps-sparing myopathy (QSM), was later found in Jews originating from other Middle Eastern countries as well as in non-Jews(4). We previously localized the gene causing HIBM in Middle Eastern Jews on chromosome 9p12-13 (ref. 5) within a genomic interval of about 700 kb (ref. 6). Haplotype analysis around the HIBM gene region of 104 affected people from 47 Middle Eastern families indicates one unique ancestral founder chromosome in this community. By contrast, single non-Jewish families from India, Georgia (USA) and the Bahamas, with QSM and linkage to the same 9p12-13 region, show three distinct haplotypes. After excluding other potential candidate genes, we eventually identified mutations in the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GIVE) gene in the HIBM families: all patients from Middle Eastern descent shared a single homozygous missense mutation, whereas distinct compound heterozygotes were identified in affected individuals of families of other ethnic origins. our findings indicate that GIVE is the gene responsible for recessive HIBM.	Hebrew Univ Jerusalem, Hadassah Med Sch, Mol Biol Unit, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Neurol, IL-91010 Jerusalem, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Crown Genome Ctr, IL-76100 Rehovot, Israel; Wolfson Govt Hosp, Dept Neurol, Holon, Israel; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Miami, Sch Med, Dept Neurol, Miami, FL USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Weizmann Institute of Science; Weizmann Institute of Science; McGill University; University of Miami; University of Miami	Mitrani-Rosenbaum, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Mol Biol Unit, IL-91010 Jerusalem, Israel.	stella@yam-suff.huji.ac.il	Barash, Mark/M-8757-2016; Beckmann, Jacques S/A-9772-2008; Shemesh, Moshe/AAR-7506-2020	Barash, Mark/0000-0002-5445-6316; Beckmann, Jacques S/0000-0002-9741-1900; Shemesh, Moshe/0000-0002-3854-6151; Mitrani-Rosenbaum, Stella/0000-0001-5335-8709				AGROV Z, 1998, CURR OPIN RHEUMATOL, V10, P543; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARGOV Z, 1984, J NEUROL SCI, V64, P33, DOI 10.1016/0022-510X(84)90053-4; ARGOV Z, 1997, INCLUSION BODY MYOSI, P200; Askanas Valerie, 1998, Current Opinion in Rheumatology, V10, P530, DOI 10.1097/00002281-199811000-00005; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Eisenberg I, 2001, EUR J HUM GENET, V9, P501, DOI 10.1038/sj.ejhg.5200665; Eisenberg I, 1999, GENOMICS, V55, P43, DOI 10.1006/geno.1998.5630; GRIGGS RC, 1995, ANN NEUROL, V38, P705, DOI 10.1002/ana.410380504; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; HUMBEL R, 1975, CLIN CHIM ACTA, V60, P143, DOI 10.1016/0009-8981(75)90119-9; Ikeuchi T, 1997, ANN NEUROL, V41, P432, DOI 10.1002/ana.410410405; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Little S, 1995, CURRENT PROTOCOLS HU; MitraniRosenbaum S, 1996, HUM MOL GENET, V5, P159, DOI 10.1093/hmg/5.1.159; NONAKA I, 1981, J NEUROL SCI, V51, P141, DOI 10.1016/0022-510X(81)90067-8; PONNAMBALAM S, 1994, GENOMICS, V24, P440, DOI 10.1006/geno.1994.1650; SADEH M, 1997, INCLUSION BODY MYOSI, P191; Salzberg SL, 2001, SCIENCE, V292, P1903, DOI 10.1126/science.1061036; Seppala R, 1999, AM J HUM GENET, V64, P1563, DOI 10.1086/302411; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221	25	364	387	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2001	29	1					83	87		10.1038/ng718	http://dx.doi.org/10.1038/ng718			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528398				2022-12-25	WOS:000170781300023
J	Takano, T; Lin, JHC; Arcuino, G; Gao, Q; Yang, J; Nedergaard, M				Takano, T; Lin, JHC; Arcuino, G; Gao, Q; Yang, J; Nedergaard, M			Glutamate release promotes growth of malignant gliomas	NATURE MEDICINE			English	Article							NMDA RECEPTOR ANTAGONIST; EXTRACELLULAR GLUTAMATE; CELLS; TRANSPORT; C6; NEUROTOXICITY; LOCALIZATION; MODULATION; EXPRESSION; ASPARTATE	Glutamate neurotoxicity has been implicated in stroke, head trauma, multiple sclerosis and neurodegenerative diseases. Although recent data show that cultured glioma cells secrete glutamate, the growth potential of brain tumors has not yet been linked to an excitotoxic mechanism. Using bioluminescence detection of glutamate release from freshly prepared brain slices, we show that implanted glioma cells continue to secrete glutamate. Moreover, gliomas with high glutamate release have a distinct growth advantage in host brain that is not present in vitro. Treatment with the NMDA receptor antagonists MK801 or memantine slowed the growth of glutamate-secreting tumors in situ, suggesting that activation of NMDA receptors facilitates tumor expansion. These findings support a new approach for therapy of brain tumors, based upon antagonizing glutamate secretion or its target receptors.	New York Med Coll, Dept Cell Biol Anat & Pathol, Valhalla, NY 10595 USA; Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14642 USA	New York Medical College; University of Rochester	Nedergaard, M (corresponding author), New York Med Coll, Dept Cell Biol Anat & Pathol, Valhalla, NY 10595 USA.	maiken_nedergaard@nymc.edu		Takano, Takahiro/0000-0002-6235-6673	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030007, R29NS030007, R01NS038073] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30007, NS38073] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramovitch R, 1998, BRIT J CANCER, V77, P440, DOI 10.1038/bjc.1998.70; Anderson CM, 2000, GLIA, V32, P1; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Behrens PF, 2000, J NEURO-ONCOL, V47, P11, DOI 10.1023/A:1006426917654; Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710; Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; CASCINO GD, 1990, EPILEPSIA, V31, pS37, DOI 10.1111/j.1528-1157.1990.tb05858.x; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Danysz W, 1997, NEUROSCI BIOBEHAV R, V21, P455, DOI 10.1016/S0149-7634(96)00037-1; Davis KE, 1998, J NEUROSCI, V18, P2475; FISHER B, 1967, CANCER, V20, P23, DOI 10.1002/1097-0142(1967)20:1<23::AID-CNCR2820200103>3.0.CO;2-P; FOSSE VM, 1986, J NEUROCHEM, V47, P340; Graf MR, 1999, J IMMUNOL, V163, P5544; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Innocenti B, 2000, J NEUROSCI, V20, P1800; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Kanda T, 1996, LIFE SCI, V59, P1607, DOI 10.1016/0024-3205(96)00492-4; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/archneur.1995.00540310091021; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Pace A, 1998, J EXP CLIN CANC RES, V17, P479; PAILLAS JE, 1991, J NEURORADIOLOGY, V18, P79; Palmer GC, 1999, ANN NY ACAD SCI, V890, P406, DOI 10.1111/j.1749-6632.1999.tb08020.x; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Russell D., 1989, PATHOLOGY TUMORS NER; Scali C, 2000, EUR J NEUROSCI, V12, P1900, DOI 10.1046/j.1460-9568.2000.00075.x; Schiffer D., 1997, BRAIN TUMORS BIOL PA; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Swanson RA, 1997, J NEUROSCI, V17, P932; Warr O, 1999, J PHYSIOL-LONDON, V514, P783, DOI 10.1111/j.1469-7793.1999.783ad.x; Ye ZC, 1999, CANCER RES, V59, P4383; Ye ZC, 1999, J NEUROSCI, V19, P10767, DOI 10.1523/JNEUROSCI.19-24-10767.1999; Zhang W, 2000, CANCER RES, V60, P5395; Zhang W, 1999, CANCER RES, V59, P1994	44	407	427	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1010	1015		10.1038/nm0901-1010	http://dx.doi.org/10.1038/nm0901-1010			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533703				2022-12-25	WOS:000170853300025
J	Bansal-Pakala, P; Jember, AGH; Croft, M				Bansal-Pakala, P; Jember, AGH; Croft, M			Signaling through OX40 (CD134) breaks peripheral T-cell tolerance	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; IN-VIVO; CTLA-4 BLOCKADE; CLONAL ANERGY; B-CELLS; KAPPA-B; ANTITUMOR IMMUNITY; OX-40 LIGAND; INDUCTION; RECEPTOR	Peripheral T-cell tolerance is a mechanism to limit autoimmunity, but represents a major obstacle in diseases such as cancer. Tolerance is due to limited accumulation of antigen-specific T cells accompanied by functional hypo-responsiveness, and is induced by antigen encounter in a non-inflammatory environment. In contrast to advances in preventing induction of T-cell tolerance, there has been little progress in defining targets to reverse established tolerance. Here we show that signals from a single dose of an agonistic antibody against OX40 (CD134, a member of the tumor necrosis-factor family of receptors) can break an existing state of tolerance in the CD4(+) T-cell compartment. OX40 signals promote T-cell expansion after the hypo-responsive phenotype is induced and restore normal functionality. These data highlight the potent costimulatory capacity of OX40, and indicate OX40 as a target for therapeutic intervention in a variety of related diseases.	La Jolla Inst Allergy & Immunol, Div Immunochem, San Diego, CA USA	La Jolla Institute for Immunology	Croft, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Immunochem, San Diego, CA USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042944] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42944] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Akiba H, 1999, J IMMUNOL, V162, P7058; AlShamkhani A, 1996, EUR J IMMUNOL, V26, P1695, DOI 10.1002/eji.1830260805; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CALDERHEAD DM, 1993, J IMMUNOL, V151, P5261; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; Croft M, 1997, J IMMUNOL, V159, P3257; DESILVA DR, 1991, J IMMUNOL, V147, P3261; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Garza KM, 2000, J EXP MED, V191, P2021, DOI 10.1084/jem.191.11.2021; GODFREY WR, 1994, J EXP MED, V180, P757, DOI 10.1084/jem.180.2.757; Gramaglia I, 1998, J IMMUNOL, V161, P6510; Gramaglia I, 2000, J IMMUNOL, V165, P3043, DOI 10.4049/jimmunol.165.6.3043; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kopf M, 1999, IMMUNITY, V11, P699, DOI 10.1016/S1074-7613(00)80144-2; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Maxwell JR, 2000, J IMMUNOL, V164, P107, DOI 10.4049/jimmunol.164.1.107; Murata K, 2000, J EXP MED, V191, P365, DOI 10.1084/jem.191.2.365; Pape KA, 1998, J IMMUNOL, V160, P4719; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; ROMBALL CG, 1993, J EXP MED, V178, P1637, DOI 10.1084/jem.178.5.1637; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Shrikant P, 1999, IMMUNITY, V11, P483, DOI 10.1016/S1074-7613(00)80123-5; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; Weinberg AD, 2000, J IMMUNOL, V164, P2160, DOI 10.4049/jimmunol.164.4.2160	44	192	210	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					907	912		10.1038/90942	http://dx.doi.org/10.1038/90942			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479622				2022-12-25	WOS:000171740400027
J	Hodgson, J				Hodgson, J			ADMET - turning chemicals into drugs	NATURE BIOTECHNOLOGY			English	Article																		Bowen WP, 2000, DRUG METAB DISPOS, V28, P781; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lehman Brothers and McKinsey & Company, 2001, FRUITS GEN	3	260	283	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					722	726		10.1038/90761	http://dx.doi.org/10.1038/90761			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479558				2022-12-25	WOS:000170188600017
J	Salcini, AE; Hilliard, MA; Croce, A; Arbucci, S; Luzzi, P; Tacchetti, C; Daniell, L; De Camilli, P; Pelicci, PG; Di Fiore, PP; Bazzicalupo, P				Salcini, AE; Hilliard, MA; Croce, A; Arbucci, S; Luzzi, P; Tacchetti, C; Daniell, L; De Camilli, P; Pelicci, PG; Di Fiore, PP; Bazzicalupo, P			The Eps15 C-elegans homologue EHS-1 is implicated in synaptic vesicle recycling	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASE SUBSTRATE; CLATHRIN-MEDIATED ENDOCYTOSIS; CAENORHABDITIS-ELEGANS; EH-DOMAIN; PROTEIN; BINDING; MUTATIONS; DYNAMIN	Eps15 represents the prototype of a family of evolutionarily conserved proteins that are characterized by the presence of the EH domain, a protein-protein interaction module(1,2), and that are involved in many aspects of intracellular vesicular sorting(3). Although biochemical and functional studies have implicated Eps15 in endocytosis(4,5), its function in the endocytic machinery remains unclear. Here we show that the Caenorhabditis elegans gene, zk1248.3 (ehs-1), is the orthologue of Eps15 in nematodes, and that its product, EHS-1, localizes to synaptic-rich regions. ehs-l-impaired worms showed temperature-dependent depletion of synaptic vesicles and uncoordinated movement. These phenotypes could be correlated with a presynaptic defect in neurotransmission. Impairment of EHS-1 function in dyn-1(ky51) worms, which express a mutant form of dynamin and display a temperature-sensitive locomotion defects, resulted in a worsening of the dyn-1 phenotype and uncoordination at the permissive temperature. Thus, ehs-1 and dyn-1 interact genetically. Moreover, mammalian Eps15 and dynamin protein were shown to interact in vivo. Taken together, our results indicate that EHS-1 acts in synaptic vesicle recycling and that its function might be linked to that of dynamin.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; Univ Genoa, Dept Expt Med, Anat Sect, Genoa, Italy; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; IFOM, I-20134 Milan, Italy; FIRC Inst Mol Oncol, I-20134 Milan, Italy; Univ Milan, Dipartimento Med Chirurg & Odontoiatria, I-20122 Milan, Italy	IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Genoa; Yale University; Howard Hughes Medical Institute; Yale University; IFOM - FIRC Institute of Molecular Oncology; IFOM - FIRC Institute of Molecular Oncology; University of Milan	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Di Fiore, Pier Paolo/K-2130-2012; Pelicci, Pier Giuseppe/AAL-6572-2020; Salcini, Anna Elisabetta/G-4472-2017	Di Fiore, Pier Paolo/0000-0002-2252-0950; Salcini, Anna Elisabetta/0000-0001-5828-2512; Hilliard, Massimo A/0000-0001-7458-5812; TACCHETTI, CARLO/0000-0003-4602-000X	Telethon [E.0942, D.068, D.090, GTF01018] Funding Source: Medline	Telethon(Fondazione Telethon)		Barral JM, 1998, J CELL BIOL, V143, P1215, DOI 10.1083/jcb.143.5.1215; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; EPSTEIN HF, 1976, J COMP PHYSIOL, V110, P317, DOI 10.1007/BF00659147; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grant D, 1998, GENETICS, V149, P1019; Iannolo G, 1997, CANCER RES, V57, P240; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	24	54	58	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					755	760		10.1038/35087075	http://dx.doi.org/10.1038/35087075			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483962				2022-12-25	WOS:000170393200022
J	Wang, JB; Mager, J; Chen, YJ; Schneider, E; Cross, JC; Nagy, A; Magnuson, T				Wang, JB; Mager, J; Chen, YJ; Schneider, E; Cross, JC; Nagy, A; Magnuson, T			Imprinted X inactivation maintained by a mouse Polycomb group gene	NATURE GENETICS			English	Article							CHROMOSOME INACTIVATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; DROSOPHILA; EMBRYOS; COMPLEX; EED; DIFFERENTIATION; MAINTENANCE; ACETYLATION	In mammals, dosage compensation of X-linked genes is achieved by the transcriptional silencing of one X chromosome in the female (reviewed in ref. 1). This process, called X inactivation, is usually random in the embryo proper. In marsupials and the extra-embryonic region of the mouse, however, X inactivation is imprinted: the paternal X chromosome is preferentially inactivated whereas the maternal X is always active. Having more than one active X chromosome is deleterious to extra-embryonic development in the mouse(2). Here we show that the gene eed (embryonic ectoderm development)(3,4), a member of the mouse Polycomb group (Pc-G) of genes, is required for primary and secondary trophoblast giant cell development in female embryos. Results from mice carrying a paternally inherited X-linked green fluorescent protein (GFP) transgene implicate eed in the stable maintenance of imprinted X inactivation in extra-embryonic tissues. Based on the recent finding that the Eed protein interacts with histone deacetylases, we suggest that this maintenance activity involves hypoacetylation of the inactivated paternal X chromosome in the extra-embryonic tissues.	Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Univ Calgary, Dept Biochem & Mol Biol, Genes & Dev Res Grp, Calgary, AB, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of North Carolina; University of North Carolina Chapel Hill; University of Calgary; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Magnuson, T (corresponding author), Univ N Carolina, Dept Genet, CB 7264,102 Mason Farm Rd, Chapel Hill, NC 27599 USA.		Nagy, Andras/G-6465-2013; Cross, James/AAU-2973-2020; Cross, James/F-4814-2011	Nagy, Andras/0000-0003-4311-0413; Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378				BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Faust C, 1998, DEVELOPMENT, V125, P4495; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Hadjantonakis AK, 1998, NAT GENET, V19, P220, DOI 10.1038/896; Hansen RS, 1996, HUM MOL GENET, V5, P1345, DOI 10.1093/hmg/5.9.1345; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Keohane AM, 1998, DEV GENET, V22, P65, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;65::AID-DVG7&gt;3.0.CO;2-5; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MIGEON BR, 1988, NATURE, V335, P93, DOI 10.1038/335093a0; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng J, 2000, MOL CELL BIOL, V20, P3069, DOI 10.1128/MCB.20.9.3069-3078.2000; O'Neill LP, 1999, EMBO J, V18, P2897, DOI 10.1093/emboj/18.10.2897; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823; Schumacher A, 1996, NATURE, V384, P648, DOI 10.1038/384648a0; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; Tanaka M, 1999, MECH DEVELOP, V87, P129, DOI 10.1016/S0925-4773(99)00158-6; Tie F, 1998, DEVELOPMENT, V125, P3483; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	28	277	283	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					371	375		10.1038/ng574	http://dx.doi.org/10.1038/ng574			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479595				2022-12-25	WOS:000170174800019
J	Duncan, MC; Cope, MJTV; Goode, BL; Wendland, B; Drubin, DG				Duncan, MC; Cope, MJTV; Goode, BL; Wendland, B; Drubin, DG			Yeast Eps15-like endocytic protein, Pan1p, activates the Arp2/3 complex	NATURE CELL BIOLOGY			English	Article							CORTICAL ACTIN CYTOSKELETON; ALDRICH-SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; INTERNALIZATION STEP; BUDDING YEAST; I MYOSINS; WASP; ORGANIZATION; NUCLEATION; ASSOCIATE	Longstanding evidence supports a role for actin in endocytosis; an intact actin cytoskeleton is required for endocytosis in yeast, and drugs that inhibit actin polymerization inhibit endocytosis in both yeast and mammalian cells, The yeast Arp2/3 complex is required for the internalization step of endocytosis, In addition, some early endocytic events in mammalian cells are associated with the formation of actin tails similar to those generated by activated Arp2/3 complex. However, until now no Arp2/3 complex activator has been identified among proteins known to mediate early steps in endocytosis, Here we show that the yeast endocytic protein Pan1p binds to and activates the Arp2/3 complex, Genetic interactions between PAN1 and mutants of Arp2/3 subunits, or of the Arp2/3 activator LAS17, provide evidence for this activity in vivo. We suggest that Pan1p forms the core of an endocytic complex and physically couples actin polymerization nucleated by the Arp2/3 complex to the endocytic machinery, thus providing the forces necessary for endocytosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	University of California System; University of California Berkeley; Johns Hopkins University	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.			Duncan, Mara/0000-0002-2383-0109; Cope, Jamie/0000-0002-6960-8271				BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Geli MI, 1998, J CELL SCI, V111, P1031; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Guthrie C, 1991, GUIDE YEAST GENETICS; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Skoble J, 2000, J CELL BIOL, V150, P527, DOI 10.1083/jcb.150.3.527; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288	30	133	134	2	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					687	690		10.1038/35083087	http://dx.doi.org/10.1038/35083087			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433303				2022-12-25	WOS:000169727000022
J	Lee, MJ; Gergely, F; Jeffers, K; Peak-Chew, SY; Raff, JW				Lee, MJ; Gergely, F; Jeffers, K; Peak-Chew, SY; Raff, JW			Msps/XMAP215 interacts with the centrosomal protein D-TACC to regulate microtubule behaviour	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; EARLY DROSOPHILA EMBRYO; GAMMA-TUBULIN; MITOTIC SPINDLE; XENOPUS EGGS; COILED-COIL; IN-VITRO; PLUS-END; NUCLEATION; GENE	The XMAP215/ch-TOG/Msps family of microtubule-associated proteins (MAPs) promote microtubule growth in vitro and are concentrated at centrosomes in vivo. We show here that Msps (mini-spindles protein) interacts with the centrosomal protein D-TACC, and that this interaction strongly influences microtubule behaviour in Drosophila embryos. If D-TACC levels ave reduced, Msps does not concentrate at the centrosomes efficiently and the centrosomal microtubules appear to be destabilized. If D-TACC levels are increased, both D-TACC and Msps accumulate around the centrosomes/spindle poles, and the centrosomal microtubules appear to be stabilized. We show that the interaction between D-TACC and Msps is evolutionarily conserved. We propose that D-TACC and Msps normally cooperate to stabilize centrosomal microtubules by binding to their minus ends and binding to their plus ends as they grow out from the centrosome.	CRC, Wellcome Inst, Dept Genet, Cambridge CB2 1QR, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Wellcome Trust Sanger Institute; MRC Laboratory Molecular Biology	Raff, JW (corresponding author), CRC, Wellcome Inst, Dept Genet, Tennis Court Rd, Cambridge CB2 1QR, England.	j.raff@welc.cam.ac.uk		Gergely, Fanni/0000-0002-2441-8095				Avides MD, 1999, SCIENCE, V283, P1733, DOI 10.1126/science.283.5408.1733; Charrasse S, 1998, J CELL SCI, V111, P1371; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Compton DA, 1998, J CELL SCI, V111, P1477; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; CULLEN CF, NATURE CELL BIOL, V3, P637; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Erickson HP, 2000, NAT CELL BIOL, V2, pE93, DOI 10.1038/35014084; FELIX MA, 1994, J CELL BIOL, V124, P19, DOI 10.1083/jcb.124.1.19; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; GLOVER DM, 1993, SCI AM, V268, P62, DOI 10.1038/scientificamerican0693-62; Gunawardane RN, 2000, CURR TOP DEV BIOL, V49, P55; HEUER JG, 1995, DEVELOPMENT, V121, P3861; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Kidd D, 1997, J CELL SCI, V110, P209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; Oegema K, 1997, J CELL SCI, V110, P1573; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spittle C, 2000, J BIOL CHEM, V275, P20748, DOI 10.1074/jbc.M002597200; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; SUNKEL CE, 1995, EMBO J, V14, P28, DOI 10.1002/j.1460-2075.1995.tb06972.x; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	42	212	214	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					643	649		10.1038/35083033	http://dx.doi.org/10.1038/35083033			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433296				2022-12-25	WOS:000169727000015
J	Murakami, H; Nurse, P				Murakami, H; Nurse, P			Regulation of premeiotic S phase and recombination-related double-strand DNA breaks during meiosis in fission yeast	NATURE GENETICS			English	Letter							CELL-CYCLE CONTROL; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; REPLICATION; INITIATION; GENES; P65(CDC18); MECHANISMS	The meiotic cell cycle is characterized by high levels of recombination induced by DNA double-strand breaks (DSBs). which appear after completion of premeiotic S phase(1-5), leading to the view that initiation of recombination depends on meiotic DNA replication(6,7). It has also been indicated that DNA replication initiation proteins may differ between the meiotic and mitotic cell cycles, giving rise to an altered S phase, which could contribute to the high level of recombination during meiosis(8). We have investigated these possibilities in the fission yeast Schizosaccharomyces pombe and found that core DNA replication initiation proteins used during the mitotic cell cycle(9,0), including Cdc18p (budding yeast Cdc6p), Cdc19p (Mcm2p), Cdc21p (Mcm4p) and Orp1p (Orc1p), are also required for premeiotic S phase. Reduced activity of these proteins prevents completion of DNA replication but not formation of DSBs. We conclude that recombination-related DSB formation does not depend on the completion of meiotic DNA replication and we propose two parallel developmental sequences during the meiotic cell cycle: one for premeiotic S phase and the other for initiating recombination.	Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Murakami, H (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	hmura@med.nagoya-cu.ac.jp						BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; Borde V, 2000, SCIENCE, V290, P806, DOI 10.1126/science.290.5492.806; Cervantes MD, 2000, MOL CELL, V5, P883, DOI 10.1016/S1097-2765(00)80328-7; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Ding R, 1998, MOL GEN GENET, V258, P663, DOI 10.1007/s004380050780; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Esposito R. E., 1981, MOL BIOL YEAST SACCH, V11, P211; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; Fox ME, 1998, PROG NUCLEIC ACID RE, V61, P345, DOI 10.1016/S0079-6603(08)60831-4; IINO Y, 1995, GENETICS, V140, P1235; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kupiec M., 1997, MOL CELLULAR BIOL YE, P889; Li YF, 1997, GENETICS, V146, P57; LIN YK, 1994, GENETICS, V136, P769; MACNEILL SA, 1997, MOL CELLULAR BIOL YE, P697; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murakami H, 1999, GENE DEV, V13, P2581, DOI 10.1101/gad.13.19.2581; Murakami H, 2000, BIOCHEM J, V349, P1, DOI 10.1042/0264-6021:3490001; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Smith KN, 2001, CURR BIOL, V11, P88, DOI 10.1016/S0960-9822(01)00026-4; SUGIYAMA A, 1994, EMBO J, V13, P1881, DOI 10.1002/j.1460-2075.1994.tb06457.x; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103; Yamada T, 1997, TELECOMMUN SYST, V8, P1, DOI 10.1023/A:1019145000942; Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x; Zenvirth D, 2000, CURR GENET, V38, P33, DOI 10.1007/s002940000126	29	49	51	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					290	293		10.1038/90142	http://dx.doi.org/10.1038/90142			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431703				2022-12-25	WOS:000169656400025
J	Smaglik, P				Smaglik, P			Pharmacogenetics initiative galvanizes public and private sectors (Reprinted from Nature, vol 410, pg 393-394, 2001)	NATURE BIOTECHNOLOGY			English	Reprint								Skills in genetics and clinical research are in demand as academia and industry try to tailor treatments to their patients.										Smaglik P, 2001, NATURE, V410, P393, DOI 10.1038/35066732	1	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					691	692		10.1038/90324	http://dx.doi.org/10.1038/90324			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433290				2022-12-25	WOS:000169677200031
J	Littlefield, R; Almenar-Queralt, A; Fowler, VM				Littlefield, R; Almenar-Queralt, A; Fowler, VM			Actin dynamics at pointed ends regulates thin filament length in striated muscle	NATURE CELL BIOLOGY			English	Article							FLUORESCENTLY LABELED ACTIN; CHICK CARDIAC MYOCYTES; SKELETAL-MUSCLE; CAPPING-PROTEIN; CELL MOTILITY; ADP-ACTIN; Z-LINE; TROPOMODULIN; FIBROBLASTS; POLYMERIZATION	Regulation of actin dynamics at filament ends determines the organization and turnover of actin cytoskeletal structures. In striated muscle, it is believed that tight capping of the fast-growing (barbed) ends by Cap Z and of the slow-growing (pointed) ends by tropomodulin (Tmod) stabilizes the uniform lengths of actin (thin) filaments in myofibrils. Here we demonstrate for the first time that both Cap Z and Tmod are dynamic on the basis of the rapid incorporation of microinjected rhodamine-labelled actin (rho-actin) at both barbed and pointed ends and from the photobleaching of green fluorescent protein (GFP)-labelled Tmod, Unexpectedly, the inhibition of actin dynamics at pointed ends by GFP-Tmod overexpression results in shorter thin filaments, whereas the inhibition of actin dynamics at barbed ends by cytochalasin D has no effect on length. These data demonstrate that the actin filaments in myofibrils ave relatively dynamic despite the presence of capping proteins, and that regulated actin assembly at pointed ends determines the length of thin filaments.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Fowler, VM (corresponding author), Scripps Res Inst, Dept Cell Biol, 10596 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM 34225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; Almenar-Queralt A, 1999, J CELL SCI, V112, P1111; AMATO PA, 1986, J CELL BIOL, V102, P1074, DOI 10.1083/jcb.102.3.1074; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287; DOME JS, 1988, CELL DIFFER DEV, V23, P37, DOI 10.1016/0045-6039(88)90035-8; DRAEGER A, 1990, J CELL BIOL, V111, P2463, DOI 10.1083/jcb.111.6.2463; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; Gregorio CC, 1996, TRENDS CARDIOVAS MED, V6, P136, DOI 10.1016/1050-1738(96)00022-9; Hart MC, 1999, J CELL BIOL, V147, P1287, DOI 10.1083/jcb.147.6.1287; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; IMANAKAYOSHIDA K, 1993, CELL MOTIL CYTOSKEL, V26, P301, DOI 10.1002/cm.970260405; ISHIWATA S, 1985, J CELL BIOL, V100, P282, DOI 10.1083/jcb.100.1.282; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; MCKENNA N, 1985, J CELL BIOL, V100, P292, DOI 10.1083/jcb.100.1.292; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Nwe TM, 1999, EXP CELL RES, V252, P33, DOI 10.1006/excr.1999.4611; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANGER JW, 1984, J CELL BIOL, V98, P825, DOI 10.1083/jcb.98.3.825; SCHAFER DA, 1993, CELL MOTIL CYTOSKEL, V25, P317, DOI 10.1002/cm.970250403; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; SCHAFER DA, 1995, J CELL BIOL, V128, P61, DOI 10.1083/jcb.128.1.61; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Suzuki H, 1998, TISSUE CELL, V30, P274, DOI 10.1016/S0040-8166(98)80076-1; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; TAIT JF, 1982, ARCH BIOCHEM BIOPHYS, V216, P133, DOI 10.1016/0003-9861(82)90197-7; THERIOT JA, 1992, J CELL BIOL, V119, P367, DOI 10.1083/jcb.119.2.367; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1986, DEV BIOL, V116, P119, DOI 10.1016/0012-1606(86)90048-5; Turnacioglu KK, 1998, CELL MOTIL CYTOSKEL, V40, P59, DOI 10.1002/(SICI)1097-0169(1998)40:1<59::AID-CM6>3.0.CO;2-A; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WANGER M, 1985, CAN J BIOCHEM CELL B, V63, P414, DOI 10.1139/o85-060; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0	50	171	173	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					544	551		10.1038/35078517	http://dx.doi.org/10.1038/35078517			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389438				2022-12-25	WOS:000169194400009
J	Ueki, Y; Tiziani, V; Santanna, C; Fukai, N; Maulik, C; Garfinkle, J; Ninomiya, C; doAmaral, C; Peters, H; Habal, M; Rhee-Morris, L; Doss, JB; Kreiberg, S; Olsen, BR; Reichenberger, E				Ueki, Y; Tiziani, V; Santanna, C; Fukai, N; Maulik, C; Garfinkle, J; Ninomiya, C; doAmaral, C; Peters, H; Habal, M; Rhee-Morris, L; Doss, JB; Kreiberg, S; Olsen, BR; Reichenberger, E			Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism	NATURE GENETICS			English	Article							IDENTIFICATION; 4P16.3; MAPS	Cherubism (MIM 118400) is an autosomal dominant inherited syndrome characterized by excessive bone degradation of the upper and lower jaws(1) followed by development of fibrous tissue masses, which causes a characteristic facial swelling. Here we describe seven mutations in the SH3-binding protein SH3BP2 (MIM 602104) on chromosome 4p16.3 that cause cherubism.	Harvard Univ, Sch Med, Harvard Forsyth Dept Oral Biol, Harvard Sch Dent Med, Boston, MA USA; Harvard Univ, Sch Med, Forsyth Inst, Boston, MA USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Univ Fed Sao Paulo, EPM, Campinas, SP, Brazil; SOBRAPAR, Inst Cirug Plast Craniofacial, Campinas, SP, Brazil; Humboldt Univ, Inst Med Genet, Sch Med, Berlin, Germany; Tampa Craniofacial Ctr, Tampa, FL USA; Univ Calif Davis, Sacramento, CA 95817 USA; So Maine Oral & Maxillofacial Surg, S Portland, ME USA; Univ Copenhagen, Sch Dent, Dept Pediat Dent, Copenhagen, Denmark	Harvard University; Harvard Medical School; Harvard School of Dental Medicine; Harvard University; Forsyth Institute; Harvard Medical School; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; Universidade Federal de Sao Paulo (UNIFESP); Humboldt University of Berlin; University of California System; University of California Davis; University of Copenhagen	Reichenberger, E (corresponding author), Harvard Univ, Sch Med, Harvard Forsyth Dept Oral Biol, Harvard Sch Dent Med, Boston, MA USA.		Tiziani, Valdenize/F-9848-2012	Tiziani, Valdenize/0000-0001-6783-9212	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R37AR036820, R01AR036819, R01AR036820] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bell SM, 1997, GENOMICS, V44, P163, DOI 10.1006/geno.1997.4849; CHOMETTE G, 1988, INT J ORAL MAX SURG, V17, P219, DOI 10.1016/S0901-5027(88)80043-2; HIRSCHHORN K, 1965, HUMANGENETIK, V1, P479; Jones WA., 1933, AM J CANC, V17, P946, DOI [10.1158/ajc.1933.946, DOI 10.1158/AJC.1933.946]; Mangion J, 1999, AM J HUM GENET, V65, P151, DOI 10.1086/302454; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Tiziani V, 1999, AM J HUM GENET, V65, P158, DOI 10.1086/302456; Zollino M, 2000, AM J MED GENET, V94, P254, DOI 10.1002/1096-8628(20000918)94:3<254::AID-AJMG13>3.0.CO;2-7	8	245	259	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					125	126		10.1038/88832	http://dx.doi.org/10.1038/88832			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381256				2022-12-25	WOS:000169011800011
J	Huser, A; Rudolph, M; Hofmann, C				Huser, A; Rudolph, M; Hofmann, C			Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors	NATURE BIOTECHNOLOGY			English	Article							MAMMALIAN-CELLS; HUMAN-SERUM; RECOMBINANT BACULOVIRUS; PROTEINS CD55; ACTIVATION; VIRUS; SYSTEM; PATHWAY; GLYCOPROTEIN; HEPATOCYTES	Baculovirus vectors are an efficient means to deliver genes into hepatocytes in vitro. In experiments that exclude components of the complement system, gene transfer is facilitated. Therefore, the complement system has been defined to represent a potent primary barrier to direct application of baculoviruses in vivo. Here we have genetically manipulated baculoviruses so that the complement-regulatory protein human decay-accelerating factor (DAF) is incorporated into the viral envelope. We found that this modification protected baculovirus vectors against complement-mediated inactivation. Complement-resistant baculovirus vectors were additionally analyzed by immunoblotting and electron microscopy, showing the extent of envelope-incorporated DAF and shape of complement-resistant baculoviruses after exposure to complement. This modified baculovirus vector allowed for an enhanced gene transfer into complement-sufficient neonatal rats in vivo, and thus represents a step in the development of improved alternative viral Vectors for gene therapy.	DeveloGen AG Berlin, D-13125 Berlin, Germany; Inst Zoo Wildtierforsch, D-10315 Berlin, Germany	Leibniz Institut fur Zoo und Wildtierforschung	Hofmann, C (corresponding author), DeveloGen AG Berlin, Robert Rossle Str 10, D-13125 Berlin, Germany.							Barsoum J, 1997, HUM GENE THER, V8, P2011, DOI 10.1089/hum.1997.8.17-2011; BARU M, 1995, GENE, V161, P143, DOI 10.1016/0378-1119(95)00281-A; BOUBLIK Y, 1995, BIO-TECHNOL, V13, P1079, DOI 10.1038/nbt1095-1079; Boyce FM, 1996, P NATL ACAD SCI USA, V93, P2348, DOI 10.1073/pnas.93.6.2348; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Carrington CA, 1997, WORLD J SURG, V21, P907, DOI 10.1007/s002689900325; Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127; COOPER NR, 1998, COMPLEMENT SYSTEM, P302; COOPER NR, 1998, COMPLEMENT SYSTEM, P309; Crossen R., 1996, BACULOVIRUS EXPRESSI; HANSCH GM, 1998, COMPLEMENT SYSTEM, P285; Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x; Harris JD, 1996, TRENDS GENET, V12, P400, DOI 10.1016/0168-9525(96)40031-2; Hayashi S, 1998, GENE THER, V5, P282, DOI 10.1038/sj.gt.3300574; Hofman JP, 1998, SPE RESERV EVAL ENG, V1, P231, DOI 10.2118/39107-PA; Hofmann C, 1998, GENE THER, V5, P531, DOI 10.1038/sj.gt.3300607; HOFMANN C, 1995, P NATL ACAD SCI USA, V92, P10099, DOI 10.1073/pnas.92.22.10099; HOHMANN AW, 1983, VIROLOGY, V125, P432, DOI 10.1016/0042-6822(83)90214-3; Jongen PJH, 2000, ACTA NEUROL SCAND, V101, P116, DOI 10.1034/j.1600-0404.2000.101002116.x; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; MARJAN J, 1994, BBA-BIOMEMBRANES, V1192, P35, DOI 10.1016/0005-2736(94)90140-6; Murphy FA, 1995, VIRUS TAXONOMY CLASS; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OREILLY OR, 1994, BACULOVIRUS EXPRESSI; Palombo F, 1998, J VIROL, V72, P5025, DOI 10.1128/JVI.72.6.5025-5034.1998; Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437; ROONEY IA, 1993, IMMUNOL RES, V12, P276, DOI 10.1007/BF02918258; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Sandig V, 1996, HUM GENE THER, V7, P1937, DOI 10.1089/hum.1996.7.16-1937; Sarkis C, 2000, P NATL ACAD SCI USA, V97, P14638, DOI 10.1073/pnas.260472897; Shoji I, 1997, J GEN VIROL, V78, P2657, DOI 10.1099/0022-1317-78-10-2657; SPEAR GT, 1995, J IMMUNOL, V155, P4376; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; SZEBENI J, 1994, BIOCHEM BIOPH RES CO, V205, P255, DOI 10.1006/bbrc.1994.2658; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; TOMLINSON S, 1993, CURR OPIN IMMUNOL, V5, P83, DOI 10.1016/0952-7915(93)90085-7; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VOLKMAN LE, 1984, VIROLOGY, V133, P354, DOI 10.1016/0042-6822(84)90401-X; Watkins NJ, 1997, IMMUNOPHARMACOLOGY, V38, P111, DOI 10.1016/S0162-3109(97)00068-4; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0	41	97	118	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					451	455		10.1038/88122	http://dx.doi.org/10.1038/88122			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329015				2022-12-25	WOS:000168394800023
J	Luhn, K; Wild, MK; Eckhardt, M; Gerardy-Schahn, R; Vestweber, D				Luhn, K; Wild, MK; Eckhardt, M; Gerardy-Schahn, R; Vestweber, D			The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter	NATURE GENETICS			English	Article							GENERALIZED DEFECT; MOLECULAR-CLONING; DOMAINS; ACID	Leukocyte adhesion deficiency II(LAD II) is characterized by the lack of fucosylated glycoconjugates, including selectin ligands, causing immunodeficiency and severe mental and growth retardation(1-3) No deficiency in fucosyltransferase activities(2,4) or in the activities of enzymes involved in GDP-fucose biosynthesis(5) has been found. Instead, the transport of GDP-fucose into isolated Golgi vesicles of LAD II cells appeared to be reduced(6). To identify the gene mutated in LAD II, we cloned 12 cDNAs from Caenorhabditis elegans, encoding multi-spanning transmembrane proteins with homology to known nucleotide sugar transporters, and transfected them into fibroblasts from an LAD II patient. One of these clones re-established expression of fucosylated glycoconjugates with high efficiency and allowed us to identify a human homolog with 55% identity, which also directed re-expression of fucosylated glycoconjugates, Both proteins were localized to the Golgi, The corresponding endogenous protein in LAD II cells had an R147C amino acid change in the conserved fourth transmembrane region. Overexpression of this mutant protein in cells from a patient with LAD did not rescue fucosylation, demonstrating that the point mutation affected the activity of the protein. Thus, we have identified the first putative CDP fucose transporter, which has been highly conserved throughout evolution. A point mutation in its gene is responsible for the disease in this patient with LAD II.	Univ Munster, ZMBE, Inst Zellbiol, D-4400 Munster, Germany; Max Planck Inst Klin & Physiol Forsch, Bad Nauheim, Germany; Univ Bonn, Inst Physiol Chem, D-5300 Bonn, Germany; Hannover Med Sch, Inst Med Mikrobiol, Hannover, Germany	University of Munster; Max Planck Society; University of Bonn; Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Vestweber, D (corresponding author), Univ Munster, ZMBE, Inst Zellbiol, D-4400 Munster, Germany.	vestweb@uni-muenster.de		Vestweber, Dietmar/0000-0002-3517-732X				Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Becker DJ, 1999, BBA-MOL BASIS DIS, V1455, P193, DOI 10.1016/S0925-4439(99)00071-X; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; GERARDYSCHAHN R, 2000, OLIGOSACCHARIDES CHE, V2, P19; Ishida N, 1999, J BIOCHEM, V126, P1107, DOI 10.1093/oxfordjournals.jbchem.a022556; Karsan A, 1998, J CLIN INVEST, V101, P2438, DOI 10.1172/JCI905; Korner C, 1999, J LEUKOCYTE BIOL, V66, P95; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, BLOOD, V97, P330, DOI 10.1182/blood.V97.1.330; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; Rost B, 1996, METHOD ENZYMOL, V266, P525; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181	23	238	252	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					69	72		10.1038/ng0501-69	http://dx.doi.org/10.1038/ng0501-69			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326279				2022-12-25	WOS:000168413300019
J	Takahashi, M; Nakanishi, H; Kawasaki, S; Nishizawa, NK; Mori, S				Takahashi, M; Nakanishi, H; Kawasaki, S; Nishizawa, NK; Mori, S			Enhanced tolerance of rice to low iron availability in alkaline soils using barley nicotianamine aminotransferase genes	NATURE BIOTECHNOLOGY			English	Article							FE NUTRITION STATUS; HORDEUM-VULGARE; PHYTOSIDEROPHORE PRODUCTION; SYNTHASE GENES; ROOTS; DEFICIENCY; BIOSYNTHESIS; METHIONINE; CLONING; PLANTS	One of the widest ranging abiotic stresses in world agriculture arises from low iron (Fe) availability due to high soil pH, with 30% of arable land too alkaline for optimal crop production. Rice is especially susceptible to low iron supply, whereas other graminaceous crops such as barley are not. A barley genomic DNA fragment containing two naat genes, which encode crucial enzymes involved in the biosynthesis of phytosiderophores, was introduced into rice using Agrobacterium-mediated transformation and pBIGRZ1. Phytosiderophores are natural iron chelators that graminaceous plants secrete from their roots to solubilize iron in the soil. The two transgenes were expressed in response to low iron nutritional status in both the shoots and roots of rice transformants. Transgenic rice expressing the two genes showed a higher nicotianamine aminotransferase activity and secreted larger amounts of phytosiderophores than nontransformants under iron-deficient conditions. Consequently, the transgenic rice showed an enhanced tolerance to low iron availability and had 4.1 times greater grain yields than that of the nontransformant rice in an alkaline soil.	Univ Tokyo, Lab Plant Mol Physiol, Tokyo 1138657, Japan; CREST, Tsukuba, Ibaraki 3058602, Japan; Inst Agr & Nat Resources, Tsukuba, Ibaraki 3058602, Japan; Univ Tokyo, Lab Plant Biotechnol, Tokyo 1138657, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Mori, S (corresponding author), Univ Tokyo, Lab Plant Mol Physiol, Tokyo 1138657, Japan.		Nakanishi, Hiromi/C-6461-2015	Nakanishi, Hiromi/0000-0001-5556-5058				AKIYAMA K, 1997, PLANT CELL PHYSL S, V38, pS94; CHU C, 1977, P S PLANT TISS CULT, P43; Higuchi K, 1996, PLANT SOIL, V178, P171, DOI 10.1007/BF00011580; Higuchi K, 1999, PLANT PHYSIOL, V119, P471, DOI 10.1104/pp.119.2.471; Higuchi K, 2001, PLANT J, V25, P159, DOI 10.1046/j.1365-313x.2001.00951.x; Itai R, 2000, J EXP BOT, V51, P1179, DOI 10.1093/jexbot/51.348.1179; KANAZAWA K, 1994, J EXP BOT, V45, P1903, DOI 10.1093/jxb/45.12.1903; Kanazawa K, 1998, SOIL SCI PLANT NUTR, V44, P717, DOI 10.1080/00380768.1998.10414499; KANAZAWA K, 1995, J EXP BOT, V46, P1241, DOI 10.1093/jxb/46.9.1241; KOBAYASHI T, 2001, IN PRESS PLANTA; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; Mihashi S., 1989, Biology of Metals, V2, P146, DOI 10.1007/BF01142553; MORI S, 1987, PLANT CELL PHYSIOL, V28, P1081; MORI S, 1991, PLANT SOIL, V130, P143, DOI 10.1007/BF00011869; NAKANISHI H, 1993, PLANT CELL PHYSIOL, V34, P401; Nakanishi H, 2000, PLANT MOL BIOL, V44, P199, DOI 10.1023/A:1006491521586; OKUMURA N, 1994, PLANT MOL BIOL, V25, P705, DOI 10.1007/BF00029608; OKUMURA N, 1991, PLANT MOL BIOL, V17, P531, DOI 10.1007/BF00040651; ROMHELD V, 1986, PLANT PHYSIOL, V80, P175, DOI 10.1104/pp.80.1.175; SHOJIMA S, 1990, PLANT PHYSIOL, V93, P1497, DOI 10.1104/pp.93.4.1497; SHOJIMA S, 1989, PLANT CELL PHYSIOL, V30, P673; Suzuki K, 1999, SOIL SCI PLANT NUTR, V45, P993, DOI 10.1080/00380768.1999.10414350; Suzuki K, 1998, PLANT PHYSIOL, V116, P725, DOI 10.1104/pp.116.2.725; TAKAGI SI, 1976, SOIL SCI PLANT NUTR, V22, P423, DOI 10.1080/00380768.1976.10433004; Takahashi M, 1999, PLANT PHYSIOL, V121, P947, DOI 10.1104/pp.121.3.947; Takizawa R, 1996, J PLANT NUTR, V19, P1189, DOI 10.1080/01904169609365190; Yamaguchi H, 2000, SOIL SCI PLANT NUTR, V46, P1, DOI 10.1080/00380768.2000.10408756; Yamaguchi H, 2000, J EXP BOT, V51, P2001, DOI 10.1093/jexbot/51.353.2001	28	233	258	6	57	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					466	469		10.1038/88143	http://dx.doi.org/10.1038/88143			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329018				2022-12-25	WOS:000168394800026
J	Avides, MD; Tavares, A; Glover, DM				Avides, MD; Tavares, A; Glover, DM			Polo kinase and Asp are needed to promote the mitotic organizing activity of centrosomes	NATURE CELL BIOLOGY			English	Article							KINESIN-LIKE PROTEIN; ABNORMAL SPINDLE; DROSOPHILA; MITOSIS; ENCODES; RING; PHOSPHORYLATION; EXTRACTS; GENE; PLX1	Interfering with the activity of polo-like kinases can lead to the formation of monopolar spindles(1-4). Polo-like kinases also regulate mitotic entry, activation of the anaphase-promoting complex and the necessary preconditions for cytokinesis(5,6). Similarities between the phenotypes of the Drosophila mutants asp and polo point towards a common role in spindle pole function. The abnormal spindles of asp mutants are bipolar but have disorganized broad poles at which gamma -tubulin has an abnormal distribution(7). Moreover, the synergism or of polo(1) asp(E3) double mutants indicates a possible involvement of these genes in a common process(8). Asp is a microtubule-associated protein of relative molecular mass 220,000 (M-r 220K) found at the face of the centrosome that contacts spindle microtubules. In partially purified centrosomes, it is required with gamma -tubulin to organize microtubule asters(7). Here, we show that Asp is the previously identified M,220K substrate of Polo kinase(9). Polo phosphorylates Asp in vitro, converting it into an MPM2 epitope, Polo and Asp proteins immunoprecipitate together and exist as part of a 25-38S complex. Extracts of polo-derived embryos are unable to restore the ability of salt-stripped centrosomes to nucleate microtubule asters, This can be rescued by addition of phosphorylated Asp or active Polo kinase.	Univ Cambridge, Dept Genet, Canc Res Campaign Cell Cycle Genet Grp, Cambridge CB2 3EH, England; Gulbenkian Inst Sci, Cell Div Grp, P-2781 Oeiras, Portugal; Inst Super Tecn, Dept Chem Engn, P-1096 Lisbon, Portugal	University of Cambridge; Universidade de Lisboa; Instituto Superior Tecnico	Glover, DM (corresponding author), Univ Cambridge, Dept Genet, Canc Res Campaign Cell Cycle Genet Grp, Downing St, Cambridge CB2 3EH, England.		Tavares, Alvaro Augusto MArques/D-9436-2012	Tavares, Alvaro Augusto MArques/0000-0002-7137-0944; Glover, David/0000-0003-0956-0103				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Avides MD, 1999, SCIENCE, V283, P1733, DOI 10.1126/science.283.5408.1733; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gonzalez C, 1998, CHROMOSOMA, V107, P452, DOI 10.1007/s004120050329; Inoue YH, 1998, MOL GEN GENET, V258, P334, DOI 10.1007/s004380050739; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Logarinho E, 1998, J CELL SCI, V111, P2897; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Saunders RDC, 1997, J CELL BIOL, V137, P881, DOI 10.1083/jcb.137.4.881; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x	18	107	107	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					421	424		10.1038/35070110	http://dx.doi.org/10.1038/35070110			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283617				2022-12-25	WOS:000168043900022
J	Zhao, M; Beauregard, DA; Loizou, L; Davletov, B; Brindle, KM				Zhao, M; Beauregard, DA; Loizou, L; Davletov, B; Brindle, KM			Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent	NATURE MEDICINE			English	Article							IN-VIVO DETECTION; MURINE TUMORS; IRON-OXIDE; CELL-DEATH; PHOSPHATIDYLSERINE; EXPRESSION; GLIOMA	The C-2 domain of synaptotagmin I, which binds to anionic phospholipids in cell membranes, was shown to bind to the plasma membrane of apoptotic cells by both flow cytometry and confocal microscopy. Conjugation of the protein to superparamagnetic iron oxide nanoparticles allowed detection of this binding using magnetic resonance imaging. Detection of apoptotic cells, using this novel contrast agent, was demonstrated both in vitro, with isolated apoptotic tumor cells, and in vivo, in a tumor treated with chemotherapeutic drugs.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Brindle, KM (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	kmb@mole.bio.cam.ac.uk	Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DUTTON AH, 1979, P NATL ACAD SCI USA, V76, P3392, DOI 10.1073/pnas.76.7.3392; Emoto K, 1997, EXP CELL RES, V232, P430, DOI 10.1006/excr.1997.3521; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hakumaki JM, 1999, NAT MED, V5, P1323, DOI 10.1038/15279; HASEGAWA M, 1993, Patent No. 0656368; Kabelitz D, 1998, TRANSPLANTATION, V65, P869, DOI 10.1097/00007890-199804150-00003; Kavantzas NG, 2000, PATHOLOGY, V32, P176; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; MEYN RE, 1995, ANTI-CANCER DRUG, V6, P443, DOI 10.1097/00001813-199506000-00013; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; Nunn AVW, 1996, FEBS LETT, V392, P295, DOI 10.1016/0014-5793(96)00839-3; Poptani H, 1998, CANCER GENE THER, V5, P101; Sakurai H, 1998, INT J RADIAT ONCOL, V41, P1157, DOI 10.1016/S0360-3016(98)00158-8; SHEN T, 1993, MAGN RESON MED, V29, P599, DOI 10.1002/mrm.1910290504; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Taylor AM, 1999, JMRI-J MAGN RESON IM, V9, P220, DOI 10.1002/(SICI)1522-2586(199902)9:2<220::AID-JMRI11>3.0.CO;2-A; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Weber DA, 1999, J NUCL CARDIOL, V6, P332, DOI 10.1016/S1071-3581(99)90046-6; WEISSLEDER R, 1990, RADIOLOGY, V175, P489, DOI 10.1148/radiology.175.2.2326474; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Williamson MS, 1998, GRADIVA, V6, P40	29	425	454	3	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1241	1244		10.1038/nm1101-1241	http://dx.doi.org/10.1038/nm1101-1241			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689890				2022-12-25	WOS:000172054100033
J	Gautam, N; Olofsson, AM; Herwald, H; Iversen, LF; Lundgren-Akerlund, E; Hedqvist, P; Arfors, KE; Flodgaard, H; Lindbom, L				Gautam, N; Olofsson, AM; Herwald, H; Iversen, LF; Lundgren-Akerlund, E; Hedqvist, P; Arfors, KE; Flodgaard, H; Lindbom, L			Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; TISSUE-INJURY; CAP37; INFLAMMATION; AZUROCIDIN; MONOCYTE; LEAKAGE; CDNA	Polymorphonuclear leukocyte infiltration into tissues in host defense and inflammatory disease causes increased vascular permeability and edema formation through unknown mechanisms. Here, we report the involvement of a paracrine mechanism in neutrophil-evoked alteration in endothelial barrier function. We show that upon neutrophil adhesion to the endothelial lining, leukocytic beta (2) integrin signaling triggers the release of neutrophil-borne heparin-binding protein (HBP), also known as CAP37/azurocidin, a member of the serprocidin family of neutrophil cationic proteins. HBP induced Ca++-dependent cytoskeletal rearrangement and intercellular gap formation in endothelial-cell monolayers in vitro, and increased macromolecular efflux in microvessels in vivo. Moreover, selective inactivation of HBP prevented the neutrophils from inducing endothelial hyperpermeability. Our data suggest a fundamental role of neutrophil-derived HBP in the vascular response to neutrophil trafficking in inflammation. Targeting this molecule in inflammatory disease conditions offers a new strategy for prevention of endothelial barrier dysfunction caused by misdirected leukocyte activation.	Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; Lund Univ, Dept Cell & Mol Biol, Lund, Sweden; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Sidney Kimmel Canc Ctr, San Diego, CA USA	Karolinska Institutet; Lund University; Novo Nordisk	Lindbom, L (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.	lennart.lindbom@fyfa.ki.se	Olofsson, Maria/E-8335-2012; Herwald, Heiko/AAN-3708-2021; Olofsson, Maria/F-6695-2011	Herwald, Heiko/0000-0002-8111-2842; Olofsson, Maria/0000-0002-7077-7072; Lindbom, Lennart/0000-0001-9243-257X				ALMEIDA RP, 1991, BIOCHEM BIOPH RES CO, V177, P688, DOI 10.1016/0006-291X(91)91843-2; ARFORS KE, 1987, BLOOD, V69, P338; Aveskogh M, 1997, IMMUNOGENETICS, V46, P181, DOI 10.1007/s002510050260; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Dallegri F, 1997, INFLAMM RES, V46, P382, DOI 10.1007/s000110050208; Edens HA, 2000, ADV DRUG DELIVER REV, V41, P315, DOI 10.1016/S0169-409X(00)00049-1; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; Gautam N, 1998, BRIT J PHARMACOL, V125, P1109, DOI 10.1038/sj.bjp.0702186; Gautam N, 2000, J EXP MED, V191, P1829, DOI 10.1084/jem.191.11.1829; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; Iversen LF, 1997, NAT STRUCT BIOL, V4, P265, DOI 10.1038/nsb0497-265; KASLOVSKY RA, 1990, CIRC RES, V67, P795, DOI 10.1161/01.RES.67.4.795; Kastrup JS, 2001, PROTEINS, V42, P442, DOI 10.1002/1097-0134(20010301)42:4<442::AID-PROT30>3.0.CO;2-S; Lindmark A, 1999, J LEUKOCYTE BIOL, V66, P634, DOI 10.1002/jlb.66.4.634; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; MORGAN JG, 1991, J IMMUNOL, V147, P3210; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PEREIRA HA, 1995, J LEUKOCYTE BIOL, V57, P805, DOI 10.1002/jlb.57.6.805; PEREIRA HA, 1993, P NATL ACAD SCI USA, V90, P4733, DOI 10.1073/pnas.90.10.4733; Peters DC, 1999, DRUGS, V57, P233, DOI 10.2165/00003495-199957020-00015; PETERSEN LC, 1993, EUR J BIOCHEM, V214, P271, DOI 10.1111/j.1432-1033.1993.tb17921.x; PETERSON MW, 1987, J APPL PHYSIOL, V62, P1521, DOI 10.1152/jappl.1987.62.4.1521; Rasmussen PB, 1996, FEBS LETT, V390, P109, DOI 10.1016/0014-5793(96)00639-4; RAUD J, 1994, HDB IMMUNOPHARMACOLO, P127; ROSENGREN S, 1991, INFLAMMATION, V15, P159, DOI 10.1007/BF00918643; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0	30	260	283	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1123	1127		10.1038/nm1001-1123	http://dx.doi.org/10.1038/nm1001-1123			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590435				2022-12-25	WOS:000171524500033
J	Puglielli, L; Konopka, G; Pack-Chung, E; Ingano, LAM; Berezovska, O; Hyman, BT; Chang, TY; Tanzi, RE; Kovacs, DM				Puglielli, L; Konopka, G; Pack-Chung, E; Ingano, LAM; Berezovska, O; Hyman, BT; Chang, TY; Tanzi, RE; Kovacs, DM			Acyl-coenzyme A : cholesterol acyltransferase modulates the generation of the amyloid beta-peptide	NATURE CELL BIOLOGY			English	Article							SITE 2 PROTEASE; PRECURSOR PROTEIN; ACAT INHIBITOR; COACHOLESTEROL ACYLTRANSFERASE; ALZHEIMERS-DISEASE; LIVER; EXPRESSION; MEMBRANE; RATS; HYPERCHOLESTEROLEMIA	The pathogenic event common to all forms of Alzheimer's disease is the abnormal accumulation of the amyloid beta -peptide (A beta). Here we provide strong evidence that intracellular cholesterol compartmentation modulates the generation of A beta. Using genetic, biochemical and metabolic approaches, we found that cholesteryl-ester levels are directly correlated with A beta production. Acyl-coenzyme A:cholesterol acyltransferase (ACAT), the enzyme that catalyses the formation of cholesteryl esters, modulates the generation of A beta through the tight control of the equilibrium between free cholesterol and cholesteryl esters. We also show that pharmacological inhibitors of ACAT, developed for the treatment of atherosclerosis, are potent modulators of A beta generation, indicating their potential for use in the treatment of Alzheimer's disease.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Alzheimer Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Dartmouth College	Kovacs, DM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Genet & Aging Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.	kovacs@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454; Konopka, Genevieve/0000-0002-3363-7302; Chang, Ta-Yuan/0000-0002-3249-0468				Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, CURR OPIN LIPIDOL, V8, P65, DOI 10.1097/00041433-199704000-00003; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; De Strooper B, 2000, J CELL SCI, V113, P1857; DIXON JL, 1993, J LIPID RES, V34, P167; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HARRIS WS, 1990, CLIN PHARMACOL THER, V48, P189, DOI 10.1038/clpt.1990.134; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; IRIE T, 1982, J PHARMACOBIO-DYNAM, V5, P741; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; JOHNSON WJ, 1997, SUBCELLULAR BIOCH, P235; Koudinov AR, 1998, FASEB J, V12, P1097, DOI 10.1096/fasebj.12.12.1097; KRAUSE BR, 1993, J LIPID RES, V34, P279; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Mizuno T, 1998, BBA-BIOMEMBRANES, V1373, P119, DOI 10.1016/S0005-2736(98)00097-2; Murakami S, 1997, ATHEROSCLEROSIS, V133, P97, DOI 10.1016/S0021-9150(97)00121-4; NATORI K, 1986, JPN J PHARMACOL, V42, P517, DOI 10.1254/jjp.42.517; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; Purchase TS, 1997, BIOORGAN MED CHEM, V5, P739, DOI 10.1016/S0968-0896(97)00019-9; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; REFOLO LM, 1991, J NEUROSCI, V11, P3888; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; Rogers MJ, 2000, NAT MED, V6, P21, DOI 10.1038/71484; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Simons M, 2000, NAT MED, V6, P965, DOI 10.1038/79646; SUGIYAMA Y, 1995, ATHEROSCLEROSIS, V113, P71, DOI 10.1016/0021-9150(94)05429-M; Tanzi RE, 1999, J CLIN INVEST, V104, P1175, DOI 10.1172/JCI8593; Tomita T, 1998, NEUROREPORT, V9, P911, DOI 10.1097/00001756-199803300-00027; Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	50	361	383	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					905	912		10.1038/ncb1001-905	http://dx.doi.org/10.1038/ncb1001-905			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584272				2022-12-25	WOS:000171396400015
J	Xu, CH; Inokuma, MS; Denham, J; Golds, K; Kundu, P; Gold, JD; Carpenter, MK				Xu, CH; Inokuma, MS; Denham, J; Golds, K; Kundu, P; Gold, JD; Carpenter, MK			Feeder-free growth of undifferentiated human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							HUMAN BLASTOCYSTS; HUMAN TELOMERASE; LAMININ; LINES; DIFFERENTIATION; RECEPTOR; INTEGRIN; ADHESION	Previous studies have shown that maintenance of undifferentiated human embryonic stem (hES) cells requires culture on mouse embryonic fibroblast (MEF) feeders. Here we demonstrate a successful feeder-free hES culture system in which undifferentiated cells can be maintained for at least 130 population doublings. In this system, hES cells are cultured on Matrigel or laminin in medium conditioned by MEF. The hES cells maintained on feeders or off feeders express integrin alpha6 and beta1, which may form a laminin-specific receptor. The hES cell populations in feeder-free conditions maintained a normal karyotype, stable proliferation rate, and high telomerase activity. Similar to cells cultured on feeders, hES cells maintained under feeder-free conditions expressed OCT-4, hTERT alkaline phosphatase, and surface markers including SSEA-4, Tra 1-60, and Tra 1-81. In addition, hES cells maintained without direct feeder contact formed teratomas in SCID/beige mice and differentiated in vitro into cells from all three germ layers. Thus, the cells retain fundamental characteristics of hES cells in this culture system and are suitable for scaleup production.	Geron Corp, Menlo Pk, CA 94025 USA	Geron Corporation	Carpenter, MK (corresponding author), Geron Corp, 230 Consitut Dr, Menlo Pk, CA 94025 USA.							Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; BISELL DM, 1987, J CLIN INVEST, V79, P801; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P33, DOI 10.3109/15419069309095680; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	15	1427	1753	2	165	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					971	974		10.1038/nbt1001-971	http://dx.doi.org/10.1038/nbt1001-971			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581665				2022-12-25	WOS:000171417600027
J	Ravagnan, L; Gurbuxani, S; Susin, SA; Maisse, C; Daugas, E; Zamzami, N; Mak, T; Jaattela, M; Penninger, JM; Garrido, C; Kroemer, G				Ravagnan, L; Gurbuxani, S; Susin, SA; Maisse, C; Daugas, E; Zamzami, N; Mak, T; Jaattela, M; Penninger, JM; Garrido, C; Kroemer, G			Heat-shock protein 70 antagonizes apoptosis-inducing factor	NATURE CELL BIOLOGY			English	Article							CELL-DEATH; APAF-1 APOPTOSOME; HUMAN HSP70; IN-VIVO; HEAT-SHOCK-PROTEIN-70; BCL-2; MITOCHONDRIA; CASPASES; PATHWAYS; COMPLEX	Heat-shock protein 70 (Hsp70) has been reported to block apoptosis by binding apoptosis protease activating factor-1 (Apaf-1), thereby preventing constitution of the apoptosome, the Apaf-1/cytochrome c/caspase-9 activation complex(1,2). Here we show that overexpression of Hsp70 protects Apaf-1(-/-) cells against death induced by serum withdrawal, indicating that Apaf-1 is not the only target of the anti-apoptotic action of Hsp70. We investigated the effect of Hsp70 on apoptosis mediated by the caspase-independent death effector apoptosis inducing factor (AlF), which is a mitochondrial intermembrane flavoprotein(3,4). In a cell-free system, Hsp70 prevented the AIF-induced chromatin condensation of purified nuclei. Hsp70 specifically interacted with AlF, as shown by ligand blots and co-immunoprecipitation. Cells overexpressing Hsp70 were protected against the apoptogenic effects of AIF targeted to the extramitochondrial compartment. In contrast, an anti-sense Hsp70 complementary DNA, which reduced the expression of endogenous Hsp70, increased sensitivity to the lethal effect of AIR The ATP-binding domain of Hsp70 seemed to be dispensable for inhibiting cell death induced by serum withdrawal, AIF binding and AIF inhibition, although it was required for Apaf-1 binding. Together, our data indicate that Hsp70 can inhibit apoptosis by interfering with target proteins other than Apaf-1, one of which is AIR	Fac Med & Pharm Dijon, INSERM U517, F-21033 Dijon, France; Inst Gustave Roussy, CNRS UMR 1599, F-94805 Villejuif, France; Hop Tenon, Serv Nephrol B, Hop Paris, Assistance Publ, F-75020 Paris, France; Univ Toronto, Dept Med Biophys & Immunol, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Danish Canc Soc, Inst Canc Biol, Apoptosis Lab, DK-2100 Copenhagen, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Danish Cancer Society	Garrido, C (corresponding author), Fac Med & Pharm Dijon, INSERM U517, 7 Blvd Jeanne dArc, F-21033 Dijon, France.		KROEMER, Guido/B-4263-2013; Garrido, carmen/G-1633-2018; Penninger, Josef M/I-6860-2013; Garrido, Carolina/GWM-5557-2022; Jäättelä, Marja/AAT-7932-2021; Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Garrido, carmen/0000-0003-1368-1493; Penninger, Josef M/0000-0002-8194-3777; Jäättelä, Marja/0000-0001-5950-7111; Susin, Santos A/0000-0002-3366-1628; Maisse, Carine/0000-0003-2848-1638; DAUGAS, Eric/0000-0001-7256-7979				Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Burkart V, 2000, J BIOL CHEM, V275, P19521, DOI 10.1074/jbc.M002265200; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Volloch V, 1999, FEBS LETT, V461, P73, DOI 10.1016/S0014-5793(99)01428-3; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wissing D, 1996, INT J HYPERTHER, V12, P125, DOI 10.3109/02656739609023695; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	28	701	750	3	60	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					839	843		10.1038/ncb0901-839	http://dx.doi.org/10.1038/ncb0901-839			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533664				2022-12-25	WOS:000170979600018
J	Selva, EM; Hong, K; Baeg, GH; Beverley, SM; Turco, SJ; Perrimon, N; Hacker, U				Selva, EM; Hong, K; Baeg, GH; Beverley, SM; Turco, SJ; Perrimon, N; Hacker, U			Dual role of the fringe connection gene in both heparan sulphate and fringe-dependent signalling events	NATURE CELL BIOLOGY			English	Article							DROSOPHILA WING DEVELOPMENT; NEGATIVE COMPLEMENTATION; CAENORHABDITIS-ELEGANS; SULFATE PROTEOGLYCANS; GOLGI-APPARATUS; LUNATIC FRINGE; TOUT-VELU; NOTCH; MELANOGASTER; GLYCOSYLTRANSFERASE	The precise regulation of growth factor signalling is crucial to the molecular control of development in Drosophila. Post-translational modification of signalling molecules is one of the mechanisms that modulate developmental signalling specificity. We describe a new gene, fringe connection (frc), that encodes a nucleotide-sugar transporter that transfers UDP-glucuronic acid, UDP-N-acetylglucosamine and possibly UDP-xylose from the cytoplasm into the lumen of the endoplasmic reticulum/Golgi. Embryos with the frc mutation display defects in Wingless, Hedgehog and fibroblast growth factor signalling. Clonal analysis shows that fringe-dependent Notch signalling is disrupted in frc mutant tissue.					Baeg, Gyeong-Hun/A-2951-2008	Perrimon, Norbert/0000-0001-7542-472X; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI31078] Funding Source: Medline; NIGMS NIH HHS [GM61110] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061110] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baeg GH, 2001, DEVELOPMENT, V128, P87; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; de Celis JF, 1998, DEVELOPMENT, V125, P4617; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Duffy JB, 1998, DEVELOPMENT, V125, P2263; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; FOSTER GG, 1975, GENETICS, V81, P99; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Ito K, 1997, DEVELOPMENT, V124, P761; Khare N, 2000, MECH DEVELOP, V99, P199, DOI 10.1016/S0925-4773(00)00502-5; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Klein T, 1998, DEVELOPMENT, V125, P2951; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Perrimon N, 1996, GENETICS, V144, P1681; PORTIN P, 1975, GENETICS, V81, P121; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; WILDER EL, 1995, DEVELOPMENT, V121, P477; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	51	94	95	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					809	815		10.1038/ncb0901-809	http://dx.doi.org/10.1038/ncb0901-809			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533660				2022-12-25	WOS:000170979600014
J	Altfeld, M; Walker, BD				Altfeld, M; Walker, BD			Less is more? STI in acute and chronic HIV-1 infection	NATURE MEDICINE			English	Editorial Material							STRUCTURED TREATMENT INTERRUPTIONS; CYTOTOXIC T-LYMPHOCYTE; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS-INFECTION; CELLULAR IMMUNE-RESPONSES; HIV-1-INFECTED PATIENTS; IMMUNOLOGICAL CONSEQUENCES; VIREMIA; CD8(+); CELLS	Emerging data has indicated that supervised treatment interruption (STI) of highly active antiretroviral therapy might significantly augment immune responses in HIV-1-infected patients and slow disease progression. Here the authors discuss the rationale behind STI and future directions for study.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Altfeld, M (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA.	maltfeld@partners.org; bwalker@helix.mgh.harvard.edu	Altfeld, Marcus/AAE-7306-2019	Altfeld, Marcus/0000-0001-5972-2997				Altfeld M, 2000, CURR OPIN IMMUNOL, V12, P375, DOI 10.1016/S0952-7915(00)00103-5; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; Blankson JN, 2001, J INFECT DIS, V183, P657, DOI 10.1086/318545; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Colven R, 2000, ANN INTERN MED, V133, P430, DOI 10.7326/0003-4819-133-6-200009190-00010; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Day CL, 2001, J VIROL, V75, P6279, DOI 10.1128/JVI.75.14.6279-6291.2001; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; DYBUL M, 2001, 8 C RETR OPP INF CHI; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002; Garcia F, 2001, AIDS, V15, pF29, DOI 10.1097/00002030-200106150-00002; Goulder PJR, 1999, AIDS, V13, pS121; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; GOULDER PJR, IN PRESS NATURE; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Harrer T, 1996, J IMMUNOL, V156, P2616; Hatano H, 2000, AIDS, V14, P1357, DOI 10.1097/00002030-200007070-00008; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; HERMANS P, 2001, 8 C RETR OPP INF CHI; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kilby JM, 2000, ANN INTERN MED, V133, P435, DOI 10.7326/0003-4819-133-6-200009190-00011; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Lori F, 1999, AIDS RES HUM RETROV, V15, P1333, DOI 10.1089/088922299310034; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MARKOWITZ M, 2001, 8 C RETR OPP INF CHI; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Miller V, 2001, CURR OPIN INFECT DIS, V14, P29, DOI 10.1097/00001432-200102000-00006; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Montaner LJ, 2001, TRENDS IMMUNOL, V22, P92, DOI 10.1016/S1471-4906(00)01809-3; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Ostrowski MA, 2000, J IMMUNOL, V165, P6133, DOI 10.4049/jimmunol.165.11.6133; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Papasavvas E, 2000, J INFECT DIS, V182, P766, DOI 10.1086/315748; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruiz L, 2000, AIDS, V14, P397, DOI 10.1097/00002030-200003100-00013; Ruiz L, 2001, AIDS, V15, pF19, DOI 10.1097/00002030-200106150-00001; Sarawar SR, 2001, P NATL ACAD SCI USA, V98, P6325, DOI 10.1073/pnas.101136898; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Walker BD, 2001, NAT IMMUNOL, V2, P473, DOI 10.1038/88656; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	54	41	41	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					881	884		10.1038/90901	http://dx.doi.org/10.1038/90901			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479610				2022-12-25	WOS:000171740400013
J	Palazzo, AF; Cook, TA; Alberts, AS; Gundersen, GG				Palazzo, AF; Cook, TA; Alberts, AS; Gundersen, GG			mDia mediates Rho-regulated formation and orientation of stable microtubules	NATURE CELL BIOLOGY			English	Article							DETYROSINATED MICROTUBULES; SACCHAROMYCES-CEREVISIAE; ALPHA-TUBULIN; SELECTIVE STABILIZATION; INTERMEDIATE FILAMENTS; LYSOPHOSPHATIDIC ACID; MITOTIC SPINDLE; PROTEIN-KINASE; HUMAN HOMOLOG; BINDING	Rho-GTPase stabilizes microtubules that are oriented towards the leading edge in serum-starved 3T3 fibroblasts through an unknown mechanism. We used a Rho-effector domain screen to identify mDia as a downstream Rho effector involved in microtubule stabilization. Constitutively active mDia or activation of endogenous mDia with the mDia-autoinhibitory domain stimulated the formation of stable microtubules that were capped and oriented towards the wound edge. mDia co-localized with stable microtubules when overexpressed and associated with microtubules in vitro. Rho kinase was not necessary for the formation of stable microtubules. Our results show that mDia is sufficient to generate and orient stable microtubules, and indicate that Dia-related formins are part of a conserved pathway that regulates the dynamics of microtubule ends.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Van Andel Inst, Grand Rapids, MI 49503 USA	Columbia University; Van Andel Institute	Gundersen, GG (corresponding author), Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA.		Palazzo, Alexander/B-1270-2013	Palazzo, Alexander/0000-0002-9700-1995				Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; ALBERTS AS, 2001, J BIOL CHEM; Best A, 1996, J BIOL CHEM, V271, P3756; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chang F, 1999, CURR BIOL, V9, P849, DOI 10.1016/S0960-9822(99)80372-8; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; GOTLIEB AI, 1981, J CELL BIOL, V91, P589, DOI 10.1083/jcb.91.2.589; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GURLAND G, 1995, J CELL BIOL, V131, P1275, DOI 10.1083/jcb.131.5.1275; Harris SD, 1997, EMBO J, V16, P3474, DOI 10.1093/emboj/16.12.3474; Idriss HT, 2000, CELL MOTIL CYTOSKEL, V45, P173, DOI 10.1002/(SICI)1097-0169(200003)45:3<173::AID-CM1>3.0.CO;2-O; Infante AS, 2000, J CELL SCI, V113, P3907; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; KHAWAJA S, 1988, J CELL BIOL, V106, P141, DOI 10.1083/jcb.106.1.141; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; MIKHAILOV AV, 1995, CELL MOTIL CYTOSKEL, V32, P173, DOI 10.1002/cm.970320303; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Nagasaki T, 1996, J CELL SCI, V109, P2461; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VASILIEV JM, 1976, CELL MOTILITY COLD S, V3, P279; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WEBSTER DR, 1987, P NATL ACAD SCI USA, V84, P9040, DOI 10.1073/pnas.84.24.9040; WEBSTER DR, 1990, J CELL BIOL, V111, P113, DOI 10.1083/jcb.111.1.113; WEBSTER DR, 1990, J CELL BIOL, V111, P1325; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	51	450	459	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					723	729		10.1038/35087035	http://dx.doi.org/10.1038/35087035			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483957				2022-12-25	WOS:000170393200017
J	Fontaine, P; Roy-Proulx, G; Knafo, L; Baron, C; Roy, DC; Perreault, C				Fontaine, P; Roy-Proulx, G; Knafo, L; Baron, C; Roy, DC; Perreault, C			Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease	NATURE MEDICINE			English	Article							DONOR LEUKOCYTE INFUSIONS; BONE-MARROW TRANSPLANTS; IMMUNOTHERAPY; IMMUNODOMINANCE; INDUCTION; RESPONSES	Adoptive transfer of T cells reactive to minor histocompatibility antigens has the unmatched ability to eradicate malignant hematopoietic cells. Unfortunately, its use is hampered by the associated graft-versus-host disease. The critical issue of a possible dissociation of the antileukemic effect and graft-versus-host disease by targeting specific minor histocompatibility antigens remains unresolved because of the unknown nature and number of minor histocompatibility antigens necessary or sufficient to elicit anti-leukemic activity and graft-versus-host disease. We found that injection of T lymphocytes primed against a single major histocompatibility complex class I-restricted immunodominant minor histocompatibility antigen (B6(dom1)) caused no graft-versus-host disease but produced a curative anti-leukemic response. Avoidance of graft-versus-host disease required that no other host-reactive T cells be co-injected with T cells primed with B6(dom1). Here we show that effective and non-toxic immunotherapy of hematologic malignancies can be achieved by targeting a single immunodominant minor histocompatibility antigen.	Maisonneuve Rosemont Hosp, Guy Bernier Res Ctr, Montreal, PQ, Canada	Universite de Montreal	Perreault, C (corresponding author), Maisonneuve Rosemont Hosp, Guy Bernier Res Ctr, Montreal, PQ, Canada.	c.perreault@videotron.ca	Perreault, Claude/A-7220-2008	Perreault, Claude/0000-0001-9453-7383; Roy, Denis-Claude/0000-0002-5921-1692				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barrett AJ, 2000, BLOOD, V95, P3323; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; Brochu S, 1999, BLOOD, V94, P390, DOI 10.1182/blood.V94.2.390.414k27_390_400; Cheever MA, 1997, IMMUNOL REV, V157, P177, DOI 10.1111/j.1600-065X.1997.tb00982.x; Ciubotariu R, 1998, J CLIN INVEST, V101, P398, DOI 10.1172/JCI1117; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; Drobyski WR, 1999, BLOOD, V94, P434, DOI 10.1182/blood.V94.2.434.414k42_434_441; Dulude G, 1999, J EXP MED, V189, P1329, DOI 10.1084/jem.189.8.1329; Eden PA, 1999, J IMMUNOL, V162, P4502; FONTAINE P, 1991, IMMUNOGENETICS, V34, P222, DOI 10.1007/BF00215256; Franco A, 2000, NAT IMMUNOL, V1, P145, DOI 10.1038/77827; GALE RP, 1994, ANN INTERN MED, V120, P646, DOI 10.7326/0003-4819-120-8-199404150-00004; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7; Goulmy E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/j.1600-065X.1997.tb00978.x; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; HOROWITZ MM, 1990, BLOOD, V75, P555; Johnston JV, 1996, J EXP MED, V183, P791, DOI 10.1084/jem.183.3.791; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Korngold R, 1997, Biol Blood Marrow Transplant, V3, P57; KORNGOLD R, 1983, IMMUNOL REV, V71, P5, DOI 10.1111/j.1600-065X.1983.tb01066.x; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Perreault C, 1998, IMMUNOL TODAY, V19, P69, DOI 10.1016/S0167-5699(97)01185-7; Perreault C, 1996, J CLIN INVEST, V98, P622, DOI 10.1172/JCI118832; PION S, 1995, J CLIN INVEST, V95, P1561, DOI 10.1172/JCI117829; Pion S, 1999, BLOOD, V93, P952, DOI 10.1182/blood.V93.3.952.403k33_952_962; Pion S, 1997, EUR J IMMUNOL, V27, P421, DOI 10.1002/eji.1830270212; RODERICK TH, 1989, GENETIC VARIANTS STR, P663; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7	38	141	146	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					789	794		10.1038/89907	http://dx.doi.org/10.1038/89907			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433342				2022-12-25	WOS:000169808600029
J	Propato, A; Cutrona, G; Francavilla, V; Ulivi, M; Schiaffella, E; Landt, O; Dunbar, R; Cerundolo, V; Ferrarini, M; Barnaba, V				Propato, A; Cutrona, G; Francavilla, V; Ulivi, M; Schiaffella, E; Landt, O; Dunbar, R; Cerundolo, V; Ferrarini, M; Barnaba, V			Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming	NATURE MEDICINE			English	Article							DENDRITIC CELLS; IN-VIVO; EFFICIENT PRESENTATION; ANTIGEN PRESENTATION; EXOGENOUS ANTIGEN; ENDOTHELIAL-CELLS; B-CELLS; LYMPHOCYTES; TOLERANCE; ACTIVATION	Here we show that apoptotic cells overexpress vinculin and are ingested by dendritic cells, which subsequently cross-prime vinculin-specific cytotoxic T lymphocytes (CTLs). Successful cross-priming requires that the apoptotic cells provide maturation signals to dendritic cells through CD40-CD40 ligand (CD40L) interactions. If apoptotic cells are CD40L; the help of a third T cell is needed for priming, indicating a regulatory role for apoptotic cells in determining priming or tolerance. Vinculin-specific CTL priming is also related to apoptosis in vivo, given that in HIV-seropositive individuals, the frequency of specific CTLs depends on the proportion of peripheral CD40L(+) apoptotic cells.	Univ Roma La Sapienza, Fdn Andrea Cesalpino, Dipartimento Med Interna, Rome, Italy; Ist Nazl Ric Canc, Serv Immunol Clin, I-16132 Genoa, Italy; TIB Mol Biol, Berlin, Germany; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Nuffield Dept Med, Oxford OX3 9DU, England; Univ Genoa, Dipartimento Oncol Biol & Genet, Genoa, Italy; Ist Pasteur Cenci Bolognetti, Rome, Italy	Sapienza University Rome; University of Genoa; IRCCS AOU San Martino IST; University of Oxford; University of Genoa; Fondazione Cenci Bolognetti	Barnaba, V (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Dipartimento Med Interna, Rome, Italy.		Dunbar, Rod/C-2570-2012; Barnaba, Vincenzo/AAB-1945-2019; Cutrona, Giovanna/I-7868-2018	Dunbar, Rod/0000-0001-9626-2600; Cutrona, Giovanna/0000-0002-3335-1101; Ferrarini, Manlio/0000-0002-6154-2570; Cerundolo, Vincenzo/0000-0003-0040-3793				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Badley AD, 1998, J CLIN INVEST, V102, P79, DOI 10.1172/JCI2691; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barnaba V, 1996, IMMUNOL REV, V152, P47, DOI 10.1111/j.1600-065X.1996.tb00910.x; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CACHO CAM, 1995, J IMMUNOL, V154, P5555; Carbone E, 1997, J EXP MED, V185, P2053, DOI 10.1084/jem.185.12.2053; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Cutrona G, 1999, BLOOD, V94, P3067, DOI 10.1182/blood.V94.9.3067.421a32_3067_3076; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Heath WR, 1999, CURR OPIN IMMUNOL, V11, P314, DOI 10.1016/S0952-7915(99)80050-8; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; Prezzi C, 2001, EUR J IMMUNOL, V31, P894, DOI 10.1002/1521-4141(200103)31:3<894::AID-IMMU894>3.0.CO;2-I; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Reid SD, 2000, CURR OPIN IMMUNOL, V12, P114, DOI 10.1016/S0952-7915(99)00059-X; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; Ronchetti A, 1999, J IMMUNOL, V163, P130; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Scognamiglio P, 1999, J IMMUNOL, V162, P6681; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Veronese FD, 1996, J EXP MED, V183, P2509, DOI 10.1084/jem.183.6.2509; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	45	76	80	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					807	813		10.1038/89930	http://dx.doi.org/10.1038/89930			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433345				2022-12-25	WOS:000169808600032
J	Gold, ER; Adams, WA				Gold, ER; Adams, WA			The Monsanto decision: The edge or the wedge	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Western Ontario, Fac Law, London, ON N6A 3K7, Canada	Western University (University of Western Ontario)	Gold, ER (corresponding author), Univ Western Ontario, Fac Law, London, ON N6A 3K7, Canada.			Gold, E. Richard/0000-0002-3789-9238				Fox JL, 2001, NAT BIOTECHNOL, V19, P396, DOI 10.1038/88013	1	1	1	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					587	587		10.1038/89355	http://dx.doi.org/10.1038/89355			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385467	Bronze			2022-12-25	WOS:000169081700036
J	Scheller, J; Guhrs, KH; Grosse, F; Conrad, U				Scheller, J; Guhrs, KH; Grosse, F; Conrad, U			Production of spider silk proteins in tobacco and potato	NATURE BIOTECHNOLOGY			English	Article							TRANSGENIC PLANTS; DRAGLINE SILK; EXPRESSION; ANTIBODY	Spider dragline silk is a proteinaceous fiber with remarkable mechanical properties that make it attractive for technical applications. Unfortunately, the material cannot be obtained in large quantities from spiders. We have therefore generated transgenic tobacco and potato plants that express remarkable amounts of recombinant Nephila clavipes dragline proteins, Using a gene synthesis approach, the recombinant proteins exhibit homologies of > 90% compared to their native models. Here, we demonstrate the accumulation of recombinant silk proteins, which are encoded by synthetic genes of 420-3,600 base pairs, up to a level of at least 2% of total soluble protein in the endoplasmic reticulum (ER) of tobacco and potato leaves and potato tubers, respectively. Using the present expression system, spider silk proteins up to 100 kDa could be detected in plant tissues. When produced in plants, the recombinant spidroins exhibit extreme heat stability-a property that is used to purify the spidroins by a simple and efficient procedure.	Inst Pflanzengenet & Kulturpflanzenforsch Gatersl, D-06466 Gatersleben, Germany; Inst Mol Biotechnol eV, D-07708 Jena, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Conrad, U (corresponding author), Inst Pflanzengenet & Kulturpflanzenforsch Gatersl, Corrensstr 3, D-06466 Gatersleben, Germany.		Scheller, Jürgen/K-5290-2015					ARTSAENKO O, 1995, PLANT J, V8, P745, DOI 10.1046/j.1365-313X.1995.08050745.x; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; CONRAD U, 1997, METHODS BIOTECHNOLOG, P103, DOI DOI 10.1111/J.1467-7652.2010.00523.X; Fahnestock SR, 1997, APPL MICROBIOL BIOT, V47, P23, DOI 10.1007/s002530050883; Fiedler U, 1997, IMMUNOTECHNOLOGY, V3, P205, DOI 10.1016/S1380-2933(97)00014-6; Gosline JM, 1999, J EXP BIOL, V202, P3295; Hinman MB, 2000, TRENDS BIOTECHNOL, V18, P374, DOI 10.1016/S0167-7799(00)01481-5; Hood EE, 1999, CURR OPIN BIOTECH, V10, P382, DOI 10.1016/S0958-1669(99)80069-X; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PRINCE JT, 1995, BIOCHEMISTRY-US, V34, P10879, DOI 10.1021/bi00034a022; SAITO K, 1990, PLANT CELL REP, V5, P718; Tirrell DA, 1996, SCIENCE, V271, P39, DOI 10.1126/science.271.5245.39; WANDELT CI, 1992, PLANT J, V2, P181; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x	14	242	283	5	84	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					573	577		10.1038/89335	http://dx.doi.org/10.1038/89335			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385464				2022-12-25	WOS:000169081700033
J	Stoddart, CA; Liegler, TJ; Mammano, F; Linquist-Stepps, VD; Hayden, MS; Deeks, SG; Grant, RM; Clavel, F; McCune, JM				Stoddart, CA; Liegler, TJ; Mammano, F; Linquist-Stepps, VD; Hayden, MS; Deeks, SG; Grant, RM; Clavel, F; McCune, JM			Impaired replication of protease inhibitor-resistant HIV-1 in human thymus	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; T-CELL FUNCTION; IN-VIVO; HIV-1-INFECTED INDIVIDUALS; VIROLOGICAL FAILURE; CONTROLLED TRIAL; VIRAL FITNESS; INFECTION; INDINAVIR	Many HIV-1-infected patients treated with protease inhibitors (PI) develop PI-resistant HIV-1 variants and rebounds in viremia, but their CD4(+) T-cell counts often do not fall. We hypothesized that in these patients, T-cell counts remain elevated because PI-resistant virus spares intrathymic T-cell production. To test this, we studied recombinant HIV-1 clones containing wild-type or PI-resistant protease domains, as well as uncloned isolates from patients, in activated peripheral blood mononuclear cells, human thymic organ cultures and human thymus implants in SCID-hu Thy/Liv mice. In most cases, wild-type and PI-resistant HIV-1 isolates replicated to similar degrees in peripheral blood mononuclear cells. However, the replication of PI-resistant but not wild-type HIV-1 isolates was highly impaired in thymocytes. In addition, patients who had PI-resistant HIV-1 had abundant thymus tissue as assessed by computed tomography. We propose that the inability of PI-resistant HIV-1 to replicate efficiently in thymus contributes to the preservation of CD4(+) T-cell counts in patients showing virologic rebound on PI therapy.	San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Hop Bichat Claude Bernard, IMEA, Rech Antivirale, INSERM,U552, F-75877 Paris 18, France	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Stoddart, CA (corresponding author), San Francisco Gen Hosp, Gladstone Inst Virol & Immunol, San Francisco, CA 94110 USA.		Mammano, Fabrizio/H-9423-2019; Hayden, Matthew/C-1263-2008	Mammano, Fabrizio/0000-0002-9193-7696; Grant, Robert/0000-0002-0851-7085; Hayden, Matthew/0000-0003-1670-6430	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI043864, N01AI005418, R01AI043864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER; NCRR NIH HHS [5-MO1-RR00083] Funding Source: Medline; NIAID NIH HHS [AI05418, AI43864, AI65309] Funding Source: Medline; NIMH NIH HHS [P30 MH59037] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Emini EA, 1996, ADV EXP MED BIOL, V394, P327; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hatzakis A, 2000, LANCET, V355, P599, DOI 10.1016/S0140-6736(99)10311-8; Hirsch M, 1999, J INFECT DIS, V180, P659, DOI 10.1086/314948; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; Lecossier D, 2001, J INFECT DIS, V183, P1009, DOI 10.1086/319285; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Liegler TJ, 2001, AIDS, V15, P179, DOI 10.1097/00002030-200101260-00006; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mezzaroma I, 1999, AIDS, V13, P1187, DOI 10.1097/00002030-199907090-00006; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PENN ML, IN PRESS AIDS RES HU; Rabin L, 1996, ANTIMICROB AGENTS CH, V40, P755, DOI 10.1128/AAC.40.3.755; Renaud M, 1999, AIDS, V13, P669, DOI 10.1097/00002030-199904160-00007; Rey-Cuille MA, 1998, J VIROL, V72, P3872; Rose RE, 1996, P NATL ACAD SCI USA, V93, P1648, DOI 10.1073/pnas.93.4.1648; Smith KY, 2000, J INFECT DIS, V181, P141, DOI 10.1086/315169; Stoddart CA, 2000, ANTIMICROB AGENTS CH, V44, P783, DOI 10.1128/AAC.44.3.783-786.2000; STODDART CA, 1999, HDB ANIMAL MODELS IN, P1069; Winters MA, 1998, J VIROL, V72, P5303, DOI 10.1128/JVI.72.6.5303-5306.1998; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998; Zhang LQ, 1999, J EXP MED, V190, P725, DOI 10.1084/jem.190.5.725; Zhang YM, 1997, J VIROL, V71, P6662, DOI 10.1128/JVI.71.9.6662-6670.1997	41	115	115	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					712	718		10.1038/89090	http://dx.doi.org/10.1038/89090			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385509				2022-12-25	WOS:000169081500040
J	Meguro, M; Kashiwagi, A; Mitsuya, K; Nakao, M; Kondo, I; Saitoh, S; Oshimura, M				Meguro, M; Kashiwagi, A; Mitsuya, K; Nakao, M; Kondo, I; Saitoh, S; Oshimura, M			A novel maternally expressed gene, ATP10C, encodes a putative aminophospholipid translocase associated with Angelman syndrome	NATURE GENETICS			English	Article							PRADER-WILLI; SNRPN GENE; MOUSE	Lack of a maternal contribution to the genome at the imprinted domain on proximal chromosome 15 causes Angelman syndrome (AS) associated with neurobehavioral anomalies that include severe mental retardation, ataxia and epilepsy(1,2). Although AS patients have infrequent mutations in the gene encoding an EG-AP ubiquitin ligase required for long-term synaptic potentiation (LTP), most cases are attributed to de novo maternal deletions of 15q11-q13 (ref. 3). We report here that a novel maternally expressed gene, ATP10C, maps within the most common interval of deletion and that ATP10C expression is virtually absent from AS patients with imprinting mutations, as well as from patients with maternal deletions of 15q11-q13.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet,CREST Project, Tottori 680, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Ehime Univ, Sch Med, Dept Hyg, Matsuyama, Ehime 790, Japan; Hokkaido Univ, Sch Med, Dept Pediat, Sapporo, Hokkaido 060, Japan	Japan Science & Technology Agency (JST); Tottori University; Kumamoto University; Ehime University; Hokkaido University	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet,CREST Project, Tottori 680, Japan.		Mitsuya, Kohzoh/F-4437-2010; Kashiwagi, Atsunori/H-8712-2019	Saitoh, Shinji/0000-0001-6911-3351; Mitsuya, Kohzoh/0000-0002-0950-5406				Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Bielinska B, 2000, NAT GENET, V25, P74, DOI 10.1038/75629; Cattanach BM, 1997, MAMM GENOME, V8, P472, DOI 10.1007/s003359900479; Dhar M, 2000, PHYSIOL GENOMICS, V4, P93, DOI 10.1152/physiolgenomics.2000.4.1.93; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; Gillessen-Kaesbach G, 1999, EUR J HUM GENET, V7, P638, DOI 10.1038/sj.ejhg.5200362; Halleck MS, 1999, PHYSIOL GENOMICS, V1, P139, DOI 10.1152/physiolgenomics.1999.1.3.139; Jiang YH, 1998, CURR OPIN GENET DEV, V8, P334, DOI 10.1016/S0959-437X(98)80091-9; Jiang YH, 1999, AM J HUM GENET, V65, P1, DOI 10.1086/302473; Mann MRW, 1999, HUM MOL GENET, V8, P1867, DOI 10.1093/hmg/8.10.1867; Moncla A, 1999, EUR J HUM GENET, V7, P131, DOI 10.1038/sj.ejhg.5200258; MUTIRANGURA A, 1993, GENOMICS, V18, P546, DOI 10.1016/S0888-7543(11)80011-X; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Saitoh S, 1999, CLIN GENET, V55, P277, DOI 10.1034/j.1399-0004.1999.550411.x; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329	15	116	119	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					19	20		10.1038/ng0501-19	http://dx.doi.org/10.1038/ng0501-19			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326269				2022-12-25	WOS:000168413300009
J	Mears, AJ; Kondo, M; Swain, PK; Takada, Y; Bush, RA; Saunders, TL; Sieving, PA; Swaroop, A				Mears, AJ; Kondo, M; Swain, PK; Takada, Y; Bush, RA; Saunders, TL; Sieving, PA; Swaroop, A			Nrl is required for rod photoreceptor development	NATURE GENETICS			English	Article							CELL-FATE DETERMINATION; LEUCINE-ZIPPER; PROTEIN; DEGENERATION; RECEPTOR; RETINA; GENE; CRX; HOMEODOMAIN; DISRUPTION	The protein neural retina leucine zipper (Nrl) is a basic motif-leucine zipper transcription factor that is preferentially expressed in rod photoreceptors(1,2). it acts synergistically with Crx to regulate rhodopsin transcription(3-5). Missense mutations in human NRL have been associated with autosomal dominant retinitis pigmentosa(6,7). Here we report that deletion of Nrl in mice results in the complete loss of rod function and super-normal cone function, mediated by S cones. The photoreceptors in the Nrl(-/-) retina have cone-like nuclear morphology(8) and short, sparse outer segments with abnormal disks. Analysis of retinal gene expression confirms the apparent functional transformation of rods into S cones in the Nrl(-/-) retina. On the basis of these findings, we postulate that Nrl acts as a 'molecular switch' during rod-cell development by directly modulating rod-specific genes while simultaneously inhibiting the S-cone pathway through the activation of Nr2e3.	Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Nagoya Univ, Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; NEI, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; Nagoya University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Swaroop, A (corresponding author), Univ Michigan, Dept Ophthalmol & Visual Sci, 1500 E Med Ctr Dr, Ann Arbor, MI 48105 USA.	swaroop@umich.edu		Swaroop, Anand/0000-0002-1975-1141; Saunders, Thom/0000-0003-2015-101X	NATIONAL EYE INSTITUTE [R01EY011115] Funding Source: NIH RePORTER; NEI NIH HHS [EY11115, EY07003] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Coligan JE, 1999, CURRENT PROTOCOLS PR; Fan W, 1996, EXP EYE RES, V63, P9, DOI 10.1006/exer.1996.0086; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619; HARRIS WA, 1992, NEURON, V9, P357, DOI 10.1016/0896-6273(92)90174-C; HITCHCOCK PF, 1989, J COMP NEUROL, V283, P177, DOI 10.1002/cne.902830203; Trujillo MJ, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<80::AID-HUMU27>3.0.CO;2-G; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814; Kosaka J, 1998, J NEUROSCI RES, V54, P655, DOI 10.1002/(SICI)1097-4547(19981201)54:5<655::AID-JNR10>3.3.CO;2-Q; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Saari JC, 1997, GLIA, V21, P259; Sambrook J, 2001, MOL CLONING LAB MANU; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Toda K, 1999, VISUAL NEUROSCI, V16, P391, DOI 10.1017/S0952523899162187; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VERDERBER L, 1995, INVEST OPHTH VIS SCI, V36, P1137; WILLIAMS DS, 1991, BIOESSAYS, V13, P171, DOI 10.1002/bies.950130405; Zhao XY, 1998, J BIOL CHEM, V273, P5124, DOI 10.1074/jbc.273.9.5124	31	701	713	1	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2001	29	4					447	452		10.1038/ng774	http://dx.doi.org/10.1038/ng774			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11694879				2022-12-25	WOS:000172507500021
J	Alcasabas, AA; Osborn, AJ; Bachant, J; Hu, FH; Werler, PJH; Bousset, K; Furuya, K; Diffley, JFX; Carr, AM; Elledge, SJ				Alcasabas, AA; Osborn, AJ; Bachant, J; Hu, FH; Werler, PJH; Bousset, K; Furuya, K; Diffley, JFX; Carr, AM; Elledge, SJ			Mrc1 transduces signals of DNA replication stress to activate Rad53	NATURE CELL BIOLOGY			English	Article							DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; S-PHASE; PROTEIN-KINASE; PHOSPHORYLATION; GENE; CHK1; P53	Cells experiencing DNA replication stress activate a response pathway that delays entry into mitosis and promotes DNA repair and completion of DNA replication. The protein kinases ScRad53 and SpCds1 (in baker's and fission yeast, respectively) are central to this pathway. We describe a conserved protein Mrc1, mediator of the replication checkpoint, required for activation of ScRad53 and SpCds1 during replication stress. mrc1 mutants are sensitive to hydroxyurea and have a checkpoint defect similar to rad53 and cds1 mutants. Mrc1 may be the replicative counterpart of Rad9 and Crb2, which are required for activating ScRad53 and Chk1 in response to DNA damage.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RR, E Sussex, England; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Sussex	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Carr, Antony Michael/0000-0002-2028-2389; Diffley, John/0000-0001-5184-7680				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chehab NH, 2000, GENE DEV, V14, P278; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Paciotti V, 1998, EMBO J, V17, P4199, DOI 10.1093/emboj/17.14.4199; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shieh SY, 2000, GENE DEV, V14, P289; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	32	414	426	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					958	965		10.1038/ncb1101-958	http://dx.doi.org/10.1038/ncb1101-958			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715016				2022-12-25	WOS:000172070300010
J	Meister, G; Buhler, D; Pillai, R; Lottspeich, F; Fischer, U				Meister, G; Buhler, D; Pillai, R; Lottspeich, F; Fischer, U			A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs	NATURE CELL BIOLOGY			English	Article							MUSCULAR-ATROPHY GENE; NEURONS SMN PROTEIN; PRODUCT; SURVIVAL; BINDING; IDENTIFICATION; BIOGENESIS; TRANSPORT; INTERACTS; COMPONENT	The spliceosomal snRNPs U1, U2, U4 and U5 contain a common RNP structure termed the Sm core that is formed by the binding of Sm proteins onto the U snRNA. Although isolated Sm proteins assemble spontaneously onto U snRNAs in vitro, there is increasing evidence that SMN and its interactor Gemin2 are involved in this process in vivo. Here, we describe a cell-free assay system for the assembly of U snRNPs that closely reproduces in vivo conditions. Using this system, we show that assembly of U1 snRNP depends on ATP. Immunodepletion of SMN-Gemin2 from the extract abolished assembly even though the extract contained high levels of Sm proteins. An affinity-purified macromolecular SMN complex consisting of 16 components including all Sm proteins restored assembly in the immunodepleted extract. These data provide the first direct evidence that a complex containing SMN and Gemin2 mediates the active assembly of spliceosomal U snRNPs.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Bern, CH-3012 Bern, Switzerland	Max Planck Society; University of Bern	Fischer, U (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	ufischer@biochem.mpg.de	Fischer, Utz/AAT-8422-2020; Fischer, Utz/A-4090-2016	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; HUNT SL, 1998, GENE DEV, V13, P347; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; JONES KW, IN PRESS J BIOL CHEM; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Muller B, 2000, J BIOL CHEM, V275, P24284, DOI 10.1074/jbc.M003253200; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Pu WT, 1999, MOL CELL BIOL, V19, P4113; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Zhang D, 2001, MOL CELL, V7, P319, DOI 10.1016/S1097-2765(01)00180-0	29	231	237	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					945	949		10.1038/ncb1101-945	http://dx.doi.org/10.1038/ncb1101-945			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715014				2022-12-25	WOS:000172070300008
J	Schmidt, M; Evellin, S; Weernink, PAO; vom Dorp, F; Rehmann, H; Lomasney, JW; Jakobs, KH				Schmidt, M; Evellin, S; Weernink, PAO; vom Dorp, F; Rehmann, H; Lomasney, JW; Jakobs, KH			A new phospholipase-C - calcium signalling pathway mediated by cyclic AMP and a Rap GTPase	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEIN-KINASE; N1E-115 NEUROBLASTOMA-CELLS; RECEPTOR TYROSINE KINASES; DIFFICILE TOXIN-B; EXCHANGE FACTOR; PHORBOL ESTER; CAMP; INHIBITION; STIMULATION; RHO	Stimulation of phosphoinositide-hydrolysing phospholipase C (PLC) generating inositol-1,4,5-trisphosphate is a major calcium signalling pathway used by a wide variety of membrane receptors, activating distinct PLC-beta or PLC-gamma isoforms(1-4). Here we report a new PLC and calcium signalling pathway that is triggered by cyclic AMP (cAMP) and mediated by a small GTPase of the Rap family. Activation of the adenylyl cyclase-coupled beta (2)-adrenoceptor expressed in HEK-293 cells or the endogenous receptor for prostaglandin E-1 in N1E-115 neuroblastoma cells induced calcium mobilization and PLC stimulation, seemingly caused by cAMP formation, but was independent of protein kinase A (PKA). We provide evidence that these receptor responses are mediated by a Rap GTPase, specifically Rap2B, activated by a guanine-nucleotide-exchange factor (Epac) regulated by cAMP(5,6), and involve the recently identified PLC-epsilon isoform(7-9).	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; UMC Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; UMC Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pharmacol, Chicago, IL 60611 USA	University of Duisburg Essen; Max Planck Society; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Northwestern University; Northwestern University	Schmidt, M (corresponding author), Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany.							Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chik CL, 1996, J NEUROCHEM, V67, P1005; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daniel PB, 2001, J BIOL CHEM, V276, P12938, DOI 10.1074/jbc.M009941200; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; Evellin S, 2001, N-S ARCH PHARMACOL, V363, pR61; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KANBA S, 1991, J NEUROCHEM, V57, P2011, DOI 10.1111/j.1471-4159.1991.tb06416.x; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; LIN CW, 1995, MOL PHARMACOL, V47, P131; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MATSUZAWA H, 1975, P NATL ACAD SCI USA, V72, P3472, DOI 10.1073/pnas.72.9.3472; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; PARK DJ, 1992, J BIOL CHEM, V267, P1496; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Schmidt M, 2000, J BIOL CHEM, V275, P32603, DOI 10.1074/jbc.M004784200; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Zhang CY, 1996, MOL PHARMACOL, V50, P864	35	272	286	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					1020	1024		10.1038/ncb1101-1020	http://dx.doi.org/10.1038/ncb1101-1020			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715024				2022-12-25	WOS:000172070300018
J	De Strooper, B; Annaert, W				De Strooper, B; Annaert, W			Presenilins and the intramembrane proteolysis of proteins: facts and fiction	NATURE CELL BIOLOGY			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE ACTIVITY; CAPACITATIVE CALCIUM-ENTRY; IN-VIVO; DISINTEGRIN-METALLOPROTEASE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MISSENSE MUTATIONS; BETA-APP	Missense mutations in the genes coding for presenilin 1 and presenilin 2 cause familial Alzheimer's disease - a progressive neurodegenerative disorder of the central nervous system. Loss-of-function mutations of these genes in Drosophila, Caenorhabditis elegans and mice cause severe lethal phenotypes, which implicates the presenilins genetically in the Notch signalling pathway. The hypothesis that presenilins are aspartyl proteases that cleave the amyloid precursor protein and Notch can explain the phenotypes. Direct evidence for this hypothesis is, however, difficult to obtain. Moreover, presenilin 1 is a multifunctional protein, as exemplified by its role in the Wnt/ beta -catenin signalling pathway.	Katholieke Univ Leuven, Ctr Human Genet, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	KU Leuven	De Strooper, B (corresponding author), Katholieke Univ Leuven, Ctr Human Genet, Neuronal Cell Biol Lab, Herestr 49, B-3000 Louvain, Belgium.	AD@med.kuleuven.ac.be	De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819				Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ARMOGIDA M, IN PRESS NATURE CELL; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; GU Y, 2001, J BIOL CHEM; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; Morihara T, 2000, MOL BRAIN RES, V85, P85, DOI 10.1016/S0169-328X(00)00229-1; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SASTRE M, IN PRESS EMBO REP; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; WURTMAN RJ, 1985, SCI AM, V252, P62, DOI 10.1038/scientificamerican0185-62; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; XIA X, IN PRESS P NATL ACAD; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; YU H, IN PRESS NEURON; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	82	38	43	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					E221	E225		10.1038/ncb1001-e221	http://dx.doi.org/10.1038/ncb1001-e221			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584280				2022-12-25	WOS:000171396400002
J	McCartney, BM; McEwen, DG; Grevengoed, E; Maddox, P; Bejsovec, A; Peifer, M				McCartney, BM; McEwen, DG; Grevengoed, E; Maddox, P; Bejsovec, A; Peifer, M			Drosophila APC2 and Armadillo participate in tethering mitotic spindles to cortical actin	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELLS; ADHERENS JUNCTION; BETA-CATENIN; ORGANIZATION; HOMOLOG; MICROTUBULES; ASSOCIATION; CADHERIN; DYNAMICS	Proper positioning of mitotic spindles ensures equal allocation of chromosomes to daughter cells. This often involves interactions between spindle and astral microtubules and cortical actin(1). In yeast and Caenorhabditis elegans, some of the protein machinery that connects spindles and cortex has been identified but, in most animal cells, this process remains mysterious. Here, we report that the tumour suppresser homologue APC2 and its binding partner Armadillo both play roles in spindle anchoring during the syncytial mitoses of early Drosophila embryos. Armadillo, alpha -catenin and APC2 all localize to sites of cortical spindle attachment. APC2-Armadillo complexes often localize with interphase microtubules. Zeste-white 3 kinase, which can phosphorylate Armadillo and APC, is also crucial for spindle positioning and regulates the localization of APC2-Armadillo complexes. Together, these data suggest that APC2, Armadillo and alpha -catenin provide an important link between spindles and cortical actin, and that this link is regulated by Zeste-white 3 kinase.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Duke Univ, Dept Biol, Durham, NC 27708 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Peifer, M (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.			Peifer, Mark/0000-0003-1412-3987; Bejsovec, Amy/0000-0002-8019-5789	NATIONAL CANCER INSTITUTE [F32CA079172, T32CA071341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019824, R01GM047857] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA71341, 1F32CA79172] Funding Source: Medline; NIGMS NIH HHS [1F32GM19824, GM47857] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Bloom K, 2000, NAT CELL BIOL, V2, pE96, DOI 10.1038/35014089; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FOE VE, 1993, DEV DROSOPHILA MELAN, V1, P149; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; Polakis P, 2000, GENE DEV, V14, P1837; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rothwell WF, 1998, DEVELOPMENT, V125, P1295; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Stevenson VA, 2001, NAT CELL BIOL, V3, P68, DOI 10.1038/35050579; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SULLIVAN W, 1993, DEVELOPMENT, V118, P1245; Townsley FM, 2000, CURR BIOL, V10, P1339, DOI 10.1016/S0960-9822(00)00770-3; Waterman-Storer CM, 2000, MOL BIOL CELL, V11, P2471, DOI 10.1091/mbc.11.7.2471; Yu X, 1999, MECH DEVELOP, V84, P69, DOI 10.1016/S0925-4773(99)00072-6; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064; Zhang CX, 1996, J CELL BIOL, V134, P923, DOI 10.1083/jcb.134.4.923; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	31	139	140	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					933	938		10.1038/ncb1001-933	http://dx.doi.org/10.1038/ncb1001-933			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584277				2022-12-25	WOS:000171396400020
J	Wu, Y; Berends, MJW; Sijmons, RH; Mensink, RGJ; Verlind, E; Kooi, KA; van der Sluis, T; Kempinga, C; van der Zee, AGJ; Hollema, H; Buys, CHCM; Kleibeuker, JH; Hofstra, RMW				Wu, Y; Berends, MJW; Sijmons, RH; Mensink, RGJ; Verlind, E; Kooi, KA; van der Sluis, T; Kempinga, C; van der Zee, AGJ; Hollema, H; Buys, CHCM; Kleibeuker, JH; Hofstra, RMW			A role for MLH3 in hereditary nonpolyposis colorectal cancer	NATURE GENETICS			English	Article							INTERNATIONAL-COLLABORATIVE-GROUP; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ICG-HNPCC; MUTATIONS; MUTL	We investigated a possible role of the mismatch-repair gene MLH3 in hereditary nonpolyposis colorectal cancer by scanning for mutations in 39 HNPCC families and in 288 patients suspected of having HNPCC. We identified ten different germline MLH3 variants, one frameshift and nine missense mutations, in 12 patients suspected of HNPCC. Three of the 12 also carried a mutation in MSH6.	Univ Groningen, Dept Med Genet, Groningen, Netherlands; Univ Groningen, Dept Gastroenterol, Groningen, Netherlands; Univ Groningen, Dept Pathol, Groningen, Netherlands; Univ Groningen, Dept Gynecol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	Hofstra, RMW (corresponding author), Univ Groningen, Dept Med Genet, Groningen, Netherlands.		Sijmons, Rolf/E-5829-2012	Sijmons, Rolf/0000-0001-8446-2779; Hofstra, Robert/0000-0001-7498-3829				Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Boland CR, 1998, CANCER RES, V58, P5248; Dietmaier W, 1997, CANCER RES, V57, P4749; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Jiricny J, 2000, NAT GENET, V24, P6, DOI 10.1038/71698; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Park JG, 1999, DIS COLON RECTUM, V42, P710, DOI 10.1007/BF02236922; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612	13	127	133	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					137	138		10.1038/ng1001-137	http://dx.doi.org/10.1038/ng1001-137			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586295				2022-12-25	WOS:000171374100016
J	Yang, Y; Hentati, A; Deng, HX; Dabbagh, O; Sasaki, T; Hirano, M; Hung, WY; Ouahchi, K; Yan, JH; Azim, AC; Cole, N; Gascon, G; Yagmour, A; Ben-Hamida, M; Pericak-Vance, M; Hentati, F; Siddique, T				Yang, Y; Hentati, A; Deng, HX; Dabbagh, O; Sasaki, T; Hirano, M; Hung, WY; Ouahchi, K; Yan, JH; Azim, AC; Cole, N; Gascon, G; Yagmour, A; Ben-Hamida, M; Pericak-Vance, M; Hentati, F; Siddique, T			The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis	NATURE GENETICS			English	Article							SUPEROXIDE-DISMUTASE; SPASTIC PARALYSIS; LINKAGE; REGULATOR; HOMOLOGY; FEATURES; COMPLEX; FAMILY; MUTANT; SOD1	Amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) are neurodegenerative conditions that affect large motor neurons of the central nervous system. We have identified a familial juvenile PLS (JPLS) locus overlapping the previously identified ALS2 locus on chromosome 2q33. We report two deletion mutations in a new gene that are found both in individuals with ALS2 and those with JPLS, indicating that these conditions have a common genetic origin. The predicted sequence of the protein (alsin) may indicate a mechanism for motor-neuron degeneration, as it may include several cell-signaling motifs with known functions, including three associated with guanine-nucleotide exchange factors for GTPases (GEFs).	Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA; King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia; Brown Univ, Div Pediat Neurol, Providence, RI 02912 USA; King Fahad Mil Hosp, Jeddah, Saudi Arabia; Inst Neurol, Tunis, Tunisia; Duke Univ, Med Ctr, Durham, NC USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA	Northwestern University; King Faisal Specialist Hospital & Research Center; Brown University; Universite de Tunis-El-Manar; Institut National de Neurologie; Duke University; Northwestern University; Northwestern University	Siddique, T (corresponding author), Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA.	t-siddique@northwestern.edu	AZIM, ANSER/U-3483-2019; Siddique, Teepu/AAT-8166-2021	Siddique, Teepu/0000-0001-7293-9146; Deng, Han-Xiang/0000-0002-0030-8465	NINDS NIH HHS [R01 NS40308, R01 NS37912, P01 NS21442] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037912, R01NS040308, P01NS021442] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BEAL MF, 1981, ARCH NEUROL-CHICAGO, V38, P630, DOI 10.1001/archneur.1981.00510100058008; BENHAMIDA M, 1990, BRAIN, V113, P347; Brown RH, 1998, NAT MED, V4, P1362, DOI 10.1038/3945; BROWN WF, 1992, MUSCLE NERVE, V15, P626, DOI 10.1002/mus.880150515; Chance PF, 1998, AM J HUM GENET, V62, P633, DOI 10.1086/301769; Charcot J-M, 1865, B SOC MED HOP PAR S2, V10, P24; Cleveland DW, 1999, NEURON, V24, P515, DOI 10.1016/S0896-6273(00)81108-3; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P2369, DOI 10.1093/nar/27.11.2369; den Dunnen JT, 2000, HUM MUTAT, V15, P7; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DENG HX, 1992, HUM GENET, V89, P13, DOI 10.1007/BF00207034; Deng HX, 2000, ARCH NEUROL-CHICAGO, V57, P1695, DOI 10.1001/archneur.57.12.1695; *EL ESC WORLD FED, 1994, J NEUROL SCI S, V124, P96; Erb WH, 1875, BERLINER KLIN WOCHEN, V12, P357; FISHER CM, 1977, CAN J NEUROL SCI, V4, P251, DOI 10.1017/S0317167100025075; Gascon GG, 1995, NEUROPEDIATRICS, V26, P313, DOI 10.1055/s-2007-979781; GRUNNET ML, 1989, NEUROLOGY, V39, P1530, DOI 10.1212/WNL.39.11.1530; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Heene R, 1996, FORTSCHR NEUROL PSYC, V64, P192, DOI 10.1055/s-2007-996385; Hentati A, 1998, NEUROGENETICS, V2, P55, DOI 10.1007/s100480050052; HENTATI A, 1994, NAT GENET, V7, P425, DOI 10.1038/ng0794-425; HUDSON AJ, 1993, BRAIN RES BULL, V30, P359, DOI 10.1016/0361-9230(93)90265-D; Kahana JA, 2001, SCIENCE, V291, P1718, DOI 10.1126/science.1059765; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Lehman AL, 1998, P NATL ACAD SCI USA, V95, P9436, DOI 10.1073/pnas.95.16.9436; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LermanSagie T, 1996, J CHILD NEUROL, V11, P54, DOI 10.1177/088307389601100114; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; OTT J, 1991, ANAL HUMAN GENETIC L, P194; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; PRINGLE CE, 1992, BRAIN, V115, P495, DOI 10.1093/brain/115.2.495; Rampoldi L, 2001, NAT GENET, V28, P119, DOI 10.1038/88821; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Rosa JL, 1997, ONCOGENE, V15, P1, DOI 10.1038/sj.onc.1201170; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUSSO LS, 1982, ARCH NEUROL-CHICAGO, V39, P662, DOI 10.1001/archneur.1982.00510220060015; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SHOSHANI T, 1994, J CLIN INVEST, V93, P1502, DOI 10.1172/JCI117128; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; SOTANIEMI KA, 1985, ACTA NEUROL SCAND, V71, P334; STARK FM, 1945, J NERV MENT DIS, V102, P332, DOI 10.1097/00005053-194510000-00002; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Yan D, 1998, J BIOL CHEM, V273, P19656, DOI 10.1074/jbc.273.31.19656; YOUNGER DS, 1988, ARCH NEUROL-CHICAGO, V45, P1304, DOI 10.1001/archneur.1988.00520360022005	50	562	584	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2001	29	2					160	165		10.1038/ng1001-160	http://dx.doi.org/10.1038/ng1001-160			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586297				2022-12-25	WOS:000171374100021
J	Blower, SM; Aschenbach, AN; Gershengorn, HB; Kahn, JO				Blower, SM; Aschenbach, AN; Gershengorn, HB; Kahn, JO			Predicting the unpredictable: Transmission of drug-resistant HIV	NATURE MEDICINE			English	Article							POTENT ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; TUBERCULOSIS; SUSCEPTIBILITY; CONSEQUENCES; STRATEGIES; INFECTION; INDINAVIR; REGIMENS; FAILURE	We use a mathematical model to understand (from 1996 to 2001) and to predict (from 2001 to 2005) the evolution of the epidemic of drug-resistant HIV in San Francisco. We predict the evolutionary trajectories for 1,000 different drug-resistant strains with each strain having a different fitness relative to a drug-sensitive strain. We calculate that the current prevalence of resistance is high, and predict it will continue to rise. In contrast, we calculate that transmission of resistance is currently low, and predict it will remain low. We show that the epidemic of resistance is being generated mainly by the conversion of drug-sensitive cases to drug-resistant cases, and not by the transmission of resistant strains. We also show that transmission of resistant strains has not increased the overall number of new HIV infections. Our results indicate that transmission of resistant strains is, and will remain, a relatively minor public health problem.	Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, AIDS Inst, Los Angeles, CA 90024 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Blower, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA.	sblower@biomath.ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41935] Funding Source: Medline; NIMH NIH HHS [P30MH59037] Funding Source: Medline; PHS HHS [U01A41531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Blower S, 2001, AIDS, V15, P1309, DOI 10.1097/00002030-200107060-00014; Blower S, 1999, NAT MED, V5, P358, DOI 10.1038/7328; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1998, J MOL MED, V76, P624, DOI 10.1007/s001090050260; BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Blower SM, 1998, NAT MED, V4, P673, DOI 10.1038/nm0698-673; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Blower SM, 2001, P NATL ACAD SCI USA, V98, P3618, DOI 10.1073/pnas.061029998; Catania JA, 2000, SCIENCE, V290, P717, DOI 10.1126/science.290.5492.717; *CDC, 1998, MMWR-MORBID MORTAL W, V48, P45; *CDC, 2001, MMWR-MORBID MORTAL W, V50, P117; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P773; Conway B, 2001, AIDS, V15, P1269, DOI 10.1097/00002030-200107060-00008; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Gallant JE, 2000, JAMA-J AM MED ASSOC, V283, P1329, DOI 10.1001/jama.283.10.1329; Gazzard B, 1998, LANCET, V352, P314, DOI 10.1016/S0140-6736(98)04084-7; Ghani AC, 2001, AIDS, V15, P1133, DOI 10.1097/00002030-200106150-00008; HANSEL A, 2001, AIDS, V26, P191; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HOGG RS, 1998, JAMA-J AM MED ASSOC, V279, P50; Huang W, 2001, J INFECT DIS, V183, P1455, DOI 10.1086/320192; IMAN RL, 1988, RISK ANAL, V8, P71, DOI 10.1111/j.1539-6924.1988.tb01155.x; Kleijnen JPC, 1999, RELIAB ENG SYST SAFE, V65, P147, DOI 10.1016/S0951-8320(98)00091-X; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Little SJ, 2001, BRIT MED J, V322, P1074, DOI 10.1136/bmj.322.7294.1074; Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Salomon H, 2000, AIDS, V14, pF17, DOI 10.1097/00002030-200001280-00003; *SAN FRANC DEP PUB, 2000, ANN SURV REP; Stoddart CA, 2001, NAT MED, V7, P712, DOI 10.1038/89090; Tchetgen E, 2001, J ACQ IMMUN DEF SYND, V26, P118, DOI 10.1097/00126334-200102010-00003; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6	39	185	187	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1016	1020		10.1038/nm0901-1016	http://dx.doi.org/10.1038/nm0901-1016			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533704				2022-12-25	WOS:000170853300026
J	Cleary, MA; van Raamsdonk, CD; Levorse, J; Zheng, BH; Bradley, A; Tilghman, SM				Cleary, MA; van Raamsdonk, CD; Levorse, J; Zheng, BH; Bradley, A; Tilghman, SM			Disruption of an imprinted gene cluster by a targeted chromosomal translocation in mice	NATURE GENETICS			English	Article							BECKWITH-WIEDEMANN-SYNDROME; EMBRYONIC STEM-CELLS; MOUSE; P57(KIP2); SEQUENCE; 11P15.5; DOMAIN; REGION; KVLQT1; DIFFERENTIATION	Genomic imprinting is an epigenetic process in which the activity of a gene is determined by its parent of origin. Mechanisms governing genomic imprinting are just beginning to be understood. However, the tendency of imprinted genes to exist in chromosomal clusters suggests a sharing of regulatory elements. To better understand imprinted gene clustering, we disrupted a cluster of imprinted genes on mouse distal chromosome 7 using the Cre/loxP recombination system. In mice carrying a site-specific translocation separating Cdkn1c and Kcnq1, imprinting of the genes retained on chromosome 7, including Kcnq1, Kcnq1ot1, Ascl2, H19 and lgf2, is unaffected, demonstrating that these genes are not regulated by elements near or telomeric to Cdkn1c. In contrast, expression and imprinting of the translocated Cdkn1c, Slc22a1l and Tssc3 on chromosome 11 are affected, consistent with the hypothesis that elements regulating both expression and imprinting of these genes lie within or proximal to Kcnq1. These data support the proposal that chromosomal abnormalities, including translocations, within KCNQ1 that are associated with the human disease Beckwith-Wiedemann syndrome (BWS) may disrupt CDKN1C expression. These results underscore the importance of gene clustering for the proper regulation of imprinted genes.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Sanger Ctr, Cambridge, England	Howard Hughes Medical Institute; Princeton University; Princeton University; Stanford University; University of California System; University of California San Francisco; Wellcome Trust Sanger Institute	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.		Van Raamsdonk, Catherine D./B-6207-2017	Van Raamsdonk, Catherine D./0000-0002-4309-3513; Bradley, Allan/0000-0002-2349-8839				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Brown LS, 1996, WOMEN THER, V19, P5, DOI 10.1300/J015v19n01_02; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; Cooper PR, 1998, GENOMICS, V49, P38, DOI 10.1006/geno.1998.5221; Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Lee MP, 1997, AM J HUM GENET, V61, P304, DOI 10.1086/514858; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; OKeefe D, 1997, AM J HUM GENET, V61, P295, DOI 10.1086/514854; Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Qian N, 1997, HUM MOL GENET, V6, P2021, DOI 10.1093/hmg/6.12.2021; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P108; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Thorvaldsen JL, 2000, SCIENCE, V288, P2145, DOI 10.1126/science.288.5474.2145; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yatsuki H, 2000, DNA RES, V7, P195, DOI 10.1093/dnares/7.3.195; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zheng BH, 2000, MOL CELL BIOL, V20, P648, DOI 10.1128/MCB.20.2.648-655.2000	30	46	52	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					78	82		10.1038/ng715	http://dx.doi.org/10.1038/ng715			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528397				2022-12-25	WOS:000170781300022
J	Grohmann, K; Schuelke, M; Diers, A; Hoffmann, K; Lucke, B; Adams, C; Bertini, E; Leonhardt-Horti, H; Muntoni, F; Ouvrier, R; Pfeufer, A; Rossi, R; Van Maldergem, L; Wilmshurst, JM; Wienker, TR; Sendtner, M; Rudnik-Schoneborn, S; Zerres, K; Hubner, C				Grohmann, K; Schuelke, M; Diers, A; Hoffmann, K; Lucke, B; Adams, C; Bertini, E; Leonhardt-Horti, H; Muntoni, F; Ouvrier, R; Pfeufer, A; Rossi, R; Van Maldergem, L; Wilmshurst, JM; Wienker, TR; Sendtner, M; Rudnik-Schoneborn, S; Zerres, K; Hubner, C			Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1	NATURE GENETICS			English	Article							SURVIVAL MOTOR-NEURON; DEAD BOX PROTEIN; HUMAN S-MU-BP-2; SMN GENE; COMPLEX; IDENTIFICATION; TRANSCRIPTION; DEGENERATION; HELICASE; PROMOTER	Classic spinal muscular atrophy (SMA) is caused by mutations in the telomeric copy of SMN1. Its product is involved in various cellular processes, including cytoplasmic assembly of spliceosomal small nuclear ribonucleoproteins, pre-mRNA processing and activation of transcription(1-8). Spinal muscular atrophy with respiratory distress (SMARD) is clinically and genetically distinct from SMA(9-13). Here we demonstrate that SMARD type 1 (SMARD1) results from mutations in the gene encoding immunoglobulin mu -binding protein 2 (IGHMBP2; on chromosome 11q13.2-q13.4). In six SMARD1 families, we detected three recessive missense mutations (exons 5, 11 and 12), two nonsense mutations (exons 2 and 5), one frameshift deletion (exon 5) and one splice donor-site mutation (intron 13). Mutations in mouse Ighmbp2 (ref. 14) have been shown to be responsible for spinal muscular atrophy in the neuromuscular degeneration (nmd) mouse(15), whose phenotype resembles the SMARD1 phenotype. Like the SMN1 product, IGHMBP2 colocalizes with the RNA-processing machinery in both the cytoplasm and the nucleus(16-19). Our results show that IGHMBP2 is the second gene found to be defective in spinal muscular atrophy, and indicate that IGHMBP2 and SMN share common functions important for motor neuron maintenance and integrity in mammals.	Humboldt Univ, Charite, Dept Neuropediat, D-13353 Berlin, Germany; Max Delbrueck Ctr Mol Med, Gene Mapping Ctr, D-13092 Berlin, Germany; Univ Calgary, Alberta Childrens Hosp, Div Pediat Neurol, Calgary, AB T2T 5C7, Canada; Bambino Gesu Pediat Hosp, Dept Neurosci, I-00165 Rome, Italy; Bambino Gesu Pediat Hosp, Mol Med Unit, I-00165 Rome, Italy; Childrens Hosp, D-63069 Offenbach, Germany; Hammersmith Hosp, Dept Paediat, London W12 0HS, England; Childrens Hosp Westmead, Inst Neuromuscular Res, Parramatta, NSW 2124, Australia; GSF Res Inst, Inst Human Genet, D-85764 Neuherberg, Germany; Childrens Hosp Neukolln, D-12051 Berlin, Germany; Inst Pathol & Genet, Ctr Genet Humaine, B-6280 Loveral, Belgium; Univ Bonn, Inst Med Biometry, D-53105 Bonn, Germany; Univ Wurzburg, Inst Clin Neurobiol, D-97080 Wurzburg, Germany; Rhein Westfal TH Aachen, Dept Human Genet, D-52074 Aachen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Alberta Childrens Hospital; University of Calgary; IRCCS Bambino Gesu; IRCCS Bambino Gesu; Imperial College London; University of Sydney; University of Bonn; University of Wurzburg; RWTH Aachen University	Hubner, C (corresponding author), Humboldt Univ, Charite, Dept Neuropediat, Campus Virchow Klinikum, D-13353 Berlin, Germany.		Pfeufer, Arne/B-6634-2013; Bertini, Enrico/ABG-1278-2020; Bertini, Enrico/A-2284-2014; Van Maldergem, Lionel/O-3242-2019; Van Maldergem, Lionel/G-9849-2017; Sendtner, Michael/J-1542-2012; Rudnik-Schöneborn, Sabine/F-8473-2015; Sendtner, Michael/M-8137-2014	Bertini, Enrico/0000-0001-9276-4590; Van Maldergem, Lionel/0000-0001-8880-5214; Van Maldergem, Lionel/0000-0001-8880-5214; Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Wilmshurst, Jo/0000-0001-7328-1796; Schuelke, Markus/0000-0003-2824-3891				BERTINI E, 1989, AM J MED GENET, V33, P328, DOI 10.1002/ajmg.1320330309; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Chen NN, 1997, GENE, V185, P55, DOI 10.1016/S0378-1119(96)00630-0; COOK SA, 1995, MAMM GENOME, V6, P187, DOI 10.1007/BF00293010; Cox GA, 1998, NEURON, V21, P1327, DOI 10.1016/S0896-6273(00)80652-2; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FUKITA Y, 1993, J BIOL CHEM, V268, P17463; Grishin NV, 1998, TRENDS BIOCHEM SCI, V23, P329, DOI 10.1016/S0968-0004(98)01258-4; Grohmann K, 1999, AM J HUM GENET, V65, P1459, DOI 10.1086/302636; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; Jablonka S, 2001, HUM MOL GENET, V10, P497, DOI 10.1093/hmg/10.5.497; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; McEntagart M, 2001, AM J HUM GENET, V68, P1270, DOI 10.1086/320122; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; MELLINS RB, 1974, PEDIATRICS, V53, P33; Miao M, 2000, EUR J BIOCHEM, V267, P7237, DOI 10.1046/j.1432-1327.2000.01836.x; MIZUTA TR, 1993, NUCLEIC ACIDS RES, V21, P1761, DOI 10.1093/nar/21.8.1761; Mohan WS, 1998, J LIPID RES, V39, P255; Molnar GM, 1997, P NATL ACAD SCI USA, V94, P7831, DOI 10.1073/pnas.94.15.7831; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; RudnikSchoneborn S, 1996, NEUROPEDIATRICS, V27, P8, DOI 10.1055/s-2007-973741; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Wilmshurst JM, 2001, MUSCLE NERVE, V24, P760, DOI 10.1002/mus.1067; Zerres K, 1999, Neuromuscul Disord, V9, P272, DOI 10.1016/S0960-8966(99)00016-4; Zhang Q, 1999, VIROLOGY, V255, P160, DOI 10.1006/viro.1998.9588	27	249	255	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					75	77		10.1038/ng703	http://dx.doi.org/10.1038/ng703			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528396				2022-12-25	WOS:000170781300021
J	Vorechovsky, I; Kralovicova, J; Tchilian, E; Masterman, T; Zhang, ZP; Ferry, B; Misbah, S; Chapel, H; Webster, D; Hellgren, D; Anvret, M; Hillert, J; Hammarstrom, L; Beverley, PC				Vorechovsky, I; Kralovicova, J; Tchilian, E; Masterman, T; Zhang, ZP; Ferry, B; Misbah, S; Chapel, H; Webster, D; Hellgren, D; Anvret, M; Hillert, J; Hammarstrom, L; Beverley, PC			Does 77C -> G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?	NATURE GENETICS			English	Article							POINT MUTATION; MULTIPLE-SCLEROSIS; CELL MATURATION; EXON-A; CD45; ANTIGEN; IMMUNODEFICIENCY; ABNORMALITIES; EXPRESSION; SELECTION	A 77G allele of the gene encoding CD45, also known as the protein tyrosine phosphatase receptor-type C gene (PTPRC), has been associated with multiple sclerosis (MS). Here we determine allele frequencies in large numbers of MS patients, primary immunodeficiencies linked to the major histocompatability complex (MHC) locus and over 1,000 controls to assess whether aberrant splicing of PTPRC caused by the 77C-->G polymorphism results in increased susceptibility to these diseases. Our results show no difference in the frequency of the 77G allele in patients and controls and thus do not support a causative role for the polymorphism in the development of disorders with a strong autoimmune component in etiology.	UCL, London, England; NOVUM, Karolinska Inst, Dept Biosci, Stockholm, Sweden; Edward Jenner Inst Vaccine Res, Compton, Berks, England; Huddinge Univ Hosp, Karolinska Inst, Div Neurol, Stockholm, Sweden; Sodertalje, AstraZeneca, Dept Mol Sci, Stockholm, Sweden; John Radcliffe Hosp, Dept Immunol, Oxford OX3 9DU, England	University of London; University College London; Karolinska Institutet; Karolinska Institutet; AstraZeneca; University of Oxford	Vorechovsky, I (corresponding author), UCL, Royal Free Campus, London, England.	igvo@cbt.ki.se	Tchilian, Elma Z/Q-5976-2017; Kralovicova, Jana/AAA-1693-2022	Tchilian, Elma Z/0000-0002-4869-5118; Vorechovsky, Igor/0000-0002-6740-6502; Beverley, Peter/0000-0003-0481-2180				Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Cale CM, 1997, ARCH DIS CHILD, V76, P163, DOI 10.1136/adc.76.2.163; Czyzyk J, 2000, MOL CELL BIOL, V20, P8740, DOI 10.1128/MCB.20.23.8740-8747.2000; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LEBRANCHU Y, 1991, CLIN IMMUNOL IMMUNOP, V61, P83, DOI 10.1016/S0090-1229(06)80009-7; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Tchilian EZ, 2001, J IMMUNOL, V166, P6144, DOI 10.4049/jimmunol.166.10.6144; THUDE H, 1995, EUR J IMMUNOL, V25, P2101, DOI 10.1002/eji.1830250745; Trop S, 2000, J IMMUNOL, V165, P3073, DOI 10.4049/jimmunol.165.6.3073; Vorechovsky I, 1999, AM J HUM GENET, V64, P1096, DOI 10.1086/302326; Zilch CF, 1998, EUR J IMMUNOL, V28, P22, DOI 10.1002/(SICI)1521-4141(199801)28:01<22::AID-IMMU22>3.0.CO;2-7	15	50	50	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2001	29	1					22	23		10.1038/ng723	http://dx.doi.org/10.1038/ng723			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11548742				2022-12-25	WOS:000170781300010
J	Dove, A				Dove, A			Making a living out of the art of dying	NATURE BIOTECHNOLOGY			English	Article							PROTEIN	Insights into the molecular regulators of controlled cell death-apoptosis-have provided researchers with new strategies for treating several common disorders.										Garber K, 2000, NAT BIOTECHNOL, V18, P917, DOI 10.1038/79371; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710	5	10	10	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					615	619		10.1038/90207	http://dx.doi.org/10.1038/90207			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433267				2022-12-25	WOS:000169677200012
J	Martignetti, JA; Al Aqeel, A; Al Sewairi, W; Boumah, CE; Kambouris, M; Al Mayouf, S; Sheth, KV; Al Eid, W; Dowling, O; Harris, J; Glucksman, MJ; Bahabri, S; Meyer, BF; Desnick, RJ				Martignetti, JA; Al Aqeel, A; Al Sewairi, W; Boumah, CE; Kambouris, M; Al Mayouf, S; Sheth, KV; Al Eid, W; Dowling, O; Harris, J; Glucksman, MJ; Bahabri, S; Meyer, BF; Desnick, RJ			Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome	NATURE GENETICS			English	Letter							GELATINASE-A; TISSUE INHIBITOR; IV COLLAGENASE; DOMAIN; ACTIVATION; BINDING; TIMP-2; METALLOPROTEINASE-2; DEGRADATION; MECHANISM	The inherited osteolyses or 'vanishing bone' syndromes are a group of rare disorders of unknown etiology characterized by destruction and resorption of affected bones. The multicentric osteolyses are notable for interphalangeal joint erosions that mimic severe juvenile rheumatoid arthritis (OMIMs 166300. 259600, 259610 and 277950). We recently described an autosomal recessive form of multicentric osteolysis with carpal and tarsal resorption. crippling arthritic changes, marked osteoporosis, palmar and plantar subcutaneous nodules and distinctive facies in a number of consanguineous Saudi Arabian families(1,2). We localized the disease gene to 16q12-21 by using members of these families for a genome-wide search for homozygous-by-descent microsatellite markers. Haplotype analysis narrowed the critical region to a 1.2-cM region that spans the gene encoding MMP-2 (gelatinase A, collagenase type IV; (ref. 3). We detected no MMP2 enzymatic activity in the serum or fibroblasts of affected family members. We identified two family-specific homoallelic MMP2 mutations: R101H and Y244X. The nonsense mutation effects a deletion of the substrate-binding and catalytic sites and the fibronectin type II-like and hemopexin/TIMP2 binding domains. Based on molecular modeling. the missense mutation disrupts hydrogen bond formation within the highly conserved prodomain adjacent to the catalytic zinc ion.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurobiol, Struct Neurobiol & Proteom Lab, New York, NY 10029 USA; Riyadh Armed Forces Hosp, Dept Pediat, Riyadh, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Yale Univ, Sch Med, New Haven, CT USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Prince Sultan Military Medical City; King Faisal Specialist Hospital & Research Center; Yale University	Martignetti, JA (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave & 100th St, New York, NY 10029 USA.	john.martignetti@mssm.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026824, R37DK034045] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00071] Funding Source: Medline; NICHD NIH HHS [5 P30 HD 28822] Funding Source: Medline; NIDDK NIH HHS [5 R01 DK26824, 5 R37 DK34045] Funding Source: Medline; NINDS NIH HHS [R01 NS39893] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al Aqeel A, 2000, AM J MED GENET, V93, P11, DOI 10.1002/1096-8628(20000703)93:1<11::AID-AJMG3>3.0.CO;2-3; Al-Mayouf SM, 2000, AM J MED GENET, V93, P5, DOI 10.1002/1096-8628(20000703)93:1<5::AID-AJMG2>3.0.CO;2-Y; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Butler S, 1998, OBJECT ORIENTED SYST, V5, P1; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; Creemers LB, 1998, MATRIX BIOL, V17, P35, DOI 10.1016/S0945-053X(98)90072-5; Everts V, 2000, J BONE MINER RES, V15, pS349; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kanwar YS, 1999, AM J PHYSIOL-RENAL, V277, pF934, DOI 10.1152/ajprenal.1999.277.6.F934; Karelina TV, 2000, J INVEST DERMATOL, V114, P371, DOI 10.1046/j.1523-1747.2000.00886.x; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; Rutter JL, 1998, CANCER RES, V58, P5321; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5; Yu AE, 1998, BIOL EXTRAC, P85; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	30	213	223	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					261	265		10.1038/90100	http://dx.doi.org/10.1038/90100			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431697				2022-12-25	WOS:000169656400019
J	Grant, B; Zhang, YH; Paupard, MC; Lin, SX; Hall, D; Hirsh, D				Grant, B; Zhang, YH; Paupard, MC; Lin, SX; Hall, D; Hirsh, D			Evidence that RME-1, a conserved C-elegans EH-domain protein, functions in endocytic recycling	NATURE CELL BIOLOGY			English	Article							CANINE KIDNEY-CELLS; DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; EXPRESSION; MEMBRANE	In genetic screens for new endocytosis genes in Caenorhabditis elegans we identified RME-1, a member of a conserved class of Epsl5-homology (EH)-domain proteins. Here we show that RME-1 is associated with the periphery of endocytic organelles, which is consistent with a direct role in endocytic transport. Endocytic defects in rme-l mutants indicate that the protein is likely to have a function in endocytic recycling. Evidence from studies of mammalian RME-1 also points to a function for RME-1 in recycling, specifically in the exit of membrane proteins from recycling endosomes. These studies show a conserved function in endocytic recycling for the RME-1 family of EH proteins.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Ctr C Elegans Anat, Bronx, NY 10461 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Columbia University; Yeshiva University; Albert Einstein College of Medicine; Cornell University	Grant, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, 630 W 168th St, New York, NY 10032 USA.			Grant, Barth/0000-0002-5943-8336; Zhang, Yinhua/0000-0003-0592-9153	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR012596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019167] Funding Source: NIH RePORTER; NCRR NIH HHS [R24 RR012596] Funding Source: Medline; NIGMS NIH HHS [F32 GM019167, F32 GM019167-02, F32 GM019167-01] Funding Source: Medline; NIH HHS [R24 OD010943] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		APODACA G, 1994, J BIOL CHEM, V269, P19005; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; Bettinger JC, 1996, DEVELOPMENT, V122, P2517; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BRENNER S, 1974, GENETICS, V77, P71; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; CLOKEY GV, 1986, MECH AGEING DEV, V35, P79, DOI 10.1016/0047-6374(86)90068-0; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Grant B, 1997, DEVELOPMENT, V124, P637; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GU J, 1994, BIOTECHNIQUES, V17, P257; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Haider NB, 1999, GENE, V240, P227, DOI 10.1016/S0378-1119(99)00395-9; Hall DH, 1999, DEV BIOL, V212, P101, DOI 10.1006/dbio.1999.9356; Kostich M, 2000, J CELL SCI, V113, P2595; LIN SX, 2001, NATURE CELL BIOL, V3, pR20; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; ROSENBLUTH RE, 1985, GENETICS, V109, P493; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; van Weert AWM, 2000, EUR J CELL BIOL, V79, P394, DOI 10.1078/0171-9335-00062; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Williams BD, 1995, METHOD CELL BIOL, V48, P81	33	205	208	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					573	579		10.1038/35078549	http://dx.doi.org/10.1038/35078549			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389442				2022-12-25	WOS:000169194400013
J	Laitinen, T; Daly, MJ; Rioux, JD; Kauppi, P; Laprise, C; Petays, T; Green, T; Cargill, M; Haahtela, T; Lander, ES; Laitinen, LA; Hudson, TJ; Kere, J				Laitinen, T; Daly, MJ; Rioux, JD; Kauppi, P; Laprise, C; Petays, T; Green, T; Cargill, M; Haahtela, T; Lander, ES; Laitinen, LA; Hudson, TJ; Kere, J			A susceptibility locus for asthma-related traits on chromosome 7 revealed by genome-wide scan in a founder population	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; DISEASE GENE; SERUM IGE; EXAMPLE; SEARCH	The genetics of asthma and atopy have been difficult to determine because these diseases are genetically heterogeneous and modified by environment. The pedigrees in our study (n=86) originate in eastern central Finland (Kainuu province). According to census records, this region had only 200 households (2,000 inhabitants) in the mid sixteenth to mid seventeenth centuries. The current population of 100.000 represents the expansion of these founders within the past 400 years. Because this population is relatively homogeneous(1,2), we hypothesized that the molecular genetic mechanisms underlying asthma might also have reduced heterogeneity and therefore be easier to dissect than in mixed populations. A recent twin family study supported a strong genetic component for asthma in Finland(3). We carried out a genome-wide scan for susceptibility loci in asthma in the Kainuu subpopulation. We identified two regions of suggestive linkage and studied them further with higher-density mapping. We obtained evidence for linkage in a 20-cM region of chromosome 7p14-p15 for three phenotypes: asthma, a high level of immunoglobulin E (IgE; atopy) and the combination of the phenotypes. The strongest linkage was seen for high serum IgE(non-parametric linkage (NPL) score 3.9, P=0.0001), exceeding the threshold for genome-wide significance based on simulations. We also observed linkage between this locus and asthma or atopy in two independent data sets.	Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Helsinki, Cent Hosp, Dept Pulm Med, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Allergol Dis, Helsinki, Finland; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; Chicoutimi Hosp, Chicoutimi, PQ, Canada; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Helsinki, Finland; MIT, Dept Biol, Cambridge, MA USA; Univ Helsinki, Finnish Genome Ctr, Helsinki, Finland	University of Helsinki; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; McGill University; Finland National Institute for Health & Welfare; Massachusetts Institute of Technology (MIT); University of Helsinki	Laitinen, T (corresponding author), Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland.	tarja.laitinen@helsinki.fi; juha.kere@helsinki.fi	Daly, Mark J/B-2453-2017; Rioux, John D/A-9599-2015; Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008	Daly, Mark J/0000-0002-0949-8752; Rioux, John D/0000-0001-7560-8326; Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Hudson, Thomas/0000-0002-1376-4849; Laprise, Catherine/0000-0001-5526-9945				Austerlitz F, 1999, GENET EPIDEMIOL, V16, P2, DOI 10.1002/(SICI)1098-2272(1999)16:1<2::AID-GEPI2>3.0.CO;2-9; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DANTZKER DR, 1987, AM REV RESPIR DIS, V136, P225; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; DEBRAEKELEER M, 1995, ANN HUM BIOL, V22, P111, DOI 10.1080/03014469500003772; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; GUGLIELMINO CR, 1990, AM J PHYS ANTHROPOL, V83, P57, DOI 10.1002/ajpa.1330830107; Juniper EF, 1991, HISTAMINE METHACHOLI; Kauppi P, 1998, RESP MED, V92, P1281, DOI 10.1016/S0954-6111(98)90229-3; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1998, AM J HUM GENET, V62, P994, DOI 10.1086/301792; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Mak TW, 1998, NAT MED, V4, P764, DOI 10.1038/nm0798-764; Marsh DG, 1997, NAT GENET, V15, P389; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; SAJANTILA A, 1995, GENOME RES, V5, P42, DOI 10.1101/gr.5.1.42; Vuorio AF, 1997, ARTERIOSCL THROM VAS, V17, P3127, DOI 10.1161/01.ATV.17.11.3127; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	25	152	160	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					87	91		10.1038/ng0501-87	http://dx.doi.org/10.1038/ng0501-87			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326283				2022-12-25	WOS:000168413300023
J	Narula, J; Acio, ER; Narula, N; Samuels, LE; Fyfe, B; Wood, D; Fitzpatrick, JM; Raghunath, PN; Tomaszewski, JE; Kelly, C; Steinmetz, N; Green, A; Tait, JF; Leppo, J; Blankenberg, FG; Jain, D; Strauss, HW				Narula, J; Acio, ER; Narula, N; Samuels, LE; Fyfe, B; Wood, D; Fitzpatrick, JM; Raghunath, PN; Tomaszewski, JE; Kelly, C; Steinmetz, N; Green, A; Tait, JF; Leppo, J; Blankenberg, FG; Jain, D; Strauss, HW			Annexin-V imaging for noninvasive detection of cardiac allograft rejection	NATURE MEDICINE			English	Article							MEMBRANE PHOSPHOLIPID ASYMMETRY; CELL-DEATH; IN-SITU; PHOSPHATIDYLSERINE EXPRESSION; APOPTOSIS; IDENTIFICATION; MYOCYTES; INJURY; HEARTS; VIVO	Heart transplant rejection is characterized pathologically by myocyte necrosis and apoptosis associated with interstitial! mononuclear cell infiltration. Any one of these components: can be targeted for noninvasive detection of transplant rejection. During apoptotic cell death, phosphatidylserine, a phospholipid that is normally confined to the inner leaflet of cell membrane bilayer, gets exteriorized. Technetium-99m-labeled annexin-V, an endogenous protein that has high affinity for binding to phosphatidylserine, has been administered intravenously for noninvasive identification of apoptotic cell death. In the present study of 18 cardiac allograft recipients, 13 patients had negative and five had positive myocardial uptake of annexin. These latter five demonstrated at least moderate transplant rejection and caspase-3 staining, suggesting apoptosis in their biopsy specimens. This study reveals the clinical feasibility and safety of annexin-V imaging for noninvasive detection of transplant rejection by targeting cell membrane phospholipid alterations that are commonly associated with the process of apoptosis.	Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19102 USA; Hosp Univ Penn, Philadelphia, PA 19104 USA; Thesius Imaging Corp, Cambridge, MA USA; Univ Washington, Seattle, WA 98195 USA; Univ Massachusetts, Worcester, MA 01605 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle; University of Massachusetts System; University of Massachusetts Worcester; Stanford University	Narula, J (corresponding author), Med Coll Penn & Hahnemann Univ, Philadelphia, PA 19102 USA.	jagat.narula@drexel.edu						Billingham M E, 1990, J Heart Transplant, V9, P587; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HAMMOND EH, 1989, J HEART TRANSPLANT, V8, P430; Hofstra L, 2000, LANCET, V356, P209, DOI 10.1016/S0140-6736(00)02482-X; Johnson LL, 2000, CIRCULATION, V102, P404; Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757; KASINA S, 1991, J NUCL MED, V32, P1445; Laguens RP, 1996, J HEART LUNG TRANSPL, V15, P911; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; NARULA N, 2000, MODERN PATHOL, V13, pA52; Ohno M, 1998, CIRCULATION, V98, P1422, DOI 10.1161/01.CIR.98.14.1422; Petrov A, 2000, CIRCULATION, V102, P544; Puig M, 2000, J NUCL CARDIOL, V7, P132, DOI 10.1016/S1071-3581(00)90033-3; Strauss HW, 2000, LANCET, V356, P180, DOI 10.1016/S0140-6736(00)02474-0; Szabolcs MJ, 1998, TRANSPLANTATION, V65, P804, DOI 10.1097/00007890-199803270-00007; TAIT JF, 1994, J LAB CLIN MED, V123, P741; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	22	271	282	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1347	1352		10.1038/nm1201-1347	http://dx.doi.org/10.1038/nm1201-1347			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726976				2022-12-25	WOS:000172610300041
J	Pailhoux, E; Vigier, B; Chaffaux, S; Servel, N; Taourit, S; Furet, JP; Fellous, M; Grosclaude, F; Cribiu, EP; Cotinot, C; Vaiman, D				Pailhoux, E; Vigier, B; Chaffaux, S; Servel, N; Taourit, S; Furet, JP; Fellous, M; Grosclaude, F; Cribiu, EP; Cotinot, C; Vaiman, D			A 11.7-kb deletion triggers intersexuality and polledness in goats	NATURE GENETICS			English	Article							MAMMALIAN SEX DETERMINATION; SRY; BLEPHAROPHIMOSIS; PTOSIS; REGION; MAP; IDENTIFICATION; TRANSLOCATION; DEFINITION; REVERSAL	Mammalian sex determination is governed by the presence of the sex determining region Y gene (SRY) on the Y chromosome(1). Familial cases of SRY-negative XX sex reversal are rare in humans, often hampering the discovery of new sex-determining genes(2,3). The mouse model is also insufficient to correctly apprehend the sex-determination cascade, as the human pathway is much more sensitive to gene dosage(4-6). Other species might therefore be considered in this respect(7). In goats, the polled intersex syndrome (PIS) mutation associates polledness and intersexuality(8,9). The sex reversal affects exclusively the XX individuals in a recessive manner, whereas the absence of horns is dominant in both sexes. The syndrome is caused by an autosomal gene located at chromosome band 1q43 (ref. 9), shown to be homologous to human chromosome band 3q23 (ref. 10). Through a positional cloning approach, we demonstrate that the mutation underlying PIS is the deletion of a critical 11.7-kb DNA element containing mainly repetitive sequences. This deletion affects the transcription of at least two genes: PISRT1, encoding a 1.5-kb mRNA devoid of open reading frame (ORF), and FOXL2, recently shown to be responsible for blepharophimosis ptosis epicanthus inversus syndrome (BPES) in humans(11). These two genes are located 20 and 200 kb telomeric from the deletion, respectively.	INRA, Ctr Rech, Lab Genet Biochim & Cytogenet, Dept Genet Anim, F-78352 Jouy En Josas, France; INRA, Ctr Rech, Dept Anim Physiol, Lab Biol Dev & Biotechnol, F-78352 Jouy En Josas, France; Inst Pasteur, Human Immunogenet Lab, F-75015 Paris, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Vaiman, D (corresponding author), INRA, Ctr Rech, Lab Genet Biochim & Cytogenet, Dept Genet Anim, F-78352 Jouy En Josas, France.		Vaiman, Daniel/O-6030-2015	Vaiman, Daniel/0000-0002-1915-0717; Servel, Nathalie/0000-0001-6925-6256				AASEN E, 1990, BIO-TECHNOL, V8, P1279, DOI 10.1038/nbt1290-1279; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Asdell S. A., 1944, SCIENCE, V99, P124, DOI 10.1126/science.99.2563.124; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; De Baere E, 2000, GENOMICS, V68, P296, DOI 10.1006/geno.2000.6304; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KROB G, 1994, EUR J PEDIATR, V153, P2, DOI 10.1007/s004310050077; LAWSON CT, 1995, HUM MOL GENET, V4, P963, DOI 10.1093/hmg/4.5.963; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; Praphanphoj V, 2000, GENOMICS, V65, P67, DOI 10.1006/geno.2000.6157; Schibler L, 2000, GENOME RES, V10, P311, DOI 10.1101/gr.10.3.311; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Vaiman D, 2000, TRENDS GENET, V16, P488, DOI 10.1016/S0168-9525(00)02126-0; Vaiman D, 1996, MAMM GENOME, V7, P133, DOI 10.1007/s003359900033; Vaiman D, 1996, GENETICS, V144, P279; Vaiman D, 1999, GENOMICS, V56, P31, DOI 10.1006/geno.1998.5691	22	260	270	1	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					453	458		10.1038/ng769	http://dx.doi.org/10.1038/ng769			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726932				2022-12-25	WOS:000172507500022
J	DeGiorgio, LA; Konstantinov, KN; Lee, SC; Hardin, JA; Volpe, BT; Diamond, B				DeGiorgio, LA; Konstantinov, KN; Lee, SC; Hardin, JA; Volpe, BT; Diamond, B			A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus	NATURE MEDICINE			English	Article							SUBUNIT MESSENGER-RNAS; CEREBROSPINAL-FLUID; DISEASE-ACTIVITY; GENE-EXPRESSION; NIGRAL NEURONS; HUMAN BRAIN; BINDING; AUTOANTIBODIES; PHENCYCLIDINE; DEGENERATION	In systemic lupus erythematosus, antibodies against double-stranded DNA are a major contributor to renal disease. We have previously demonstrated that the pentapeptide Asp/Glu-TrpAsp/Glu-Tyr-Ser/Gly is a molecular mimic of double-stranded DNA. This sequence is also present in the extracellular domain of murine and human NMDA (N-methyl-D-aspartate) receptor subunits NR2a and NR2b. Here we show that the NR2 receptor is recognized by both murine and human anti-DNA antibodies. Moreover, anti-DNA antibodies with this cross-reactivity mediate apoptotic death of neurons in vivo and in vitro. Finally, we show that the cerebrospinal fluid of a patient with systemic lupus erythematosus contains these antibodies and also mediates neuronal death via an apoptotic pathway. These observations indicate that lupus antibodies cross-react with DNA and NMDA receptors, gain access to cerebrospinal fluid and may mediate non-thrombotic and non-vasculitic abnormalities of the central nervous system.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University	Diamond, B (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA.	diamond@aecom.yu.edu	volpe, b/U-8409-2019	Volpe, Bruce/0000-0002-1098-1848	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049126] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049126] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akbarian S, 1996, J NEUROSCI, V16, P19; BELL CL, 1991, ARTHRITIS RHEUM, V34, P432, DOI 10.1002/art.1780340408; BLUESTEIN HG, 1983, HUM PATHOL, V14, P424, DOI 10.1016/S0046-8177(83)80287-1; Budhai L, 1996, J CLIN INVEST, V98, P1585, DOI 10.1172/JCI118952; CARR RI, 1975, J RHEUMATOL, V2, P184; Cavalheiro EA, 2001, P NATL ACAD SCI USA, V98, P5947, DOI 10.1073/pnas.121179198; CHAN TM, 1995, CLIN EXP IMMUNOL, V100, P506; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DeGiorgio LA, 1999, NEUROSCIENCE, V90, P79, DOI 10.1016/S0306-4522(98)00428-X; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Gahring LC, 2001, J IMMUNOL, V166, P1433, DOI 10.4049/jimmunol.166.3.1433; Gaynor B, 1997, P NATL ACAD SCI USA, V94, P1955, DOI 10.1073/pnas.94.5.1955; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GOLOMBEK SJ, 1986, ARTHRITIS RHEUM, V29, P1090, DOI 10.1002/art.1780290906; GonzalezCrespo MR, 1995, BRIT J RHEUMATOL, V34, P1055; Hansen C, 1996, CLIN EXP RHEUMATOL, V14, pS59; HANSON VG, 1992, J EXP MED, V176, P565, DOI 10.1084/jem.176.2.565; HE XP, 2000, NEURON, V20, P7307; JACOB L, 1987, P NATL ACAD SCI USA, V84, P2956, DOI 10.1073/pnas.84.9.2956; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jentsch JD, 1999, NEUROPSYCHOPHARMACOL, V20, P201, DOI 10.1016/S0893-133X(98)00060-8; KATZ JB, 1994, J EXP MED, V180, P925, DOI 10.1084/jem.180.3.925; Kosinski CM, 1998, J COMP NEUROL, V390, P63; Kowal C, 1999, EUR J IMMUNOL, V29, P1901, DOI 10.1002/(SICI)1521-4141(199906)29:06<1901::AID-IMMU1901>3.0.CO;2-L; Kozora E, 1996, ARTHRITIS RHEUM, V39, P2035, DOI 10.1002/art.1780391213; Kuppenbender KD, 2000, J COMP NEUROL, V419, P407, DOI 10.1002/(SICI)1096-9861(20000417)419:4<407::AID-CNE1>3.0.CO;2-I; Lefkowith JB, 1996, J CLIN INVEST, V98, P1373, DOI 10.1172/JCI118924; LIMPANASITHIKUL W, 1995, J IMMUNOL, V155, P967; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Monaghan DT, 1997, J PHARMACOL EXP THER, V280, P614; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Scherzer CR, 1998, J COMP NEUROL, V390, P75, DOI 10.1002/(SICI)1096-9861(19980105)390:1<75::AID-CNE7>3.0.CO;2-N; Sharma TA, 1999, J PHARMACOL EXP THER, V289, P1041; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Spatz L, 1997, METHODS, V11, P70, DOI 10.1006/meth.1996.0389; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VIARD JP, 1992, AUTOIMMUNITY, V12, P61, DOI 10.3109/08916939209146131; Volpe BT, 1998, NEUROSCIENCE, V83, P741, DOI 10.1016/S0306-4522(97)00424-7; Volpe BT, 1997, ANN NY ACAD SCI, V823, P185, DOI 10.1111/j.1749-6632.1997.tb48390.x; Whitney KD, 1999, ANNU REV NEUROSCI, V22, P175, DOI 10.1146/annurev.neuro.22.1.175; Whitney KD, 2000, J NEUROSCI, V20, P7307; Williamson RA, 2001, P NATL ACAD SCI USA, V98, P1793, DOI 10.1073/pnas.031567598; Yang YYL, 1998, P NATL ACAD SCI USA, V95, P13254, DOI 10.1073/pnas.95.22.13254	49	552	575	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1189	1193		10.1038/nm1101-1189	http://dx.doi.org/10.1038/nm1101-1189			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689882				2022-12-25	WOS:000172054100025
J	Cai, WW; Chow, CW; Damani, S; Gregory, SG; Marra, M; Bradley, A				Cai, WW; Chow, CW; Damani, S; Gregory, SG; Marra, M; Bradley, A			An SSLP marker-anchored BAC framework map of the mouse genome	NATURE GENETICS			English	Article							HYBRIDIZATION	We have constructed a BAC framework map of the mouse genome consisting of 2,808 PCR-confirmed BAC clusters, using a previously described method(1). Fingerprints of BACs from selected clusters confirm the accuracy of the map. Combined with BAC fingerprint data, the framework map covers 37% of the mouse genome.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Sanger Ctr, Cambridge, England; British Columbia Canc Agcy, Genome Sequence Ctr, Vancouver, BC V5Z 4E6, Canada	Baylor College of Medicine; Wellcome Trust Sanger Institute; British Columbia Cancer Agency	Bradley, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		Marra, Marco A/B-5987-2008	Marra, Marco A/0000-0001-7146-7175; Bradley, Allan/0000-0002-2349-8839; Gregory, Simon/0000-0002-7805-1743				Cai WW, 1998, GENOMICS, V54, P387, DOI 10.1006/geno.1998.5620; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; Osoegawa K, 2000, GENOME RES, V10, P116; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218	7	9	9	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					133	134		10.1038/ng1001-133	http://dx.doi.org/10.1038/ng1001-133			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586294				2022-12-25	WOS:000171374100014
J	Conlon, IJ; Dunn, GA; Mudge, AW; Raff, MC				Conlon, IJ; Dunn, GA; Mudge, AW; Raff, MC			Extracellular control of cell size	NATURE CELL BIOLOGY			English	Article							GROWTH; DIVISION; PROLIFERATION; COORDINATION; NEUREGULINS; YEAST; TIME	Both cell growth (cell mass increase) and progression through the cell division cycle are required for sustained cell proliferation(1). Proliferating cells in culture tend to double in mass before each division(2), but it is not known how growth and division rates are co-ordinated to ensure that cell size is maintained(1,3-5). The prevailing view is that coordination is achieved because cell growth is rate-limiting for cell-cycle progression(6-10). Here, we challenge this view. We have investigated the relationship between cell growth and cell-cycle progression in purified rat Schwann cells, using two extracellular signal proteins that are known to influence these cells(11-13). We find that glial growth factor (GGF) can stimulate cell-cycle progression without promoting cell growth. We have used this restricted action of GGF to show that, for cultured Schwann cells, cell growth rate alone does not determine the rate of cell-cycle progression and that cell size at division is variable and depends on the concentrations of extracellular signal proteins that stimulate cell-cycle progression, cell growth, or both.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England; MRC, Muscle & Cell Motil Unit, Randall Ctr, London SE1 1UL, England	University of London; University College London; University of London; University College London; University of London; King's College London	Conlon, IJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Torrington Pl, London WC1E 6BT, England.	i.conlon@ucl.ac.uk						Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CHENG L, 1995, J CELL BIOL, V129, P789, DOI 10.1083/jcb.129.3.789; Cheng LL, 1998, MOL CELL NEUROSCI, V12, P141, DOI 10.1006/mcne.1998.0706; Coelho CM, 2000, J CELL SCI, V113, P2927; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; DUNN GA, 1993, SYM SOC EXP BIOL, V47, P91; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; FANTES PA, 1977, J CELL SCI, V24, P51; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; MITCHISON JM, 1971, BIOL CELL CYCLE; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NURSE P, 1991, PHILOS T R SOC B, V332, P271, DOI 10.1098/rstb.1991.0055; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; PRESCOTT DM, 1956, EXP CELL RES, V11, P86, DOI 10.1016/0014-4827(56)90192-6; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Stewart HJS, 1996, EUR J NEUROSCI, V8, P553, DOI 10.1111/j.1460-9568.1996.tb01240.x; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3	22	106	109	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					918	921		10.1038/ncb1001-918	http://dx.doi.org/10.1038/ncb1001-918			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584274				2022-12-25	WOS:000171396400017
J	Nuyens, D; Stengl, M; Dugarmaa, S; Rossenbacker, T; Compernolle, V; Rudy, Y; Smits, JF; Flameng, W; Clancy, CE; Moons, L; Vos, MA; Dewerchin, M; Benndorf, K; Collen, D; Carmeliet, E; Carmeliet, P				Nuyens, D; Stengl, M; Dugarmaa, S; Rossenbacker, T; Compernolle, V; Rudy, Y; Smits, JF; Flameng, W; Clancy, CE; Moons, L; Vos, MA; Dewerchin, M; Benndorf, K; Collen, D; Carmeliet, E; Carmeliet, P			Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome	NATURE MEDICINE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; BETA-ADRENERGIC AGONISTS; INFANT-DEATH-SYNDROME; NA+ CHANNEL BLOCKADE; TORSADE-DE-POINTES; QT SYNDROME; HEART-RATE; EARLY AFTERDEPOLARIZATIONS; TRANSMURAL DISPERSION; MOLECULAR MECHANISM	Deletion of amino-acid residues 1505-1507 (KPQ) in the cardiac SCN5A Na+ channel causes autosomal dominant prolongation of the electrocardiographic QT interval (long-QT syndrome type 3 or LQT3). Excessive prolongation of the action potential at low heart rates predisposes individuals with LQT3 to fatal arrhythmias, typically at rest or during sleep. Here we report that mice heterozygous for a knock-in KPQ-deletion (SCN5A(Delta/+)) show the essential LQT3 features and spontaneously develop life-threatening polymorphous ventricular arrhythmias. Unexpectedly, sudden accelerations in heart rate or premature beats caused lengthening of the action potential with early afterdepolarization and triggered arrhythmias in Scn5a(Delta/+) mice. Adrenergic agonists normalized the response to rate acceleration in vitro and suppressed arrhythmias upon premature stimulation in vivo. These results show the possible risk of sudden heart-rate accelerations. The Scn5a(Delta/+) mouse with its predisposition for pacing-induced arrhythmia might be useful for the development of new treatments for the LQT3 syndrome.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Maastricht, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands; Klinikum Friederich Schiller Univ Jena, Inst Physiol, Jena, Germany; Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH USA; Katholieke Univ Leuven, Lab Expt Cardiac Surg, Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Maastricht University; Friedrich Schiller University of Jena; Case Western Reserve University; KU Leuven	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Stengl, Milan/CAA-2936-2022; Carmeliet, Peter/AAQ-5140-2020; Stengl, Milan/J-5918-2017; Clancy, Colleen/B-2528-2010; Stengl, Milan/AAH-1429-2022	Stengl, Milan/0000-0002-1135-0159; Carmeliet, Peter/0000-0001-7961-1821; Stengl, Milan/0000-0002-1135-0159; Stengl, Milan/0000-0002-1135-0159; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Benndorf, Klaus/0000-0002-0707-4083; Nuyens, Dieter/0000-0001-9390-3273				An RH, 1996, CIRC RES, V79, P103, DOI 10.1161/01.RES.79.1.103; Antzelevitch C, 1999, J ELECTROCARDIOL, V32, P158, DOI 10.1016/S0022-0736(99)90074-2; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Bezzina CR, 2001, CARDIOVASC RES, V49, P257, DOI 10.1016/S0008-6363(00)00272-8; BOYETT MR, 1980, PROG BIOPHYS MOL BIO, V36, P1; Burashnikov A, 1998, J CARDIOVASC ELECTR, V9, P934, DOI 10.1111/j.1540-8167.1998.tb00134.x; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Casimiro MC, 2001, P NATL ACAD SCI USA, V98, P2526, DOI 10.1073/pnas.041398998; Chandra R, 1998, AM J PHYSIOL-HEART C, V274, pH1643, DOI 10.1152/ajpheart.1998.274.5.H1643; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Clancy CE, 1999, NATURE, V400, P566, DOI 10.1038/23034; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Drici MD, 1998, CIRC RES, V83, P95, DOI 10.1161/01.RES.83.1.95; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; Nagatomo T, 1998, AM J PHYSIOL-HEART C, V275, pH2016, DOI 10.1152/ajpheart.1998.275.6.H2016; Napolitano C, 2000, J CARDIOVASC ELECTR, V11, P691, DOI 10.1111/j.1540-8167.2000.tb00033.x; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Priori SG, 1996, CIRC RES, V78, P1009, DOI 10.1161/01.RES.78.6.1009; SAGIE A, 1992, AM J CARDIOL, V70, P797, DOI 10.1016/0002-9149(92)90562-D; Schwartz PJ, 2000, NEW ENGL J MED, V343, P262, DOI 10.1056/NEJM200007273430405; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; Schwartz PJ, 2001, CIRCULATION, V103, P89; Schwartz PJ, 1998, NEW ENGL J MED, V338, P1709, DOI 10.1056/NEJM199806113382401; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Shimizu W, 2000, J AM COLL CARDIOL, V35, P778, DOI 10.1016/S0735-1097(99)00582-3; Shimizu W, 1998, CIRCULATION, V98, P2314, DOI 10.1161/01.CIR.98.21.2314; Shimizu W, 1999, CIRCULATION, V99, P1499, DOI 10.1161/01.CIR.99.11.1499; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8; Viskin S, 2000, J CARDIOVASC ELECTR, V11, P593, DOI 10.1111/j.1540-8167.2000.tb00015.x; Viswanathan PC, 1999, CARDIOVASC RES, V42, P530, DOI 10.1016/S0008-6363(99)00035-8; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; Zhou J, 1998, CIRC RES, V83, P806, DOI 10.1161/01.RES.83.8.806	40	201	206	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1021	1027		10.1038/nm0901-1021	http://dx.doi.org/10.1038/nm0901-1021			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533705				2022-12-25	WOS:000170853300027
J	Reynolds, PN; Nicklin, SA; Kaliberova, L; Boatman, BG; Grizzle, WE; Balyasnikova, IV; Baker, AH; Danilov, SM; Curiel, DT				Reynolds, PN; Nicklin, SA; Kaliberova, L; Boatman, BG; Grizzle, WE; Balyasnikova, IV; Baker, AH; Danilov, SM; Curiel, DT			Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo	NATURE BIOTECHNOLOGY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; PRIMARY PULMONARY-HYPERTENSION; ENDOTHELIAL GROWTH-FACTOR; GENE DELIVERY; IN-VIVO; ADENOVIRAL VECTORS; RECEPTOR; PROMOTER; ANTIBODY; THERAPY	The promise of gene therapy for health care will not be realized until gene delivery systems are capable of achieving efficient, cell-specific gene delivery in vivo. Here we describe an adenoviral system for achieving cell-specific transgene expression in pulmonary endothelium. The combination of transductional targeting to a pulmonary endothelial marker (angiotensin-converting enzyme, ACE) and an endothelial-specific promoter (for vascular endothelial growth factor receptor type 1, fit-1) resulted in a synergistic, 300,000-fold improvement in the selectivity of transgene expression for lung versus the usual site of vector sequestration, the liver. This combined approach should be useful for the design of other gene delivery systems.	Univ Alabama, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Gene Therapy Ctr, Birmingham, AL 35294 USA; Univ Glasgow, Dept Med & Therapeut, Glasgow, Lanark, Scotland; Univ Alabama, Div Cardiol, Birmingham, AL 35294 USA; Univ Illinois, Dept Anesthesiol, Chicago, IL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Glasgow; University of Alabama System; University of Alabama Birmingham; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Reynolds, PN (corresponding author), Univ Alabama, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA.		Baker, Andy/AAO-5250-2021	Baker, Andy/0000-0003-1441-5576; Nicklin, Stuart/0000-0002-9691-6210	NATIONAL CANCER INSTITUTE [R01CA074242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054781] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74242] Funding Source: Medline; NIDDK NIH HHS [P30 DK54781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi Y, 2000, CANCER RES, V60, P4305; ALEMANY R, 2001, IN PRESS GENE THER; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bristol JA, 2000, MOL THER, V2, P223, DOI 10.1006/mthe.2000.0120; CONRY RM, 1994, CANCER RES, V54, P1164; DANILOV S, 1994, INT IMMUNOL, V6, P1153, DOI 10.1093/intimm/6.8.1153; Danilov SM, 2001, AM J PHYSIOL-LUNG C, V280, pL1335, DOI 10.1152/ajplung.2001.280.6.L1335; DANILOV SM, 1991, LAB INVEST, V64, P118; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Franke FE., 1997, LEUCOCYTE TYPING, P749; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Harari OA, 1999, GENE THER, V6, P801, DOI 10.1038/sj.gt.3300898; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirose S, 2000, PATHOL INT, V50, P472, DOI 10.1046/j.1440-1827.2000.01068.x; HUARD J, 1995, GENE THER, V2, P107; Koeneman KS, 2000, WORLD J UROL, V18, P102, DOI 10.1007/s003450050181; Krasnykh VN, 2000, MOL THER, V1, P391, DOI 10.1006/mthe.2000.0062; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Leissner P, 2001, GENE THER, V8, P49, DOI 10.1038/sj.gt.3301343; Moraes D, 1997, CLIN CARDIOL, V20, P676, DOI 10.1002/clc.4960200804; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Nicklin SA, 2001, HYPERTENSION, V38, P65, DOI 10.1161/01.HYP.38.1.65; Nicklin SA, 2000, CIRCULATION, V102, P231, DOI 10.1161/01.CIR.102.2.231; Orte C, 2000, J PATHOL, V192, P379, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q; Raben D, 1996, GENE THER, V3, P567; Reynolds PN, 2000, MOL THER, V2, P562, DOI 10.1006/mthe.2000.0205; REYNOLDS PN, 1998, TUMOR TARGET, V3, P156; Ring CJA, 1996, GENE THER, V3, P1094; Rodman DM, 1997, AM J RESP CELL MOL, V16, P640, DOI 10.1165/ajrcmb.16.6.9191465; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Schuster DP, 1996, AM J RESP CRIT CARE, V154, P1087, DOI 10.1164/ajrccm.154.4.8887612; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wickham TJ, 2000, GENE THER, V7, P110, DOI 10.1038/sj.gt.3301115; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Yamamoto M, 2001, MOL THER, V3, P385, DOI 10.1006/mthe.2001.0275; Yee D, 1996, HUM GENE THER, V7, P1251, DOI 10.1089/hum.1996.7.10-1251	40	170	177	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					838	842		10.1038/nbt0901-838	http://dx.doi.org/10.1038/nbt0901-838			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533642				2022-12-25	WOS:000170774000022
J	Ruf, S; Hermann, M; Berger, IJ; Carrer, H; Bock, R				Ruf, S; Hermann, M; Berger, IJ; Carrer, H; Bock, R			Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit	NATURE BIOTECHNOLOGY			English	Article							CHLOROPLAST GENOME; TOBACCO CHLOROPLASTS; COMPLETE SEQUENCE; HIGHER-PLANTS; RESISTANCE; DNA; MARKER	Transgenic chloroplasts offer unique advantages in plant biotechnology, including high-level foreign protein expression, absence of epigenetic effects, and gene containment due to the lack of transgene transmission through pollen. However, broad application of plastid genome engineering in biotechnology has been largely hampered by both the lack of chloroplast transformation systems for major crop plants and the usually low plastid gene expression levels in nongreen tissues such as fruits, tubers, and other storage organs. Here we describe the development of a plastid transformation system for tomato, Lycopersicon esculentum. This is the first report on the generation of fertile transplastomic plants in a food crop with an edible fruit. We show that chromoplasts in the tomato fruit express the transgene to similar to 50% of the expression levels in leaf chloroplasts. Given the generally very high foreign protein accumulation rates that can be achieved in transgenic chloroplasts (>40% of the total soluble protein), this system paves the way to efficient production of edible vaccines, pharmaceuticals, and antibodies in tomato.	Univ Munster, Inst Biochem & Biotechnol Pflanzen, D-48143 Munster, Germany; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany; Univ Sao Paulo, ESALQ, Ctr Biotecnol Agr, BR-13418900 Piracicaba, SP, Brazil	University of Munster; University of Freiburg; Universidade de Sao Paulo	Bock, R (corresponding author), Univ Munster, Inst Biochem & Biotechnol Pflanzen, Hindenburgpl 55, D-48143 Munster, Germany.		Bock, Ralph/B-4352-2009; Carrer, Helaine/C-3159-2012; Ruf, Stephanie/AAW-8311-2020	Bock, Ralph/0000-0001-7502-6940; Carrer, Helaine/0000-0002-9329-1841; Ruf, Stephanie/0000-0002-9469-5944				BATHGATE B, 1985, PLANTA, V165, P197, DOI 10.1007/BF00395042; BENDICH AJ, 1987, BIOESSAYS, V6, P279, DOI 10.1002/bies.950060608; Bock R, 1996, EMBO J, V15, P5052, DOI 10.1002/j.1460-2075.1996.tb00885.x; BOCK R, 1995, MOL GEN GENET, V247, P439, DOI 10.1007/BF00293145; Bogorad L, 2000, TRENDS BIOTECHNOL, V18, P257, DOI 10.1016/S0167-7799(00)01444-X; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; CARRER H, 1993, MOL GEN GENET, V241, P49, DOI 10.1007/BF00280200; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Daniell H, 2001, TRENDS PLANT SCI, V6, P219, DOI 10.1016/S1360-1385(01)01922-7; Daniell H, 1999, TRENDS PLANT SCI, V4, P467, DOI 10.1016/S1360-1385(99)01503-4; De Cosa B, 2001, NAT BIOTECHNOL, V19, P71, DOI 10.1038/83559; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Hager M, 2000, APPL MICROBIOL BIOT, V54, P302, DOI 10.1007/s002530000397; Heifetz PB, 2000, BIOCHIMIE, V82, P655, DOI 10.1016/S0300-9084(00)00608-8; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; Hirose T, 1999, MOL GEN GENET, V262, P462, DOI 10.1007/s004380051106; KANEVSKI I, 1994, P NATL ACAD SCI USA, V91, P1969, DOI 10.1073/pnas.91.5.1969; Khan MS, 1999, NAT BIOTECHNOL, V17, P910, DOI 10.1038/12907; Kuroda H, 2001, PLANT PHYSIOL, V125, P430, DOI 10.1104/pp.125.1.430; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; MCBRIDE KE, 1995, BIO-TECHNOL, V13, P362, DOI 10.1038/nbt0495-362; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P493, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; PIECHULLA B, 1985, PLANT MOL BIOL, V5, P373, DOI 10.1007/BF00037558; Ruf S, 2000, J CELL BIOL, V149, P369, DOI 10.1083/jcb.149.2.369; Sidorov VA, 1999, PLANT J, V19, P209, DOI 10.1046/j.1365-313X.1999.00508.x; Sikdar SR, 1998, PLANT CELL REP, V18, P20, DOI 10.1007/s002990050525; STAUB JM, 1992, PLANT CELL, V4, P39, DOI 10.1105/tpc.4.1.39; STAUB JM, 1995, PLANT J, V7, P845, DOI 10.1046/j.1365-313X.1995.07050845.x; Staub JM, 2000, NAT BIOTECHNOL, V18, P333, DOI 10.1038/73796; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; SVAB Z, 1991, MOL GEN GENET, V228, P316, DOI 10.1007/BF00282483; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; Wakasugi T, 1998, PLANT MOL BIOL REP, V16, P231, DOI 10.1023/A:1007564209282; Ye GN, 2001, PLANT J, V25, P261, DOI 10.1046/j.1365-313x.2001.00958.x	36	323	420	2	76	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					870	875		10.1038/nbt0901-870	http://dx.doi.org/10.1038/nbt0901-870			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533648				2022-12-25	WOS:000170774000028
J	Takebayashi, Y; Pourquier, P; Zimonjic, DB; Nakayama, K; Emmert, S; Ueda, T; Urasaki, Y; Kanzaki, A; Akiyama, S; Popescu, N; Kraemer, KH; Pommier, Y				Takebayashi, Y; Pourquier, P; Zimonjic, DB; Nakayama, K; Emmert, S; Ueda, T; Urasaki, Y; Kanzaki, A; Akiyama, S; Popescu, N; Kraemer, KH; Pommier, Y			Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair	NATURE MEDICINE			English	Article							DNA TOPOISOMERASE-I; MINOR-GROOVE; CARIBBEAN TUNICATE; MECHANISM; ACTIVATION; DAMAGE; CANCER; DRUG	While investigating the novel anticancer drug ecteinascidin 743 (Et743), a natural marine product isolated from the Caribbean sea squirt, we discovered a new cell-killing mechanism mediated by DNA nucleotide excision repair (NER). A cancer cell line selected for resistance to Et743 had chromosome alterations in a region that included the gene implicated in the hereditary disease xeroderma pigmentosum (XPG, also known as Ercc5). Complementation with wild-type XPG restored the drug sensitivity. Xeroderma pigmentosum cells deficient in the NER genes XPG, XPA, XPD or XPF were resistant to Et743, and sensitivity was restored by complementation with wildtype genes. Moreover, studies of cells deficient in XPC or in the genes implicated in Cockayne syndrome (CSA and CSS) indicated that the drug sensitivity is specifically dependent on the transcription-coupled pathway of NER. We found that Et743 interacts with the transcription-coupled NER machinery to induce lethal DNA strand breaks.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Sendai, Miyagi 980, Japan; Kagoshima Univ, Fac Med, Canc Res Inst, Dept Canc Chemotherapy, Kagoshima 890, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tohoku University; Kagoshima University	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	pommier@nih.gov	Zimonjic, Drazen/AAX-7513-2020; Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005; Kraemer, Kenneth/0000-0002-2689-3316	Intramural NIH HHS [Z01 BC004517-31] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC004517] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Bergmann E, 2001, TRENDS GENET, V17, P279, DOI 10.1016/S0168-9525(01)02280-6; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; Damia G, 2001, INT J CANCER, V92, P583, DOI 10.1002/ijc.1221; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Delaloge S, 2001, J CLIN ONCOL, V19, P1248, DOI 10.1200/JCO.2001.19.5.1248; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Hoeijmakers JHJ, 2001, MUTAT RES-DNA REPAIR, V485, P43, DOI 10.1016/S0921-8777(00)00079-3; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Khan SG, 1999, J INVEST DERMATOL, V112, P402; Kohn KW, 1996, BIOESSAYS, V18, P505, DOI 10.1002/bies.950180613; LAMBERT B, 1988, NUCLEIC ACIDS RES, V16, P1063, DOI 10.1093/nar/16.3.1063; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; Rinehart KL, 2000, MED RES REV, V20, P1; RINEHART KL, 1990, J NAT PROD, V53, P771, DOI 10.1021/np50070a001; Ryan DP, 2001, CLIN CANCER RES, V7, P231; SAKAI R, 1992, P NATL ACAD SCI USA, V89, P11456, DOI 10.1073/pnas.89.23.11456; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Seaman FC, 1998, J AM CHEM SOC, V120, P13028, DOI 10.1021/ja983091x; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Taamma A, 2001, J CLIN ONCOL, V19, P1256, DOI 10.1200/JCO.2001.19.5.1256; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takebayashi Y, 2001, CLIN CANCER RES, V7, P185; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	36	289	304	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					961	966		10.1038/91008	http://dx.doi.org/10.1038/91008			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479630				2022-12-25	WOS:000171740400035
J	Yamauchi, T; Kamon, J; Waki, H; Terauchi, Y; Kubota, N; Hara, K; Mori, Y; Ide, T; Murakami, K; Tsuboyama-Kasaoka, N; Ezaki, O; Akanuma, Y; Gavrilova, O; Vinson, C; Reitman, ML; Kagechika, H; Shudo, K; Yoda, M; Nakano, Y; Tobe, K; Nagai, R; Kimura, S; Tomita, M; Froguel, P; Kadowaki, T				Yamauchi, T; Kamon, J; Waki, H; Terauchi, Y; Kubota, N; Hara, K; Mori, Y; Ide, T; Murakami, K; Tsuboyama-Kasaoka, N; Ezaki, O; Akanuma, Y; Gavrilova, O; Vinson, C; Reitman, ML; Kagechika, H; Shudo, K; Yoda, M; Nakano, Y; Tobe, K; Nagai, R; Kimura, S; Tomita, M; Froguel, P; Kadowaki, T			The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity	NATURE MEDICINE			English	Article							ACTIVATED RECEPTOR-ALPHA; PPAR-GAMMA; DIABETES-MELLITUS; ADIPOSE-TISSUE; PROTEIN; MICE; EXPRESSION; GENE; SENSITIVITY; METABOLISM	Adiponectin is an adipocyte-derived hormone. Recent genome-wide scans have mapped a susceptibility locus for type 2 diabetes and metabolic syndrome to chromosome 3q27, where the gene encoding adiponectin is located. Here we show that decreased expression of adiponectin correlates with insulin resistance in mouse models of altered insulin sensitivity. Adiponectin decreases insulin resistance by decreasing triglyceride content in muscle and liver in obese mice. This effect results from increased expression of molecules involved in both fatty-acid combustion and energy dissipation in muscle. Moreover, insulin resistance in lipoatrophic mice was completely reversed by the combination of physiological doses of adiponectin and leptin, but only partially by either adiponectin or leptin alone. We conclude that decreased adiponectin is implicated in the development of insulin resistance in mouse models of both obesity and lipoatrophy. These data also indicate that the replenishment of adiponectin might provide a novel treatment modality for insulin resistance and type 2 diabetes.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan; Pasteur Inst Lille, CNRS, Inst Biol, Lille, France; Natl Inst Hlth & Nutr, Div Clin Nutr, Tokyo 162, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo, Japan; NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo, Japan	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; National Institute of Health & Nutrition - Japan; Asahi Life Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Terauchi, Yasuo/AAO-4347-2020; sheng, jian/E-9474-2012; Kubota, Naoto/N-7892-2015; Waki, Hironori/AAE-3942-2020; Reitman, Marc/B-4448-2013; FROGUEL, Philippe/O-6799-2017	Waki, Hironori/0000-0002-5302-9793; Reitman, Marc/0000-0002-0426-9475; FROGUEL, Philippe/0000-0003-2972-0784; Kagechika, Hiroyuki/0000-0002-6747-1013	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK047031] Funding Source: NIH RePORTER; Medical Research Council [G0000477] Funding Source: Medline; MRC [G0000477] Funding Source: UKRI	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Ebisawa M, 1999, CHEM PHARM BULL, V47, P1778; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kahn CR, 1996, ANNU REV MED, V47, P509; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Masuzaki H, 1999, DIABETES, V48, P1615, DOI 10.2337/diabetes.48.8.1615; Matsuzawa Y, 1999, ANN NY ACAD SCI, V892, P146, DOI 10.1111/j.1749-6632.1999.tb07793.x; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; MONDON CE, 1981, AM J PHYSIOL, V240, pE482, DOI 10.1152/ajpendo.1981.240.5.E482; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	37	3752	4056	6	444	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2001	7	8					941	946		10.1038/90984	http://dx.doi.org/10.1038/90984			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479627				2022-12-25	WOS:000171740400032
J	Yasutomo, K; Horiuchi, T; Kagami, S; Tsukamoto, H; Hashimura, C; Urushihara, M; Kuroda, Y				Yasutomo, K; Horiuchi, T; Kagami, S; Tsukamoto, H; Hashimura, C; Urushihara, M; Kuroda, Y			Mutation of DNASE1 in people with systemic lupus erythematosus	NATURE GENETICS			English	Article								Systemic lupus erythematosus (SLE) is a highly prevalent human autoimmune diseases that causes progressive glomerulonephritis, arthritis and an erythematoid rash(1,2). Mice deficient in deoxyribonuclease I (Dnase1) develop an SLE-like syndrome(3). Here we describe two patients with a heterozygous nonsense mutation in exon 2 of DNASE1, decreased DNASE1 activity and an extremely high immunoglobulin G titer against nucleosomal antigens. These data are consistent with the hypothesis that a direct connection exists between low activity of DNASE1 and progression of human SLE.	Univ Tokushima, Sch Med, Dept Pediat, Tokushima 7708503, Japan; Kyushu Univ, Fac Med, Dept Internal Med 1, Fukuoka 8128582, Japan	Tokushima University; Kyushu University	Kuroda, Y (corresponding author), Univ Tokushima, Sch Med, Dept Pediat, Tokushima 7708503, Japan.			Yasutomo, Koji/0000-0003-0411-2037				Amoura Z, 1997, ARTHRITIS RHEUM, V40, P2217, DOI 10.1002/art.1780401217; Arnett F C, 2000, Int Rev Immunol, V19, P297, DOI 10.3109/08830180009055501; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Eilat D, 1999, IMMUNOL TODAY, V20, P339, DOI 10.1016/S0167-5699(99)01457-7; Herrmann M, 2000, IMMUNOL TODAY, V21, P424, DOI 10.1016/S0167-5699(00)01675-3; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Tsao B P, 2000, Int Rev Immunol, V19, P319, DOI 10.3109/08830180009055502; Vyse TJ, 1998, ANNU REV IMMUNOL, V16, P261, DOI 10.1146/annurev.immunol.16.1.261; Wagrowska-Danilewicz M, 1998, J NEPHROL, V11, P44; Wu JM, 1999, ARTHRITIS RHEUM, V42, P2601, DOI 10.1002/1529-0131(199912)42:12<2601::AID-ANR13>3.0.CO;2-4	10	419	440	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					313	314		10.1038/91070	http://dx.doi.org/10.1038/91070			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479590				2022-12-25	WOS:000170174800009
J	Zhou, B; Westaway, SK; Levinson, B; Johnson, MA; Gitschier, J; Hayflick, SJ				Zhou, B; Westaway, SK; Levinson, B; Johnson, MA; Gitschier, J; Hayflick, SJ			A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome	NATURE GENETICS			English	Article							REGIONAL DISTRIBUTION; ALZHEIMERS-DISEASE; ESCHERICHIA-COLI; COENZYME-A; IRON; BRAIN; CYSTEINE; PATHOGENESIS; PEROXIDATION; PARKINSONS	Hallervorden-Spatz syndrome (HSS) is an autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain. Clinical features include extrapyramidal dysfunction, onset in childhood, and a relentlessly progressive course(1). Histologic study reveals iron deposits in the basal ganglia(2). In this respect, HSS may serve as a model for complex neurodegenerative diseases, such as Parkinson disease(3), Alzheimer disease(4), Huntington diseases and human immunodeficiency virus (HIV) encephalopathy(6), in which pathologic accumulation of iron in the brain is also observed. Thus, understanding the biochemical defect in HSS may provide key insights into the regulation of iron metabolism and its perturbation in this and other neurodegenerative diseases. Here we show that HSS is caused by a defect in a novel pantothenate kinase gene and propose a mechanism for oxidative stress in the pathophysiology of the disease.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hayflick, SJ (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	hayflick@ohsu.edu						ABIKO Y, 1967, J BIOCHEM, V61, P290, DOI 10.1093/oxfordjournals.jbchem.a128547; Afshar K, 2001, GENETICS, V157, P1267; ANGELINI L, 1992, J NEUROL, V239, P417, DOI 10.1007/BF00856805; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; COPPETO JR, 1990, NEUROLOGY, V40, P1359, DOI 10.1212/WNL.40.9.1359; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P70, DOI 10.1001/archneur.1974.00490310072012; GRAVEL RA, 1994, AM J HUM GENET, V55, P51; HEAFIELD MT, 1990, NEUROSCI LETT, V110, P216, DOI 10.1016/0304-3940(90)90814-P; HILL JM, 1984, NEUROSCIENCE, V11, P595, DOI 10.1016/0306-4522(84)90046-0; Karim MA, 2000, AM J HUM GENET, V67, P185; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Miszkziel KA, 1997, MAGN RESON IMAGING, V15, P1113, DOI 10.1016/S0730-725X(97)00089-1; PARK BE, 1975, NEUROLOGY, V25, P1172, DOI 10.1212/WNL.25.12.1172; PERRY TL, 1985, ANN NEUROL, V18, P482, DOI 10.1002/ana.410180411; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SEARLE AJF, 1983, BIOCHEM J, V212, P549, DOI 10.1042/bj2120549; SHEVELL M, 1992, NEUROLOGY, V42, P2214, DOI 10.1212/WNL.42.11.2214; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; SWAIMAN KF, 1991, ARCH NEUROL-CHICAGO, V48, P1285, DOI 10.1001/archneur.1991.00530240091029; Taylor TD, 1996, NAT GENET, V14, P479, DOI 10.1038/ng1296-479; TRIPATHI RC, 1992, ACTA NEUROPATHOL, V83, P113, DOI 10.1007/BF00308470; VALLARI DS, 1987, J BACTERIOL, V169, P5795, DOI 10.1128/jb.169.12.5795-5800.1987; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang EY, 2000, REDOX REP, V5, P371, DOI 10.1179/135100000101535942; Yoon SJ, 2000, MUTAT RES-FUND MOL M, V448, P97, DOI 10.1016/S0027-5107(00)00005-1; Yun M, 2000, J BIOL CHEM, V275, P28093	30	526	562	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					345	349		10.1038/ng572	http://dx.doi.org/10.1038/ng572			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479594				2022-12-25	WOS:000170174800014
J	Bressler, J; Tsai, TF; Wu, MY; Tsai, SF; Ramirez, MA; Armstrong, D; Beaudet, AL				Bressler, J; Tsai, TF; Wu, MY; Tsai, SF; Ramirez, MA; Armstrong, D; Beaudet, AL			The SNRPN promoter is not required for genomic imprinting of the PraderWilli/Angelman domain in mice	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; EMBRYONIC STEM-CELLS; MOUSE NECDIN GENE; ANGELMAN-SYNDROME; DNA METHYLATION; REGION; EXPRESSION; LETHALITY; MUTATIONS; DELETION	In mice and humans, the locus encoding the gene for small nuclear ribonucleoprotein N (SNRPN/Snrpn), as well as other loci in the region are subject to genomic imprinting. The SNRPN promoter is embedded in a maternally methylated CpG island, is expressed only from the paternal chromosome and lies within an imprinting center that is required for switching to and/or maintenance of the paternal epigenotype. We show here that a 0.9-kb deletion of exon 1 of mouse Snrpn did not disrupt imprinting or elicit any obvious phenotype. although it did allow the detection of previously unknown upstream exons. In contrast, a larger, overlapping 4.8-kb deletion caused a partial or mosaic imprinting defect and perinatal lethality when paternally inherited.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan	Baylor College of Medicine; Baylor College of Medicine; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Beaudet, AL (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Tsai, Shih-Feng/E-3997-2010		NICHD NIH HHS [HD-37283] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037283] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abuin A, 1996, MOL CELL BIOL, V16, P1851; Bielinska B, 2000, NAT GENET, V25, P74, DOI 10.1038/75629; Blaydes SM, 1999, MAMM GENOME, V10, P549, DOI 10.1007/s003359901042; Brannan CI, 1999, CURR OPIN GENET DEV, V9, P164, DOI 10.1016/S0959-437X(99)80025-2; Buiting K, 1998, AM J HUM GENET, V63, P170, DOI 10.1086/301935; Buiting K, 1999, HUM GENET, V105, P665, DOI 10.1007/s004390051160; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; Conroy JM, 1997, AM J HUM GENET, V61, P388, DOI 10.1086/514852; DELOS ST, 2000, AM J HUM GENET, V67, P1067; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Farber C, 1999, HUM MOL GENET, V8, P337, DOI 10.1093/hmg/8.2.337; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FergusonSmith AC, 1996, NAT GENET, V14, P119, DOI 10.1038/ng1096-119; Gabriel JM, 1998, MAMM GENOME, V9, P788, DOI 10.1007/s003359900868; Gabriel JM, 1999, P NATL ACAD SCI USA, V96, P9258, DOI 10.1073/pnas.96.16.9258; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Gillessen-Kaesbach G, 1999, EUR J HUM GENET, V7, P638, DOI 10.1038/sj.ejhg.5200362; Glenn CC, 1996, AM J HUM GENET, V58, P335; Gray TA, 1999, P NATL ACAD SCI USA, V96, P5616, DOI 10.1073/pnas.96.10.5616; Huq AHMM, 1997, GENOME RES, V7, P642, DOI 10.1101/gr.7.6.642; Jiang YH, 1998, CURR OPIN GENET DEV, V8, P334, DOI 10.1016/S0959-437X(98)80091-9; Kuslich CD, 1999, AM J HUM GENET, V64, P70, DOI 10.1086/302177; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Mann MRW, 1999, HUM MOL GENET, V8, P1867, DOI 10.1093/hmg/8.10.1867; Muscatelli F, 2000, HUM MOL GENET, V9, P3101, DOI 10.1093/hmg/9.20.3101; MUTIRANGURA A, 1993, GENOMICS, V18, P546, DOI 10.1016/S0888-7543(11)80011-X; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; REIS A, 1994, AM J HUM GENET, V54, P741; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; Sambrook J., 2002, MOL CLONING LAB MANU; Schulze A, 1996, NAT GENET, V12, P452, DOI 10.1038/ng0496-452; Shemer R, 2000, NAT GENET, V26, P440, DOI 10.1038/82571; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sun YM, 1996, HUM MOL GENET, V5, P517, DOI 10.1093/hmg/5.4.517; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; Tilghman SM, 1998, NAT GENET, V18, P206, DOI 10.1038/ng0398-206; Tsai TF, 1999, NAT GENET, V22, P15, DOI 10.1038/8722; Tsai TF, 1999, HUM MOL GENET, V8, P1357, DOI 10.1093/hmg/8.8.1357; Watrin F, 1997, EUR J HUM GENET, V5, P324, DOI 10.1159/000484784; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25	49	85	87	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					232	240		10.1038/90067	http://dx.doi.org/10.1038/90067			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431693				2022-12-25	WOS:000169656400015
J	Han, MY; Gao, XH; Su, JZ; Nie, S				Han, MY; Gao, XH; Su, JZ; Nie, S			Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules	NATURE BIOTECHNOLOGY			English	Article							SEMICONDUCTOR NANOCRYSTALS; CHEMICAL-ANALYSIS; GENE-EXPRESSION; ARRAYS; MICROARRAY; DENSITY; SYSTEM; NUMBER; ASSAY; ACID	Multicolor optical coding for biological assays has been achieved by embedding different-sized quantum dots (zinc sulfide-capped cadmium selenide nanocrystals) into polymeric microbeads at precisely controlled ratios. Their novel optical properties (e.g., size-tunable emission and simultaneous excitation) render these highly luminescent quantum dots (QDs) ideal fluorophores for wavelength-and-intensity multiplexing. The use of 10 intensity levels and 6 colors could theoretically code one million nucleic acid or protein sequences. Imaging and spectroscopic measurements indicate that the QD-tagged beads are highly uniform and reproducible, yielding bead identification accuracies as high as 99.99% under favorable conditions. DNA hybridization studies demonstrate that the coding and target signals can be simultaneously read at the single-bead level. This spectral coding technology is expected to open new opportunities in gene expression studies, high-throughput screening, and medical diagnostics.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Nie, S (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.		Nie, Shuming/E-4843-2011; Gao, Xiaohu/C-8869-2009; Han, Ming-Yong/ABC-6398-2021; Han, Ming-Yong/Z-5506-2019	Han, Ming-Yong/0000-0002-7519-6779; 				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Chen JW, 2000, GENOME RES, V10, P549, DOI 10.1101/gr.10.4.549; Clark HA, 1999, ANAL CHEM, V71, P4831, DOI 10.1021/ac990629o; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Dickinson TA, 1999, ANAL CHEM, V71, P2192, DOI 10.1021/ac981457i; DORSEY JG, 1994, ANAL CHEM, V66, P857; Ferguson JA, 2000, ANAL CHEM, V72, P5618, DOI 10.1021/ac0008284; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Fu AY, 1999, NAT BIOTECHNOL, V17, P1109, DOI 10.1038/15095; Fulton RJ, 1997, CLIN CHEM, V43, P1749; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; Hermkens PHH, 1996, TETRAHEDRON, V52, P4527, DOI 10.1016/0040-4020(96)00216-5; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; Kagan CR, 1996, PHYS REV LETT, V76, P1517, DOI 10.1103/PhysRevLett.76.1517; Mandecki W, 2000, ABSTR PAP AM CHEM S, V219, pU755; Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y; Micic OI, 1998, J PHYS CHEM B, V102, P9791, DOI 10.1021/jp981703u; Miraglia S, 1999, J BIOMOL SCREEN, V4, P193, DOI 10.1177/108705719900400407; Mitchell GP, 1999, J AM CHEM SOC, V121, P8122, DOI 10.1021/ja991662v; MORAN EJ, 1995, J AM CHEM SOC, V117, P10787, DOI 10.1021/ja00148a039; Nirmal M, 1999, ACCOUNTS CHEM RES, V32, P407, DOI 10.1021/ar9700320; Pathak S, 2001, J AM CHEM SOC, V123, P4103, DOI 10.1021/ja0058334; Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m; Prummer M, 2000, ANAL CHEM, V72, P443, DOI 10.1021/ac991116k; RAMSEY JM, 1995, NAT MED, V1, P1093, DOI 10.1038/nm1095-1093; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Steemers FJ, 2000, NAT BIOTECHNOL, V18, P91, DOI 10.1038/72006; WOOLLEY AT, 1994, P NATL ACAD SCI USA, V91, P11348, DOI 10.1073/pnas.91.24.11348; Yang BZ, 1997, POLYM J, V29, P737, DOI 10.1295/polymj.29.737; Zhang K, 1998, BRAIN RES, V786, P219, DOI 10.1016/S0006-8993(97)01449-2	34	2343	2688	31	898	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					631	635		10.1038/90228	http://dx.doi.org/10.1038/90228			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433273				2022-12-25	WOS:000169677200017
J	Isalan, M; Klug, A; Choo, Y				Isalan, M; Klug, A; Choo, Y			A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter	NATURE BIOTECHNOLOGY			English	Article							DNA RECOGNITION; TRANSCRIPTION FACTORS; PROTEINS; SELECTION; DOMAINS; PHAGE; SEQUENCES; COMPLEX; DESIGN; CODE	DNA-binding domains with predetermined sequence specificity are engineered by selection of zinc finger modules using phage display, allowing the construction of customized transcription factors. Despite remarkable progress in this field. the available protein-engineering methods are deficient in many respects, thus hampering the applicability of the technique. Here we present a rapid and convenient method that can be used to design zinc finger proteins against a variety of DNA-binding sites. This is based on a pair of pre-made zinc finger phage-display libraries, which are used in parallel to select two DNA-binding domains each of which recognizes given 5 base pair sequences, and whose products are recombined to produce a single protein that recognizes a composite (9 base pair) site of predefined sequence. Engineering using this system can be completed in less than two weeks and yields proteins that bind sequence-specifically to DNA with K-d values in the nanomolar range. To illustrate the technique, we have selected seven different proteins to bind various regions of the human immunodeficiency virus 1 (HIV-1) promoter.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Choo, Y (corresponding author), Gendaq Ltd, 1-3 Burtonhole Lane, London NW7 1AD, England.			Choo, Yen/0000-0002-3348-9602; Isalan, Mark/0000-0002-4652-0365	Medical Research Council [U.1051.04.011(78830), MC_U105184324] Funding Source: Medline; MRC [MC_U105184324] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Choo Y, 1998, NAT STRUCT BIOL, V5, P264, DOI 10.1038/nsb0498-264; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHOO Y, 1995, CURR OPIN BIOTECH, V6, P431, DOI 10.1016/0958-1669(95)80073-5; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Isalan M, 1998, BIOCHEMISTRY-US, V37, P12026, DOI 10.1021/bi981358z; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; Isalan M, 2000, J MOL BIOL, V295, P471, DOI 10.1006/jmbi.1999.3366; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kang JS, 2000, J BIOL CHEM, V275, P8742, DOI 10.1074/jbc.275.12.8742; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Moore M, 2001, P NATL ACAD SCI USA, V98, P1432, DOI 10.1073/pnas.98.4.1432; Moore M, 2001, P NATL ACAD SCI USA, V98, P1437, DOI 10.1073/pnas.98.4.1437; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Thiesen HJ, 1996, GENE EXPRESSION, V5, P229; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	31	145	311	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					656	660		10.1038/90264	http://dx.doi.org/10.1038/90264			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433278	Green Accepted			2022-12-25	WOS:000169677200022
J	Mathis, L; Kulesa, PM; Fraser, SE				Mathis, L; Kulesa, PM; Fraser, SE			FGF receptor signalling is required to maintain neural progenitors during Hensen's node progression	NATURE CELL BIOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; FIBROBLAST-GROWTH-FACTOR; CHICK-EMBRYO; FATE MAP; ANTEROPOSTERIOR AXIS; CELL REARRANGEMENT; XENOPUS EMBRYOS; MOUSE EMBRYO; STEM-CELLS; INDUCTION	Previous analyses of labelled clones of cells within the developing nervous system of the mouse have indicated that descendants are initially dispersed rostrocaudally followed by more local proliferation, which is consistent with the progressing node's contributing descendants from a resident population of progenitor cells as it advances caudally. Here we electroporated an expression vector encoding green fluorescent protein into the chicken embryo near Hensen's node to test and confirm the pattern inferred in the mouse. This provides a model in which a proliferative stem zone is maintained in the node by a localized signal; those cells that are displaced out of the stem zone go on to contribute to the growing axis. To test whether fibroblast growth factor (FGF) signalling could be involved in the maintenance of the stem zone, we co-electroporated a dominant-negative FGF receptor with a lineage marker, and found that it markedly alters the elongation of the spinal cord primordium. The results indicate that FGF receptor signalling promotes the continuous development of the posterior nervous system by maintaining presumptive neural progenitors in the region near Hensen's node. This offers a potential explanation for the mixed findings on FGF in the growth and patterning of the embryonic axis.	CALTECH, Biol Imaging Ctr, Beckman Inst 139 74, Pasadena, CA 91125 USA	California Institute of Technology	Fraser, SE (corresponding author), CALTECH, Biol Imaging Ctr, Beckman Inst 139 74, Pasadena, CA 91125 USA.	sefraser@caltech.edu	Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				ALVAREZ IS, 1991, DEV BIOL, V143, P78, DOI 10.1016/0012-1606(91)90056-9; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Bouwmeester T, 1997, BIOESSAYS, V19, P855, DOI 10.1002/bies.950191005; Brown JM, 2000, CURR BIOL, V10, P869, DOI 10.1016/S0960-9822(00)00601-1; Catala M, 1996, DEVELOPMENT, V122, P2599; Cox WG, 1995, DEVELOPMENT, V121, P4349; Darnell DK, 1999, DEVELOPMENT, V126, P2505; Davidson BP, 1999, DEV BIOL, V211, P11, DOI 10.1006/dbio.1999.9276; Doniach T, 1995, CELL, V83, P1067, DOI 10.1016/0092-8674(95)90133-7; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Godsave SF, 1997, INT J DEV BIOL, V41, P57; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATADA Y, 1994, DEVELOPMENT, V120, P2879; Henrique D, 1997, GENE DEV, V11, P603, DOI 10.1101/gad.11.5.603; Holowacz T, 1999, DEV BIOL, V205, P296, DOI 10.1006/dbio.1998.9108; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; KELLER R, 1992, DEV DYNAM, V193, P218, DOI 10.1002/aja.1001930303; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KELLER R, 1988, DEVELOPMENT, V103, P193; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; Koshida S, 1998, DEVELOPMENT, V125, P1957; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kulesa PM, 2000, DEVELOPMENT, V127, P1161; KULESA PM, 1998, DEB BIOL, V15, P327; LAMB TM, 1995, DEVELOPMENT, V121, P3627; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Mathis L, 1999, DEVELOPMENT, V126, P4095; Mathis L, 2000, DEVELOPMENT, V127, P1277; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nicolas JF, 1996, DEVELOPMENT, V122, P2933; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P83, DOI 10.1002/jez.1401200104; Okada A, 1999, EXP NEUROL, V156, P394, DOI 10.1006/exnr.1999.7033; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Psychoyos D, 1996, DEVELOPMENT, V122, P1523; Rowan AM, 1999, DEVELOPMENT, V126, P2921; SCHOENWOLF GC, 1979, AM J ANAT, V155, P445, DOI 10.1002/aja.1001550404; SCHOENWOLF GC, 1989, DEVELOPMENT, V106, P427; SELLECK MAJ, 1992, NATO ADV SCI I A-LIF, V231, P23; Slack JMW, 1996, BIOCHEM SOC SYMP, P1; Smith JL, 1998, CURR TOP DEV BIOL, V40, P79, DOI 10.1016/S0070-2153(08)60365-8; Storey KG, 1998, DEVELOPMENT, V125, P473; UENO H, 1992, J BIOL CHEM, V267, P1470; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WOO K, 1995, DEVELOPMENT, V121, P2595; Woo K, 1998, DEV BIOL, V197, P283, DOI 10.1006/dbio.1998.8870; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254; YAMADA T, 1994, DEVELOPMENT, V120, P3051; YAMAGUCHI TP, 1992, DEV BIOL, V152, P75, DOI 10.1016/0012-1606(92)90157-C; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	53	105	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					559	566		10.1038/35078535	http://dx.doi.org/10.1038/35078535			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389440				2022-12-25	WOS:000169194400011
J	Maier, S; Tertilt, C; Chambron, N; Gerauer, K; Huser, N; Heidecke, CD; Pfeffer, K				Maier, S; Tertilt, C; Chambron, N; Gerauer, K; Huser, N; Heidecke, CD; Pfeffer, K			Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28(-/-) mice	NATURE MEDICINE			English	Article							CLASS-I MOLECULES; CD8(+) T-CELLS; CD28-DEFICIENT MICE; GRAFT-REJECTION; BLOCKADE; EXPRESSION; ANTIGEN; CD28; TRANSPLANTATION; COSTIMULATION	Successful transplantation of allogeneic organs is an important objective in modern medicine. However, sophisticated immune defense mechanisms, primarily evolved to combat infections, often work against medical transplantation. To investigate the roles of natural and adaptive immune responses in transplant rejection, we functionally inactivated key effector systems of the innate (NK cells) and the adaptive immune system (CD28-mediated costimulation of T cells) in mice. Neither of these interventions alone led to acceptance of allogeneic vascularized cardiac grafts. In contrast, inhibition of NK-receptor-bearing cells combined with CD28-costimulation blockade established long-term graft acceptance. These results indicate a concerted interplay between innate and adaptive immune surveillance for graft rejection. Thus we suggest that inactivation of NK-receptor-bearing cells could be a new strategy for successful survival of solid-organ transplants.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; Tech Univ Munich, Dept Surg, D-8000 Munich, Germany	Technical University of Munich; Technical University of Munich	Pfeffer, K (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany.			Pfeffer, Klaus/0000-0002-5652-6330				Abbas AK, 2000, CELL, V100, P129, DOI 10.1016/S0092-8674(00)81689-X; BIRON CA, 1982, J IMMUNOL, V129, P2788; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; Colonna M, 1997, IMMUNOL REV, V155, P127, DOI 10.1111/j.1600-065X.1997.tb00945.x; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; DHAMIDHARKA VR, 2000, NAT MED, V6, P115; Endres R, 1997, IMMUNITY, V7, P419, DOI 10.1016/S1074-7613(00)80363-5; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; Hale DA, 1997, TRANSPLANTATION, V64, P897, DOI 10.1097/00007890-199709270-00018; HEIDECKE CD, 1985, TRANSPLANTATION, V40, P441; Honey K, 1999, J IMMUNOL, V163, P4805; JOHNSON JG, 1993, IMMUNOL RES, V12, P48, DOI 10.1007/BF02918368; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; Karre K, 1997, NATURE, V386, P446, DOI 10.1038/386446a0; KARRE K, 1998, SPECIFICITY FUNCTION; Kawai K, 1996, TRANSPLANTATION, V61, P352, DOI 10.1097/00007890-199602150-00003; Kimachi K, 1997, EUR J IMMUNOL, V27, P3310, DOI 10.1002/eji.1830271230; KLEIN J, 1982, IMMUNOLOGY SCI SELFN, P476; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LANIER LL, 1995, CURR OPIN IMMUNOL, V7, P626, DOI 10.1016/0952-7915(95)80068-9; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li YS, 1998, TRANSPLANTATION, V66, P1387, DOI 10.1097/00007890-199811270-00021; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lin H, 1998, J EXP MED, V188, P199, DOI 10.1084/jem.188.1.199; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; Manning TC, 1997, J IMMUNOL, V159, P4665; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Newell KA, 1999, J IMMUNOL, V163, P2358; Ortaldo JR, 1998, J IMMUNOL, V160, P1158; PEARSON TC, 1994, TRANSPLANTATION, V57, P1701, DOI 10.1097/00007890-199457120-00002; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHELTON MW, 1992, TRANSPLANTATION, V54, P278, DOI 10.1097/00007890-199208000-00017; Shi FD, 2000, NAT IMMUNOL, V1, P245, DOI 10.1038/79792; Skold M, 2000, EUR J IMMUNOL, V30, P2488, DOI 10.1002/1521-4141(200009)30:9<2488::AID-IMMU2488>3.0.CO;2-F; Szot GL, 2000, TRANSPLANTATION, V69, P904; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; Warrens A N, 1994, Transpl Immunol, V2, P103, DOI 10.1016/0966-3274(94)90036-1; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P14, DOI 10.1016/S0167-5699(97)80008-4	45	174	182	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					557	562		10.1038/87880	http://dx.doi.org/10.1038/87880			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329056				2022-12-25	WOS:000169961100034
J	Max, M; Shanker, YG; Huang, LQ; Rong, M; Liu, Z; Campagne, F; Weinstein, H; Damak, S; Margolskee, RF				Max, M; Shanker, YG; Huang, LQ; Rong, M; Liu, Z; Campagne, F; Weinstein, H; Damak, S; Margolskee, RF			Tas1r3, encoding a new candidate taste receptor, is allelic to the sweet responsiveness locus Sac	NATURE GENETICS			English	Article							SACCHARIN PREFERENCE; BITTER; MICE; SUBSTANCES; RESPONSES; GUSTDUCIN; GENETICS; SUCROSE; CELLS	The ability to taste the sweetness of carbohydrate-rich foodstuffs has a critical role in the nutritional status of humans. Although several components of bitter transduction pathways have been identified(1-6), the receptors and other sweet transduction elements remain unknown. The Sac locus in mouse, mapped to the distal end of chromosome 4 (refs. 7-9), is the major determinant of differences between sweet-sensitive and -insensitive strains of mice in their responsiveness to saccharin, sucrose and other sweeteners(10-13). To identify the human Sac locus, we searched for candidate genes within a region of approximately one million base pairs of the sequenced human genome syntenous to the region of Sac in mouse. From this search, we identified a likely candidate: T1R3, a previously unknown G protein-coupled receptor (GPCR) and the only GPCR in this region. Mouse Tas1r3 (encoding T1r3) maps to within 20,000 bp of the marker closest to Sac (ref. 9) and, like human TA5IR3, is expressed selectively in taste receptor cells. By comparing the sequence of Tas1r3 from several independently derived strains of mice, we identified a specific polymorphism that assorts between taster and non-taster strains. According to models of its structure. T1r3 from non-tasters is predicted to have an extra amino-terminal glycosylation site that, if used, would interfere with dimerization.	NYU, Mt Sinai Sch Med, Howard Hughes Med Inst, New York, NY 10012 USA; NYU, Mt Sinai Sch Med, Dept Phys & Biophys, New York, NY USA; NYU, Mt Sinai Sch Med, Inst Computat Biomed, New York, NY USA	Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Margolskee, RF (corresponding author), NYU, Mt Sinai Sch Med, Howard Hughes Med Inst, 550 1st Ave, New York, NY 10012 USA.	Bob@inka.mssm.edu	Campagne, Fabien/F-5158-2010; WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; Margolskee, Robert/0000-0002-9572-2887; Campagne, Fabien/0000-0001-6237-3564; Huang, Liquan/0000-0003-3400-0685	NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH057241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003155] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00310, DC03155] Funding Source: Medline; NIMH NIH HHS [MH57241] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Bachmanov AA, 1997, MAMM GENOME, V8, P545, DOI 10.1007/s003359900500; Blizard DA, 1999, CHEM SENSES, V24, P373, DOI 10.1093/chemse/24.4.373; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CAPELESS CG, 1995, CHEM SENSES, V20, P291, DOI 10.1093/chemse/20.3.291; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; FULLER JL, 1974, J HERED, V65, P33, DOI 10.1093/oxfordjournals.jhered.a108452; HIJI Y, 1975, NATURE, V256, P427, DOI 10.1038/256427a0; Hogan B, 1994, MANIPULATING MOUSE E; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Huang LQ, 1999, NAT NEUROSCI, V2, P1055, DOI 10.1038/15981; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li X, 2001, MAMM GENOME, V12, P13, DOI 10.1007/s003350010236; LUSH IE, 1989, GENET RES, V53, P95, DOI 10.1017/S0016672300027968; LUSH IE, 1995, GENET RES, V66, P167, DOI 10.1017/S0016672300034510; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Nakashima K, 1998, CELL PHYSIOL BIOCHEM, V8, P224, DOI 10.1159/000016285; Rossler P, 2000, CHEM SENSES, V25, P413, DOI 10.1093/chemse/25.4.413; Rossler P, 1998, EUR J CELL BIOL, V77, P253; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0	25	433	469	2	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					58	63		10.1038/88270	http://dx.doi.org/10.1038/88270			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326277				2022-12-25	WOS:000168413300017
J	Murphy, CD				Murphy, CD			Methods of treatment: Is there any protection available in Europe?	NATURE BIOTECHNOLOGY			English	Article									Boult Wade Tennant, London WC1X 8BT, England		Murphy, CD (corresponding author), Boult Wade Tennant, Verulam Gardens,70 Grays Rd, London WC1X 8BT, England.							*EPC, 2000, DIPL C REV EPC MUN 2; 1985, OJ EPO, V64	2	1	1	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					481	482		10.1038/88163	http://dx.doi.org/10.1038/88163			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329021				2022-12-25	WOS:000168394800029
J	Cuesta, A; Pedrola, L; Sevilla, T; Garcia-Planells, J; Chumillas, MJ; Mayordomo, F; LeGuern, E; Marin, I; Vilchez, JJ; Palau, F				Cuesta, A; Pedrola, L; Sevilla, T; Garcia-Planells, J; Chumillas, MJ; Mayordomo, F; LeGuern, E; Marin, I; Vilchez, JJ; Palau, F			The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease	NATURE GENETICS			English	Article							CMT4A LOCUS; TRANSFERASES	We identified three distinct mutations and six mutant alleles in GDAP1 in three families with axonal Charcot-Marie-Tooth (CMT) neuropathy and vocal cord paresis, which were previously linked to the CMT4A locus on chromosome 8q21.1. These results establish the molecular etiology of CMT4A (MIM 214400) and suggest that it may be associated with both axonal and demyelinating phenotypes.	CSIC, Inst Biomed, Lab Genet & Mol Med, E-46010 Valencia, Spain; Univ Valencia, Hosp La Fe, Dept Neurol, E-46100 Valencia, Spain; Univ Valencia, Hosp La Fe, Dept Clin Neurophysiol, E-46100 Valencia, Spain; Univ Valencia, Hosp La Fe, Dept Pathol, E-46100 Valencia, Spain; Hop La Pitie Salpetriere, INSERM, U289, F-75651 Paris, France; Hop La Pitie Salpetriere, Dept Genet Cytogenet & Foetopathol, F-75651 Paris, France; Univ Valencia, Dept Genet, E-46100 Valencia, Spain; Univ Valencia, Inst Cavanilles Biodivers & Biol Evolut, E-46100 Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Hospital Universitari i Politecnic La Fe; University of Valencia; Hospital Universitari i Politecnic La Fe; University of Valencia; Hospital Universitari i Politecnic La Fe; University of Valencia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Valencia; University of Valencia	Palau, F (corresponding author), CSIC, Inst Biomed, Lab Genet & Mol Med, Jaime Roig 11, E-46010 Valencia, Spain.	fpalau@ibv.csic.es	Palau, Francesc/A-9391-2014; Sevilla, Teresa/L-3292-2017; Marin, Ignacio/A-9524-2009	Palau, Francesc/0000-0002-8635-5421; Marin, Ignacio/0000-0002-1315-8961; Garcia-Planells, Javier/0000-0002-3224-2966; Sevilla, Teresa/0000-0003-4716-2667; Pedrola, Laia/0000-0002-3031-6124; Vilchez, Juan J/0000-0002-0532-2872				Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Baxter RV, 2002, NAT GENET, V30, P21, DOI 10.1038/ng796; Ben Othmane K, 1998, NEUROGENETICS, V2, P18, DOI 10.1007/s100480050047; BENOTHMANE K, 1995, GENOMICS, V28, P286, DOI 10.1006/geno.1995.1143; Dyck P.J, 1993, PNP, P1094; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HENTATI F, 2001, ACTA MYOL, V20, P25; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Lewis RA, 2000, MUSCLE NERVE, V23, P1472, DOI 10.1002/1097-4598(200010)23:10<1472::AID-MUS3>3.0.CO;2-#; Liu H, 1999, J NEUROCHEM, V72, P1781, DOI 10.1046/j.1471-4159.1999.0721781.x; Lupski JR, 2001, METABOLIC MOL BASES, P5759; OTHMANE KB, 1993, HUM MOL GENET, V2, P1625, DOI 10.1093/hmg/2.10.1625; Salinas AE, 1999, CURR MED CHEM, V6, P279; SEVILLA T, 2001, ACTA MYOL, V20, P49	14	261	269	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2002	30	1					22	25		10.1038/ng798	http://dx.doi.org/10.1038/ng798			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743580				2022-12-25	WOS:000173105600007
J	Becker, C; Pohla, H; Frankenberger, B; Schuler, T; Assenmacher, M; Schendel, DJ; Blankenstein, T				Becker, C; Pohla, H; Frankenberger, B; Schuler, T; Assenmacher, M; Schendel, DJ; Blankenstein, T			Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay	NATURE MEDICINE			English	Article							RENAL-CELL CARCINOMAS; ANTIGEN; EXPRESSION	Successful adoptive T-cell therapy has been demonstrated in viral disease(1,2) and selected forms of cancer(3). However, it is limited by the difficulty to efficiently isolate and amplify autologous tumor-reactive T-cell clones. Tetramers of major histocompatibility complex (MHC) class I and peptide have facilitated the characterization of CD8(+) T cells specific for tumor-associated antigens(4,5). However, for adoptive T-cell therapy, MHC-tetramers have limitations: they require knowledge of tumor antigens, which is often not available; they select T cells with a single specificity, thereby posing risk for selection of tumor escape variants; they do not select for function, so that T cells may be anergic when isolated from cancer patients; and they do not allow the isolation of CD4(+) T cells that can be essential for tumor rejection(6). Because interferon (IFN)-gamma is essential for tumor rejection(7,8), we isolated live T cells based on their IFN-gamma production(9). IFN-gamma secreted by previously activated T cells is retained on the cell surface, allowing their specific isolation and expansion(10). We show here that IFN-gamma (+) but not IFN-gamma (-) T cells from tumor-immunized mice are cytolytic and mediate tumor rejection upon adoptive transfer. Importantly, tumor-specific T cells can be enriched from lymphocytes infiltrating human renal cell carcinoma by the IFN-gamma capture assay.	Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Munich, Dept Urol, Lab Tumor Immunol, Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany; Free Univ Berlin, Inst Immunol, D-1000 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Miltenyi Biotec; Free University of Berlin	Blankenstein, T (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.	klahn@mdc-berlin.de	Becker, Christian/AAD-4549-2020; Becker, Christian/GLS-0862-2022; Pohla, Heike/GRS-3277-2022; Becker, Christian/F-5384-2010	Becker, Christian/0000-0002-1716-7208; Becker, Christian/0000-0002-1716-7208; Becker, Christian/0000-0002-1716-7208				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BARTH RJ, 1991, J EXP MED, V173, P647, DOI 10.1084/jem.173.3.647; BERNHARD H, 1994, INT J CANCER, V59, P837, DOI 10.1002/ijc.2910590621; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Chiodoni C, 1999, J EXP MED, V190, P125, DOI 10.1084/jem.190.1.125; Hoffman DMJ, 2000, SEMIN ONCOL, V27, P221; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Jantzer P, 1998, CANCER RES, V58, P3078; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Pardoll DM, 1998, CURR OPIN IMMUNOL, V10, P588, DOI 10.1016/S0952-7915(98)80228-8; Pohla H, 2000, BONE MARROW TRANSPL, V25, pS83, DOI 10.1038/sj.bmt.1702362; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Schendel DJ, 2000, GENE THER, V7, P2007, DOI 10.1038/sj.gt.3301349; Schendel DJ, 1997, J MOL MED-JMM, V75, P400, DOI 10.1007/s001090050125; Schepers E J, 1993, Implant Dent, V2, P151, DOI 10.1097/00008505-199309000-00002; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0	20	140	152	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1159	1162		10.1038/nm1001-1159	http://dx.doi.org/10.1038/nm1001-1159			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590442				2022-12-25	WOS:000171524500040
J	Smithies, O				Smithies, O			Forty years with homologous recombination	NATURE MEDICINE			English	Editorial Material									Univ N Carolina, Dept Pathol, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Smithies, O (corresponding author), Univ N Carolina, Dept Pathol, Brinkhous Bullitt Bldg, Chapel Hill, NC 27514 USA.								0	39	53	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1083	1086		10.1038/nm1001-1083	http://dx.doi.org/10.1038/nm1001-1083			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590419				2022-12-25	WOS:000171524500014
J	Miceli-Richard, C; Lesage, S; Rybojad, M; Prieur, AM; Manouvrier-Hanu, S; Hafner, R; Chamaillard, M; Zouali, H; Thomas, G; Hugot, JP				Miceli-Richard, C; Lesage, S; Rybojad, M; Prieur, AM; Manouvrier-Hanu, S; Hafner, R; Chamaillard, M; Zouali, H; Thomas, G; Hugot, JP			CARD15 mutations in Blau syndrome	NATURE GENETICS			English	Article							FAMILIAL GRANULOMATOUS ARTHRITIS; EARLY-ONSET; SKIN RASH; SARCOIDOSIS; IRITIS	We have identified three missense mutations in the nucleotide-binding domain (NBD) of CARD15/NOD2 in four French and German families with Blau syndrome. Our findings indicate that, in addition to Crohn disease, CARD15 is involved in the susceptibility to a second granulomatous disorder.	CEPH, Fdn Jean Dausset, Paris, France; Hop Robert Debre, F-75019 Paris, France; Hop Necker Enfants Malad, Dept Pediat Immunol, Paris, France; Hop Jeanne de Flandre, Dept Genet, Lille, France; Childrens Hosp, Dept Pediat Rheumatol, Garmish Partenkirchen, Germany; INSERM, U434, Paris, France	Foundation Jean Dausset-CEPH; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hugot, JP (corresponding author), CEPH, Fdn Jean Dausset, Paris, France.		Hugot, Jean-Pierre/F-6594-2012; Chamaillard, Mathias/L-6542-2013	Chamaillard, Mathias/0000-0002-0243-9717; Hugot, Jean-Pierre/0000-0002-8446-6056				BLAU EB, 1985, J PEDIATR-US, V107, P689, DOI 10.1016/S0022-3476(85)80394-2; HAFNER R, 1993, CLIN EXP RHEUMATOL, V11, P685; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Manouvrier-Hanu S, 1998, AM J MED GENET, V76, P217, DOI 10.1002/(SICI)1096-8628(19980319)76:3<217::AID-AJMG4>3.0.CO;2-N; MILLER JJ, 1986, J PEDIATR-US, V109, P387, DOI 10.1016/S0022-3476(86)80411-5; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P21228, DOI 10.1074/jbc.M011381200; Tromp G, 1996, AM J HUM GENET, V59, P1097	9	701	737	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					19	20		10.1038/ng720	http://dx.doi.org/10.1038/ng720			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528384				2022-12-25	WOS:000170781300008
J	Parkinson, NJ; Olsson, CL; Hallows, JL; McKee-Johnson, J; Keogh, BP; Noben-Trauth, K; Kujawa, SG; Tempel, BL				Parkinson, NJ; Olsson, CL; Hallows, JL; McKee-Johnson, J; Keogh, BP; Noben-Trauth, K; Kujawa, SG; Tempel, BL			Mutant beta-spectrin 4 causes auditory and motor neuropathies in quivering mice	NATURE GENETICS			English	Article							CHANNEL; NEURONS; EXPRESSION	The autosomal recessive mouse mutation quivering (qv), which arose spontaneously in 1953, produces progressive ataxia with hind limb paralysis, deafness and tremor(1). Six additional spontaneous alleles, qv(J), qv(2J), qv(3J), qv(4J) qv(ind) and qv(Ind2J), have been identified(2,3). Ear twitch responses (Preyer's reflex) to sound are absent in homozygous qv/qv mice, although cochlear morphology seems normal and cochlear potentials recorded at the round window are no different from those of control mice(4). However, responses from brainstem auditory nuclei show abnormal transmission of auditory information, indicating that, in contrast to the many known mutations causing deafness originating in the cochlea, deafness in qv is central in origin(4-6). Here we report that quivering mice carry loss-of-function mutations in the mouse beta -spectrin 4 gene (Spnb4) that cause alterations in ion channel localization in myelinated nerves; this provides a rationale for the auditory and motor neuropathies of these mice.	Univ Washington, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Natl Inst Deafness & Other Commun Disorders, Neurogenet Sect, NIH, Rockville, MD USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Tempel, BL (corresponding author), Univ Washington, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA.				NIDCD NIH HHS [DC02739, DC04661, Z01DC00056-01, DC00018] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000056, R01DC002739, P30DC004661, Z01DC000036] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; BOCK GR, 1983, ACTA OTO-LARYNGOL, V96, P371, DOI 10.3109/00016488309132722; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; BRONSON RT, 1992, J NEUROGENET, V8, P71, DOI 10.3109/01677069209084153; DEOL MS, 1983, BRAIN RES, V258, P177, DOI 10.1016/0006-8993(83)91248-9; Grosson CLS, 1996, MOL BRAIN RES, V42, P222, DOI 10.1016/S0169-328X(96)00123-4; Hallows JL, 1998, J NEUROSCI, V18, P5682; HORNER KC, 1985, BRAIN RES, V331, P217, DOI 10.1016/0006-8993(85)91547-1; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; Keogh B, 1998, J CELL PHYSIOL, V176, P624, DOI 10.1002/(SICI)1097-4652(199809)176:3<624::AID-JCP19>3.0.CO;2-Z; Kujawa SG, 1999, J NEUROPHYSIOL, V82, P863, DOI 10.1152/jn.1999.82.2.863; Leal A, 2001, AM J HUM GENET, V68, P269, DOI 10.1086/316934; RAUCH SD, 1987, MOUSE NEWS LETT, V78, P44; Sambrook J., 2002, MOL CLONING LAB MANU; Trussell LO, 1999, ANNU REV PHYSIOL, V61, P477, DOI 10.1146/annurev.physiol.61.1.477; Tse WT, 2001, J BIOL CHEM, V276, P23974, DOI 10.1074/jbc.M009307200; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WILLIAMS GW, 1998, NIX NUCLEOTIDE IDENT; WILLIAMS GW, 1999, PIX PEPTIDE IDENTIFI; YOON C. H., 1957, JOUR HEREDITY, V48, P176; Zeng FG, 1999, NEUROREPORT, V10, P3429, DOI 10.1097/00001756-199911080-00031	24	98	100	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					61	65		10.1038/ng710	http://dx.doi.org/10.1038/ng710			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528393				2022-12-25	WOS:000170781300018
J	Dietzel, S; Belmont, AS				Dietzel, S; Belmont, AS			Reproducible but dynamic positioning of DNA in chromosomes during mitosis	NATURE CELL BIOLOGY			English	Article							METAPHASE CHROMOSOMES; SISTER CHROMATIDS; VISUALIZATION; SCAFFOLD	How DNA is folded into chromosomes is unknown. Mitotic chromosome banding shows reproducibility in longitudinal compaction at a resolution of several megabase pairs, but it is less clear whether DNA sequences are targeted laterally to specific locations. The in vitro chromosome assembly of prokaryotic DNA(1) suggests that there is a lack of sequence requirements for chromosome condensation, implying an absence of DNA targeting. Protein extraction experiments indicate, however, that specific DNA sequences may bind to a chromosome scaffold(2,3). Chromosome banding patterns, using dyes with differential sequence specificity, have been interpreted to result from the alignment of AT-rich sequences in a partially helically folded chromosome scaffold(4). But fluorescence in situ hybridization experiments, perhaps owing to technical limitations, have shown at best only slight deviation from a random, lateral sequence distributions. Here we show that there is highly reproducible targeting of specific chromosome segments to the metaphase chromatid axis, but that these segments localize to the periphery of prophase and telophase chromosomes. Unfolding intermediates during anaphase and telophase suggest that sequence repositioning occurs through the global uncoiling of an underlying chromatid structure.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Belmont, AS (corresponding author), Univ Munich, Inst Anthropol & Humangenet, Richard Wagner St 10-1, D-80333 Munich, Germany.	asbel@uiuc.edu		Dietzel, Steffen/0000-0001-5725-3242	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042516] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM042516] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Belmont AS, 1997, NATO ASI 3 HIGH TECH, V31, P261; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Dernburg AF, 1998, METHOD CELL BIOL, V53, P187; Hart CM, 1998, CURR OPIN GENET DEV, V8, P519, DOI 10.1016/S0959-437X(98)80005-1; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9	13	33	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					767	770		10.1038/35087089	http://dx.doi.org/10.1038/35087089			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483964				2022-12-25	WOS:000170393200024
J	Perlman, R; Schiemann, WP; Brooks, MW; Lodish, HF; Weinberg, RA				Perlman, R; Schiemann, WP; Brooks, MW; Lodish, HF; Weinberg, RA			TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; TERMINAL KINASE SAPK/JNK; HEPATOCYTE CELL-LINES; SIGNAL-TRANSDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; INTERACTING PROTEIN; RECEPTOR COMPLEX; DOMAIN PROTEIN; B-CELLS; PATHWAY	Transforming growth factor-beta (TGF-beta) is a multifunctional growth factor that has a principal role in growth control through both its cytostatic effect on many different epithelial cell types and its ability to induce programmed cell death in a variety of other cell types. Here we have used a screen for proteins that interact physically with the cytoplasmic domain of the type II TGF-beta receptor to isolate the gene encoding Daxx - a protein associated with the Fas receptor that mediates activation of Jun amino-terminal kinase (JNK) and programmed cell death induced by Fas. The carboxy-terminal portion of Daxx functions as a dominant-negative inhibitor of TGF-beta -induced apoptosis in B-cell lymphomas, and antisense oligonucleotides to Daxx inhibit TGF-beta -induced apoptosis in mouse hepatocytes. Furthermore, Daxx is involved in mediating JNK activation by TGF-beta. Our findings associate Daxx directly with the TGF-beta apoptotic-signalling pathway, and make a biochemical connection between the receptors for TGF-beta and the apoptotic machinery.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; DANG H, 1995, J IMMUNOL, V155, P3205; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOODWIN GH, 1989, ISOLATION NUCL, P97; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LEDAI J, 1999, P NATL ACAD SCI USA, V96, P1427; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCMAHON JB, 1986, CANCER RES, V46, P4665; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	50	281	311	1	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					708	714		10.1038/35087019	http://dx.doi.org/10.1038/35087019			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483955				2022-12-25	WOS:000170393200015
J	Savelyeva, N; Munday, R; Spellerberg, MB; Lomonossoff, GP; Stevenson, FK				Savelyeva, N; Munday, R; Spellerberg, MB; Lomonossoff, GP; Stevenson, FK			Plant viral genes in DNA idiotypic vaccines activate linked CD4(+) T-cell mediated immunity against B-cell malignancies	NATURE BIOTECHNOLOGY			English	Article							IN-VIVO; ANTIGEN PRESENTATION; PROTECTIVE IMMUNITY; DENDRITIC CELLS; IMMUNIZATION; EXPRESSION; LYMPHOMA; PROTEIN; IMMUNOLOGY; ANTIBODIES	DNA delivery of tumor antigens can activate specific immune attack on cancer cells. However, antigens may be weak, and immune capacity can be compromised. Fusion of genes encoding activating sequences to the tumor antigen sequence facilitates promotion and manipulation of effector pathways. Idiotypic determinants of B-cell tumors, encoded by the variable region genes, are clone-specific tumor antigens. When assembled as single-chain Fv (ScFv) alone in a DNA vaccine, immunogenicity is low. Previously, we found that fusion of a sequence from tetanus toxin (fragment C; FrC) promoted anti-idiotypic protection against lymphoma and myeloma. We have now investigated an alternative fusion gene derived from a plant virus, potato virus X coat protein, a primary antigen in humans. When fused to scFv, the self-aggregating protein generates protection against lymphoma and myeloma. In contrast to scFv-FrC, protection against lymphoma is mediated by CD4(+) T cells, as is protection against myeloma. Plant viral proteins offer new opportunities to activate immunity against linked T-cell epitopes to attack cancer.	Southampton Univ Hosp Trust, Tenovus Lab, Mol Immunol Grp, Southampton SO16 6YD, Hants, England; John Innes Inst, Dept Virus Res, Norwich NR4 7UH, Norfolk, England	University of Southampton; University Hospital Southampton NHS Foundation Trust; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Stevenson, FK (corresponding author), Southampton Univ Hosp Trust, Tenovus Lab, Mol Immunol Grp, Southampton SO16 6YD, Hants, England.	ns1@soton.ac.uk	Savelyeva, Natalia N/B-3969-2009	Stevenson, Freda/0000-0002-0933-5021				Biragyn A, 1999, NAT BIOTECHNOL, V17, P253, DOI 10.1038/6995; Brennan FR, 1999, VACCINE, V17, P1846, DOI 10.1016/S0264-410X(98)00485-X; Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Conry RM, 1996, GENE THER, V3, P67; Corr M, 1999, J IMMUNOL, V163, P4721; Cruz SS, 1996, P NATL ACAD SCI USA, V93, P6286, DOI 10.1073/pnas.93.13.6286; Dalsgaard K, 1997, NAT BIOTECHNOL, V15, P248, DOI 10.1038/nbt0397-248; Dembic Z, 2000, P NATL ACAD SCI USA, V97, P2697, DOI 10.1073/pnas.050579897; ERICKSON JW, 1981, J MOL BIOL, V147, P337, DOI 10.1016/0022-2836(81)90444-7; Gerloni M, 2000, P NATL ACAD SCI USA, V97, P13269, DOI 10.1073/pnas.230429197; GOODMAN RM, 1975, VIROLOGY, V68, P299, DOI 10.1016/0042-6822(75)90273-1; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; HAWKINS RE, 1994, BLOOD, V83, P3279; HAYNES JR, 1986, BIO-TECHNOL, V4, P637, DOI 10.1038/nbt0786-637; Hinrichs J, 1997, J VIROL METHODS, V66, P195, DOI 10.1016/S0166-0934(97)00057-8; King CA, 1998, NAT MED, V4, P1281, DOI 10.1038/3266; Lomonossoff GP, 1996, CURR OPIN STRUC BIOL, V6, P176, DOI 10.1016/S0959-440X(96)80072-8; McInerney TL, 1999, VACCINE, V17, P1359, DOI 10.1016/S0264-410X(98)00388-0; Mumberg D, 1999, P NATL ACAD SCI USA, V96, P8633, DOI 10.1073/pnas.96.15.8633; Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074-7613(00)80218-6; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Smolenska L, 1998, FEBS LETT, V441, P379, DOI 10.1016/S0014-5793(98)01586-5; Spellerberg MB, 1997, J IMMUNOL, V159, P1885; STEVENSON FK, 1995, IMMUNOL REV, V145, P211, DOI 10.1111/j.1600-065X.1995.tb00083.x; STEVENSON FK, 1999, REV CLIN EXP HEMATOL, V9, P2; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; TURPEN TH, 1995, BIO-TECHNOL, V13, P53, DOI 10.1038/nbt0195-53; Ulmer JB, 1996, IMMUNOLOGY, V89, P59, DOI 10.1046/j.1365-2567.1996.d01-718.x; Zhu D, 1998, IMMUNOLOGY, V93, P162, DOI 10.1046/j.1365-2567.1998.00428.x; Zinkernagel RM, 1997, CIBA F SYMP, V204, P105	32	57	64	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					760	764		10.1038/90816	http://dx.doi.org/10.1038/90816			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479570				2022-12-25	WOS:000170188600028
J	Subramaniam, R; Desveaux, D; Spickler, C; Michnick, SW; Brisson, N				Subramaniam, R; Desveaux, D; Spickler, C; Michnick, SW; Brisson, N			Direct visualization of protein interactions in plant cells	NATURE BIOTECHNOLOGY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; SALICYLIC-ACID; TRANSCRIPTION FACTORS; DISEASE RESISTANCE; PR-1 GENE; INDUCTION; NPR1; COMPLEMENTATION; PATTERNS; DEFENSE	The protein NPR1/NIM1 is required for the induction of systemic acquired resistance (SAR) in plants and has been shown to interact with members of the TGA/OBF family of basic leucine zipper (bZIP) transcription factors. However, to date, there is no method available to monitor such interactions in plant cells. We report here an in vivo protein fragment complementation assay (PCA), based on association of reconstituted murine dihydrofolate reductase (mDHFR) with a fluorescent probe to detect protein-protein interaction in planta. We demonstrate that the interaction between Arabidopsis NPR1/NIM1 and the bZIP factor TGA2 is induced by the regulators of SAR, salicylic acid (SA), and its analog 2,6-dichloroisonicotinic acid (INA) with distinct specific specific responses. Furthermore, the induced interaction is localized predominantly in the nucleus. Protein fragment complementation assays could be of value to agricultural research by providing a system for high-throughput biochemical pathway mapping and for screening of small molecules that modulate protein interactions.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Brisson, N (corresponding author), Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada.							Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Delaney TP, 1997, PLANT PHYSIOL, V113, P5, DOI 10.1104/pp.113.1.5; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; Draper J, 1997, TRENDS PLANT SCI, V2, P162, DOI 10.1016/S1360-1385(97)01030-3; ENYEDI AJ, 1993, PLANT PHYSIOL, V101, P1375, DOI 10.1104/pp.101.4.1375; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Friedrich L, 1996, PLANT J, V10, P61, DOI 10.1046/j.1365-313X.1996.10010061.x; Gadella TWJ, 1999, TRENDS PLANT SCI, V4, P287, DOI 10.1016/S1360-1385(99)01426-0; Kinkema M, 2000, PLANT CELL, V12, P2339, DOI 10.1105/tpc.12.12.2339; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1439, DOI 10.1007/BF00016484; MATTON DP, 1993, PLANT MOL BIOL, V22, P279, DOI 10.1007/BF00014935; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; Reinold S, 1996, PLANT PHYSIOL, V112, P131, DOI 10.1104/pp.112.1.131; Remy I, 1999, P NATL ACAD SCI USA, V96, P5394, DOI 10.1073/pnas.96.10.5394; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; TEERI TH, 1989, EMBO J, V8, P343, DOI 10.1002/j.1460-2075.1989.tb03383.x; VERNOOIJ B, 1995, MOL PLANT MICROBE IN, V8, P228, DOI 10.1094/MPMI-8-0228; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523; Zhou JM, 2000, MOL PLANT MICROBE IN, V13, P191, DOI 10.1094/MPMI.2000.13.2.191	26	99	112	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					769	772		10.1038/90831	http://dx.doi.org/10.1038/90831			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479572				2022-12-25	WOS:000170188600030
J	Chan, HM; Krstic-Demonacos, M; Smith, L; Demonacos, C; La Thangue, NB				Chan, HM; Krstic-Demonacos, M; Smith, L; Demonacos, C; La Thangue, NB			Acetylation control of the retinoblastoma tumour-suppressor protein	NATURE CELL BIOLOGY			English	Article							FAMILY; GROWTH; P300; E2F; P53; CBP/P300; PRODUCT; BINDING; TRANSFORMATION; HATS	The retinoblastoma tumour-suppressor protein (pRb) and p300/CBP co-activator proteins are important for control of proliferation and in tumour cells these are sequestered by viral oncoproteins such as E1A, pRb is involved in negatively regulating growth, and p300/CBP proteins have histone acetyltransferase (HAT) activity, which influences gene expression. Although it is known that phosphorylation by G1 cyclin-dependent kinases (CDKs) regulates pRb activity, the nature and role of other post-translational modifications is not understood. Here we identify acetylation as a new type of modification and level of control in pRb function. Adenovirus E1A, which binds p300/CBP through an amino-terminal transformation-sensitive domain, stimulates the acetylation of pRb by recruiting p300 and pRb into a multimeric-protein complex. Furthermore, pRb acetylation is under cell-cycle control, and acetylation hinders the phosphorylation of pRb by cyclin-dependent kinases, pRb binds more strongly when acetylated to the MDM2 oncoprotein, which indicates that acetylation may regulate protein-protein interactions in the pRb pathway. The acetylation of pRb defines a new level of cell-cycle control mediated by HAT. Furthermore, our results establish a relationship between p300, pRb and acetylation in which E1A acts to recruit and target a cellular HAT activity to pRb.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk	Demonacos, Constantinos/K-1277-2019	Demonacos, Constantinos/0000-0002-4515-755X	Medical Research Council [G9400953] Funding Source: Medline; MRC [G9400953] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; DYSON N, 1992, CANCER SURV, V12, P161; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HSEIH IK, 1999, MOL CELL, V3, P181; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kung AL, 2000, GENE DEV, V14, P272; LASSAM NJ, 1979, CELL, V18, P781, DOI 10.1016/0092-8674(79)90131-4; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	41	227	237	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					667	674		10.1038/35083062	http://dx.doi.org/10.1038/35083062			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433299				2022-12-25	WOS:000169727000018
J	Sun, TQ; Lu, BW; Feng, JJ; Reinhard, C; Jan, YN; Fantl, WJ; Williams, LT				Sun, TQ; Lu, BW; Feng, JJ; Reinhard, C; Jan, YN; Fantl, WJ; Williams, LT			PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTION FACTOR LEF-1; EMBRYONIC-AXIS FORMATION; SEGMENT-POLARITY GENE; C-ELEGANS EMBRYOS; BETA-CATENIN; SIGNALING PATHWAYS; CELL POLARITY; XENOPUS DEVELOPMENT; SPEMANN ORGANIZER; WINGLESS PROTEIN	Wnt signalling regulates beta -catenin-dependent developmental processes through the Dishevelled protein (Dsh), Dsh regulates two distinct pathways, one mediated by beta -catenin and the other by Jun kinase (JNK), We have purified a Dsh-associated kinase from Drosophila that encodes a homologue of Caenorhabditis elegans PAR-I, a known determinant of polarity during asymmetric cell divisions. Treating cells with Wnt increases endogenous PAR-I activity coincident with Dsh phosphorylation, PAR-1 potentiates Wnt activation of the beta -catenin pathway but blocks the JNK pathway. Suppressing endogenous PAR-1 function inhibits Wnt signalling through beta -catenin in mammalian cells, and Xenopus and Drosophila embryos, PAR-1 seems to be a positive regulator of the beta -catenin pathway and an inhibitor of the JNK pathway. These findings show that PAR-I, a regulator of polarity, is also a modulator of Wnt-beta -catenin signalling, indicating a link between two important developmental pathways.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol & Biochem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Novartis; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Williams, LT (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299; Lu, Bingwei/0000-0002-5807-7014	NHLBI NIH HHS [P0 HL43821] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; Cox DN, 2001, CURR BIOL, V11, P75, DOI 10.1016/S0960-9822(01)00027-6; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; Espinosa L, 1998, CYTOGENET CELL GENET, V81, P278, DOI 10.1159/000015046; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murphy JE, 1998, P NATL ACAD SCI USA, V95, P1517, DOI 10.1073/pnas.95.4.1517; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, DEVELOPMENT, V120, P369; PELFER M, 2000, SCIENCE, V287, P1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	191	207	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					628	636		10.1038/35083016	http://dx.doi.org/10.1038/35083016			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433294				2022-12-25	WOS:000169727000013
J	Brown, KE; Amoils, S; Horn, JM; Buckle, VJ; Higgs, DR; Merkenschlager, M; Fisher, AG				Brown, KE; Amoils, S; Horn, JM; Buckle, VJ; Higgs, DR; Merkenschlager, M; Fisher, AG			Expression of alpha- and beta-globin genes occurs within different nuclear domains in haemopoietic cells	NATURE CELL BIOLOGY			English	Article							CHROMOSOME STRUCTURE; CHROMATIN-STRUCTURE; MOUSE; ACTIVATION; LOCUS; LOCALIZATION; EVOLUTION; REGION	The alpha- and beta -globin gene clusters have been extensively studied(1-3). Regulation of these genes ensures that proteins derived from both loci are produced in balanced amounts, and that expression is tissue-restricted and specific to developmental stages. Here we compare the subnuclear location of the endogenous alpha- and beta -globin loci in primary human cells in which the genes are either actively expressed or silent. In erythroblasts, the alpha- and beta -globin genes are localized in areas of the nucleus that are discrete from alpha -satellite-rich constitutive heterochromatin. However, in cycling lymphocytes, which do not express globin genes, the distribution of alpha- and beta -globin genes was markedly different. beta -globin loci, in common with several inactive genes studied here (human c-fms and SOX-1) and previously (mouse lambda5, CD4, CD8 alpha, RAGs, TdT and Sox-1)(4,5), were associated with pericentric heterochromatin in a high proportion of cycling lymphocytes. In contrast, alpha -globin genes were not associated with centromeric heterochromatin in the nucleus of normal human lymphocytes, in lymphocytes from patients with alpha -thalassaemia lacking the regulatory HS-40 element or entire upstream region of the alpha -globin locus, or in mouse erythroblasts and lymphocytes derived from human alpha -globin transgenic mice. These data show that the normal regulated expression of alpha- and beta -globin gene clusters occurs in different nuclear environments in primary haemopoietic cells.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, MRC Clin Sci Ctr,Lymphocyte Dev Grp, London W12 0NN, England; John Radcliffe Hosp, Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England	Imperial College London; University of Oxford	Fisher, AG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, MRC Clin Sci Ctr,Lymphocyte Dev Grp, Du Cane Rd, London W12 0NN, England.	amanda.fisher@csc.mrc.ac.uk		Merkenschlager, Matthias/0000-0003-2889-3288				ASHMUN RA, 1989, BLOOD, V73, P827; Barbour VM, 2000, BLOOD, V96, P800, DOI 10.1182/blood.V96.3.800.015k11a_800_807; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bulger M, 2000, P NATL ACAD SCI USA, V97, P14560, DOI 10.1073/pnas.97.26.14560; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; CONKIE D, 1975, EXP CELL RES, V93, P315, DOI 10.1016/0014-4827(75)90456-5; CRADDOCK CF, 1995, EMBO J, V14, P1718, DOI 10.1002/j.1460-2075.1995.tb07161.x; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hardison R, 1998, J EXP BIOL, V201, P1099; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; IJDO JW, 1991, NUCLEIC ACIDS RES, V19, P4780, DOI 10.1093/nar/19.17.4780; JIMENEZ G, 1992, NUCLEIC ACIDS RES, V20, P5797, DOI 10.1093/nar/20.21.5797; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; Malas S, 1997, MAMM GENOME, V8, P866, DOI 10.1007/s003359900597; MORLEY BJ, 1991, BLOOD, V78, P1355; Schubeler D, 2000, GENE DEV, V14, P940; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; Tufarelli C, 2001, GENOMICS, V71, P307, DOI 10.1006/geno.2000.6394; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; WAYE JS, 1987, CHROMOSOMA, V95, P182, DOI 10.1007/BF00330349; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	30	132	134	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					602	606		10.1038/35078577	http://dx.doi.org/10.1038/35078577			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389446				2022-12-25	WOS:000169194400017
J	Cho, C; Willis, WD; Goulding, EH; Haesook, JH; Choi, YC; Hecht, NB; Eddy, EM				Cho, C; Willis, WD; Goulding, EH; Haesook, JH; Choi, YC; Hecht, NB; Eddy, EM			Haploinsufficiency of protamine-1 or-2 causes infertility in mice	NATURE GENETICS			English	Article							MAMMALIAN SPERM NUCLEI; MALE GERM-CELLS; MOUSE PROTAMINE-1; PROTEINS; SEQUENCE; FERTILITY; DEFICIENT; GENES; CDNA	Protamines are the major DNA-binding proteins in the nucleus of sperm in most vertebrates(1-5) and package the DNA in a volume less than 5% of a somatic cell nucleus(6). Many mammals have one protamine, but a few species, including humans and mice, have two(7-13). Here we use gene targeting to determine if the second protamine provides redundancy to an essential process, or if both protamines are necessary. We disrupted the coding sequence of one allele of either Prm1 or Prm2 in embryonic stem (ES) cells derived from 129-strain mice, and injected them into blastocysts from C57BL/6-strain mice. Male chimeras produced 129-genotype sperm with disrupted Prm1 or Prm2 alleles, but failed to sire offspring carrying the 129 genome. We also found that a decrease in the amount of either protamine disrupts nuclear formation, processing of protamine-2 and normal sperm function. Our studies show that both protamines are essential and that haploinsufficiency caused by a mutation in one allele of Prm1or Prm2 prevents genetic transmission of both mutant and wild-type alleles.	NIEHS, Gamet Biol Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Penn, Med Ctr, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Eddy, EM (corresponding author), NIEHS, Gamet Biol Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	eddy@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070076, ZIAES070076] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALHORN R, 1977, BIOCHEMISTRY-US, V16, P4074, DOI 10.1021/bi00637a021; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; BALHORN R, 1988, EXPERIENTIA, V44, P52, DOI 10.1007/BF01960243; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; BELLVE AR, 1975, DEV BIOL, V47, P349, DOI 10.1016/0012-1606(75)90289-4; BRAUN RE, 1989, NATURE, V337, P373, DOI 10.1038/337373a0; CALDWELL KA, 1991, P NATL ACAD SCI USA, V88, P2407, DOI 10.1073/pnas.88.6.2407; CHO C, 1997, PCR METHOD DISTINGUI; DEBARLE M, 1995, MOL REPROD DEV, V40, P84, DOI 10.1002/mrd.1080400111; DEYEBRA L, 1993, J BIOL CHEM, V268, P10553; DOMENJOUD L, 1988, NUCLEIC ACIDS RES, V16, P7733, DOI 10.1093/nar/16.15.7733; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HECHT NB, 1990, J REPROD FERTIL, V88, P679, DOI 10.1530/jrf.0.0880679; Hecht NB, 1989, HISTONES OTHER BASIC, P347; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KOSOWER NS, 1992, J ANDROL, V13, P342; Kuratani S, 1997, DEV DYNAM, V209, P139, DOI 10.1002/(SICI)1097-0177(199706)209:2<139::AID-AJA1>3.0.CO;2-J; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; MCKAY DJ, 1985, BIOSCIENCE REP, V5, P383, DOI 10.1007/BF01116555; Meistrich M., 1989, HISTONES OTHER BASIC, P165; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; STANKER LH, 1993, MOL IMMUNOL, V30, P1633, DOI 10.1016/0161-5890(93)90436-F; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; WYROBEK AJ, 1976, BIOPHYS J, V16, P811, DOI 10.1016/S0006-3495(76)85730-X; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683	28	388	405	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2001	28	1					82	86		10.1038/ng0501-82	http://dx.doi.org/10.1038/ng0501-82			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326282				2022-12-25	WOS:000168413300022
J	Nishiyama, M; Muto, E; Inoue, Y; Yanagida, T; Higuchi, H				Nishiyama, M; Muto, E; Inoue, Y; Yanagida, T; Higuchi, H			Substeps within the 8-nm step of the ATPase cycle of single kinesin molecules	NATURE CELL BIOLOGY			English	Article							MOTOR DOMAINS; DIMERIC KINESIN; FORCE; TUBULIN; NCD; HYDROLYSIS; PROTEIN	Kinesin is a molecular motor that moves processively(1-4) by regular 8-nm steps along microtubules(5-11). The processivity of this movement is explained by a hand-overhand model in which the two heads of kinesin work in a coordinated manner. One head remains bound to the microtubule while the other steps from the alpha beta -tubulin dimer behind the attached head to the dimer in front. The overall movement is 8 nm per ATPase cycle(9-13). To investigate elementary processes within the 8-nm step, we have developed a new assay that resolves nanometre displacements of single kinesin molecules with microsecond accuracy. Our data show that the 8-nm step can be resolved into fast and slow substeps, each corresponding to a displacement of similar to4 nm. The substeps are most probably generated by structural changes in one head of kinesin, leading to rectified forward thermal motions of the partner head(14). It is also possible that the kinesin steps along the 4-nm repeat of tubulin monomers.	Osaka Univ, Fac Engn Sci, Dept Biophys Engn, Toyonaka, Osaka 5608531, Japan; JST, PRESTO, Form & Funct, Mino, Osaka 5620035, Japan; JST, ICORP, Single Mol Proc Project, Mino, Osaka 5620035, Japan; Osaka Univ, Grad Sch Med, Dept Physiol & Biosignaling, Suita, Osaka 5650871, Japan; Tohoku Univ, Grad Sch Engn, Dept Met, Sendai, Miyagi 9808579, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Sendai, Miyagi 9808579, Japan	Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University; Tohoku University; Tohoku University	Yanagida, T (corresponding author), Osaka Univ, Fac Engn Sci, Dept Biophys Engn, 1-3 Machikaneyama, Toyonaka, Osaka 5608531, Japan.	yanagida@phys1.med.osaka-u.ac.jp	Nishiyama, Masayoshi/F-8857-2012; Yanagida, Toshio/D-1919-2009; Nishiyama, Masayoshi/AAI-4579-2021; Muto, Etsuko/N-7965-2015	Muto, Etsuko/0000-0001-5812-1436; Nishiyama, Masayoshi/0000-0002-0525-3766				Allersma MW, 1998, BIOPHYS J, V74, P1074, DOI 10.1016/S0006-3495(98)74031-7; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; KUDO S, 1990, NATURE, V346, P677, DOI 10.1038/346677a0; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; Nishiyama M, 2000, BIOPHYS J, V78, p122A; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tucker C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960	25	120	123	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					425	428		10.1038/35070116	http://dx.doi.org/10.1038/35070116			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283618				2022-12-25	WOS:000168043900023
J	Hodgson, G; Hager, JH; Volik, S; Hariono, S; Wernick, M; Moore, D; Albertson, DG; Pinkel, D; Collins, C; Hanahan, D; Gray, JW				Hodgson, G; Hager, JH; Volik, S; Hariono, S; Wernick, M; Moore, D; Albertson, DG; Pinkel, D; Collins, C; Hanahan, D; Gray, JW			Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas	NATURE GENETICS			English	Article							PROTEIN PHOSPHATASE 2A; CDNA MICROARRAYS; TRANSGENIC MICE; CELL-LINES; HYBRIDIZATION; DNA; CHROMOSOME-16; AMPLIFICATION; ONCOGENE; AMPLICON	Carcinomas that develop in the pancreatic islets of transgenic mice expressing the SV40 T-antigens (Tag) under transcriptional control of the rat insulin II promoter (RIP) progress through well-characterized stages that are similar to aspects of human tumor progression, including hyperplastic growth, increased angiogenesis and reduced apoptosis'. The latter two stages have been associated with recurrent loss of heterozygosity (LOH)(2) and reduced genome copy number(3) on chromosomes 9 (LOH9) and 16 (LOH16), aberrations which we believe contribute to these phenotypes. Earlier analyses localized LOH9 to approximately 3 Mb and LOH16 to approximately 30 Mb (both syntenic with human 3q21-q25) but were limited by low throughput and a lack of informative polymorphic markers. Here we show that comparative genomic hybridization to DNA microarrays (array CGH)(4-7) overcomes these limitations by allowing efficient, genome-wide analyses of relative genome copy number. The CGH arrays used in these experiments carried BACs distributed at 2-20-MB intervals across the mouse genome and at higher density in regions of interest. Using array CGH, we further narrowed the loci for LOH9 and LOH16 and defined new or previously unappreciated recurrent regions of copy-number decrease on chromosomes 6, 8 and 14 (syntenic with human chromosomes 12p11-p13, 16q24.3 and 13q11-q32, respectively) and regions of copy-number increase on chromosomes 2 and 4 (syntenic to human chromosomes 20q13.2 and 1p32-p36, respectively). Our analyses of human genome sequences syntenic to these regions suggest that CYP24, PFDN4, STMN1, CDKN1B, PPP2R3 and FSTL1 are candidate oncogenes or tumor-suppressor genes. We also show that irradiation and genetic background influence the spectrum of aberrations present in these tumors.	Univ Calif San Francisco, Ctr Canc, Canc Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, Breast Oncol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Gray, JW (corresponding author), Univ Calif San Francisco, Ctr Canc, Canc Genet Program, Box 0808, San Francisco, CA 94143 USA.	jgray@cc.ucsf.edu			NCI NIH HHS [R37-CA45234, CA82103, CA78601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA082103, R37CA045234, R01CA078601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Han CS, 2000, GENOME RES, V10, P714, DOI 10.1101/gr.10.5.714; Heiskanen MA, 2000, CANCER RES, V60, P799; Iijima M, 1996, ACTA MED OKAYAMA, V50, P73; Korenberg JR, 1999, GENOME RES, V9, P514; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; PARANGI S, 1995, CANCER RES, V55, P6071; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Shi YP, 1997, GENE CHROMOSOME CANC, V19, P104, DOI 10.1002/(SICI)1098-2264(199706)19:2<104::AID-GCC6>3.3.CO;2-S; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; STAHELI IJP, 2001, EXP CELL RES, V264, P148; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	25	229	236	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					459	464		10.1038/ng771	http://dx.doi.org/10.1038/ng771			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11694878				2022-12-25	WOS:000172507500023
J	Lei, BF; DeLeo, FR; Hoe, NP; Graham, MR; Mackie, SM; Cole, RL; Liu, MY; Hill, HR; Low, DE; Federle, MJ; Scott, JR; Musser, JM				Lei, BF; DeLeo, FR; Hoe, NP; Graham, MR; Mackie, SM; Cole, RL; Liu, MY; Hill, HR; Low, DE; Federle, MJ; Scott, JR; Musser, JM			Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis	NATURE MEDICINE			English	Article							COMPLEMENT RECEPTOR TYPE-3; HYALURONIC-ACID CAPSULE; FC-GAMMA-RIII; BINDING-SITE; M-PROTEIN; MAC-1; IDENTIFICATION; ACTIVATION; VIRULENCE; CR3	Microbial pathogens must evade the human immune system to survive, disseminate and cause disease. By proteome analysis of the bacterium Group A Streptococcus (GAS), we identified a secreted protein with homology to the alpha -subunit of Mac-1, a leukocyte beta (2) integrin required for innate immunity to invading microbes. The GAS Mac-1-like protein (Mac) was secreted by most pathogenic strains, produced in log-phase and controlled by the covR-covS two-component gene regulatory system, which also regulates transcription of other GAS virulence factors. Patients with GAS infection had titers of antibody specific to Mac that correlated with the course of disease, demonstrating that Mac was produced in vivo. Mac bound to CD16 (Fc gamma RIIIB) on the surface of human polymorphonuclear leukocytes and inhibited opsonophagocytosis and production of reactive oxygen species, which resulted in significantly decreased pathogen killing. Thus, by mimicking a host-cell receptor required for an innate immune response, the GAS Mac protein inhibits professional phagocyte function by a novel strategy that enhances pathogen survival, establishment of infection and dissemination.	NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, Hamilton, MT 59840 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Emory University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Lei, BF (corresponding author), NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, Hamilton, MT 59840 USA.		Federle, Michael J./E-5522-2017; Low, Donald/B-1726-2012	Lei, Benfang Lei/0000-0001-8133-6021; DeLeo, Frank/0000-0003-3150-2516	NIAID NIH HHS [T32AI07470, AI20823] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000900, ZIAAI000900, T32AI007470, Z01AI000921] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beall B, 1997, J CLIN MICROBIOL, V35, P1231, DOI 10.1128/JCM.35.5.1231-1235.1997; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN G, 1988, ANTIBODIES, V1, P81; Chaussee MS, 2001, INFECT IMMUN, V69, P822, DOI 10.1128/IAI.69.2.822-831.2001; CORBI AL, 1988, J BIOL CHEM, V263, P12403; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 1999, J CLIN INVEST, V103, P1261, DOI 10.1172/JCI5118; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Ernst JD, 2000, CELL MICROBIOL, V2, P379, DOI 10.1046/j.1462-5822.2000.00075.x; Federle MJ, 1999, J BACTERIOL, V181, P3649, DOI 10.1128/JB.181.12.3649-3657.1999; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Galon J, 1996, J IMMUNOL, V157, P1184; Heath A, 1999, INFECT IMMUN, V67, P5298, DOI 10.1128/IAI.67.10.5298-5305.1999; Hoe NP, 2000, J INFECT DIS, V182, P1425, DOI 10.1086/315882; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HORSTMANN RD, 1992, INFECT IMMUN, V60, P5036, DOI 10.1128/IAI.60.12.5036-5041.1992; Ingalls RR, 1997, J IMMUNOL, V159, P433; Ji YD, 1996, INFECT IMMUN, V64, P503, DOI 10.1128/IAI.64.2.503-510.1996; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Musser JM, 1998, BIOMED RES REP, P185; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; ROSS GD, 1987, COMPLEMENT INFLAMMAT, V4, P61, DOI 10.1159/000463010; Schnitzler N, 1999, NAT MED, V5, P231, DOI 10.1038/5597; SEHGAL G, 1993, J IMMUNOL, V150, P4571; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; STOCKL J, 1995, J IMMUNOL, V154, P5452; TANIGUCHISIDLE A, 1992, J BIOL CHEM, V267, P635; Thakker M, 1998, INFECT IMMUN, V66, P5183, DOI 10.1128/IAI.66.11.5183-5189.1998; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WHITNACK E, 1982, J CLIN INVEST, V69, P1042, DOI 10.1172/JCI110508; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	38	132	138	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2001	7	12					1298	1305		10.1038/nm1201-1298	http://dx.doi.org/10.1038/nm1201-1298			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726969				2022-12-25	WOS:000172610300034
J	Rebuffat, A; Bernasconi, A; Ceppi, M; Wehrli, H; Verca, SB; Ibrahim, M; Frey, BM; Frey, FJ; Rusconi, S				Rebuffat, A; Bernasconi, A; Ceppi, M; Wehrli, H; Verca, SB; Ibrahim, M; Frey, BM; Frey, FJ; Rusconi, S			Selective enhancement of gene transfer by steroid-mediated gene delivery	NATURE BIOTECHNOLOGY			English	Article							ESTROGEN-RECEPTOR-BETA; GLUCOCORTICOID RECEPTOR; NUCLEAR IMPORT; PLASMID DNA; PROSTATE-CANCER; BREAST-CANCER; EXPRESSION; CELLS; EFFICIENT; PEPTIDE	The incorporation of transgenes into the host cells' nuclei is problematic using conventional nonviral gene delivery technologies. Here we describe a strategy, called steroid-mediated gene delivery (SMGD), which uses steroid receptors as shuttles to facilitate the uptake of transfected DNA into the nucleus. We use glucocorticoid receptors (GRs) as a model system with which to test the principle of SMGD. To this end, we synthesized and tested several bifunctional steroid derivatives, finally focusing on a compound named DR9NP, consisting of a dexamethasone backbone linked to a psoralen moiety using a nine-atom chemical spacer. DR9NP binds to the GR in either its free or DNA-crosslinked form, inducing the translocation of the GR to the nucleus. The expression of transfected DR9NP-decorated reporter plasmids is enhanced in dividing cells: expression of steroid-decorated reporter plasmids depends on the presence of the GR, is independent of the transactivation potential of the GR, and correlates with enhanced nuclear accumulation of the transgene in GR-positive cells. The SMGD effect is also observed in cells naturally expressing GRs and is significantly increased in nondividing cell cultures. We propose that SMGD could be used as a platform for selective targeting of transgenes in nonviral somatic gene transfer.	Univ Fribourg, UNIFR, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Bern, Inselspital, Div Nephrol, CH-3010 Bern, Switzerland; UNIFR, Inst Histol, CH-1700 Fribourg, Switzerland	University of Fribourg; University of Bern; University Hospital of Bern	Rusconi, S (corresponding author), Univ Fribourg, UNIFR, Inst Biochem, CH-1700 Fribourg, Switzerland.							Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; Burleson F., 1992, VIROLOGY LAB MANUAL, V1st ed.; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Coonrod A, 1997, GENE THER, V4, P1313, DOI 10.1038/sj.gt.3300536; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREY F, 2000, Patent No. 0011018; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Graham FL, 1991, METHOD MOL BIOL, P109; Hagstrom JE, 1997, J CELL SCI, V110, P2323; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; HEARST JE, 1981, ANNU REV BIOPHYS BIO, V10, P69, DOI 10.1146/annurev.bb.10.060181.000441; Heider H, 2000, BIOTECHNIQUES, V28, P260, DOI 10.2144/00282st02; HEIM R, 1995, NATURE, V373, P664; HOECK W, 1989, J BIOL CHEM, V264, P14396; Jaffuel D, 2000, AM J RESP CRIT CARE, V162, P57, DOI 10.1164/ajrccm.162.1.9901006; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maniatis T., 1989, MOL CLONING LAB MANU; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIYATA Y, 1991, J BIOL CHEM, V266, P8779; Pratt WB, 2001, TRENDS PLANT SCI, V6, P54, DOI 10.1016/S1360-1385(00)01843-4; Precious B., 1991, VIROLOGY PRACTICAL A, P128; Reid P, 1999, INVEST NEW DRUG, V17, P271, DOI 10.1023/A:1006344807086; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; RUSCONI S, 2001, IN PRESS MOL THERAPY; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Speirs V, 1999, CANCER RES, V59, P5421; Whittaker GR, 1998, VIROLOGY, V246, P1, DOI 10.1006/viro.1998.9165; Wilke M, 1996, GENE THER, V3, P1133; WRIGHT APH, 1993, J STEROID BIOCHEM, V47, P11, DOI 10.1016/0960-0760(93)90052-X; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zelphati O, 1999, HUM GENE THER, V10, P15, DOI 10.1089/10430349950019156; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	43	71	78	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1155	1161		10.1038/nbt1201-1155	http://dx.doi.org/10.1038/nbt1201-1155			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731785				2022-12-25	WOS:000172524400029
J	Grivel, JC; Ito, Y; Faga, G; Santoro, F; Shaheen, F; Malnati, MS; Fitzgerald, W; Lusso, P; Margolis, L				Grivel, JC; Ito, Y; Faga, G; Santoro, F; Shaheen, F; Malnati, MS; Fitzgerald, W; Lusso, P; Margolis, L			Suppression of CCR5-but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; SYNCYTIUM-INDUCING PHENOTYPE; VIRUS TYPE-1 INFECTION; BETA-CHEMOKINES; BIOLOGICAL PHENOTYPE; CORECEPTOR USAGE; PROGNOSTIC VALUE; CC-CHEMOKINES; IN-VIVO; REPLICATION	HIV-1 infects target cells via a receptor complex formed by CD4 and a chemokine receptor, primarily CCR5 or CXCR4 (ref. 1). Commonly, HIV-1 transmission is mediated by CCR5-tropic variants, also designated slow/low, non-syncytia-inducer or macrophage-tropic, which dominate the early stages of HIV-1 infection and frequently persist during the entire course of the disease(2-9). In contrast, HIV-1 variants that use CXCR4 are typically detected at the later stages, and are associated with a rapid decline in CD4(+) T cells and progression to AIDS (refs. 2,7-11). Disease progression is also associated with the emergence of concurrent infections that may affect the course of HIV disease by unknown mechanisms. A lymphotropic agent frequently reactivated in HIV-Infected patients is human herpesvirus 6 (HHV-6), which has been proposed as a cofactor in AIDS progression(12). Here we show that in human lymphoid tissue ex vivo(13-15) HHV-6 affects HIV-1 infection in a coreceptor-dependent manner, suppressing CCR5-tropic but not CXCR4-tropic HIV-1 replication, as shown with both uncloned viral isolates and isogenic molecular chimeras. Furthermore, we demonstrate that HHV-6 increases the production of the CCR5 ligand RANTES ('regulated upon activation, normal T-cell expressed and secreted'), the most potent HIV-inhibitory CC chemokine(16), and that exogenous RANTES mimics the effects of HHV-6 on HIV-1, providing a mechanism for the selective blockade of CCR5-tropic HIV-1. Our data suggest that HHV-6 may profoundly influence the course of HIV-1 infection.	NICHHD, Lab Cellular & Mol Biophys, Bethesda, MD 20892 USA; DIBIT San Raffaele Sci Inst, Unit Human Virol, Milan, Italy; Univ Bologna, Dept Clin & Expt Med, Bologna, Italy; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Bologna; University of Pennsylvania	Margolis, L (corresponding author), NICHHD, Lab Cellular & Mol Biophys, Bethesda, MD 20892 USA.		Malnati, Mauro/AAN-4207-2020; Ito, Yoshinori/A-7591-2016; Faga, Giovanni/AAB-5540-2021	Malnati, mauro/0000-0001-5355-1680; Grivel, Jean-Charles/0000-0003-0365-3181	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001416] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001416] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bjorndal A, 1997, J VIROL, V71, P7478; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Dolei A, 1998, AIDS, V12, P183, DOI 10.1097/00002030-199802000-00008; FENYO EM, 1988, J VIROL, V62, P4414; FENYO EM, 1993, AIDS, V7, P1673, DOI 10.1097/00002030-199312000-00020; Fouchier RAM, 1996, VIROLOGY, V219, P87, DOI 10.1006/viro.1996.0225; Glushakova S, 1997, AIDS RES HUM RETROV, V13, P461, DOI 10.1089/aid.1997.13.461; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; Glushakova S, 1999, J CLIN INVEST, V104, pR7, DOI 10.1172/JCI7403; Gordon CJ, 1999, J VIROL, V73, P684, DOI 10.1128/JVI.73.1.684-694.1999; Grivel JC, 1999, NAT MED, V5, P344, DOI 10.1038/6565; Kelly MD, 1998, J IMMUNOL, V160, P3091; Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Koot M, 1999, J INFECT DIS, V179, P254, DOI 10.1086/314539; Locatelli G, 2000, J CLIN MICROBIOL, V38, P4042, DOI 10.1128/JCM.38.11.4042-4048.2000; LUSSO P, 1995, IMMUNOL TODAY, V16, P67, DOI 10.1016/0167-5699(95)80090-5; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Smyth RJ, 1998, J VIROL, V72, P4478, DOI 10.1128/JVI.72.5.4478-4484.1998; TERSMETTE M, 1989, LANCET, V1, P983; Watt G, 2000, LANCET, V356, P475, DOI 10.1016/S0140-6736(00)02557-5; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364	31	90	93	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	2001	7	11					1232	1235		10.1038/nm1101-1232	http://dx.doi.org/10.1038/nm1101-1232			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689888				2022-12-25	WOS:000172054100031
J	Saada, A; Shaag, A; Mandel, H; Nevo, Y; Eriksson, S; Elpeleg, O				Saada, A; Shaag, A; Mandel, H; Nevo, Y; Eriksson, S; Elpeleg, O			Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy	NATURE GENETICS			English	Article							SKELETAL-MUSCLE; MTDNA DEPLETION; CLONING; EXPRESSION; CDNA; DISEASE; LIVER; GENE	The mitochondrial deoxyribonucleotide (dNTP) pool is separated from the cytosolic pool because the mitochondria inner membrane is impermeable to charged molecules. The mitochondrial pool is maintained by either import of cytosolic dNTPs through dedicated transporters(1,2) or by salvaging deoxynucleasides within the mitochondria; apparently, enzymes of the de novo dNTP synthesis pathway are not present in the mitochondria. In non-replicating cells, where cytosolic dNTP synthesis is downregulated, mtDNA synthesis depends solely on the mitochondrial salvage pathway enzymes, the deoxyribonucleosides kinases. Two of the four human deoxyribonucleoside kinases, deoxyguanosine kinase (dGK) and thymidine kinase-2 (TK2), are expressed in mitochondria(3-6). Human dGK efficiently phosphorylates deoxyguanosine and deoxyadenosine, whereas TK2 phosphorylates deoxythymidine, deoxycytidine and deoxyuridine. Here we identify two mutations in TK2, histidine 90 to asparagine and isoleucine 181 to asparagine, in four individuals who developed devastating myopathy and depletion of muscular mitochondrial DNA in infancy. In these individuals, the activity of TK2 in muscle mitochondria is reduced to 14-45% of the mean value in healthy control individuals. Mutations in TK2 represent a new etiology for mitochondrial DNA depletion, underscoring the importance of the mitochondrial dNTP pool in the pathogenesis of mitochondrial depletion.	Hebrew Univ Jerusalem, Fac Med, Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel; Rambam Med Ctr, Dept Pediat, IL-31096 Haifa, Israel; Tel Aviv Sourasky Med Ctr, Pediat Neurol Unit, IL-65211 Tel Aviv, Israel; Swedish Univ Agr Sci, Dept Vet Med Chem, SE-75123 Uppsala, Sweden	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Swedish University of Agricultural Sciences	Elpeleg, O (corresponding author), Hebrew Univ Jerusalem, Fac Med, Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.		Saada, Ann/J-6864-2017	Saada, Ann/0000-0003-2951-0656				BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0; BODNAR AG, 1993, AM J HUM GENET, V53, P663; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; DOOIJEWAARD G, 1976, BIOCHIM BIOPHYS ACTA, V440, P1, DOI 10.1016/0005-2728(76)90109-2; Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1; FISCHER JC, 1985, CLIN CHIM ACTA, V153, P23, DOI 10.1016/0009-8981(85)90135-4; HOPPEL C, 1969, ARCH BIOCHEM BIOPHYS, V135, P173, DOI 10.1016/0003-9861(69)90528-1; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; MARIOTTI C, 1995, J NEUROL, V242, P547, DOI 10.1007/BF00868806; MORAES CT, 1991, AM J HUM GENET, V48, P492; Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Spelbrink JN, 1998, HUM GENET, V102, P327, DOI 10.1007/s004390050700; Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935; TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209; Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0	28	451	462	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2001	29	3					342	344		10.1038/ng751	http://dx.doi.org/10.1038/ng751			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687801				2022-12-25	WOS:000171911000024
J	Wielockx, B; Lannoy, K; Shapiro, SD; Itoh, T; Itohara, S; Vandekerckhove, J; Libert, C				Wielockx, B; Lannoy, K; Shapiro, SD; Itoh, T; Itohara, S; Vandekerckhove, J; Libert, C			Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy	NATURE MEDICINE			English	Article							TNF-ALPHA; ALPHA(1)-ACID GLYCOPROTEIN; PROINFLAMMATORY MEDIATORS; EXTRACELLULAR-MATRIX; LIVER-FAILURE; MICE; GELATINASE; ACTIVATION; ARTHRITIS; ANGIOGENESIS	Acute and fulminant liver failure induced by viral hepatitis, alcohol or other hepatotoxic drugs, are associated with tumor necrosis factor (TNF) production. In a mouse model of lethal hepatitis induced by TNF, apoptosis and necrosis of hepatocytes, but also lethality, hypothermia and influx of leukocytes into the liver, are prevented by a broad-spectrum matrix metalloproteinase (MMP) inhibitor, BB-94. Mice deficient in MMP-2, MMP-3 or MMP-9 had lower levels of apoptosis and necrosis of hepatocytes, and better survival. We found induction of MMP-9 activity and fibronectin degradation. Our findings suggest that several MMPs play a critical role in acute, fulminant hepatitis by degrading the extracellular matrix and allowing massive leukocyte influx in the liver. BB-94 also prevented lethality in TNF/interferon-gamma therapy in tumor-bearing mice. A broad-spectrum MMP inhibitor may be potentially useful for the treatment of patients with acute and perhaps chronic liver failure, and in cancer therapies using inflammatory cytokines.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium; Washington Univ, Med Ctr, Jewish Hosp, Dept Med, St Louis, MO USA; Shionogi & Co Ltd, Shionogi Inst Med Sci, Osaka, Japan; RIKEN Brain Sci Inst, Lab Behav Genet, Wako, Saitama, Japan; Flanders Interuniv Inst Biotechnol, Dept Biochem, Ghent, Belgium	Ghent University; Barnes-Jewish Hospital; Washington University (WUSTL); Shionogi & Company Limited; RIKEN	Libert, C (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Ghent, Belgium.	claude.libert@dmb.rug.ac.be	Itohara, Shigeyoshi/I-8769-2012; Wielockx, Ben/AAC-6854-2020; Libert, Claude/A-6504-2010	Itohara, Shigeyoshi/0000-0002-2410-9989; Wielockx, Ben/0000-0002-4923-2596; 				ALEXANDER RB, 1991, BIOL THERAPY CANCER, P378; Amour A, 1999, ANN NY ACAD SCI, V878, P728, DOI 10.1111/j.1749-6632.1999.tb07774.x; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Bernal W, 1999, EUR J GASTROEN HEPAT, V11, P977, DOI 10.1097/00042737-199909000-00005; Beyaert R, 1998, CYTOKINES, P335, DOI 10.1016/B978-012498340-3/50025-7; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; Brennan FM, 1997, BRIT J RHEUMATOL, V36, P643; BROUCKAERT PGG, 1986, INT J CANCER, V38, P763, DOI 10.1002/ijc.2910380521; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; EVERAERDT B, 1994, J IMMUNOL, V152, P5041; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giavazzi R, 1998, CLIN CANCER RES, V4, P985; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; JAESCHKE H, 1991, AM J PHYSIOL, V261, pG1051, DOI 10.1152/ajpgi.1991.261.6.G1051; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kowdley KV, 1999, AM J GASTROENTEROL, V94, P1132, DOI 10.1111/j.1572-0241.1999.01132.x; LEIST M, 1995, J IMMUNOL, V154, P1307; LIBERT C, 1994, J EXP MED, V180, P1571, DOI 10.1084/jem.180.4.1571; LIBERT C, 1994, EUR J IMMUNOL, V24, P2237, DOI 10.1002/eji.1830240945; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Marcellin P, 1999, J HEPATOL, V31, P9, DOI 10.1016/S0168-8278(99)80368-7; MARTINEZHERNANDEZ A, 1993, VIRCHOWS ARCH A, V423, P1, DOI 10.1007/BF01606425; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Murdoch WJ, 1999, J REPROD FERTIL, P353; MUTO Y, 1988, LANCET, V2, P72; Pugin J, 1999, AM J RESP CELL MOL, V20, P458, DOI 10.1165/ajrcmb.20.3.3311; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SHIRATORI Y, 1990, HEPATOLOGY, V11, P183, DOI 10.1002/hep.1840110205; Skotnicki JS, 1999, ANN NY ACAD SCI, V878, P61, DOI 10.1111/j.1749-6632.1999.tb07674.x; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takenaka K, 1998, DIGEST DIS SCI, V43, P887, DOI 10.1023/A:1018898905478; Van Molle W, 1999, J IMMUNOL, V163, P5235; VanMolle W, 1997, J IMMUNOL, V159, P3555; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yamamoto M, 1998, J MED CHEM, V41, P1209, DOI 10.1021/jm970404a; Yu Q, 2000, GENE DEV, V14, P163	49	158	164	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1202	1208		10.1038/nm1101-1202	http://dx.doi.org/10.1038/nm1101-1202			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689884				2022-12-25	WOS:000172054100027
J	Dunker, AK; Obradovic, Z				Dunker, AK; Obradovic, Z			The protein trinity - linking function and disorder	NATURE BIOTECHNOLOGY			English	Editorial Material							COMPLEX; CALCINEURIN		Washington State Univ, Sch Mol Biosci, Pullman, WA 99124 USA; Temple Univ, Ctr Informat Sci & Technol, Philadelphia, PA 19122 USA	Washington State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dunker, AK (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99124 USA.			Obradovic, Zoran/0000-0002-2051-0142				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Dunker A K, 2000, Genome Inform Ser Workshop Genome Inform, V11, P161; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Fischer E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI DOI 10.1002/CBER.18940270364; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Iakoucheva LM, 2001, PROTEIN SCI, V10, P560, DOI 10.1110/ps.29401; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Mirsky AE, 1936, P NATL ACAD SCI USA, V22, P439, DOI 10.1073/pnas.22.7.439; Namba K, 2001, GENES CELLS, V6, P1, DOI 10.1046/j.1365-2443.2001.00384.x; REEVES R, 2001, IN PRESS GENES; ROMERO P, 1997, P IEEE INT C NEUR NE, V1, P90; SCHULZ, 1979, MOL MECH BIOL RECOGN, P79; VUCETIC S, 2001, P INT JOINT INNS IEE, V4, P2718; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; WU H, 1931, CHINESE J PHYSL, V1, P219	19	469	479	0	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					805	806		10.1038/nbt0901-805	http://dx.doi.org/10.1038/nbt0901-805			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533628				2022-12-25	WOS:000170774000010
J	Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sondhi, J; Naidenko, OV; Kronenberg, M; Koezuka, Y; Delovitch, TL; Gombert, JM; Leite-De-Moraes, M; Gouarin, C; Zhu, R; Hameg, A; Nakayama, T; Taniguchi, M; Lepault, F; Lehuen, A; Bach, JF; Herbelin, A				Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sharif, S; Arreaza, GA; Zucker, P; Mi, QS; Sondhi, J; Naidenko, OV; Kronenberg, M; Koezuka, Y; Delovitch, TL; Gombert, JM; Leite-De-Moraes, M; Gouarin, C; Zhu, R; Hameg, A; Nakayama, T; Taniguchi, M; Lepault, F; Lehuen, A; Bach, JF; Herbelin, A			Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes	NATURE MEDICINE			English	Article							NKT CELLS; MICE; THYMOCYTES; CD1D; INTERLEUKIN-4; DEFICIENCY; TOLERANCE; GRAFTS; MOUSE; BETA	Type 1 diabetes (T1D) in non-obese diabetic (NOD) mice may be favored by immune dysregulation leading to the hyporesponsiveness of regulatory T cells and activation of effector T-helper type 1 (Th1) cells'. The immunoregulatory activity of natural killer T (NKT) cells is well documented(2,3) and both interleukin (IL)-4 and IL-10 secreted by NKT cells have important roles in mediating this activity(4,5). NKT cells are less frequent and display deficient IL-4 responses in both NOD mice(6,7) and individuals at risk for T1D (ref. 8), and this deficiency may lead to T1D (refs. 1,6-9). Thus, given that NKT cells respond to the alpha -galactosylceramide (alpha -GalCer) glycolipid in a CD1d-restricted manner by secretion of Th2 cytokines(10-12), we reasoned that activation of NKT cells by alpha -GalCer might prevent the onset and/or recurrence of T1D. Here we show that alpha -GalCer treatment, even when initiated after the onset of insulitis, protects female NOD mice from T1D and prolongs the survival of pancreatic islets transplanted into newly diabetic NOD mice. In addition, when administered after the onset of insulitis, alpha -GalCer and IL-7 displayed synergistic effects, possibly via the ability of IL-7 to render NKT cells fully responsive to alpha -GalCer. Protection from T1D by alpha -GalCer was associated with the suppression of both T- and B-cell autoimmunity to islet beta cells and with a polarized Th2-like response in spleen and pancreas of these mice. These findings raise the possibility that alpha -GalCer treatment might be used therapeutically to prevent the onset and recurrence of human T1D.	John P Robarts Res Inst, Autoimmun Diabet Grp, London, ON, Canada; La Jolla Inst Allergy & Immunol, San Diego, CA USA; Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma, Japan; Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada	Western University (University of Western Ontario); La Jolla Institute for Immunology; Kirin Brewery Company Limited; Western University (University of Western Ontario); Western University (University of Western Ontario)	Delovitch, TL (corresponding author), John P Robarts Res Inst, Autoimmun Diabet Grp, London, ON, Canada.	del@rri.on.ca; bach@necker.fr	Nakayama, Toshinori/E-1067-2017; de Moraes, Maria Leite/AAV-9159-2020; Herbelin, Andre/D-3096-2017	Nakayama, Toshinori/0000-0002-1434-2007; de Moraes, Maria Leite/0000-0002-2891-2269; Herbelin, Andre/0000-0003-0193-7084; Lehuen, Agnes/0000-0002-0450-3321				Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Burdin N, 1999, EUR J IMMUNOL, V29, P2014, DOI 10.1002/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G; Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Gombert JM, 1996, EUR J IMMUNOL, V26, P2989, DOI 10.1002/eji.1830261226; Gombert JM, 1996, INT IMMUNOL, V8, P1751, DOI 10.1093/intimm/8.11.1751; Hameg A, 2000, J IMMUNOL, V165, P4917, DOI 10.4049/jimmunol.165.9.4917; Hammond KJL, 1998, J EXP MED, V187, P1047, DOI 10.1084/jem.187.7.1047; Herbelin A, 1998, J IMMUNOL, V161, P2620; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Ikehara Y, 2000, J CLIN INVEST, V105, P1761, DOI 10.1172/JCI8922; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KI SN, 2001, P NATL ACAD SCI USA, V98, P2577; Laloux V, 2001, J IMMUNOL, V166, P3749, DOI 10.4049/jimmunol.166.6.3749; Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831; LEPAULT F, 1995, EUR J IMMUNOL, V25, P1502, DOI 10.1002/eji.1830250605; Lepault F, 2000, J IMMUNOL, V164, P240, DOI 10.4049/jimmunol.164.1.240; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Osman Y, 2000, EUR J IMMUNOL, V30, P1919, DOI 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3; Rabinovitch A, 1997, TRANSPLANTATION, V64, P1525, DOI 10.1097/00007890-199712150-00004; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Singh N, 1999, J IMMUNOL, V163, P2373; Sonoda KH, 2001, J IMMUNOL, V166, P42, DOI 10.4049/jimmunol.166.1.42; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Tori M, 1999, TRANSPLANT P, V31, P2741, DOI 10.1016/S0041-1345(99)00548-5; Van der Vliet HJJ, 1999, IMMUNOLOGY, V98, P557, DOI 10.1046/j.1365-2567.1999.00920.x; Vicari AP, 1996, INT IMMUNOL, V8, P1759, DOI 10.1093/intimm/8.11.1759; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	33	518	550	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1057	1062		10.1038/nm0901-1057	http://dx.doi.org/10.1038/nm0901-1057			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533711				2022-12-25	WOS:000170853300033
J	Curtis, ARJ; Fey, C; Morris, CM; Bindoff, LA; Ince, PG; Chinnery, PF; Coulthard, A; Jackson, MJ; Jackson, AP; McHale, DP; Hay, D; Barker, WA; Markham, AF; Bates, D; Curtis, A; Burn, J				Curtis, ARJ; Fey, C; Morris, CM; Bindoff, LA; Ince, PG; Chinnery, PF; Coulthard, A; Jackson, MJ; Jackson, AP; McHale, DP; Hay, D; Barker, WA; Markham, AF; Bates, D; Curtis, A; Burn, J			Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease	NATURE GENETICS			English	Article							NEURODEGENERATIVE DISEASES; HUMAN-H; IRON; MAP; CERULOPLASMIN; METABOLISM; METALS; BRAIN	We describe here a previously unknown, dominantly inherited, late-onset basal ganglia disease, variably presenting with extrapyramidal features similar to those of Huntington's disease (HD) or parkinsonism. We mapped the disorder, by linkage analysis, to 19q13.3, which contains the gene for ferritin light polypeptide (FTL). We found an adenine insertion at position 460-461 that is predicted to alter carboxy-terminal residues of the gene product. Brain histochemistry disclosed abnormal aggregates of ferritin and iron. Low serum ferritin levels also characterized patients. Ferritin, the main iron storage protein, is composed of 24 subunits of two types (heavy, H and light, L) which form a soluble, hollow sphere(1). Brain iron deposition increases normally with age, especially in the basal ganglia, and is a suspected causative factor in several neurodegenerative diseases(2) in which it correlates with visible pathology(3), possibly by its involvement in toxic free-radical reactions(4). We found the same mutation in five apparently unrelated subjects with similar extrapyramidal symptoms. An abnormality in ferritin strongly indicates a primary function for iron in the pathogenesis of this new disease, for which we propose the name 'neuroferritinopathy'.	Inst Human Genet, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Newcastle Upon Tyne, Newcastle Gen Hosp, Ctr Dev Clin Brain Ageing, Joint MRC, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Hosp NHS Trust, Dept Neurol, Newcastle Upon Tyne, Tyne & Wear, England; Newcastle Hosp NHS Trust, Dept Neuropathol, Newcastle Upon Tyne, Tyne & Wear, England; Newcastle Hosp NHS Trust, Dept Radiol, Newcastle Upon Tyne, Tyne & Wear, England; St Jamess Univ Hosp, Mol Med Unit, Leeds, W Yorkshire, England	Newcastle University - UK; Newcastle General Hospital; Newcastle University - UK; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Saint James's University Hospital; University of Leeds	Burn, J (corresponding author), Inst Human Genet, 19-20 Claremont Pl, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.		Jackson, Andrew P/D-3442-2009; Ince, Paul G/A-5064-2009; Coulthard, Alan/C-3649-2011	Jackson, Andrew P/0000-0002-8739-2646; Ince, Paul G/0000-0001-6677-8753; Coulthard, Alan/0000-0003-1110-9207; Bindoff, Laurence/0000-0003-0988-276X; Chinnery, Patrick/0000-0002-7065-6617; Burn, John/0000-0002-9823-2322; Morris, Christopher/0000-0002-3749-0993				ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; DEXTER DT, 1992, ANN NEUROL, V32, pS94, DOI 10.1002/ana.410320716; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; GATTI RA, 1987, AM J HUM GENET, V41, P654; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Hilditch-Maguire P, 2000, HUM MOL GENET, V9, P2789, DOI 10.1093/hmg/9.19.2789; Jappelli R, 1998, BIOCHEM BIOPH RES CO, V250, P342, DOI 10.1006/bbrc.1998.9317; Juan SH, 1999, ARCH BIOCHEM BIOPHYS, V361, P295, DOI 10.1006/abbi.1998.0998; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; MCGILL JR, 1987, HUM GENET, V76, P66; MORRIS CM, 1992, ACTA ANAT, V144, P235; Nappi AJ, 2000, CELL MOL BIOL, V46, P637; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; SANTORO C, 1986, NUCLEIC ACIDS RES, V14, P2863, DOI 10.1093/nar/14.7.2863; Sheth S, 2000, ANNU REV MED, V51, P443, DOI 10.1146/annurev.med.51.1.443; Takahashi Y, 1996, HUM MOL GENET, V5, P81, DOI 10.1093/hmg/5.1.81; Taylor TD, 1996, NAT GENET, V14, P479, DOI 10.1038/ng1296-479; WORWOOD M, 1987, HAEMATOLOGIA, V20, P229	23	394	401	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					350	354		10.1038/ng571	http://dx.doi.org/10.1038/ng571			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11438811				2022-12-25	WOS:000170174800015
J	Ueno, S; Maruki, Y; Nakamura, M; Tomemori, Y; Kamae, K; Tanabe, H; Yamashita, Y; Matsuda, S; Kaneko, S; Sano, A				Ueno, S; Maruki, Y; Nakamura, M; Tomemori, Y; Kamae, K; Tanabe, H; Yamashita, Y; Matsuda, S; Kaneko, S; Sano, A			The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis	NATURE GENETICS			English	Article							LINKAGE	Chorea-acanthocytosis is a neurodegenerative disorder with peripheral red cell acanthocytosis'. Linkage of chorea-acanthocytosis to chromosome 9q21 has been found(2). We refined the locus region and identified a previously unknown, full-length cDNA encoding a presumably structural protein, which we called chorein, We found a deletion in the coding region of the cDNA leading to a frame shift resulting in the production of a truncated protein in both alleles of patients and in single alleles of obligate carriers.	Ehime Univ, Sch Med, Dept Neuropsychiat, Shigenobu, Ehime 79102, Japan; Matsuyama Red Cross Hosp, Dept Neurol, Matsuyama, Ehime, Japan; Ehime Univ, Sch Med, Dept Anat, Shigenobu, Ehime, Japan; Hirosaki Univ, Sch Med, Dept Neuropsychiat, Hirosaki, Aomori 036, Japan	Ehime University; Matsuyama Red Cross Hospital; Ehime University; Hirosaki University	Sano, A (corresponding author), Ehime Univ, Sch Med, Dept Neuropsychiat, Shigenobu, Ehime 79102, Japan.	sano@m.ehime-u.ac.jp		Sano, Akira/0000-0001-5843-9786				BRIN MF, 1993, HDB CLIN NEUROLOGY, V19, P271; Cavalli G, 1995, Ann Ital Med Int, V10, P249; FAILLACE RT, 1982, ANN INTERN MED, V96, P616, DOI 10.7326/0003-4819-96-5-616; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Redding K, 1996, MOL CELL BIOL, V16, P6208; Rubio JP, 1997, AM J HUM GENET, V61, P899, DOI 10.1086/514876; Rubio JP, 1999, GENOMICS, V57, P84, DOI 10.1006/geno.1999.5758; Stege JT, 1999, DEV GENET, V25, P64, DOI 10.1002/(SICI)1520-6408(1999)25:1<64::AID-DVG7>3.0.CO;2-1; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777	10	191	197	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					121	122		10.1038/88825	http://dx.doi.org/10.1038/88825			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381254				2022-12-25	WOS:000169011800009
J	Butler, SL; Hansen, MST; Bushman, FD				Butler, SL; Hansen, MST; Bushman, FD			A quantitative assay for HIV DNA integration in vivo	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; BLOOD MONONUCLEAR-CELLS; TRANSCRIPTION; REPLICATION; PERSISTENCE; VECTORS; PCR	Early steps of infection by HIV-1 involve entry of the viral core into cells, reverse transcription to form the linear viral DNA, and integration of that DNA into a chromosome of the host. The unintegrated DNA can also follow non-productive pathways, in which it is circularized by recombination between DNA long-terminal repeats (LTRs), circularized by ligation of the DNA ends or degraded. Here we report quantitative methods that monitor formation of reverse transcription products, two-LTR circles and integrated proviruses. The integration assay employs a novel quantitative form of Alu-PCR that should be generally applicable to studies of integrating viruses and gene transfer vectors.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Salk Institute	Bushman, FD (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIAID NIH HHS [AI34786] Funding Source: Medline; NIGMS NIH HHS [GM56553] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056553] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	14	558	592	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					631	634		10.1038/87979	http://dx.doi.org/10.1038/87979			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329067				2022-12-25	WOS:000169961100045
J	Mabbott, NA; Bruce, ME; Botto, M; Walport, MJ; Pepys, MB				Mabbott, NA; Bruce, ME; Botto, M; Walport, MJ; Pepys, MB			Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie	NATURE MEDICINE			English	Article							FOLLICULAR DENDRITIC CELLS; LYMPHOID-TISSUES; PRION PROTEIN; MICE LACKING; AGENT; PRP; REPLICATION; INFECTION; SPLEENS; SYSTEM	Following peripheral exposure to transmissible spongiform encephalopathies (TSEs), infectivity usually accumulates in lymphoid tissues before neuroinvasion. The host prion protein (PrPc) is critical for TSE agent replication and accumulates as an abnormal, detergent insoluble, relatively proteinase-resistant isoform (PrPSc) in diseased tissues(1,2). Early PrPSc accumulation takes place on follicular dendritic cells (FDCs) within germinal centers in lymphoid tissues of patients with variant Creutzfeldt-Jakob disease(3) (vCJD), sheep with natural scrapie(4) or rodents following experimental peripheral infection with scrapie(5-7). In mouse scrapie models, the absence of FDCs blocks scrapie replication and PrPSc accumulation in the spleen, and neuroinvasion is significantly impaired(6-9). The mechanisms by which the TSE agent initially localizes to lymphoid follicles and interacts with FDCs are unknown. Antigens are trapped and retained on the surface of FDCs through interactions between complement and cellular complement receptors(10,11). Here we show that in mice, both temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays the onset of disease following peripheral infection, and reduces the early accumulation of PrPSc in the spleen. Thus, in the early stages of infection, C3 and perhaps C1q contribute to the localization of TSE infectivity in lymphoid tissue and may be therapeutic targets.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh, Midlothian, Scotland; Imperial Coll Sch Med, Div Med, London, England; UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Amyloidosis & Acute Phase Prot, London, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh; Imperial College London; University of London; University College London; UCL Medical School	Mabbott, NA (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh, Midlothian, Scotland.	neil.mabbott@bbsrc.ac.uk	Mabbott, Neil/AAF-8777-2020	Mabbott, Neil/0000-0001-7395-1796; Walport, Mark/0000-0001-7220-5273				Beringue V, 2000, J PATHOL, V190, P495, DOI 10.1002/(SICI)1096-9896(200003)190:4&lt;495::AID-PATH535&gt;3.0.CO;2-T; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Cutler AJ, 1998, J EXP MED, V187, P1789, DOI 10.1084/jem.187.11.1789; DICKINSON AG, 1969, J COMP PATHOL, V79, P15, DOI 10.1016/0021-9975(69)90021-8; Farquhar C, 1999, LANCET, V353, P117, DOI 10.1016/S0140-6736(98)05395-1; FARQUHAR CF, 1994, J GEN VIROL, V75, P495, DOI 10.1099/0022-1317-75-3-495; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; Mabbott NA, 2000, J VIROL, V74, P3338, DOI 10.1128/JVI.74.7.3338-3344.2000; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Nielsen CH, 2000, IMMUNOLOGY, V100, P4, DOI 10.1046/j.1365-2567.2000.00009.x; Norsworthy PJ, 1999, MAMM GENOME, V10, P789, DOI 10.1007/s003359901093; PAPAMICHAIL M, 1975, SCAND J IMMUNOL, V4, P343, DOI 10.1111/j.1365-3083.1975.tb02635.x; PEPYS MB, 1977, IMMUNOLOGY, V33, P491; PEPYS MB, 1976, TRANSPLANT REV-DENMA, V32, P93; PEPYS MB, 1979, J IMMUNOL METHODS, V30, P105, DOI 10.1016/0022-1759(79)90085-1; Qin DH, 1998, J IMMUNOL, V161, P4549; Tas SW, 1999, J IMMUNOL, V163, P5056; Taylor PR, 1998, J BIOL CHEM, V273, P1699, DOI 10.1074/jbc.273.3.1699; VANDENBERG TK, 1992, EUR J IMMUNOL, V22, P957, DOI 10.1002/eji.1830220412; vanKeulen LJM, 1996, J CLIN MICROBIOL, V34, P1228, DOI 10.1128/JCM.34.5.1228-1231.1996; Wuillemin WA, 1997, J IMMUNOL, V159, P1953	28	193	196	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					485	487		10.1038/86562	http://dx.doi.org/10.1038/86562			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283677				2022-12-25	WOS:000167960500045
J	Nakano, M; Yamada, K; Fain, J; Sener, EC; Selleck, CJ; Awad, AH; Zwaan, J; Mullaney, PB; Bosley, TM; Engle, EC				Nakano, M; Yamada, K; Fain, J; Sener, EC; Selleck, CJ; Awad, AH; Zwaan, J; Mullaney, PB; Bosley, TM; Engle, EC			Homozygous mutations in ARIX (PHOX2A) result in congenital fibrosis of the extraocular muscles type 2	NATURE GENETICS			English	Article							DUANES RETRACTION SYNDROME; HOMEODOMAIN PROTEIN; GENE; TRANSCRIPTION; MAPS; EXPRESSION; PROMOTER; DEFECTS	Isolated strabismus affects 1-5% of the general population(1). Most forms of strabismus are multifactorial in origin; although there is probably an inherited component, the genetics of these disorders remain unclear. The congenital fibrosis syndromes (CFS) represent a subset of monogenic isolated strabismic disorders that are characterized by restrictive ophthalmoplegia, and include congenital fibrosis of the extraocular muscles (CFEOM) and Duane syndrome (DURS)(2). Neuropathologic studies indicate that these disorders may result from the maldevelopment of the oculomotor (nIII), trochlear (nIV) and abducens (nVI) cranial nerve nuclei(3-5). To date, five CFS loci have been mapped (FEOM1, FEOM2, FEOM3, DURS1 and DURS2)(6-10), but no genes have been identified. Here, we report three mutations in ARIX (also known as PHOX2A) in four CFEOM2 pedigrees. ARIX encodes a homeodomain transcription factor protein previously shown to be required for nIIInIV development in mouse and zebrafish(1,12). Two of the mutations are predicted to disrupt splicing, whereas the third alters an amino acid within the conserved brachyury-like domain(13,14). These findings confirm the hypothesis that CFEOM2 results from the abnormal development of nIII/nIV (ref. 7) and emphasize a critical role for ARIX in the development of these midbrain motor nuclei(13-19).	Hacettepe Univ, Ankara, Turkey; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA USA; King Khalid Eye Specialist Hosp, Riyadh 11462, Saudi Arabia; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA	Hacettepe University; Harvard University; Boston Children's Hospital; Harvard Medical School; King Khaled Eye Specialist Hospital; University of Texas System; University of Texas Health San Antonio	Engle, EC (corresponding author), Hacettepe Univ, Ankara, Turkey.	engle@enders.tch.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012498] Funding Source: NIH RePORTER; NEI NIH HHS [EY12498] Funding Source: Medline; NICHD NIH HHS [P30HD18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adachi M, 2000, DNA CELL BIOL, V19, P539, DOI 10.1089/104454900439773; Appukuttan B, 1999, AM J HUM GENET, V65, P1639, DOI 10.1086/302656; Brown HW., 1950, STRABISMUS OPHTHALMI, P205; Doherty EJ, 1999, INVEST OPHTH VIS SCI, V40, P1687; Engle EC, 1997, AM J HUM GENET, V60, P1150; ENGLE EC, 1995, AM J HUM GENET, V57, P1086; Engle EC, 1997, ANN NEUROL, V41, P314, DOI 10.1002/ana.410410306; Engle EC, 1998, OX MG MED G, P477; Guo S, 1999, NEURON, V24, P555, DOI 10.1016/S0896-6273(00)81112-5; HOTCHKISS MG, 1980, ARCH OPHTHALMOL-CHIC, V98, P870, DOI 10.1001/archopht.1980.01020030864013; MILLER NR, 1982, ARCH OPHTHALMOL-CHIC, V100, P1468; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Osoegawa K, 2001, GENOME RES, V11, P483, DOI 10.1101/gr.169601; Pattyn A, 2000, DEVELOPMENT, V127, P1349; Pattyn A, 2000, MOL CELL NEUROSCI, V15, P235, DOI 10.1006/mcne.1999.0826; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; Ross M.T., 1999, CURRENT PROTOCOLS HU; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; Tiveron MC, 1996, J NEUROSCI, V16, P7649; Tullio-Pelet A, 2000, NAT GENET, V26, P332, DOI 10.1038/81642; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VINCENT C, 1994, HUM MOL GENET, V3, P1859, DOI 10.1093/hmg/3.10.1859; Wang SM, 1998, AM J HUM GENET, V63, P517, DOI 10.1086/301980; Yang CY, 1998, J NEUROCHEM, V71, P1813; Zellmer E, 1995, J NEUROSCI, V15, P8109; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919	30	141	157	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					315	320		10.1038/ng744	http://dx.doi.org/10.1038/ng744			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11600883				2022-12-25	WOS:000171911000019
J	Wilson, JF; Weale, ME; Smith, AC; Gratrix, F; Fletcher, B; Thomas, MG; Bradman, N; Goldstein, DB				Wilson, JF; Weale, ME; Smith, AC; Gratrix, F; Fletcher, B; Thomas, MG; Bradman, N; Goldstein, DB			Population genetic structure of variable drug response	NATURE GENETICS			English	Article							FUNCTIONAL-SIGNIFICANCE; CYP1A2 GENE; METABOLISM; CYP2D6; POLYMORPHISMS; DEBRISOQUINE; MEPHENYTOIN; CYP2C19; HUMANS; DEFECT	Geographic patterns of genetic variation, including variation at drug metabolizing enzyme (DME) loci and drug targets, indicate that geographic structuring of inter-individual variation in drug response may occur frequently. This raises two questions: how to represent human population genetic structure in the evaluation of drug safety and efficacy, and how to relate this structure to drug response. We address these by (i) inferring the genetic structure present in a heterogeneous sample and (ii) comparing the distribution of DME variants across the inferred genetic clusters of individuals. We find that commonly used ethnic labels are both insufficient and inaccurate representations of the inferred genetic clusters, and that drug-metabolizing profiles, defined by the distribution of DME variants, differ significantly among the clusters. We note, however, that the complexity of human demographic history means that there is no obvious natural clustering scheme, nor an obvious appropriate degree of resolution. Our comparison of drug-metabolizing profiles across the inferred clusters establishes a framework for assessing the appropriate level of resolution in relating genetic structure to drug response.	UCL, Dept Biol, Galton Lab, London, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; UCL, Dept Biol, Ctr Genet Anthropol, London, England; Genost Ltd, London WC1A 2HN, England	University of London; University College London; University of Oxford; University of London; University College London	Wilson, JF (corresponding author), UCL, Dept Biol, Galton Lab, Mortimer St, London, England.	d.goldstein@ucl.ac.uk	Thomas, Mark G/A-2219-2012; Wilson, James F/A-5704-2009; Weale, Michael E/F-2587-2010; Goldstein, David/AAY-8125-2020	Thomas, Mark G/0000-0002-2452-981X; Wilson, James F/0000-0001-5751-9178; Weale, Michael E/0000-0003-4593-1186; 				Basile VS, 2000, MOL PSYCHIATR, V5, P410, DOI 10.1038/sj.mp.4000736; Bernal ML, 1999, PHARMACOGENETICS, V9, P657, DOI 10.1097/00008571-199910000-00013; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; Daly D. A., 1993, AM J SPEECH-LANG PAT, V2, P6, DOI [10.1044/1058-0360.0202.06., DOI 10.1044/1058-0360.0202.06]; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Ferguson RJ, 1998, J PHARMACOL EXP THER, V284, P356; Gaedigk A, 1998, PHARMACOGENETICS, V8, P305, DOI 10.1097/00008571-199808000-00004; Gaedigk A, 1999, PHARMACOGENETICS, V9, P669, DOI 10.1097/01213011-199912000-00002; Goldstein JA, 1996, METHOD ENZYMOL, V272, P210, DOI 10.1016/S0076-6879(96)72025-6; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KOHLMEIER L, 1997, DESIGN CONCEPTS NUTR, P312; Krajinovic M, 1999, BLOOD, V93, P1496, DOI 10.1182/blood.V93.5.1496.405a36_1496_1501; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Pritchard JK, 2000, GENETICS, V155, P945; Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x; Sachse C, 1999, BRIT J CLIN PHARMACO, V47, P445, DOI 10.1046/j.1365-2125.1999.00898.x; Seielstad MT, 1998, NAT GENET, V20, P278, DOI 10.1038/3088; WEBER WW, 1997, PHARMACOGENETICS; Wilson JF, 2000, AM J HUM GENET, V67, P926, DOI 10.1086/303083; 1998, INT C HARM ETHN FACT	21	326	339	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					265	269		10.1038/ng761	http://dx.doi.org/10.1038/ng761			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11685208				2022-12-25	WOS:000171911000011
J	Schwartz, TH; Bonhoeffer, T				Schwartz, TH; Bonhoeffer, T			In vivo optical mapping of epileptic foci and surround inhibition in ferret cerebral cortex	NATURE MEDICINE			English	Article							VISUAL-CORTEX; EPILEPTOGENESIS; MECHANISMS; SEIZURES; PATTERNS	The population of neurons participating in an epileptiform event varies from moment to moment. Most techniques currently used to localize epileptiform events in vivo have spatial and/or temporal sampling limitations. Here we show in an animal model that optical imaging based on intrinsic signals is an excellent method for in vivo mapping of clinically relevant epileptiform events, such as interictal spikes, ictal onsets, ictal spread and secondary homotopic foci. In addition, a decrease in the optical signal correlates spatially with a decrease in neuronal activity recorded from cortex surrounding an epileptic focus. Optical mapping of epilepsy might be a useful adjunct in the surgical treatment of neocortical epilepsy, which critically depends on the precise localization of intrinsically epileptogenic neurons.	Max Planck Inst Neurobiol, Munich, Germany	Max Planck Society	Schwartz, TH (corresponding author), Max Planck Inst Neurobiol, Munich, Germany.	tschwartz1@nyc.rr.com	Bonhoeffer, Tobias/B-9481-2009; Schwartz, Theodore/AAK-3320-2020	Bonhoeffer, Tobias/0000-0001-7897-6634; 				ANDREW RD, 1994, NEUROSCIENCE, V62, P371, DOI 10.1016/0306-4522(94)90372-7; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bonhoeffer Tobias, 1996, P55; Buzaki G, 1997, EPILEPSY COMPREHENSI, P819; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; ENGEL J, 1997, EPILEPSY COMPREHENSI, P499; FEDERICO P, 1994, NEUROSCIENCE, V58, P461, DOI 10.1016/0306-4522(94)90073-6; Goldensohn E S, 1986, Adv Neurol, V44, P559; GUMNIT RJ, 1965, ELECTROEN CLIN NEURO, V19, P63, DOI 10.1016/0013-4694(65)90007-6; HAGLUND MM, 1992, NATURE, V358, P668, DOI 10.1038/358668a0; HAUSER WEA, 1990, EPILLEPSY FREQUENCY; HOCHMAN DW, 1995, SCIENCE, V270, P99, DOI 10.1126/science.270.5233.99; Kiper DC, 1999, J NEUROPHYSIOL, V82, P3082, DOI 10.1152/jn.1999.82.6.3082; OLIVIER A, 1991, CONT ISSUES NEUROLOG, P150; ORBACH HS, 1985, J NEUROSCI, V5, P1886; Prince DA, 1997, CAN J PHYSIOL PHARM, V75, P500, DOI 10.1139/cjpp-75-5-500; PRINCE DA, 1967, ARCH NEUROL-CHICAGO, V16, P194, DOI 10.1001/archneur.1967.00470200082007; QUESNEY LF, 1995, ADV NEUROL, V66, P243; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X; SCHWARTZKROIN PA, 1975, BRAIN RES, V99, P59, DOI 10.1016/0006-8993(75)90608-3; STANSFELD CE, 1986, NEUROSCI LETT, V64, P299, DOI 10.1016/0304-3940(86)90345-9; SZENTE M, 1979, ELECTROEN CLIN NEURO, V46, P605, DOI 10.1016/0013-4694(79)90014-2; SZENTE MB, 1994, BRAIN RES, V648, P203, DOI 10.1016/0006-8993(94)91119-3; WIESER HG, 1979, EPILEPSIA, V20, P47, DOI 10.1111/j.1528-1157.1979.tb04775.x; WYLER AR, 1980, EPILEPSY WINDOW BRAI, P51	26	136	142	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1063	1067		10.1038/nm0901-1063	http://dx.doi.org/10.1038/nm0901-1063			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533712				2022-12-25	WOS:000170853300034
J	Seeliger, MW; Grimm, C; Stahlberg, F; Friedburg, C; Jaissle, G; Zrenner, E; Guo, H; Reme, CE; Humphries, P; Hofmann, F; Biel, M; Fariss, RN; Redmond, TM; Wenzel, A				Seeliger, MW; Grimm, C; Stahlberg, F; Friedburg, C; Jaissle, G; Zrenner, E; Guo, H; Reme, CE; Humphries, P; Hofmann, F; Biel, M; Fariss, RN; Redmond, TM; Wenzel, A			New views on RPE65 deficiency: the rod system is the source of vision in a mouse model of Leber congenital amaurosis	NATURE GENETICS			English	Article							RETINAL DYSTROPHY; CONE DYSTROPHY; ALPHA-SUBUNIT; MUTATIONS; PHOTORECEPTORS; CHANNEL; GENE; MICE	Leber congenital amaurosis (LCA) is the most serious form of the autosomal recessive childhood-onset retinal dystrophies. Mutations in the gene encoding RPE65, a protein vital for regeneration of the visual pigment rhodopsin in the retinal pigment epithelium(1), account for 10-15% of LCA cases(2,3). Whereas previous studies of RPE65 deficiency in both animal models(1,4) and patients(5,6) attributed remaining visual function to cones, we show here that light-evoked retinal responses in fact originate from rods. For this purpose, we selectively impaired either rod or cone function in Rpe65(-/-) mice by generating double-mutant mice with models of pure cone function(7) (rhodopsin-deficient mice; Rho(-/-)) and pure rod function, (cyclic nucleotide-gated channel alpha3-deficient mice; Cnga3(-/-)). The electroretinograms (ERGs) of Rpe65(-/-) and Rpe65(-/-)Cnga3(-/-) mice were almost identical, whereas there was no assessable response in Rpe65(-/-)Rho(-/-) mice. Thus, we conclude that the rod system is the source of vision in RPE65 deficiency. Furthermore, we found that lack of RPE65 enables rods to mimic cone function by responding under normally cone-isolating lighting conditions. We propose as a mechanism decreased rod sensitivity due to a reduction in rhodopsin content to less than 1%. In general, the dissection of pathophysiological processes in animal models through the introduction of additional, selective mutations is a promising concept in functional genetics.	Univ Tubingen, Dept Ophthalmol, Retinal Electrodiagnost Res Grp, D-72074 Tubingen, Germany; Univ Zurich Hosp, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland; Swedish Univ Agr Sci, Fac Vet Med, Dept Med & Surg, S-75007 Uppsala, Sweden; Univ Dublin Trinity Coll, Dept Genet, Dublin 2, Ireland; Tech Univ Munich, Inst Pharmakol & Toxikol, D-8000 Munich, Germany; Univ Munich, Zentrum Pharmaforsch, Dept Pharm, D-80539 Munich, Germany; NEI, Lab Mechanisms Ocular Dis, Bethesda, MD 20892 USA; NEI, Retinal Cell & Mol Biol Lab, Bethesda, MD 20892 USA	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University Zurich Hospital; Swedish University of Agricultural Sciences; Trinity College Dublin; Technical University of Munich; University of Munich; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Seeliger, MW (corresponding author), Univ Tubingen, Dept Ophthalmol, Retinal Electrodiagnost Res Grp, D-72074 Tubingen, Germany.		Biel, Martin/G-1175-2014; Fariss, Robert/ABI-1771-2020	Biel, Martin/0000-0002-9974-3052; Redmond, T. Michael/0000-0002-1813-5291; Grimm, Christian/0000-0001-9318-4352; Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Arden, 1991, PRINCIPLES PRACTICE; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; CONNER JD, 1977, SCIENCE, V195, P698, DOI 10.1126/science.841308; DOWLING JE, 1960, AM J OPHTHALMOL, V50, P875, DOI 10.1016/0002-9394(60)90340-8; FISHMAN GA, 1990, ELECTROPHYSIOLOGIC T; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Hirano AA, 2000, J COMP NEUROL, V421, P80, DOI 10.1002/(SICI)1096-9861(20000522)421:1<80::AID-CNE5>3.0.CO;2-O; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Jaissle GB, 2001, INVEST OPHTH VIS SCI, V42, P506; Kohl S, 1998, NAT GENET, V19, P257, DOI 10.1038/935; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; MARMOR M, 1995, DOC OPHTHALMOL, V89, P99; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925; Paupoo AAV, 2000, J PHYSIOL-LONDON, V529, P469, DOI 10.1111/j.1469-7793.2000.00469.x; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; Sadowski Bettina, 1994, Ophthalmologe, V91, P719; Thomas MM, 1999, J PHYSIOL-LONDON, V518, P479, DOI 10.1111/j.1469-7793.1999.0479p.x; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000	26	203	206	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					70	74		10.1038/ng712	http://dx.doi.org/10.1038/ng712			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528395				2022-12-25	WOS:000170781300020
J	Berg, AH; Combs, TP; Du, XL; Brownlee, M; Scherer, PE				Berg, AH; Combs, TP; Du, XL; Brownlee, M; Scherer, PE			The adipocyte-secreted protein Acrp30 enhances hepatic insulin action	NATURE MEDICINE			English	Article							ADIPOSE-SPECIFIC GENE; TISSUE; THIAZOLIDINEDIONES; RESISTANCE; LIPODYSTROPHY; ADIPONECTIN; MECHANISMS; ENDOCRINE; OBESITY; PLASMA	Acrp30 is a circulating protein synthesized in adipose tissue. A single injection in mice of purified recombinant Acrp30 leads to a 2-3-fold elevation in circulating Acrp30 levels, which triggers a transient decrease in basal glucose levels. Similar treatment in ob/ob, NOD (non-obese diabetic) or streptozotocin-treated mice transiently abolishes hyperglycemia. This effect on glucose is not associated with an increase in insulin levels. Moreover, in isolated hepatocytes, Acrp30 increases the ability of sub-physiological levels of insulin to suppress glucose production. We thus propose that Acrp30 is a potent insulin enhancer linking adipose tissue and whole-body glucose metabolism.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA.	scherer@aecom.yu.edu	sheng, jian/E-9474-2012; Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NIDDK NIH HHS [T32-DK 07513-15, 1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513, R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Cherrington AD, 1999, DIABETES, V48, P1198, DOI 10.2337/diabetes.48.5.1198; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Ganda OP, 2000, ANN INTERN MED, V133, P304, DOI 10.7326/0003-4819-133-4-200008150-00017; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gupta G, 2000, AM J PHYSIOL-ENDOC M, V278, pE985, DOI 10.1152/ajpendo.2000.278.6.E985; Harlow E., 1988, ANTIBODIES LAB MANUA; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; KONDO N, 1992, J BIOL CHEM, V267, P473; LANG CH, 1987, METABOLISM, V36, P180, DOI 10.1016/0026-0495(87)90015-1; Leffert H L, 1979, Methods Enzymol, V58, P536; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Meng YG, 2000, GENE, V242, P201, DOI 10.1016/S0378-1119(99)00524-7; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Reginato MJ, 1999, TRENDS ENDOCRIN MET, V10, P9, DOI 10.1016/S1043-2760(98)00110-6; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REID KBM, 1982, BIOCHEM J, V203, P559, DOI 10.1042/bj2030559; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244	33	2025	2147	1	89	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					947	953		10.1038/90992	http://dx.doi.org/10.1038/90992			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479628				2022-12-25	WOS:000171740400033
J	Smith, ES; Mandokhot, A; Evans, EE; Mueller, L; Borrello, MA; Sahasrabudhe, DM; Zauderer, M				Smith, ES; Mandokhot, A; Evans, EE; Mueller, L; Borrello, MA; Sahasrabudhe, DM; Zauderer, M			Lethality-based selection of recombinant genes in mammalian cells: Application to identifying tumor antigens	NATURE MEDICINE			English	Article							CYTOLYTIC T-LYMPHOCYTES; MYELIN BASIC-PROTEIN; HUMAN-MELANOMA; REJECTION ANTIGEN; VACCINIA VIRUS; IDENTIFICATION; EXPRESSION; VECTORS; MICE	Many biological processes result in either cell death or cessation of cell growth. However, plasmid- and retrovirus-based mammalian expression vectors in which it has been possible to construct representative cDNA libraries cannot be readily recovered from cells that are not actively dividing. This has limited the efficiency of selection of recombinant genes that mediate either lytic events or growth arrest. Examples include genes that encode the target antigens of cytotoxic T cells, genes that promote stem-cell differentiation and pro-apoptotic genes. We have successfully constructed representative cDNA libraries in a poxvirus-based vector that can be recovered from cells that have undergone lethality-based selection. This strategy has been applied to selection of a gene that encodes a cytotoxic T-cell target antigen common to several independently derived tumors.	Vaccinex Inc, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Canc, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Zauderer, M (corresponding author), Vaccinex Inc, Rochester, NY USA.			Evans, Elizabeth/0000-0002-9287-9221				Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; COLLINS JL, 1982, NATURE, V299, P169, DOI 10.1038/299169a0; Harrington CJ, 1998, IMMUNITY, V8, P571, DOI 10.1016/S1074-7613(00)80562-2; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; KUWANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P58, DOI 10.1016/S0006-291X(05)81458-5; LIN Y, 1985, J NATL CANCER I, V74, P1025; Merchlinsky M, 1997, VIROLOGY, V238, P444, DOI 10.1006/viro.1997.8828; MOSS B, 1992, CURR TOP MICROBIOL, V158, P25; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; PARK SB, 1994, PAC ASSOC KOREAN ST, V1, P163; PECKHAM I, 1989, GENE DEV, V3, P2062, DOI 10.1101/gad.3.12b.2062; SAHASRABUDHE DM, 1993, J IMMUNOL, V151, P6302; SIMONIC T, 1994, BBA-GENE STRUCT EXPR, V1219, P706, DOI 10.1016/0167-4781(94)90232-1; SOMOGYI P, 1993, VIROLOGY, V197, P439, DOI 10.1006/viro.1993.1608; Targoni OS, 1998, J EXP MED, V187, P2055, DOI 10.1084/jem.187.12.2055; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703	22	11	22	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					967	972		10.1038/91017	http://dx.doi.org/10.1038/91017			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479631				2022-12-25	WOS:000171740400036
J	Cullen, CF; Ohkura, H				Cullen, CF; Ohkura, H			Msps protein is localized to acentrosomal poles to ensure bipolarity of Drosophila meiotic spindles	NATURE CELL BIOLOGY			English	Article							MICROTUBULE MOTOR PROTEIN; KINESIN-LIKE PROTEIN; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; ORGANIZATION; CENTROSOME; SEPARATION; COMPONENT; PATHWAYS; MEIOSIS	The female meiotic spindle is commonly formed in a centrosome-independent manner. Here we report the identification of proteins at acentrosomal poles in the female meiotic spindle of Drosophila, The acentrosomal poles contain at least two proteins, Mini-spindles (Msps) and D-TACC, which are also associated with mitotic centrosomes. These proteins interact with one another and are both required for maintaining the bipolarity of acentrosomal spindles. The polar localization of Msps is dependent on D-TACC and Ncd, a kinesin-like microtubule motor. We propose that the polar localization of Msps mediated by D-TACC and Ncd may be crucial for the stabilization of meiotic spindle bipolarity.	Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Ohkura, H (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland.			Ohkura, Hiroyuki/0000-0003-4059-431X				ASHBURNER M, 1989, DROSPHILA; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Charrasse S, 1998, J CELL SCI, V111, P1371; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; GLOVER DM, 1993, SCI AM, V268, P62, DOI 10.1038/scientificamerican0693-62; HARLOW F, 1988, ANTIBODIES LAB MANUA; HATSUMI M, 1992, J CELL SCI, V103, P1013; HATSUMI M, 1992, J CELL SCI, V101, P547; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; KOMMA DJ, 1991, EMBO J, V10, P419, DOI 10.1002/j.1460-2075.1991.tb07963.x; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; LINDSLEY DL, 1992, GENOME DROSPHILA MEL; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCKIM KS, 1995, SCIENCE, V270, P1595, DOI 10.1126/science.270.5242.1595; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; Sambrook J., 2002, MOL CLONING LAB MANU; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Spittle C, 2000, J BIOL CHEM, V275, P20748, DOI 10.1074/jbc.M002597200; Tavosanis G, 1997, EMBO J, V16, P1809, DOI 10.1093/emboj/16.8.1809; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; WHITFIELD WGF, 1988, J CELL SCI, V89, P467; Wilson PG, 1998, DEV BIOL, V199, P273, DOI 10.1006/dbio.1998.8900; WOODS A, 1989, J CELL SCI, V93, P491	36	127	129	1	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					637	642		10.1038/35083025	http://dx.doi.org/10.1038/35083025			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433295				2022-12-25	WOS:000169727000014
J	Van Goethem, G; Dermaut, B; Lofgren, A; Martin, JJ; Van Broeckhoven, C				Van Goethem, G; Dermaut, B; Lofgren, A; Martin, JJ; Van Broeckhoven, C			Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions	NATURE GENETICS			English	Article							MITOCHONDRIAL-DNA POLYMERASE; MULTIPLE DELETIONS; REPLICATION; DISORDER; GAMMA; GENE	Progressive external ophthalmoplegias (PEO) characterized by accumulation of large-scale mitochondrial DNA (mtDNA) deletions are rare human diseases. We mapped a new locus for dominant PEO at 15q22-q26 in a Belgian pedigree and identified a heterozygous mutation (Y955C) in the polymerase motif B of the mtDNA polymerase gamma (POLG). We identified three additional POLG missense mutations compatible with recessive PEO In two nuclear families. POLG is the only DNA polymerase responsible for mtDNA replication.	Univ Antwerp VIB, Born Bunge Fdn, Dept Mol Genet, B-2610 Antwerp, Belgium; Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium; Univ Antwerp, Born Bunge Fdn, Neuropathol Lab, Dept Med, B-2610 Antwerp, Belgium	Flanders Institute for Biotechnology (VIB); University of Antwerp; University of Antwerp; University of Antwerp	Van Broeckhoven, C (corresponding author), Univ Antwerp VIB, Born Bunge Fdn, Dept Mol Genet, Univ Pl 1, B-2610 Antwerp, Belgium.	cvbroeck@uia.ua.ac.be	Van Broeckhoven, Christine/G-8362-2017; Dermaut, Bart/AAM-2483-2020; Van Broeckhoven, Christine/M-7853-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665				Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Heringa Jaap, 1994, P87; Iyengar B, 1999, GENETICS, V153, P1809; Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445; Liu HT, 2000, J VIROL, V74, P11681, DOI 10.1128/JVI.74.24.11681-11689.2000; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Pinz KG, 2000, J BIOL CHEM, V275, P12509, DOI 10.1074/jbc.275.17.12509; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; Van Goethem G, 2000, J MED GENET, V37, P547, DOI 10.1136/jmg.37.7.547; VanGoethem G, 1997, EUR J NEUROL, V4, P476; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	18	595	604	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					211	212		10.1038/90034	http://dx.doi.org/10.1038/90034			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431686				2022-12-25	WOS:000169656400008
J	Waikel, RL; Kawachi, Y; Waikel, PA; Wang, XJ; Roop, DR				Waikel, RL; Kawachi, Y; Waikel, PA; Wang, XJ; Roop, DR			Deregulated expression of c-Myc depletes epidermal stem cells	NATURE GENETICS			English	Letter							HUMAN KERATINOCYTE MIGRATION; DIFFERENTIATION; FIBRONECTIN; INTEGRIN; PROLIFERATION; MARKERS; DEATH; MICE	The beta -catenin/TCF signaling pathway is essential for the maintenance of epithelial stem cells in the small intestine(1). c-Myc a downstream target of beta -catenin/TCF (ref. 2), can induce differentiation of epidermal stem cells in vitro(3). To determine the role of c-Myc in epidermal stem cells in vivo, we have targeted expression of human MYC2 to the hair follicles and the basal layer of mouse epidermis using a keratin 14 vector (K14,MYC2), Adult K14,MYC2 mice gradually lose their hair and develop spontaneous ulcerated lesions due to a severe impairment in wound healing; their keratinocytes show impaired migration in response to wounding. The expression of beta1 integrin, which is preferentially expressed in epidermal stem cells(4) is unusually low in the epidermis of K14.MYC2 mice. Label-retaining analysis to identify epidermal stem cells reveals a 75% reduction in the number of stem cells in 3-month-old K14.MYC2 mice, compared with wildtype mice. We conclude that deregulated expression of c-Myc in stem cells reduces beta1 integrin expression, which is essential to both keratinocyte migration and stem cell maintenance.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025479] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA052607, R01CA079998] Funding Source: NIH RePORTER; NCI NIH HHS [CA52607, CA09197, CA79998] Funding Source: Medline; NIAMS NIH HHS [AR62228] Funding Source: Medline; NICHD NIH HHS [HD25479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Arin MJ, 2001, J CELL BIOL, V152, P645, DOI 10.1083/jcb.152.3.645; ARNOLD I, IN PRESS CURR BIOL; Barr LF, 1998, CANCER RES, V58, P5537; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Bickenbach JR, 1998, EXP CELL RES, V244, P184, DOI 10.1006/excr.1998.4163; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; GUO M, 1990, J CELL SCI, V96, P197; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; KIM JP, 1992, J CELL PHYSIOL, V151, P443, DOI 10.1002/jcp.1041510303; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; MACKENZIE IC, 1985, CELL TISSUE RES, V242, P551; POTTEN CS, 1982, CELL TISSUE KINET, V15, P305, DOI 10.1111/j.1365-2184.1982.tb01050.x; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WANG XT, 1995, J BEHAV DECIS MAKING, V8, P279, DOI 10.1002/bdm.3960080405; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427	25	259	275	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					165	168		10.1038/88889	http://dx.doi.org/10.1038/88889			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381265				2022-12-25	WOS:000169011800020
J	Yu, J; Langridge, WHR				Yu, J; Langridge, WHR			A plant-based multicomponent vaccine protects mice from enteric diseases	NATURE BIOTECHNOLOGY			English	Article							TOXIN-B-SUBUNIT; CHOLERA-TOXIN; ANTIBODY-RESPONSES; TRANSGENIC PLANTS; IMMUNE-RESPONSES; SURFACE-ANTIGEN; ORAL VACCINES; MUCOSAL; IMMUNIZATION; EXPRESSION	Cholera toxin (CT) B and A2 subunit complementary DNAs (cDNAs) were fused to a rotavirus enterotoxin and enterotoxigenic Escherichia coli fimbrial antigen genes and transferred into potato. Immunoblot and enzyme-linked immunosorbent assay (ELISA) results indicated that the fusion antigens were synthesized in transformed tuber tissues and assembled into cholera holotoxin-like structures that retained enterocyte-binding affinity. Orally immunized mice generated detectable levels of serum and intestinal antibodies against the pathogen antigens. Elevated levels of interleukin 2 (IL2) and interferon gamma (INF gamma) detected in immunogen-challenged spleen cells from the immunized mice indicated the presence of a strong Th 1 immune response to the three plant-synthesized antigens. This result was supported by flow cytometry analysis of immunized mouse spleen cells that showed a significant increase in CD4(+) lymphocyte numbers. Diarrhea symptoms were reduced in severity and duration in passively immunized mouse neonates following rotavirus challenge. The results suggest that food plants can function as Vaccines for simultaneous protection against infectious virus and bacterial diseases.	Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA; Loma Linda Univ, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Langridge, WHR (corresponding author), Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA.							Angel J, 1998, J INFECT DIS, V177, P455, DOI 10.1086/517374; Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381; Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810; Arakawa T, 1998, NAT BIOTECHNOL, V16, P934, DOI 10.1038/nbt1098-934; Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; Bloom P D, 1996, Semin Gastrointest Dis, V7, P151; Conner Margaret E., 1996, P325, DOI 10.1016/B978-012410580-5/50026-1; COX DS, 1984, INT ARCH ALLER A IMM, V75, P126, DOI 10.1159/000233602; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DERTZBAUGH MT, 1990, INFECT IMMUN, V58, P70, DOI 10.1128/IAI.58.1.70-79.1990; HAJISHENGALLIS G, 1995, J IMMUNOL, V154, P4322; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z; Horie Y, 1999, VIROLOGY, V262, P398, DOI 10.1006/viro.1999.9912; Ishida S, 1997, J INFECT DIS, V175, P1317, DOI 10.1086/516462; JACKSON RJ, 1993, INFECT IMMUN, V61, P4272, DOI 10.1128/IAI.61.10.4272-4279.1993; LYCKE N, 1986, IMMUNOLOGY, V59, P301; MACKENZIE SJ, 1984, J IMMUNOL, V133, P1818; Marinaro M, 1999, J IMMUNOL, V162, P114; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; Modelska A, 1998, P NATL ACAD SCI USA, V95, P2481, DOI 10.1073/pnas.95.5.2481; Pascual DW, 1999, INFECT IMMUN, V67, P6249; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; SVENNERHOLM AM, 1984, J INFECT DIS, V149, P884, DOI 10.1093/infdis/149.6.884; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; Williams NA, 1999, IMMUNOL TODAY, V20, P95, DOI 10.1016/S0167-5699(98)01397-8; XUAMANO JC, 1994, VACCINE, V12, P903, DOI 10.1016/0264-410X(94)90033-7	28	178	210	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					548	552		10.1038/89297	http://dx.doi.org/10.1038/89297			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385459	Bronze			2022-12-25	WOS:000169081700028
J	LaRochelle, WJ; Jeffers, M; McDonald, WF; Chillakuru, RA; Giese, NA; Lokker, NA; Sullivan, C; Boldog, FL; Yang, MJ; Vernet, C; Burgess, CE; Fernandes, E; Deegler, LL; Rittman, B; Shimkets, J; Shimkets, RA; Rothberg, JM; Lichenstein, HS				LaRochelle, WJ; Jeffers, M; McDonald, WF; Chillakuru, RA; Giese, NA; Lokker, NA; Sullivan, C; Boldog, FL; Yang, MJ; Vernet, C; Burgess, CE; Fernandes, E; Deegler, LL; Rittman, B; Shimkets, J; Shimkets, RA; Rothberg, JM; Lichenstein, HS			PDGFD, a new protease-activated growth factor	NATURE CELL BIOLOGY			English	Article							ALPHA-RECEPTOR; MICE; IDENTIFICATION; ESTABLISHES; MECHANISM; DEFICIENT; DOMAINS	Platelet-derived growth factor (PDGF) has been directly implicated in developmental and physiological processes(1-5), as well as in human cancer, fibrotic diseases and arteriosclerosis(6). The PDGF family currently consists of at least three gene products, PDGF-A, PDGF-B and PDGF-C, which selectively signal through two PDGF receptors (PDGFRs) to regulate diverse cellular functions. After two decades of searching, PDGF-A and B were the only ligands identified for PDGFRs. Recently, however, database mining has resulted in the discovery of a third member of the PDGF family PDGF-C-7,C-8, a functional analogue of PDGF-A that requires proteolytic activation. PDGF-A and PDGF-C selectively activate PDGFR-alpha (7,9,10) whereas PDGF-B activates both PDGFR-alpha and PDGFR-beta (9,11). Here we identify and characterize a new member of the PDGF family, PDGF D, which also requires proteolytic activation. Recombinant, purified PDGF-D induces DNA synthesis and growth in cells expressing PDGFRs. In cells expressing individual PDGFRs, PDGF-D binds to and activates PDGFR-beta but not PDGFR-alpha. However, in cells expressing both PDGFRs, PDGF-D activates both receptors. This indicates that PDGFR-alpha activation may result from PDGFR-alpha/beta heterodimerization.	Curagen Corp, New Haven, CT 06511 USA; COR Therapeut, S San Francisco, CA 94080 USA		LaRochelle, WJ (corresponding author), Curagen Corp, 555 Long Wharf Dr, New Haven, CT 06511 USA.							Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUCHER P, 1994, ISMB, V2, P53; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; Hamada T, 2000, FEBS LETT, V475, P97, DOI 10.1016/S0014-5793(00)01640-9; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Pignatelli D, 1998, HORM METAB RES, V30, P464, DOI 10.1055/s-2007-978915; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Thielens NM, 1999, IMMUNOPHARMACOLOGY, V42, P3, DOI 10.1016/S0162-3109(99)00019-3	21	300	333	1	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					517	521		10.1038/35074593	http://dx.doi.org/10.1038/35074593			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331882				2022-12-25	WOS:000168592500024
J	Ma, LL; Yamada, S; Wirtz, D; Coulombe, PA				Ma, LL; Yamada, S; Wirtz, D; Coulombe, PA			A 'hot-spot' mutation alters the mechanical properties of keratin filament networks	NATURE CELL BIOLOGY			English	Article							DYNAMIC CROSS-LINKING; EPIDERMOLYSIS-BULLOSA; POINT MUTATIONS; DISEASES	Keratins 5 and 14 polymerize to form the intermediate filament network in the progenitor basal cells of many stratified epithelia including epidermis, where it provides crucial mechanical support. Inherited mutations in K5 or K14 result in epidermolysis bullosa simplex (EBS), a skin-fragility disorder(1). The impact that such mutations exert on the intrinsic mechanical properties of K5/K14 filaments is unknown. Here we show, by using differential interference contrast microscopy, that a 'hot-spot' mutation in K14 greatly reduces the ability of reconstituted mutant filaments to bundle under crosslinking conditions. Rheological assays measure similar small-deformation mechanical responses for crosslinked solutions of wild-type and mutant keratins. The mutation, however, markedly reduces the resilience of crosslinked networks against large deformations. Single-particle tracking, which probes the local organization of filament networks, shows that the mutant polymer exhibits highly heterogeneous structures compared to those of wild-type filaments. Our results indicate that the fragility of epithelial cells expressing mutant keratin may result from an impaired ability of keratin polymers to be crosslinked into a functional network.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ma, LL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	coulombe@jhmi.edu	Yamada, Soichiro/B-7360-2019; Wirtz, Denis/A-3257-2010	Yamada, Soichiro/0000-0001-6413-0814; 				AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; [Anonymous], 1980, VISCOELASTIC PROPERT; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; CHAN YM, 1994, J CELL SCI, V107, P765; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Goldmann WH, 1997, EUR J BIOCHEM, V246, P373, DOI 10.1111/j.1432-1033.1997.00373.x; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; LeDuc P, 1999, NATURE, V399, P564, DOI 10.1038/21148; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; Ma LL, 1999, J BIOL CHEM, V274, P19145, DOI 10.1074/jbc.274.27.19145; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; Pulkkinen L, 1996, HUM MOL GENET, V5, P1539, DOI 10.1093/hmg/5.10.1539; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; WILSON AK, 1992, J CELL BIOL, V119, P401, DOI 10.1083/jcb.119.2.401; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	24	123	127	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					503	506		10.1038/35074576	http://dx.doi.org/10.1038/35074576			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331879				2022-12-25	WOS:000168592500021
J	Seoane, J; Pouponnot, C; Staller, P; Schader, M; Eilers, M; Massague, J				Seoane, J; Pouponnot, C; Staller, P; Schader, M; Eilers, M; Massague, J			TGF beta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15(INK4b)	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; C-MYC; GENE-EXPRESSION; POZ DOMAIN; TRANSCRIPTION; PROTEIN; REPRESSION; PROMOTER; ASSOCIATION	Transforming growth factor-beta (TGF beta) is a cytokine that arrests epithelial cell division by switching off the proto-oncogene c-myc and rapidly switching on cyclin-dependent kinase (CDK) inhibitors such as p15(INK4b). Gene responses to TGF beta involve Smad transcription factors that are directly activated by the TGF beta receptor. Why downregulation of c-myc expression by TGF beta is required for rapid activation of p15(INK4b) has remained unknown. Here we provide evidence that TGF beta signalling prevents recruitment of Myc to the p15(INK4b) transcriptional initiator by Myc-interacting zinc-finger protein 1 (Miz-1). This relieves repression and enables transcriptional activation by a TGF beta -induced Smad protein complex that recognizes an upstream p15(INK4b) promoter region and contacts Miz-1. Thus, two separate TGF beta -dependent inputs - Smad-mediated transactivation and relief of repression by Myc - keep tight control over p15(INK4b) activation.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	j-massague@ski.mskcc.org	Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974; Eilers, Martin/0000-0002-0376-6533; Massague, Joan/0000-0001-9324-8408				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLAASSEN GF, 2000, P NATL ACAD SCI US; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Dang CV, 1999, MOL CELL BIOL, V19, P1; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAA A, 2000, CELL, V100, P229; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu B, 1999, MOL CELL BIOL, V19, P424; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	47	387	406	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					400	408		10.1038/35070086	http://dx.doi.org/10.1038/35070086			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283614				2022-12-25	WOS:000168043900019
J	Mandel, H; Szargel, R; Labay, V; Elpeleg, O; Saada, A; Shalata, A; Anbinder, Y; Berkowitz, D; Hartman, C; Barak, M; Eriksson, S; Cohen, N				Mandel, H; Szargel, R; Labay, V; Elpeleg, O; Saada, A; Shalata, A; Anbinder, Y; Berkowitz, D; Hartman, C; Barak, M; Eriksson, S; Cohen, N			The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA	NATURE GENETICS			English	Article							MTDNA DEPLETION; LIVER; EXPRESSION; CLONING; LOCALIZATION; DEFECTS; CDNA	Mitochondrial DNA (mtDNA)-depletion syndromes (MDS; OMIM 251880) are phenotypically heterogeneous, autosomal-recessive disorders characterized by tissue-specific reduction in mtDNA copy number(1-8). Affected individuals with the hepatocerebral form of MDS have early progressive liver failure and neurological abnormalities, hypoglycemia and increased lactate in body fluids. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes (I, III, IV, V) and mtDNA depletion(1-4,8-13). We used homozygosity mapping in three kindreds of Druze origin to map the gene causing hepatocerebral MDS to a region of 6.1 cM on chromosome 2p13, between markers D2S291 and D2S2116. This interval encompasses the gene (DGUOK) encoding the mitochondrial deoxyguanosine kinase (dGK)(14-16). We identified a single-nucleotide deletion (204delA) within the coding region of DGUOK that segregates with the disease in the three kindreds studied. Western-blot analysis did not detect dGK protein in the liver of affected individuals. The main supply of deoxyribonucleotides (dNTPs) for mtDNA synthesis comes from the salvage pathway initiated by dGK and thymidine kinase-2 (TK2)(17-19). The association of mtDNA depletion with mutated DGUOK suggests that the salvage-pathway enzymes are involved in the maintenance of balanced mitochondrial dNTP pools.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Pediat,Metab Dis Unit, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Tamkin Human Mol Genet Res Facil, Dept Genet, IL-31096 Haifa, Israel; Shaare Zedek Med Ctr, Metab Dis Unit, Jerusalem, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Pediat Gastroenterol & Nutr Unit, IL-31096 Haifa, Israel; Western Galilee Med Ctr, Neonatal Intens Care Unit, Nahariyya, Israel; Swedish Univ Agr Sci, Dept Vet Med Chem, Uppsala, Sweden	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Western Galilee Hospital; Swedish University of Agricultural Sciences	Cohen, N (corresponding author), RW Johnson Pharmaceut Res Inst, 1000 Rd 202, Raritan, NJ 08869 USA.		Saada, Ann/J-6864-2017	Saada, Ann/0000-0003-2951-0656				ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Bakker HD, 1996, J PEDIATR-US, V128, P683, DOI 10.1016/S0022-3476(96)80135-1; BODNAR AG, 1993, AM J HUM GENET, V53, P663; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1; GIBLETT ER, 1976, NEW ENGL J MED, V295, P1375, DOI 10.1056/NEJM197612092952409; Gyapay Gabor, 1996, Methods (Orlando), V9, P91, DOI 10.1006/meth.1996.0012; Hirano M, 2000, BRAIN PATHOL, V10, P451; Jenuth JP, 1996, BIOCHEM CELL BIOL, V74, P219, DOI 10.1139/o96-022; Johansson M, 1996, GENOMICS, V38, P450, DOI 10.1006/geno.1996.0654; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; Jullig M, 2000, EUR J BIOCHEM, V267, P5466, DOI 10.1046/j.1432-1327.2000.01607.x; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; MAASWINKELMOOIJ PD, 1996, J PEDIATR, V128, P979; Marin-Garcia J, 2000, PEDIATR NEUROL, V22, P122, DOI 10.1016/S0887-8994(99)00117-4; MARRIOTI C, 1995, J NEUROL, V242, P547; MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X; MORAES CT, 1991, AM J HUM GENET, V48, P492; Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Shaag A, 1999, AM J MED GENET, V82, P177, DOI 10.1002/(SICI)1096-8628(19990115)82:2<177::AID-AJMG15>3.3.CO;2-0; Spelbrink JN, 1998, HUM GENET, V102, P327, DOI 10.1007/s004390050700; Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935; Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0	31	402	413	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2001	29	3					337	341		10.1038/ng746	http://dx.doi.org/10.1038/ng746			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687800				2022-12-25	WOS:000171911000023
J	Greaves, S				Greaves, S			Moving on up and down	NATURE CELL BIOLOGY			English	Article														Greaves, Sarah/0000-0001-7802-0261					0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					E228	E228		10.1038/ncb1001-e228	http://dx.doi.org/10.1038/ncb1001-e228			1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584282				2022-12-25	WOS:000171396400004
J	Koller, D; Ruedl, C; Loetscher, M; Vlach, J; Oehen, S; Oertle, K; Schirinzi, M; Deneuve, E; Moser, R; Kopf, M; Bailey, JE; Renner, W; Bachmann, MF				Koller, D; Ruedl, C; Loetscher, M; Vlach, J; Oehen, S; Oertle, K; Schirinzi, M; Deneuve, E; Moser, R; Kopf, M; Bailey, JE; Renner, W; Bachmann, MF			A high-throughput alphavirus-based expression cloning system for mammalian cells	NATURE BIOTECHNOLOGY			English	Article							SINDBIS-VIRUS; MOLECULAR-CLONING; GENE-EXPRESSION; VECTORS; EFFICIENT; RECEPTOR; ANTIGEN; CDNA; RNA	We have developed a widely applicable functional genomics strategy based on alphavirus expression vectors. The technology allows for rapid identification of genes encoding a functional activity such as binding of a defined ligand. Complementary DNA (cDNA) libraries were expressed in mammalian cells following infection with recombinant Sindbis virus (SIN replicon particles), a member of the Alphavirus genus. Virus-infected cells that specifically bound a ligand of choice were isolated using fluorescence-activated cell sorting (FACS). Replication-competent, infective SIN replicon particles harboring the corresponding cDNA were amplified in a next step. Within one round of selection, viral clones encoding proteins recognized by monoclonal antibodies or Fc-fusion molecules could be isolated and sequenced. Moreover, using the same viral libraries, a plaque-lift assay was established that allowed the identification of secreted, intracellular, and membrane proteins.	Cytos Biotechnol AG, CH-8952 Schlieren, Switzerland; Swiss Fed Inst Technol, Inst Biotechnol, Zurich, Switzerland; Basel Inst Immunol, Basel, Switzerland; IBR Inc, CH-9545 Waengi, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bachmann, MF (corresponding author), Cytos Biotechnol AG, Wagistr 21, CH-8952 Schlieren, Switzerland.	bachmann@cytos.com	Ruedl, christiane/A-2219-2011; Kopf, Manfred/B-6907-2009	Ruedl, christiane/0000-0002-5599-6541; Kopf, Manfred/0000-0002-0628-7140				ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Boutros M, 2000, NAT CELL BIOL, V2, pE53, DOI 10.1038/35008678; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Datwyler DA, 1999, J MOL MED, V77, P859, DOI 10.1007/s001099900071; Frolov I, 1999, J VIROL, V73, P3854, DOI 10.1128/JVI.73.5.3854-3865.1999; FROLOV I, 1994, J VIROL, V68, P8111, DOI 10.1128/JVI.68.12.8111-8117.1994; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; Gardner JP, 2000, J VIROL, V74, P11849, DOI 10.1128/JVI.74.24.11849-11857.2000; Granziero L, 1997, J IMMUNOL METHODS, V203, P131, DOI 10.1016/S0022-1759(97)00018-5; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JOHNSTON RE, 1974, J VIROL, V14, P1076, DOI 10.1128/JVI.14.5.1076-1082.1974; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Lever AML, 2000, CURR OPIN MOL THER, V2, P488; Lundstrom K, 1999, J RECEPT SIGNAL TR R, V19, P673, DOI 10.3109/10799899909036679; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; Onishi M, 1996, EXP HEMATOL, V24, P324; SEED B, 1995, CURR OPIN BIOTECH, V6, P567, DOI 10.1016/0958-1669(95)80094-8; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIMONSEN H, 1994, TRENDS PHARMACOL SCI, V15, P437, DOI 10.1016/0165-6147(94)90052-3; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; WEISS BG, 1991, J VIROL, V65, P4017, DOI 10.1128/JVI.65.8.4017-4025.1991; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607	27	22	33	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					851	855		10.1038/nbt0901-851	http://dx.doi.org/10.1038/nbt0901-851			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533644				2022-12-25	WOS:000170774000024
J	O'Brien, LE; Jou, TS; Pollack, AL; Zhang, QH; Hansen, SH; Yurchenco, P; Mostov, KE				O'Brien, LE; Jou, TS; Pollack, AL; Zhang, QH; Hansen, SH; Yurchenco, P; Mostov, KE			Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly	NATURE CELL BIOLOGY			English	Article							MDCK CELL POLARITY; BASEMENT-MEMBRANE; PLASMA-MEMBRANE; COLLAGEN OVERLAY; SMALL GTPASES; MORPHOGENESIS; INTEGRIN; POLYMERIZATION; PROTEINS; CYSTS	Cellular polarization involves the generation of asymmetry along an intracellular axis. In a multicellular tissue, the asymmetry of individual cells must conform to the overlying architecture of the tissue. However, the mechanisms that couple cellular polarization to tissue morphogenesis are poorly understood Here, we report that orientation of apical polarity in developing Madin-Darby canine kidney (MDCK) epithelial cysts requires the small GTPase Rac1 and the basement membrane component laminin. Dominant-negative Rac1 alters the supramolecular assembly of endogenous MDCK laminin and causes a striking inversion of apical polarity. Exogenous laminin is recruited to the surface of these cysts and rescues apical polarity. These findings implicate Racl-mediated laminin assembly in apical pole orientation. By linking apical orientation to generation of the basement membrane, epithelial cells ensure the coordination of polarity with tissue architecture.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Univ Arizona, Hlth Sci Ctr, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; University of Arizona; University of Arizona Health Sciences; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mostov, KE (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	mostov@itsa.ucsf.edu		mostov, keith/0000-0002-8123-6247; Hansen, Steen/0000-0002-9408-4676; JOU, TZUU-SHUH/0000-0003-4341-5137; Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Brown NH, 2000, DEV BIOL, V223, P1, DOI 10.1006/dbio.2000.9711; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; EKBLOM M, 1993, ANN NY ACAD SCI, V857, P194; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Knust E, 2000, CURR OPIN GENET DEV, V10, P471, DOI 10.1016/S0959-437X(00)00115-5; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LALLIER T, 1990, NEUROSCI RES, pS126, DOI 10.1016/0921-8696(90)90041-Z; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; MCATEER JA, 1988, SCANNING MICROSCOPY, V2, P1739; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Schuger L, 1998, INT J DEV BIOL, V42, P217; SCHWIMMER R, 1995, J CELL SCI, V108, P2487; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; THIERY G, 1995, J HISTOCHEM CYTOCHEM, V43, P1079, DOI 10.1177/43.10.7560886; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yang Y, 1998, DEVELOPMENT, V125, P2621; YAP AS, 1994, EXP CELL RES, V213, P319, DOI 10.1006/excr.1994.1205; YURCHENCO PD, 1994, METHOD ENZYMOL, V245, P489; Zuk A, 1996, J CELL SCI, V109, P1875	41	352	354	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					831	838		10.1038/ncb0901-831	http://dx.doi.org/10.1038/ncb0901-831			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533663				2022-12-25	WOS:000170979600017
J	Howorka, S; Cheley, S; Bayley, H				Howorka, S; Cheley, S; Bayley, H			Sequence-specific detection of individual DNA strands using engineered nanopores	NATURE BIOTECHNOLOGY			English	Article							PROTEIN PORE; POLYNUCLEOTIDE MOLECULES; POLYMER-CHAIN; SINGLE; CHANNEL; DISCRIMINATION; BIOSENSOR; TRANSPORT; MEMBRANES; ANALYTES	We describe biosensor elements that are capable of identifying individual DNA strands with single-base resolution. Each biosensor element consists of an individual DNA oligonucleotide covalently attached within the lumen of the cc-hemolysin (alpha HL) pore to form a "DNA-nanopore". The binding of single-stranded DNA (ssDNA) molecules to the tethered DNA strand causes changes in the ionic current flowing through a nanopore. On the basis of DNA duplex lifetimes. the DNA-nanopores are able to discriminate between individual DNA strands up to 30 nucleotides in length differing by a single base substitution. This was exemplified by the detection of a drug resistance-conferring mutation in the reverse transcriptase gene of HIV. In addition, the approach was used to sequence a complete codon in an individual DNA strand tethered to a nanopore.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Howorka, S (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.			Bayley, Hagan/0000-0003-2499-6116; Howorka, Stefan/0000-0002-6527-2846				ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; Cheley S, 1999, PROTEIN SCI, V8, P1257, DOI 10.1110/ps.8.6.1257; COREY DR, 1995, BIOCONJUGATE CHEM, V6, P93, DOI 10.1021/bc00031a011; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Gu LQ, 2001, SCIENCE, V291, P636, DOI 10.1126/science.291.5504.636; Henrickson SE, 2000, PHYS REV LETT, V85, P3057, DOI 10.1103/PhysRevLett.85.3057; Howorka S, 2000, J AM CHEM SOC, V122, P2411, DOI 10.1021/ja993221h; Hulteen JC, 1998, J AM CHEM SOC, V120, P6603, DOI 10.1021/ja980045o; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079; Movileanu L, 2000, NAT BIOTECHNOL, V18, P1091, DOI 10.1038/80295; Quake SR, 2000, SCIENCE, V290, P1536, DOI 10.1126/science.290.5496.1536; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rief M, 1999, NAT STRUCT BIOL, V6, P346; Schmidt C, 2000, ANGEW CHEM INT EDIT, V39, P3137, DOI 10.1002/1521-3773(20000901)39:17<3137::AID-ANIE3137>3.0.CO;2-D; SMITH SM, 1995, ENG APPL ARTIF INTEL, V8, P271, DOI 10.1016/0952-1976(95)00013-Q; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Stora T, 1999, ANGEW CHEM INT EDIT, V38, P389, DOI 10.1002/(SICI)1521-3773(19990201)38:3<389::AID-ANIE389>3.0.CO;2-U; Strunz T, 1999, P NATL ACAD SCI USA, V96, P11277, DOI 10.1073/pnas.96.20.11277; Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696	24	613	721	6	275	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					636	639		10.1038/90236	http://dx.doi.org/10.1038/90236			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433274				2022-12-25	WOS:000169677200018
J	Bremer, C; Tung, CH; Weissleder, R				Bremer, C; Tung, CH; Weissleder, R			In vivo molecular target assessment of matrix metalloproteinase inhibition	NATURE MEDICINE			English	Article							IV COLLAGENASE; TISSUE INHIBITORS; CATHEPSIN-B; CANCER; EXPRESSION; METASTASIS; GELATINASE; BLOOD; CELLS; SPECIFICITY	A number of different matrix metalloproteinase (MMP) inhibitors have been developed as cytostatic and anti-angiogenic agents and are currently in clinical testing. One major hurdle in assessing the efficacy of such drugs has been the inability to sense or image anti-proteinase activity directly and non-invasively in vivo. We show here that novel, biocompatible near-infrared fluorogenic MMP substrates can be used as activatable reporter probes to sense MMP activity in intact tumors in nude mice. Moreover, we show for the first time that the effect of MMP inhibition can be directly imaged using this approach within hours after initiation of treatment using the potent MMP inhibitor, prinomastat (AC3340). The developed probes, together with novel near-infrared fluorescence imaging technology will enable the detailed analysis of a number of proteinases critical for advancing the therapeutic use of clinical proteinase inhibitors.	Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University	Tung, CH (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.		Tung, Ching-Hsuan/AIE-6009-2022; Tung, Ching-Hsuan/AHC-5070-2022	Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; /0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [R33CA088365, R21CA088365] Funding Source: NIH RePORTER; NCI NIH HHS [CA088365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWN PD, 1990, CANCER RES, V50, P6184; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Callahan RJ, 1998, AM J ROENTGENOL, V171, P137, DOI 10.2214/ajr.171.1.9648777; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chance B, 1998, ANN NY ACAD SCI, V838, P29, DOI 10.1111/j.1749-6632.1998.tb08185.x; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIES B, 1993, CANCER RES, V53, P5365; Drummond AH, 1999, ANN NY ACAD SCI, V878, P228, DOI 10.1111/j.1749-6632.1999.tb07688.x; Erlichman C, 2001, ANN ONCOL, V12, P389, DOI 10.1023/A:1011183905848; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Giraudon P, 1997, MOL PSYCHIATR, V2, P107, DOI 10.1038/sj.mp.4000218; Haq M, 2000, CANCER RES, V60, P3207; HOISKIN BP, 1995, ANAL BIOCHEM, V227, P148; Ishiguro N, 1999, J RHEUMATOL, V26, P34; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Lozonschi L, 1999, CANCER RES, V59, P1252; Maekawa R, 1999, CANCER RES, V59, P1231; Mahmood U, 1999, RADIOLOGY, V213, P866, DOI 10.1148/radiology.213.3.r99dc14866; Marecos E, 1998, BIOCONJUGATE CHEM, V9, P184, DOI 10.1021/bc970146w; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Moses MA, 1998, CANCER RES, V58, P1395; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; STEARNS ME, 1993, CANCER RES, V53, P878; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Tung CH, 2000, CANCER RES, V60, P4953; Tung CH, 1999, BIOCONJUGATE CHEM, V10, P892, DOI 10.1021/bc990052h; Van Noorden CJF, 1998, CLIN EXP METASTAS, V16, P159; VanNoorden CJF, 1997, ANAL BIOCHEM, V252, P71, DOI 10.1006/abio.1997.2312; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543; Wojtowicz-Praga S, 1998, J CLIN ONCOL, V16, P2150, DOI 10.1200/JCO.1998.16.6.2150; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x; Zucker S, 1999, ANN NY ACAD SCI, V878, P208, DOI 10.1111/j.1749-6632.1999.tb07686.x	43	587	632	1	116	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					743	748		10.1038/89126	http://dx.doi.org/10.1038/89126			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385514				2022-12-25	WOS:000169081500045
J	Stewart, GR; Snewin, VA; Walzl, G; Hussell, T; Tormay, P; O'Gaora, P; Goyal, M; Betts, J; Brown, IN; Young, DB				Stewart, GR; Snewin, VA; Walzl, G; Hussell, T; Tormay, P; O'Gaora, P; Goyal, M; Betts, J; Brown, IN; Young, DB			Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection	NATURE MEDICINE			English	Article							STREPTOMYCES-ALBUS-G; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; MOLECULAR CHAPERONES; STRESS PROTEINS; FUSION PROTEINS; GENE; DNAK; MICE; INDUCTION	Elevated expression of heat-shock proteins (HSPs) can benefit a microbial pathogen struggling to penetrate host defenses during infection, but at the same time might provide a crucial signal alerting the host immune system to its presence. To determine which of these effects predominate, we constructed a mutant strain of Mycobacterium tuberculosis that constitutively overexpresses Hsp70 proteins. Although the mutant was fully virulent in the initial stage of infection, it was significantly impaired in its ability to persist during the subsequent chronic phase. Induction of microbial genes encoding HSPs might provide a novel strategy to boost the immune response of individuals with latent tuberculosis infection.	Univ London Sch Pharm, Dept Microbiol & Infect Dis, London, England; Univ London Sch Pharm, Dept Biochem, Ctr Mol Microbiol & Infect, London, England; Univ Hertfordshire, Dept Biosci, Hatfield AL10 9AB, Herts, England; GlaxoSmithKline, Stevenage, Herts, England	University of London; University College London; University of London School of Pharmacy; University of London; University College London; University of London School of Pharmacy; University of Hertfordshire; GlaxoSmithKline	Stewart, GR (corresponding author), Univ London Sch Pharm, Dept Microbiol & Infect Dis, London, England.		Hussell, Tracy/O-4630-2014; O'Gaora, Peadar/F-9400-2011; Walzl, Gerhard/N-6371-2016	Hussell, Tracy/0000-0001-7186-6141; O'Gaora, Peadar/0000-0002-6417-7054; Stewart, Graham/0000-0002-6867-6248; Walzl, Gerhard/0000-0003-2487-125X; Goyal, Madhu/0000-0001-7921-4586				Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baldwin SL, 1998, INFECT IMMUN, V66, P2951, DOI 10.1128/IAI.66.6.2951-2959.1998; BLUM P, 1992, J BACTERIOL, V174, P7436, DOI 10.1128/jb.174.22.7436-7444.1992; Bucca G, 2000, MOL MICROBIOL, V38, P1093, DOI 10.1046/j.1365-2958.2000.02194.x; BUCCA G, 1997, J BACTERIOL, V179, pS999; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X; COHEN IR, 1991, IMMUNOL TODAY, V12, P105, DOI 10.1016/0167-5699(91)90093-9; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; De Smet KAL, 1999, MICROBIOL-UK, V145, P3177, DOI 10.1099/00221287-145-11-3177; Dussurget O, 2001, INFECT IMMUN, V69, P529, DOI 10.1128/IAI.69.1.529-533.2001; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Grandvalet C, 1997, MOL MICROBIOL, V23, P77, DOI 10.1046/j.1365-2958.1997.1811563.x; Grandvalet C, 1999, MOL MICROBIOL, V31, P521, DOI 10.1046/j.1365-2958.1999.01193.x; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x; Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403; LEE BY, 1995, J CLIN INVEST, V96, P245, DOI 10.1172/JCI118028; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Manabe YC, 1999, P NATL ACAD SCI USA, V96, P12844, DOI 10.1073/pnas.96.22.12844; Mangan JA, 1997, NUCLEIC ACIDS RES, V25, P675, DOI 10.1093/nar/25.3.675; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; MEHLERT A, 1989, MOL MICROBIOL, V3, P125, DOI 10.1111/j.1365-2958.1989.tb01801.x; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Parish T, 1997, MICROBIOL-UK, V143, P2267, DOI 10.1099/00221287-143-7-2267; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; Pelicic V, 1996, J BACTERIOL, V178, P1197, DOI 10.1128/jb.178.4.1197-1199.1996; Qoronfleh MW, 1998, INFECT IMMUN, V66, P3024, DOI 10.1128/IAI.66.6.3024-3027.1998; Rhoades ER, 1997, TUBERCLE LUNG DIS, V78, P57, DOI 10.1016/S0962-8479(97)90016-2; Simmons CP, 2001, J IMMUNOL, V166, P1106, DOI 10.4049/jimmunol.166.2.1106; Spohn G, 1999, MOL MICROBIOL, V34, P663, DOI 10.1046/j.1365-2958.1999.01625.x; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; VANBOGELEN RA, 1987, GENE DEV, V1, P525, DOI 10.1101/gad.1.6.525; Wu SC, 1998, J BACTERIOL, V180, P2830, DOI 10.1128/JB.180.11.2830-2835.1998; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG DB, 1991, INFECT IMMUN, V59, P3086, DOI 10.1128/IAI.59.9.3086-3093.1991	45	118	121	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					732	737		10.1038/89113	http://dx.doi.org/10.1038/89113			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385512				2022-12-25	WOS:000169081500043
J	Hofmann, TG; Moller, A; Sirma, H; Zentgraf, H; Taya, Y; Droge, W; Will, H; Schmitz, ML				Hofmann, TG; Moller, A; Sirma, H; Zentgraf, H; Taya, Y; Droge, W; Will, H; Schmitz, ML			Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2	NATURE CELL BIOLOGY			English	Article							P53-REGULATED GENE-EXPRESSION; CREB BINDING-PROTEIN; DNA-DAMAGE; NUCLEAR-BODIES; SERINE/THREONINE KINASE; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTORS; PREMATURE SENESCENCE; POTENTIAL MEDIATOR; TUMOR-SUPPRESSOR	Transcriptional activity of p53, a central regulatory switch in a network controlling cell proliferation and apoptosis, is modulated by protein stability and post-translational modifications including phosphorylation and acetylation. Here we demonstrate that the human serine/threonine kinase homeodomain-interacting protein kinase-2 (HIPK2) colocalizes and interacts with p53 and CREB-binding protein (CBP) within promyelocytic leukaemia (PML) nuclear bodies. HIPK2 is activated by ultraviolet (UV) radiation and selectively phosphorylates p53 at Ser 46, thus facilitating the CBP-mediated acetylation of p53 at Lys 382, and promoting p53-dependent gene expression. Accordingly, the kinase function of HIPK2 mediates the increased expression of p53 target genes, which results in growth arrest and the enhancement of UV-induced apoptosis. Interference with HIPK2 expression by antisense oligonucleotides impairs UV-induced apoptosis. Our results imply that HIPK2 is a novel regulator of p53 effector functions involved in cell growth, proliferation and apoptosis.	German Canc Res Ctr, Div Immunochem G0200, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Appl Tumour Virol, D-69120 Heidelberg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany; Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Pette Institute; National Cancer Center - Japan	Hofmann, TG (corresponding author), Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	l.schmitz@dkfz.de	Schmitz, M. Lienhard/D-9328-2017; Möller, Andreas/O-1063-2015	Schmitz, M. Lienhard/0000-0002-6984-7192; Möller, Andreas/0000-0002-8618-6998				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	48	490	508	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					1	10		10.1038/ncb715	http://dx.doi.org/10.1038/ncb715			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11740489				2022-12-25	WOS:000173381500009
J	El-Assal, SED; Alonso-Blanco, C; Peeters, AJM; Raz, V; Koornneef, M				El-Assal, SED; Alonso-Blanco, C; Peeters, AJM; Raz, V; Koornneef, M			A QTL for flowering time in Arabidopsis reveals a novel allele of CRY2	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCUS; THALIANA; TOMATO; PROTEINS; MUTANTS; GENE; PHOTORECEPTORS; AGROBACTERIUM; CRYPTOCHROMES; DEFICIENT	Variation of flowering time is found in the natural populations of many plant species. The underlying genetic variation, mostly of a quantitative nature, is presumed to reflect adaptations to different environments contributing to reproductive success. Analysis of natural variation for flowering time in Arabidopsis thaliana has identified several quantitative trait loci (QTL)(1), which have yet to be characterized at the molecular level. A major environmental factor that determines flowering time is photoperiod or day length, the length of the light period, which changes across the year differently with geographical latitude(2). We identified the EDI locus as a QTL partly accounting for the difference in flowering response to the photoperiod between two Arabidopsis accessions: the laboratory strain Landsberg erecta (Ler), originating in Northern Europe, and Cvi, collected in the tropical Cape Verde Islands(3). Positional cloning of the EDI QTL showed it to be a novel allele of CRY2, encoding the blue-light photoreceptor cryptochrome-2 that has previously been shown to promote flowering in long-day (LD) photoperiods(4). We show that the unique EDI flowering phenotype results from a single amino-acid substitution that reduces the light-induced downregulation of CRY2 in plants grown under Short photoperiods, leading to early flowering.	Univ Wageningen & Res Ctr, Genet Lab, NL-6703 HA Wageningen, Netherlands; Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Utrecht, Dept Plant Ecophysiol, NL-3584 CA Utrecht, Netherlands; Univ Wageningen & Res Ctr, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Utrecht University; Wageningen University & Research	Koornneef, M (corresponding author), Univ Wageningen & Res Ctr, Genet Lab, Dreijenlaan 2, NL-6703 HA Wageningen, Netherlands.	maarten.koornneef@genetics.dpw.wau.nl	Alonso-Blanco, Carlos/F-8864-2016; Peeters, Anton J.M./B-9610-2011	Alonso-Blanco, Carlos/0000-0002-4738-5556; Koornneef, Maarten/0000-0002-7759-4869				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Alonso-Blanco C, 1998, GENETICS, V149, P749; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Chou IT, 1997, PLANT MOL BIOL, V35, P873, DOI 10.1023/A:1005930024796; Devlin PF, 2000, PLANT CELL, V12, P2499, DOI 10.1105/tpc.12.12.2499; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; Fridman E, 2000, P NATL ACAD SCI USA, V97, P4718, DOI 10.1073/pnas.97.9.4718; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; JANSEN RC, 1995, THEOR APPL GENET, V91, P33, DOI 10.1007/BF00220855; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; KARLSSON BH, 1993, AM J BOT, V80, P646, DOI 10.2307/2445435; Kliebenstein DJ, 2001, PLANT CELL, V13, P681, DOI 10.1105/tpc.13.3.681; KOORNNEEF M, 1995, PHYSIOL PLANTARUM, V95, P260, DOI 10.1111/j.1399-3054.1995.tb00836.x; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Maloof JN, 2001, NAT GENET, V29, P441, DOI 10.1038/ng777; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Mizoguchi T, 2000, TRENDS PLANT SCI, V5, P409, DOI 10.1016/S1360-1385(00)01747-7; Mockler TC, 1999, DEVELOPMENT, V126, P2073; Neff MM, 1998, PLANT J, V14, P387, DOI 10.1046/j.1365-313X.1998.00124.x; PETERS JL, 1992, PHOTOCHEM PHOTOBIOL, V56, P75, DOI 10.1111/j.1751-1097.1992.tb09605.x; Raz V, 1999, DEVELOPMENT, V126, P3661; SESSA G, 1995, PLANT MOL BIOL, V28, P537, DOI 10.1007/BF00020400; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Swarup K, 1999, PLANT J, V20, P67, DOI 10.1046/j.1365-313X.1999.00577.x; Takahashi Y, 2001, P NATL ACAD SCI USA, V98, P7922, DOI 10.1073/pnas.111136798; Thomas B., 1997, PHOTOPERIODISM PLANT; VANTUINEN A, 1995, MOL GEN GENET, V246, P133, DOI 10.1007/BF00294675; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473	36	299	314	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2001	29	4					435	440		10.1038/ng767	http://dx.doi.org/10.1038/ng767			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726930				2022-12-25	WOS:000172507500019
J	Kwon, CH; Zhu, XY; Zhang, JY; Knoop, LL; Tharp, R; Smeyne, RJ; Eberhart, CG; Burger, PC; Baker, SJ				Kwon, CH; Zhu, XY; Zhang, JY; Knoop, LL; Tharp, R; Smeyne, RJ; Eberhart, CG; Burger, PC; Baker, SJ			Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease	NATURE GENETICS			English	Article							CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; SIGNALING PATHWAY; PROSTATE-CANCER; COWDEN-SYNDROME; PTEN(+/-) MICE; GLIOMA-CELLS; GENE; EXPRESSION; PTEN/MMAC1	Somatic inactivation of PTEN occurs in different human tumors including glioblastoma, endometrial carcinoma and prostate carcinoma. Germline mutations in PTEN result in a range of phenotypic abnormalities that occur with variable penetrance, including neurological features such as macrocephaly, seizures, ataxia and Lhermitte-Duclos disease (also described as dysplastic gangliocytoma of the cerebellum). Homozygous deletion of Pten causes embryonic lethality in mice. To investigate function in the brain, we used Cre-loxP technology to selectively inactivate Pten in specific mouse neuronal populations. Loss of Pten resulted in progressive macrocephaly and seizures. Neurons lacking Pten expressed high levels of phosphorylated Akt and showed a progressive increase in soma size without evidence of abnormal proliferation. Cerebellar abnormalities closely resembled the histopathology of human Lhermitte-Duclos disease. These results indicate that Pten regulates neuronal size in vivo in a cell-autonomous manner and provide new insights into the etiology of Lhermitte-Duclos disease.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University	Baker, SJ (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale, Memphis, TN 38105 USA.	suzanne.baker@stjude.org	Baker, Suzanne J/N-8167-2018; Kwon, Chang-hyuk/E-3450-2011		NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71907, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheyney IW, 1999, CANCER RES, V59, P2318; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Furnari FB, 1998, CANCER RES, V58, P5002; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Goldowitz D, 2000, J NEUROSCI, V20, P4129; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Huang H, 1999, DEVELOPMENT, V126, P5365; Iida S, 1998, INT J MOL MED, V1, P925; KUHAR SG, 1993, DEVELOPMENT, V117, P97; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Marcus CD, 1996, NEURORADIOLOGY, V38, P529; Marino S, 2000, GENE DEV, V14, P994; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; MUCKE L, 1991, NEW BIOL, V3, P465; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RAINOV NG, 1995, CLIN NEUROL NEUROSUR, V97, P175, DOI 10.1016/0303-8467(95)00017-E; Robinson S, 2000, NEUROSURGERY, V46, P371, DOI 10.1097/00006123-200002000-00021; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stambolic V, 2000, CANCER RES, V60, P3605; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Tuli S, 1997, CAN J NEUROL SCI, V24, P155, DOI 10.1017/S031716710002151X; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; VINCHON M, 1994, J NEUROL NEUROSUR PS, V57, P699, DOI 10.1136/jnnp.57.6.699; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhu XY, 2001, CANCER RES, V61, P4569; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	50	342	356	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2001	29	4					404	411		10.1038/ng781	http://dx.doi.org/10.1038/ng781			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726927				2022-12-25	WOS:000172507500015
J	Maloof, JN; Borevitz, JO; Dabi, T; Lutes, J; Nehring, RB; Redfern, JL; Trainer, GT; Wilson, JM; Asami, T; Berry, CC; Weigel, D; Chory, J				Maloof, JN; Borevitz, JO; Dabi, T; Lutes, J; Nehring, RB; Redfern, JL; Trainer, GT; Wilson, JM; Asami, T; Berry, CC; Weigel, D; Chory, J			Natural variation in light sensitivity of Arabidopsis	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCUS; PHYTOCHROME; EVOLUTION; RESPONSES; THALIANA; SURFACE; PROTEIN; PLANTS; SHADE; SIZE	Because plants depend on light for growth, their development and physiology must suit the particular light environment. Plants native to different environments show heritable, apparently adaptive, changes in their response to light(1,2). As a first step in unraveling the genetic and molecular basis of these naturally occurring differences, we have characterized intraspecific variation in a light-dependent developmental process-seedling emergence. We examined 141 Arabidopsis thaliana accessions for their response to four light conditions, two hormone conditions and darkness. There was significant variation in all conditions, confirming that Arabidopsis is a rich source of natural genetic diversity. Hierarchical clustering revealed that some accessions had response patterns similar to known photoreceptor mutants, suggesting changes in specific signaling pathways. We found that the unusual far-red response of the Lm-2 accession is due to a single amino-acid change in the phytochrome A (PHYA) protein. This change stabilizes the light-labile PHYA protein in light and causes a 100-fold shift in the threshold for far-red light sensitivity. Purified recombinant Lm-2 PHYA also shows subtle photochemical differences and has a reduced capacity for autophosphorylation. These biochemical changes contrast with previously characterized natural alleles in loci controlling plant development, which result in altered gene expression or loss of gene function(3-9).	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Calif San Diego, Dept Family Prevent Med, La Jolla, CA 92093 USA; Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany	Salk Institute; Howard Hughes Medical Institute; Salk Institute; RIKEN; University of California System; University of California San Diego; Max Planck Society	Weigel, D (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022; Borevitz, Justin/B-5423-2012	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Borevitz, Justin/0000-0001-8408-3699; Maloof, Julin/0000-0002-9623-2599	NIGMS NIH HHS [GM52413, GM08666] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso-Blanco C, 1999, P NATL ACAD SCI USA, V96, P4710, DOI 10.1073/pnas.96.8.4710; Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Asami T, 1999, TRENDS PLANT SCI, V4, P348, DOI 10.1016/S1360-1385(99)01456-9; Briggs WR, 2001, PLANT CELL, V13, P993, DOI 10.1105/tpc.13.5.993; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Clough RC, 1997, PLANT CELL ENVIRON, V20, P713, DOI 10.1046/j.1365-3040.1997.d01-107.x; Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; DUDLEY SA, 1995, FUNCT ECOL, V9, P655, DOI 10.2307/2390158; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELASSAL SE, 2001, NATURE GENET, V29; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; Fridman E, 2000, P NATL ACAD SCI USA, V97, P4718, DOI 10.1073/pnas.97.9.4718; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; JOHNSON FS, 1976, PHOTOCHEM PHOTOBIOL, V23, P179, DOI 10.1111/j.1751-1097.1976.tb07239.x; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LOPEZJUEZ E, 1992, PLANT CELL, V4, P241, DOI 10.1105/tpc.4.3.241; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Murphy JT, 1997, PHOTOCHEM PHOTOBIOL, V65, P750, DOI 10.1111/j.1751-1097.1997.tb01920.x; NAGATANI A, 1984, PLANT CELL PHYSIOL, V25, P1059; Neff MM, 2000, GENE DEV, V14, P257; Pinheiro J, 2001, MIXED EFFECTS MODELS; ROBERTSON A, 1959, BIOMETRICS, V15, P469, DOI 10.2307/2527750; Schmitt J, 1999, AM NAT, V154, pS43, DOI 10.1086/303282; Schumacher K, 1999, GENE DEV, V13, P3259, DOI 10.1101/gad.13.24.3259; Sharbel TF, 2000, MOL ECOL, V9, P2109, DOI 10.1046/j.1365-294X.2000.01122.x; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	30	217	226	0	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2001	29	4					441	446		10.1038/ng777	http://dx.doi.org/10.1038/ng777			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	498JZ	11726931				2022-12-25	WOS:000172507500020
J	Wolf, D; Witte, V; Laffert, B; Blume, K; Stromer, E; Trapp, S; D'Aloja, P; Schurmann, A; Baur, AS				Wolf, D; Witte, V; Laffert, B; Blume, K; Stromer, E; Trapp, S; D'Aloja, P; Schurmann, A; Baur, AS			HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals	NATURE MEDICINE			English	Article							PROTEIN-KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; IMMUNODEFICIENCY VIRUS NEF; MIDDLE-T-ANTIGEN; RHESUS MACAQUES; TYPE-1 NEF; CELLS; COMPLEX; DEATH; GENE	A highly conserved signaling property of Nef proteins encoded by human or simian immunodeficiency virus is the binding and activation of a PAK kinase whose function is unclear. Here we show that Nef-mediated p2l-activated kinase (PAK) activation involves phosphatidylinositol 3-kinase, which acts upstream of PAK and is bound and activated by Nef similar to the manner of Polyoma virus middle T antigen. The Nef-associated phosphatidylinositol-3-PAK complex phosphorylated the pro-apoptotic Bad protein without involving the protein kinase B-Akt kinase, which is generally believed to inactivate Bad by serine phosphorylation. Consequently, Nef, but not a Nef mutant incapable of activating PAK, blocked apoptosis in T cells induced by serum starvation or HIV replication. Nef anti-apoptotic effects are likely a crucial mechanism for viral replication in the host and thus in AIDS pathogenesis.	Univ Erlangen Nurnberg, Dept Dermatol Erlangen, Erlangen, Germany; Rhein Westfal TH Aachen, Inst Pharmakol & Toxikol, D-5100 Aachen, Germany	University of Erlangen Nuremberg; RWTH Aachen University	Baur, AS (corresponding author), Univ Erlangen Nurnberg, Dept Dermatol Erlangen, Erlangen, Germany.	andreas.baur@derma.med.uni-erlangen.de		Schurmann, Annette/0000-0002-4113-4377; d'aloja, paola/0000-0001-5780-0277				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arold ST, 2001, TRENDS BIOCHEM SCI, V26, P356, DOI 10.1016/S0968-0004(01)01846-1; Arora VK, 2000, J VIROL, V74, P11081, DOI 10.1128/JVI.74.23.11081-11087.2000; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Boulanger E, 1998, ANN BIOL CLIN-PARIS, V56, P643; BRADLY AD, 2000, BLOOD, V96, P2951; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Dahl J, 1998, J VIROL, V72, P3221, DOI 10.1128/JVI.72.4.3221-3226.1998; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hinton HJ, 1999, J IMMUNOL, V162, P7002; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Khan IH, 1998, J VIROL, V72, P5820, DOI 10.1128/JVI.72.7.5820-5830.1998; Kim YH, 1999, VIROLOGY, V257, P208, DOI 10.1006/viro.1999.9642; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Lang SM, 1997, NAT MED, V3, P860, DOI 10.1038/nm0897-860; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Lu XB, 1996, CURR BIOL, V6, P1677, DOI 10.1016/S0960-9822(02)70792-6; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Meinl E, 1998, IMMUNOL TODAY, V19, P474, DOI 10.1016/S0167-5699(98)01309-7; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wijkander J, 1997, J BIOL CHEM, V272, P21520, DOI 10.1074/jbc.272.34.21520; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	47	235	245	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1217	1224		10.1038/nm1101-1217	http://dx.doi.org/10.1038/nm1101-1217			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689886				2022-12-25	WOS:000172054100029
J	Daly, MJ; Rioux, JD; Schaffner, SE; Hudson, TJ; Lander, ES				Daly, MJ; Rioux, JD; Schaffner, SE; Hudson, TJ; Lander, ES			High-resolution haplotype structure in the human genome	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; MAXIMUM-LIKELIHOOD; SEQUENCE VARIATION; REGION; COMPLEX; GENE; IDENTIFICATION; RECOMBINATION; PROMOTER	Linkage disequilibrium (LD) analysis is traditionally based on individual genetic markers and often yields an erratic, nonmonotonic picture, because the power to detect allelic associations depends on specific properties of each marker, such as frequency and population history. Ideally, LD analysis should be based directly on the underlying haplotype structure of the human genome, but this structure has remained poorly understood. Here we report a high-resolution analysis of the haplotype structure across 500 kilobases. on chromosome 5q31 using 103 single-nucleotide polymorphisms (SNPs) in a European-derived population. The results show a picture of discrete haplotype blocks (of tens to hundreds of kilobases), each with limited diversity punctuated by apparent sites of recombination. In addition, we develop an analytical model for LID mapping based on such haplotype blocks. If our observed structure is general (and published data suggest that it may be), it offers a coherent framework for creating a haplotype map of the human genome.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; McGill Univ, Montreal Genome Ctr, Montreal, PQ, Canada; MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University; Massachusetts Institute of Technology (MIT)	Daly, MJ (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	mjdaly@genome.wi.mit.edu; lander@wi.mit.edu	Daly, Mark J/B-2453-2017; Rioux, John D/A-9599-2015	Daly, Mark J/0000-0002-0949-8752; Rioux, John D/0000-0001-7560-8326; Schaffner, Stephen/0000-0001-6699-3568				Bonnen PE, 2000, AM J HUM GENET, V67, P1437, DOI 10.1086/316908; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; D'Alfonso S, 2000, GENES IMMUN, V1, P231, DOI 10.1038/sj.gene.6363666; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; HEDRICK PW, 1987, GENETICS, V117, P331; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Jordanides N, 2000, GENES IMMUN, V1, P451, DOI 10.1038/sj.gene.6363699; Krawczak M, 1998, AM J HUM GENET, V63, P474, DOI 10.1086/301965; KRUGLYAK L, 1995, AM J HUM GENET, V56, P1212; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEWONTIN RC, 1964, GENETICS, V49, P49; Moffatt MF, 2000, HUM MOL GENET, V9, P1011, DOI 10.1093/hmg/9.7.1011; Nachman MW, 2000, GENETICS, V156, P297; Park HY, 2000, CLIN EXP PHARMACOL P, V27, P690, DOI 10.1046/j.1440-1681.2000.03321.x; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Smith A, 1998, PHARM SCI TECHNOL TO, V1, P92, DOI 10.1016/S1461-5347(98)00027-3; SVED J A, 1971, Theoretical Population Biology, V2, P125; Templeton AR, 2000, AM J HUM GENET, V66, P69, DOI 10.1086/302699	25	1257	1367	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2001	29	2					229	232		10.1038/ng1001-229	http://dx.doi.org/10.1038/ng1001-229			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586305				2022-12-25	WOS:000171374100033
J	Loi, P; Ptak, G; Barboni, B; Fulka, J; Cappai, P; Clinton, M				Loi, P; Ptak, G; Barboni, B; Fulka, J; Cappai, P; Clinton, M			Genetic rescue of an endangered mammal by cross-species nuclear transfer using post-mortem somatic cells	NATURE BIOTECHNOLOGY			English	Article							FETAL; CYTOPLASM; EMBRYOS; CLONING; CATTLE; MICE	Since the advent of procedures for cloning animals, conservation biologists have proposed using this technology to preserve endangered mammals. Here we report the successful cloning of a wild endangered animal, Ovis orientalis musimon, using oocytes collected from a closely related, domesticated species, Ovis aries. We injected enucleated sheep oocytes with granulosa cells collected from two female mouflons found dead in the pasture. Blastocyst-stage cloned embryos transferred into sheep foster mothers established two pregnancies, one of which produced an apparently normal mouflon. Our findings support the use of cloning for the expansion of critically endangered populations.	Agr Univ Krakow, Dept Anim Reprod, Krakow, Poland; Inst Anim Prod, Prague, Czech Republic; Inst Zootech, Sassari, Italy; Roslin Inst, Dept Gene Express & Dev, Edinburgh, Midlothian, Scotland	Agricultural University Krakow; Czech Research Institute of Animal Science; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute		loi@ifv.vet.unite.it		Ptak, Grazyna/0000-0003-1437-4698				Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Corley-Smith GE, 1999, MOL REPROD DEV, V53, P363, DOI 10.1002/(SICI)1098-2795(199907)53:3&lt;363::AID-MRD12&gt;3.0.CO;2-0; Dominko T, 1999, BIOL REPROD, V60, P1496, DOI 10.1095/biolreprod60.6.1496; Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Galli C, 1999, Cloning, V1, P161, DOI 10.1089/15204559950019924; HANSET R, 1974, ANN MED VET, V119, P71; HILTONTAYLOR C, 2000, 2000 2UCN RED LIST T; JAMIESON A, 1994, ANIM GENET, V25, P37, DOI 10.1111/j.1365-2052.1994.tb00401.x; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; KENNETH L, 2001, CURR BIOL, V11, pRU245; Kikyo N, 2000, J CELL SCI, V113, P11; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Lanza R P, 2000, Cloning, V2, P79, DOI 10.1089/152045500436104; Loi P, 1998, BIOL REPROD, V58, P1177, DOI 10.1095/biolreprod58.5.1177; Margules CR, 2000, NATURE, V405, P243, DOI 10.1038/35012251; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Ptak G, 1999, BIOL REPROD, V61, P1568, DOI 10.1095/biolreprod61.6.1568; Ryder OA, 2000, SCIENCE, V288, P275, DOI 10.1126/science.288.5464.275; Steinborn R, 2000, NAT GENET, V25, P255, DOI 10.1038/77000; Visscher PM, 2001, NATURE, V409, P303, DOI 10.1038/35053160; Vogel G, 2001, SCIENCE, V291, P409; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; White K L, 1999, Cloning, V1, P47, DOI 10.1089/15204559950020085; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	26	294	354	0	108	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					962	964		10.1038/nbt1001-962	http://dx.doi.org/10.1038/nbt1001-962			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581663				2022-12-25	WOS:000171417600025
J	Miyagawa, Y; Tamoi, M; Shigeoka, S				Miyagawa, Y; Tamoi, M; Shigeoka, S			Overexpression of a cyanobacterial fructose-1,6-/sedoheptulose-1,7-bisphosphatase in tobacco enhances photosynthesis and growth	NATURE BIOTECHNOLOGY			English	Article							SUCROSE-PHOSPHATE SYNTHASE; TRANSGENIC TOBACCO; CO2 ASSIMILATION; ANTISENSE RNA; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; MOLECULAR CHARACTERIZATION; HYDROGEN-PEROXIDE; RUBISCO ACTIVASE; POTATO PLANTS; REDUCTION	Transgenic tobacco plants expressing a cyanobacterial fructose-1,6/sedoheptulose-1, 7-bisphosphatase targeted to chloroplasts show enhanced photosynthetic efficiency and growth characteristics under atmospheric conditions (360 p.p.m. CO2). Compared with wild-type tobacco, final dry matter and photosynthetic CO2 fixation of the transgenic plants were 1.5-fold and 1.24-fold higher, respectively. Transgenic tobacco also showed a 1.2-fold increase in initial activity of ribulose 1,5 bisphosphate carboxylase/oxygenase (Rubisco) compared with wild-type plants. Levels of intermediates in the Calvin cycle and the accumulation of carbohydrates were also higher than those in wild-type plants. This is the first report in which expression of a single plastid-targeted enzyme has been shown to improve carbon fixation and growth in transgenic plants.	Kinki Univ, Grad Sch Adv Life Sci, Nara 6318505, Japan; Kinki Univ, Fac Agr, Dept Food & Nutr, Nara 6318505, Japan	Kindai University (Kinki University); Kindai University (Kinki University)	Shigeoka, S (corresponding author), Kinki Univ, Grad Sch Adv Life Sci, Nara 6318505, Japan.		Tamoi, Masahiro/AAJ-1054-2021					BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Fridlyand LE, 1999, PHOTOSYNTH RES, V61, P227, DOI 10.1023/A:1006342812049; FROMMER WB, 1995, J EXP BOT, V46, P587, DOI 10.1093/jxb/46.6.587; GALTIER N, 1993, PLANT PHYSIOL, V101, P535, DOI 10.1104/pp.101.2.535; Haake V, 1998, PLANT J, V14, P147, DOI 10.1046/j.1365-313X.1998.00089.x; Harrison EP, 1998, PLANTA, V204, P27, DOI 10.1007/s004250050226; Huber SC, 1996, ANNU REV PLANT PHYS, V47, P431, DOI 10.1146/annurev.arplant.47.1.431; HUDSON GS, 1992, PLANT PHYSIOL, V98, P294, DOI 10.1104/pp.98.1.294; KOSSMANN J, 1994, PLANT J, V6, P637, DOI 10.1046/j.1365-313X.1994.6050637.x; Leegood R. C., 1993, P247; LIN TP, 1988, PLANT PHYSIOL, V86, P1131, DOI 10.1104/pp.86.4.1131; Ludewig F, 1998, FEBS LETT, V429, P147, DOI 10.1016/S0014-5793(98)00580-8; Miyagawa Y, 2000, PLANT CELL PHYSIOL, V41, P311, DOI 10.1093/pcp/41.3.311; Olcer H, 2001, PLANT PHYSIOL, V125, P982, DOI 10.1104/pp.125.2.982; PAUL MJ, 1995, PLANT J, V7, P535, DOI 10.1046/j.1365-313X.1995.7040535.x; Poolman MG, 2001, EUR J BIOCHEM, V268, P2810, DOI 10.1046/j.1432-1327.2001.02153.x; PORTIS AR, 1995, J EXP BOT, V46, P1285, DOI 10.1093/jxb/46.special_issue.1285; PRICE GD, 1995, PLANTA, V195, P369, DOI 10.1007/BF00202594; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; SALVUCCI ME, 1985, PHOTOSYNTH RES, V7, P193, DOI 10.1007/BF00037012; Sharkey T. D., 1998, P111; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; STITT M, 1994, PLANT CELL ENVIRON, V17, P465, DOI 10.1111/j.1365-3040.1994.tb00144.x; STITT M, 1995, ANNU REV PLANT PHYS, V46, P341, DOI 10.1146/annurev.pp.46.060195.002013; SUGITA M, 1987, MOL GEN GENET, V209, P247, DOI 10.1007/BF00329650; Tamoi M, 1998, BBA-PROTEIN STRUCT M, V1383, P232, DOI 10.1016/S0167-4838(97)00208-2; Tamoi M, 1996, ARCH BIOCHEM BIOPHYS, V334, P27, DOI 10.1006/abbi.1996.0425; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; WOODROW IE, 1993, PLANTA, V191, P421, DOI 10.1007/BF00195743	30	238	290	3	55	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					965	969		10.1038/nbt1001-965	http://dx.doi.org/10.1038/nbt1001-965			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581664				2022-12-25	WOS:000171417600026
J	Mourez, M; Kane, RS; Mogridge, J; Metallo, S; Deschatelets, P; Sellman, BR; Whitesides, GM; Collier, RJ				Mourez, M; Kane, RS; Mogridge, J; Metallo, S; Deschatelets, P; Sellman, BR; Whitesides, GM; Collier, RJ			Designing a polyvalent inhibitor of anthrax toxin	NATURE BIOTECHNOLOGY			English	Article							PROTECTIVE ANTIGEN; LETHAL FACTOR; TRANSLOCATION	Screening peptide libraries is a proven strategy for identifying inhibitors of protein-ligand interactions. Compounds identified in these screens often bind to their targets with low affinities. When the target protein is present at a high density on the surface of cells or other biological surfaces, it is sometimes possible to increase the biological activity of a weakly binding ligand by presenting multiple copies of it on the same molecule. We isolated a peptide from a phage display library that binds weakly to the heptameric cell-binding subunit of anthrax toxin and prevents the interaction between cell-binding and enzymatic moieties. A molecule consisting of multiple copies of this nonnatural peptide, covalently linked to a flexible backbone, prevented assembly of the toxin complex in vitro and blocked toxin action in an animal model. This result demonstrates that protein-protein interactions can be inhibited by a synthetic, polymeric, polyvalent inhibitor in vivo.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	jcollier@hms.harvard.edu		Collier, R John/0000-0002-2427-4239				ARORA N, 1993, J BIOL CHEM, V268, P3334; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; Gordon EJ, 1998, NATURE, V392, P30, DOI 10.1038/32073; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; MAMMEN M, 1995, J MED CHEM, V38, P4179, DOI 10.1021/jm00021a007; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; MATROSOVICH MN, 1990, FEBS LETT, V272, P209, DOI 10.1016/0014-5793(90)80486-3; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rao JH, 1998, SCIENCE, V280, P708, DOI 10.1126/science.280.5364.708; SPATTENSTEIN A, 1991, J AM CHEM SOC, V113, P686; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	24	236	255	1	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					958	961		10.1038/nbt1001-958	http://dx.doi.org/10.1038/nbt1001-958			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581662				2022-12-25	WOS:000171417600024
J	Wilkinson, CRM; Seeger, M; Hartmann-Petersen, R; Stone, M; Wallace, M; Semple, C; Gordon, C				Wilkinson, CRM; Seeger, M; Hartmann-Petersen, R; Stone, M; Wallace, M; Semple, C; Gordon, C			Proteins containing the UBA domain are able to bind to multi-ubiquitin chains	NATURE CELL BIOLOGY			English	Article							SCHIZOSACCHAROMYCES-POMBE; PROTEASE SUBUNIT; 26S PROTEASOME; DNA-REPAIR; GENE; PATHWAY; COMPONENT	The UBA domain is a motif found in a variety of proteins, some of which are associated with the ubiquitin-proteasome system(1,2). We describe the isolation of a fission-yeast gene, mud1(+), which encodes a UBA domain containing protein that is able to bind multi-ubiquitin chains. We show that the UBA domain is responsible for this activity. Two other proteins containing this motif, the fission-yeast homologues of Rad23 and Dsk2, are also shown to bind multi-ubiquitin chains via their UBA domains. These two proteins are implicated, along with the fission-yeast Pus1(S5a/Rpn10) subunit of the 26 S proteasome, in the recognition and turnover of substrates by this proteolytic complex.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Gordon, C (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	colin.gordon@hgu.mrc.ac.uk	Hartmann-Petersen, Rasmus/K-4434-2014; Semple, Colin A M/A-5613-2009	Hartmann-Petersen, Rasmus/0000-0002-4155-7791; Semple, Colin A M/0000-0003-1765-4118				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dubiel W, 1999, CURR BIOL, V9, pR554, DOI 10.1016/S0960-9822(99)80353-4; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; He XW, 1998, J CELL SCI, V111, P1635; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Lombaerts M, 2000, BIOCHEM BIOPH RES CO, V268, P210, DOI 10.1006/bbrc.2000.2100; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Sambrook J., 2000, MOL CLONING, V3rd; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weiss C, 1997, OPT EXPRESS, V1, P272, DOI 10.1364/OE.1.000272; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182	21	339	353	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					939	943		10.1038/ncb1001-939	http://dx.doi.org/10.1038/ncb1001-939			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584278				2022-12-25	WOS:000171396400021
J	Kaushal, S; Amiel, GE; Guleserian, KJ; Shapira, OM; Perry, T; Sutherland, FW; Rabkin, E; Moran, AM; Schoen, FJ; Atala, A; Soker, S; Bischoff, J; Mayer, JE				Kaushal, S; Amiel, GE; Guleserian, KJ; Shapira, OM; Perry, T; Sutherland, FW; Rabkin, E; Moran, AM; Schoen, FJ; Atala, A; Soker, S; Bischoff, J; Mayer, JE			Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo	NATURE MEDICINE			English	Article							NITRIC-OXIDE; STRESS; DIFFERENTIATION; INHIBITION; RELAXATION; EXPRESSION; RETENTION; ADHESION; ARTERIES; GRAFTS	Arterial conduits are increasingly preferred for surgical bypass because of inherent functional properties conferred by arterial endothelial cells, especially nitric oxide production in response to physiologic stimuli. Here we tested whether endothelial progenitor cells (EPCs) can replace arterial endothelial cells and promote patency in tissue-engineered small-diameter blood vessels (4 mm). We isolated EPCs from peripheral blood of sheep, expanded them ex vivo and then seeded them on decellularized porcine iliac vessels. EPC-seeded grafts remained patent for 130 days as a carotid interposition graft in sheep, whereas non-seeded grafts occluded within 15 days. The EPC-explanted grafts exhibited contractile activity and nitric-oxide-mediated vascular relaxation that were similar to native carotid arteries. These results indicate that EPCs can function similarly to arterial endothelial cells and thereby confer longer vascular-graft survival. Due to their unique properties, EPCs might have other general applications for tissue-engineered structures and in treating vascular diseases.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiac Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Childrens Hosp, Dept Urol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Cardiothorac Surg, Boston, MA 02118 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Boston University	Bischoff, J (corresponding author), Childrens Hosp, Dept Surg, Boston, MA 02115 USA.	joyce.bischoff@tch.harvard.edu	BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974; Atala, Anthony/0000-0001-8186-2160; Aikawa, Elena/0000-0001-7835-2135	NHLBI NIH HHS [R01 HL60463, R01 HL60490, R01 HL060490-04, R01 HL060490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060490, R01HL060463] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Dardik A, 1999, J VASC SURG, V29, P157, DOI 10.1016/S0741-5214(99)70357-5; DAVIDS L, 1999, TISSUE ENG PROSTHETI, P3; DEUTSCH M, 1999, TISSUE ENG PROSTHETI, P180; Gehling UM, 2000, BLOOD, V95, P3106; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; KEANEY JF, 1995, PROG CARDIOVASC DIS, V38, P129, DOI 10.1016/S0033-0620(05)80003-9; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; KUBES P, 1994, AM J PHYSIOL, V267, pH931, DOI 10.1152/ajpheart.1994.267.3.H931; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; MIYATA T, 1991, J SURG RES, V50, P485, DOI 10.1016/0022-4804(91)90029-L; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; ORTENWALL P, 1988, SURGERY, V103, P199; PEARSON PJ, 1992, ANN THORAC SURG, V54, P1078, DOI 10.1016/0003-4975(92)90073-D; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; ROSENMAN JE, 1985, J VASC SURG, V2, P778, DOI 10.1067/mva.1985.avs0020778; Schmidt CE, 2000, BIOMATERIALS, V21, P2215, DOI 10.1016/S0142-9612(00)00148-4; Shapira OM, 1999, CIRCULATION, V100, P322; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Sullivan S. J., 2000, PRINCIPLES TISSUE EN, P447; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012	41	669	742	4	92	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1035	1040		10.1038/nm0901-1035	http://dx.doi.org/10.1038/nm0901-1035			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533707	Green Accepted			2022-12-25	WOS:000170853300029
J	Miller, HL				Miller, HL			The Bush administration deals a blow to biotechnology - and itself	NATURE BIOTECHNOLOGY			English	Editorial Material																		[Anonymous], 1992, Nature, V356, P1; *COUNC AGR SCI TEC, 1998, 10 COUNC AGR SCI TEC; *I FOOD TECHN, 1996, APPR OV PLANTS INH T; *US NAT RES COUNC, 1989, FIELD TEST GEN MOD O	4	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					807	808		10.1038/nbt0901-807	http://dx.doi.org/10.1038/nbt0901-807			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533629				2022-12-25	WOS:000170774000011
J	Furstenthal, L; Swanson, C; Kaiser, BK; Eldridge, AG; Jackson, PK				Furstenthal, L; Swanson, C; Kaiser, BK; Eldridge, AG; Jackson, PK			Triggering ubiquitination of a CDK inhibitor at origins of DNA replication	NATURE CELL BIOLOGY			English	Article							DEPENDENT KINASE INHIBITOR; CYCLIN-E; S-PHASE; RECOGNITION COMPLEX; PROTEIN; DEGRADATION; NEDD8; CENTROSOME; P27(KIP1); BINDING	To ensure proper timing of the G1-S transition in the cell cycle, the cyclin E-Cdk2 complex, which is responsible for the initiation of DNA replication, is restrained by the p21(Cip1)/p27(Kip1)/p57(Kip2) family of CDK (cyclin-dependent kinase) inhibitors in humans and by the related p27(Xic1) protein in Xenopus. Activation of cyclin E-Cdk2 is linked to the ubiquitination of human p27(Kip1) or Xenopus p27(Xic1) by SCF (for Skp1-Cullin-F-box protein) ubiquitin ligases. For human p27(Kip1), ubiquitination requires direct phosphorylation by cyclin E-Cdk2. We show here that Xic1 ubiquitination does not require phosphorylation by cyclin E-Cdk2, but it does require nuclear accumulation of the Xic1-cyclin E-Cdk2 complex and recruitment of this complex to chromatin by the origin-recognition complex together with Cdc6 replication preinitiation factors; it also requires an activation step necessitating cyclin E-Cdk2-kinase and SCF ubiquitin-ligase activity, and additional factors associated with mini-chromosome maintenance proteins, including the inactivation of geminin. Components of the SCF ubiquitin-ligase complex, including Skp1 and Cul1, are also recruited to chromatin through cyclin E-Cdk2 and the preinitiation complex. Thus, activation of the cyclin E-Cdk2 kinase and ubiquitin-dependent destruction of its inhibitor are spatially constrained to the site of a properly assembled preinitiation complex.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University	Jackson, PK (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr,MC 5324, Stanford, CA 94305 USA.	pjackson@stanford.edu		Jackson, Peter/0000-0002-1742-2539				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chuang LC, 2001, J BIOL CHEM, V276, P1610, DOI 10.1074/jbc.M008896200; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; Hartley RS, 1997, DEV BIOL, V188, P312, DOI 10.1006/dbio.1997.8647; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Jares P, 2000, GENE DEV, V14, P1528; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	51	62	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					715	722		10.1038/35087026	http://dx.doi.org/10.1038/35087026			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483956				2022-12-25	WOS:000170393200016
J	Xu, T; Bajjalieh, SM				Xu, T; Bajjalieh, SM			SV2 modulates the size of the readily releasable pool of secretory vesicles	NATURE CELL BIOLOGY			English	Article							ADRENAL CHROMAFFIN CELLS; SNARE COMPLEX; NEUROTRANSMITTER RELEASE; MEMBRANE-FUSION; SYNAPTIC EXOCYTOSIS; KINETIC COMPONENTS; SYNAPTOTAGMIN-I; PROTEIN; CA2+; SYNTAXIN	The exocytosis of neurotransmitters is regulated by calcium and is plastic - features that suggest specialized regulation of the basic membrane trafficking process. Here we show that Synaptic Vesicle Protein 2 (SV2), a protein specific to neurons and endocrine cells, is required to maintain a pool of vesicles available for calcium-stimulated exocytosis. Direct measures of exocytosis in adrenal chromaffin cells showed that the calcium-induced exocytotic burst, which operationally defines the readily releasable pool of vesicles, was significantly reduced in mice lacking SV2A. Burst kinetics were normal in cells from MA knockout animals, however, indicating that SV2 functions before the final events of fusion. Analyses of SDS-resistant SNARE (soluble NSF (N-ethylmaleimide-sensitive fusion) attachment protein receptor) complexes in brain tissue showed that loss of SV2A was associated with fewer SDS-resistant complexes. Our observations indicate that SV2 may modulate the formation of protein complexes required for fusion and therefore the progression of vesicles to a fusion-competent state.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bajjalieh, SM (corresponding author), Huazhong Univ Sci & Technol, Sch Life Sci, Wuhan 430074, Peoples R China.		Xu, Tao/G-5474-2010					Bajjalieh SM, 1999, CURR OPIN NEUROBIOL, V9, P321, DOI 10.1016/S0959-4388(99)80047-6; BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Gillis K. D., 1995, SINGLE CHANNEL RECOR; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; ISHIZUKA T, 1995, BIOCHEM BIOPH RES CO, V213, P1107, DOI 10.1006/bbrc.1995.2241; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Janz R, 1999, NEUROSCIENCE, V94, P1279, DOI 10.1016/S0306-4522(99)00370-X; Janz R, 1998, J NEUROSCI, V18, P9269; Janz R, 1999, NEURON, V24, P1003, DOI 10.1016/S0896-6273(00)81046-6; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINIAL M, 1993, TRENDS BIOCHEM SCI, V18, P248, DOI 10.1016/0968-0004(93)90173-K; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Lonart G, 2000, J BIOL CHEM, V275, P27703; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Pyle RA, 2000, J BIOL CHEM, V275, P17195, DOI 10.1074/jbc.M000674200; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1997, BIOPHYS J, V73, P532, DOI 10.1016/S0006-3495(97)78091-3; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	53	163	171	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					691	698		10.1038/35087000	http://dx.doi.org/10.1038/35087000			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483953				2022-12-25	WOS:000170393200013
J	Chen, P; Hao, WS; Rife, L; Wang, XP; Shen, DW; Chen, J; Ogden, T; Van Boemel, GB; Wu, LY; Yang, M; Fong, HKW				Chen, P; Hao, WS; Rife, L; Wang, XP; Shen, DW; Chen, J; Ogden, T; Van Boemel, GB; Wu, LY; Yang, M; Fong, HKW			A photic visual cycle of rhodopsin regeneration is dependent on Rgr	NATURE GENETICS			English	Letter							PIGMENT-EPITHELIUM; VITAMIN-A; OPSIN HOMOLOG; RETINOCHROME; CHROMOPHORE; ISOMERS; RETINA; EYE	During visual excitation, rhodopsin undergoes photoactivation and bleaches to opsin and all-trans-retinal(1,2). To regenerate rhodopsin and maintain normal visual sensitivity, the all-trans isomer must be metabolized and reisomerized to produce the chromophore 11-cis-retinal in biochemical steps that constitute the visual cycle and involve the retinal pigment epithelium (RPE; refs, 3-8). A key step in the visual cycle is isomerization of an all-trans retinoid to 11-cis-retinol in the RPE (refs, 9-11). It could be that the retinochrome-like opsins. peropsin, or the retinal G protein-coupled receptor (RGR) opsin12-16 are isomerases in the RPE. In contrast to visual pigments. RGR is bound predominantly to endogenous all-transretinal, and irradiation of RGR in vitro results in stereospecific conversion of the bound all-trans isomer to 11-cis-retinal(17). Here we show that RGR is involved in the formation of 11-cis-retinal in mice and functions in a light-dependent pathway of the rod visual cycle. Mutations in the human gene encoding RGR are associated with retinitis pigmentosa(18).	Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Doheny Eye Inst, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Doheny Eye Institute	Fong, HKW (corresponding author), Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.				NEI NIH HHS [EY08364, EY03040] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY003040, R01EY008364] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; CHEN P, 2001, J BIOL CHEM     0327; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; GROENENDIJK GWT, 1980, BIOCHIM BIOPHYS ACTA, V617, P430, DOI 10.1016/0005-2760(80)90009-0; Hao WS, 1996, BIOCHEMISTRY-US, V35, P6251, DOI 10.1021/bi952420k; Hao WS, 1999, J BIOL CHEM, V274, P6085, DOI 10.1074/jbc.274.10.6085; HUBBARD R, 1952, J GEN PHYSIOL, V36, P269, DOI 10.1085/jgp.36.2.269; JIANG M, 1993, INVEST OPHTH VIS SCI, V34, P3669; LANDERS GM, 1990, METHOD ENZYMOL, V189, P70; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496; OZAKI K, 1986, VISION RES, V26, P691, DOI 10.1016/0042-6989(86)90083-0; OZAKI K, 1983, BIOPHYS J, V44, P127, DOI 10.1016/S0006-3495(83)84285-4; PANDEY S, 1994, EXP EYE RES, V58, P605, DOI 10.1006/exer.1994.1055; RANDO RR, 1991, J BIOENERG BIOMEMBR, V23, P133; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Stryer L, 1991, Harvey Lect, V87, P129; Tao L, 1998, Mol Vis, V4, P25; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6; [No title captured]	25	143	145	1	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					256	260		10.1038/90089	http://dx.doi.org/10.1038/90089			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431696				2022-12-25	WOS:000169656400018
J	Kibar, Z; Vogan, KJ; Groulx, N; Justice, MJ; Underhill, DA; Gros, P				Kibar, Z; Vogan, KJ; Groulx, N; Justice, MJ; Underhill, DA; Gros, P			Ltap, a mammalian homolog of Drosophila Strabismus/Van Gogh, is altered in the mouse neural tube mutant Loop-tail	NATURE GENETICS			English	Letter							CONVERGENT EXTENSION MOVEMENTS; TISSUE POLARITY; MESSENGER-RNA; PDZ DOMAINS; DEFECTS; GASTRULATION; RECOGNITION; EXPRESSION; VICINITY; MUTATION	Neural tube defects (NTDs) such as spina bifida and anencephaly are common congenital malformations in humans (1/1,000 births) that result from failure of the neural tube to close during embryogenesis(1,2). The etiology of NTDs is complex, with both genetic and environmental contributions; the genetic component has been extensively studied with mouse models(3). Loop-tail (Lp) is a semidominant mutation on mouse chromosome 1 (ref. 4). In the two known Lp alleles (Lp. Lp(m1Jus)), heterozygous mice exhibit a characteristic looped tail, and homozygous embryos show a completely open neural tube in the hindbrain and spinal region, a condition similar to the severe craniorachischisis defect in humans(4-6). Morphological and neural patterning studies indicate a role for the Lp gene product in controlling early morphogenesis and patterning of both axial midline structures and the developing neural plate(7). The 0.6-cM/0.7-megabase (Mb) Lp interval is delineated proximally by D1Mit113/Apoa2/Fcer1g and distally by Fcer1a/D1Mit149/Spna1 and contains a minimum of 17 transcription units(8-11). One of these genes, Ltap, encodes a homolog of Drosophila Strabismus/Van Gogh (Stbm/Vang), a component of the frizzled/dishevelled tissue polarity pathway(12-14). Ltap is expressed broadly in the neuroectoderm throughout early neurogenesis and is altered in two independent Lp alleles, identifying this gene as a strong candidate for Lp.	McGill Univ, Dept Biochem, Montreal, PQ, Canada; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada	McGill University; Harvard University; Harvard Medical School; Baylor College of Medicine; University of Alberta	Gros, P (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.			Vogan, Kyle/0000-0001-9565-9665; Underhill, Darrell/0000-0003-0957-7407	NCI NIH HHS [P01 CA75719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; CAMPBELL LR, 1986, TERATOLOGY, V34, P171, DOI 10.1002/tera.1420340206; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; Djiane A, 2000, DEVELOPMENT, V127, P3091; Doudney K, 2001, GENOMICS, V72, P180, DOI 10.1006/geno.2000.6463; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gerrelli D, 1997, DEV BRAIN RES, V102, P217, DOI 10.1016/S0165-3806(97)00099-0; Greene NDE, 1998, MECH DEVELOP, V73, P59, DOI 10.1016/S0925-4773(98)00029-X; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; Kibar Z, 2001, GENOMICS, V72, P331, DOI 10.1006/geno.2000.6493; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MULLICK A, 1995, GENOMICS, V26, P479, DOI 10.1016/0888-7543(95)80166-J; SMITH LJ, 1962, J EMBRYOL EXP MORPH, V10, P73; Sokol S, 2000, NAT CELL BIOL, V2, pE124, DOI 10.1038/35017136; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEIN KF, 1953, J HERED, V44, P59, DOI 10.1093/oxfordjournals.jhered.a106356; STRONG LC, 1949, J HERED, V40, P329, DOI 10.1093/oxfordjournals.jhered.a105976; Taylor MF, 1998, ANTISENSE NUCLEIC A, V8, P199, DOI 10.1089/oli.1.1998.8.199; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Underhill DA, 1999, GENOMICS, V55, P185, DOI 10.1006/geno.1998.5643; Underhill DA, 2000, MAMM GENOME, V11, P633, DOI 10.1007/s003350010118; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILSON DB, 1992, ACTA ANAT, V143, P89; Wolff T, 1998, DEVELOPMENT, V125, P1149	30	388	395	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					251	255		10.1038/90081	http://dx.doi.org/10.1038/90081			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431695				2022-12-25	WOS:000169656400017
J	Nestle, FO; Banchereau, J; Hart, D				Nestle, FO; Banchereau, J; Hart, D			Dendritic cells: On the move from bench to bedside	NATURE MEDICINE			English	Editorial Material							CANCER-IMMUNOTHERAPY; PROSTATE-CANCER; METASTATIC MALIGNANCIES; PEPTIDE VACCINATION; MELANOMA PATIENTS; ANTIGEN; IMMUNITY; MATURE; INJECTION; VACCINES		Mater Med Res Inst, S Brisbane, Qld, Australia; Univ Zurich, Dept Dermatol, Sch Med, Zurich, Switzerland; Baylor Inst Immunol Res, Dallas, TX USA	Mater Research; University of Zurich; Baylor Scott & White Health	Hart, D (corresponding author), Mater Med Res Inst, S Brisbane, Qld, Australia.							Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANCHEREAU J, 2000, J EXP MED, V192; Barratt-Boyes SM, 2000, J IMMUNOL, V164, P2487, DOI 10.4049/jimmunol.164.5.2487; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Boczkowski D, 2000, CANCER RES, V60, P1028; CLARK GJ, 1998, DENDRITIC CELLS BIOL, P555; Dhodapkar MV, 2000, J CLIN INVEST, V105, pR9, DOI 10.1172/JCI9051; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Eggert AAO, 1999, CANCER RES, V59, P3340; Feuerstein B, 2000, J IMMUNOL METHODS, V245, P15, DOI 10.1016/S0022-1759(00)00269-6; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; Fong L, 2001, J IMMUNOL, V166, P4254, DOI 10.4049/jimmunol.166.6.4254; Gilboa E, 1998, CANCER IMMUNOL IMMUN, V46, P82, DOI 10.1007/s002620050465; HART DN, 2000, LEUCOCYTE TYPING, V7; Hart DNJ, 1999, IMMUNOL CELL BIOL, V77, P451, DOI 10.1046/j.1440-1711.1999.00859.x; Heiser A, 2001, CANCER RES, V61, P3388; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Kammula US, 2000, J NATL CANCER I, V92, P1336, DOI 10.1093/jnci/92.16.1336; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lodge PA, 2000, CANCER RES, V60, P829; Lotze MT, 1997, ADV EXP MED BIOL, V417, P551; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; MCGUCKIN MA, 2000, LEUCOCYTE TYPING, V7; Morse MA, 1999, CLIN CANCER RES, V5, P1331; Morse MA, 1999, CANCER RES, V59, P56; Murphy GP, 1999, PROSTATE, V38, P73; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Panelli MC, 2000, J IMMUNOL, V164, P495, DOI 10.4049/jimmunol.164.1.495; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romero P, 1998, MOL MED TODAY, V4, P305, DOI 10.1016/S1357-4310(98)01280-5; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Serody JS, 2000, J IMMUNOL, V164, P4961, DOI 10.4049/jimmunol.164.9.4961; Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894; Thomas R, 1999, MELANOMA RES, V9, P474, DOI 10.1097/00008390-199910000-00007; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Timmerman JM, 1999, ANNU REV MED, V50, P507; Toes REM, 1998, J IMMUNOL, V160, P4449; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7	44	242	269	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					761	765		10.1038/89863	http://dx.doi.org/10.1038/89863			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433329				2022-12-25	WOS:000169808600014
J	Antonny, B; Madden, D; Hamamoto, S; Orci, L; Schekman, R				Antonny, B; Madden, D; Hamamoto, S; Orci, L; Schekman, R			Dynamics of the COPII coat with GTP and stable analogues	NATURE CELL BIOLOGY			English	Article							ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; ACTIVATING PROTEIN; BINDING-PROTEIN; VESICLE FORMATION; FACTOR-I; TRANSPORT; COMPLEX; CARGO; HYDROLYSIS	We have developed an assay to monitor the assembly of the COPII coat onto liposomes in real time. We show that with Sar1pGTP bound to liposomes, a single round of assembly and disassembly of the COPII coat lasts a few seconds. The two large COPII complexes Sec23/24p and Sec13/31p bind almost instantaneously (in less than 1 s) to Sar1pGTP-doped liposomes. This binding is followed by a fast (less than 10 s) disassembly due to a 10-fold acceleration of the GTPase-activating protein activity of Sec23/24p by the Sec13/31p complex. Experiments with the phosphate analogue BeFx suggest that Sec23/24p provides residues directly involved in GTP hydrolysis on Sar1p.	Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Geneva, Dept Morphol, Ctr Med Univ, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Antonny, Bruno/ABH-7434-2020	Antonny, Bruno/0000-0002-9166-8668				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Happe S, 2000, TRAFFIC, V1, P342, DOI 10.1034/j.1600-0854.2000.010407.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Malsam J, 1999, FEBS LETT, V462, P267, DOI 10.1016/S0014-5793(99)01543-4; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Pepperkok R, 2000, J CELL SCI, V113, P135; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; VANHOLDE DE, 1985, PHYSICAL BIOCH; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	30	220	231	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					531	537		10.1038/35078500	http://dx.doi.org/10.1038/35078500			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389436				2022-12-25	WOS:000169194400007
J	Matzke, R; Jacobson, K; Radmacher, M				Matzke, R; Jacobson, K; Radmacher, M			Direct, high-resolution measurement of furrow stiffening during division of adherent cells	NATURE CELL BIOLOGY			English	Article							ATOMIC-FORCE MICROSCOPE; ELASTIC PROPERTIES; CONTRACTILE RING; ACTIN-FILAMENTS; ANIMAL-CELLS; CYTOKINESIS; MECHANISM	It is unclear whether cell division is driven by cortical relaxation outside the equatorial region or cortical contractility within the developing furrow alone. To approach this question, a technique is required that can monitor spatially-resolved changes in cortical stiffness with good time resolution. We employed atomic force microscopy (AFM), in force-mapping mode, to track dynamic changes in the stiffness of the cortex of adherent cultured cells along a single scan-line during M phase, from metaphase to cytokinesis. Video microscopy, which we used to correlate the AFM data with mitotic events identified by light microscopy, indicated that the AFM force-mapping technique does not perturb dividing cells. Here we show that cortical stiffening occurs over the equatorial region about 160 seconds before any furrow appears, and that this stiffening markedly increases as the furrow starts. By contrast, polar relaxation of cells does not seem to be an obligatory event for cell division to occur.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ Munich, Ctr Nanosci, D-80799 Munich, Germany; Univ Gottingen, Drittes Phys Inst, D-37073 Gottingen, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Munich; University of Gottingen	Jacobson, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	frap@med.unc.edu	Jacobson, Kenneth Alan/A-1530-2009; Radmacher, Manfred/A-3956-2012	Jacobson, Kenneth Alan/0000-0001-8104-1493; Radmacher, Manfred/0000-0001-8744-4541				BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; CAO LG, 1990, J CELL BIOL, V111, P1905, DOI 10.1083/jcb.111.5.1905; Cao LG, 1996, MOL BIOL CELL, V7, P225, DOI 10.1091/mbc.7.2.225; Domke J, 1998, LANGMUIR, V14, P3320, DOI 10.1021/la9713006; Domke J, 2000, COLLOID SURFACE B, V19, P367, DOI 10.1016/S0927-7765(00)00145-4; Dvorak JA, 1998, EXP CELL RES, V242, P69, DOI 10.1006/excr.1998.4077; FISHKIND DJ, 1993, J CELL BIOL, V123, P837, DOI 10.1083/jcb.123.4.837; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; Glotzer M, 1997, CURR OPIN CELL BIOL, V9, P815, DOI 10.1016/S0955-0674(97)80082-8; Green RA, 2012, ANNU REV CELL DEV BI, V28, P29, DOI 10.1146/annurev-cellbio-101011-155718; HARRIS AK, 1994, NATO ADV SCI INST SE, V84, P37; RADMACHER M, 1994, BIOPHYS J, V66, P2159, DOI 10.1016/S0006-3495(94)81011-2; Radmacher M, 1996, BIOPHYS J, V70, P556, DOI 10.1016/S0006-3495(96)79602-9; Radmacher M, 1997, IEEE ENG MED BIOL, V16, P47, DOI 10.1109/51.582176; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Rotsch C, 1999, P NATL ACAD SCI USA, V96, P921, DOI 10.1073/pnas.96.3.921; Sanger JM, 2000, MICROSC RES TECHNIQ, V49, P190, DOI 10.1002/(SICI)1097-0029(20000415)49:2<190::AID-JEMT12>3.0.CO;2-B; Sneddon IN., 1965, INT J ENG SCI, V3, P47, DOI [10.1016/0020-7225(65)90019-4, DOI 10.1016/0020-7225(65)90019-4, 10.1016/0020-7225(65)90019-4.477, DOI 10.1016/0020-7225(65)90019-4.477]; WHITE JG, 1983, J THEOR BIOL, V101, P289, DOI 10.1016/0022-5193(83)90342-9; Wolf WA, 1999, CELL MOL LIFE SCI, V55, P108, DOI 10.1007/s000180050274; WOLPERT L, 1960, INT REV CYTOL, V10, P163	23	248	265	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					607	610		10.1038/35078583	http://dx.doi.org/10.1038/35078583			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389447				2022-12-25	WOS:000169194400018
J	Oosthuyse, B; Moons, L; Storkebaum, E; Beck, H; Nuyens, D; Brusselmans, K; Van Dorpe, J; Hellings, P; Gorselink, M; Heymans, S; Theilmeier, G; Dewerchin, M; Laudenbach, V; Vermylen, P; Raat, H; Acker, T; Vleminckx, V; Van den Bosch, L; Cashman, N; Fujisawa, H; Drost, MR; Sciot, R; Bruyninckx, F; Hicklin, DJ; Ince, C; Gressens, P; Lupu, F; Plate, KH; Robberecht, W; Herbert, JM; Collen, D; Carmeliet, P				Oosthuyse, B; Moons, L; Storkebaum, E; Beck, H; Nuyens, D; Brusselmans, K; Van Dorpe, J; Hellings, P; Gorselink, M; Heymans, S; Theilmeier, G; Dewerchin, M; Laudenbach, V; Vermylen, P; Raat, H; Acker, T; Vleminckx, V; Van den Bosch, L; Cashman, N; Fujisawa, H; Drost, MR; Sciot, R; Bruyninckx, F; Hicklin, DJ; Ince, C; Gressens, P; Lupu, F; Plate, KH; Robberecht, W; Herbert, JM; Collen, D; Carmeliet, P			Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration	NATURE GENETICS			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; FACTOR MESSENGER-RNA; SPINAL-CORD; INDUCIBLE FACTOR-1; FACTOR EXPRESSION; MODEL; VEGF; MECHANISMS; BINDING; ANGIOGENESIS	Hypoxia stimulates angiogenesis through the binding of hypoxia-inducible factors to the hypoxia-response element in the vascular endothelial growth factor (Vegf) promotor. Here, we report that deletion of the hypoxia-response element in the Vegf promotor reduced hypoxic Vegf expression in the spinal cord and caused adult-onset progressive motor neuron degeneration, reminiscent of amyotrophic lateral sclerosis, The neurodegeneration seemed to be due to reduced neural vascular perfusion. In addition. Vegf(165) promoted survival of motor neurons during hypoxia through binding to Vegf receptor 2 and neuropilin 1. Acute ischemia is known to cause nonselective neuronal death. Our results indicate that chronic vascular insufficiency and, possibly, insufficient Vegf-dependent neuroprotection lead to the select degeneration of motor neurons.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; FAU Erlangen Nurnberg, Dept Neuropathol, D-91054 Erlangen, Germany; Katholieke Univ Leuven, Fac Med, B-3000 Louvain, Belgium; Univ Maastricht, CARIM, NL-6200 MD Maastricht, Netherlands; Hop Robert Debre, INSERM E9935, F-75019 Paris, France; Hop Robert Debre, Serv Neruol Pediat, F-75019 Paris, France; Univ Amsterdam, Dept Anesthesiol, Amsterdam, Netherlands; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Nagoya Univ, Dept Biol Mol, Nagoya, Aichi 46401, Japan; ImClone Syst Inc, New York, NY 10014 USA; Thrombosis Res Inst, Vasc Biol Lab, London SW3 6LR, England	Flanders Institute for Biotechnology (VIB); KU Leuven; University of Erlangen Nuremberg; KU Leuven; Maastricht University; Maastricht University Medical Centre (MUMC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Amsterdam; University of Toronto; Nagoya University; Eli Lilly; Thrombosis Research Institute	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Lupu, Florea/AAV-3257-2021; Carmeliet, Peter/AAQ-5140-2020; Lupu, Florea/C-3162-2009; Van Den Bosch, Ludo/B-7258-2012; Hellings, Peter W/I-4068-2018; gressens, pierre/M-7557-2017; Storkebaum, Erik/B-5389-2017	Lupu, Florea/0000-0003-1249-9278; Carmeliet, Peter/0000-0001-7961-1821; Lupu, Florea/0000-0003-1249-9278; Hellings, Peter W/0000-0001-6898-688X; gressens, pierre/0000-0002-0909-4221; Storkebaum, Erik/0000-0002-9519-5642; sciot, raf/0000-0003-2244-5839; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Heymans, Stephane/0000-0001-9477-7803; Acker, Till/0000-0001-6357-7227; Van Den Bosch, Ludo/0000-0003-0104-4067; Nuyens, Dieter/0000-0001-9390-3273				Al Theys P, 1999, J NEUROL, V246, P438, DOI 10.1007/s004150050379; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; Bromberg MB, 1999, CURR OPIN NEUROL, V12, P581, DOI 10.1097/00019052-199910000-00012; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gorselink M, 2000, PFLUG ARCH EUR J PHY, V439, P665, DOI 10.1007/s004240050991; Green SL, 1999, LAB ANIM SCI, V49, P480; Gupta M, 2000, BLOOD, V96, P491; Hayashi T, 1999, NEUROPATH APPL NEURO, V25, P63; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; KAWAMURA Y, 1977, J NEUROPATH EXP NEUR, V36, P853, DOI 10.1097/00005072-197709000-00009; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; Kong JM, 1998, J NEUROSCI, V18, P3241; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; Lang-Lazdunski L, 2000, STROKE, V31, P208, DOI 10.1161/01.STR.31.1.208; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; Martin LJ, 2000, INT J MOL MED, V5, P3; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nohl H, 1997, EXP GERONTOL, V32, P485, DOI 10.1016/S0531-5565(96)00169-6; Ochiai-Kanai R, 1999, BRAIN RES, V847, P59, DOI 10.1016/S0006-8993(99)02020-X; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Rivard A, 2000, J BIOL CHEM, V275, P29643, DOI 10.1074/jbc.M001029200; ROBBERECHT WL, 2000, AMYOTROPHIC LATERAL, P211; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; Schultz A, 1999, CIRCULATION, V100, P547, DOI 10.1161/01.CIR.100.5.547; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vandenberghe W, 1998, BRAIN RES, V807, P1, DOI 10.1016/S0006-8993(98)00569-1; Williamson TL, 1998, P NATL ACAD SCI USA, V95, P9631, DOI 10.1073/pnas.95.16.9631; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8	46	795	832	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					131	138		10.1038/88842	http://dx.doi.org/10.1038/88842			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381259				2022-12-25	WOS:000169011800014
J	Lee, SH; Girard, S; Macina, D; Busa, M; Zafer, A; Belouchi, A; Gros, P; Vidal, SM				Lee, SH; Girard, S; Macina, D; Busa, M; Zafer, A; Belouchi, A; Gros, P; Vidal, SM			Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily	NATURE GENETICS			English	Article							RESISTANCE LOCUS CMV1; GENE-COMPLEX; LY49; MHC; FAMILY; MAP; CHROMOSOME-6; SPECIFICITY; RECOGNITION; EXPRESSION	Cytomegalovirus is the leading cause of congenital viral disease and the most important opportunistic infection in immunocompromised patients(1,2). We have used a mouse experimental infection model (MCMV) to study the genetic parameters of host/virus interaction. Susceptibility to infection with MCMV is controlled by Cmv1, a chromosome 6 locus that regulates natural killer (NK) cell activity against virally infected targets(3-5). Here, we use a positional cloning strategy to isolate the gene mutated at the Cmv1 locus. Cmv1 maps within a 0.35-cM interval defined by markers D6Ott8 and D6Ott115, which corresponds to a physical distance of 1.6 Mb (refs. 6-8). A transcript map of the region identified 19 genes(8), including members of the killer cell lectin-like receptor family a (Klra, formerly Ly49; refs. 9-12), which encode inhibitory or activating NK cell receptors that interact with MHC class I molecules(13-15). Klra genes have different copy numbers and genomic organization, and are highly polymorphic among inbred strains, making it difficult to distinguish between normal allelic variants and distinct Klra genes(15-17), or possible mutations associated with Cmv1. The recombinant inbred strain BXD-8/Ty (BXD-8; ref. 18), derived from Cmv1(r) C57BL/6 (B6, resistant) and Cmv1(s) DBA/2 (susceptible), is of particular interest because it is highly susceptible to MCMV infection despite having a B6 haplotype at Cmv1, We determined that MCMV susceptibility in BXD-8 is associated with the deletion of Klra8 (formerly Ly49h).	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Galileo Genom Inc, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	University of Ottawa; McGill University	Vidal, SM (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada.							BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; Brown MG, 1997, IMMUNOL REV, V155, P53, DOI 10.1111/j.1600-065X.1997.tb00939.x; Brown MG, 1997, GENOMICS, V42, P16, DOI 10.1006/geno.1997.4721; DELAINE M, 1995, PHYS WORLD, V8, P6; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; Depatie C, 1997, GENOMICS, V39, P154, DOI 10.1006/geno.1996.4498; Depatie C, 1999, INT IMMUNOL, V11, P1541, DOI 10.1093/intimm/11.9.1541; Depatie C, 2000, GENOMICS, V66, P161, DOI 10.1006/geno.2000.6186; Farrell H, 2000, MICROBES INFECT, V2, P521, DOI 10.1016/S1286-4579(00)00315-4; Gosselin P, 1999, J LEUKOCYTE BIOL, V66, P165, DOI 10.1002/jlb.66.1.165; HO M, 1994, TRANSPLANT P, V5, P7; Hoglund P, 1997, IMMUNOL REV, V155, P11, DOI 10.1111/j.1600-065X.1997.tb00936.x; Hurme M, 1998, SCAND J INFECT DIS, V30, P447, DOI 10.1080/00365549850161403; Idris AH, 1998, J EXP MED, V188, P2243, DOI 10.1084/jem.188.12.2243; Idris AH, 1999, P NATL ACAD SCI USA, V96, P6330, DOI 10.1073/pnas.96.11.6330; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Kuboto A, 1999, J IMMUNOL, V163, P212; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Makrigiannis AP, 2000, J LEUKOCYTE BIOL, V68, P765; Makrigiannis AP, 2000, IMMUNOL RES, V21, P39, DOI 10.1385/IR:21:1:39; McQueen KL, 1998, IMMUNOGENETICS, V48, P174, DOI 10.1007/s002510050421; Nakamura MC, 1999, J EXP MED, V189, P493, DOI 10.1084/jem.189.3.493; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1990, J EXP MED, V171, P1469, DOI 10.1084/jem.171.5.1469; SCALZO AA, 1995, GENOMICS, V27, P435, DOI 10.1006/geno.1995.1074; Smith HRC, 2000, J EXP MED, V191, P1341, DOI 10.1084/jem.191.8.1341; SMITH HRC, 1994, J IMMUNOL, V153, P1068; Takei F, 1997, IMMUNOL REV, V155, P67, DOI 10.1111/j.1600-065X.1997.tb00940.x; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; Threlkeld MG, 1995, MANDELL DOUGLAS BENN, P1351	30	331	337	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					42	45		10.1038/ng0501-42	http://dx.doi.org/10.1038/ng0501-42			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326273				2022-12-25	WOS:000168413300013
J	Zennou, V; Serguera, C; Sarkis, C; Colin, F; Perret, E; Mallet, J; Charneau, P				Zennou, V; Serguera, C; Sarkis, C; Colin, F; Perret, E; Mallet, J; Charneau, P			The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain	NATURE BIOTECHNOLOGY			English	Article							LENTIVIRAL VECTORS; GENE DELIVERY; IN-VIVO; INFECTION; GENOME	During HIV-1 reverse transcription, central initiation of the plus-strand DNA at the central polypurine tract (cPPT) and central termination at the central termination sequence (CTS) lead to the formation of a three-stranded DNA structure: the HIV-1 central DNA flap. We recently reported that the DNA flap acts as a cis-active determinant of HIV-1 genome nuclear import. Commonly employed HIV-1-derived vectors (HR vectors) lack the central DNA flap. Here we report that the insertion of this DNA flap sequence into HR vectors (TRIP vectors) improves gene transduction in neural cells, ex vivo and in vivo, in rat brain. When neural cells are exposed to increasing concentrations of TRIP vector particles, transgene expression correlates with the dose of vector. This effect contrasts with the plateau observed when using an HR vector. We further demonstrate that the increase of in vivo transduction efficiency obtained with TRIP vectors is due to the stimulation of their genome nuclear import.	Inst Pasteur, Unite Oncol Virale, F-75724 Paris 15, France; Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmit & Proc Neurodegenerat, F-75013 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Charneau, P (corresponding author), Inst Pasteur, Unite Oncol Virale, 25-28 Rue Dr Roux, F-75724 Paris 15, France.		CHARNEAU, Pierre/M-1565-2017; Serguera, Ché/J-8918-2012	CHARNEAU, Pierre/0000-0003-1184-5773; Serguera, Che/0000-0002-9210-0636				BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BUCCARON MH, 1995, NEUROBIOL DIS, V2, P37, DOI 10.1006/nbdi.1995.0004; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Cisterni C, 2000, J NEUROCHEM, V74, P1820, DOI 10.1046/j.1471-4159.2000.0741820.x; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; Kim VN, 1998, J VIROL, V72, P811, DOI 10.1128/JVI.72.1.811-816.1998; Levi S, 1998, J CELL SCI, V111, P335; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ridet JL, 1999, HUM GENE THER, V10, P271, DOI 10.1089/10430349950019057; Sambrook J., 2002, MOL CLONING LAB MANU; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	17	171	192	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					446	450		10.1038/88115	http://dx.doi.org/10.1038/88115			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329014				2022-12-25	WOS:000168394800022
J	Feuerer, M; Beckhove, P; Bai, LH; Solomayer, EF; Bastert, G; Diel, IJ; Pedain, C; Oberniedermayr, M; Schirrmacher, V; Umansky, V				Feuerer, M; Beckhove, P; Bai, LH; Solomayer, EF; Bastert, G; Diel, IJ; Pedain, C; Oberniedermayr, M; Schirrmacher, V; Umansky, V			Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow	NATURE MEDICINE			English	Article							LYMPHOCYTES; BREAST; PEPTIDE; ANTIGEN; IDENTIFICATION; VACCINATION; ACTIVATION; MATURATION; IMMUNITY; PROTEIN	In an analysis of 84 primary-operated breast cancer patients and 11 healthy donors, we found that the bone marrow of most patients contained memory T cells with specificity for tumor-associated antigens. Patients' bone marrow and peripheral blood contained CD8(+) T cells that specifically bound HLA/peptide tetramers. In short-term culture with autologous dendritic cells pre-pulsed with tumor lysates, patients' memory T cells from bone marrow (but not peripheral blood) could be specifically reactivated to interferon-gamma -producing and cytotoxic effector cells. A single transfer of restimulated bone-marrow T cells into NOD/SCID mice caused regression of autologous tumor xenotransplants associated with infiltration by human T cells and tumor-cell apoptosis and necrosis. T cells from peripheral blood showed much lower anti-tumor reactivity. Our findings reveal an innate, specific recognition of breast cancer antigens and point to a possible novel cancer therapy using patients' bone-marrow-derived memory T cells.	German Canc Res Ctr, Tumor Immunol Program, Div Cellular Immunol, D-6900 Heidelberg, Germany; Univ Hosp, Dept Obstet & Gynecol, Heidelberg, Germany; Univ Hosp, Dept Obstet & Gynecol, Giessen, Germany; St Josephs Hosp, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Umansky, V (corresponding author), German Canc Res Ctr, Tumor Immunol Program, Div Cellular Immunol, D-6900 Heidelberg, Germany.	v.umansky@dkfz-heidelberg.de						BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Briskin M, 1997, AM J PATHOL, V151, P97; Brossart P, 1996, J EXP MED, V183, P2449, DOI 10.1084/jem.183.6.2449; Brossart P, 1999, BLOOD, V93, P4309, DOI 10.1182/blood.V93.12.4309.412k19_4309_4317; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; Disis ML, 1999, CLIN CANCER RES, V5, P1289; ERLE DJ, 1994, J IMMUNOL, V153, P517; Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1152>3.0.CO;2-Q; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Kuroda MJ, 2000, BLOOD, V96, P1474, DOI 10.1182/blood.V96.4.1474.h8001474_1474_1479; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lanzavecchia A, 2000, CURR OPIN IMMUNOL, V12, P92, DOI 10.1016/S0952-7915(99)00056-4; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Muerkoster S, 1998, CLIN CANCER RES, V4, P3095; Muller M, 1998, CANCER RES, V58, P5439; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; PAPAYANNOPOULOU T, 1997, P NATL ACAD SCI USA, V92, P9647; Paramithiotis E, 1997, P NATL ACAD SCI USA, V94, P208, DOI 10.1073/pnas.94.1.208; Price PW, 1999, EUR J IMMUNOL, V29, P1051, DOI 10.1002/(SICI)1521-4141(199903)29:03<1051::AID-IMMU1051>3.0.CO;2-Y; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SCHIRRMACHER V, 1993, IMMUNOL CELL BIOL, V71, P311, DOI 10.1038/icb.1993.36; Schuler G, 1999, DENDRITIC CELLS BIOL, P515; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P2268, DOI 10.1073/pnas.96.5.2268; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Slavin RG, 1996, PEDIATR PULM, V21, P1, DOI 10.1002/1099-0496(199601)21:1<1::AID-PPUL1950210102>3.0.CO;2-K; Slifka MK, 1997, BLOOD, V90, P2103, DOI 10.1182/blood.V90.5.2103; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; Valmori D, 2000, CANCER RES, V60, P4499; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; Visonneau S, 1998, AM J PATHOL, V152, P1299; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	45	242	250	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					452	458		10.1038/86523	http://dx.doi.org/10.1038/86523			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283672				2022-12-25	WOS:000167960500040
J	Kim, MS; Kwon, HJ; Lee, YM; Baek, JH; Jang, JE; Lee, SW; Moon, EJ; Kim, HS; Lee, SK; Chung, HY; Kim, CW; Kim, KW				Kim, MS; Kwon, HJ; Lee, YM; Baek, JH; Jang, JE; Lee, SW; Moon, EJ; Kim, HS; Lee, SK; Chung, HY; Kim, CW; Kim, KW			Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-PROLIFERATION; DNA METHYLATION; HYPOXIA MARKER; MESSENGER-RNA; UP-REGULATION; APOPTOSIS; P53; HIF-1-ALPHA; EXPRESSION	Low oxygen tension influences tumor progression by enhancing angiogenesis; and histone deacetylases (HDAC) are implicated in alteration of chromatin assembly and tumorigenesis. Here we show induction of HDAC under hypoxia and elucidate a role for HDAC in the regulation of hypoxia-induced angiogenesis. Overexpressed wild-type HDAC1 downregulated expression of p53 and von Hippel-Lindau tumor suppressor genes and stimulated angiogenesis of human endothelial cells. A specific HDAC inhibitor, trichostatin A (TSA), upregulated p53 and von Hippel-Lindau expression and downregulated hypoxia-inducible factor-1 alpha and vascular endothelial growth factor. TSA also blocked angiogenesis in vitro and in vivo. TSA specifically inhibited hypoxia-induced angiogenesis in the Lewis lung carcinoma model. These results indicate that hypoxia enhances HDAC function and that HDAC is closely involved in angiogenesis through suppression of hypoxia-responsive tumor suppressor genes.	Seoul Natl Univ, Coll Pharm, Angiogenesis Res Lab, Seoul, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea	Seoul National University (SNU); Pusan National University; Pusan National University; Sejong University; Seoul National University (SNU)	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Angiogenesis Res Lab, Seoul, South Korea.	qwonkim@plaza.snu.ac.kr	권, 호정/AAS-3642-2021; Kim, Kyu Won/AAJ-7213-2020; Kim, Chul-Woo/F-7008-2011					Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Conrad KP, 1997, AM J REPROD IMMUNOL, V37, P240; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Kim KW, 1998, CANCER RES, V58, P348; Kim MS, 2000, INT J CANCER, V87, P269, DOI 10.1002/1097-0215(20000715)87:2&lt;269::AID-IJC19&gt;3.0.CO;2-W; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krieg M, 1998, BLOOD, V92, P3388, DOI 10.1182/blood.V92.9.3388.421a09_3388_3393; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; MEININGER CJ, 1988, AM J PHYSIOL, V255, pH554, DOI 10.1152/ajpheart.1988.255.3.H554; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; PASSANITI A, 1992, LAB INVEST, V67, P519; Prowse AH, 1997, AM J HUM GENET, V60, P765; Ravi R, 2000, GENE DEV, V14, P34; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Varia MA, 1998, GYNECOL ONCOL, V71, P270, DOI 10.1006/gyno.1998.5163; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Wood SM, 1997, INT J BIOCHEM CELL B, V29, P1419, DOI 10.1016/S1357-2725(97)00129-5; Yamamoto H, 1996, CANCER RES, V56, P3605; Zhong H, 1999, CANCER RES, V59, P5830	45	554	598	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					437	443		10.1038/86507	http://dx.doi.org/10.1038/86507			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283670				2022-12-25	WOS:000167960500038
J	Pabst, T; Mueller, BU; Harakawa, N; Schoch, C; Haferlach, T; Behre, G; Hiddemann, W; Zhang, DE; Tenen, DG				Pabst, T; Mueller, BU; Harakawa, N; Schoch, C; Haferlach, T; Behre, G; Hiddemann, W; Zhang, DE; Tenen, DG			AML1-ETO downregulates the granulocytic differentiation factor C/EBP alpha in t(8;21) myeloid leukemia	NATURE MEDICINE			English	Article							ENHANCER-BINDING-PROTEIN; STIMULATING FACTOR-RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; FUSION PROTEIN; GENE PROMOTER; TRANSCRIPTION FACTORS; MESSENGER-RNA; EXPRESSION; CELLS; AML1/ETO	The transcription factor CCAAT/enhancer binding protein alpha, or C/EBP alpha, encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBP alpha triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold fewer CEBPA RNA levels and undetectable C/EBP alpha protein levels compared with other subgroups of AML patients. Conditional expression of RUNX7-CBF2T7 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBP alpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBP alpha in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBP alpha expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias.	Harvard Univ, Sch Med, Harvard Inst Med, Div Hematol Oncol, Boston, MA 02115 USA; Natl Res Ctr Environm & Hlth, Dept Med 3, Grosshadern, Munich, Germany; Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Acute Myeloid Leukemia, Munich, Germany; Scripps Res Inst, La Jolla, CA USA	Harvard University; Harvard Medical School; University of Munich; University of Munich; Scripps Research Institute	Tenen, DG (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Div Hematol Oncol, Boston, MA 02115 USA.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [P01CA072009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056745] Funding Source: NIH RePORTER; NCI NIH HHS [CA72009] Funding Source: Medline; NHLBI NIH HHS [HL56745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASOU H, 1991, BLOOD, V77, P2031; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; ERICKSON P, 1992, BLOOD, V80, P1825; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HUETTNER C, 1995, AM J PATHOL, V146, P317; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Schwaller J, 1997, BRIT J HAEMATOL, V99, P896, DOI 10.1046/j.1365-2141.1997.4863289.x; SCOTT LM, 1992, BLOOD, V80, P1725; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	45	367	383	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					444	451		10.1038/86515	http://dx.doi.org/10.1038/86515			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283671				2022-12-25	WOS:000167960500039
J	Evangelista, M; Pruyne, D; Amberg, DC; Boone, C; Bretscher, A				Evangelista, M; Pruyne, D; Amberg, DC; Boone, C; Bretscher, A			Formins direct Arp2/3-independent actin filament assembly to polarize cell growth in yeast	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEIN; BUD-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; ARP2/3 COMPLEX; BUDDING YEAST; SECRETORY VESICLES; PLASMA-MEMBRANE; MITOTIC SPINDLE; MYOSIN-I; CYTOSKELETON	Formins have been implicated in the regulation of cytoskeletal structure in animals and fungi. Here we show that the formins Bni1 and Bnr1 of budding yeast stimulate the assembly of actin filaments that function as precursors to tropomyosin-stabilized cables that direct polarized cell growth. With loss of formin function, cables disassemble, whereas increased formin activity causes the hyperaccumulation of cable-like filaments. Unlike the assembly of cortical actin patches, cable assembly requires profilin but not the Arp2/3 complex. Thus formins control a distinct pathway for assembling actin filaments that organize the overall polarity of the cell.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	Queens University - Canada; Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Toronto; University of Toronto	Evangelista, M (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.				NIGMS NIH HHS [GM39066] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039066] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; Amberg DC, 1998, MOL BIOL CELL, V9, P3259, DOI 10.1091/mbc.9.12.3259; Amberg DC, 1997, MOL BIOL CELL, V8, P729, DOI 10.1091/mbc.8.4.729; CADWELL RC, 1994, PCR METH APPL, V3, P136; CHENEVERT J, 1994, GENETICS, V136, P1287; DRUBIN DG, 2000, CELL POLARITY; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Fujiwara T, 1999, MOL CELL BIOL, V19, P8016; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; Geli MI, 1998, J CELL SCI, V111, P1031; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Haarer BK, 1996, GENETICS, V144, P495; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kikyo M, 1999, ONCOGENE, V18, P7046, DOI 10.1038/sj.onc.1203184; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; Miller RK, 1998, J CELL BIOL, V140, P377, DOI 10.1083/jcb.140.2.377; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Naqvi SN, 1998, CURR BIOL, V8, P959, DOI 10.1016/S0960-9822(98)70396-3; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne D, 2000, J CELL SCI, V113, P571; Pruyne DW, 1998, J CELL BIOL, V143, P1931, DOI 10.1083/jcb.143.7.1931; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rossanese OW, 2001, J CELL BIOL, V153, P47, DOI 10.1083/jcb.153.1.47; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer JM, 2000, GENETICS, V156, P523; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Theesfeld CL, 1999, J CELL BIOL, V146, P1019, DOI 10.1083/jcb.146.5.1019; Vallen EA, 2000, MOL BIOL CELL, V11, P593, DOI 10.1091/mbc.11.2.593; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Yin HW, 2000, NATURE, V406, P1013, DOI 10.1038/35023024; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; Zeller R, 1999, CELL TISSUE RES, V296, P85, DOI 10.1007/s004410051269	53	207	210	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					32	41		10.1038/ncb718	http://dx.doi.org/10.1038/ncb718			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11740490				2022-12-25	WOS:000173381500013
J	Moskalenko, S; Henry, DO; Rosse, C; Mirey, G; Camonis, JH; White, MA				Moskalenko, S; Henry, DO; Rosse, C; Mirey, G; Camonis, JH; White, MA			The exocyst is a Ral effector complex	NATURE CELL BIOLOGY			English	Article							BASOLATERAL PLASMA-MEMBRANE; GTP-BINDING PROTEINS; RNA-INTERFERENCE; CA2+-DEPENDENT EXOCYTOSIS; SEC6/8 COMPLEX; TRANSPORT; INVOLVEMENT; INTERACTS; VESICLES; ENDOCYTOSIS	Delivery of cytoplasmic vesicles to discrete plasma-membrane domains is critical for establishing and maintaining cell polarity, neurite differentiation and regulated exocytosis. The exocyst is a multisubunit complex required for vectorial targeting of a subset of secretory vesicles. Mechanisms that regulate the activity of this complex in mammals are unknown. Here we show that Sec5, an integral component of the exocyst, is a direct target for activated Ral GTPases. Ral GTPases regulate targeting of basolateral proteins in epithelial cells, secretagogue-dependent exocytosis in neuroendocrine cells and assembly of exocyst complexes. These observations define Ral GTPases as critical regulators of vesicle trafficking.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Inst Curie, INSERM, U528, F-75248 Paris, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moskalenko, S (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Michael.white@UTSouthwestern.edu	Rosse, Carine/L-4775-2017; Mirey, Gladys/H-5676-2019	Mirey, Gladys/0000-0002-0095-1864	NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NCI NIH HHS [CA71443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; de Leeuw HPJC, 1999, THROMB HAEMOSTASIS, V82, P1177, DOI 10.1055/s-0037-1614349; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Littleton JT, 2000, J CELL BIOL, V150, pF77, DOI 10.1083/jcb.150.2.F77; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park JB, 2001, EXP MOL MED, V33, P54, DOI 10.1038/emm.2001.10; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WICK PF, 1993, J BIOL CHEM, V268, P10983; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	44	325	331	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					66	72		10.1038/ncb728	http://dx.doi.org/10.1038/ncb728			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11740492				2022-12-25	WOS:000173381500018
J	Veigel, C; Wang, F; Bartoo, ML; Sellers, JR; Molloy, JE				Veigel, C; Wang, F; Bartoo, ML; Sellers, JR; Molloy, JE			The gated gait of the processive molecular motor, myosin V	NATURE CELL BIOLOGY			English	Article							ACTIN; MOVEMENT; KINETICS; BINDING	Class V myosins are actin-based molecular motors involved in vesicular and organellar transport. Single myosin V molecules move processively along F-actin, taking several 36-nm steps for each diffusional encounter. Here we have measured the mechanical interactions between mouse brain myosin V and rabbit skeletal F-actin. The working stroke produced by a myosin V head is similar to25 nm, consisting of two separate mechanical phases (20 + 5 nm). We show that there are preferred myosin binding positions (target zones) every 36 nm along the actin filament, and propose that the 36-nm steps of the double-headed motor are a combination of the working stroke (25 nm) of the bound head and a biased, thermally driven diffusive movement (11 nm) of the free head onto the next target zone. The second phase of the working stroke (5 nm) acts as a gate - like an escapement in a clock, coordinating the ATPase cycles of the two myosin V heads. This mechanism increases processivity and enables a single myosin V molecule to travel distances of several hundred nanometres along the actin filament.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	University of York - UK; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Veigel, C (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.			Molloy, Justin/0000-0002-8307-2450	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004229, Z01HL004229] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berger CEM, 2001, J BIOL CHEM, V276, P23240, DOI 10.1074/jbc.M100524200; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Howard J., 2001, MECH MOTOR PROTEINS; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Miller KE, 2000, J BIOL CHEM, V275, P2598, DOI 10.1074/jbc.275.4.2598; Molloy J. E., 1995, Biophysical Journal, V68, P298; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Rao A, 2000, HIPPOCAMPUS, V10, P527, DOI 10.1002/1098-1063(2000)10:5<527::AID-HIPO3>3.0.CO;2-B; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Sellers J. R., 1999, MYOSINS; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; WRAY JS, 1979, NATURE, V280, P325, DOI 10.1038/280325a0	22	308	311	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					59	65		10.1038/ncb732	http://dx.doi.org/10.1038/ncb732			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11740494				2022-12-25	WOS:000173381500017
J	Karberg, M; Guo, HT; Zhong, J; Coon, R; Perutka, J; Lambowitz, AM				Karberg, M; Guo, HT; Zhong, J; Coon, R; Perutka, J; Lambowitz, AM			Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria	NATURE BIOTECHNOLOGY			English	Article							DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; REPLACEMENT; MOBILITY; EXPRESSION; CHROMOSOME; SYSTEM; CELLS; RNA	Mobile group II introns can be retargeted to insert into virtually any desired DNA target. Here we show that retargeted group II introns can be used for highly specific chromosomal gene disruption in Escherichia coli and other bacteria at frequencies of 0.1-22%. Furthermore, the introns can be used to introduce targeted chromosomal breaks, which can be repaired by transformation with a homologous DNA fragment, enabling the introduction of point mutations. Because of their wide host range, mobile group II introns should be useful for genetic engineering and functional genomics in a wide variety of bacteria.	Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Sch Biol Sci, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Lambowitz, AM (corresponding author), Univ Texas, Dept Chem & Biochem, Inst Mol & Cellular Biol, Austin, TX 78712 USA.		Zhong, Jin/M-6859-2018	Zhong, Jin/0000-0002-3554-1275	NIGMS NIH HHS [GM37949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; BELFORT M, 2002, IN PRESS MOBILE DNA; Cousineau B, 1998, CELL, V94, P451, DOI 10.1016/S0092-8674(00)81586-X; Cousineau B, 2000, NATURE, V404, P1018, DOI 10.1038/35010029; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; Ellis HM, 2001, P NATL ACAD SCI USA, V98, P6742, DOI 10.1073/pnas.121164898; Eskes R, 2000, MOL CELL BIOL, V20, P8432, DOI 10.1128/MCB.20.22.8432-8446.2000; Eskes R, 1997, CELL, V88, P865, DOI 10.1016/S0092-8674(00)81932-7; Guo HT, 2000, SCIENCE, V289, P452, DOI 10.1126/science.289.5478.452; Guo HT, 1997, EMBO J, V16, P6835, DOI 10.1093/emboj/16.22.6835; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Matsuura M, 1997, GENE DEV, V11, P2910, DOI 10.1101/gad.11.21.2910; Mohr G, 2000, GENE DEV, V14, P559; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; PAYNE SM, 1983, J BACTERIOL, V155, P949, DOI 10.1128/JB.155.3.949-955.1983; Posfai G, 1999, NUCLEIC ACIDS RES, V27, P4409, DOI 10.1093/nar/27.22.4409; Puchta H, 1996, P NATL ACAD SCI USA, V93, P5055, DOI 10.1073/pnas.93.10.5055; Saldanha R, 1999, BIOCHEMISTRY-US, V38, P9069, DOI 10.1021/bi982799l; Sambrook J., 2002, MOL CLONING LAB MANU; Singh NN, 2001, J MOL BIOL, V309, P361, DOI 10.1006/jmbi.2001.4658; TSAI SP, 1989, J GEN MICROBIOL, V135, P2561; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	28	154	184	3	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1162	1167		10.1038/nbt1201-1162	http://dx.doi.org/10.1038/nbt1201-1162			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731786				2022-12-25	WOS:000172524400030
J	Watanabe, ME				Watanabe, ME			Can bioremediation bounce back?	NATURE BIOTECHNOLOGY			English	Article							TRANSGENIC PLANTS; HYDROCARBONS; REMEDIATION; METALS; GENE; SOIL											Adrian L, 2000, NATURE, V408, P580, DOI 10.1038/35046063; Bizily SP, 2000, NAT BIOTECHNOL, V18, P213, DOI 10.1038/72678; Brim H, 2000, NAT BIOTECHNOL, V18, P85, DOI 10.1038/71986; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; CLEMENS S, 2001, EUR J BIOCHEM, V268, P1; Doty SL, 2000, P NATL ACAD SCI USA, V97, P6287, DOI 10.1073/pnas.97.12.6287; *EPA, 542B99009 EPA; French CE, 1999, NAT BIOTECHNOL, V17, P491, DOI 10.1038/8673; Glass D. J, 1999, US INT MARKETS PHYTO; GLASS DJ, 1994, APPLIED BIOTECHNOLOGY FOR SITE REMEDIATION, P256; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; Ma LQ, 2001, NATURE, V409, P579, DOI 10.1038/35054664; Persans MW, 2000, BIOTECHNOL GENET ENG, V17, P389, DOI 10.1080/02648725.2000.10647999; Ripp S, 2000, ENVIRON SCI TECHNOL, V34, P846, DOI 10.1021/es9908319; Rugh CL, 1996, P NATL ACAD SCI USA, V93, P3182, DOI 10.1073/pnas.93.8.3182; Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925; SCHNOOR JL, 1998, TE9801 GROUND WAT RE; Strong LC, 2000, ENVIRON MICROBIOL, V2, P91, DOI 10.1046/j.1462-2920.2000.00079.x; *US EPA, 2001, 542R01006 US EPA; Valls M, 2000, NAT BIOTECHNOL, V18, P661, DOI 10.1038/76516	20	34	36	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1111	1115		10.1038/nbt1201-1111	http://dx.doi.org/10.1038/nbt1201-1111			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731774				2022-12-25	WOS:000172524400014
J	Barcellos, LF; Caillier, S; Dragone, L; Elder, M; Vittinghoff, E; Bucher, P; Lincoln, RR; Pericak-Vance, M; Haines, JL; Weiss, A; Hauser, SL; Oksenberg, JR				Barcellos, LF; Caillier, S; Dragone, L; Elder, M; Vittinghoff, E; Bucher, P; Lincoln, RR; Pericak-Vance, M; Haines, JL; Weiss, A; Hauser, SL; Oksenberg, JR			PTPRC (CD45) is not associated with the development of multiple sclerosis in US patients	NATURE GENETICS			English	Article							POLYMORPHISM; MUTATION; LINKAGE	A C-->G nucleotide transition in exon 4 of PTPRC (encoding protein-tyrosine phosphatase receptor-type C, also known as CD45) was recently reported to be genetically associated with the development of multiple sclerosis (MS)(1). We performed an extensive evaluation of this polymorphism using large family-based and case-control comparisons. Overall, we observed no evidence of genetic association between the PTPRC polymorphism and MS susceptibility or disease course.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Duke Univ, Med Ctr, Dept Med, Ctr Human Genet, Durham, NC USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Program Human Genet, Nashville, TN 37232 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; Vanderbilt University	Oksenberg, JR (corresponding author), Univ Calif San Francisco, Dept Neurol, 513 Parnassus Ave, San Francisco, CA 94143 USA.		Hauser, Stephen L/J-2978-2016; Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026799, R01NS032830] Funding Source: NIH RePORTER; NINDS NIH HHS [NS32830, NS26799] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCELLOS LF, IN PRESS BRAIN; Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070; GOODKIN DE, 1991, ARCH NEUROL-CHICAGO, V48, P805, DOI 10.1001/archneur.1991.00530200041016; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; Liao HX, 2000, J IMMUNOL, V165, P148, DOI 10.4049/jimmunol.165.1.148; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; Martin ER, 2001, AM J HUM GENET, V68, P1065, DOI 10.1086/319525; Oksenberg JR, 2001, J NEUROIMMUNOL, V113, P171, DOI 10.1016/S0165-5728(00)00444-6; Templeton AR, 2000, GENETICS, V156, P1259	9	54	54	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					23	24		10.1038/ng722	http://dx.doi.org/10.1038/ng722			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528386				2022-12-25	WOS:000170781300011
J	Zimprich, A; Grabowski, M; Asmus, F; Naumann, M; Berg, D; Bertram, M; Scheidtmann, K; Kern, P; Winkelmann, F; Muller-Myhsok, B; Riedel, L; Bauer, M; Muller, T; Castro, M; Meitinger, T; Strom, TM; Gasser, T				Zimprich, A; Grabowski, M; Asmus, F; Naumann, M; Berg, D; Bertram, M; Scheidtmann, K; Kern, P; Winkelmann, F; Muller-Myhsok, B; Riedel, L; Bauer, M; Muller, T; Castro, M; Meitinger, T; Strom, TM; Gasser, T			Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome	NATURE GENETICS			English	Article							GIRDLE MUSCULAR-DYSTROPHY; HEREDITARY ESSENTIAL MYOCLONUS; ONSET TORSION DYSTONIA; D2 DOPAMINE-RECEPTOR; ALPHA-SARCOGLYCAN; COMPLEX; FAMILY; 2D	The dystonias are a common clinically and genetically heterogeneous group of movement disorders. More than ten loci for inherited forms of dystonia have been mapped, but only three mutated genes have been identified so far. These are DYT1, encoding torsin A(1) and mutant in the early-onset generalized form, GCH1 (formerly known as DYT5), encoding GTP-cyclohydrolase I and mutant in dominant dopa-responsive dystonia(2), and TH, encoding tyrosine hydroxylase and mutant in the recessive form of the disease(3). Myoclonus-dystonia syndrome (MDS; DYT11) is an autosomal dominant disorder characterized by bilateral, alcohol-sensitive myoclonic jerks involving mainly the arms and axial muscles(4,5). Dystonia, usually torticollis and/or writer's cramp, occurs in most but not all affected patients and may occasionally be the only symptom of the disease(6,7). In addition, patients often show prominent psychiatric abnormalities, including panic attacks and obsessive-compulsive behavior(8-10). In most MDS families, the disease is linked to a locus on chromosome 7q21 (refs. 11-13). Using a positional cloning approach, we have identified five different heterozygous loss-of-function mutations in the gene for epsilon -sarcoglycan (SGCE), which we mapped to a refined critical region of about 3.2 Mb. SGCE is expressed in all brain regions examined. Pedigree analysis shows a marked difference in penetrance depending on the parental origin of the disease allele, This is indicative of a maternal imprinting mechanism, which has been demonstrated in the mouse epsilon -sarcoglycan gene(14).	Univ Munich, Klinikum Grosshadern, Dept Neurol, Munich, Germany; GSF Munich, Natl Res Ctr, Inst Human Genet, Munich, Germany; Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-8000 Munich, Germany; Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany; Heidelberg Univ, Dept Neurol, D-6900 Heidelberg, Germany; Neurol Hosp, Bad Aibling, Germany; Klinikum Buch, Dept Neurol, Berlin, Germany; Inst Psychiat, Dept Neurol, Munich, Germany; Bernhard Nocht Inst Trop Med, Hamburg, Germany; LionBiosci AG, Heidelberg, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Wurzburg; Ruprecht Karls University Heidelberg; Bernhard Nocht Institut fur Tropenmedizin	Gasser, T (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurol, Munich, Germany.	tgasser@brain.nefo.med.uni-muenchen.de	Müller-Myhsok, Bertram/A-3289-2013; Gasser, Thomas/GNH-5293-2022; Zimprich, Alexander/A-5232-2017; Berg, Daniela/A-8728-2019; Meitinger, Thomas/O-1318-2015	Gasser, Thomas/0000-0002-1069-1146; Zimprich, Alexander/0000-0002-1668-5177; Berg, Daniela/0000-0001-5796-5442; Meitinger, Thomas/0000-0002-8838-8403; Castro, Mirna/0000-0002-3452-9215; Winkelmann, Juliane/0000-0003-2667-9691; Bauer, Michaela/0000-0001-8717-3278				Asmus F, 2001, ANN NEUROL, V49, P121, DOI 10.1002/1531-8249(200101)49:1<121::AID-ANA20>3.0.CO;2-8; DOHENY D, 2000, MOVEMENT DISORD, V15, pS162; Durr A, 2000, ANN NEUROL, V48, P127; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; FAHN S, 1991, MOVEMENT DISORD, V6, P237, DOI 10.1002/mds.870060308; Gasser T, 1998, Adv Neurol, V78, P325; Gasser T, 1996, MOVEMENT DISORD, V11, P363, DOI 10.1002/mds.870110403; Grimes DA, 2001, MOVEMENT DISORD, V16, P106, DOI 10.1002/1531-8257(200101)16:1<106::AID-MDS1022>3.0.CO;2-7; Hewett J, 2000, HUM MOL GENET, V9, P1403, DOI 10.1093/hmg/9.9.1403; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; Imamura M, 2000, HUM MOL GENET, V9, P3091, DOI 10.1093/hmg/9.20.3091; Klein C, 2000, AM J HUM GENET, V67, P1314; Klein C, 1999, P NATL ACAD SCI USA, V96, P5173, DOI 10.1073/pnas.96.9.5173; Kurlan R, 1988, Adv Neurol, V50, P385; KURLAN R, 1987, MOVEMENT DISORD, V2, P301, DOI 10.1002/mds.870020407; KYLLERMAN M, 1990, MOVEMENT DISORD, V5, P270, DOI 10.1002/mds.870050403; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LUDECKE B, 1995, HUM GENET, V95, P123; LUNDEMO G, 1985, ACTA NEUROL SCAND, V72, P176; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Nygaard TG, 1999, ANN NEUROL, V46, P794, DOI 10.1002/1531-8249(199911)46:5<794::AID-ANA19>3.0.CO;2-2; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Quinn N P, 1988, Adv Neurol, V50, P391; Scheidtmann K, 2000, NERVENARZT, V71, P839, DOI 10.1007/s001150050673; Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9; Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989	27	331	346	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2001	29	1					66	69		10.1038/ng709	http://dx.doi.org/10.1038/ng709			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528394				2022-12-25	WOS:000170781300019
J	Chen, FS; Yu, G; Arawaka, S; Nishimura, M; Kawarai, T; Yu, H; Tandon, A; Supala, A; Song, YQ; Rogaeva, E; Milman, P; Sato, C; Yu, C; Janus, C; Lee, J; Song, LX; Zhang, LL; Fraser, PE; St George-Hyslop, PH				Chen, FS; Yu, G; Arawaka, S; Nishimura, M; Kawarai, T; Yu, H; Tandon, A; Supala, A; Song, YQ; Rogaeva, E; Milman, P; Sato, C; Yu, C; Janus, C; Lee, J; Song, LX; Zhang, LL; Fraser, PE; St George-Hyslop, PH			Nicastrin binds to membrane tethered Notch	NATURE CELL BIOLOGY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; MISSENSE MUTATIONS; MAMMALIAN-CELLS; PRESENILIN; GENE; ENDOPROTEOLYSIS; DROSOPHILA	The presenilins(1,2) and nicastrin(3), a type 1 transmembrane glycoprotein, form high molecular weight complexes that are involved in cleaving the beta -amyloid precursor protein (beta APP)(3-7) and Notch(8-11) in their transmembrane domains. The former process (termed gamma -secretase cleavage) generates amyloid beta -peptide (A beta), which is involved in the pathogenesis of Alzheimer's disease. The latter process (termed S3-site cleavage) generates Notch intracellular domain (NICD), which is involved in intercellular signalling. Nicastrin binds both full-length beta APP and the substrates of gamma -secretase (C99- and C83-beta APP fragments), and modulates the activity of gamma -secretase. Although absence of the Caenorhabditis elegans nicastrin homologue (aph-2) is known to cause an embryonic-lethal glp-1 phenotype(3,12), the role of nicastrin in this process has not been explored. Here we report that nicastrin binds to membrane-tethered forms of Notch (substrates for S3-site cleavage of Notch), and that, although mutations in the conserved 312-369 domain of nicastrin strongly modulate gamma -secretase, they only weakly modulate the S3-site cleavage of Notch. Thus, nicastrin has a similar role in processing Notch and beta APP, but the 312-369 domain may have differential effects on these activities. In addition, we report that the Notch and beta APP pathways do not significantly compete with each other.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada; Shiga Univ Med Sci, Mol Neurosci Res Ctr, Shiga 5202192, Japan; Schering Plough Corp, Res Inst, Dept CNS & Cardiovsc Res, Kenilworth, NJ 07033 USA; Toronto Western Hosp, Univ Hlth Network, Dept Med Neurol, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto; Shiga University of Medical Science; Merck & Company; Schering Plough Corporation; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, PH (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.		Kawarai, Toshitaka/C-2822-2013; Song, You-Qiang/E-5207-2011; Song, You-qiang/C-4401-2009	Kawarai, Toshitaka/0000-0003-4547-8131; Arawaka, Shigeki/0000-0002-1505-3012; Yu, Wai Haung/0000-0001-7186-6731; St George-Hyslop, Peter/0000-0003-0796-7209; Song, You-Qiang/0000-0001-9407-2256				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Goutte C, 2000, DEVELOPMENT, V127, P2481; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Okochi M., 2000, J BIOL CHEM; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; RAV WJ, 1999, J BIOL CHEM, V274, P36801; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang DM, 2000, NEUROREPORT, V11, P3227, DOI 10.1097/00001756-200009280-00035; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966	30	113	116	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					751	754		10.1038/35087069	http://dx.doi.org/10.1038/35087069			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483961				2022-12-25	WOS:000170393200021
J	Fukamachi, S; Shimada, A; Shima, A				Fukamachi, S; Shimada, A; Shima, A			Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka	NATURE GENETICS			English	Article							GERM-CELL MUTAGENESIS; ORYZIAS-LATIPES; JAPANESE MEDAKA; TEST SYSTEM; RECEPTOR; DELETION; NEURONS; MODEL; FISH	Pigmentation of the skin is of great social, clinical and cosmetic significance. Several genes that, when mutated, give rise to altered coat color in mice have been identified; their analysis(1-6) has provided some insight into melanogenesis and human pigmentation diseases. Such analyses do not, however, fully inform on the pigmentation of lower vertebrates because mammals have only one kind of chromatophore, the melanocyte. In contrast, the medaka (a small, freshwater teleost) is a suitable model of the lower vertebrates because it has all kinds of chromatophores. The basic molecular genetics of fish are known(7,8) and approximately 70 spontaneous pigmentation mutants have been isolated(9). One of these, an orange-red variant, is a homozygote of a well-known and common allele, b, and has been bred for hundreds of years by the Japanese. Here, we report the first successful positional cloning of a medaka gene (AIM1): one that encodes a transporter that mediates melanin synthesis. The protein is predicted to consist of 12 transmembrane domains and is 55% identical to a human EST of unknown function isolated from melanocytes and melanoma cells. We also isolated a highly homologous gene from the mouse, indicating a conserved function of vertebrate melanogenesis. Intriguingly, these proteins have sequence and structural similarities to plant sucrose transporters, suggesting a relevance of sucrose in melanin synthesis. Analysis of AIM1 orthologs should provide new insights into the regulation of melanogenesis in both teleosts and mammals.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Kashiwa, Chiba 2770882, Japan; Univ Tokyo, Sch Sci, Dept Biol Sci, Radiat Biol Lab,Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Fukamachi, S (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Kashiwa No Ha 5-1-5, Kashiwa, Chiba 2770882, Japan.			Fukamachi, Shoji/0000-0001-7967-1883				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrews NC, 1999, INT J BIOCHEM CELL B, V31, P991, DOI 10.1016/S1357-2725(99)00065-5; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Ferdinandusse S, 2000, NAT GENET, V24, P188, DOI 10.1038/72861; Fukamachi Shoji, 2001, Mutation Research, V458, P19, DOI 10.1016/S1383-5726(01)00009-7; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; Harada M, 2001, CANCER RES, V61, P1089; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HIROSE E, 1993, PIGM CELL RES, V6, P45, DOI 10.1111/j.1600-0749.1993.tb00580.x; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HYODO-TAGUCHI Y, 1980, Zoological Magazine (Tokyo), V89, P283; Kilty John E., 1992, Current Opinion in Biotechnology, V3, P675, DOI 10.1016/0958-1669(92)90015-B; Koga A, 1999, PIGM CELL RES, V12, P252, DOI 10.1111/j.1600-0749.1999.tb00758.x; Lemoine R, 2000, BBA-BIOMEMBRANES, V1465, P246, DOI 10.1016/S0005-2736(00)00142-5; Matsuda M, 2001, GENES GENET SYST, V76, P61, DOI 10.1266/ggs.76.61; Mount DB, 1998, J EXP BIOL, V201, P2091; NAKAYASU M, 1977, J CELL PHYSIOL, V92, P49, DOI 10.1002/jcp.1040920107; Naruse K, 2000, GENETICS, V154, P1773; SAEKI H, 1978, J CELL PHYSIOL, V94, P139, DOI 10.1002/jcp.1040940203; SHIMA A, 1994, ENVIRON HEALTH PERSP, V102, P33, DOI 10.1289/ehp.94102s1233; SHIMA A, 1991, P NATL ACAD SCI USA, V88, P2545, DOI 10.1073/pnas.88.6.2545; Shimada A, 1998, MUTAT RES-FUND MOL M, V399, P149, DOI 10.1016/S0027-5107(97)00253-4; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Tomita H, 1990, BIOL MEDAKA, P111; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107	28	175	183	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					381	385		10.1038/ng584	http://dx.doi.org/10.1038/ng584			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479596				2022-12-25	WOS:000170174800021
J	Bennett, JJ; Tjuvajev, J; Johnson, P; Doubrovin, M; Akhurst, T; Malholtra, S; Hackman, T; Balatoni, J; Finn, R; Larson, SM; Federoff, H; Blasberg, R; Fong, YM				Bennett, JJ; Tjuvajev, J; Johnson, P; Doubrovin, M; Akhurst, T; Malholtra, S; Hackman, T; Balatoni, J; Finn, R; Larson, SM; Federoff, H; Blasberg, R; Fong, YM			Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer	NATURE MEDICINE			English	Article							KINASE GENE-TRANSFER; REPLICATION-COMPETENT; CHEMOTHERAPEUTIC-AGENTS; LIVER METASTASES; MALIGNANT GLIOMA; COLON-CARCINOMA; PHASE-I; THERAPY; EXPRESSION; TYPE-1	Molecular therapy using viruses would benefit greatly from a non-invasive modality for assessing dissemination of viruses. Here we investigated whether positron emission tomography (PET) scanning using [I-124]-5-iodo-2'-fluoro-1-beta -D-arabinofuranosyl-uracil (FIAU) could image cells infected with herpes simplex viruses (HSV). Using replication-competent HSV-1 oncolytic viruses with thymidine kinase (TK) under control of different promoters, we demonstrate that viral infection, proliferation and promoter characteristics all interact to influence FIAU accumulation and imaging. In vivo, as few as 1 x 10(7) viral particles injected into a 0.5-cm human colorectal tumor can be detected by [I-124]FIAU PET imaging. PET signal intensity is significantly greater at 48 hours compared with that at 8 hours after viral injection, demonstrating that PET scanning can detect changes in TK activity resulting from local viral proliferation. We also show the ability of FIAU-PET scanning to detect differences in viral infectivity at 0.5 log increments. Non-invasive imaging might be useful in assessing biologically relevant distribution of virus in therapies using replication-competent HSV.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiol & Med Phys, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Radiochem Cyclotron Core Facil, New York, NY 10021 USA; Neurovir, Vancouver, BC, Canada; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org	Doubrovin, Mikhail/C-5859-2017	Doubrovin, Mikhail/0000-0001-6607-2646	NCI NIH HHS [R24 CA83084, R01 CA72632, P50 CA86438, R01 CA61524, R01 CA69769, R01 CA75416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061524, R01CA072632, R24CA083084, P50CA086438, R01CA075416, R01CA069769] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani SJ, 1999, CANCER RES, V59, P2055; Alauddin MM, 1996, NUCL MED BIOL, V23, P787, DOI 10.1016/0969-8051(96)00075-3; Balatoni J. A., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P103; Bennett JJ, 2000, J MOL MED-JMM, V78, P166, DOI 10.1007/s001090000092; Carew JF, 1999, HUM GENE THER, V10, P1599, DOI 10.1089/10430349950017608; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; DELUCA NA, 1988, J VIROL, V62, P732, DOI 10.1128/JVI.62.3.732-743.1988; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; JOLLY D, 1994, CANCER GENE THER, V1, P51; Karpoff HM, 1997, J CLIN INVEST, V99, P799, DOI 10.1172/JCI119226; KOOBY DA, 1999, FASEB J, V6, P499; LORENCE RM, 1994, CANCER RES, V54, P6017; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MCGEOCH DJ, 1985, J MOL BIOL, V181, P1, DOI 10.1016/0022-2836(85)90320-1; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; ORKIN SH, 1997, REPORT RECOMMENDATIO, P135; Rampling R, 2000, GENE THER, V7, P859, DOI 10.1038/sj.gt.3301184; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev JG, 1998, CANCER RES, V58, P4333; Tjuvajev JG, 1999, CANCER RES, V59, P5186; Tjuvajev JG, 1996, CANCER RES, V56, P4087; Tjuvajev Juri G., 1999, Neoplasia (New York), V1, P315, DOI 10.1038/sj.neo.7900053; Topf N, 1998, GENE THER, V5, P507, DOI 10.1038/sj.gt.3300611; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; YAZAKI T, 1995, CANCER RES, V55, P4752; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Zuckerman JB, 1999, HUM GENE THER, V10, P2973, DOI 10.1089/10430349950016384	29	87	99	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					859	863		10.1038/89991	http://dx.doi.org/10.1038/89991			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433353				2022-12-25	WOS:000169808600040
J	Ciurea, A; Hunziker, L; Martinic, MMA; Oxenius, A; Hengartner, H; Zinkernagel, RM				Ciurea, A; Hunziker, L; Martinic, MMA; Oxenius, A; Hengartner, H; Zinkernagel, RM			CD4(+) T-cell-epitope escape mutant virus selected in vivo	NATURE MEDICINE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; RECEPTOR ANTAGONISTS; DEFICIENT MICE; IMMUNE-RESPONSES; VIRAL-INFECTION; IN-VIVO; VARIANTS; PERSISTENCE; HIV-1; CLEARANCE	Mutations in viral genomes that affect T-cell-receptor recognition by CD8(+) cytotoxic T lymphocytes have been shown to allow viral evasion from immune surveillance during persistent viral infections. Although CD4(+) T-helper cells are crucially involved in the maintenance of effective cytotoxic T-lymphocyte and neutralizing-antibody responses, their role in viral clearance and therefore in imposing similar selective pressures on the virus is unclear. We show here that transgenic virus-specific CD4(+) T cells, transferred into mice persistently infected with lymphocytic choriomeningitis virus, select for T-helper epitope mutant viruses that are not recognized. Together with the observed antigenic variation of the same T-helper epitope during polyclonal CD4(+) T-cell responses in infected pore-forming protein-deficient C57BL/6 mice, this finding indicates that viral escape from CD4(+) T lymphocytes is a possible mechanism of virus persistence.	Univ Hosp, Inst Expt Immunol, Zurich, Switzerland	University of Zurich; University Zurich Hospital	Ciurea, A (corresponding author), Univ Hosp, Inst Expt Immunol, Zurich, Switzerland.		Oxenius, Annette/G-7794-2015	Martinic, Marianne/0000-0003-4407-3423; Hunziker, Lukas/0000-0003-0081-8518; Ciurea, Adrian/0000-0002-7870-7132				BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; Borrow P, 1998, IMMUNOL REV, V164, P37, DOI 10.1111/j.1600-065X.1998.tb01206.x; Borrow Persephone, 1997, P593; Ciurea A, 2001, J EXP MED, V193, P297, DOI 10.1084/jem.193.3.297; Ciurea A, 2000, P NATL ACAD SCI USA, V97, P2749, DOI 10.1073/pnas.040558797; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Guidotti LG, 1999, J EXP MED, V189, P1555, DOI 10.1084/jem.189.10.1555; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Harcourt GC, 1998, J EXP MED, V188, P1785, DOI 10.1084/jem.188.10.1785; HOTCHIN JE, 1958, CAN J MICROBIOL, V4, P149, DOI 10.1139/m58-016; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kamperschroer C, 1999, CELL IMMUNOL, V193, P134, DOI 10.1006/cimm.1999.1458; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LEHMANNGRUBE F, 1993, J VIROL, V67, P332, DOI 10.1128/JVI.67.1.332-339.1993; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MOSKOPHIDIS D, 1995, J GEN VIROL, V76, P381, DOI 10.1099/0022-1317-76-2-381; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MULLER D, 1992, SCIENCE, V255, P1576, DOI 10.1126/science.1347959; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; Oxenius A, 1996, J EXP MED, V183, P2209, DOI 10.1084/jem.183.5.2209; Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7; Parren PWHI, 1999, AIDS, V13, pS137; Perarnau B, 1999, EUR J IMMUNOL, V29, P1243, DOI 10.1002/(SICI)1521-4141(199904)29:04<1243::AID-IMMU1243>3.0.CO;2-A; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RAULET DH, 1994, ADV IMMUNOL, V55, P381; Reid SW, 1996, J EXP MED, V184, P2279, DOI 10.1084/jem.184.6.2279; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Varga SM, 1998, J IMMUNOL, V161, P3215; Wang H, 1999, J IMMUNOL, V162, P4177; Zajac AJ, 1996, P NATL ACAD SCI USA, V93, P14730, DOI 10.1073/pnas.93.25.14730; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125	45	61	61	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					795	800		10.1038/89915	http://dx.doi.org/10.1038/89915			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433343				2022-12-25	WOS:000169808600030
J	Cumming, RC; Lightfoot, J; Beard, K; Youssoufian, H; O'Brien, PJ; Buchwald, M				Cumming, RC; Lightfoot, J; Beard, K; Youssoufian, H; O'Brien, PJ; Buchwald, M			Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1	NATURE MEDICINE			English	Article							DISULFIDE-BOND FORMATION; GLUTATHIONE TRANSFERASES; INTERLEUKIN-3 WITHDRAWAL; STRESS; GENE; FAC; OVEREXPRESSION; IDENTIFICATION; INACTIVATION; LOCALIZATION	The Fanconi anemia group C protein (FANCC) plays an important role in hematopoiesis by ensuring the survival of hematopoietic progenitor cells through an unknown mechanism. We investigated the function of FANCC by identifying FANCC-binding proteins in hematopoietic cells. Here we show that glutathione S-transferase P1-1 (GSTP1) interacts with FANCC, and that overexpression of both proteins in a myeloid progenitor cell line prevents apoptosis following factor deprivation. FANCC increases GSTP1 activity after the induction of apoptosis. GSTP1 is an enzyme that catalyzes the detoxification of xenobiotics and by-products of oxidative stress, and it is frequently upregulated in neoplastic cells. Although FANCC lacks homology with conventional disulfide reductases, it functions by preventing the formation of inactivating disulfide bonds within GSTP1 during apoptosis. The prevention of protein oxidation by FANCC reveals a novel mechanism of enzyme regulation during apoptosis and has implications for the treatment of degenerative diseases with thiol reducing agents.	Hosp Sick Children, Res Inst, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Grad Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Fac Pharm, Toronto, ON, Canada; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Baylor College of Medicine	Buchwald, M (corresponding author), Hosp Sick Children, Res Inst, Program Genet & Genom Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	buchwald@sickkids.on.ca	Cumming, Robert/G-2185-2010					Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Bojes HK, 1999, CELL DEATH DIFFER, V6, P61, DOI 10.1038/sj.cdd.4400452; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Garcia-Higuera I, 1999, Curr Opin Hematol, V6, P83, DOI 10.1097/00062752-199903000-00005; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Haneline LS, 1998, BLOOD, V91, P4092; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hoshino T, 1998, BLOOD, V91, P4379, DOI 10.1182/blood.V91.11.4379.411k14_4379_4386; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; JOENJE H, 1989, FANCONI ANEMIA CLIN, P174; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Kruyt FAE, 1998, BLOOD, V92, P3050, DOI 10.1182/blood.V92.9.3050.421k56_3050_3056; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Otsuki T, 1999, J CELL PHYSIOL, V179, P79, DOI 10.1002/(SICI)1097-4652(199904)179:1<79::AID-JCP10>3.0.CO;2-O; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Ruppitsch W, 1998, FEBS LETT, V422, P99, DOI 10.1016/S0014-5793(97)01608-6; SATO K, 1989, ADV CANCER RES, V52, P205; SHEA TC, 1988, CANCER RES, V48, P527; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; TERADA T, 1993, ARCH BIOCHEM BIOPHYS, V300, P495, DOI 10.1006/abbi.1993.1067; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang JX, 1998, CANCER RES, V58, P3538; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wong JCY, 1997, MAMM GENOME, V8, P522, DOI 10.1007/s003359900490; Yin ZM, 2000, CANCER RES, V60, P4053; Youssoufian H, 1996, J CLIN INVEST, V97, P2003, DOI 10.1172/JCI118635; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	45	184	185	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2001	7	7					814	820		10.1038/89937	http://dx.doi.org/10.1038/89937			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433346				2022-12-25	WOS:000169808600033
J	Ellson, CD; Gobert-Gosse, S; Anderson, KE; Davidson, K; Erdjument-Bromage, H; Tempst, P; Thuring, JW; Cooper, MA; Lim, ZY; Holmes, AB; Gaffney, PRJ; Coadwell, J; Chilvers, ER; Hawkins, PT; Stephens, LR				Ellson, CD; Gobert-Gosse, S; Anderson, KE; Davidson, K; Erdjument-Bromage, H; Tempst, P; Thuring, JW; Cooper, MA; Lim, ZY; Holmes, AB; Gaffney, PRJ; Coadwell, J; Chilvers, ER; Hawkins, PT; Stephens, LR			Ptdlns(3)P regulates the neutrophil oxidase complex by binding to the PX domain of p40(phox)	NATURE CELL BIOLOGY			English	Article							NADPH OXIDASE; COMPONENT; PROTEINS	The production of reactive oxygen species (ROS) by neutrophils has a vital role in defence against a range of infectious agents, and is driven by the assembly of a multi-protein complex containing a minimal core of five proteins: the two membrane-bound subunits of cytochrome b(558) (gp91(phox) and p22(phox)) and three soluble factors (GTP-Rac, p47(phox) and p67(phox) (refs 1, 2). This minimal complex can reconstitute ROS formation in vitro in the presence of non-physiological amphiphiles such as sos, p40(phox) has subsequently been discovered as a binding partner for p67(phox) (ref. 3), but its role in ROS formation is unclear, Phosphoinositide-3-OH kinases (PI(3)Ks) have been implicated in the intracellular signalling pathways coordinating ROS formation(4,5) but through an unknown mechanism. We show that the addition of p40(phox) to the minimal core complex allows a lipid product of PI(3)Ks, phosphatidylinositol 3-phosphate (PtdIns(3)P), to stimulate specifically the formation of ROS, This effect was mediated by binding of PtdIns(S)P to the PX domain(6) of p40(phox). These results offer new insights into the roles for PI(3)Ks and p40(phox) in ROS formation and define a cellular ligand for the orphan PX domain.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Univ Lyon 1, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ Cambridge, Sch Clin Med, Dept Med, Div Resp Med, Cambridge CB2 2QQ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Memorial Sloan Kettering Cancer Center; University of Cambridge; University of London; University College London; University of Cambridge	Stephens, LR (corresponding author), Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England.	len.stephens@bbsrc.ac.uk	stephanie, gobert/AAC-4061-2020; Cooper, Matthew A./C-7988-2009	Cooper, Matthew A./0000-0003-3147-3460; Chilvers, Edwin/0000-0002-4230-9677; stephens, len/0000-0002-2771-3487; Tempst, Paul/0000-0002-6680-3987; Anderson, Karen/0000-0002-7394-6660; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Hawkins, Phillip/0000-0002-6979-0464				ABO A, 1992, J BIOL CHEM, V267, P16767; Condliffe AM, 1998, FEBS LETT, V439, P147, DOI 10.1016/S0014-5793(98)01358-1; Condliffe AM, 2000, NATURE, V404, P135, DOI 10.1038/35004693; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P184; DIEHOLD BA, 2001, NATURE IMMUNOL, V2, P211; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Painter GF, 1999, J CHEM SOC PERK T 1, P923, DOI 10.1039/a900278b; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; RAGGIOLINI M, 1987, EXP CELL RES, V169, P408; Scianimanico S, 1999, CELL MICROBIOL, V1, P19, DOI 10.1046/j.1462-5822.1999.00002.x; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Stenmark H, 1999, J CELL SCI, V112, P4175; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; WIENTJES FB, 1995, SEMIN CELL BIOL, V6, P357, DOI 10.1016/S1043-4682(05)80006-6; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	19	345	352	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					679	682		10.1038/35083076	http://dx.doi.org/10.1038/35083076			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433301				2022-12-25	WOS:000169727000020
J	Denning, C; Burl, S; Ainslie, A; Bracken, J; Dinnyes, A; Fletcher, J; King, T; Ritchie, M; Ritchie, WA; Rollo, M; de Sousa, P; Travers, A; Wilmut, I; Clark, AJ				Denning, C; Burl, S; Ainslie, A; Bracken, J; Dinnyes, A; Fletcher, J; King, T; Ritchie, M; Ritchie, WA; Rollo, M; de Sousa, P; Travers, A; Wilmut, I; Clark, AJ			Deletion of the alpha(1,3)galactosyl transferase (GGTA1) gene and the prion protein (PrP) gene in sheep	NATURE BIOTECHNOLOGY			English	Article							CLONED TRANSGENIC CALVES; FETAL FIBROBLASTS; NUCLEAR TRANSFER; SOMATIC-CELLS; MICE; SCRAPIE; ALPHA-1,3-GALACTOSYLTRANSFERASE; XENOTRANSPLANTATION; RESISTANT	Nuclear transfer offers a cell-based route for producing precise genetic modifications in a range of animal species. Using sheep, we report reproducible targeted gene deletion at two independent loci in fetal fibroblasts. Vital regions were deleted from the alpha (1,3)galactosyl transferase (GGTA1)gene, which may account for the hyperacute rejection of xenografted organs, and from the prion protein (PrP) gene, which is directly associated with spongiform encephalopathies in humans and animals. Reconstructed embryos were prepared using cultures of targeted or nontargeted donor cells. Eight pregnancies were maintained to term and four PrP-/+ lambs were born. Although three of these perished soon after birth, one survived for 12 days. These data show that lambs carrying targeted gene deletions can be generated by nuclear transfer.	Roslin Inst, Dept Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Clark, AJ (corresponding author), Roslin Inst, Dept Gene Express & Dev, Roslin EH25 9PS, Midlothian, Scotland.		De Sousa, Paul A/H-7416-2013; denning, chris/D-4777-2013; Dinnyes, Andras/D-5131-2013	De Sousa, Paul A/0000-0003-0745-2504; Dinnyes, Andras/0000-0003-3791-2583; Denning, Chris/0000-0003-0802-8617				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Clark AJ, 2000, TRANSGENIC RES, V9, P263, DOI 10.1023/A:1008974616402; Crick SJ, 1998, J ANAT, V193, P105, DOI 10.1046/j.1469-7580.1998.19310105.x; De Sousa P. A., 2000, Theriogenology, V53, P214; GALILI U, 1988, J BIOL CHEM, V263, P17755; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; Lee IY, 1998, GENOME RES, V8, P1022, DOI 10.1101/gr.8.10.1022; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Sedivy J. M., 1999, SCIENCE, V283, P9; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; van der Laan LJW, 2000, NATURE, V407, P90, DOI 10.1038/35024089; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; WEISSMANN C, 1994, ANN NY ACAD SCI, V724, P235, DOI 10.1111/j.1749-6632.1994.tb38913.x; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	23	185	254	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					559	562		10.1038/89313	http://dx.doi.org/10.1038/89313			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385461				2022-12-25	WOS:000169081700030
J	McGinnis, RE; Fox, H; Yates, P; Cameron, LA; Barnes, MR; Gray, IC; Spurr, NK; Hurko, O; St Clair, D				McGinnis, RE; Fox, H; Yates, P; Cameron, LA; Barnes, MR; Gray, IC; Spurr, NK; Hurko, O; St Clair, D			Failure to confirm NOTCH4 association with schizophrenia in a large population-based sample from Scotland	NATURE GENETICS			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN GENE; LOCUS; SUSCEPTIBILITY	The NOTCH4 gene was recently reported to be associated with schizophrenia(1) based on TDT analysis of 80 British trios. The strongest evidence for association derived from two microsatellites. We genotyped both loci in a large sample of unrelated Scottish schizophrenics and controls, but failed to replicate the reported association, finding instead that each putative schizophrenia-associated allele had a somewhat lower frequency in schizophrenics than in controls.	SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; Univ Aberdeen, Sch Med, Dept Mental Hlth, Aberdeen, Scotland	GlaxoSmithKline; University of Aberdeen	McGinnis, RE (corresponding author), SmithKline Beecham Pharmaceut, New Frontiers Sci Pk, Harlow CM19 5AD, Essex, England.		St Clair, David/AAN-2412-2021	Barnes, Michael/0000-0001-9097-7381; McGinnis, Ralph/0000-0003-4540-9857				BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; McGinnis R, 2000, AM J HUM GENET, V67, P1340; SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Wei J, 2000, NAT GENET, V25, P376, DOI 10.1038/78044	6	46	47	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					128	129		10.1038/88839	http://dx.doi.org/10.1038/88839			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381258				2022-12-25	WOS:000169011800013
J	Cacalano, NA; Sanden, D; Johnston, JA				Cacalano, NA; Sanden, D; Johnston, JA			Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras	NATURE CELL BIOLOGY			English	Article							RECEPTOR BETA-CHAIN; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; PROTEIN; INTERLEUKIN-2; MEDIATE; KINASE; JAKS; JAB	Suppressors of cytokine signalling (SOCS, also known as CIS and SSI) are encoded by immediate early genes that act in a feedback loop to inhibit cytokine responses and activation of 'signal transducer and activator of transcription' (STAT). Here we show that SOCS-3 is strongly tyrosine-phosphorylated in response to many growth factors, including interleukin-2 (IL-2), erythropoietin (EPO), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). The principal phosphorylation sites on SOCS-3 are residues 204 and 221 at the carboxy terminus, and upon phosphorylation tyrosine 221 interacts with the Ras inhibitor p120 RasGAP. After IL-2 stimulation, phosphorylated SOCS-3 strongly inhibits STAT5 activation but, by binding to RasGAP, maintains activation of extracellular-signal-regulated kinase (ERK). A tyrosine mutant of SOCS-3 still blocks STAT phosphorylation, but also strongly inhibits IL-2-dependent activation of ERK and cell proliferation. Moreover, it also inhibits EPO- and PDGF-induced proliferation and ERK activation. Therefore, although SOCS proteins inhibit growth-factor responses, tyrosine phosphorylation of SOCS-3 can ensure cell survival and proliferation through the Ras pathway.	DNAX Res Inst Mol & Cellular Biol Inc, Res Inst, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Cacalano, NA (corresponding author), Queens Univ Belfast, Dept Immunol, Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	jim.johnston@qub.ac.uk						Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 1999, EMBO J, V18, P904; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; MUI, 1996, EMBO J, V5, P2425; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; OShea JJ, 1997, J CLIN IMMUNOL, V17, P431, DOI 10.1023/A:1027388508570; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	164	172	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					460	465		10.1038/35074525	http://dx.doi.org/10.1038/35074525			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331873				2022-12-25	WOS:000168592500015
J	Delgado, M; Abad, C; Martinez, C; Laceta, J; Gomariz, RP				Delgado, M; Abad, C; Martinez, C; Laceta, J; Gomariz, RP			Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; T-CELLS; MACROPHAGES; ANTIBODIES; ACTIVATION; INDUCTION; CYTOKINE	Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease of unknown etiology, characterized by chronic inflammation in the joints and subsequent destruction of the cartilage and bone. We describe here a new strategy for the treatment of arthritis: administration of the neuropeptide vasoactive intestinal peptide (VIP). Treatment with VIP significantly reduced incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease. Our data indicate VIP as a viable candidate for the development of treatments for RA.	Univ Complutense, Fac Biol, Dept Cell Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Delgado, M (corresponding author), Univ Complutense, Fac Biol, Dept Cell Biol, E-28040 Madrid, Spain.		Leceta, Javier/H-6940-2017; Martínez, Carmen/AAC-2077-2020; Delgado, Mario/P-1524-2016; Gomariz, Rosa P./H-2470-2017; Martinez/G-9713-2017	Leceta, Javier/0000-0003-4845-0046; Delgado, Mario/0000-0003-1893-5982; Abad, Catalina/0000-0001-9144-9310; Gomariz, Rosa P./0000-0003-2839-1923; Martinez/0000-0003-3541-0571				BRENNAN FM, 1989, LANCET, V2, P244; Butler DM, 1999, EUR J IMMUNOL, V29, P2205, DOI 10.1002/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z; Butler DM, 1997, J IMMUNOL, V159, P2867; Delgado M, 1999, ANN NY ACAD SCI, V897, P401, DOI 10.1111/j.1749-6632.1999.tb07909.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 1999, J IMMUNOL, V163, P3629; Dinant HJ, 1999, PHARM WORLD SCI, V21, P49, DOI 10.1023/A:1008661630718; Doncarli A, 1997, EUR J IMMUNOL, V27, P1451, DOI 10.1002/eji.1830270623; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Horsfall AC, 1997, J IMMUNOL, V159, P5687; Joosten LAB, 1997, ARTHRITIS RHEUM, V40, P249, DOI 10.1002/art.1780400209; Kusaba M, 1998, J RHEUMATOL, V25, P1466; Malfait AM, 1998, CLIN EXP IMMUNOL, V111, P377; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MORO O, 1996, J BIOL CHEM, V271, P966; Myers LK, 1997, LIFE SCI, V61, P1861, DOI 10.1016/S0024-3205(97)00480-3; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Robbins JR, 1999, DEV BIOL, V212, P255, DOI 10.1006/dbio.1999.9373; Seetharaman R, 1999, J IMMUNOL, V163, P1577; SEKI N, 1988, J IMMUNOL, V140, P1477; Takeba Y, 1999, ARTHRITIS RHEUM-US, V42, P2418, DOI 10.1002/1529-0131(199911)42:11<2418::AID-ANR21>3.0.CO;2-7; TAYLOR PC, 1995, EUR J IMMUNOL, V25, P763, DOI 10.1002/eji.1830250321; Walmsley M, 1996, ARTHRITIS RHEUM-US, V39, P495, DOI 10.1002/art.1780390318; Watt I., 1996, Arthritis and Rheumatism, V39, pS123; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629	33	326	349	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					563	568		10.1038/87887	http://dx.doi.org/10.1038/87887			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329057				2022-12-25	WOS:000169961100035
J	Stoeckli, M; Chaurand, P; Hallahan, DE; Caprioli, RM				Stoeckli, M; Chaurand, P; Hallahan, DE; Caprioli, RM			Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues	NATURE MEDICINE			English	Article							INTRAOPERATIVE DIAGNOSIS; LASER-DESORPTION; NEURONS; MICROSCOPY; CARCINOMA; PEPTIDES; SECTIONS; PATTERN; TUMORS; BRAIN		Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37212 USA	Vanderbilt University	Caprioli, RM (corresponding author), Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37212 USA.				NATIONAL CANCER INSTITUTE [R01CA070937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58506, CA 70937] Funding Source: Medline; NIGMS NIH HHS [GM 58008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Chaurand P, 1999, ANAL CHEM, V71, P5263, DOI 10.1021/ac990781q; Cheng L, 1999, J CLIN ONCOL, V17, P3182, DOI 10.1200/JCO.1999.17.10.3182; Firlik KS, 1999, J NEUROSURG, V91, P454, DOI 10.3171/jns.1999.91.3.0454; Gibbs JF, 1999, ANN SURG ONCOL, V6, P699; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Jimenez CR, 1998, BIOCHEMISTRY-US, V37, P2070, DOI 10.1021/bi971848b; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; LEVISETTI R, 1993, SCANNING MICROSCOPY, V7, P1161; LI KW, 1994, J BIOL CHEM, V269, P30288; Longacre TA, 1999, AM J SURG PATHOL, V23, P69, DOI 10.1097/00000478-199901000-00007; Moroz LL, 1999, J EXP BIOL, V202, P333; NELSON DF, 1993, CLIN ONCOLOGY, P617; Pacholski ML, 1999, CHEM REV, V99, P2977, DOI 10.1021/cr980137w; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; Richter T, 1999, J CLIN PATHOL, V52, P461, DOI 10.1136/jcp.52.6.461; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Shah AB, 1998, ACTA CYTOL, V42, P1149, DOI 10.1159/000332104; Silbergeld DL, 1997, J NEUROSURG, V86, P525, DOI 10.3171/jns.1997.86.3.0525; Stoeckli M, 1999, J AM SOC MASS SPECTR, V10, P67, DOI 10.1016/S1044-0305(98)00126-3; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; Todd PJ, 1997, ANAL CHEM, V69, pA529, DOI 10.1021/ac971763g; Turner RR, 1999, AM J CLIN PATHOL, V112, P627; VALASKOVIC GA, 1992, SCANNING MICROSCOPY, V6, P305; Wang HW, 1999, IEEE T BIO-MED ENG, V46, P1246, DOI 10.1109/10.790502	26	898	948	8	263	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					493	496		10.1038/86573	http://dx.doi.org/10.1038/86573			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283679				2022-12-25	WOS:000167960500047
J	Jang, CW; Chen, CH; Chen, CC; Chen, JY; Su, YH; Chen, RH				Jang, CW; Chen, CH; Chen, CC; Chen, JY; Su, YH; Chen, RH			TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; PROGRAMMED CELL-DEATH; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL COOPERATION; SIGNALING PATHWAYS; DOWN-REGULATION; LEUKEMIA CELLS; RECEPTOR; PROTEIN; ACTIVATION	Transforming growth factor-beta (TGF-beta) and TGF-beta-related factors induce apoptosis in a variety of tissues; however, the mechanism underlying this induction is largely unknown. Here, we demonstrate that TGF-beta induces the expression of the death-associated protein kinase (DAP-kinase) as an immediate early response in cells that undergo apoptosis in response to TGF-beta. DAP-kinase is a positive mediator of apoptosis induced by certain cytokines and oncogenes. We show that the DAP-kinase promoter is activated by TGF-beta through the action of Smad2, Smad3 and Smad4. Overexpression of DAP-kinase triggers apoptosis in the absence of TGF-beta, whereas inhibition of DAP-kinase activity protects cells from TGF-beta-induced apoptosis, blocks TGF-beta-induced release of cytochrome c from mitochondria and prevents TGF-beta-induced dissipation of the mitochondrial membrane potential. Our findings indicate that DAP-kinase mediates TGF-beta-dependent apoptosis by linking Smads to mitochondrial-based pro-apoptotic events.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 100, Taiwan	National Taiwan University	Jang, CW (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 100, Taiwan.		Chen, Ruey-Hwa/G-6121-2019; Su, Yi-Hsien/F-2910-2014	Chen, Ruey-Hwa/0000-0001-8124-5832; 				Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Brodin G, 1999, CANCER RES, V59, P2731; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Macias D, 1997, DEVELOPMENT, V124, P1109; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Merino R, 1999, ANN NY ACAD SCI, V887, P120, DOI 10.1111/j.1749-6632.1999.tb07927.x; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Park US, 2000, ONCOGENE, V19, P3384, DOI 10.1038/sj.onc.1203674; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Takiya S, 1995, J CLIN PATHOL, V48, P1093, DOI 10.1136/jcp.48.12.1093; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	50	326	339	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					51	58		10.1038/ncb731	http://dx.doi.org/10.1038/ncb731			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11740493	Green Published			2022-12-25	WOS:000173381500016
J	Osborne, LR; Li, M; Pober, B; Chitayat, D; Bodurtha, J; Mandel, A; Costa, T; Grebe, T; Cox, S; Tsui, LC; Scherer, SW				Osborne, LR; Li, M; Pober, B; Chitayat, D; Bodurtha, J; Mandel, A; Costa, T; Grebe, T; Cox, S; Tsui, LC; Scherer, SW			A 1.5 million-base pair inversion polymorphism in families with Williams-Beuren syndrome	NATURE GENETICS			English	Article							SYNDROME-DELETION; INSITU HYBRIDIZATION; ELASTIN GENE; 7Q11.23; DNA; HEMIZYGOSITY; SEQUENCES; DISORDER; REPEATS; REGION	Williams-Beuren syndrome (WBS) is most often caused by hemizygous deletion of a 1.5-Mb interval encompassing at least 17 genes at 7q11.23 (refs. 1,2). As with many other haploinsufficiency diseases, the mechanism underlying the WBS deletion is thought to be unequal meiotic recombination, probably mediated by the highly homologous DNA that flanks the commonly deleted region(3). Here, we report the use of interphase fluorescence in situ hybridization (FISH) and pulsed-field gel electrophoresis (PFGE) to identify a genomic polymorphism in families with WBS, consisting of an inversion of the WBS region. We have observed that the inversion is hemizygous in 3 of 11 (27%) atypical affected individuals who show a subset of the WBS phenotypic spectrum but do not carry the typical WBS microdeletion. Two of these individuals also have a parent who carries the inversion. In addition, in 4 of 12 (33%) families with a proband carrying the WBS deletion, we observed the inversion exclusively in the parent transmitting the disease-related chromosome. These results suggest the presence of a newly identified genomic variant within the population that may be associated with the disease. It may result in predisposition to primarily WBS-causing microdeletions, but may also cause translocations and inversions.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Hosp Sick Children, Dept Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA USA; Atlantic Res Ctr, Dept Pediat, Halifax, NS, Canada; Univ Arizona, Phoenix Genet Program, Phoenix, AZ USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Yale University; Virginia Commonwealth University; University of Arizona	Scherer, SW (corresponding author), Univ Toronto, Dept Mol & Med Genet, 1 Kings Coll Cirle, Toronto, ON, Canada.	steve@genet.sickkids.on.ca	Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999	Canadian Institutes of Health Research [38103] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Baumer A, 1998, HUM MOL GENET, V7, P887, DOI 10.1093/hmg/7.5.887; Botta A, 1999, J MED GENET, V36, P478; Chute I, 1997, GENOMICS, V46, P51, DOI 10.1006/geno.1997.5007; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; Giglio S, 2001, AM J HUM GENET, V68, P874, DOI 10.1086/319506; Gorlach A, 1997, J CLIN INVEST, V100, P1907, DOI 10.1172/JCI119721; GREEN JE, 1990, AIDS RES HUM RETROV, V6, P85; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Ji YG, 2000, GENOME RES, V10, P597, DOI 10.1101/gr.10.5.597; Jobling MA, 1998, CURR BIOL, V8, P1391, DOI 10.1016/S0960-9822(98)00020-7; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kara-Mostefa A, 1999, AM J HUM GENET, V64, P1475, DOI 10.1086/302362; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LOWERY MC, 1995, AM J HUM GENET, V57, P49; MARI A, 1995, HUM GENET, V96, P444; Meng X, 1998, GENOMICS, V52, P130, DOI 10.1006/geno.1998.5412; NICKERSON E, 1995, AM J HUM GENET, V56, P1156; Osborne LR, 1999, MOL GENET METAB, V67, P1, DOI 10.1006/mgme.1999.2844; Osborne LR, 1997, GENOMICS, V45, P402, DOI 10.1006/geno.1997.4923; Peoples R, 2000, AM J HUM GENET, V66, P47, DOI 10.1086/302722; Pezzi N, 2000, FASEB J, V14, P581, DOI 10.1096/fasebj.14.3.581; Pober BR, 1996, CHILD ADOL PSYCH CL, V5, P929, DOI 10.1016/S1056-4993(18)30341-9; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; Tassabehji M, 1999, AM J HUM GENET, V64, P118, DOI 10.1086/302214; Valero MC, 2000, GENOMICS, V69, P1, DOI 10.1006/geno.2000.6312; von Dadelszen P, 2000, AM J MED GENET, V90, P270, DOI 10.1002/(SICI)1096-8628(20000214)90:4<270::AID-AJMG2>3.0.CO;2-R	30	222	235	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					321	325		10.1038/ng753	http://dx.doi.org/10.1038/ng753			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11685205	Green Accepted			2022-12-25	WOS:000171911000020
J	Rietdorf, J; Ploubidou, A; Reckmann, I; Holmstrom, A; Frischknecht, F; Zettl, M; Zimmermann, T; Way, M				Rietdorf, J; Ploubidou, A; Reckmann, I; Holmstrom, A; Frischknecht, F; Zettl, M; Zimmermann, T; Way, M			Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus	NATURE CELL BIOLOGY			English	Article							ALDRICH-SYNDROME PROTEIN; AXONAL-TRANSPORT; TYROSINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; ANTEROGRADE TRANSPORT; VIRAL TRANSPORT; CELL; MEMBRANE; GOLGI; GLYCOPROTEIN	Vaccinia virus, a close relative of the causative agent of smallpox, exploits actin polymerization to enhance its cell-to-cell spread. We show that actin-based motility of vaccinia is initiated only at the plasma membrane and remains associated with it. There must therefore be another form of cytoplasmic viral transport, from the cell centre, where the virus replicates, to the periphery. Video analysis reveals that GFP-labelled intracellular enveloped virus particles (IEVs) move from their perinuclear site of assembly to the plasma membrane on microtubules. We show that the viral membrane protein A36R, which is essential for actin-based motility of vaccinia, is also involved in microtubule-mediated movement of IEVs. We further show that conventional kinesin is recruited to IEVs via the light chain TPR repeats and is required for microtubule-based motility of the virus. Vaccinia thus sequentially exploits the microtubule and actin cytoskeletons to enhance its cell-to-cell spread.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Way, M (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.	m.way@ICRF.icnet.uk	Zimmermann, Timo/G-1681-2015	Zimmermann, Timo/0000-0001-7098-0700; Way, Michael/0000-0001-7207-2722; Frischknecht, Friedrich/0000-0002-8332-6668				Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; BLASCO R, 1993, J VIROL, V67, P3319, DOI 10.1128/JVI.67.6.3319-3325.1993; BLASCO R, 1992, J VIROL, V66, P4170, DOI 10.1128/JVI.66.7.4170-4179.1992; BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Chanson H, 1996, J HYDRAUL RES, V34, P279, DOI 10.1080/00221689609498505; Cudmore S, 1996, J CELL SCI, V109, P1739; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; Frankel G, 2001, TRENDS MICROBIOL, V9, P214, DOI 10.1016/S0966-842X(01)02016-9; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Goosney DL, 2000, ANNU REV CELL DEV BI, V16, P173, DOI 10.1146/annurev.cellbio.16.1.173; Goosney DL, 2001, INFECT IMMUN, V69, P3315, DOI 10.1128/IAI.69.5.3315-3322.2001; Gross BS, 1999, BLOOD, V94, P4166, DOI 10.1182/blood.V94.12.4166.424k36_4166_4176; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Herrera E, 1998, J VIROL, V72, P294, DOI 10.1128/JVI.72.1.294-302.1998; HILLER G, 1985, J VIROL, V55, P651, DOI 10.1128/JVI.55.3.651-659.1985; HIRT P, 1986, J VIROL, V58, P757, DOI 10.1128/JVI.58.3.757-764.1986; Holland DJ, 1999, J VIROL, V73, P8503, DOI 10.1128/JVI.73.10.8503-8511.1999; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; Hollinshead M, 2001, J CELL BIOL, V154, P389, DOI 10.1083/jcb.200104124; Kalman D, 1999, NAT CELL BIOL, V1, P389, DOI 10.1038/14087; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2000, CURR OPIN CELL BIOL, V12, P503, DOI 10.1016/S0955-0674(00)00123-X; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Leopold PL, 2000, HUM GENE THER, V11, P151, DOI 10.1089/10430340050016238; Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929; Mathew E, 1998, J VIROL, V72, P2429, DOI 10.1128/JVI.72.3.2429-2438.1998; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; McIntosh AAG, 1996, J VIROL, V70, P272, DOI 10.1128/JVI.70.1.272-281.1996; Miranda-Saksena M, 2000, J VIROL, V74, P1827, DOI 10.1128/JVI.74.4.1827-1839.2000; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Ong LL, 2000, J BIOL CHEM, V275, P32854, DOI 10.1074/jbc.M005650200; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; PENFOLD MET, 1994, P NATL ACAD SCI USA, V91, P6529, DOI 10.1073/pnas.91.14.6529; Ploubidou A, 2000, EMBO J, V19, P3932, DOI 10.1093/emboj/19.15.3932; Ploubidou A, 2001, CURR OPIN CELL BIOL, V13, P97, DOI 10.1016/S0955-0674(00)00180-0; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rogers SL, 2000, CURR OPIN CELL BIOL, V12, P57, DOI 10.1016/S0955-0674(99)00057-5; Rottger S, 1999, J VIROL, V73, P2863; Sanderson CM, 1998, J VIROL, V72, P1235, DOI 10.1128/JVI.72.2.1235-1243.1998; Sanderson CM, 1998, J GEN VIROL, V79, P1415, DOI 10.1099/0022-1317-79-6-1415; SAWIN KE, 1992, J CELL SCI, V101, P303; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; Sheetz MP, 1999, EUR J BIOCHEM, V262, P19, DOI 10.1046/j.1432-1327.1999.00340.x; SIEGERT F, 1989, J CELL SCI, V93, P325; Sodeik B, 2000, TRENDS MICROBIOL, V8, P465, DOI 10.1016/S0966-842X(00)01824-2; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Tolonen N, 2001, MOL BIOL CELL, V12, P2031, DOI 10.1091/mbc.12.7.2031; Toomre D, 1999, J CELL SCI, V112, P21; TSUTSUI K, 1983, J ELECTRON MICROSC, V32, P125; VALE RD, 1999, KINESIN CONVENTIONAL, P398; Vallance BA, 2000, P NATL ACAD SCI USA, V97, P8799, DOI 10.1073/pnas.97.16.8799; van Eijl H, 2000, VIROLOGY, V271, P26, DOI 10.1006/viro.2000.0260; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Ward BM, 2001, J VIROL, V75, P4802, DOI 10.1128/JVI.75.10.4802-4813.2001; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Wolffe EJ, 1997, J VIROL, V71, P3904, DOI 10.1128/JVI.71.5.3904-3915.1997; Wolffe EJ, 1998, VIROLOGY, V244, P20, DOI 10.1006/viro.1998.9103; Wolffe EJ, 2001, J VIROL, V75, P303, DOI 10.1128/JVI.75.1.303-310.2001	64	220	229	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					992	1000		10.1038/ncb1101-992	http://dx.doi.org/10.1038/ncb1101-992			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715020				2022-12-25	WOS:000172070300014
J	Braybrook, C; Doudney, K; Marcano, ACB; Arnason, A; Bjornsson, A; Patton, MA; Goodfellow, PJ; Moore, GE; Stanier, P				Braybrook, C; Doudney, K; Marcano, ACB; Arnason, A; Bjornsson, A; Patton, MA; Goodfellow, PJ; Moore, GE; Stanier, P			The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia	NATURE GENETICS			English	Article							FAMILY; CPX; EXPRESSION; MUTATIONS; LINKAGE; XQ21.3; LIMB	Formation of the secondary palate is a complex step during craniofacial development. Disturbance of the events affecting palatogenesis results in a failure of the palate to close. As a consequence of deformity, an affected child will have problems with feeding, speech, hearing, dentition and psychological development. Cleft palate occurs frequently, affecting approximately 1 in 1,500 births; it is usually considered a sporadic occurrence(1) resulting from an interaction between genetic and environmental factors(2). Although several susceptibility loci have been implicated, attempts to link genetic variation to functional effects have met with little success(3). Cleft palate with ankyloglossia (CPX; MIM 303400) is inherited as a semidominant X-linked disorder previously described in several large families of different ethnic origins(4-11) and has been the subject of several studies that localized the causative gene to Xq21 (refs. 10-13). Here we show that CPX is caused by mutations in the gene encoding the recently described T-box transcription factor TBX22 (ref. 14). Members of the T-box gene family are known to play essential roles in early vertebrate development, especially in mesoderm specification(15). We demonstrate that TBX22 is a major gene determinant crucial to human palatogenesis. The spectrum of nonsense, splice-site, frameshift and missense mutations we have identified in this study indicates that the cleft phenotype results from a complete loss of TBX22 function.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England; Univ Sao Paulo, Hosp Reabilitacao Anomalias Craniofaciais, Dept Genet, Sao Paulo, Brazil; Univ Hosp, Dept Plast Surg, IS-101 Reykjavik, Iceland; Univ London St Georges Hosp, Sch Med, Med Genet Unit, London SW17 0RE, England; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Bloodbank, IS-101 Reykjavik, Iceland	Imperial College London; Universidade de Sao Paulo; Landspitali National University Hospital; St Georges University London; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Stanier, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Du Cane Rd,Hammersmith Campus, London W12 0NN, England.		Doudney, Kit/Q-9728-2019; Stanier, Philip/C-1593-2008; Moore, Gudrun/A-2092-2009	Doudney, Kit/0000-0002-0089-1152; Stanier, Philip/0000-0001-9340-8117; Moore, Gudrun/0000-0002-2099-3420				Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BIXLER D, 1987, AM J MED GENET, V28, P503, DOI 10.1002/ajmg.1320280229; BJORNSSON A, 1989, CLEFT PALATE J, V26, P3; Braybrook C, 2001, HUM GENET, V108, P537, DOI 10.1007/s004390100518; Braybrook C, 2001, GENOMICS, V72, P128, DOI 10.1006/geno.2000.6478; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; Forbes SA, 1996, GENOMICS, V31, P36, DOI 10.1006/geno.1996.0006; FRASER FC, 1980, CURRENT RES TRENDS P, P357; GORSKI SM, 1992, AM J HUM GENET, V50, P1129; GORSKI SM, 1994, HUM GENET, V94, P141; HALL B D, 1987, American Journal of Medical Genetics, V26, P239, DOI 10.1002/ajmg.1320260140; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Laugier-Anfossi F, 2000, GENE, V255, P289, DOI 10.1016/S0378-1119(00)00326-7; LECK I, 1984, BRIT MED BULL, V40, P390, DOI 10.1093/oxfordjournals.bmb.a072010; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; LOWRY RB, 1970, PEDIATRICS, V46, P123; MOORE GE, 1987, NATURE, V326, P91, DOI 10.1038/326091a0; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Prescott NJ, 2000, HUM GENET, V106, P345, DOI 10.1007/s004390051048; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Richardson MP, 1998, GENE, V206, P145, DOI 10.1016/S0378-1119(97)00586-6; ROLLNICK BR, 1986, AM J MED GENET, V24, P465, DOI 10.1002/ajmg.1320240309; RUSHTON AR, 1979, HUM GENET, V48, P179, DOI 10.1007/BF00286901; Sozen MA, 2001, NAT GENET, V29, P141, DOI 10.1038/ng740; STANIER P, 1993, GENOMICS, V17, P549, DOI 10.1006/geno.1993.1370; Tada M, 2001, DEV GROWTH DIFFER, V43, P1; Wakeling EL, 1998, EUR J HUM GENET, V6, P158, DOI 10.1038/sj.ejhg.5200179; WIKTOP CJ, 1967, HDB CONGENITAL MALFO; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0	32	186	194	2	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					179	183		10.1038/ng730	http://dx.doi.org/10.1038/ng730			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11559848				2022-12-25	WOS:000171374100024
J	Capecchi, MR				Capecchi, MR			Generating mice with targeted mutations	NATURE MEDICINE			English	Editorial Material							CULTURED MAMMALIAN-CELLS; EMBRYONIC STEM-CELLS; BETA-GLOBIN GENE; THYMIDINE KINASE GENE; HOMOLOGOUS RECOMBINATION; CARCINOMA-CELLS; MOUSE EMBRYOS; GERM-LINE; TERATOCARCINOMA CELLS; DNA-SEQUENCES		Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Capecchi, MR (corresponding author), Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84132 USA.							BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; COSTANTINI F, 1981, NATURE, V294, P92, DOI 10.1038/294092a0; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS M, 1981, J REPROD FERTIL, V62, P625; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; EVANS MJ, 1972, J EMBRYOL EXP MORPH, V28, P163; EVANS MJ, 1975, ROCH S TER DIFF; EVANS MJ, 1983, GENETIC MANIPULATION; FOLGER K, 1984, COLD SPRING HARB SYM, V49, P123, DOI 10.1101/SQB.1984.049.01.016; FOLGER KR, 1985, MOL CELL BIOL, V5, P59, DOI 10.1128/MCB.5.1.59; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8927, DOI 10.1073/pnas.86.22.8927; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LEVINSON B, 1982, NATURE, V295, P568, DOI 10.1038/295568a0; LOVELLBADGE RH, 1980, J EMBRYOL EXP MORPH, V59, P187; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; Pierce G B, 1967, Curr Top Dev Biol, V2, P223; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMITHIES O, 1955, NATURE, V176, P1265, DOI 10.1038/1761265a0; SMITHIES O, 1962, NATURE, V196, P232, DOI 10.1038/196232a0; SMITHIES O, 1967, SCIENCE, V157, P267, DOI 10.1126/science.157.3786.267; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SMITHIES O, 1953, BIOCHEM J, V55, P57, DOI 10.1042/bj0550057; Stevens L C, 1967, Adv Morphog, V6, P1; STINNAKRE MG, 1981, J EMBRYOL EXP MORPH, V61, P117; Sturtevant AH, 1925, GENETICS, V10, P117; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; WAGNER EF, 1981, P NATL ACAD SCI-BIOL, V78, P5016, DOI 10.1073/pnas.78.8.5016; WAGNER TE, 1981, P NATL ACAD SCI-BIOL, V78, P6376, DOI 10.1073/pnas.78.10.6376; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG EA, 1987, MOL CELL BIOL, V7, P2294, DOI 10.1128/MCB.7.6.2294	51	75	90	1	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2001	7	10					1086	1090		10.1038/nm1001-1086	http://dx.doi.org/10.1038/nm1001-1086			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590420				2022-12-25	WOS:000171524500015
J	Gorelik, L; Flavell, RA				Gorelik, L; Flavell, RA			Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells	NATURE MEDICINE			English	Article							TGF-BETA; CTLA-4 BLOCKADE; ANTIGEN; LYMPHOCYTES; EXPRESSION; INDUCTION; SECRETION; RESPONSES; TOLERANCE; ANTIBODY	Despite the existence of tumor-specific antigens and demonstrated presence of tumor-specific immune cells, the majority of tumors manage to avoid immune-mediated destruction. Various mechanisms have been suggested for tumor evasion from immune response. One such mechanism is thought to be mediated by transforming growth factor-beta (TGF-beta), an immunosuppressive cytokine found at the site of most tumors. We demonstrate here that T-cell-specific blockade of TGF-beta signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells. In addition, we provide mechanisms through which abrogation of TGF-beta signaling leads to the enhancement of anti-tumor immunity. Our data indicate that T-cell-specific blockade of TGF-beta signaling has strong therapeutic potential to shift the balance of the immune response in favor of anti-tumor immunity.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute	Flavell, RA (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA.							Agarwal RK, 1999, J IMMUNOL, V162, P2648; AWWAD M, 1988, J EXP MED, V168, P2193, DOI 10.1084/jem.168.6.2193; Chakravarthy D, 1999, INT J ONCOL, V15, P187; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 1996, J IMMUNOL, V156, P4298; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lefrancois L, 2000, J IMMUNOL, V164, P725, DOI 10.4049/jimmunol.164.2.725; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; Maeda H, 1996, J IMMUNOL, V156, P73; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NELSON RC, 1994, SPORT SCI REV, V3, P1; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Seo N, 1999, J IMMUNOL, V163, P242; Shrikant P, 1999, IMMUNITY, V11, P483, DOI 10.1016/S1074-7613(00)80123-5; Sotomayor EM, 1999, P NATL ACAD SCI USA, V96, P11476, DOI 10.1073/pnas.96.20.11476; Sullivan TJ, 2001, P NATL ACAD SCI USA, V98, P2587, DOI 10.1073/pnas.051632398; Tamada K, 1997, J IMMUNOL, V158, P4846; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; VANROOZENDAAL CEP, 1995, MOL CELL ENDOCRINOL, V111, P1, DOI 10.1016/0303-7207(95)03539-J	25	607	663	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1118	1122		10.1038/nm1001-1118	http://dx.doi.org/10.1038/nm1001-1118			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590434				2022-12-25	WOS:000171524500032
J	Guillemin, K; Williams, T; Krasnow, MA				Guillemin, K; Williams, T; Krasnow, MA			A nuclear lamin is required for cytoplasmic organization and egg polarity in Drosophila	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA; MUSCULAR-DYSTROPHY; SPATIAL-ORGANIZATION; GENE-EXPRESSION; TRACHEAL SYSTEM; PORE COMPLEXES; A/C GENE; LOCALIZATION; GURKEN; OOGENESIS	Nuclear lamins are intermediate filaments that compose the nuclear lamina - the filamentous meshwork underlying the inner nuclear membrane - and are required for nuclear assembly, organization and maintenance. Here we present evidence that a nuclear lamin is also required for cytoplasmic organization in two highly polarized cell types. Zygotic loss-of-function mutations in the Drosophila gene encoding the principal lamin (Dm(0)) disrupt the directed outgrowth of cytoplasmic extensions from terminal cells of the tracheal system. Germline mutant clones disrupt dorsal-ventral polarity of the oocyte. In mutant oocytes, transcripts of the dorsal determinant Gurken, a transforming growth factor-alpha homologue, fail to localize properly around the anterodorsal surface of the oocyte nucleus; their ventral spread results in dorsalized eggs that resemble those of the classical dorsalizing mutations squid and fs(1)K10. The requirement of a nuclear lamin for cytoplasmic as well as nuclear organization has important implications for both the cellular functions of lamins and the pathogenesis of human diseases caused by lamin mutations.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Krasnow, MA (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.		Alioto, Tyler/AAF-6342-2020; Alioto, Tyler/K-7267-2015	Alioto, Tyler/0000-0002-2960-5420; Alioto, Tyler/0000-0002-2960-5420; Guillemin, Karen/0000-0001-6004-9955				Bonne G, 2000, ANN NEUROL, V48, P170, DOI 10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chou TB, 1996, GENETICS, V144, P1673; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FULTON AB, 1993, J CELL BIOCHEM, V52, P148, DOI 10.1002/jcb.240520206; GRUENBAUM Y, 1988, J CELL BIOL, V106, P585, DOI 10.1083/jcb.106.3.585; Guillemin K, 1996, DEVELOPMENT, V122, P1353; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Marshall Wallace F., 1999, Results and Problems in Cell Differentiation, V25, P283; McGrail M, 1997, DEVELOPMENT, V124, P2409; Mitsui T, 1997, J NEUROPATH EXP NEUR, V56, P94, DOI 10.1097/00005072-199701000-00010; Nilson LA, 1999, CURR TOP DEV BIOL, V44, P203; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; OSMAN M, 1990, GENOMICS, V8, P217, DOI 10.1016/0888-7543(90)90274-X; Peri F, 1999, MECH DEVELOP, V81, P75, DOI 10.1016/S0925-4773(98)00228-7; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Saunders C, 1999, MOL CELL, V3, P43, DOI 10.1016/S1097-2765(00)80173-2; SERANO TL, 1995, MECH DEVELOP, V51, P183, DOI 10.1016/0925-4773(95)00363-0; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; Toniolo D, 1999, CURR OPIN GENET DEV, V9, P275, DOI 10.1016/S0959-437X(99)80041-0; VERHEYEN E, 1994, DROSOPHILA MELANOGAS, P545; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6	33	62	65	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					848	851		10.1038/ncb0901-848	http://dx.doi.org/10.1038/ncb0901-848			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533666				2022-12-25	WOS:000170979600020
J	Savkur, RS; Philips, AV; Cooper, TA				Savkur, RS; Philips, AV; Cooper, TA			Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy	NATURE GENETICS			English	Article							SKELETAL-MUSCLE CELLS; MESSENGER-RNA; BINDING-PROTEIN; TRIPLET REPEAT; CTG REPEAT; CUG REPEAT; EXPRESSION; EXPANSION; VARIANTS; SENSITIVITY	Myotonic dystrophy type 1 (DM1) is caused by a CTG trinucleotide expansion in the 3' untranslated region of the DM protein kinase gene. People with DM1 have an unusual form of insulin resistance caused by a defect in skeletal muscle. Here we demonstrate that alternative splicing of the insulin receptor (IR) pre-mRNA is aberrantly regulated in DM1 skeletal muscle tissue, resulting in predominant expression of the lower-signaling nonmuscle isoform (IR-A). IR-A also predominates in DM1 skeletal muscle cultures, which exhibit a decreased metabolic response to insulin relative to cultures from normal controls. Steady-state levels of CUG-BP, a regulator of pre-mRNA splicing proposed to mediate some aspects of DM1 pathogenesis, are increased in DM1 skeletal muscle; overexpression of CUG-BP in normal cells induces a switch to IR-A. The CUG-BP protein mediates this switch through an intronic element located upstream of the alternatively spliced exon 11, and specifically binds within this element in vitro. These results support a model in which increased expression of a splicing regulator contributes to insulin resistance in DM1 by affecting IR alternative splicing.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Cooper, TA (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.				NIAMS NIH HHS [R01AR45653] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045653] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENECKE H, 1992, J CLIN INVEST, V89, P2066, DOI 10.1172/JCI115819; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DEPIRRO R, 1982, SCIENCE, V216, P311, DOI 10.1126/science.7063889; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Furling D, 1999, ENDOCRINOLOGY, V140, P4244, DOI 10.1210/en.140.9.4244; KELLERER M, 1993, DIABETOLOGIA, V36, P628, DOI 10.1007/BF00404072; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; Korade-Mirnics Z, 1999, HUM MOL GENET, V8, P1017, DOI 10.1093/hmg/8.6.1017; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; Morrone A, 1997, J CLIN INVEST, V99, P1691, DOI 10.1172/JCI119332; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOXLEY RT, 1978, J CLIN INVEST, V62, P857, DOI 10.1172/JCI109198; MOXLEY RT, 1984, ANN NEUROL, V15, P157, DOI 10.1002/ana.410150208; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SARABIA V, 1992, J CLIN INVEST, V90, P1386, DOI 10.1172/JCI116005; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; Tapscott SJ, 2000, SCIENCE, V289, P1701, DOI 10.1126/science.289.5485.1701; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 2001, J BIOL CHEM, V276, P7820, DOI 10.1074/jbc.M005960200; VIALETTES B, 1986, HORM METAB RES, V18, P395, DOI 10.1055/s-2007-1012325; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	39	573	599	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					40	47		10.1038/ng704	http://dx.doi.org/10.1038/ng704			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528389				2022-12-25	WOS:000170781300014
J	Dai, RM; Li, CCH				Dai, RM; Li, CCH			Valosin-containing protein is a multiubiquitin chain targeting factor required in ubiquitin-proteasome degradation	NATURE CELL BIOLOGY			English	Article							AAA-ATPASE; CYCLIN-E; PATHWAY; BINDING; SUBUNIT; INVOLVEMENT; ACTIVATION; HOMOLOG	The ubiquitin-proteasome (Ub-Pr) degradation pathway regulates many cellular activities(1,2), but how ubiquitinated substrates are targeted to the proteasome is not understood. We have shown previously that valosin-containing protein (VCP) physically and functionally targets the ubiquitinated nuclear factor kappaB inhibitor, I kappaB alpha, to the proteasome for degradation(3). VCP is an abundant and a highly conserved member of the AAA (ATPases associated with a variety of cellular activities) family(5-7). Besides acting as a chaperone in membrane fusions, VCP has been shown to have a role in a number of seemingly unrelated cellular activities. Here we report that loss of VCP function results in an inhibition of Ub-Pr-mediated degradation and an accumulation of ubiquitinated proteins. VCP associates with ubiquitinated proteins through the direct binding of its amino-terminal domain to the multi-ubiquitin chains of substrates. Furthermore, its N-terminal domain is required in Ub-Pr-mediated degradation. We conclude that VCP is a multi-ubiquitin chain-targeting factor that is required in the degradation of many Ub-Pr pathway substrates, and provide a common mechanism that underlies many of the functions of VCP.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Li, CCH (corresponding author), NCI, Intramural Res Support Program, SAIC Frederick, Frederick, MD 21702 USA.							Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BECKWITH M, 1990, J NATL CANCER I, V82, P501, DOI 10.1093/jnci/82.6.501; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Leon A, 1999, MOL BIOL CELL, V10, P3825, DOI 10.1091/mbc.10.11.3825; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; MOIR D, 1982, GENETICS, V100, P547; Neuwald AF, 1999, GENOME RES, V9, P27; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yen CH, 2000, J IMMUNOL, V165, P6372, DOI 10.4049/jimmunol.165.11.6372; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Zwickl P, 1999, NAT CELL BIOL, V1, pE97, DOI 10.1038/12097	30	367	369	1	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					740	744		10.1038/35087056	http://dx.doi.org/10.1038/35087056			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483959				2022-12-25	WOS:000170393200019
J	Thornsberry, JM; Goodman, MM; Doebley, J; Kresovich, S; Nielsen, D; Buckler, ES				Thornsberry, JM; Goodman, MM; Doebley, J; Kresovich, S; Nielsen, D; Buckler, ES			Dwarf8 polymorphisms associate with variation in flowering time	NATURE GENETICS			English	Letter							MOLECULAR EVOLUTION; MAIZE; GENE	Historically, association tests have been used extensively in medical genetics(1-2), but have had virtually no application in plant genetics. One obstacle to their application is the structured populations often found in crop plants(3), which may lead to nonfunctional. spurious associations(4). In this study. statistical methods to account for population structure(5) were extended for use with quantitative variation and applied to our evaluation of maize flowering time. Mutagenesis and quantitative trait locus (QTL) studies suggested that the maize gene Dwarf8 might affect the quantitative variation of maize flowering time and plant height(6-8). The wheat orthologs of this gene contributed to the increased yields seen in the 'Green Revolution' varieties(6). We used association approaches to evaluate Dwarf8 sequence polymorphisms from 92 maize inbred lines. Population structure was estimated using a Bayesian analysis(4) of 141 simple sequence repeat (SSR) loci. Our results indicate that a suite of polymorphisms associate with differences in flowering time, which include a deletion that may alter a key domain in the coding region. The distribution of nonsynonymous polymorphisms suggests that Dwarf8 has been a target of selection.	N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; N Carolina State Univ, Dept Crop Sci, Raleigh, NC 27695 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA; N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA; N Carolina State Univ, USDA ARS, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of Wisconsin System; University of Wisconsin Madison; Cornell University; University of North Carolina; North Carolina State University; United States Department of Agriculture (USDA); University of North Carolina; North Carolina State University	Buckler, ES (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	buckler@statgen.ncsu.edu	Peng, Bo/A-6920-2009; Buckler, Edward/L-7651-2019; Buckler, Edward/GPS-4932-2022	Peng, Bo/0000-0001-8225-2284; Buckler, Edward/0000-0002-3100-371X; Nielsen, Dahlia/0000-0003-0123-6085				Hey J, 1997, GENETICS, V145, P833; Kende H, 2001, PLANT PHYSIOL, V125, P81, DOI 10.1104/pp.125.1.81; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOESTER RP, 1993, CROP SCI, V33, P1209, DOI 10.2135/cropsci1993.0011183X003300060020x; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Nei M., 1987, MOL EVOLUTIONARY GEN; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 2000, GENETICS, V155, P945; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; SCHON CC, 1994, CROP SCI, V34, P378, DOI 10.2135/cropsci1994.0011183X003400020014x; TAJIMA F, 1989, GENETICS, V123, P585; TEMPLETON AR, 1995, GENETICS, V140, P403; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; White SE, 1999, GENETICS, V153, P1455	19	786	955	7	199	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2001	28	3					286	289		10.1038/90135	http://dx.doi.org/10.1038/90135			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431702				2022-12-25	WOS:000169656400024
J	Bonni, S; Wang, HR; Causing, CG; Kavsak, P; Stroschein, SL; Luo, KX; Wrana, JL				Bonni, S; Wang, HR; Causing, CG; Kavsak, P; Stroschein, SL; Luo, KX; Wrana, JL			TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation	NATURE CELL BIOLOGY			English	Article							TRANSFORMING-GROWTH-FACTOR; KAPPA-B-ALPHA; SMAD PROTEINS; DEPENDENT DEGRADATION; SKI ONCOPROTEIN; CO-REPRESSOR; RECEPTOR; TRCP; PHOSPHORYLATION; CATENIN	The receptor-regulated Smad proteins are essential intracellular mediators of signal transduction by the transforming growth factor-beta (TGF-beta) superfamily of growth factors and are also important as regulators of gene transcription. Here we describe a new role for TGF-beta -regulated Smad2 and Smad3 as components of a ubiquitin ligase complex. We show that in the presence of TGF-beta signalling, Smad2 interacts through its proline-rich PPXY motif with the tryptophan-rich WW domains of Smurf2, a recently identified E3 ubiquitin ligases. TGF-beta also induces the association of Smurf2 with the transcriptional cc-repressor SnoN and we show that Smad2 can function to mediate this interaction. This allows Smurf2 HECT domain to target SnoN for ubiquitin-mediated degradation by the proteasome. Thus, stimulation by TGF-beta can induce the assembly of a Smad2-Smurf2 ubiquitin ligase complex that functions to target substrates for degradation.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Calif Berkeley, Div Life Sci, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Wrana, JL (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Wrana, Jeffrey/F-8857-2013; Kavsak, Pete/K-8089-2019	Wang, Hong-Rui/0000-0002-2916-8849				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; ROTIN D, 1997, CURR TOP MICROBIOL, P115; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	39	259	282	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					587	595		10.1038/35078562	http://dx.doi.org/10.1038/35078562			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389444				2022-12-25	WOS:000169194400015
J	Chen, G; Hayhurst, A; Thomas, JG; Harvey, BR; Iverson, BL; Georgiou, G				Chen, G; Hayhurst, A; Thomas, JG; Harvey, BR; Iverson, BL; Georgiou, G			Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS)	NATURE BIOTECHNOLOGY			English	Article							PHAGE-DISPLAY; FILAMENTOUS PHAGE; ANTIBODY; SURFACE; SPECIFICITY; SELECTION; MEMBRANE; SYSTEM; MUTAGENESIS; KINETICS	Periplasmic expression with cytometric screening (PECS) is a powerful and rapid "display-less" technology for isolating ligand-binding proteins from diverse libraries. Escherichia coli expressing a library of proteins secreted into the periplasmic space are incubated with a fluorescent conjugate of the target ligand. Under the proper conditions, ligands as large as about 10 kDa can equilibrate within the periplasmic space without compromising the cell's integrity or viability. The bacterial cell envelope effectively serves as a dialysis bag to selectively retain receptor-fluorescent probe complexes but not free ligand. Cells displaying increased fluorescence are then isolated by flow cytometry. We demonstrate that scFv antibodies with both very high and low affinity to digoxigenin can be isolated from libraries screened by PEGS using a benchtop flow cytometer. We also show that preexisting libraries constructed for display on filamentous bacteriophage can be screened by PEGS without the need for subcloning. In fact, PEGS was found to select for proteins that could be missed by conventional phage panning and screening methods.	Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Univ Texas, Dept Chem Engn, Austin, TX USA; Univ Texas, Dept Chem & Biochem, Austin, TX USA; Univ Texas, Biomed Engn Program, Austin, TX USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Iverson, BL (corresponding author), Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA.	biverson@utxvms.cc.utexas.edu; gg@che.utexas.edu		Hayhurst, Andrew/0000-0003-4612-8707				Boder ET, 1998, BIOTECHNOL PROGR, V14, P55, DOI 10.1021/bp970144q; Boder ET, 2000, METHOD ENZYMOL, V328, P430, DOI 10.1016/S0076-6879(00)28410-3; BOEKE JD, 1982, MOL GEN GENET, V186, P185, DOI 10.1007/BF00331849; BRISSETTE JL, 1990, P NATL ACAD SCI USA, V87, P862, DOI 10.1073/pnas.87.3.862; Chen G, 1999, PROTEIN ENG, V12, P349, DOI 10.1093/protein/12.4.349; COREY DR, 1993, GENE, V128, P129; Daugherty PS, 1999, PROTEIN ENG, V12, P613, DOI 10.1093/protein/12.7.613; Daugherty PS, 1998, PROTEIN ENG, V11, P825, DOI 10.1093/protein/11.9.825; Daugherty PS, 2000, J IMMUNOL METHODS, V243, P211, DOI 10.1016/S0022-1759(00)00236-2; DECAD GM, 1976, J BACTERIOL, V128, P325, DOI 10.1128/JB.128.1.325-336.1976; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; Fu AY, 1999, NAT BIOTECHNOL, V17, P1109, DOI 10.1038/15095; Georgiou G, 2001, ADV PROTEIN CHEM, V55, P293, DOI 10.1016/S0065-3233(01)55007-X; Gough KC, 1999, J IMMUNOL METHODS, V228, P97, DOI 10.1016/S0022-1759(99)00080-0; Hayhurst A, 1999, PROTEIN EXPRES PURIF, V15, P336, DOI 10.1006/prep.1999.1035; Homma T, 1982, Tokai J Exp Clin Med, V7 Suppl, P171; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; MacKenzie R, 1998, J IMMUNOL METHODS, V220, P39, DOI 10.1016/S0022-1759(98)00143-4; Maenaka K, 1996, BIOCHEM BIOPH RES CO, V218, P682, DOI 10.1006/bbrc.1996.0122; Marciano DK, 1999, SCIENCE, V284, P1516, DOI 10.1126/science.284.5419.1516; Martinez MB, 1999, J BIOTECHNOL, V71, P59, DOI 10.1016/S0168-1656(99)00015-2; Olsen MJ, 2000, NAT BIOTECHNOL, V18, P1071, DOI 10.1038/80267; Rakonjac J, 1998, J MOL BIOL, V282, P25, DOI 10.1006/jmbi.1998.2006; Rakonjac J, 1999, J MOL BIOL, V289, P1253, DOI 10.1006/jmbi.1999.2851; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; SCHILDBACH JF, 1993, J BIOL CHEM, V268, P21739; SHORT MK, 1995, J BIOL CHEM, V270, P28541, DOI 10.1074/jbc.270.48.28541; Shusta EV, 1999, CURR OPIN BIOTECH, V10, P117, DOI 10.1016/S0958-1669(99)80020-2; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6	32	106	126	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					537	542		10.1038/89281	http://dx.doi.org/10.1038/89281			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385457				2022-12-25	WOS:000169081700026
J	Chiariello, M; Marinissen, MJ; Gutkind, JS				Chiariello, M; Marinissen, MJ; Gutkind, JS			Regulation of c-myc expression by PDGF through Rho GTPases	NATURE CELL BIOLOGY			English	Article							SRC FAMILY KINASES; PROTEIN-COUPLED RECEPTORS; FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; TYROSINE KINASES; CELL-CYCLE; CDC42; ACTIVATION; RAC; BINDING	Src family protein-tyrosine kinases have a central role in several biological functions, including cell adhesion and spreading, chemotaxis, cell cycle progression, differentiation and apoptosis. surprisingly, these kinases also participate in mitogenic signalling by receptors that themselves exhibit an intrinsic protein-tyrosine kinase activity, including those for platelet-derived growth factor (PDGF), epidermal growth factor and colony-stimulating factor-1. Indeed, Src kinases are strictly required for the nuclear expression of the c-myc proto-oncogene and thus for DNA synthesis in response to PDGF. However, the nature of the signalling pathways by which Src kinases participate in the induction of c-myc expression by tyrosine kinase receptors is still unknown. Here we show that PDGF enhances c-myc expression and stimulates the c-myc promoter in a Src-dependent manner, and that neither Ras nor the mitogen-activated protein kinase pathway mediate these effects. In contrast, we present evidence that PDGF stimulates Vav2 through Src, thereby initiating the activation of a Rac-dependent pathway that controls the expression of the c-myc proto-oncogene.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.		Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Chiariello, Mario/0000-0001-8434-5177; Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EISENMAN RN, 1995, NATURE, V378, P438, DOI 10.1038/378438a0; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Waltenberger J, 1999, CIRC RES, V85, P12; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	50	112	112	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					580	586		10.1038/35078555	http://dx.doi.org/10.1038/35078555			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389443				2022-12-25	WOS:000169194400014
J	Shimizu, K; Sugiyama, S; Aikawa, M; Fukumoto, Y; Rabkin, E; Libby, P; Mitchell, RN				Shimizu, K; Sugiyama, S; Aikawa, M; Fukumoto, Y; Rabkin, E; Libby, P; Mitchell, RN			Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy	NATURE MEDICINE			English	Article							CHRONIC REJECTION; EXPRESSION; ORIGIN; GRAFT	Long-term solid-organ allografts typically develop diffuse arterial intimal lesions (graft arterial disease; GAD), consisting of smooth-muscle cells (SMC), extracellular matrix and admired mononuclear leukocytes. GAD eventually culminates in vascular stenosis and ischemic graft failure. Although the exact mechanisms are unknown, chronic low-level alloresponses likely induce inflammatory cells and/or dysfunctional vascular wall cells to secrete growth factors that promote SMC intimal recruitment, proliferation and matrix synthesis(1-3). Although prior work demonstrated that the endothelium and medial SMCs lining GAD lesions in cardiac allografts are donor-derived, the intimal SMC origin could not be determined(4). They are generally presumed to originate from the donor media(5), leading to interventions that target donor medial SMC proliferation, with limited efficacy(6,7). However, other reports indicate that allograft vessels may contain host-derived endothelium and SMCs (refs. 8,9). Moreover, subpopulations of bone-marrow and circulating cells can differentiate into endothelium(10,11), and implanted synthetic vascular grafts are seeded by host SMCs and endothelium(12,13). Here we used murine aortic transplants to formally identify the source of SMCs in GAD lesions. Allografts in beta -galactosidase transgenic recipients showed that intimal SMCs derived almost exclusively from host cells. Bone-marrow transplantation of beta -galactosidase-expressing cells into aortic allograft recipients demonstrated that intimal cells included those of marrow origin. Thus, smooth-muscle-like cells in GAD lesions can originate from circulating bone-marrow-derived precursors.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med,Leducq Ctr Cardiovasc Res, Dept Med,Cardiovasc Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mitchell, RN (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.	rmitchell@rics.bwh.harvard.edu	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X; Aikawa, Masanori/0000-0002-9275-2079; Aikawa, Elena/0000-0001-7835-2135	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043364] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-43364] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND R, 1972, SURGERY, V72, P744; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Campbell JH, 1999, CIRC RES, V85, P1173; DILLEY RJ, 1992, CELL TISSUE RES, V269, P281, DOI 10.1007/BF00319619; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; Hasegawa S, 1998, AM J PATHOL, V153, P69, DOI 10.1016/S0002-9440(10)65547-2; Hayry P, 1998, TRANSPL P, V30, P3993, DOI 10.1016/S0041-1345(98)01316-5; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; KENNEDY LJ, 1971, NEW ENGL J MED, V285, P884, DOI 10.1056/NEJM197110142851603; LIBBY P, 1989, TRANSPLANT P, V21, P3677; LIBBY P, 1994, CLIN TRANSPLANT, V8, P313; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PLISSONNIER D, 1995, TRANSPLANTATION, V60, P414, DOI 10.1097/00007890-199509000-00003; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; WU MHD, 1995, J VASC SURG, V21, P862, DOI 10.1016/S0741-5214(05)80019-9; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	25	398	414	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2001	7	6					738	741		10.1038/89121	http://dx.doi.org/10.1038/89121			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385513				2022-12-25	WOS:000169081500044
J	Bains, W				Bains, W			The parts list of life	NATURE BIOTECHNOLOGY			English	Editorial Material									Amedis Pharmaceut, Royston, England		Bains, W (corresponding author), Amedis Pharmaceut, Royston, England.	williams.bains@amedis-pharma.com						Bains W, 1997, NAT BIOTECHNOL, V15, P396, DOI 10.1038/nbt0597-396; CAIRNSSMITH AG, 1977, BIOSYSTEMS, V9, P105, DOI 10.1016/0303-2647(77)90019-3; CALKINS K, 2001, BIOCENTURY, V9, P1; Cornish-Bowden A, 2000, NAT BIOTECHNOL, V18, P267, DOI 10.1038/73696; Courtneidge SA, 1998, CURR OPIN BIOTECH, V9, P632, DOI 10.1016/S0958-1669(98)80142-0; GOULD SJ, 1994, SCI AM, V271, P85; JONSSON B, 1994, BRIT J PSYCHIAT, V164, P665, DOI 10.1192/bjp.164.5.665; KURGANOV BI, 1990, TRENDS BIOCHEM SCI, V18, P405; Shinbrot T, 2001, NATURE, V410, P251, DOI 10.1038/35065689; Smith DA, 1999, CURR OPIN CHEM BIOL, V3, P373, DOI 10.1016/S1367-5931(99)80056-8; Strohman RC, 1997, NAT BIOTECHNOL, V15, P1224, DOI 10.1038/nbt1197-1224; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Strohman RC, 2000, NAT BIOTECHNOL, V18, P575, DOI 10.1038/76317; Walters WP, 1999, CURR OPIN CHEM BIOL, V3, P384, DOI 10.1016/S1367-5931(99)80058-1	14	21	21	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					401	402		10.1038/88044	http://dx.doi.org/10.1038/88044			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11328996				2022-12-25	WOS:000168394800009
J	Llanos, S; Clark, PA; Rowe, J; Peters, G				Llanos, S; Clark, PA; Rowe, J; Peters, G			Stabilization of p53 by p14(ARF) without relocation of MDM2 to the nucleolus	NATURE CELL BIOLOGY			English	Article							CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR; NUCLEAR EXPORT; ALTERNATIVE PRODUCT; LOCALIZATION; P19(ARF); DEGRADATION; PROTEINS; LOCUS; RB	The alternative product of the human INK4a/ARF locus, p14(ARF), has the potential to act as a tumour suppressor by binding to and inhibiting the p53 antagonist MDM2. Current models propose that ARF function depends on its ability to sequester MDM2 in the nucleolus. Here we describe situations in which stabilization of MDM2 and p53 occur without relocalization of endogenous MDM2 from the nucleoplasm. Conversely, forms of Apr that do not accumulate in the nucleolus retain the capacity to stabilize MDM2 and p53. We therefore propose that nucleolar localization is not essential for ARF function but may enhance the availability of ARF to inhibit MDM2.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Llanos, S (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		, Susana/AAA-9282-2019	Llanos, Susana/0000-0002-8555-9326				BATES S, 1994, ONCOGENE, V9, P71; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; DALTON S, 1992, CELL, V68, P397; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; James M C, 2000, Prog Cell Cycle Res, V4, P71; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Ochs RL, 1998, METHOD CELL BIOL, V53, P303; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUEILE DE, 1997, P NATL ACAD SCI USA, V94, P669; QUELLE DE, 1995, CELL, V83, P993; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	38	218	223	1	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					445	452		10.1038/35074506	http://dx.doi.org/10.1038/35074506			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331871				2022-12-25	WOS:000168592500013
J	Anderson, MG; Smith, RS; Hawes, NL; Zabaleta, A; Chang, B; Wiggs, JL; John, SWM				Anderson, MG; Smith, RS; Hawes, NL; Zabaleta, A; Chang, B; Wiggs, JL; John, SWM			Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice	NATURE GENETICS			English	Article							BROWN LOCUS PROTEIN; OCULOCUTANEOUS ALBINISM; DISPERSION SYNDROME; MOUSE MUTATION; IRIS ATROPHY; TYROSINASE; MELANOCYTES; MELANOMA; TYRP1; GP75	Pigmentary glaucoma is a significant cause of human blindness. Abnormally liberated iris pigment and cell debris enter the ocular drainage structures, leading to increased intraocular pressure (IOP) and glaucoma(1-3). DBA/2J (D2) mice develop a form of pigmentary glaucoma involving iris pigment dispersion (IPD) and iris stromal atrophy (ISA)(4,5). Using high-resolution mapping techniques, sequencing and functional genetic tests, we show that IPD and ISA result from mutations in related genes encoding melanosomal proteins. IPD is caused by a premature stop codon mutation in the Gpnmb (Gpnmb(R150X)) gene, as proved by the occurrence of IPD only in D2 mice that are homozygous with respect to Gpnmb(R150X). otherwise, similar D2 mice that are not homozygous for Gpnmb(R150X) do not develop IPD. ISA is caused by the recessive Tyrp1(b) mutant allele and rescued by the transgenic introduction of wildtype Tyrp1. We hypothesize that IPD and ISA alter melanosomes, allowing toxic intermediates of pigment production to leak from melanosomes, causing iris disease and subsequent pigmentary glaucoma. This is supported by the rescue of IPD and ISA in D2 eyes with substantially decreased pigment production. These data indicate that pigment production and mutant melanosomal protein genes may contribute to human pigmentary glaucoma. The fact that hypopigmentation profoundly alleviates the D2 disease indicates that therapeutic strategies designed to decrease pigment production may be beneficial in human pigmentary glaucoma.	Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA; Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA	Howard Hughes Medical Institute; Jackson Laboratory; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Tufts University	John, SWM (corresponding author), Howard Hughes Med Inst, Bar Harbor, ME 04609 USA.		Anderson, Michael/B-4580-2009	Anderson, Michael/0000-0001-5730-6105; Chang, Bo/0000-0001-8259-7290	NATIONAL EYE INSTITUTE [F32EY007015] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY007015] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andersen JS, 1997, ARCH OPHTHALMOL-CHIC, V115, P384, DOI 10.1001/archopht.1997.01100150386012; Anderson MG, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-1; Boissy RE, 1996, AM J HUM GENET, V58, P1145; Boissy RE, 1998, EXP DERMATOL, V7, P198, DOI 10.1111/j.1600-0625.1998.tb00324.x; CAMPBELL DG, 1996, GLAUCOMAS, V2, P975; Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; EPSTEIN DL, 1997, CHANDLER GRANTS GLAU, P220; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; Lalouette A, 1998, GENOMICS, V50, P9, DOI 10.1006/geno.1998.5314; Manga P, 1997, AM J HUM GENET, V61, P1095, DOI 10.1086/301603; MOYER FH, 1966, AM ZOOL, V6, P43; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; RITCH R, 1993, AM J OPHTHALMOL, V115, P707, DOI 10.1016/S0002-9394(14)73635-9; Stjernschantz J, 2000, ACTA OPHTHALMOL SCAN, V78, P618, DOI 10.1034/j.1600-0420.2000.078006618.x; SUGAR HS, 1966, AM J OPHTHALMOL, V62, P499; SWANK RT, 1991, GENET RES, V58, P51, DOI 10.1017/S0016672300029608; TAI T, 1983, CANCER RES, V43, P2773; TAYLOR BA, 1996, GENETIC VARIANTS STR, V2, P1597; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Wistrand PJ, 1997, SURV OPHTHALMOL, V41, pS129, DOI 10.1016/S0039-6257(97)80020-3; ZDARSKY E, 1990, GENETICS, V126, P443	30	327	343	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					81	85		10.1038/ng794	http://dx.doi.org/10.1038/ng794			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743578				2022-12-25	WOS:000173105600018
J	Dumont, EA; Reutelingsperger, CPM; Smits, JFM; Daemen, MJAP; Doevendans, PAF; Wellens, HJJ; Hofstra, L				Dumont, EA; Reutelingsperger, CPM; Smits, JFM; Daemen, MJAP; Doevendans, PAF; Wellens, HJJ; Hofstra, L			Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart	NATURE MEDICINE			English	Article							DEATH	We report a novel real-time imaging model to visualize apoptotic membrane changes of single cardiomyocytes in the injured heart of the living mouse, using fluorescent labeled annexin-V. Annexin-V binds to externalized phosphatidylserine (PS) of cells undergoing programmed cell death. With high-magnification (x100-160) real-time imaging, we visualized the binding of annexin-V to single cardiomyocytes. Kinetic studies at the single-cell level revealed that cardiomyocytes started to bind annexin-V within minutes after reperfusion, following an ischemic period of 30 minutes. The amount of bound annexin-V increased rapidly and reached a maximum within 20-25 minutes. Caspase inhibitors decreased the number of annexin-V-positive cardiomyocytes and slowed down the rate of PS exposure of cardiomyocytes that still bound annexin-V. This technology to study cell biology in the natural environment will enhance knowledge of intracellular signaling pathways relevant for cell-death regulation and strategies to manipulate these pathways for therapeutic effect.	Cardiovasc Res Inst Maastricht, Maastricht, Netherlands	Maastricht University	Dumont, EA (corresponding author), Cardiovasc Res Inst Maastricht, Univ Singel 50, Maastricht, Netherlands.							Bell JI, 1999, NAT MED, V5, P477, DOI 10.1038/8353; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Dumont EAWJ, 2000, CIRCULATION, V102, P1564, DOI 10.1161/01.CIR.102.13.1564; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; KOOPMAN G, 1994, BLOOD, V84, P5; MARTIN SJ, 1995, J EXP MED, V182, P552; Plymale DR, 1999, NAT MED, V5, P351, DOI 10.1038/6574; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; Tempany CMC, 2001, JAMA-J AM MED ASSOC, V285, P562, DOI 10.1001/jama.285.5.562; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang M, 2001, P NATL ACAD SCI USA, V98, P2616, DOI 10.1073/pnas.051626698	11	171	178	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	2001	7	12					1352	1355		10.1038/nm1201-1352	http://dx.doi.org/10.1038/nm1201-1352			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	500DH	11726977				2022-12-25	WOS:000172610300042
J	Kleter, GA; van der Krieken, WM; Kok, EJ; Bosch, D; Jordi, W; Gilissen, LWJ				Kleter, GA; van der Krieken, WM; Kok, EJ; Bosch, D; Jordi, W; Gilissen, LWJ			Regulation and exploitation of genetically modified crops	NATURE BIOTECHNOLOGY			English	Article							BIOTECHNOLOGY; FLAVONOIDS; METABOLISM		Natl Inst Qual Control Agr Prod, Wageningen, Netherlands; Plant Res Int, Wageningen, Netherlands		Kleter, GA (corresponding author), Natl Inst Qual Control Agr Prod, Wageningen, Netherlands.		Kok, Esther J/B-3919-2013; gilisen, luud/F-5496-2017	Kok, Esther J/0000-0003-1472-6710; 				[Anonymous], 1999, ENH REG DEC MAK APPR; Dove A, 2001, NAT BIOTECHNOL, V19, P117, DOI 10.1038/84365; Eaton EA, 1996, DRUG METAB DISPOS, V24, P232; *EUR COMM, 2001, PROP COM 2001 182 FI; *EUR COMM, 2001, 13412001 EC SANCO; *EUR COMM, 1997, EUDR RUL GOV MED PRO; *EUR COMM, 2001, BIL TRAD REL; *EUR COMM SCI COMM, 1999, OP REQ CONS PLAC MAR; *EUR PARL, 2000, PROP DIR EUR PARL CO; *EUR UN, 2001, MEMO00277 EU; FAO/WHO, 2017, FAO WHO SCI ADV PROG, P1; Gaskell G, 2000, NAT BIOTECHNOL, V18, P935, DOI 10.1038/79403; IARC, 1999, IARC MON, p[73, 497]; *INT AG RES CANC, 1983, IARC MON EV CARC RIS, V31, P213; *INT AG RES CANC, 1983, IARC MON, V31, P171; JAMES C, 2000, GLOBAL STATUS COMMER; KLETER GA, 2001, EXPLOITATION REGULAT; Kong QX, 2001, P NATL ACAD SCI USA, V98, P11539, DOI 10.1073/pnas.191617598; *LEATH FOOD RES AS, 2001, FUNCT FOOD MARK INN; LI Y, 1994, DRUG METAB DISPOS, V22, P566; Lucca P, 2001, THEOR APPL GENET, V102, P392, DOI 10.1007/s001220051659; Muir SR, 2001, NAT BIOTECHNOL, V19, P470, DOI 10.1038/88150; Priest SH, 2000, NAT BIOTECHNOL, V18, P939, DOI 10.1038/79412; Sevenier R, 1998, NAT BIOTECHNOL, V16, P843, DOI 10.1038/nbt0998-843; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; *US FDA, 2001, LAB DIET SUPPL; *US FDA, 2000, ABBR NEW DRUG APPL A; *US FDA, 2001, FDA ANN PROP DRAFT G; *US FDA, 2001, LIST COMPL CONS BIOE; *US FDA, 1999, 000030 FDA GRAS CTR; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; 1992, FED REG         0529, V57, P22984	32	16	19	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1105	1110		10.1038/nbt1201-1105	http://dx.doi.org/10.1038/nbt1201-1105			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731773				2022-12-25	WOS:000172524400013
J	Reubinoff, BE; Itsykson, P; Turetsky, T; Pera, MF; Reinhartz, E; Itzik, A; Ben-Hur, T				Reubinoff, BE; Itsykson, P; Turetsky, T; Pera, MF; Reinhartz, E; Itzik, A; Ben-Hur, T			Neural progenitors from human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN BLASTOCYSTS; PRECURSOR CELLS; MOUSE EMBRYOS; SPINAL-CORD; ES CELLS; IN-VITRO; DIFFERENTIATION; NEURONS; LINES	The derivation of neural progenitor cells from human embryonic stem (ES) cells is of value both in the study of early human neurogenesis and in the creation of an unlimited source of donor cells for neural transplantation therapy. Here we report the generation of enriched and expandable preparations of proliferating neural progenitors from human ES cells. The neural progenitors could differentiate in vitro into the three neural lineages-astrocytes, oligodendrocytes, and mature neurons. When human neural progenitors were transplanted into the ventricles of newborn mouse brains, they incorporated in large numbers into the host brain parenchyma, demonstrated widespread distribution, and differentiated into progeny of the three neural lineages. The transplanted cells migrated along established brain migratory tracks in the host brain and differentiated in a region-specific manner, indicating that they could respond to local cues and participate in the processes of host brain development. Our observations set the stage for future developments that may allow the use of human ES cells for the treatment of neurological disorders.	Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Neurol, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel; Monash Univ, Monash Inst Reprod & Dev, Melbourne, Vic 3004, Australia	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Monash University	Reubinoff, BE (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel.		PERA, MARTIN/A-9812-2012	PERA, MARTIN/0000-0001-6239-0428; Reubinoff, Benjamin/0000-0003-0353-1299				Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mujtaba T, 1999, DEV BIOL, V214, P113, DOI 10.1006/dbio.1999.9418; Murray K, 1997, J NEUROSCI RES, V50, P146; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1999, TRENDS NEUROSCI, V22, P357, DOI 10.1016/S0166-2236(99)01428-9; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; van Eijk MJT, 1999, BIOL REPROD, V60, P1093, DOI 10.1095/biolreprod60.5.1093; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Wolpert L., 1998, PRINCIPLES DEV	36	839	982	2	54	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1134	1140		10.1038/nbt1201-1134	http://dx.doi.org/10.1038/nbt1201-1134			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731782				2022-12-25	WOS:000172524400026
J	Bodine, SC; Stitt, TN; Gonzalez, M; Kline, WO; Stover, GL; Bauerlein, R; Zlotchenko, E; Scrimgeour, A; Lawrence, JC; Glass, DJ; Yancopoulos, GD				Bodine, SC; Stitt, TN; Gonzalez, M; Kline, WO; Stover, GL; Bauerlein, R; Zlotchenko, E; Scrimgeour, A; Lawrence, JC; Glass, DJ; Yancopoulos, GD			Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; PHAS-I; GLYCOGEN-SYNTHASE; CALCINEURIN; EXPRESSION; INSULIN; IGF-1; GENE; TRANSLATION; MODULATION	Skeletal muscles adapt to changes in their workload by regulating fibre size by unknown mechanisms(1,2). The roles of two signalling pathways implicated in muscle hypertrophy on the basis of findings in vitro(3-6), Akt/mTOR (mammalian target of rapamycin) and calcineurin/NFAT (nuclear factor of activated T cells), were investigated in several models of skeletal muscle hypertrophy and atrophy in vivo. The Akt/mTOR pathway was upregulated during hypertrophy and downregulated during muscle atrophy. Furthermore, rapamycin, a selective blocker of mTOR(7), blocked hypertrophy in all models tested, without causing atrophy in control muscles. In contrast, the calcineurin pathway was not activated during hypertrophy in vivo, and inhibitors of calcineurin, cyclosporin A and FK506 did not blunt hypertrophy. Finally, genetic activation of the Akt/mTOR pathway was sufficient to cause hypertrophy and prevent atrophy in vivo, whereas genetic blockade of this pathway blocked hypertrophy in vivo. We conclude that the activation of the Akt/mTOR pathway and its downstream targets, p70(S6K) and PHAS-1/4E-BP1, is requisitely involved in regulating skeletal muscle fibre size, and that activation of the Akt/mTOR pathway can oppose muscle atrophy induced by disuse.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Med, Charlottesville, VA 22908 USA	Regeneron; University of Virginia; University of Virginia	Bodine, SC (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	sue.bodine@regeneron.com; george@regeneron.com	Glass, David/AAI-3910-2021; Scrimgeour, Angus/D-6794-2013; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164; Bodine, Sue/0000-0002-5742-9145				Adams GR, 1996, J APPL PHYSIOL, V81, P2509, DOI 10.1152/jappl.1996.81.6.2509; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Baar K, 1999, Exerc Sport Sci Rev, V27, P333; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Carson J A, 1997, Exerc Sport Sci Rev, V25, P301; Dunn SE, 2000, J CELL BIOL, V151, P663, DOI 10.1083/jcb.151.3.663; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lowe DA, 1999, CELL TISSUE RES, V296, P531, DOI 10.1007/s004410051314; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; Roy RR, 1997, J APPL PHYSIOL, V83, P280, DOI 10.1152/jappl.1997.83.1.280; Roy RR, 1999, J APPL PHYSIOL, V87, P634, DOI 10.1152/jappl.1999.87.2.634; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMASON DB, 1987, J APPL PHYSIOL, V63, P130, DOI 10.1152/jappl.1987.63.1.130; TUNG CO, 1999, ANNU REV BIOCHEM, V68, P965; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; WONG TS, 1990, J APPL PHYSIOL, V69, P1718, DOI 10.1152/jappl.1990.69.5.1718	37	1805	1891	7	202	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					1014	1019		10.1038/ncb1101-1014	http://dx.doi.org/10.1038/ncb1101-1014			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715023				2022-12-25	WOS:000172070300017
J	Buchholz, F; Stewart, AF				Buchholz, F; Stewart, AF			Alteration of Cre recombinase site specificity by substrate-linked protein evolution	NATURE BIOTECHNOLOGY			English	Article							LOXP SPACER REGION; IN-VITRO; MAMMALIAN-CELLS; IDENTIFYING DETERMINANTS; DIRECTED EVOLUTION; CASSETTE EXCHANGE; FLP RECOMBINASE; DNA; INTEGRATION; EXPRESSION	Directed molecular evolution was applied to generate Cre recombinase variants that recognize a new DNA target sequence. Cre was adapted in a three-stage strategy to evolve recombinases to specifically recombine the new site. This complex multicycle task was made feasible by an improved directed-evolution procedure that relies on placing the recombination substrate next to the recombinase coding region. Consequently, those DNA molecules carrying the coding region for a successful recombinase are physically marked by the action of that recombinase on the linked substrate and are easily retrieved from a large background of unsuccessful candidates by PCR amplification. We term this procedure substrate-linked protein evolution (SLiPE). The method should facilitate the development of new recombinases and other DNA-modifying enzymes for applications in genetic engineering, functional genomics, and gene therapy.	Univ Calif San Francisco, Hooper Res Fdn, San Francisco, CA 94143 USA; Tech Univ Dresden, MPI, CBG, D-01307 Dresden, Germany	University of California System; University of California San Francisco; Max Planck Society; Technische Universitat Dresden	Buchholz, F (corresponding author), Univ Calif San Francisco, Hooper Res Fdn, 513 Parnassus Ave, San Francisco, CA 94143 USA.	fraenk@itsa.ucsf.edu	Stewart, A. Francis/E-7789-2010; Buchholz, Frank/B-4700-2017	Buchholz, Frank/0000-0002-4577-3344	NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Choulika A, 1996, J VIROL, V70, P1792, DOI 10.1128/JVI.70.3.1792-1798.1996; DORGAI L, 1995, J MOL BIOL, V252, P178, DOI 10.1006/jmbi.1995.0486; Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Feng YQ, 1999, J MOL BIOL, V292, P779, DOI 10.1006/jmbi.1999.3113; Flowers CC, 1997, J VIROL, V71, P2685, DOI 10.1128/JVI.71.4.2685-2692.1997; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Guo HT, 2000, SCIENCE, V289, P452, DOI 10.1126/science.289.5478.452; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HABU Y, 1999, NUCL ACIDS S SER, V42, P295; Hennighausen L, 1999, NAT BIOTECHNOL, V17, P1062, DOI 10.1038/15046; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; Jermutus L, 1998, CURR OPIN BIOTECH, V9, P534, DOI 10.1016/S0958-1669(98)80042-6; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; Kim ST, 2001, J CELL BIOCHEM, V80, P321, DOI 10.1002/1097-4644(20010301)80:3<321::AID-JCB40>3.0.CO;2-C; Lauth M, 2000, GENESIS, V27, P153, DOI 10.1002/1526-968X(200008)27:4<153::AID-GENE40>3.0.CO;2-B; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Lee YS, 1998, BIOCHEM BIOPH RES CO, V253, P588, DOI 10.1006/bbrc.1998.9814; LOGIE C, 1995, P NATL ACAD SCI USA, V92, P5940, DOI 10.1073/pnas.92.13.5940; Metzger D, 1999, CURR OPIN BIOTECH, V10, P470, DOI 10.1016/S0958-1669(99)00012-9; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Pluckthun A, 2001, ADV PROTEIN CHEM, V55, P367, DOI 10.1016/S0065-3233(01)55009-3; Roberts RW, 1999, CURR OPIN CHEM BIOL, V3, P268, DOI 10.1016/S1367-5931(99)80042-8; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Russ AP, 1996, J VIROL, V70, P4927, DOI 10.1128/JVI.70.8.4927-4932.1996; Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141; Satoh W, 2000, J VIROL, V74, P10631, DOI 10.1128/JVI.74.22.10631-10638.2000; Seibler J, 1998, BIOCHEMISTRY-US, V37, P6229, DOI 10.1021/bi980288t; Soukharev S, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.18.e21; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Tawfik DS, 1998, NAT BIOTECHNOL, V16, P652, DOI 10.1038/nbt0798-652; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; YAGIL E, 1995, J MOL BIOL, V252, P163, DOI 10.1006/jmbi.1995.0485; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	46	117	156	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2001	19	11					1047	1052		10.1038/nbt1101-1047	http://dx.doi.org/10.1038/nbt1101-1047			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	489QH	11689850				2022-12-25	WOS:000172002600020
J	Lyden, D; Hattori, K; Dias, S; Costa, C; Blaikie, P; Butros, L; Chadburn, A; Heissig, B; Marks, W; Witte, L; Wu, Y; Hicklin, D; Zhu, ZP; Hackett, NR; Crystal, RG; Moore, MAS; Hajjar, KA; Manova, K; Benezra, R; Rafii, S				Lyden, D; Hattori, K; Dias, S; Costa, C; Blaikie, P; Butros, L; Chadburn, A; Heissig, B; Marks, W; Witte, L; Wu, Y; Hicklin, D; Zhu, ZP; Hackett, NR; Crystal, RG; Moore, MAS; Hajjar, KA; Manova, K; Benezra, R; Rafii, S			Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth	NATURE MEDICINE			English	Article							PROGENITOR CELLS; MOBILIZATION; CONTRIBUTES; LETHALITY; KINASE	The role of bone marrow (BM)-derived precursor cells in tumor angiogenesis is not known, We demonstrate here that tumor angiogenesis is associated with recruitment of hematopoietic and circulating endothelial precursor cells (CEPs). We used the angiogenic defective, tumor resistant ld-mutant mice to show that transplantation of wild-type BM or vascular endothelial growth factor (VEGF)-mobilized stem cells restore tumor angiogenesis and growth. We detected donor-derived CEPs throughout the neovessels of tumors and Matrigel-plugs in an Id1(+/-)Id3(-/-) host, which were associated with VEGF-receptor-1-positive (VEGFR1(+))myeloid cells. The angiogenic defect in ld-mutant mice was due to impaired VEGF-driven mobilization of VEGFR2(+) CEPs and impaired proliferation and incorporation of VEGFR1(+) cells. Although targeting of either VEGFR1 or VEGFR2 alone partially blocks the growth of tumors, inhibition of both VEGFR1 and VEGFR2 was necessary to completely ablate tumor growth. These data demonstrate that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggest new clinical strategies to block tumor growth.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Cellular Biochem & Biophys, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Hematol Oncol, New York, NY USA; Cornell Univ, Coll Med, Dept Pulm Med, New York, NY USA; Cornell Univ, Coll Med, Dept Pathol, New York, NY USA; Cornell Univ, Coll Med, Dept Pediat, New York, NY USA; ImClone Syst Inc, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University; Cornell University; Eli Lilly	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.	r-benezra@ski.mskcc.org; srafii@med.cornell.edu	Dias, Sergio/L-1250-2014; Heissig, Beate/AAF-6771-2021	Dias, Sergio/0000-0002-7603-4616; Heissig, Beate/0000-0002-0348-5934; Costa, Carla/0000-0001-5977-6207	NCI NIH HHS [CA 08748] Funding Source: Medline; NHLBI NIH HHS [HL66592, R01 HL61849, HL67839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061849, P01HL067839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gill M, 2001, CIRC RES, V88, P167; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Prewett M, 1999, CANCER RES, V59, P5209; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAM PP, 1999, DEVELOPMENT, V124, P1631; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	29	1518	1628	4	101	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1194	1201		10.1038/nm1101-1194	http://dx.doi.org/10.1038/nm1101-1194			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689883				2022-12-25	WOS:000172054100026
J	Wojcik, E; Basto, R; Serr, M; Scaerou, F; Karess, R; Hays, T				Wojcik, E; Basto, R; Serr, M; Scaerou, F; Karess, R; Hays, T			Kinetochore dynein: its dynamics and role in the transport of the Rough deal checkpoint protein	NATURE CELL BIOLOGY			English	Article							ACCURATE CHROMOSOME SEGREGATION; CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; CELL CORTEX; DROSOPHILA; MITOSIS; ZW10; COMPONENT; DYNACTIN	We describe the dynamics of kinetochore dynein-dynactin in living Drosophila embryos and examine the effect of mutant dynein on the metaphase checkpoint. A functional conjugate of dynamitin with green fluorescent protein accumulates rapidly at prometaphase kinetochores, and subsequently migrates off kinetochores towards the poles during late prometaphase and metaphase. This behaviour is seen for several metaphase checkpoint proteins, including Rough deal (Rod). In neuroblasts, hypomorphic dynein mutants accumulate in metaphase and block the normal redistribution of Rod from kinetochores to microtubules. By transporting checkpoint proteins away from correctly attached kinetochores, dynein might contribute to shutting off the metaphase checkpoint, allowing anaphase to ensue.	Virginia Tech Univ, Dept Biol, Blacksburg, VA 24061 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, St Paul, MN 55108 USA; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Virginia Polytechnic Institute & State University; University of Minnesota System; University of Minnesota Twin Cities; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Wojcik, E (corresponding author), Virginia Tech Univ, Dept Biol, Blacksburg, VA 24061 USA.			Karess, Roger/0000-0002-7299-0600; Wojcik, Edward/0000-0002-3023-0312	NIGMS NIH HHS [R01 GM053695, GM19123, GM44757] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053695, R01GM044757, R56GM044757] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Banks JD, 2001, CURR BIOL, V11, pR128, DOI 10.1016/S0960-9822(01)00059-8; Basto R, 2000, NAT CELL BIOL, V2, P939, DOI 10.1038/35046592; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Chan GKT, 2000, NAT CELL BIOL, V2, P944, DOI 10.1038/35046598; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gardner RD, 2000, TRENDS CELL BIOL, V10, P154, DOI 10.1016/S0962-8924(00)01727-X; Gepner J, 1996, GENETICS, V142, P865; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; GONZALEZ C, 1994, CELL CYCLE PRACTICAL, P143; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heil-Chapdelaine RA, 2000, MOL BIOL CELL, V11, P863, DOI 10.1091/mbc.11.3.863; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; McGrail M, 1997, DEVELOPMENT, V124, P2409; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; Palazzo RE, 1999, J CELL SCI, V112, P1291; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; Scaerou F, 1999, J CELL SCI, V112, P3757; SCAEROU F, IN PRESS J CELL SCI; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Theurkauf WE, 1999, METHOD CELL BIOL, V61, P317; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153; Williams BC, 1996, J CELL BIOL, V134, P1127, DOI 10.1083/jcb.134.5.1127	38	164	166	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					1001	1007		10.1038/ncb1101-1001	http://dx.doi.org/10.1038/ncb1101-1001			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715021				2022-12-25	WOS:000172070300015
J	Tuttle, RL; Gill, NS; Pugh, W; Lee, JP; Koeberlein, B; Furth, EE; Polonsky, KS; Naji, A; Birnbaum, MJ				Tuttle, RL; Gill, NS; Pugh, W; Lee, JP; Koeberlein, B; Furth, EE; Polonsky, KS; Naji, A; Birnbaum, MJ			Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKB alpha	NATURE MEDICINE			English	Article							INSULIN-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; S6 KINASE; DROSOPHILA; SIZE; MICE; ACTIVATION; APOPTOSIS; MODEL; MASS	The physiological performance of an organ depends on an interplay between changes in cellular function and organ size, determined by cell growth, proliferation and death. Nowhere is this more evident than in the endocrine pancreas, where disturbances in function or mass result in severe disease. Recently, the insulin signal-transduction pathway has been implicated in both the regulation of hormone secretion from beta cells in mammals as well as the determination of cell and organ size in Drosophila melanogaster. A prominent mediator of the actions of insulin and insulin-like growth factor 1 (IGF-1) is the 3'-phosphoinositide-dependent protein kinase Akt, also known as protein kinase B (PKB). Here we report that overexpression of active Akt1 in the mouse beta cell substantially affects compartment size and function. There was a significant increase in both beta -cell size and total islet mass, accompanied by improved glucose tolerance and complete resistance to experimental diabetes.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Washington University (WUSTL)	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK19525, R01 DK56886, P30DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK056886, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Coffer PJ, 1998, BIOCHEM J, V335, P1; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEYNER S, 1994, BIOESSAYS, V16, P55, DOI 10.1002/bies.950160109; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; OBrien BA, 1996, J PATHOL, V178, P176; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	30	424	446	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1133	1137		10.1038/nm1001-1133	http://dx.doi.org/10.1038/nm1001-1133			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590437				2022-12-25	WOS:000171524500035
J	Cooper, MA; Dultsev, FN; Minson, T; Ostanin, VP; Abell, C; Klenerman, D				Cooper, MA; Dultsev, FN; Minson, T; Ostanin, VP; Abell, C; Klenerman, D			Direct and sensitive detection of a human virus by rupture event scanning	NATURE BIOTECHNOLOGY			English	Article							HERPES-SIMPLEX VIRUS; BIOSENSORS	We have developed a sensitive, economical method that directly detects viruses by making use of the interaction between type 1 herpes simplex virus (HSV1) and specific antibodies covalently attached to the oscillating surface of a quartz crystal microbalance (QCM). The virions were detached from the surface by monotonously increasing the amplitude of oscillation of the QCM, while using the QCM to sensitively detect the acoustic noise produced when the interactions were broken. We term this process rupture event scanning (REVS). The method is quantitative over at least six orders of magnitude, and its sensitivity approaches detection of a single virus particle.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Cambridge; University of Cambridge	Cooper, MA (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.		Ostanin, Victor/B-7045-2015; Cooper, Matthew A./C-7988-2009	Cooper, Matthew A./0000-0003-3147-3460; Klenerman, David/0000-0001-7116-6954				Babic N, 1999, J GEN VIROL, V80, P2403, DOI 10.1099/0022-1317-80-9-2403; Ballantine D, 1997, ACOUSTIC WAVE SENSOR, P36, DOI [DOI 10.1016/B978-012077460-9/50003-4, 10.1016/b978-012077460-9/50003-4]; BUCKMASTER EA, 1984, J MED VIROL, V13, P193, DOI 10.1002/jmv.1890130209; Dultsev FN, 2000, LANGMUIR, V16, P5036, DOI 10.1021/la990789v; DYBWAD GL, 1985, J APPL PHYS, V58, P2789, DOI 10.1063/1.335874; Janshoff A, 2000, ANGEW CHEM INT EDIT, V39, P4004, DOI 10.1002/1521-3773(20001117)39:22<4004::AID-ANIE4004>3.0.CO;2-2; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kolomenskii AA, 1998, J APPL PHYS, V84, P2404, DOI 10.1063/1.368367; KONIG B, 1994, ANAL CHEM, V66, P341, DOI 10.1021/ac00075a005; McDonough R. N., 2004, DETECTION SIGNALS NO; Merkel R, 1999, NATURE, V397, P50, DOI 10.1038/16219; MINSON AC, 1986, J GEN VIROL, V67, P1001, DOI 10.1099/0022-1317-67-6-1001; MINSON AC, 1998, TOPLEY WILSONS MICRO, V1, P325; Wang AW, 1998, SENSOR ACTUAT B-CHEM, V49, P13, DOI 10.1016/S0925-4005(98)00127-0; WARD MD, 1990, SCIENCE, V249, P1000, DOI 10.1126/science.249.4972.1000; WATSON DH, 1963, VIROLOGY, V19, P250, DOI 10.1016/0042-6822(63)90062-X	16	159	172	0	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					833	837		10.1038/nbt0901-833	http://dx.doi.org/10.1038/nbt0901-833			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533641				2022-12-25	WOS:000170774000021
J	Sonoshita, M; Takaku, K; Sasaki, N; Sugimoto, Y; Ushikubi, F; Narumiya, S; Oshima, M; Taketo, MM				Sonoshita, M; Takaku, K; Sasaki, N; Sugimoto, Y; Ushikubi, F; Narumiya, S; Oshima, M; Taketo, MM			Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice	NATURE MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; MESSENGER-RNA; COLON CARCINOGENESIS; EXPRESSION; GENE; SYNTHASE; GROWTH; CELLS; E-2; ANGIOGENESIS	Arachidonic acid is metabolized to prostaglandin H-2 (PGH(2)) by cyclooxygenase (COX). COX-2, the inducible COX isozyme, has a key role in intestinal polyposis(1,2). Among the metabolites of PGH,, PGE, is implicated in tumorigenesis because its level is markedly elevated in tissues of intestinal adenoma and colon cancer(3). Here we show that homozygous deletion of the gene encoding a cell-surface receptor of PGE(2), EP2, causes decreases in number and size of intestinal polyps in Apc(Delta 716) mice (a mouse model for human familial adenomatous polyposis). This effect is similar to that of COX-2 gene disruption. We also show that COX-2 expression is boosted by PGE(2) through the EP2 receptor via a positive feedback loop. Homozygous gene knockout for other PGE(2) receptors, EP1 or EP3, did not affect intestinal polyp formation in Apc(Delta 716) mice. We conclude that EP2 is the major receptor mediating the PGE(2) signal generated by COX-2 upregulation in intestinal polyposis, and that increased cellular CAMP stimulates expression of more COX-2 and vascular endothelial growth factor in the polyp stroma.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto, Japan; Kyoto Univ, Grad Sch Pharmacuet Sci, Dept Physiol Sci, Kyoto, Japan; Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 078, Japan	University of Tokyo; Kyoto University; Kyoto University; Asahikawa Medical College	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo, Japan.		SONOSHITA, MASAHIRO/Q-1571-2019; Sasaki, Nobuya/F-6579-2012; Sugimoto, Yukihiko/AAV-6470-2021; Sonoshita, Masahiro/AAE-5516-2019; Oshima, Masanobu/F-9958-2014	SONOSHITA, MASAHIRO/0000-0003-2890-336X; Sugimoto, Yukihiko/0000-0001-6973-932X; Oshima, Masanobu/0000-0002-3304-0004				Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Daniel TO, 1999, CANCER RES, V59, P4574; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hewitt RE, 1997, BRIT J CANCER, V75, P221, DOI 10.1038/bjc.1997.37; Hinz B, 2000, BIOCHEM BIOPH RES CO, V278, P790, DOI 10.1006/bbrc.2000.3885; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; KARGMAN SL, 1995, CANCER RES, V55, P2556; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Morimoto K, 1997, AM J PHYSIOL-GASTR L, V272, pG681, DOI 10.1152/ajpgi.1997.272.3.G681; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Watanabe K, 1999, CANCER RES, V59, P5093; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yamada Y, 2000, CANCER RES, V60, P3323; Yang VW, 1998, CANCER RES, V58, P1750	26	501	517	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2001	7	9					1048	1051		10.1038/nm0901-1048	http://dx.doi.org/10.1038/nm0901-1048			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533709	Green Submitted			2022-12-25	WOS:000170853300031
J	Anikster, Y; Huizing, M; White, J; Shevchenko, YO; Fitzpatrick, DL; Touchman, JW; Compton, JG; Bale, SJ; Swank, RT; Gahl, WA; Toro, JR				Anikster, Y; Huizing, M; White, J; Shevchenko, YO; Fitzpatrick, DL; Touchman, JW; Compton, JG; Bale, SJ; Swank, RT; Gahl, WA; Toro, JR			Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico	NATURE GENETICS			English	Article							LOCUS HETEROGENEITY; VESICLE FORMATION; AP-3 ADAPTER; PROTEINS; DUPLICATION; ALBINISM; SUBUNIT; COMPLEX; MODELS; MOUSE	Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism and a storage pool deficiency due to an absence of platelet dense bodies(1-3). Lysosomal ceroid lipofuscinosis, pulmonary fibrosis and granulomatous colitis are occasional manifestations of the disease(4). HPS occurs witha frequency of one in 1800 in northwest Puerto Rico(5) due to a founder effect(6). Several non-Puerto Rican patients also have mutations in HPS1(7,8), which produces a protein of unknown function(9). Another gene, ADTB3A, causes HPS in the pearl mouse(10) and in two brothers with HPS-2 (refs. 11,12). ADTB3A encodes a coat protein involved in vesicle formation(3,13), implicating HPS as a disorder of membrane trafficking. We sought to identify other HPS-causing genes(7,8,14). Using homozygosity mapping on pooled DNA of 6 families from central Puerto Rico, we localized a new HPS susceptibility gene to a 1.6-cM interval on chromosome 3q24. The gene, HPS3, has 17 exons, and a putative 113.7-kD product expected to reveal how new vesicles form in specialized cells. The homozygous, disease-causing mutation is a large deletion and represents the secon example of a founder mutation causing HPS on the small island of Puerto Rico. We also present an allele-specific assay for diagnosing individuals heterozygous or homozygous for this mutation.	NICHHD, Sect Human Biochem Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Lab Med, Minneapolis, MN 55455 USA; Natl Inst Hlth Intramural Sequencing Ctr, NIH, Gaithersburg, MD USA; NIAMSD, Genet Studies Sect, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Roswell Park Cancer Institute	Gahl, WA (corresponding author), NICHHD, Sect Human Biochem Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA.		Huizing, Marjan/AAR-8860-2020		NCI NIH HHS [CA16506] Funding Source: Medline; NHLBI NIH HHS [HL31698] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031698] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONARAKIS SE, 2001, METABOLIC MOL BASES, V1, P359; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Dell'Angelica EC, 2000, J BIOL CHEM, V275, P1300, DOI 10.1074/jbc.275.2.1300; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; Emr SD, 1997, CURR OPIN CELL BIOL, V9, P475, DOI 10.1016/S0955-0674(97)80021-X; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gahl WA, 1998, NEW ENGL J MED, V338, P1258, DOI 10.1056/NEJM199804303381803; Hazelwood S, 1997, AM J HUM GENET, V61, P1088, DOI 10.1086/301611; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Iwata F, 2000, OPHTHALMOLOGY, V107, P783, DOI 10.1016/S0161-6420(99)00150-5; KING RA, 2001, METABOLIC MOL BASES, V4, P5587; Luria SE, 1943, GENETICS, V28, P491; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Oh J, 1998, AM J HUM GENET, V62, P593, DOI 10.1086/301757; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Sambrook J., 2002, MOL CLONING LAB MANU; SANTIAGOGONZALE.J, 1985, AIBONITO NOTAS HIST; Shotelersuk V, 2000, AM J MED, V108, P423, DOI 10.1016/S0002-9343(99)00436-2; Shotelersuk V, 1998, MOL GENET METAB, V65, P85, DOI 10.1006/mgme.1998.2729; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Swank RT, 1996, LAB ANIM SCI, V46, P56; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Toro J, 1999, ARCH DERMATOL, V135, P774, DOI 10.1001/archderm.135.7.774; Witkop C J, 1990, Bol Asoc Med P R, V82, P333; WITKOP CJ, 1987, AM J HEMATOL, V26, P305, DOI 10.1002/ajh.2830260403	30	153	155	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					376	380		10.1038/ng576	http://dx.doi.org/10.1038/ng576			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11455388				2022-12-25	WOS:000170174800020
J	Gao, B; Gu, JZ; She, CW; Shu, AL; Yang, MS; Tan, Z; Yang, XP; Guo, SZ; Feng, GY; He, L				Gao, B; Gu, JZ; She, CW; Shu, AL; Yang, MS; Tan, Z; Yang, XP; Guo, SZ; Feng, GY; He, L			Mutations in IHH, encoding Indian hedgehog, cause brachydactyly type A-1	NATURE GENETICS			English	Article							SONIC-HEDGEHOG; RECEPTOR; GENE; VERTEBRATE; PROTEIN; DIFFERENTIATION	Brachyclactyly type A-1 (BDA-1; MIM 112500) is characterized by shortening or missing of the middle phalanges (Fig. 1a)(1). It was first identified by Farabee in 1903 (ref. 2), is the first recorded example of a human anomaly with Mendelian autosomal-dominant inheritance and, as such, is cited in most genetic and biological textbooks. Here we show that mutations in IHH, which encodes Indian hedgehog, cause BDA-1. We have identified three heterozygous missense mutations in the region encoding the amino-terminal signaling domain in all affected members of three large, unrelated families. The three mutant amino acids, which are conserved across all vertebrates and invertebrates studied so far, are predicted to be adjacent on the surface of IHH.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China; Shanghai Jiao Tong Univ, BioX Life Sci Res Ctr, Shanghai 200030, Peoples R China; Guiyang Women & Childrens Hosp, Guiyang, Peoples R China; Huaihua Teachers Coll, Dept Biol, Hunan, Peoples R China; Huaihua Med Jr Coll, Hunan, Peoples R China; Chinese Natl Genome Ctr Shanghai, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	He, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.		Yang, Xinping/HGA-6104-2022; Yang(秧), Maosheng(茂盛)/J-9581-2012; Gao, Bo/F-4688-2013; Pillay, Nischalan/F-9536-2012	Yang(秧), Maosheng(茂盛)/0000-0002-0566-6093; Gao, Bo/0000-0002-8684-5199; Yang, Xinping/0000-0003-4086-4180				Bell J., 1951, TREASURY HUMAN INHER, P1; Bosse K, 2000, AM J HUM GENET, V67, P492, DOI 10.1086/303028; Capdevila J, 2000, CELL MOL LIFE SCI, V57, P1682, DOI 10.1007/PL00000651; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; FARABEE W, 1903, THESIS HARVARD U; FITCH N, 1979, J MED GENET, V16, P36, DOI 10.1136/jmg.16.1.36; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; NAOYUKI F, 1999, P NATL ACAD SCI USA, V96, P10992; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Polinkovsky A, 1997, NAT GENET, V17, P18, DOI 10.1038/ng0997-18; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; Yang XP, 2000, AM J HUM GENET, V66, P892, DOI 10.1086/302806	22	174	202	3	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2001	28	4					386	388		10.1038/ng577	http://dx.doi.org/10.1038/ng577			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11455389				2022-12-25	WOS:000170174800022
J	Magre, J; Delepine, M; Khallouf, E; Gedde-Dahl, T; Van Maldergem, L; Sobel, E; Papp, J; Meier, M; Megarbane, A; Lathrop, M; Capeau, J				Magre, J; Delepine, M; Khallouf, E; Gedde-Dahl, T; Van Maldergem, L; Sobel, E; Papp, J; Meier, M; Megarbane, A; Lathrop, M; Capeau, J		BSCL Working Grp	Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13	NATURE GENETICS			English	Article							DEPENDENT DIABETES-MELLITUS; GENERALIZED LIPODYSTROPHY; HUMAN GENOME; GK RAT; MAP; EXPRESSION	Congenital generalized lipodystrophy, or Berardinelli-Seip syndrome (BSCL), is a rare autosomal recessive disease characterized by a near-absence of adipose tissue from birth or early infancy and severe insulin resistance(1-4). Other clinical and biological features include acanthosis nigricans, hyperandrogenism, muscular hypertrophy, hepatomegaly, altered glucose tolerance or diabetes mellitus, and hypertriglyceridemia. A locus (BSCL1) has been mapped to 9q34 with evidence of heterogeneity(5). Here, we report a genome screen of nine BSCL families from two geographical clusters (in Lebanon and Norway). We identified a new disease locus, designated BSCL2, within the 2.5-Mb interval flanked by markers D11S4076 and D11S480 on chromosome 11q13. Analysis of 20 additional families of various ethnic origins led to the identification of 11 families in which the disease cosegregates with the 11q13 locus; the remaining families provide confirmation of linkage to 9q34. Sequence analysis of genes located in the 11q13 interval disclosed mutations in a gene homologous to the murine guanine nucleotide-binding protein (G protein), gamma3-linked gene(6) (Gng3lg) in all BSCL2-linked families. BSCL2 is most highly expressed in brain and testis and encodes a protein (which we have called seipin) of unknown function. Most of the variants are null mutations and probably result in a severe disruption of the protein. These findings are of general importance for understanding the molecular mechanisms underlying regulation of body fat distribution and insulin resistance.	Univ Paris 06, Fac Med St Antoine, INSERM, U402, F-75012 Paris, France; Ctr Natl Genotypage, Paris, France; Hotel Dieu France, Serv Pediat, Beirut, Lebanon; Univ Oslo, Inst Forens Med, Oslo, Norway; Univ Oslo, Dept Dermatol, Oslo, Norway; Univ Oslo, Dept Internal Med, Oslo, Norway; Univ Oslo, Dept Pediat, Oslo, Norway; Univ Oslo, Rikshosp, N-0027 Oslo, Norway; Inst Pathol & Genet, Ctr Genet Humaine, Loveral, Belgium; Univ St Joseph, Fac Med, Unite Genet Med, Beirut, Lebanon	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CEA; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; Saint Joseph University Beirut	Magre, J (corresponding author), Univ Paris 06, Fac Med St Antoine, INSERM, U402, 27 Rue Chaligny, F-75012 Paris, France.	magre@st-antoine.inserm.fr	Van Maldergem, Lionel/O-3242-2019; GRIGORESCU, FLORIN/C-2238-2013; Van Maldergem, Lionel/G-9849-2017; MAGRE, Jocelyne/D-4788-2015; Megarbane, Andre/ABD-5574-2021; VERLOES, Alain/E-7287-2014	Van Maldergem, Lionel/0000-0001-8880-5214; GRIGORESCU, FLORIN/0000-0002-3095-5639; Van Maldergem, Lionel/0000-0001-8880-5214; Medina, Jose Luiz/0000-0001-7229-9679; Stephenson, Terence/0000-0001-8871-7847; VERLOES, Alain/0000-0003-4819-0264; SAVASTA, Salvatore/0000-0001-9238-0749; o'rahilly, stephen/0000-0003-2199-4449; Sobel, Eric/0000-0002-1718-0031; Lacombe, Didier/0000-0002-8956-2207				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BERARDINELLI W, 1954, J CLIN ENDOCR METAB, V14, P193, DOI 10.1210/jcem-14-2-193; CORBIN A, 1974, ACTA ENDOCRINOL-COP, V77, P209, DOI 10.1530/acta.0.0770209; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Downes GB, 1998, GENOMICS, V53, P220, DOI 10.1006/geno.1998.5508; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Galli J, 1996, NAT GENET, V12, P31, DOI 10.1038/ng0196-31; Garg A, 1999, J CLIN ENDOCR METAB, V84, P3390, DOI 10.1210/jc.84.9.3390; Gauguier D, 1996, NAT GENET, V12, P38, DOI 10.1038/ng0196-38; GeddeDahl T, 1996, ACTA PAEDIATR, V85, P52; HUSEMAN C, 1978, J PEDIATR-US, V93, P221, DOI 10.1016/S0022-3476(78)80500-9; Inoue S, 2000, BIOCHEM BIOPH RES CO, V268, P553, DOI 10.1006/bbrc.2000.2170; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LAWRENCE RD, 1946, LANCET, V250, P724; MABRY CC, 1973, J PEDIATR-US, V82, P625, DOI 10.1016/S0022-3476(73)80588-8; MABRY CC, 1972, J PEDIATR-US, V81, P990, DOI 10.1016/S0022-3476(72)80559-6; Moller David E., 1993, P49; Panz VR, 1997, HUM GENET, V101, P118, DOI 10.1007/s004390050598; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEIP M, 1959, Acta Paediatr, V48, P555; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Sobel E, 1996, AM J HUM GENET, V58, P1323; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; VANDERVORM ER, 1993, DIABETOLOGIA, V36, P172, DOI 10.1007/BF00400701; VanMaldergem L, 1996, AM J MED GENET, V64, P506, DOI 10.1002/(SICI)1096-8628(19960823)64:3<506::AID-AJMG12>3.0.CO;2-P; Vigouroux C, 2000, DIABETES, V49, P1958, DOI 10.2337/diabetes.49.11.1958; Vigouroux C, 1997, J CLIN ENDOCR METAB, V82, P3438, DOI 10.1210/jc.82.10.3438; Watanabe TK, 1999, GENOMICS, V58, P233, DOI 10.1006/geno.1999.5789; Yu W, 1997, GENOME RES, V7, P353, DOI 10.1101/gr.7.4.353	30	511	532	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2001	28	4					365	370		10.1038/ng585	http://dx.doi.org/10.1038/ng585			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	458CC	11479539				2022-12-25	WOS:000170174800018
J	Saito, M; Iwawaki, T; Taya, C; Yonekawa, H; Noda, M; Inui, Y; Mekada, E; Kimata, Y; Tsuru, A; Kohno, K				Saito, M; Iwawaki, T; Taya, C; Yonekawa, H; Noda, M; Inui, Y; Mekada, E; Kimata, Y; Tsuru, A; Kohno, K			Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice	NATURE BIOTECHNOLOGY			English	Article							AMINO-ACID SEQUENCE; GENETIC ABLATION; GROWTH-FACTOR; LINEAGE ABLATION; ADIPOSE-TISSUE; EXPRESSION; PROTEINS; RIBOSYLATION; INVOLVEMENT; ACTIVATION	Specific cell ablation is a useful method for analyzing the in vivo function of cells. We have developed a simple and sensitive method for conditional cell ablation in transgenic mice, called "toxin receptor-mediated cell knockout." We expressed the diphtheria toxin (DT) receptor in transgenic mice using a hepatocyte-specific promoter and found that injection of DT caused fulminant hepatitis. Three independently established transgenic lines demonstrated a good correlation between the sensitivity of hepatocytes to DT and the expression level of the DT receptors. Moreover, the degree of hepatocyte damage was easily controlled over a wide range of doses of injected DT without any obvious abnormalities in other cells or tissues. This system is useful for generating mouse models of disease and for studying the recovery or regeneration of tissues from cell damage or loss. As DT is a potent inhibitor of protein synthesis in both growing and non-growing cells, the method is applicable to a wide range of cells and tissues in mice or in other DT-insensitive animals.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Ikoma, Nara 6300101, Japan; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 1138613, Japan; Kurume Univ, Inst Life Sci, Div Cell Biol, Kurume, Fukuoka 8390861, Japan	Nara Institute of Science & Technology; Tokyo Metropolitan Institute of Medical Science; Kurume University	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Ikoma, Nara 6300101, Japan.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551; Mekada, Eisuke/0000-0001-8858-4781; Iwawaki, Takao/0000-0001-8753-1979				BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HONJO T, 1968, J BIOL CHEM, V243, P3553; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Kaneko S, 2000, SCIENCE, V289, P633, DOI 10.1126/science.289.5479.633; KIMATA Y, 1994, J BIOL CHEM, V269, P13497; KISO S, 1995, HEPATOLOGY, V22, P1584, DOI 10.1016/0270-9139(95)90168-X; KOBAYASHI K, 1992, P NATL ACAD SCI USA, V89, P1631, DOI 10.1073/pnas.89.5.1631; KOBAYASHI K, 1995, P NATL ACAD SCI USA, V92, P1132, DOI 10.1073/pnas.92.4.1132; KOHNO K, 1987, J BIOL CHEM, V262, P12298; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; Lee P, 1998, P NATL ACAD SCI USA, V95, P11371, DOI 10.1073/pnas.95.19.11371; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PAPPENHEIMER AM, 1982, J INFECT DIS, V145, P94, DOI 10.1093/infdis/145.1.94; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; ROBINSON EA, 1974, J BIOL CHEM, V249, P5088; ROSS SR, 1993, GENE DEV, V7, P1318, DOI 10.1101/gad.7.7b.1318; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VANNESS BG, 1980, J BIOL CHEM, V255, P717; Watanabe D, 1998, CELL, V95, P17, DOI 10.1016/S0092-8674(00)81779-1; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	35	345	355	3	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					746	750		10.1038/90795	http://dx.doi.org/10.1038/90795			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479567				2022-12-25	WOS:000170188600025
J	Betz, RC; Schoser, BGH; Kasper, D; Ricker, K; Ramirez, A; Stein, V; Torbergsen, T; Lee, YA; Nothen, MM; Wienker, TF; Malin, JP; Propping, P; Reis, A; Mortier, W; Jentsch, TJ; Vorgerd, M; Kubisch, C				Betz, RC; Schoser, BGH; Kasper, D; Ricker, K; Ramirez, A; Stein, V; Torbergsen, T; Lee, YA; Nothen, MM; Wienker, TF; Malin, JP; Propping, P; Reis, A; Mortier, W; Jentsch, TJ; Vorgerd, M; Kubisch, C			Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease	NATURE GENETICS			English	Article							GIRDLE MUSCULAR-DYSTROPHY; CAVEOLIN-3; COMPLEX	Hereditary rippling muscle disease (RMD) is an autosomal dominant human disorder characterized by mechanically triggered contractions of skeletal muscle(1-4). Genome-wide linkage analysis has identified an RMD locus on chromosome 3p25. We found missense mutations in positional candidate CAM (encoding caveolin 3; ref. 5) in all five families analyzed. Mutations in CAM have also been described in limb-girdle muscular dystrophy type 1C (LGMD1C; refs. 6,7), demonstrating the allelism of dystrophic and non-dystrophic muscle diseases.	Univ Bonn, Inst Human Genet, D-53111 Bonn, Germany; Univ Hamburg, Neurol Klin, Hamburg, Germany; Univ Hamburg, Znetrum Mol Neurobiol, Hamburg, Germany; Univ Wurzburg, Neurol Klin, D-8700 Wurzburg, Germany; Univ Tromso Hosp, Dept Neurol, N-9012 Tromso, Norway; Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Berlin, Germany; Univ Bonn, Inst Med Biometrie Informat & Epidemiol, D-53111 Bonn, Germany; Ruhr Univ Bochum, Padiatr Klin, D-4630 Bochum, Germany	University of Bonn; University of Hamburg; University of Hamburg; University of Wurzburg; UiT The Arctic University of Tromso; University Hospital of North Norway; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Bonn; Ruhr University Bochum	Kubisch, C (corresponding author), Univ Bonn, Inst Human Genet, Wilhelmstr 31, D-53111 Bonn, Germany.		Betz, Regina C/E-8591-2011; Vorgerd, Matthias/GRS-7540-2022; Reis, André/D-2309-2009; Ramirez, Alfredo/S-5126-2019; Kubisch, Christian/F-1893-2011; Schoser, Benedikt/AAH-6286-2020; Nöthen, Markus/B-2027-2009	Betz, Regina C/0000-0001-5024-3623; Vorgerd, Matthias/0000-0002-1782-4642; Reis, André/0000-0002-6301-6363; Ramirez, Alfredo/0000-0003-4991-763X; Kubisch, Christian/0000-0003-4220-0978; Nöthen, Markus/0000-0002-8770-2464; Stein, Valentin/0000-0003-1222-4928; Schoser, Benedikt/0000-0002-2757-8131; Jentsch, Thomas/0000-0002-3509-2553				Carbone I, 2000, NEUROLOGY, V54, P1373, DOI 10.1212/WNL.54.6.1373; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; Hagiwara Y, 2000, HUM MOL GENET, V9, P3047, DOI 10.1093/hmg/9.20.3047; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; RICKER K, 1989, ARCH NEUROL-CHICAGO, V46, P405, DOI 10.1001/archneur.1989.00520400065020; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; STEPHAN DA, 1994, NEUROLOGY, V44, P1915, DOI 10.1212/WNL.44.10.1915; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; TORBERGSEN T, 1975, ACTA NEUROL SCAND, V51, P225, DOI 10.1111/j.1600-0404.1975.tb07603.x; Vorgerd M, 1999, NEUROLOGY, V52, P1453, DOI 10.1212/WNL.52.7.1453; Williams G, 1996, AM J PHYSIOL-REG I, V270, pR145, DOI 10.1152/ajpregu.1996.270.1.R145	15	135	141	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					218	219		10.1038/90050	http://dx.doi.org/10.1038/90050			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431690				2022-12-25	WOS:000169656400012
J	Eis, PS; Olson, MC; Takova, T; Curtis, ML; Olson, SM; Vener, TI; Ip, HS; Vedvik, KL; Bartholomay, CT; Allawi, HT; Ma, WP; Hall, JG; Morin, MD; Rushmore, TH; Lyamichev, VI; Kwiatkowski, RW				Eis, PS; Olson, MC; Takova, T; Curtis, ML; Olson, SM; Vener, TI; Ip, HS; Vedvik, KL; Bartholomay, CT; Allawi, HT; Ma, WP; Hall, JG; Morin, MD; Rushmore, TH; Lyamichev, VI; Kwiatkowski, RW			An invasive cleavage assay for direct quantitation of specific RNAs	NATURE BIOTECHNOLOGY			English	Article							DNA; IDENTIFICATION; IL-1-BETA; KINETICS; GENOME	RNA quantitation is becoming increasingly important in basic. pharmaceutical, and clinical research. For example, quantitation of viral RNAs can predict disease progression and therapeutic efficacy(1). Likewise. gene expression analysis of diseased versus normal, or untreated versus treated, tissue can identify relevant biological responses or assess the effects of pharmacological agents(2). As the focus of the Human Genome Project moves toward gene expression analysis, the field will require a flexible RNA analysis technology that can quantitatively monitor multiple forms of alternatively transcribed and/or processed RNAs (refs 3,4). We have applied the principles of invasive cleavage(5) and engineered an improved 5'-nuclease to develop an isothermal, fluorescence resonance energy transfer (FRET)-based(6) signal amplification method for detecting RNA in both total RNA and cell lysate samples. This detection format, termed the RNA invasive cleavage assay, obviates the need for target amplification or additional enzymatic signal enhancement(7). In this report, we describe the assay and present data demonstrating its capabilities for sensitive (<100 copies per reaction), specific (discrimination of 95% homologous sequences, 1 in <greater than or equal to>20,000), and quantitative (1.2-fold changes in RNA levels) detection of unamplified RNA in both single- and biplex-reaction formats.	Third Wave Technol, Madison, WI 53719 USA; Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA	Merck & Company	Eis, PS (corresponding author), Third Wave Technol, 502 S Rosa Rd, Madison, WI 53719 USA.	peis@twt.com		Ip, Hon/0000-0003-4844-7533; Eis, Peggy/0000-0002-3075-8707	NIGMS NIH HHS [2 R44 GM57711-02A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM057711] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allawi HT, 2001, RNA, V7, P314, DOI 10.1017/S1355838201001698; Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CHAUDHARY LR, 1994, CALCIFIED TISSUE INT, V55, P16, DOI 10.1007/BF00310163; GHOSH SS, 1994, NUCLEIC ACIDS RES, V22, P3155, DOI 10.1093/nar/22.15.3155; Hall JG, 2000, P NATL ACAD SCI USA, V97, P8272, DOI 10.1073/pnas.140225597; Herbert A, 1999, NAT GENET, V21, P265, DOI 10.1038/6780; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kwiatkowski RW, 1999, MOL DIAGN, V4, P353, DOI 10.1016/S1084-8592(99)80012-5; Lane MJ, 1997, NUCLEIC ACIDS RES, V25, P611, DOI 10.1093/nar/25.3.611; Lyamichev V, 1999, NAT BIOTECHNOL, V17, P292, DOI 10.1038/7044; Lyamichev VI, 2000, BIOCHEMISTRY-US, V39, P9523, DOI 10.1021/bi0007829; Ma WP, 2000, J BIOL CHEM, V275, P24693, DOI 10.1074/jbc.M002268200; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; *NIH, 2000, BLAST NAT CTR BIOT I; Reynaldo LP, 2000, J MOL BIOL, V297, P511, DOI 10.1006/jmbi.2000.3573; Van Arsdell SW, 2000, BIOTECHNIQUES, V28, P1220; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; 2001, SCIENCE, V291, P1145	20	57	97	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					673	676		10.1038/90290	http://dx.doi.org/10.1038/90290			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433281				2022-12-25	WOS:000169677200025
J	Xia, HB; Mao, QW; Davidson, BL				Xia, HB; Mao, QW; Davidson, BL			The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors	NATURE BIOTECHNOLOGY			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; CENTRAL-NERVOUS-SYSTEM; ENZYME REPLACEMENT THERAPY; LYSOSOMAL STORAGE; GENE-TRANSFER; MURINE; DELIVERY; CELLS; BRAIN	Treatment of inherited genetic diseases of the brain remains an intractable problem. Methods to improve the distribution of enzymes that are injected or expressed from transduced cells will be required for many human brain therapies. Recent studies showed that a peptide, the protein transduction domain (PTD) from HIV Tat, could improve the distribution of cytoplasmic reporter proteins when administered systemically as fusion proteins or cross-linked chimeras. The utility of this motif for noncytoplasmic proteins has not been determined. Here, we tested how the Tat motif affected uptake and biodistribution of the lysosomal enzyme beta -glucuronidase, the protein deficient in the disease mucopolysaccharidosis VII, when expressed from viral vectors. The Tat motif allowed for mannose-6-phosphate (M6P) independent uptake in vitro and significantly increased the distribution of beta -glucuronidase secreted from transduced cells after intravenous or direct brain injection in mice of recombinant vectors. Thus, enzymes modified to contain protein transduction motifs may represent a general strategy for improving the distribution of secreted proteins following in vivo gene transfer.	Univ Iowa, Coll Med, Dept Internal Med, Program Gene Therapy, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Program Gene Therapy, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Program Gene Therapy, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Davidson, BL (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Program Gene Therapy, Iowa City, IA 52242 USA.				NICHD NIH HHS [HD33531] Funding Source: Medline; NIDDK NIH HHS [DK54759] Funding Source: Medline; NINDS NIH HHS [NS34568] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034568] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Frisella WA, 2001, MOL THER, V3, P351, DOI 10.1006/mthe.2001.0274; Ghodsi A, 1999, EXP NEUROL, V160, P109, DOI 10.1006/exnr.1999.7205; Ghodsi A, 1998, HUM GENE THER, V9, P2331, DOI 10.1089/hum.1998.9.16-2331; GLASER JH, 1973, J LAB CLIN MED, V82, P969; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Stein CS, 1999, J VIROL, V73, P3424, DOI 10.1128/JVI.73.4.3424-3429.1999	15	148	160	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					640	644		10.1038/90242	http://dx.doi.org/10.1038/90242			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433275				2022-12-25	WOS:000169677200019
J	Bailey, JE				Bailey, JE			Complex biology with no parameters	NATURE BIOTECHNOLOGY			English	Editorial Material									ETH Zurich, Inst Biotechnol, Swiss Fed Inst Technol, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bailey, JE (corresponding author), ETH Zurich, Inst Biotechnol, Swiss Fed Inst Technol, Zurich, Switzerland.							Bailey J.E., 1986, BIOCH ENG FUNDAMENTA, P228; Bono H, 1998, GENOME RES, V8, P203, DOI 10.1101/gr.8.3.203; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; FEINBERG M, 1974, CHEM ENG SCI, V29, P775, DOI 10.1016/0009-2509(74)80195-8; HORN F, 1972, ARCH RATION MECH AN, V47, P81; SCHLOSSER PM, 1994, CHEM ENG SCI, V49, P1749, DOI 10.1016/0009-2509(94)80061-8; WEI J, 1962, ADV CATAL, V13, P203, DOI 10.1016/S0360-0564(08)60289-8	8	82	90	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					503	504		10.1038/89204	http://dx.doi.org/10.1038/89204			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385433				2022-12-25	WOS:000169081700008
J	Khan, J; Wei, JS; Ringner, M; Saal, LH; Ladanyi, M; Westermann, F; Berthold, F; Schwab, M; Antonescu, CR; Peterson, C; Meltzer, PS				Khan, J; Wei, JS; Ringner, M; Saal, LH; Ladanyi, M; Westermann, F; Berthold, F; Schwab, M; Antonescu, CR; Peterson, C; Meltzer, PS			Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks	NATURE MEDICINE			English	Article							MOLECULAR CLASSIFICATION; DIFFERENTIAL-DIAGNOSIS; NEUROECTODERMAL TUMOR; CDNA MICROARRAYS; EWINGS-SARCOMA; HUMAN BREAST; CELL TUMORS; ROUND-CELL; GROWTH; PATTERNS	The purpose of this study was to develop a method of classifying cancers to specific diagnostic categories based on their gene expression signatures using artificial neural networks (ANNs). We trained the ANNs using the small, round blue-cell tumors (SRBCTs) as a model. These cancers belong to four distinct diagnostic categories and often present diagnostic dilemmas in clinical practice. The ANNs correctly classified all samples and identified the genes most relevant to the classification. Expression of several of these genes has been reported in SRBCTs, but most have not been associated with these cancers. To test the ability of the trained ANN models to recognize SRSCTs, we analyzed additional blinded samples that were not previously used for the training procedure, and correctly classified them in all cases. This study demonstrates the potential applications of these methods for tumor diagnosis and the Identification of candidate targets for therapy.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, Ctr Adv Technol, Gaithersburg, MD USA; Univ Lund, Dept Theoret Phys, Complex Syst Div, S-22362 Lund, Sweden; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; German Canc Res Ctr, Dept Cytogenet, D-6900 Heidelberg, Germany; Univ Cologne, Klin Kinderheilkunde, Dept Pediat, Cologne, Germany	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Lund University; Memorial Sloan Kettering Cancer Center; Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Khan, J (corresponding author), NHGRI, Canc Genet Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.		Westermann, Frank/F-7509-2013; Ringnér, Markus/G-3641-2011; Ladanyi, Marc/AAG-8585-2019; Saal, Lao H/A-2919-2011; Khan, Javed/P-9157-2014	Ringnér, Markus/0000-0001-5469-8940; Saal, Lao H/0000-0002-0815-1896; 	NATIONAL CANCER INSTITUTE [Z01SC010366] Funding Source: NIH RePORTER; NCI NIH HHS [Z01 SC010366-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdolmaleki P, 1997, Radiat Med, V15, P283; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ashizawa K, 1999, ACAD RADIOL, V6, P2, DOI 10.1016/S1076-6332(99)80055-5; Bishop C. M., 1995, NEURAL NETWORKS PATT; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; Chen Y., 1997, BIOMED OPTICS, V2, P364; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DeRisi J, 1996, NAT GENET, V14, P457; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; Heden B, 1997, CIRCULATION, V96, P1798, DOI 10.1161/01.CIR.96.6.1798; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jollife I. T., 1986, PRINCIPAL COMPONENT; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Khan J, 1998, CANCER RES, V58, P5009; KOVAR H, 1990, ONCOGENE, V5, P1067; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; LEE MGS, 1984, NUCLEIC ACIDS RES, V12, P5823, DOI 10.1093/nar/12.14.5823; McKarney LA, 1997, INT J DEV BIOL, V41, P485; McManus AP, 1996, J PATHOL, V178, P116, DOI 10.1002/(SICI)1096-9896(199602)178:2<116::AID-PATH494>3.0.CO;2-H; Mu J, 1998, J BIOL CHEM, V273, P34850, DOI 10.1074/jbc.273.52.34850; Nagano T, 1998, MOL BRAIN RES, V53, P13, DOI 10.1016/S0169-328X(97)00271-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIZZO P, 1997, PRINCIPLES PRACTICE; Savchenko VL, 2000, NEUROSCIENCE, V96, P195, DOI 10.1016/S0306-4522(99)00538-2; SHAOUL E, 1995, ONCOGENE, V10, P1553; SILIPO R, 1995, COMPUT BIOMED RES, V28, P305, DOI 10.1006/cbmr.1995.1021; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; STROHMAN RC, 1983, SCIENCE, V221, P955, DOI 10.1126/science.6879193; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P8893; TAYLOR C, 1993, BRIT J CANCER, V67, P128, DOI 10.1038/bjc.1993.22; TRICHE TJ, 1983, HUM PATHOL, V14, P569	40	1841	2014	3	263	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2001	7	6					673	679		10.1038/89044	http://dx.doi.org/10.1038/89044			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	438YH	11385503	Green Accepted			2022-12-25	WOS:000169081500034
J	Medico, E; Gambarotta, G; Gentile, A; Comoglio, PM; Soriano, P				Medico, E; Gambarotta, G; Gentile, A; Comoglio, PM; Soriano, P			A gene trap vector system for identifying transcriptionally responsive genes	NATURE BIOTECHNOLOGY			English	Article							HEPATOCYTE GROWTH-FACTOR; EMBRYONIC STEM-CELLS; DEVELOPMENTAL GENES; C-MYC; PROTEIN; EXPRESSION; IDENTIFICATION; FIBROBLASTS; SCREEN; ENZYME	We present a method for fast and efficient trapping of genes whose transcription is regulated by exogenous stimuli. We constructed a promoterless retroviral vector transducing a green fluorescent protein(1)-nitroreductase(2) (GFNR) fusion protein downstream from a splice acceptor site. Flow cytometric analysis of the infected population allows identification and sorting of cells in which the trap is integrated downstream from an active promoter. Conversely, the nitroreductase (NTR) moiety allows pharmacological selection against constitutive GFNR expression. Using hepatocyte growth factor (HGF) stimulation of liver cells(3) combined with either positive or negative selection. we recovered cell populations carrying traps in induced or suppressed genes, respectively. Several distinct responsive clones were isolated, and regulated expression of the trapped gene was confirmed at the RNA level. Positive and negative selection can be calibrated to recover traps in genes showing different levels of basal expression or transcriptional regulation. The flexibility and efficiency of the GFNR-based trap screening procedure make it suitable for wide surveys of transcriptionally regulated genes.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Dev Biol, Seattle, WA 98109 USA	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Fred Hutchinson Cancer Center	Medico, E (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy.	emedico@ircc.unito.it	Comoglio, Paolo/G-6323-2011; Gambarotta, Giovanna/I-8473-2012; Medico, Enzo/AAC-3185-2021; gentile, alessandra/L-4299-2013; Soriano, Philippe M/E-5797-2015	Gambarotta, Giovanna/0000-0002-8380-5925; Medico, Enzo/0000-0002-3917-2438; gentile, alessandra/0000-0002-3367-8833; Soriano, Philippe M/0000-0002-0427-926X; Comoglio, Paolo/0000-0002-7056-5328	NICHD NIH HHS [HD25326, HD24875] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R37HD025326, R01HD025326] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Baker RK, 1997, DEV BIOL, V185, P201, DOI 10.1006/dbio.1997.8541; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Bonaldo P, 1998, EXP CELL RES, V244, P125, DOI 10.1006/excr.1998.4208; Bridgewater JA, 1995, EUR J CANCER, V31A, P2362, DOI 10.1016/0959-8049(95)00436-X; Bridgewater JA, 1997, HUM GENE THER, V8, P709, DOI 10.1089/hum.1997.8.6-709; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Desiderio MA, 1998, EXP CELL RES, V242, P401, DOI 10.1006/excr.1998.4073; Forrester LM, 1996, P NATL ACAD SCI USA, V93, P1677, DOI 10.1073/pnas.93.4.1677; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gogos JA, 1997, J VIROL, V71, P1644, DOI 10.1128/JVI.71.2.1644-1650.1997; Ishida Y, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e35; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Komada M, 2000, GENE DEV, V14, P1332; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; OCHMAN H, 1988, GENETICS, V120, P621; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Whitney M, 1998, NAT BIOTECHNOL, V16, P1329, DOI 10.1038/4302	24	49	56	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2001	19	6					579	582		10.1038/89343	http://dx.doi.org/10.1038/89343			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	438YK	11385465				2022-12-25	WOS:000169081700034
J	Basu, S; Nagy, JA; Pal, S; Vasile, E; Eckelhoefer, IA; Bliss, VS; Manseau, EJ; Dasgupta, PS; Dvorak, HF; Mukhopadhyay, D				Basu, S; Nagy, JA; Pal, S; Vasile, E; Eckelhoefer, IA; Bliss, VS; Manseau, EJ; Dasgupta, PS; Dvorak, HF; Mukhopadhyay, D			The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor	NATURE MEDICINE			English	Article							ASCITES TUMOR-GROWTH; RHEUMATOID-ARTHRITIS; PITUITARY-ADENOMAS; B-16 MELANOMA; PATHOGENESIS; ACCUMULATION; EXPRESSION; HYPERPERMEABILITY; SCHIZOPHRENIA; INNERVATION	Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.							Ashraf S, 1997, CLIN EXP METASTAS, V15, P484, DOI 10.1023/A:1018466608614; BACIC F, 1991, J NEUROCHEM, V57, P1774, DOI 10.1111/j.1471-4159.1991.tb06380.x; Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9; Basu S, 1999, DIGEST DIS SCI, V44, P916, DOI 10.1023/A:1026644110737; Basu S, 2000, ENDOCRINE, V12, P237, DOI 10.1385/ENDO:12:3:237; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Braunwald E, 1998, LANCET, V352, P1771, DOI 10.1016/S0140-6736(98)03212-7; Brown LF, 1997, REGULATION ANGIOGENE; Chamary VL, 2000, EUR J SURG ONCOL, V26, P588, DOI 10.1053/ejso.2000.0952; DASGUPTA PS, 1987, J CANCER RES CLIN, V113, P363, DOI 10.1007/BF00397720; DASILVA JAP, 1990, J RHEUMATOL, V17, P1592; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; Egan MF, 1997, CURR OPIN NEUROBIOL, V7, P701, DOI 10.1016/S0959-4388(97)80092-X; EWING AG, 1983, SCIENCE, V221, P169, DOI 10.1126/science.6857277; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; GOLDSTEIN M, 1992, FASEB J, V6, P2413, DOI 10.1096/fasebj.6.7.1348713; GRAYBIEL AM, 1990, ADV NEUROL, V53, P17; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; HEEG K, 1985, J IMMUNOL METHODS, V77, P237, DOI 10.1016/0022-1759(85)90036-5; KATZUNG BG, 1998, BASIC CLIN PHARM; Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99-1082com; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Nagai Y, 2000, HORM METAB RES, V32, P326, DOI 10.1055/s-2007-978645; NAGY JA, 1995, CANCER RES, V55, P360; NAGY JA, 1995, CANCER RES, V55, P376; NAGY JA, 1995, CANCER RES, V55, P369; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Otsuka F, 1999, REGUL PEPTIDES, V83, P31, DOI 10.1016/S0167-0115(99)00048-8; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; RICCI A, 1994, J AUTON PHARMACOL, V14, P61, DOI 10.1111/j.1474-8673.1994.tb00590.x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Takechi Akihiko, 1994, Neurologia Medico-Chirurgica, V34, P729, DOI 10.2176/nmc.34.729; Turner HE, 2000, J ENDOCRINOL, V165, P475, DOI 10.1677/joe.0.1650475; WICK MM, 1978, J INVEST DERMATOL, V71, P163, DOI 10.1111/1523-1747.ep12546959.1; WICK MM, 1979, J NATL CANCER I, V63, P1465; WICK MM, 1979, CANCER TREAT REP, V63, P991; WICK MM, 1981, CANCER TREAT REP, V65, P861; WICK MM, 1981, J NATL CANCER I, V66, P351; WICK MM, 1980, CANCER RES, V40, P1414; ZAROSLINSKI JF, 1977, P ROY SOC MED, V70, P2, DOI 10.1177/00359157770700S202	41	289	312	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					569	574		10.1038/87895	http://dx.doi.org/10.1038/87895			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329058				2022-12-25	WOS:000169961100036
J	Harrison, JC; Bardes, ESG; Ohya, Y; Lew, DJ				Harrison, JC; Bardes, ESG; Ohya, Y; Lew, DJ			A role for the Pkc1p/Mpk1p kinase cascade in the morphogenesis checkpoint	NATURE CELL BIOLOGY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; MAP KINASE; CELL MORPHOGENESIS; SWE1P DEGRADATION; SHUTTLE VECTORS; PROTEIN; PATHWAY; GENE; ACTIVATION; INTEGRITY	In many cells the timing of entry into mitosis is controlled by the balance between the activity of inhibitory Wee1-related kinases (Swe1p in budding yeast) and the opposing effect of Cdc25-related phosphatases (Mih1p in budding yeast) that act on the cyclin-dependent kinase Cdc2 (Cdc28p in budding yeast)(1). Wee1 and Cdc25 are key elements in the G2 arrest mediated by diverse checkpoint controls(2). In budding yeast, a 'morphogenesis checkpoint' that involves Swe1p and Mih1p delays mitotic activation of Cdc28p(3). Many environmental stresses (such as shifts in temperature or osmolarity) provoke transient depolarization of the actin cytoskeleton, during which bud construction is delayed while cells adapt to environmental conditions. During this delay, the morphogenesis checkpoint halts the cell cycle in G2 phase until actin can repolarize and complete bud construction, thus preventing the generation of binucleate cells(4). A similar G2 delay can be triggered by mutations or drugs that specifically impair actin organization(5), indicating that it is probably actin disorganization itself, rather than specific environmental stresses, that triggers the delay. The G2 delay involves stabilization of Swe1p in response to various actin perturbations(6), although this alone is insufficient to produce a long G2 delay(7).	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Bunkyo Ku, Tokyo 1130033, Japan	Duke University; University of Tokyo	Lew, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.							BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Guthrie C, 1991, GUIDE YEAST GENETICS; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Lew DJ, 2000, CURR OPIN GENET DEV, V10, P47, DOI 10.1016/S0959-437X(99)00051-9; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; Marini NJ, 1996, EMBO J, V15, P3040, DOI 10.1002/j.1460-2075.1996.tb00667.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; McMillan JN, 1999, MOL CELL BIOL, V19, P5981; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Moore DD, 1995, GLOB MOB SURV; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; SIKORSKI RS, 1989, GENETICS, V122, P19; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	35	114	119	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2001	3	4					417	420		10.1038/35070104	http://dx.doi.org/10.1038/35070104			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	421CE	11283616				2022-12-25	WOS:000168043900021
J	Weninger, WJ; Mohun, T				Weninger, WJ; Mohun, T			Phenotyping transgenic embryos: a rapid 3-D screening method based on episcopic fluorescence image capturing	NATURE GENETICS			English	Article							GENE-EXPRESSION; 3-DIMENSIONAL RECONSTRUCTION; ATRIOVENTRICULAR JUNCTION; SERIAL SECTIONS; IN-VIVO; MOUSE; HEART; VISUALIZATION; TRISOMY-16; MORPHOLOGY	We describe a technique suitable for routine three-dimensional (3-D) analysis of mouse embryos that is based on episcopic fluorescence images captured during serial sectioning of wax-embedded specimens. We have used this procedure to describe the cardiac phenotype and associated blood vessels of trisomic 16 (Ts16) and Cited2-null mutant mice, as well as the expression pattern of an Myf5 enhancer/beta-galactosidase transgene. The consistency of the images and their precise alignment are ideally suited for 3-D analysis using video animations, virtual resectioning or commercial 3-D reconstruction software packages. Episcopic fluorescence image capturing (EFIC) provides a simple and powerful tool for analyzing embryo and organ morphology in normal and transgenic embryos.	Univ Vienna, Dept Anat, Integrat Morphol Grp, A-1090 Vienna, Austria; Natl Inst Med Res, Dev Biol Div, London NW7 1AA, England	University of Vienna; MRC National Institute for Medical Research	Weninger, WJ (corresponding author), Univ Vienna, Dept Anat, Integrat Morphol Grp, Waehringerstr 16, A-1090 Vienna, Austria.	Wolfgang.Weninger@univie.ac.at; tmohun@nimr.mrc.ac.uk		Weninger, Wolfgang J/0000-0003-0575-0073				Anderson RH, 1998, CARDIOVASC RES, V39, P155, DOI 10.1016/S0008-6363(98)00037-6; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333; Hecksher-Sorensen J, 2001, MECH DEVELOP, V100, P59, DOI 10.1016/S0925-4773(00)00508-6; LAAN AC, 1989, ANAT RECORD, V224, P443, DOI 10.1002/ar.1092240313; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; MCLEAN MR, 1987, ANAT REC, V219, P434, DOI 10.1002/ar.1092190415; Mohun TJ, 2000, DEV BIOL, V218, P74, DOI 10.1006/dbio.1999.9559; ODGAARD A, 1990, J MICROSC-OXFORD, V159, P335, DOI 10.1111/j.1365-2818.1990.tb03038.x; Scarborough J, 1997, J ANAT, V191, P117, DOI 10.1046/j.1469-7580.1997.19110117.x; Smith BR, 1999, SCI AM, V280, P76, DOI 10.1038/scientificamerican0399-76; Spoor F, 2000, J ANAT, V197, P61, DOI 10.1046/j.1469-7580.2000.19710061.x; Streicher J, 2000, NAT GENET, V25, P147, DOI 10.1038/75989; Streicher J, 1997, ANAT REC, V248, P583; Summerbell D, 2000, DEVELOPMENT, V127, P3745; TJUVAJEV JG, 1995, CANCER RES, V55, P6126; Tjuvajev JG, 1996, CANCER RES, V56, P4087; VERBEEK FJ, 1995, 3 DIMENSIONAL RECONS; Webb S, 1997, CARDIOVASC RES, V34, P515, DOI 10.1016/S0008-6363(97)00064-3; WENINGER W, 1995, COMPUTER ASSISTED 3; Weninger WJ, 1998, ANAT EMBRYOL, V197, P341, DOI 10.1007/s004290050144	21	133	136	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2002	30	1					59	65		10.1038/ng785	http://dx.doi.org/10.1038/ng785			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743576				2022-12-25	WOS:000173105600014
J	Wettschureck, N; Rutten, H; Zywietz, A; Gehring, D; Wilkie, TM; Chen, J; Chien, KR; Offermanns, S				Wettschureck, N; Rutten, H; Zywietz, A; Gehring, D; Wilkie, TM; Chen, J; Chien, KR; Offermanns, S			Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of G alpha(q)/G alpha(11) in cardiomyocytes	NATURE MEDICINE			English	Article							CARDIAC-HYPERTROPHY; MICE; RECEPTOR; EXPRESSION; FAILURE; OVEREXPRESSION; CARDIOMYOPATHY; MYOCYTES; PATHWAYS; GROWTH	Myocardial hypertrophy is an adaptational response of the heart to increased work load, but it is also associated with a high risk of cardiac mortality(1-3) due to its established role in the development of cardiac failure, one of the leading causes of death in developed countries. Multiple growth factors(2,3) and various downstream signaling pathways involving, for example, ras', gp-130 (ref. 4), JNK/p38 (refs. 5,6) and calcineurin/NFAT/CaM-kinase(7) have been implicated in the hypertrophic response. However, there is evidence that the initial phase in the development of myocardial hypertrophy involves the formation of cardiac para- and/or autocrine factors like endothelin-1, norepinephrine or angiotensin II (refs. 7,8), the receptors of which are coupled to G-proteins of the G(q/11)-, G(12/13)- and G(i/o)-families(5,6,8). Cardiomyocyte-specific transgenic overexpression of alpha (1)-adrenergic or angiotensin (AT(1))-receptors as well as of the G(q) alpha -subunit, G alpha (q), results in myocardial hypertrophy(9-12). These data demonstrate that chronic activation of the G(q)/G(11)-family is sufficient to induce myocardial hypertrophy. In order to test whether G(q)/G(11) mediate the physiological hypertrophy response to pressure overload, we generated a mouse line lacking both G alpha (q) and G alpha (11) in cardiomyocytes. These mice showed no detectable ventricular hypertrophy in response to pressure-overload induced by aortic constriction. The complete lack of a hypertrophic response proves that the G(q)/G(11)-mediated pathway is essential for cardiac hypertrophy induced by pressure overload and makes this signaling process an interesting target for interventions to prevent myocardial hypertrophy.	Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany; Aventis Pharma, DG Cardiovasc, Frankfurt, Germany; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA	Ruprecht Karls University Heidelberg; Sanofi-Aventis; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany.	stefan.offermanns@urz.uni-heidelberg.de	Chen, Ju/E-5579-2011; Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Wettschureck, Nina/0000-0001-6858-1460; Offermanns, Stefan/0000-0001-8676-6805				Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Griendling KK, 1996, ANNU REV PHARMACOL, V36, P281, DOI 10.1146/annurev.pharmtox.36.1.281; Hamawaki M, 1998, AM J PHYSIOL-HEART C, V274, pH868, DOI 10.1152/ajpheart.1998.274.3.H868; Harada K, 1998, CIRCULATION, V97, P1952, DOI 10.1161/01.CIR.97.19.1952; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hilal-Dandan R, 2000, J MOL CELL CARDIOL, V32, P1211, DOI 10.1006/jmcc.2000.1156; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Yamazaki T, 1999, ANN NY ACAD SCI, V874, P38, DOI 10.1111/j.1749-6632.1999.tb09223.x	25	295	305	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2001	7	11					1236	1240		10.1038/nm1101-1236	http://dx.doi.org/10.1038/nm1101-1236			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	490LV	11689889				2022-12-25	WOS:000172054100032
J	Kurahashi, H; Emanuel, BS				Kurahashi, H; Emanuel, BS			Unexpected high rate of de novo constitutional t(11;22) translocations in sperm from normal males	NATURE GENETICS			English	Article							IN-SITU HYBRIDIZATION; DOUBLE-STRAND BREAKS; RECIPROCAL TRANSLOCATION; 22Q11 BREAKPOINTS; CLUSTERED 11Q23; FAMILIES	Junction fragments from the constitutional t(11;22)(q23;q11) translocation have previously been cloned and sequenced. Here we report a high incidence of translocation-specific PCR products in sperm DNA from normal individuals. Somatic DNA from these and other normal individuals or from people with chromosomal breakage syndromes do not yield PCR junction fragments, indicating that this translocation originates during meiosis.	Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Emanuel, BS (corresponding author), Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Abramson Res Ctr Bldg,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA039926] Funding Source: NIH RePORTER; NCI NIH HHS [CA39926] Funding Source: Medline; NICHD NIH HHS [HD26979] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Armstrong SJ, 2000, AM J HUM GENET, V67, P601, DOI 10.1086/303052; Edelmann L, 1999, AM J HUM GENET, V65, P1608, DOI 10.1086/302689; Edelmann L, 2001, AM J HUM GENET, V68, P1, DOI 10.1086/316952; Estop AM, 1999, HUM GENET, V104, P412, DOI 10.1007/s004390050977; Kurahashi H, 2000, HUM MOL GENET, V9, P2727, DOI 10.1093/hmg/9.18.2727; Kurahashi H, 2000, AM J HUM GENET, V67, P763, DOI 10.1086/303054; Kurahashi H, 2000, HUM MOL GENET, V9, P1665, DOI 10.1093/hmg/9.11.1665; KURAHASHI H, IN PRESS HUM MOL GEN; Majewski J, 2000, GENOME RES, V10, P1108, DOI 10.1101/gr.10.8.1108; Nasar F, 2000, MOL CELL BIOL, V20, P3449, DOI 10.1128/MCB.20.10.3449-3458.2000; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Shaikh TH, 1999, AM J HUM GENET, V65, P1595, DOI 10.1086/302666; Van Assche E, 1999, MOL HUM REPROD, V5, P682, DOI 10.1093/molehr/5.7.682; ZACKAI EH, 1980, AM J MED GENET, V7, P507, DOI 10.1002/ajmg.1320070412	14	60	65	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					139	140		10.1038/ng1001-139	http://dx.doi.org/10.1038/ng1001-139			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586296				2022-12-25	WOS:000171374100017
J	Perreault, M; Marette, A				Perreault, M; Marette, A			Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; SKELETAL-MUSCLE; ADIPOSE-TISSUE; HEART-DISEASE; MICE LACKING; L-ARGININE; EXPRESSION; RECEPTOR; RATS; HYPERINSULINEMIA	Inducible nitric oxide synthase (iNOS) is induced by inflammatory cytokines in skeletal muscle and fat. It has been proposed that chronic iNOS induction may cause muscle insulin resistance. Here we show that iNOS expression is increased in muscle and fat of genetic and dietary models of obesity. Moreover, mice in which the gene encoding iNOS was disrupted (Nos2(-/-) mice) are protected from high-fat-induced insulin resistance. Whereas both wild-type and Nos2(-/-) mice developed obesity on the high-fat diet, obese Nos2(-/-) mice exhibited improved glucose tolerance, normal insulin sensitivity in vivo and normal insulin-stimulated glucose uptake in muscles. iNOS induction in obese wild-type mice was associated with impairments in phosphatidylinositol 3-kinase and Akt activation by insulin in muscle. These defects were fully prevented in obese Nos2(-/-) mice. These findings provide genetic evidence that iNOS is involved in the development of muscle insulin resistance in diet-induced obesity.	Univ Laval, Hosp Res Ctr, Dept Anat & Physiol, Lipid Res Unit, St Foy, PQ G1K 7P4, Canada; Univ Laval, Hosp Res Ctr, Res Ctr Energy Metab, St Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Marette, A (corresponding author), Univ Laval, Hosp Res Ctr, Dept Anat & Physiol, Lipid Res Unit, St Foy, PQ G1K 7P4, Canada.		Marette, Andre/E-9342-2013					Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; Behr-Roussel D, 2000, CIRCULATION, V102, P1033, DOI 10.1161/01.CIR.102.9.1033; Cromheeke KM, 1999, CARDIOVASC RES, V43, P744, DOI 10.1016/S0008-6363(99)00148-0; Dawson V L, 1995, Adv Pharmacol, V34, P323; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Grundy SM, 1999, AM J CARDIOL, V83, p25F; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Kapur S, 1997, DIABETES, V46, P1691, DOI 10.2337/diabetes.46.11.1691; Kapur S, 1999, AM J PHYSIOL-ENDOC M, V276, pE635, DOI 10.1152/ajpendo.1999.276.4.E635; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Liu DB, 2000, DIABETES, V49, P1116, DOI 10.2337/diabetes.49.7.1116; MACMICKING JD, 1995, CELL, V81, P1170; Maggi LB, 2000, DIABETES, V49, P346, DOI 10.2337/diabetes.49.3.346; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Perreault M, 2000, DIABETOLOGIA, V43, P427, DOI 10.1007/s001250051325; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Pilon G, 2000, HORM METAB RES, V32, P480, DOI 10.1055/s-2007-978674; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shulman GI, 1999, AM J CARDIOL, V84, p3J; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Stichtenoth DO, 1998, BRIT J RHEUMATOL, V37, P246; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weyer C, 2000, DIABETES, V49, P2094, DOI 10.2337/diabetes.49.12.2094; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	42	395	423	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1138	1143		10.1038/nm1001-1138	http://dx.doi.org/10.1038/nm1001-1138			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590438				2022-12-25	WOS:000171524500036
J	Sevier, CS; Cuozzo, JW; Vala, A; Aslund, F; Kaiser, CA				Sevier, CS; Cuozzo, JW; Vala, A; Aslund, F; Kaiser, CA			A flavoprotein oxidase defines a new endoplasmic reticulum pathway for biosynthetic disulphide bond formation	NATURE CELL BIOLOGY			English	Article							LIVER-REGENERATION; SULFHYDRYL OXIDASE; YEAST SCERV1; PROTEIN; GENE; ISOMERASE; AUGMENTOR; GROWTH; IDENTIFICATION; THIOREDOXIN	Ero1 and Pdi1 are essential elements of the pathway for the formation of disulphide bonds within the endoplasmic reticulum (ER). By screening for alternative oxidation pathways in Saccharomyces cerevisiae, we identified EM as a gene that when overexpressed can restore viability and disulphide bond formation to an ero1-1 mutant strain. EM encodes a luminal ER protein of relative molecular mass 22,000. Purified recombinant Erv2p is a flavoenzyme that can catalyse O-2-dependent formation of disulphide bonds. Erv2p transfers oxidizing equivalents to Pdi1p by a dithiol-disulphide exchange reaction, indicating that the Erv2p-dependent pathway for disulphide bond formation closely parallels that of the previously identified Ero1p-dependent pathway.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kaiser, CA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ckaiser@mit.edu		Sevier, Carolyn/0000-0003-3245-6988; Cuozzo, John/0000-0002-6229-0395				Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P747, DOI 10.1002/hep.1840200328; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; Gliszczynska A, 1998, J CHROMATOGR A, V822, P59, DOI 10.1016/S0021-9673(98)00557-3; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hofhaus G, 1999, EUR J CELL BIOL, V78, P349, DOI 10.1016/S0171-9335(99)80069-7; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Lewis T, 2000, J VIROL, V74, P1275, DOI 10.1128/JVI.74.3.1275-1285.2000; LISOWSKY T, 1992, MOL GEN GENET, V232, P58, DOI 10.1007/BF00299137; Lisowsky T, 2001, DIGEST LIVER DIS, V33, P173, DOI 10.1016/S1590-8658(01)80074-8; LIU HP, 1992, GENETICS, V132, P665; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTENS M, 1995, INTEGRATIVE THERAPIE, V1, P3; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; SIMONEN TC, 1993, P S IAEA, P41; Stein G, 1998, YEAST, V14, P171, DOI 10.1002/(SICI)1097-0061(19980130)14:2<171::AID-YEA209>3.0.CO;2-U; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310	37	149	157	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					874	882		10.1038/ncb1001-874	http://dx.doi.org/10.1038/ncb1001-874			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584268				2022-12-25	WOS:000171396400011
J	Le Stunff, C; Fallin, D; Bougneres, P				Le Stunff, C; Fallin, D; Bougneres, P			Paternal transmission of the very common class IINSVNTR alleles predisposes to childhood obesity	NATURE GENETICS			English	Article							SUSCEPTIBILITY LOCUS IDDM2; INSULIN GENE; VARIABLE NUMBER; MINISATELLITE; EXPRESSION; FETUS; TDT	To identify some of the genetic factors that contribute to obesity in children of Central European and North African descent, we studied the parental transmission of alleles at the insulin locus to offspring with early-onset obesity. A variable nucleotide tandem repeat (VNTR) polymorphism upstream of the insulin gene (INS) is associated with variations in the expression of INS and the nearby gene encoding insulin-like growth factor 2 (IGF2). We found an excess of paternal transmission of class I VNTR alleles to obese children: children who inherited a class I allele from their father (but not those inheriting it from their mother) had a relative risk of early-onset obesity of 1.8. Due to the frequency of class I alleles in this population, this risk concerns 65-70% of all infants. These results suggest that increased in utero expression of paternal INS or IGF2 due to the class I INS VNTR allele may predispose off spring to postnatal fat deposition.	Hop St Vincent de Paul, Dept Pediat Endocrinol, F-75674 Paris, France; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University	Bougneres, P (corresponding author), Hop St Vincent de Paul, Dept Pediat Endocrinol, F-75674 Paris, France.	pbougneres@mageos.com	LE STUNFF, CATHERINE/Y-3270-2018	LE STUNFF, CATHERINE/0000-0001-8419-0451				Battaglia FC, 1998, DIABETES CARE, V21, pB70; Bennett ST, 1996, J AUTOIMMUN, V9, P415, DOI 10.1006/jaut.1996.0057; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Bundred P, 2001, BMJ-BRIT MED J, V322, P326, DOI 10.1136/bmj.322.7282.326; Catalano PM, 1998, DIABETES CARE, V21, pB85; CAVALLISFORZA LL, 1994, HIST GEOGRAPHY HUMAN, P169; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; DIETZ WH, 1994, AM J CLIN NUTR, V59, P955, DOI 10.1093/ajcn/59.5.955; DUNGER DB, 1998, NAT GENET, V19, P268; Eaves IA, 1999, NAT GENET, V22, P324, DOI 10.1038/11890; FREEMAN JV, 1995, INT J EPIDEMIOL, V24, P970, DOI 10.1093/ije/24.5.970; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Huxtable SJ, 2000, DIABETES, V49, P126, DOI 10.2337/diabetes.49.1.126; International Obesity Task Force, 1998, OB PREV MAN GLOB EP; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; Le Stunff C, 2000, NAT GENET, V26, P444, DOI 10.1038/82579; Lew A, 2000, P NATL ACAD SCI USA, V97, P12508, DOI 10.1073/pnas.97.23.12508; Moore GE, 2001, DIABETES, V50, P199, DOI 10.2337/diabetes.50.1.199; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Schaid DJ, 1999, GENET EPIDEMIOL, V16, P250, DOI 10.1002/(SICI)1098-2272(1999)16:3<250::AID-GEPI2>3.0.CO;2-T; SHAM PC, 1995, ANN HUM GENET, V59, P323, DOI 10.1111/j.1469-1809.1995.tb00751.x; TANIGUCHI A, 1986, J LIPID RES, V27, P925; Vafiadis P, 1996, J AUTOIMMUN, V9, P397, DOI 10.1006/jaut.1996.0054; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; Whitaker RC, 1998, J PEDIATR-US, V132, P768, DOI 10.1016/S0022-3476(98)70302-6	28	88	90	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2001	29	1					96	99		10.1038/ng707	http://dx.doi.org/10.1038/ng707			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528401				2022-12-25	WOS:000170781300026
J	Mercer, DF; Schiller, DE; Elliott, JF; Douglas, DN; Hao, CH; Rinfret, A; Addison, WR; Fischer, KP; Churchill, TA; Lakey, JRT; Tyrrell, DLJ; Kneteman, NM				Mercer, DF; Schiller, DE; Elliott, JF; Douglas, DN; Hao, CH; Rinfret, A; Addison, WR; Fischer, KP; Churchill, TA; Lakey, JRT; Tyrrell, DLJ; Kneteman, NM			Hepatitis C virus replication in mice with chimeric human livers	NATURE MEDICINE			English	Article							BLOOD MONONUCLEAR-CELLS; ADULT HUMAN HEPATOCYTES; MOUSE-LIVER; TRANSPLANTATION; INFECTION; CULTURE; GENOME; PCR	Lack of a small animal model of the human hepatitis C virus (HCV) has impeded development of antiviral therapies against this epidemic infection. By transplanting normal human hepatocytes into SCID mice carrying a plasminogen activator transgene (Alb-uPA), we generated mice with chimeric human livers. Homozygosity of Alb-uPA was associated with significantly higher levels of human hepatocyte engraftment, and these mice developed prolonged HCV infections with high viral titers after inoculation with infected human serum. Initial increases in total viral load were up to 1950-fold, with replication confirmed by detection of negative-strand viral RNA in transplanted livers. HCV viral proteins were localized to human hepatocyte nodules, and infection was serially passaged through three generations of mice confirming both synthesis and release of infectious viral particles. These chimeric mice represent the first murine model suitable for studying the human hepatitis C virus in vivo.	Univ Alberta, Surg Med Res Inst, Dept Surg, Edmonton, AB, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; Univ Alberta, Dept Pathol, Edmonton, AB, Canada; Hop St Luc, CHUM, Ctr Rech, Montreal, PQ H2X 1P1, Canada	University of Alberta; University of Alberta; University of Alberta; Universite de Montreal	Kneteman, NM (corresponding author), Univ Alberta, Surg Med Res Inst, Dept Surg, Edmonton, AB, Canada.			schiller, dan/0000-0001-7190-5198				BALLET F, 1984, HEPATOLOGY, V4, P849, DOI 10.1002/hep.1840040509; Brody RI, 1998, AM J CLIN PATHOL, V110, P32; Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CLEMENT B, 1984, HEPATOLOGY, V4, P373, DOI 10.1002/hep.1840040305; DORKO K, 1994, CELL TRANSPLANT, V3, P387, DOI 10.1177/096368979400300505; HECKEL JL, 1990, CELL, V62, P447, DOI 10.1016/0092-8674(90)90010-C; LANFORD RE, 1995, J VIROL, V69, P8079, DOI 10.1128/JVI.69.12.8079-8083.1995; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Mellor J, 1998, J GEN VIROL, V79, P705, DOI 10.1099/0022-1317-79-4-705; MURPHY D, 1994, J INFECT DIS, V169, P473, DOI 10.1093/infdis/169.2.473; Petersen J, 1998, P NATL ACAD SCI USA, V95, P310, DOI 10.1073/pnas.95.1.310; Petersen J, 1999, HEPATOLOGY, V30, p423A; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; RHIM JA, 1995, P NATL ACAD SCI USA, V92, P4942, DOI 10.1073/pnas.92.11.4942; RYAN CM, 1993, SURGERY, V113, P48; SANDGREN E, 1991, CELL, V68, P245; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; ZIETKIEWICZ E, 1992, P NATL ACAD SCI USA, V89, P8448, DOI 10.1073/pnas.89.18.8448	22	688	771	0	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					927	933		10.1038/90968	http://dx.doi.org/10.1038/90968			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479625	Bronze			2022-12-25	WOS:000171740400030
J	Hiroi, Y; Kudoh, S; Monzen, K; Ikeda, Y; Yazaki, Y; Nagai, R; Komuro, I				Hiroi, Y; Kudoh, S; Monzen, K; Ikeda, Y; Yazaki, Y; Nagai, R; Komuro, I			Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation	NATURE GENETICS			English	Letter							HOLT-ORAM-SYNDROME; T-BOX GENES; TRANSCRIPTION FACTORS CSX/NKX-2.5; CONGENITAL HEART-DISEASE; MUTATIONS; LIMB; TINMAN; EXPRESSION; GATA-4; CELLS	The cardiac homeobox protein Nkx2-5 is essential in cardiac development, and mutations in Csx (which encodes Nkx2-5) cause various congenital heart diseases(1-5). Using the yeast two-hybrid system with Nkx2-5 as the 'bait', we isolated the T-box-containing transcription factor Tbx5; mutations in TBX5 cause heart and limb malformations in Holt-Gram syndrome(6-8) (HOS). Co-transfection of Nkx2-5 and Tbx5 into COS-7 cells showed that they also associate with each other in mammalian cells. Glutathione S-transferase (GST) 'pull-down' assays indicated that the N-terminal domain and N-terminal part of the T-box of Tbx5 and the homeodomain of Nkx2-5 were necessary for their interaction. Tbx5 and Nkx2-5 directly bound to the promoter of the gene for cardiac-specific natriuretic peptide precursor type A (Nppa) in tandem, and both transcription factors showed synergistic activation. Deletion analysis showed that both the N-terminal domain and T-box of Tbx5 were important for this transactivation. A G80R mutation of Tbx5, which causes substantial cardiac defects with minor skeletal abnormalities in HOS, did not activate Nppa or show synergistic activation, whereas R237Q, which causes upper-limb malformations without cardiac abnormalities(8). activated the Nppa promoter to a similar extent to that of wildtype Tbx5. P19CL6 cell lines(9,10) overexpressing wildtype Tbx5 started to beat earlier and expressed cardiac-specific genes more abundantly than did parental P19CL6 cells, whereas cell lines expressing the G80R mutant did not differentiate into beating cardiomyocytes. These results indicate that two different types of cardiac transcription factors synergistically induce cardiac development.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; Kanazawa Med Univ, Dept Cardiovasc Med, Kanazawa, Ishikawa, Japan; Int Med Ctr Japan, Tokyo, Japan	Chiba University; University of Tokyo; Kanazawa Medical University; National Center for Global Health & Medicine - Japan	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba, Japan.		Pillay, Nischalan/F-9536-2012					AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Basson CT, 1999, P NATL ACAD SCI USA, V96, P2919, DOI 10.1073/pnas.96.6.2919; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; BODMER R, 1993, DEVELOPMENT, V118, P719; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; HabaraOhkubo A, 1996, CELL STRUCT FUNCT, V21, P101, DOI 10.1247/csf.21.101; Horb ME, 1999, DEVELOPMENT, V126, P1739; Hosoda T, 1999, JPN CIRC J, V63, P425, DOI 10.1253/jcj.63.425; Kasahara H, 2000, J CLIN INVEST, V106, P299, DOI 10.1172/JCI9860; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Koshiba-Takeuchi K, 2000, SCIENCE, V287, P134, DOI 10.1126/science.287.5450.134; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Li QY, 1997, NAT GENET, V15, P21; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Rodriguez-Esteban C, 1999, NATURE, V398, P814, DOI 10.1038/19769; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; Takeuchi JK, 1999, NATURE, V398, P810, DOI 10.1038/19762; Tanaka M, 1998, DEV GENET, V22, P239, DOI 10.1002/(SICI)1520-6408(1998)22:3<239::AID-DVG6>3.3.CO;2-G; Tanaka M, 1999, DEVELOPMENT, V126, P1269	29	435	449	0	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					276	280		10.1038/90123	http://dx.doi.org/10.1038/90123			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431700				2022-12-25	WOS:000169656400022
J	Marchant, JS; Stutzmann, GE; Leissring, MA; LaFerla, FM; Parker, I				Marchant, JS; Stutzmann, GE; Leissring, MA; LaFerla, FM; Parker, I			Multiphoton-evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling	NATURE BIOTECHNOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; RED FLUORESCENCE; CORAL; PHOTOACTIVATION; TIME	DsRed, a recently cloned red fluorescent protein, has attracted great interest as an expression tracer and fusion partner for multicolor imaging. We report that three-photon excitation (lambda <760 nm) rapidly changes the fluorescence of DsRed from red to green when viewed subsequently by conventional (one-photon) epifluorescence. Mechanistically, three-photon excitation (<lambda> <760 nm) selectively bleaches the mature, red-emitting form of DsRed, thereby enhancing emission from the immature green form through reduction of fluorescence resonance energy transfer (FRET). The "greening" effect occurs in live mammalian cells at the cellular and subcellular levels, and the resultant color change persists for >30 h without affecting cell viability. This technique allows individual cells, organelles, and fusion proteins to be optically marked and has potential utility for studying cell lineage, organelle dynamics, and protein trafficking, as well as for selective retrieval of cells from a population. We describe optimal parameters to induce the color change of DsRed, and demonstrate applications that show the potential of this optical highlighter.	Univ Calif Irvine, Dept Neurobiol & Behav, Cellular & Mol Neurobiol Lab, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Lab Mol Neuropathogenesis, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Parker, I (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, Cellular & Mol Neurobiol Lab, Irvine, CA 92697 USA.		LEISSRING, MALCOLM/AAW-5361-2021; Marchant, Jonathan/Q-5484-2019; MARCHANT, Jonathan/B-8051-2009	LEISSRING, MALCOLM/0000-0001-7185-4255; Marchant, Jonathan/0000-0001-6592-0877; MARCHANT, Jonathan/0000-0001-6592-0877	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048071, R37GM048071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG016573] Funding Source: NIH RePORTER; NIA NIH HHS [AG00096, AG16573] Funding Source: Medline; NIGMS NIH HHS [GM48071] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Callamaras N, 1999, CELL CALCIUM, V26, P271, DOI 10.1054/ceca.1999.0085; Denk Winfried, 1995, P445; Elowitz MB, 1997, CURR BIOL, V7, P809, DOI 10.1016/S0960-9822(06)00342-3; Fradkov AF, 2000, FEBS LETT, V479, P127, DOI 10.1016/S0014-5793(00)01895-0; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Heikal AA, 2000, P NATL ACAD SCI USA, V97, P11996, DOI 10.1073/pnas.97.22.11996; Jakobs S, 2000, FEBS LETT, V479, P131, DOI 10.1016/S0014-5793(00)01896-2; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Sawin KE, 1997, CURR BIOL, V7, pR606, DOI 10.1016/S0960-9822(06)00313-7; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; XU C, 2000, IMAGING NEURONS	14	84	87	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2001	19	7					645	649		10.1038/90249	http://dx.doi.org/10.1038/90249			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	449HA	11433276				2022-12-25	WOS:000169677200020
J	Hovanes, K; Li, TWH; Munguia, JE; Truong, T; Milovanovic, T; Marsh, JL; Holcombe, RF; Waterman, ML				Hovanes, K; Li, TWH; Munguia, JE; Truong, T; Milovanovic, T; Marsh, JL; Holcombe, RF; Waterman, ML			beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer	NATURE GENETICS			English	Article							COLORECTAL-CANCER; ALPHA-ENHANCER; TRANSCRIPTIONAL ACTIVATION; PROTEIN; GENE; TARGET; APC; LOCALIZATION; CARCINOMA; CONTAINS	Constitutive activation of the Wnt signaling pathway is a root cause of many colon cancers(1-3). Activation of this pathway is caused by genetic mutations that stabilize the beta -catenin protein, allowing it to accumulate in the nucleus and form complexes with any member of the lymphoid enhancer factor (LEF1) and T-cell factor (TCF1, TCF3, TCF4) family of transcription factors (referred to collectively as LEF/TCFs) to activate transcription of target genes(3,4). Target genes such as MYC. CCND1. MMP7 and TCF7 (refs, 5-9) are normally expressed in colon tissue, so it has been proposed that abnormal expression levels or patterns imposed by beta -catenin/TCF complexes have a role in tumor progression. We report here that LEF1 is a new type of target gene ectopically activated in colon cancer. The pattern of this ectopic expression is unusual because it derives from selective activation of a promoter for a full-length LEF1 isoform that binds beta -catenin, but not a second, intronic promoter that drives expression of a dominant-negative isoform. beta -catenin/TCF complexes can activate the promoter for full-length LEF1, indicating that in cancer high levels of these complexes misregulate transcription to favor a positive feedback loop for Wnt signaling by inducing selective expression of full-length, beta -catenin-sensitive forms of LEF/TCFs.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA USA; Univ Calif Irvine, Irvine Med Ctr, Div Hematol Oncol, Orange, CA 92668 USA; Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Waterman, ML (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA.		truong, therese/A-2837-2013	truong, therese/0000-0002-2943-6786	NCI NIH HHS [R01 CA-83982] Funding Source: Medline; NICHD NIH HHS [R01 HD36049, R01 HD36081] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036081, R01HD036049] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA083982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; SPOLSKI R, 1988, EUR J IMMUNOL, V18, P295; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	22	399	419	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					53	57		10.1038/88264	http://dx.doi.org/10.1038/88264			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326276				2022-12-25	WOS:000168413300016
J	Nurnberg, P; Thiele, H; Chandler, D; Hohne, W; Cunningham, ML; Ritter, H; Leschik, G; Uhlmann, K; Mischung, C; Harrop, K; Goldblatt, J; Borochowitz, ZU; Kotzot, D; Westermann, F; Mundlos, S; Braun, HS; Laing, N; Tinschert, S				Nurnberg, P; Thiele, H; Chandler, D; Hohne, W; Cunningham, ML; Ritter, H; Leschik, G; Uhlmann, K; Mischung, C; Harrop, K; Goldblatt, J; Borochowitz, ZU; Kotzot, D; Westermann, F; Mundlos, S; Braun, HS; Laing, N; Tinschert, S			Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia	NATURE GENETICS			English	Article							CHROMOSOME 5P	Craniometaphyseal dysplasia (CMD) is a bone dysplasia characterized by overgrowth and sclerosis of the craniofacial bones and abnormal modeling of the metaphyses of the tubular hones. Hyperostosis and sclerosis of the skull may lead to cranial nerve compressions resulting in hearing loss and facial palsy(1,2). An autosomal dominant form of the disorder (MIM 123000) was linked to chromosome 5p15.2-p14.1 (ref. 3) within a region harboring the human homolog (ANKH) of the mouse progressive ankylosis tank) gene(4). The ANK protein spans the outer cell membrane and shuttles inorganic pyrophosphate(4) (PPi, a major inhibitor of physiologic and pathologic calcification, bone mineralization and bone resorption(5). Here we carry out mutation analysis of ANKH, revealing six different mutations in eight of nine families. The mutations predict single amino acid substitutions, deletions or insertions. Using a helix prediction program, we propose for the ANK molecule 12 membrane-spanning helices with an alternate inside/out orientation and a central channel permitting the passage of PPi. The mutations occur at highly conserved amino acid residues presumed to be located in the cytosolic portion of the protein. Our results link the PPI channel ANK with bone formation and remodeling.	Humboldt Univ, Univ Klinikum Charite, Inst Med Genet, Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Biochem, Berlin, Germany; Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Berlin, Germany; Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Australian Neuromuscular Res Inst, Queen Elizabeth II Med Ctr, Nedlands, WA 6009, Australia; Univ Washington, Seattle, WA 98195 USA; Childrens Hosp & Reg Med Ctr, Dept Pediat, Childrens Craniofacial Ctr, Seattle, WA 98195 USA; King Edward Mem Hosp, Hlth Dept Western Australia, Genet Serv, Subiaco, WA, Australia; Technion Israel Inst Technol, Fac Med, Bnai Zion Med Ctr, Simon Winter Inst Human Genet, IL-32000 Haifa, Israel; Univ Zurich, Inst Med Genet, Zurich, Switzerland; Univ Cologne, Kinderklin, Cologne, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Western Australia; University of Washington; University of Washington Seattle; Seattle Children's Hospital; King Edward Memorial Hospital; University of Western Australia; Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Zurich; University of Cologne	Nurnberg, P (corresponding author), Humboldt Univ, Univ Klinikum Charite, Inst Med Genet, Berlin, Germany.		Thiele, Holger/ABE-6792-2020; Mundlos, Stefan/ABH-9585-2020; Westermann, Frank/F-7509-2013	Thiele, Holger/0000-0002-0169-998X; Laing, Nigel/0000-0001-5111-3732; Mundlos, Stefan/0000-0002-9788-3166				Andrew LJ, 1999, AM J HUM GENET, V64, P136, DOI 10.1086/302186; BEIGHTON P, 1995, J MED GENET, V32, P370, DOI 10.1136/jmg.32.5.370; CHANDLER D, IN PRESS HUM GENET; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FLEISCH H, 1981, METAB BONE DIS RELAT, V3, P279, DOI 10.1016/0221-8747(81)90044-8; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; HUGHES AE, 1995, HUM MOL GENET, V4, P1225, DOI 10.1093/hmg/4.7.1225; Iughetti P., 2000, AM J MED GENET, V95, P482; JACKSON WPU, 1954, ARCH INTERN MED, V94, P871, DOI 10.1001/archinte.1954.00250060005001; Nurnberg P, 1997, AM J HUM GENET, V61, P918, DOI 10.1086/514880; OVERHAUSER J, 1994, HUM MOL GENET, V3, P247, DOI 10.1093/hmg/3.2.247; Schwahn B, 1996, MONATSSCHR KINDERH, V144, P1073, DOI 10.1007/s001120050068; SPRANGER J, 1965, Z Kinderheilkd, V93, P64, DOI 10.1007/BF00438568; TAYLOR D B, 1989, Australasian Radiology, V33, P84, DOI 10.1111/j.1440-1673.1989.tb03242.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tinschert S, 1998, AM J MED GENET, V77, P175, DOI 10.1002/(SICI)1096-8628(19980518)77:3<175::AID-AJMG1>3.0.CO;2-P; [No title captured]	18	167	181	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2001	28	1					37	41		10.1038/ng0501-37	http://dx.doi.org/10.1038/ng0501-37			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	427NW	11326272				2022-12-25	WOS:000168413300012
J	Synold, TW; Dussault, I; Forman, BM				Synold, TW; Dussault, I; Forman, BM			The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux	NATURE MEDICINE			English	Article							PREGNANE-X-RECEPTOR; HUMAN CYTOCHROMES P450; P-GLYCOPROTEIN; MULTIDRUG TRANSPORTER; ACTIVATED RECEPTOR; ANTITUMOR-ACTIVITY; HORMONE RECEPTORS; HUMAN HEPATOCYTES; GENE SUBFAMILY; N-COR	Cytochrome P450 3A4 is an important mediator of drug catabolism that can be regulated by the steroid and xenobiotic receptor (SXR). We show here that SXR also regulates drug efflux by activating expression of the gene MDR1, which encodes the protein P-glycoprotein (ABCB1). Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance. In contrast, docetaxel (Taxotere), a closely related antineoplastic agent, did not activate SXR and displayed superior pharmacokinetic properties. Docetaxel's silent properties reflect its inability to displace transcriptional corepressors from SXR. We also found that ET-743, a potent antineoplastic agent, suppressed MDR1 transcription by acting as an inhibitor of SXR. These findings demonstrate how the molecular activities of SXR can be manipulated to control drug clearance.	City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Duarte, CA 91010 USA	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Forman, BM (corresponding author), City Hope Natl Med Ctr, Dept Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Synold, Timothy/0000-0002-4075-2544	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Clarke SJ, 1999, CLIN PHARMACOKINET, V36, P99, DOI 10.2165/00003088-199936020-00002; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; Dorr RT, 1997, PHARMACOTHERAPY, V17, pS96; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Eckardt JR, 1997, AM J HEALTH-SYST PH, V54, pS2, DOI 10.1093/ajhp/54.suppl_2.S2; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2000, GENE DEV, V14, P121; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; Izbicka E, 1998, ANN ONCOL, V9, P981, DOI 10.1023/A:1008224322396; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kearns CM, 1997, PHARMACOTHERAPY, V17, pS105; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kostrubsky VE, 1998, ARCH BIOCHEM BIOPHYS, V355, P131, DOI 10.1006/abbi.1998.0730; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496; Masuyama H, 2001, MOL CELL ENDOCRINOL, V172, P47, DOI 10.1016/S0303-7207(00)00395-6; MCKINNON RA, 1995, GUT, V36, P259, DOI 10.1136/gut.36.2.259; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Monsarrat B, 1997, B CANCER, V84, P125; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Pallis M, 2000, BLOOD, V95, P2897, DOI 10.1182/blood.V95.9.2897.009k14_2897_2904; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; Royer I, 1996, CANCER RES, V56, P58; Ruth AC, 2000, CANCER RES, V60, P2576; SAKUMA T, 1995, ARCH BIOCHEM BIOPHYS, V319, P267, DOI 10.1006/abbi.1995.1291; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith DA, 1998, XENOBIOTICA, V28, P1095, DOI 10.1080/004982598238859; Sparreboom A, 1998, ANTI-CANCER DRUG, V9, P1, DOI 10.1097/00001813-199801000-00001; Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	43	690	722	0	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					584	590		10.1038/87912	http://dx.doi.org/10.1038/87912			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329060				2022-12-25	WOS:000169961100038
J	Brooks, DG; Kitchen, SG; Kitchen, CMR; Scripture-Adams, DD; Zack, JA				Brooks, DG; Kitchen, SG; Kitchen, CMR; Scripture-Adams, DD; Zack, JA			Generation of HIV latency during thymopoiesis	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; VIRUS TYPE-1 INFECTION; REPLICATION; LYMPHOCYTES; RESERVOIR; COMBINATION; PERSISTENCE; EXPRESSION; DISRUPTION; THYMUS	The use of combination antiretroviral therapy results in a substantial reduction in viremia, a rebound of CD4(+) T cells and increased survival for HIV-infected individuals. However, this treatment does not result in the total eradication of HIV. Rather, the virus is thought to remain latent in a subset of cells, where it avoids elimination by the immune system. In this state the virus is capable of reactivation of productive infection following cessation of therapy. These latently infected cells are very few in number and it has thus been difficult to determine their origin and to study the molecular nature of the latent viral genome. HIV replication is linked to cellular gene transcription and requires target cell activation. Therefore, should an activated, infected cell become transcriptionally inactive prior to cytopathic effects, the viral genome might be maintained in a latent state. We used the SCID-hu (Thy/Liv) mouse model to establish that activation-inducible HIV can be generated at high frequency during thymopoiesis, a process where previously activated cells mature towards quiescence. Moreover, we showed that these cells can be exported into the periphery where the virus remains latent until T-cell receptor stimulation, indicating that the thymus might be a source of latent HIV in humans.	Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, AIDS Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Zack, JA (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA.	jzack@ucla.edu	Ramirez, Christina/AAT-5088-2021	Ramirez, Christina/0000-0002-8435-0416; Scripture-Adams, Deirdre/0000-0002-3676-1771; Brooks, David/0000-0001-7763-8764	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036554, R37AI036059, R01AI036059] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 36059, AI 36554] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; ARRIGO SJ, 1989, J VIROL, V63, P4875, DOI 10.1128/JVI.63.11.4875-4881.1989; Berkowitz RD, 1998, J IMMUNOL, V161, P3702; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1998, J EXP MED, V188, P617; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Jamieson BD, 1998, J VIROL, V72, P6520, DOI 10.1128/JVI.72.8.6520-6526.1998; JAMIESON BD, 1995, J VIROL, V69, P6259, DOI 10.1128/JVI.69.10.6259-6264.1995; Kitchen SG, 1997, J VIROL, V71, P6928, DOI 10.1128/JVI.71.9.6928-6934.1997; KOLLMANN TR, 1994, J EXP MED, V179, P513, DOI 10.1084/jem.179.2.513; Korin YD, 1999, J VIROL, V73, P6526, DOI 10.1128/JVI.73.8.6526-6532.1999; Livingstone WJ, 1996, LANCET, V348, P649, DOI 10.1016/S0140-6736(96)02091-0; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; Pedroza-Martins L, 1998, J VIROL, V72, P9441, DOI 10.1128/JVI.72.12.9441-9452.1998; Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006; Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000; Schmid I, 2000, CYTOMETRY, V39, P108, DOI 10.1002/(SICI)1097-0320(20000201)39:2<108::AID-CYTO3>3.0.CO;2-4; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353	36	159	164	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2001	7	4					459	464		10.1038/86531	http://dx.doi.org/10.1038/86531			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283673				2022-12-25	WOS:000167960500041
J	Winston, R				Winston, R			Embryonic stem cell research - The case for ...	NATURE MEDICINE			English	Editorial Material							PREIMPLANTATION EMBRYOS		Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, London, England	Imperial College London	Winston, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, London, England.							Blau HM, 1999, SEMIN CELL DEV BIOL, V10, P267, DOI 10.1006/scdb.1999.0311; Delhanty JDA, 1997, HUM GENET, V99, P755, DOI 10.1007/s004390050443; EDWARDS RG, 1992, FETAL TISSUE TRANSPL, pR11; EVANS MJ, 1981, NATURE, V292, P7634; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Ourednik V, 2000, NOVART FDN SYMP, V231, P242, DOI 10.1002/0470870834.ch15; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shinohara T, 2000, DEV BIOL, V220, P401, DOI 10.1006/dbio.2000.9655; Sinclair KD, 1999, J REPROD FERTIL, V116, P177, DOI 10.1530/jrf.0.1160177	13	16	20	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					396	397		10.1038/86442	http://dx.doi.org/10.1038/86442			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283652				2022-12-25	WOS:000167960500018
J	Yan, H; Dobbie, Z; Gruber, SB; Markowitz, S; Romans, K; Giardiello, FM; Kinzler, KW; Vogelstein, B				Yan, H; Dobbie, Z; Gruber, SB; Markowitz, S; Romans, K; Giardiello, FM; Kinzler, KW; Vogelstein, B			Small changes in expression affect predisposition to tumorigenesis	NATURE GENETICS			English	Article								We have used quantitative measures of gene expression to show that constitutional 50% decreases in expression of one adenomatous polyposis coli tumor suppressor gene (APC) allele can lead to the development of familial adenop polyposis.	Johns Hopkins Med Inst, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21231 USA; Univ Basel Hosp, Res Dept, Res Grp Human Genet, CH-4031 Basel, Switzerland; Univ Michigan, Sch Med, Div Med & Mol Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Howard Hughes Med Inst, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Basel; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Case Western Reserve University; Case Western Reserve University Hospital; Howard Hughes Medical Institute; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Vogelstein, B (corresponding author), Johns Hopkins Med Inst, Howard Hughes Med Inst, Baltimore, MD 21231 USA.			Edsall, Lee Elizabeth/0000-0002-0326-2829	NATIONAL CANCER INSTITUTE [R01CA140316] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONARAKIS SE, 2001, METABOLIC MOL BASES, P356; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Johnson NA, 2000, J THEOR BIOL, V205, P527, DOI 10.1006/jtbi.2000.2070; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Laken SJ, 1999, P NATL ACAD SCI USA, V96, P2322, DOI 10.1073/pnas.96.5.2322; Royall R., 1997, STAT EVIDENCE LIKELI; Shih IM, 2001, CANCER RES, V61, P818; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; Zhou W, 2001, NAT BIOTECHNOL, V19, P78, DOI 10.1038/83572	10	188	192	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					25	26		10.1038/ng799	http://dx.doi.org/10.1038/ng799			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11743581				2022-12-25	WOS:000173105600008
J	Hannink, N; Rosser, SJ; French, CE; Basran, A; Murray, JAH; Nicklin, S; Bruce, NC				Hannink, N; Rosser, SJ; French, CE; Basran, A; Murray, JAH; Nicklin, S; Bruce, NC			Phytodetoxification of TNT by transgenic plants expressing a bacterial nitroreductase	NATURE BIOTECHNOLOGY			English	Article							PENTAERYTHRITOL TETRANITRATE REDUCTASE; ENTEROBACTER-CLOACAE; 2,4,6-TRINITROTOLUENE; PHYTOREMEDIATION; TRANSFORMATION; METABOLISM; EXPLOSIVES; SOILS; GENE	There is major international concern over the wide-scale contamination of soil and associated ground water by persistent explosives residues. 2,4,6-Trinitrotoluene (TNT) is one of the most recalcitrant and toxic of all the military explosives. The lack of affordable and effective cleanup technologies for explosives contamination requires the development of better processes. Significant effort has recently been directed toward the use of plants to extract and detoxify TNT. To explore the possibility of overcoming the high phytotoxic effects of TNT, we expressed bacterial nitroreductase in tobacco plants. Nitroreductase catalyzes the reduction of TNT to hydroxyaminodinitrotoluene (HADNT), which is subsequently reduced to aminodinitrotoluene derivatives (ADNTs). Transgenic plants expressing nitroreductase show a striking increase in ability to tolerate, take up, and detoxify TNT. Our work suggests that expression of nitroreductase (NR) in plants suitable for phytoremediation could facilitate the effective cleanup of sites contaminated with high levels of explosives.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Def Sci & Technol Lab, Sevenoaks TN14 7BP, Kent, England	University of Cambridge; Defence Science & Technology Laboratory	Bruce, NC (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.		Murray, James AH/D-3399-2009	Murray, James AH/0000-0002-2282-3839; Rosser, Susan/0000-0002-2560-6485; Bruce, Neil Charles/0000-0003-0398-2997				ANDERSON TA, 1993, ENVIRON SCI TECHNOL, V27, P2630, DOI 10.1021/es00049a001; Bhadra R, 1999, ENVIRON SCI TECHNOL, V33, P446, DOI 10.1021/es980635m; Bizily SP, 1999, P NATL ACAD SCI USA, V96, P6808, DOI 10.1073/pnas.96.12.6808; BRYANT C, 1991, J BIOL CHEM, V266, P4126; Coleman JOD, 1997, TRENDS PLANT SCI, V2, P144, DOI 10.1016/S1360-1385(97)01019-4; CUNNINGHAM SD, 1995, TRENDS BIOTECHNOL, V13, P393, DOI 10.1016/S0167-7799(00)88987-8; Doty SL, 2000, P NATL ACAD SCI USA, V97, P6287, DOI 10.1073/pnas.97.12.6287; French CE, 1999, NAT BIOTECHNOL, V17, P491, DOI 10.1038/8673; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; HARVEY SD, 1990, J CHROMATOGR, V518, P361, DOI 10.1016/S0021-9673(01)93196-6; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Pavlostathis SG, 1998, ENVIRON TOXICOL CHEM, V17, P2266, DOI [10.1002/etc.5620171117, 10.1897/1551-5028(1998)017&lt;2266:TOTBTA&gt;2.3.CO;2]; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider K, 1996, ENVIRON SCI POLLUT R, V3, P135, DOI 10.1007/BF02985519; Schnoor J.L., 1995, ENV SCI TECH, V29, P318; Thompson PL, 1998, ENVIRON SCI TECHNOL, V32, P975, DOI 10.1021/es970799n; WHONG WZ, 1984, MUTAT RES, V136, P209, DOI 10.1016/0165-1218(84)90054-5; Wierzbicka M, 1999, ENVIRON POLLUT, V104, P41, DOI 10.1016/S0269-7491(98)00156-0	20	172	186	2	64	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2001	19	12					1168	1172		10.1038/nbt1201-1168	http://dx.doi.org/10.1038/nbt1201-1168			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	498RN	11731787				2022-12-25	WOS:000172524400031
J	Kawaguchi, TK; Skaletsky, H; Brown, LG; Minx, PJ; Cordum, HS; Waterston, RH; Wilson, RK; Silber, S; Oates, R; Rozen, S; Page, DC				Kawaguchi, TK; Skaletsky, H; Brown, LG; Minx, PJ; Cordum, HS; Waterston, RH; Wilson, RK; Silber, S; Oates, R; Rozen, S; Page, DC			The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men	NATURE GENETICS			English	Article							INTRACYTOPLASMIC SPERM INJECTION; DAZ GENE-CLUSTER; INTRACHROMOSOMAL RECOMBINATION; AZOOSPERMIC MEN; MICRODELETIONS; SEQUENCE; INTERVAL; GENOME; FAMILY; LOCUS	Deletions of the AZFc (azoospermia factor c) region of the Y chromosome are the most common known cause of spermatogenic failure. We determined the complete nucleotide sequence of AZFc by identifying and distinguishing between near-identical amplicons (massive repeat units) using an iterative mapping-sequencing process. A complex of three palindromes, the largest spanning 3 Mb with 99.97% identity between its arms, encompasses the AZFc region. The palindromes are constructed from six distinct families of amplicons, with unit lengths of 115-678 kb, and may have resulted from tandem duplication and inversion during primate evolution. The palindromic complex contains 11 families of transcription units, all expressed in testis. Deletions of AZFc that cause infertility are remarkably uniform, spanning a 3.5-Mb segment and bounded by 229-kb direct repeats that probably served as substrates for homologous recombination.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; St Lukes Hosp, Infertil Ctr St Louis, St Louis, MO 63107 USA; Boston Univ, Sch Med, Dept Urol, Boston, MA 02228 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); Saint Luke's Hospital - Missouri; Boston University	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	page_admin@wi.mit.edu	Wilson, Richard K./AAF-4139-2019; Rozen, Steven G./J-5939-2013	Wilson, Richard K./0000-0002-1992-1358; Rozen, Steven G./0000-0002-4288-0056; Oates, Robert/0000-0003-2330-6697				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Blanco P, 2000, J MED GENET, V37, P752, DOI 10.1136/jmg.37.10.752; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chai NN, 1998, GENOMICS, V49, P283, DOI 10.1006/geno.1998.5255; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; Girardi SK, 1997, HUM REPROD, V12, P1635, DOI 10.1093/humrep/12.8.1635; Glaser B, 1998, CHROMOSOME RES, V6, P481, DOI 10.1023/A:1009256613348; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; Kamp C, 2000, HUM MOL GENET, V9, P2563, DOI 10.1093/hmg/9.17.2563; Kleiman SE, 1999, HUM REPROD, V14, P33, DOI 10.1093/humrep/14.1.33; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; Lahn BT, 1999, SCIENCE, V286, P964, DOI 10.1126/science.286.5441.964; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEWIN B, 1995, CELL, V80, P1, DOI 10.1016/0092-8674(95)90442-5; LIU L, 1987, NUCLEIC ACIDS RES, V15, P9461, DOI 10.1093/nar/15.22.9461; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Mulhall JP, 1997, HUM REPROD, V12, P503; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; Ohno S., 1967, SEX CHROMOSOMES SEX; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; Page DC, 1999, HUM REPROD, V14, P1722, DOI 10.1093/humrep/14.7.1722; Pearson W R, 2000, Methods Mol Biol, V132, P185; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Rozen S, 2000, Methods Mol Biol, V132, P365; Sargent CA, 1999, J MED GENET, V36, P670; Saxena R, 2000, GENOMICS, V67, P256, DOI 10.1006/geno.2000.6260; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; Silber SJ, 1998, HUM REPROD, V13, P3332, DOI 10.1093/humrep/13.12.3332; Simoni M, 1997, FERTIL STERIL, V67, P542, DOI 10.1016/S0015-0282(97)80083-0; Sun C, 1999, NAT GENET, V23, P429, DOI 10.1038/70539; Sun C, 2000, HUM MOL GENET, V9, P2291, DOI 10.1093/oxfordjournals.hmg.a018920; Tilford CA, 2001, NATURE, V409, P943, DOI 10.1038/35057170; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Vogel T, 1999, HUM REPROD, V14, P3023, DOI 10.1093/humrep/14.12.3023; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; Yen PH, 1998, GENOMICS, V54, P5, DOI 10.1006/geno.1998.5526	49	457	497	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					279	286		10.1038/ng757	http://dx.doi.org/10.1038/ng757			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687796				2022-12-25	WOS:000171911000013
J	Randow, F; Seed, B				Randow, F; Seed, B			Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability	NATURE CELL BIOLOGY			English	Article							HEAT-SHOCK-PROTEIN; TOLL-LIKE RECEPTOR-4; HSP90 MOLECULAR CHAPERONE; IN-VIVO FUNCTION; CRYSTAL-STRUCTURE; ATP BINDING; TLR4; LIPOPOLYSACCHARIDE; HYDROLYSIS; MUTATIONS	Chaperone proteins are thought to promote the correct folding and assembly of newly synthesized proteins and to facilitate restoration of the folded state under environmental conditions that favour protein denaturation. They are among the most ubiquitous and highly conserved of all proteins. The eukaryotic endoplasmic reticulum (ER) chaperone gp96 in particular has long been thought to be indispensable for cell survival. Here we report that a screen for genes required for the immune response to bacterial endotoxins has identified a B-cell line deficient in gp96. Absence of gp96 is compatible with cellular survival even under stress conditions and causes a defect in the formation of only a small subset of cell surface receptors. Toll-like receptors are retained intracellularly in the absence of gp96, explaining the unresponsiveness of the mutant to microbial stimuli.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Seed, B (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, 50 Blossom St, Boston, MA 02114 USA.							Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hoshino K, 1999, J IMMUNOL, V162, P3749; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	32	275	280	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2001	3	10					891	896		10.1038/ncb1001-891	http://dx.doi.org/10.1038/ncb1001-891			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	479GJ	11584270				2022-12-25	WOS:000171396400013
J	Mazeyrat, S; Saut, N; Grigoriev, V; Mahadevaiah, SK; Ojarikre, OA; Rattigan, A; Bishop, C; Eicher, EM; Mitchell, MJ; Burgoyne, PS				Mazeyrat, S; Saut, N; Grigoriev, V; Mahadevaiah, SK; Ojarikre, OA; Rattigan, A; Bishop, C; Eicher, EM; Mitchell, MJ; Burgoyne, PS			A Y-encoded subunit of the translation initiation factor Eif2 is essential for mouse spermatogenesis	NATURE GENETICS			English	Article							UBIQUITIN-ACTIVATING ENZYME-E1; EXPRESSION ANALYSIS; MALE-INFERTILITY; CHROMOSOME GENE; INTERVAL; REGION; MICE; SPERMATOCYTES; SPERMATOGONIA; TRANSCRIPT	In mouse and man, deletions of specific regions of the Y chromosome have been linked to early failure of spermatogenesis and consequent sterility; the Y chromosomal gene(s) with this essential early role in spermatogenesis have not been identified. The partial deletion of the mouse Y short arm (the Sxr(b) deletion) that occurred when Tp(Y)1Ct(Sxr-b) (hereafter Sxr(b)) arose from Tp(Y)1CT(Sxr-b) (hereafter Sxr(a)) defines Spy, a Y chromosomal factor essential for normal spermatogonial proliferation(1-3). Molecular analysis has identified six genes that lie within the deletion: Ube1y1 (refs. 4,5), Smcy(6), Uty(7), Usp9y (also known as Dffry)(8), Eif2s3y (also known as Eif-2 gammaY)(9) and Dby(10); all have closely similar X-encoded homologs. of the Y-encoded genes, Ube1y1 and Dby have been considered strong candidates for mouse Spy function(4,5,10,11), whereas Smcy has been effectively ruled out as a candidate(12). There is no Ube1y1 homolog in man, and DBY, either alone or in conjunction with USP9Y, is the favored candidate for an early spermatogenic role(10,13-15). Here we show that introduction of Ube1y1 and Dby as transgenes. into Sxr(b)-deletion mice fails to overcome the spermatogenic block. However, the introduction of Eif2s3y restores normal spermatogonial proliferation and progression through meiotic prophase. Therefore, Eif2s3y, which encodes a subunit of the eukaryotic translation initiation factor Eif2, is Spy.	Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Fac Med Marseille, INSERM, U491, F-13385 Marseille 5, France; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Jackson Lab, Bar Harbor, ME 04609 USA	MRC National Institute for Medical Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Baylor College of Medicine; Jackson Laboratory	Burgoyne, PS (corresponding author), Natl Inst Med Res, MRC, Div Dev Genet, Mill Hill, London NW7 1AA, England.		Mitchell, Michael/I-3987-2016	Mitchell, Michael/0000-0003-2052-7347	NCI NIH HHS [CA34196] Funding Source: Medline; NIGMS NIH HHS [GM20919] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020919, R37GM020919] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agulnik AI, 1999, MAMM GENOME, V10, P926, DOI 10.1007/s003359901116; AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; Agulnik AI, 2001, MAMM GENOME, V12, P112, DOI 10.1007/s003350010249; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; Burgoyne PS, 2000, CYTOGENET CELL GENET, V91, P57, DOI 10.1159/000056819; DRESSER DW, 1995, HUM MOL GENET, V4, P1613, DOI 10.1093/hmg/4.9.1613; Ehrmann IE, 1998, HUM MOL GENET, V7, P1725, DOI 10.1093/hmg/7.11.1725; Foresta C, 2000, HUM MOL GENET, V9, P1161, DOI 10.1093/hmg/9.8.1161; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LEVY ER, 1986, CYTOGENET CELL GENET, V42, P208, DOI 10.1159/000132280; Levy N, 2000, MAMM GENOME, V11, P164, DOI 10.1007/s003350010031; Mahaffey CL, 1997, GENOMICS, V41, P123, DOI 10.1006/geno.1997.4611; Mazeyrat S, 1998, HUM MOL GENET, V7, P1713, DOI 10.1093/hmg/7.11.1713; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; MITCHELL MJ, 2000, GENETIC BASIS MALE I, P233; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Odorisio T, 1996, DEV BIOL, V180, P336, DOI 10.1006/dbio.1996.0305; Sargent CA, 1999, J MED GENET, V36, P670; SIMPSON EM, 1991, GENOMICS, V11, P601, DOI 10.1016/0888-7543(91)90067-O; Sun C, 1999, NAT GENET, V23, P429, DOI 10.1038/70539; SUTCLIFFE MJ, 1991, MOL REPROD DEV, V30, P81, DOI 10.1002/mrd.1080300202; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; VOGT PH, 1996, ADV DEV BIO, V4, P191	30	124	128	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					49	53		10.1038/ng717	http://dx.doi.org/10.1038/ng717			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528390				2022-12-25	WOS:000170781300015
J	Parant, J; Chavez-Reyes, A; Little, NA; Yan, W; Reinke, V; Jochemsen, AG; Lozano, G				Parant, J; Chavez-Reyes, A; Little, NA; Yan, W; Reinke, V; Jochemsen, AG; Lozano, G			Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53	NATURE GENETICS			English	Article							MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; DEGRADATION; APOPTOSIS; REGION	The p53 protein can inhibit cell cycling or induce apoptosis, and is thus a critical regulator of tumorigenesis'. This protein is negatively regulated by a physical interaction with MDM2, an E3 ubiquitin ligase(2-4). This interaction is critical for cell viability; loss of Mdm2 causes cell death in vitro and in vivo in a p53-dependent manner(5-7). The recently discovered(8) MDM2-related protein MDM4 (also known as MDMX) has some of the same properties as MDM2. MDM4 binds and inhibits p53 transcriptional activity in vitro. Unlike MDM2, however, MDM4 does not cause nuclear export or degradation of p53 (refs. 9,10). To study MDM4 function in vivo, we deleted Mdm4 in mice. Mdm4-null mice died at 7.5-8.5 dpc, owing to loss of cell proliferation and not induction of apoptosis. To assess the importance of p53 in the death of Mdm4(-/-) embryos, we crossed in the Trp53-null allele. The loss of Trp53 completely rescued the Mdm4(-/-) embryonic lethality. Thus, MDM2 and MDM4 are nonoverlapping critical regulators of p53 in vivo. These data define a new pathway of p53 regulation and raise the possibility that increased MDM4 levels and the resulting inactivation of p53 contribute to the development of human tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; Univ Autonoma Nuevo Leon, Sch Biol Sci, Dept Microbiol & Immunol, Monterrey, NL, Mexico; Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	University of Texas System; UTMD Anderson Cancer Center; Universidad Autonoma de Nuevo Leon; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.		Chavez-Reyes, Arturo/ABG-1231-2020	Chavez-Reyes, Arturo/0000-0002-6655-815X				de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LUNA RMD, 1995, NATURE, V378, P203; Manova K, 1998, DEV DYNAM, V213, P293, DOI 10.1002/(SICI)1097-0177(199811)213:3<293::AID-AJA6>3.0.CO;2-D; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Parant JM, 2001, GENE, V270, P277, DOI 10.1016/S0378-1119(01)00432-2; Ramos YFM, 2001, CANCER RES, V61, P1839; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILKINSON DG, 1998, IN SITU HYBRIDIZATIO	18	403	408	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2001	29	1					92	95		10.1038/ng714	http://dx.doi.org/10.1038/ng714			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	468WN	11528400				2022-12-25	WOS:000170781300025
J	Toma, JG; Akhavan, M; Fernandes, KJL; Barnabe-Heider, F; Sadikot, A; Kaplan, DR; Miller, FD				Toma, JG; Akhavan, M; Fernandes, KJL; Barnabe-Heider, F; Sadikot, A; Kaplan, DR; Miller, FD			Isolation of multipotent adult stem cells from the dermis of mammalian skin	NATURE CELL BIOLOGY			English	Article							MARROW STROMAL CELLS; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW; IN-VIVO; PROGENITOR CELLS; NEURONS; RAT; EXPRESSION; BRAIN; DIFFERENTIATE	We describe here the isolation of stem cells from juvenile and adult rodent skin. These cells derive from the dermis, and clones of individual cells can proliferate and differentiate in culture to produce neurons, glia, smooth muscle cells and adipocytes. Similar precursors that produce neuron-specific proteins upon differentiation can be isolated from adult human scalp. Because these cells (termed SKPs for skin-derived precursors) generate both neural and mesodermal progeny, we propose that they represent a novel multipotent adult stem cell and suggest that skin may provide an accessible, autologous source of stem cells for transplantation.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Div Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Toma, JG (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.							Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gloster A, 1999, J COMP NEUROL, V405, P45, DOI 10.1002/(SICI)1096-9861(19990301)405:1<45::AID-CNE4>3.0.CO;2-M; GLOSTER A, 1994, J NEUROSCI, V14, P7319; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; NURSE CA, 1984, NEUROSCIENCE, V13, P563, DOI 10.1016/0306-4522(84)90249-5; Park JK, 1999, J NEUROSCI, V19, P10383; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Toma JG, 2000, J NEUROSCI, V20, P7648; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	31	1234	1392	1	67	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2001	3	9					778	784		10.1038/ncb0901-778	http://dx.doi.org/10.1038/ncb0901-778			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	472JC	11533656				2022-12-25	WOS:000170979600010
J	Farassati, F; Yang, AD; Lee, PWK				Farassati, F; Yang, AD; Lee, PWK			Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; BRAIN-TUMORS; MUTANT G207; CANCER; TRANSFORMATION; INHIBITOR; REOVIRUS; THERAPY; GLIOMA; PKR	The importance of herpes simplex viruses (HSV) as human pathogens and the emerging prospect of using mutant derivatives of HSV-1 as potential anti-cancer therapeutics have necessitated a thorough investigation into the molecular basis of host-cell permissiveness to HSV. Here we show that NIH-3T3 cells transformed with the oncogenes v-erbB, activated sos or activated ras become significantly more permissive to HSV-1. Inhibitors of the Ras signalling pathway, such as farnesyl transferase inhibitor 1 and PD98069, effectively suppressed HSV-1 infection of ras-transformed cells. Enhanced permissiveness of the transformed cells was linked to the inhibition of virus-induced activation (phosphorylation) of the double-stranded RNA-activated protein kinase (PKR), thereby allowing viral transcripts to be translated in these cells. An HSV-1-derived oncolytic mutant, R3616, was also found to infect preferentially both transformed cells and PKR-/- (but not PKR+/+) mouse embryo fibroblasts. These observations suggest that HSV-1 specifically targets cells with an activated Ras signalling pathway, and have important ramifications in the use of engineered HSV in cancer therapy, the development of strategies against HSV infections, and the controversial role of HSV in human cancers.	Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Andreansky S, 1997, CANCER RES, V57, P1502; Andreansky SS, 1996, P NATL ACAD SCI USA, V93, P11313, DOI 10.1073/pnas.93.21.11313; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Coukos G, 2000, CANCER GENE THER, V7, P275, DOI 10.1038/sj.cgt.7700130; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dong ZG, 1999, ANTICANCER RES, V19, P3743; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Helbing CC, 1997, CANCER RES, V57, P1255; JONES C, 1995, CLIN MICROBIOL REV, V8, P549, DOI 10.1128/CMR.8.4.549; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Markert JM, 2000, REV MED VIROL, V10, P17, DOI 10.1002/(SICI)1099-1654(200001/02)10:1<17::AID-RMV258>3.0.CO;2-G; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; Oyama M, 2000, HUM GENE THER, V11, P1683, DOI 10.1089/10430340050111331; Roizman B, 1996, FIELDS VIROLOGY, P2231; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; YAZAKI T, 1995, CANCER RES, V55, P4752	30	182	188	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2001	3	8					745	750		10.1038/35087061	http://dx.doi.org/10.1038/35087061			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	461ZF	11483960				2022-12-25	WOS:000170393200020
J	Bafico, A; Liu, GZ; Yaniv, A; Gazit, A; Aaronson, SA				Bafico, A; Liu, GZ; Yaniv, A; Gazit, A; Aaronson, SA			Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow	NATURE CELL BIOLOGY			English	Article							SPEMANN ORGANIZER; SECRETED PROTEIN; RECEPTOR; ANTAGONIST; FAMILY; MEMBER; IDENTIFICATION; TRANSDUCTION; DROSOPHILA; LIGANDS	Wnt signalling has an important role in cell fate determination, tissue patterning and tumorigenesis(1-4). Secreted antagonists of Wnt include Frizzled (Fz)-related proteins (FRPs)(5-7), Cerberus(8), Wnt inhibitory factor (WIF)(9) and Dickkopf (Dkk)(10,11). FRPs, Cerberus and WIF have all been shown to act by binding and sequestering Wnt, We report a novel mechanism of Wnt-signalling inhibition by human Dkk-1, Dkk-1 demonstrated no interaction with Wnt but bound a single cell surface site with high affinity (K-D = 0.39 nM). Its receptor was detectable in a complex with a relative molecular mass of 240,000 (M-r 240K) with [I-125] Dkk-1 by covalent affinity cross-linking. Wnt signalling through beta -catenin is mediated by the Fz receptor(12) and a recently identified low-density-lipoprotein-receptor-related co-receptor, LRP6/Arrow(13-15). Overproduction of the 200K LRP6 protein, but not of Fz, strikingly increased Dkk-1 binding as well as the amount of the 240K crosslinked complex, which was shown to be composed of Dkk-1 and LRP6. Moreover, Dkk-1 function was completely independent of Fz but LRP6 dramatically interfered with the Dkk-1 inhibition of Wnt signalling. Thus, unlike Wnt antagonists, which exert their effects by molecular mimicry of Fz(5-7) Or Wnt sequestration through other mechanisms(8,9), Dkk-1 specifically inhibits canonical Wnt signalling by binding to the LRP6 component of the receptor complex.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel	Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA71672-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Dale TC, 1998, BIOCHEM J, V329, P209; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110	27	629	689	0	36	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					683	686		10.1038/35083081	http://dx.doi.org/10.1038/35083081			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433302				2022-12-25	WOS:000169727000021
J	Ma, ZG; Morris, SW; Valentine, V; Li, M; Herbrick, JA; Cui, XL; Bouman, D; Li, Y; Mehta, PK; Nizetic, D; Kaneko, Y; Chan, GCF; Chan, LC; Squire, J; Scherer, SW; Hitzler, JK				Ma, ZG; Morris, SW; Valentine, V; Li, M; Herbrick, JA; Cui, XL; Bouman, D; Li, Y; Mehta, PK; Nizetic, D; Kaneko, Y; Chan, GCF; Chan, LC; Squire, J; Scherer, SW; Hitzler, JK			Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia	NATURE GENETICS			English	Article							SPLIT ENDS; PROTEIN; NONRANDOM; PATHWAY; ENCODES	t(1;22) is the principal translocation of acute megakaryoblastic leukemias. Here we show this chromosomal rearrangement to result in the fusion of two novel genes. RNA-binding motif protein-15 (RBM15). an RNA recognition motif-encoding gene with homology to Drosophila spen. and Megakaryoblastic Leukemia-1 (MKL1), a gene encoding an SAP (SAF-A/B. Acinus and PIAS) DNA-binding domain.	Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Canc & Blood, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38163 USA; Univ London, Sch Pharm, Ctr Appl Mol Biol, London WC1N 1AX, England; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 3630806, Japan; Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Div Haematol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Div Haematol, Hong Kong, Hong Kong, Peoples R China; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of London; University College London; University of London School of Pharmacy; University of Hong Kong; University of Hong Kong; University of Toronto; University of Toronto; University of Toronto	Hitzler, JK (corresponding author), Univ Toronto, Hosp Sick Children, Dept Paediat, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada.		Squire, Jeremy A/A-9352-2012; Scherer, Stephen W./B-3785-2013; Nizetic, Dean/F-9509-2015	Squire, Jeremy A/0000-0002-9863-468X; Scherer, Stephen W./0000-0002-8326-1999; Nizetic, Dean/0000-0001-5486-5761	NATIONAL CANCER INSTITUTE [R01CA087064] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87064, CA-27165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bernstein J, 2000, LEUKEMIA, V14, P216, DOI 10.1038/sj.leu.2401639; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARROLL A, 1991, BLOOD, V78, P748; Chen FL, 2000, CURR BIOL, V10, P943, DOI 10.1016/S0960-9822(00)00625-4; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kuang B, 2000, DEVELOPMENT, V127, P1517; LION T, 1992, BLOOD, V79, P3325; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MITCHEL PJ, 1989, SCIENCE, V245, P372; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Rebay I, 2000, GENETICS, V154, P695; Wiellette EL, 1999, DEVELOPMENT, V126, P5373	15	228	239	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					220	221		10.1038/90054	http://dx.doi.org/10.1038/90054			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431691				2022-12-25	WOS:000169656400013
J	Njajou, OT; Vaessen, N; Joosse, M; Berghuis, B; van Dongen, JWF; Breuning, MH; Snijders, PJLM; Rutten, WPF; Sandkuijl, LA; Oostra, BA; van Duijn, CM; Heutink, P				Njajou, OT; Vaessen, N; Joosse, M; Berghuis, B; van Dongen, JWF; Breuning, MH; Snijders, PJLM; Rutten, WPF; Sandkuijl, LA; Oostra, BA; van Duijn, CM; Heutink, P			A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis	NATURE GENETICS			English	Article							HEREDITARY HEMOCHROMATOSIS; IRON; GENE; TRANSPORTER; NRAMP2	Hereditary hemochromatosis (HH) is a very common disorder characterized by iron overload and multi-organ damage. Several genes involved in iron metabolism have been implicated in the pathology of HH (refs. 1-4). We report that a mutation in the gene encoding Solute Carrier family 11, member A3 (SLC11A3). also known as ferroportin. is associated with autosomal dominant hemochromatosis.	Erasmus Univ, Dept Epidemiol & Biostat, Genet Epidemiol Unit, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Anthropogenet, NL-2300 RA Leiden, Netherlands; Stichting Huisarts Lab, Breda, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Njajou, OT (corresponding author), Erasmus Univ, Dept Epidemiol & Biostat, Genet Epidemiol Unit, NL-3000 DR Rotterdam, Netherlands.		Breuning, Martijn H/E-3429-2010	Heutink, Peter/0000-0001-5218-1737				Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; EASON RJ, 1990, AUST NZ J MED, V20, P226, DOI 10.1111/j.1445-5994.1990.tb01024.x; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; GOOSSENS JP, 1977, LANCET, P1106; Haile DJ, 2000, CYTOGENET CELL GENET, V88, P328, DOI 10.1159/000015522; Kaplan J, 2000, NATURE, V403, P711, DOI 10.1038/35001691; KATO J, IN PRESS AM J HUM GE; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Pietrangelo A, 1999, NEW ENGL J MED, V341, P725, DOI 10.1056/NEJM199909023411003; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379	15	368	380	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2001	28	3					213	214		10.1038/90038	http://dx.doi.org/10.1038/90038			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	448XZ	11431687				2022-12-25	WOS:000169656400009
J	van den Heuvel, M				van den Heuvel, M			Straight or split: signals to transcription	NATURE CELL BIOLOGY			English	Editorial Material							HEDGEHOG TARGET GENES; CUBITUS-INTERRUPTUS; DROSOPHILA; WINGLESS; PROTEIN; GROWTH; DIFFERENTIATION; ACTIVATION; FAMILY	Since the discovery of substances in serum media that are able to drive cells into proliferation and/or differentiation, investigators have tried to understand how such signalling molecules can influence cells to change their behaviour. The complex nature of the responses to signals, and the equally complex signalling pathway leading to those responses, have made life difficult for the researcher. However, recent evidence obtained in genetic developmental systems indicates that a multiplicity of downstream events can be accomplished by regulation of the activity of just one transcription factor.	Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, Oxford OX1 3QX, England	University of Oxford	van den Heuvel, M (corresponding author), Univ Oxford, Dept Human Anat & Genet, MRC, Funct Genet Unit, S Pk Rd, Oxford OX1 3QX, England.							Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; AZA BP, 1997, CELL, V89, P1043; Biesecker LG, 1997, NAT GENET, V17, P259, DOI 10.1038/ng1197-259; BLANC PA, 2000, DEVELOPMENT, V127, P4293; CAPDEVILA J, 2000, ENCY LIFE SCI; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; Methot N, 2001, DEVELOPMENT, V128, P733; Morel V, 2000, GENE DEV, V14, P377; Muller B, 2000, DEVELOPMENT, V127, P2999; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NUSSE R, 1988, TRENDS GENET, V2, P244; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; VANDENHEUVEL M, 2000, ENCY LIFE SCI; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6	26	4	4	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2001	3	7					E155	E156		10.1038/35083101	http://dx.doi.org/10.1038/35083101			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	450DV	11433306				2022-12-25	WOS:000169727000003
J	Grewal, PK; Holzfeind, PJ; Bittner, RE; Hewitt, JE				Grewal, PK; Holzfeind, PJ; Bittner, RE; Hewitt, JE			Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse	NATURE GENETICS			English	Letter							MUSCULAR-DYSTROPHY; GENE; CHROMOSOME-8; MICE; GLYCOPROTEIN; MEMBRANE; PROTEIN; COMPLEX; LAMININ; FAMILY	Spontaneous and engineered mouse mutants have facilitated our understanding of the pathogenesis of muscular dystrophy and they provide models for the development of therapeutic approaches'. The mouse myodystrophy (myd) mutation produces an autosomal recessive, neuromuscular phenotype(2). Homozygotes have an abnormal gait, show abnormal posturing when suspended by the tail and are smaller than littermate controls. Serum creatine kinase is elevated and muscle histology is typical of a progressive myopathy with focal areas of acute necrosis and clusters of regenerating fibers(3). Additional aspects of the phenotype include sensorineural deafness, reduced lifespan and decreased reproductive fitness(2,3). The myd mutation maps to mouse chromosome 8 at approximately 33 centimorgans (cM) (refs. 2,4-7). Here we show that the gene mutated in myd encodes a glycosyltransferase. Large. The human homolog of this gene (LARGE) maps to chromosome 22q, In myd, an intragenic deletion of exons 4-7 causes a frameshift in the resultant mRNA and a premature termination codon before the first of the two catalytic domains. On immunoblots, a monoclonal antibody to alpha -dystroglycan (a component of the dystrophin-associated glycoprotein complex) shows reduced binding in myd,which we attribute to altered glycosylation of this protein. We speculate that abnormal posttranslational modification of alpha -dystroglycan may contribute to the myd phenotype.	Univ Nottingham, Queens Med Ctr, Genet Inst, Nottingham NG7 2UH, England; Univ Vienna, Neuromuscular Res Dept, Inst Anat, A-1010 Vienna, Austria	University of Nottingham; University of Vienna	Hewitt, JE (corresponding author), Univ Nottingham, Queens Med Ctr, Genet Inst, Nottingham NG7 2UH, England.	jane.hewitt@nottingham.ac.uk						Allamand V, 2000, HUM MOL GENET, V9, P2459, DOI 10.1093/hmg/9.16.2459; Aravind L, 1999, CURR BIOL, V9, pR836, DOI 10.1016/S0960-9822(00)80039-1; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; GEE SH, 1993, J BIOL CHEM, V268, P14972; Grewal PK, 1997, MAMM GENOME, V8, P394, DOI 10.1007/s003359900454; Grewal PK, 1998, MAMM GENOME, V9, P603, DOI 10.1007/s003359900829; Grewal PK, 1998, GENE, V216, P13, DOI 10.1016/S0378-1119(98)00334-5; Grewal PK, 1999, GENE, V240, P389, DOI 10.1016/S0378-1119(99)00459-X; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KIM J, IN PRESS GENOMICS; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; LANE PW, 1976, J HERED, V67, P135, DOI 10.1093/oxfordjournals.jhered.a108687; MATHEWS KD, 1995, J NEUROPATH EXP NEUR, V54, P601, DOI 10.1093/whq/54.4.601; MATHEWS KD, 1995, MUSCLE NERVE, pS98; Matthews KD, 1996, CURR OPIN NEUROL, V9, P394; MILLS KA, 1995, MAMM GENOME, V6, P278, DOI 10.1007/BF00352416; NUTTING DF, 1980, J HERED, V71, P15, DOI 10.1093/oxfordjournals.jhered.a109302; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1	27	249	252	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					151	154		10.1038/88865	http://dx.doi.org/10.1038/88865			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381262				2022-12-25	WOS:000169011800017
J	Howe, JR; Bair, JL; Sayed, MG; Anderson, ME; Mitros, FA; Petersen, GM; Velculescu, VE; Traverso, G; Vogelstein, B				Howe, JR; Bair, JL; Sayed, MG; Anderson, ME; Mitros, FA; Petersen, GM; Velculescu, VE; Traverso, G; Vogelstein, B			Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis	NATURE GENETICS			English	Letter							COWDEN-DISEASE; SIGNALING PATHWAYS; SMAD PROTEINS; CANCER; CELLS; PTEN; SMAD4/DPC4; CARCINOMA; KINASE; BREAST	Juvenile polyposis (JP; OMIM 174900) is an autosomal dominant gastrointestinal hamartomatous polyposis syndrome in which patients are at risk for developing gastrointestinal cancers(1,2). Previous studies have demonstrated a locus for JP mapping to 18q21.1 (ref. 3) and germline mutations in the homolog of the gene for mothers against decapentaplegic. Drosophila. (MADH4. also known as SMAD4) in several JP families(4). However, mutations in MADH4 are only present in a subset of JP cases'. and although mutations in the gene for phosphatase and tensin homolog (PTEN) have been described in a few families(6,7), undefined genetic heterogeneity remains. Using a genome-wide screen in four JP kindreds without germline mutations in MADH4 or PTEN, we identified linkage with markers from chromosome 10q22-23 (maximum lod score of 4.74, theta =0.00). We found no recombinants using markers developed from the vicinity of the gene for bone morphogenetic protein receptor 1A (BMPR1A), a serine-threonine kinase type I receptor involved in bone morphogenetic protein (BMP) signaling(8). Genomic sequencing of BMPR1A in each of these JP kindreds disclosed germline nonsense mutations in all affected kindred members but not in normal control individuals. These findings indicate involvement of an additional gene in the transforming growth factor-beta (TGF-beta) superfamily in the genesis of JP, and document an unanticipated function for BMP in colonic epithelial growth control.	Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Mayo Clin & Mayo Fdn, Clin Epidemiol Sect, Rochester, MN 55905 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Oncol Ctr, Baltimore, MD USA	University of Iowa; University of Iowa; Mayo Clinic; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Howe, JR (corresponding author), Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA.		Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X; Howe, James/0000-0001-5312-5972	NATIONAL CANCER INSTITUTE [R01CA043460, P50CA062924, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460, CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Eng C, 1998, AM J HUM GENET, V62, P1020, DOI 10.1086/301847; Fink SP, 2001, CANCER RES, V61, P256; GENTRY WC, 1974, ARCH DERMATOL, V109, P521, DOI 10.1001/archderm.109.4.521; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Houlston R, 1998, HUM MOL GENET, V7, P1907, DOI 10.1093/hmg/7.12.1907; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 1998, ANN SURG ONCOL, V5, P751, DOI 10.1007/BF02303487; Howe JR, 1998, AM J HUM GENET, V62, P1129, DOI 10.1086/301840; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Raida M, 1999, INT J CANCER, V83, P38, DOI 10.1002/(SICI)1097-0215(19990924)83:1<38::AID-IJC8>3.3.CO;2-2; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Woodford-Richens K, 2000, CANCER RES, V60, P2477	30	454	484	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2001	28	2					184	187		10.1038/88919	http://dx.doi.org/10.1038/88919			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381269				2022-12-25	WOS:000169011800024
J	Medley, GF; Lindop, NA; Edmunds, WJ; Nokes, DJ				Medley, GF; Lindop, NA; Edmunds, WJ; Nokes, DJ			Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control	NATURE MEDICINE			English	Article							TRANSMISSION DYNAMICS; MATHEMATICAL-MODEL; VACCINATION; BIFURCATION; INFECTION; IMMUNIZATION; PREVALENCE; COUNTRIES; DISEASE; HBV	Hepatitis-B virus infection is globally ubiquitous, but its distribution is very heterogeneous, with prevalence of serological markers in various nations ranging from less than 1% to more than 90%. We propose an explanation for this diversity using a mathematical model of hepatitis-B virus transmission dynamics that shows, for the first time,'catastrophic' behavior using realistic epidemiological processes and parameters. Our major conclusion is that the prevalence of infection is largely determined by a feedback mechanism that relates the rate of transmission, average age at infection and age-related probability of developing carriage following infection. Using the model we identify possible, highly non-linear, consequences of chemotherapy and immunization interventions, for which the starting prevalence of carriers is the most influential, predictive quantity. Taken together, our results demand a re-evaluation of public health policy towards hepatitis-B.	Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England; Xilinx Scotland, Edinburgh, Midlothian, Scotland; CDSC, Immunisat Dis, London, England; Wellcome Trust Res Labs, Kenya Unit, Kilifi, Kenya	University of Warwick; Xilinx	Medley, GF (corresponding author), Univ Warwick, Dept Biol Sci, Ecol & Epidemiol Grp, Coventry CV4 7AL, W Midlands, England.	graham.medley@warwick.ac.uk	Medley, Graham/B-7289-2008	Medley, Graham/0000-0002-0030-7278				ANDERSON R E, 1992, P95; ANDERSON R M, 1991; Dushoff J, 1998, J MATH BIOL, V36, P227, DOI 10.1007/s002850050099; Dushoff J, 1996, J THEOR BIOL, V180, P181, DOI 10.1006/jtbi.1996.0094; Edmunds W J, 1998, Commun Dis Public Health, V1, P221; Edmunds WJ, 1999, STAT MED, V18, P3263, DOI 10.1002/(SICI)1097-0258(19991215)18:23&lt;3263::AID-SIM315&gt;3.0.CO;2-3; Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313, DOI 10.1017/S0950268800001497; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; Edmunds WJ, 1996, STAT MED, V15, P2215, DOI 10.1002/(SICI)1097-0258(19961030)15:20&lt;2215::AID-SIM369&gt;3.0.CO;2-2; Gay NJ, 1998, BRIT MED J, V316, P1457, DOI 10.1136/bmj.316.7142.1457; Greenhalgh D, 2000, MATH BIOSCI, V165, P1, DOI 10.1016/S0025-5564(00)00012-2; Hadeler KP, 1997, MATH BIOSCI, V146, P15, DOI 10.1016/S0025-5564(97)00027-8; HADELER KP, 1995, MATH BIOSCI, V128, P41, DOI 10.1016/0025-5564(94)00066-9; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; HUANG WZ, 1992, SIAM J APPL MATH, V52, P835, DOI 10.1137/0152047; HYAMS KC, 1995, CLIN INFECT DIS, V20, P992, DOI 10.1093/clinids/20.4.992; KUZNETSOV YA, 1994, J MATH BIOL, V32, P109, DOI 10.1007/BF00163027; MAYANS MV, 1990, LANCET, V336, P1107, DOI 10.1016/0140-6736(90)92580-B; MAYANS MV, 1994, LANCET, V343, P761, DOI 10.1016/S0140-6736(94)91838-4; Maynard JE, 1988, VIRAL HEPATITIS LIVE, P967; MCLEAN AR, 1994, P ROY SOC B-BIOL SCI, V256, P7, DOI 10.1098/rspb.1994.0042; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; Mortimer PP, 1997, BRIT MED J, V314, P1036, DOI 10.1136/bmj.314.7086.1036; O'Connell T, 2000, EPIDEMIOL INFECT, V125, P701, DOI 10.1017/S095026880000491X; OKOTH FA, 1991, E AFR MED J, V68, P515; Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462; POSTON T, 1978, CASTROPHE THEORY ITS; SCHREEDER MT, 1983, AM J EPIDEMIOL, V118, P543, DOI 10.1093/oxfordjournals.aje.a113659; SIMON CP, 1992, SIAM J APPL MATH, V52, P541, DOI 10.1137/0152030; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; van den Driessche P, 2000, J MATH BIOL, V40, P525, DOI 10.1007/s002850000032; WHITTLE HC, 1983, LANCET, V1, P1203; Williams JR, 1996, EPIDEMIOL INFECT, V116, P71, DOI 10.1017/S0950268800058970; Wilson JN, 2000, EPIDEMIOL INFECT, V124, P295, DOI 10.1017/S0950268800003605; Wodarz D, 1999, P NATL ACAD SCI USA, V96, P14464, DOI 10.1073/pnas.96.25.14464; Zhao SJ, 2000, INT J EPIDEMIOL, V29, P744, DOI 10.1093/ije/29.4.744	36	121	126	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2001	7	5					619	624		10.1038/87953	http://dx.doi.org/10.1038/87953			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329065				2022-12-25	WOS:000169961100043
J	Klein, MA; Kaeser, PS; Schwarz, P; Weyd, H; Xenarios, I; Zinkernagel, RM; Carroll, MC; Verbeek, JS; Botto, M; Walport, MJ; Molina, H; Kalinke, U; Acha-Orbea, H; Aguzzi, A				Klein, MA; Kaeser, PS; Schwarz, P; Weyd, H; Xenarios, I; Zinkernagel, RM; Carroll, MC; Verbeek, JS; Botto, M; Walport, MJ; Molina, H; Kalinke, U; Acha-Orbea, H; Aguzzi, A			Complement facilitates early prion pathogenesis	NATURE MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; FOLLICULAR DENDRITIC CELLS; T-DEPENDENT ANTIGEN; B-CELLS; TARGETED DISRUPTION; TONSIL BIOPSY; MICE; SCRAPIE; EXPRESSION; PRP	New-variant Creutzfeldt-Jakob disease and scrapie are typically initiated by extracerebral exposure to the causative agent, and exhibit early prion replication in lymphoid organs(1,2). In mouse scrapie, depletion of B-lymphocytes prevents neuropathogenesis after intraperitoneal inoculation(3,4), probably due to impaired lymphotoxin-dependent maturation of follicular dendritic cells(5) (FDCs), which are a major extracerebral prion reservoir(6). FDCs trap immune complexes with Fc-gamma receptors and C3d/C4b-opsonized antigens with CD21/CD35 complement receptors. We examined whether these mechanisms participate in peripheral prion pathogenesis. Depletion of circulating immunoglobulins or of individual Fc-gamma receptors had no effect on scrapie pathogenesis if B-cell maturation was unaffected. However, mice deficient in C3, C1q, Bf/C2, combinations thereof(7,8) or complement receptors(9) were partially or fully protected against spongiform encephalopathy upon intraperitoneal exposure to limiting amounts of prions. Splenic accumulation of prion infectivity and PrPSc was delayed, indicating that activation of specific complement components is involved in the initial trapping of prions in lymphoreticular organs early after infection.	Univ Zurich, Inst Neuropathol, Zurich, Switzerland; Univ Zurich, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Ctr Blood Res, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands; Imperial Coll Sch Med, Div Med, Rheumatol Sect, London, England; Washington Univ, Sch Med, Div Rheumatol, St Louis, MO USA; European Mol Biol Lab, Mouse Biol Programme, Monterotondo, Italy; Univ Lausanne, Lausanne Branch, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	University of Zurich; University of Zurich; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Imperial College London; Washington University (WUSTL); European Molecular Biology Laboratory (EMBL); University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne	Aguzzi, A (corresponding author), Univ Zurich, Inst Neuropathol, Schmelzbergstr, Zurich, Switzerland.		Aguzzi, Adriano/A-3351-2008; Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; Kalinke, Ulrich/0000-0003-0503-9564; Walport, Mark/0000-0001-7220-5273; Aguzzi, Adriano/0000-0002-0344-6708				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; Carroll MC, 1998, SEMIN IMMUNOL, V10, P279, DOI 10.1006/smim.1998.0120; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; EBENBICHLER CF, 1991, J EXP MED, V174, P1417, DOI 10.1084/jem.174.6.1417; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fischer MB, 1998, SCIENCE, V280, P582, DOI 10.1126/science.280.5363.582; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; Seiler P, 1998, J VIROL, V72, P2253, DOI 10.1128/JVI.72.3.2253-2258.1998; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SZAKAL AK, 1968, EXP MOL PATHOL, V8, P75, DOI 10.1016/0014-4800(68)90007-5; Takahashi K, 1996, COLLOID SURFACE B, V6, P379, DOI 10.1016/0927-7765(96)01276-3; Taylor PR, 1998, J BIOL CHEM, V273, P1699, DOI 10.1074/jbc.273.3.1699; Wu XB, 2000, J IMMUNOL, V165, P3119, DOI 10.4049/jimmunol.165.6.3119; YAMAKAWA M, 1992, IMMUNOLOGY, V76, P378	31	260	265	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2001	7	4					488	492		10.1038/86567	http://dx.doi.org/10.1038/86567			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	419QQ	11283678				2022-12-25	WOS:000167960500046
J	Zou, YR; Sunshine, MJ; Taniuchi, I; Hatam, F; Killeen, N; Littman, DR				Zou, YR; Sunshine, MJ; Taniuchi, I; Hatam, F; Killeen, N; Littman, DR			Epigenetic silencing of CD4 in T cells committed to the cytotoxic lineage	NATURE GENETICS			English	Article							HISTONE DEACETYLASE; GENE-EXPRESSION; METHYLATION; REPRESSION; SELECTION; PROLIFERATION; TRANSCRIPTION; INACTIVATION; INHERITANCE; THYMOCYTES	The process of thymocyte development culminates in the maturation of helper (CD4(+)) and cytotoxic (CD8(+)) T cells from their common precursors, the CD4(+)CD8(+) double-positive cells(1,2). A crucial step during lineage specification is the termination of expression of either the CD4 or the CD8 coreceptor(3,4). A silencer element within the first intron of the CD4 gene is sufficient for CD4 transcriptional repression in cells of the cytotoxic lineage, as well as in thymocytes at earlier stages of differentiation(5,6). Here we show that the function of the CD4 silencer is required only at distinct stages of development. Its deletion before the initiation of lineage specification resulted in CD4 derepression throughout thymocyte differentiation. By contrast, once cells committed to the cytotoxic CD8(+) lineage, the CD4 locus remained silent through subsequent mitoses, even when the silencer element was excised. The epigenetic inheritance of the silenced CD4 locus was not affected by the inhibition of DNA methylation or histone deacetylation, and may thus involve other mechanisms that ensure a stable state of gene expression.	NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	New York University; Howard Hughes Medical Institute; New York University; University of California System; University of California San Francisco	Littman, DR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA.	yz2001@columbia.edu; littman@saturn.med.nyu.edu	Taniuchi, Ichiro/N-6399-2015	Taniuchi, Ichiro/0000-0002-9853-9068; Sunshine, Mary Jean/0000-0002-2188-7881				Basson MA, 2000, IMMUNOL TODAY, V21, P509, DOI 10.1016/S0167-5699(00)01711-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Berg LJ, 2001, CURR OPIN IMMUNOL, V13, P232, DOI 10.1016/S0952-7915(00)00209-0; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Clerc P, 2000, SCIENCE, V290, P1518, DOI 10.1126/science.290.5496.1518; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Ellmeier W, 1997, IMMUNITY, V7, P537, DOI 10.1016/S1074-7613(00)80375-1; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Marrack P, 1997, CURR OPIN IMMUNOL, V9, P250, DOI 10.1016/S0952-7915(97)80144-6; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; von Boehmer H, 2000, CURR BIOL, V10, pR642, DOI 10.1016/S0960-9822(00)00665-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481	33	148	155	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2001	29	3					332	336		10.1038/ng750	http://dx.doi.org/10.1038/ng750			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	488AC	11687799				2022-12-25	WOS:000171911000022
J	Date, H; Onodera, O; Tanaka, H; Iwabuchi, K; Uekawa, K; Igarashi, S; Koike, R; Hiroi, T; Yuasa, T; Awaya, Y; Sakai, T; Takahashi, T; Nagatomo, H; Sekijima, Y; Kawachi, I; Takiyama, Y; Nishizawa, M; Fukuhara, N; Saito, K; Sugano, S; Tsuji, S				Date, H; Onodera, O; Tanaka, H; Iwabuchi, K; Uekawa, K; Igarashi, S; Koike, R; Hiroi, T; Yuasa, T; Awaya, Y; Sakai, T; Takahashi, T; Nagatomo, H; Sekijima, Y; Kawachi, I; Takiyama, Y; Nishizawa, M; Fukuhara, N; Saito, K; Sugano, S; Tsuji, S			Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene	NATURE GENETICS			English	Article							CEREBELLAR ATROPHY HMSNCA; HEREDITARY MOTOR; LINKAGE ANALYSIS; PROTEINS; FEATURES; FAMILY	Friedreich ataxia (FRDA), the most common autosomal recessive neurodegenerative disease among Europeans and people of European descent, is characterized by an early onset (usually before the age of 25), progressive ataxia, sensory loss, absence of tendon reflexes and pyramidal weakness of the legs(1-4). We have recently identified a unique group of patients whose clinical presentations are characterized by autosomal recessive inheritance, early age of onset, FRDA-like clinical presentations and hypoalbuminemia. Linkage to the FRDA locus, however, was excluded. Given the similarities of the clinical presentations to those of the recently described ataxia with oculomotor apraxia (AOA) linked to chromosome 9p13, we confirmed that the disorder of our patients is also linked to the same locus(5). We narrowed the candidate region and have identified a new gene encoding a member of the histidine triad (HIT) superfamily as the 'causative' gene. We have called its product aprataxin; the gene symbol is APTX. Although many HIT proteins have been identified, aprataxin is the first to be linked to a distinct phenotype.	Niigata Univ, Brain Res Inst, Dept Neurol, Niigata 951, Japan; Kanagawa Rehabil Ctr, Dept Neurol & Psychiat, Kanagawa, Japan; Natl Kumamoto Minami Hosp, Dept Neurol, Kumamoto, Japan; Hosoki Hosp, Kouchi, Japan; Kohnodai Hosp, Natl Ctr Neurol & Psychiat, Dept Neurol, Tokyo, Japan; Seibo Hosp, Dept Pediat, Tokyo, Japan; Natl Chikugo Hosp, Fukuoka, Japan; Yokohama City Univ, Med Ctr, Dept Psychiat, Kanagawa, Japan; Shinshu Univ, Sch Med, Dept Med 3, Nagano, Japan; Jichi Med Sch, Dept Neurol, Minami Kawachi, Tochigi 32904, Japan; Natl Saigata Hosp, Dept Neurol, Niigata, Japan; Tokyo Womens Med Univ, Sch Med, Dept Pediat, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Virol, Tokyo, Japan	Niigata University; National Center for Neurology & Psychiatry - Japan; Yokohama City University; Shinshu University; Jichi Medical University; Tokyo Women's Medical University; University of Tokyo	Tsuji, S (corresponding author), Niigata Univ, Brain Res Inst, Dept Neurol, 1 Asahimachi, Niigata 951, Japan.		Kawachi, Izumi/AFE-8189-2022; Onodera, Osamu/K-7327-2013	Onodera, Osamu/0000-0003-3354-5472; Saito, Kayoko/0000-0003-2632-0873				AICARDI J, 1988, ANN NEUROL, V24, P497, DOI 10.1002/ana.410240404; ARAIE M, 1977, JPN J OPHTHALMOL, V21, P355; Barbot C, 2001, ARCH NEUROL-CHICAGO, V58, P201, DOI 10.1001/archneur.58.2.201; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; COGAN DG, 1953, AM J OPHTHALMOL, V36, P433, DOI 10.1016/0002-9394(53)90553-4; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Friedreich N., 1876, VIRCHOWS ARCH PATHOL, V68, P145, DOI 10.1007/BF01879049; Friedreich N., 1877, VIRCHOWS ARCH PATHOL, V70, P140, DOI 10.1007/BF01936635; FUKUHARA N, 1995, J NEUROL SCI, V133, P140, DOI 10.1016/0022-510X(95)00176-3; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; INOUE N, 1971, CLIN NEUROL TOKYO, V11, P855; KAWASAKI S, 1982, CLIN NEUROL, V22, P15; KOIKE R, 1998, NEUROL MED, V48, P237; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kubota Hiroshi, 1995, Brain and Nerve (Tokyo), V47, P289; KURITATAKAHASHI S, NEUROOPHTHALMOL, V12, P41; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1985, AM J HUM GENET, V37, P482; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Moreira MD, 2001, AM J HUM GENET, V68, P501, DOI 10.1086/318191; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 2001, MOL CLONING LAB MANU, V1; Sekijima Y, 1998, J NEUROL SCI, V158, P30, DOI 10.1016/S0022-510X(98)00103-8; Seraphin B., 1992, DNA Sequence, V3, P177, DOI 10.3109/10425179209034013; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UEKAWA K, 1992, CLIN NEUROL, V32, P1067	28	274	286	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					184	188		10.1038/ng1001-184	http://dx.doi.org/10.1038/ng1001-184			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11586299				2022-12-25	WOS:000171374100025
J	Dove, A				Dove, A			The bittersweet promise of glycobiology	NATURE BIOTECHNOLOGY			English	Article								Carbohydrates play a wide range of important roles in the body and, despite the challenges posed by glycobiology, are now tempting targets for drug developers.										Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Plante OJ, 2001, SCIENCE, V291, P1523, DOI 10.1126/science.1057324; Weikert S, 1999, NAT BIOTECHNOL, V17, P1116, DOI 10.1038/15104; Zitzmann N, 1999, P NATL ACAD SCI USA, V96, P11878, DOI 10.1073/pnas.96.21.11878	4	140	143	1	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2001	19	10					913	917		10.1038/nbt1001-913	http://dx.doi.org/10.1038/nbt1001-913			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	479RP	11581651				2022-12-25	WOS:000171417600014
J	AbdAlla, S; Lother, H; el Massiery, A; Quitterer, U				AbdAlla, S; Lother, H; el Massiery, A; Quitterer, U			Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness	NATURE MEDICINE			English	Article							OXIDATIVE STRESS; B-2 RECEPTOR; PRESSOR-RESPONSE; MODULATION; EXPRESSION; ECLAMPSIA; CALCIUM	Several examples of functional G-protein-coupled receptor heterodimers have been identified. However, it is not known whether receptor heterodimerization is involved in the pathogenesis of human disorders. Here we show that in preeclamptic hypertensive women, a significant increase in heterodimerization occurs between the AT(1)-receptor for the vasopressor angiotensin II and the B-2-receptor for the vasodepressor bradykinin. AT(1)-B-2-receptor heterodimerization in preeclampsia correlated with a 4-5-fold increase in B-2-receptor protein levels. Expression of the AT(1)-B-2 heterodimer increased the responsiveness to angiotensin II and conferred resistance in AT(1)-receptors to inactivation by reactive oxygen species raised in normotensive and preeclamptic pregnancies. We suggest that AT(1)-B-2 heterodimers contribute to angiotensin II hypersensitivity in preeclampsia. Moreover, we identify preeclampsia as the first disorder associated with altered G-protein-coupled receptor heterodimerization.	Inst Pharmakol & Toxikol, Wurzburg, Germany; Ain Champs Univ Hosp, Med Res Ctr, Cairo, Egypt; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany	University of Wurzburg; Heinrich Pette Institute; University of Hamburg	Quitterer, U (corresponding author), Inst Pharmakol & Toxikol, Wurzburg, Germany.	toph029@rzbox.uni-wuerzburg.de						AALKJAER C, 1985, CLIN SCI, V69, P477, DOI 10.1042/cs0690477; AbdAlla S, 1996, EUR J BIOCHEM, V241, P498, DOI 10.1111/j.1432-1033.1996.00498.x; AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; ABDULKARIM R, 1961, AM J OBSTET GYNECOL, V82, P246, DOI 10.1016/0002-9378(61)90053-9; Akoev VR, 1998, BBA-BIOMEMBRANES, V1371, P284, DOI 10.1016/S0005-2736(98)00037-6; Belfort MA, 1996, AM J OBSTET GYNECOL, V174, P687, DOI 10.1016/S0002-9378(96)70451-9; BELLOMO G, 1987, J BIOL CHEM, V262, P1530; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CUNNINGHAM FG, 1992, NEW ENGL J MED, V326, P927; DEJONG CLD, 1991, CLIN PERINATOL, V18, P683, DOI 10.1016/S0095-5108(18)30491-3; Devi LA, 2000, TRENDS PHARMACOL SCI, V21, P324, DOI 10.1016/S0165-6147(00)01519-4; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; Haddad EB, 2000, MOL PHARMACOL, V57, P1123; HALLER H, 1989, AM J HYPERTENS, V2, P238, DOI 10.1093/ajh/2.4.238; Hubel CA, 1999, P SOC EXP BIOL MED, V222, P222, DOI 10.1046/j.1525-1373.1999.d01-139.x; Masse J, 1998, CLIN BIOCHEM, V31, P251, DOI 10.1016/S0009-9120(98)00021-6; ONEY T, 1982, AM J OBSTET GYNECOL, V142, P17; Pesquero JB, 1996, IMMUNOPHARMACOLOGY, V33, P36, DOI 10.1016/0162-3109(96)00080-X; Pouliot L, 1998, OBSTET GYNECOL, V91, P591, DOI 10.1016/S0029-7844(97)00702-3; Quitterer U, 1999, J BIOL CHEM, V274, P14773, DOI 10.1074/jbc.274.21.14773; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Rath Hope Heidi, 2000, Protein Expression and Purification, V18, P269; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; TOUYZ RM, 1993, J HYPERTENS, V11, P551, DOI 10.1097/00004872-199305000-00011; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; Vagnoni KE, 1998, AM J PHYSIOL-HEART C, V275, pH1845, DOI 10.1152/ajpheart.1998.275.5.H1845	29	373	390	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2001	7	9					1003	1009		10.1038/nm0901-1003	http://dx.doi.org/10.1038/nm0901-1003			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	470CR	11533702				2022-12-25	WOS:000170853300024
J	Taguchi, H; Ueno, T; Tadakuma, H; Yoshida, M; Funatsu, T				Taguchi, H; Ueno, T; Tadakuma, H; Yoshida, M; Funatsu, T			Single-molecule observation of protein-protein interactions in the chaperonin system	NATURE BIOTECHNOLOGY			English	Article							ARTIFICIAL PROTEINS; ALPHA-LACTALBUMIN; RANDOM SEQUENCES; FOLDING REACTION; RNA-POLYMERASE; ATPASE CYCLE; REAL-TIME; GROEL; BINDING; INTERMEDIATE	We have analyzed the dynamics of the chaperonin (GroEL)-cochaperonin (GroES) interaction at the single-molecule level. In the presence of ATP and non-native protein, binding of GroES to the immobilized GroEL occurred at a rate that is consistent with bulk kinetics measurements. However, the release of GroES from GroEL occurred after a lag period (similar to3 s) that was not recognized in earlier bulk-phase studies. This observation suggests a new kinetic intermediate in the GroEL-GroES reaction pathway.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Waseda Univ, Sch Sci & Engn, Dept Phys, Tokyo 1698555, Japan	Tokyo Institute of Technology; Waseda University	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.		Taguchi, Hideki/B-6946-2009; taguchi, hideki/AAM-2663-2021; Funatsu, Takashi/Q-1404-2015	Taguchi, Hideki/0000-0002-6612-9339; taguchi, hideki/0000-0002-6612-9339; Funatsu, Takashi/0000-0002-9656-8308				Aoki K, 1997, J BIOL CHEM, V272, P32158, DOI 10.1074/jbc.272.51.32158; Aoki K, 2000, J BIOL CHEM, V275, P13755, DOI 10.1074/jbc.275.18.13755; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Harada Y, 1998, METHOD CELL BIOL, V55, P117; Harada Y, 1999, BIOPHYS J, V76, P709, DOI 10.1016/S0006-3495(99)77237-1; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; Prijambada ID, 1996, FEBS LETT, V382, P21, DOI 10.1016/0014-5793(96)00123-8; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Strick TR, 2000, NATURE, V404, P901, DOI 10.1038/35009144; Tanaka N, 1999, J MOL BIOL, V292, P173, DOI 10.1006/jmbi.1999.3041; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Viani MB, 2000, NAT STRUCT BIOL, V7, P644, DOI 10.1038/77936; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yamasaki R, 1999, J MOL BIOL, V292, P965, DOI 10.1006/jmbi.1999.3129; ZONDLO J, 1995, BIOCHEMISTRY-US, V34, P10334, DOI 10.1021/bi00033a003	37	89	90	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2001	19	9					861	865		10.1038/nbt0901-861	http://dx.doi.org/10.1038/nbt0901-861			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	468TJ	11533646				2022-12-25	WOS:000170774000026
J	Nakada, K; Inoue, K; Ono, T; Isobe, K; Ogura, A; Goto, Y; Nonaka, I; Hayashi, JI				Nakada, K; Inoue, K; Ono, T; Isobe, K; Ogura, A; Goto, Y; Nonaka, I; Hayashi, JI			Inter-mitochondrial complementation: Mitochondria-specific system preventing mice from expression of disease phenotypes by mutant mtDNA	NATURE MEDICINE			English	Article							WILD-TYPE; MOUSE; DNA; DELETION; CELLS; EMBRYOGENESIS; DYSFUNCTION; ELIMINATION; MYOPATHY; GENOME	Here we investigated the pathogenesis of deletion mutant mitochondrial (mt)DNA by generating mice with mutant mtDNA carrying a 4696-basepair deletion (Delta mtDNA4696), and by using cytochrome c oxidase (COX) electron micrographs to identify COX activity at the individual mitochondrial level. All mitochondria in tissues with Delta mtDNA4696 showed normal COX activity until Delta mtDNA4696 accumulated predominantly; this prevented mice from expressing disease phenotypes. Moreover, we did not observe coexistence of COX-positive and -negative mitochondria within single cells. These results indicate the occurrence of inter-mitochondrial complementation through exchange of genetic contents between exogenously introduced mitochondria with Delta mtDNA4696 and host mitochondria with normal mtDNA. This complementation shows a mitochondria-specific mechanism for avoiding expression of deletion-mutant mtDNA, and opens the possibility of a gene therapy in which mitochondria possessing full-length DNA are introduced.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan; Natl Inst Infect Dis, Dept Vet Sci, Tokyo, Japan	University of Tsukuba; University of Tsukuba; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; National Institute of Infectious Diseases (NIID)	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki, Japan.		Ogura, Atsuo/J-3916-2014	Ogura, Atsuo/0000-0003-0447-1988				CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LOMBES A, 1989, REV NEUROL-FRANCE, V145, P671; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x; NONAKA I, 1989, J NEUROL SCI, V92, P193, DOI 10.1016/0022-510X(89)90136-6; Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Shitara H, 2000, GENETICS, V156, P1277; SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Yamaoka M, 2000, GENETICS, V155, P301; Yamaoka M, 2001, BIOCHEM BIOPH RES CO, V282, P707, DOI 10.1006/bbrc.2001.4646; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	22	324	336	0	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					934	940		10.1038/90976	http://dx.doi.org/10.1038/90976			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479626				2022-12-25	WOS:000171740400031
J	Zhang, HX; Blumwald, E				Zhang, HX; Blumwald, E			Transgenic salt-tolerant tomato plants accumulate salt in foliage but not in fruit	NATURE BIOTECHNOLOGY			English	Article							NA+/H+ ANTIPORT; WATER-STRESS; ARABIDOPSIS; TONOPLAST; PROLINE; GROWTH; OVEREXPRESSION; SALINITY; MEMBRANE; SYSTEM	Transgenic tomato plants overexpressing a vacuolar Na+/H+ antiport were able to grow, flower, and produce fruit in the presence of 200 mM sodium chloride. Although the leaves accumulated high sodium concentrations, the tomato fruit displayed very low sodium content. Contrary to the notion that multiple traits introduced by breeding into crop plants are needed to obtain salt-tolerant plants, the modification of a single trait significantly improved the salinity tolerance of this crop plant. These results demonstrate that with a combination of breeding and transgenic plants it could be possible to produce salt-tolerant crops with far fewer target traits than had been anticipated. The accumulation of sodium in the leaves and not in the fruit demonstrates the utility of such a modification in preserving the quality of the fruit.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Univ Calif Davis, Davis, CA 95616 USA	University of Toronto; University of California System; University of California Davis	Blumwald, E (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.		Blumwald, Eduardo/Y-2751-2019					Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060; BLUMWALD E, 1985, PLANT PHYSIOL, V78, P163, DOI 10.1104/pp.78.1.163; Blumwald E, 1997, ADV BOT RES, V25, P401, DOI 10.1016/S0065-2296(08)60159-7; Cuartero J, 1999, SCI HORTIC-AMSTERDAM, V78, P83, DOI 10.1016/S0304-4238(98)00191-5; CZONKA LN, 1991, ANNU REV MICROBIOL, V45, P569; Davies WJ, 2000, J EXP BOT, V51, P1617, DOI 10.1093/jexbot/51.350.1617; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EHRET DL, 1986, J EXP BOT, V37, P1294, DOI 10.1093/jxb/37.9.1294; Ghassemi F., 1995, SALINIZATION LAND WA; JEFFERSON RA, 1987, EMBO J, V6, P3901; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; LEE DR, 1989, CAN J BOT, V67, P1898, DOI 10.1139/b89-241; LEIGH RA, 1984, NEW PHYTOL, V97, P1, DOI 10.1111/j.1469-8137.1984.tb04103.x; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; Maathuis FJM, 1999, ANN BOT-LONDON, V84, P123, DOI 10.1006/anbo.1999.0912; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; Nanjo T, 1999, FEBS LETT, V461, P205, DOI 10.1016/S0014-5793(99)01451-9; Ramirez J, 1998, J BACTERIOL, V180, P5860; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; SCHOBERT B, 1977, J THEOR BIOL, V68, P17, DOI 10.1016/0022-5193(77)90224-7; SMIRNOFF N, 1989, PHYTOCHEMISTRY, V28, P1057, DOI 10.1016/0031-9422(89)80182-7; THOMAS BR, 1981, THEOR APPL GENET, V59, P215, DOI 10.1007/BF00265495; Walker DJ, 1996, P NATL ACAD SCI USA, V93, P10510, DOI 10.1073/pnas.93.19.10510; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YEO AR, 1990, THEOR APPL GENET, V79, P377, DOI 10.1007/BF01186082; Zhu JK, 2000, PLANT PHYSIOL, V124, P941, DOI 10.1104/pp.124.3.941	29	738	901	2	150	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2001	19	8					765	768		10.1038/90824	http://dx.doi.org/10.1038/90824			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458HH	11479571				2022-12-25	WOS:000170188600029
J	Miao, H; Wei, BR; Peehl, DM; Li, Q; Alexandrou, T; Schelling, JR; Rhim, JS; Sedor, JR; Burnett, E; Wang, BC				Miao, H; Wei, BR; Peehl, DM; Li, Q; Alexandrou, T; Schelling, JR; Rhim, JS; Sedor, JR; Burnett, E; Wang, BC			Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway	NATURE CELL BIOLOGY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; SH2 DOMAINS; CELL-LINE; TRANSFORMATION; ADHESION; BINDING; LIGANDS; EPHRINS; FAMILY	Interactions between Eph receptor tyrosine kinases (RTKs) and membrane-anchored ephrin ligands critically regulate axon pathfinding and development of the cardiovascular system, as well as migration of neural cells. Similar to other RTKs, ligand-activated Eph kinases recruit multiple signalling and adaptor proteins, several of which are involved in growth regulation(1,2). However, in contrast to other RTKs, activation of Eph receptors fails to promote cell proliferation(3,4) or to transform rodent fibroblasts(5), indicating that Eph kinases may initiate signalling pathways that are distinct from those transmitted by other RTKs. Here we show that stimulation of endogenous EphA kinases with ephrin-A1 potently inhibits the Ras/MAPK cascade in a range of cell types, and attenuates activation of mitogen-activated protein kinase (MAPK) by receptors for platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and Vascular endothelial growth factor (VEGF). In prostatic epithelial cells and endothelial cells, but not fibroblasts, treatment with ephrin-A1 inhibits cell proliferation. Our results identify EphA kinases as negative regulators of the Ras/MAPK pathway that exert anti-mitogenic functions in a cell-type-specific manner.	Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Ireland Canc Ctr, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44109 USA; Stanford Univ, Dept Urol, Stanford, CA 94305 USA; Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Stanford University; Uniformed Services University of the Health Sciences - USA	Miao, H (corresponding author), Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Res, Metrohlth Campus,2500 Metrohlth Dr, Cleveland, OH 44109 USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Bruce V, 1999, BRAIN RES, V821, P169, DOI 10.1016/S0006-8993(99)01112-9; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LEE MS, 1993, ONCOGENE, V8, P387; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Peehl DM, 1997, CARCINOGENESIS, V18, P1643, DOI 10.1093/carcin/18.8.1643; PEEHL DM, 1992, CULTURE EPITHELIAL C, P159; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	24	268	281	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2001	3	5					527	530		10.1038/35074604	http://dx.doi.org/10.1038/35074604			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	430TX	11331884				2022-12-25	WOS:000168592500026
J	Babu, GJ; Loukianov, E; Loukianova, T; Pyne, GJ; Huke, S; Osol, G; Low, RB; Paul, RJ; Periasamy, M				Babu, GJ; Loukianov, E; Loukianova, T; Pyne, GJ; Huke, S; Osol, G; Low, RB; Paul, RJ; Periasamy, M			Loss of SM-B myosin affects muscle shortening velocity and maximal force development	NATURE CELL BIOLOGY			English	Article							HEAVY-CHAIN ISOFORMS; SMOOTH-MUSCLE; MOTOR DOMAIN; INSERT; IDENTIFICATION; EXPRESSION; CDNA; DIVERSITY; VESSELS; RATS	We used an exon-specific gene-targeting strategy to generate a mouse model deficient only in the SM-B myosin isoform. Here we show that deletion of exon-5B (specific for SM-B) in the gene for the heavy chain of smooth muscle myosin results in a complete loss of SM-B myosin and switching of splicing to the SM-A isoform, without affecting SM1 and SM2 myosin content. Loss of SM-B myosin does not affect survival or cause any overt smooth muscle pathology. Physiological analysis reveals that absence of SM-B myosin results in a significant decrease in maximal force generation and velocity of shortening in smooth muscle tissues. This is the first in vivo study to demonstrate a functional role for the SM-B myosin isoform. We conclude that the extra seven-residue insert in the surface loop 1 of SM-B myosin is a critical determinant of crossbridge cycling and velocity of shortening.	Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Vermont, Dept Obstet & Gynecol, Burlington, VT 05405 USA; Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University of Vermont; University of Vermont	Periasamy, M (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		Babu, Gopal/AAB-7787-2021	Babu, Gopal/0000-0001-7833-5300; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038355, R29HL038355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38355-15] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; Babu GJ, 2000, MICROSC RES TECHNIQ, V50, P532, DOI 10.1002/1097-0029(20000915)50:6<532::AID-JEMT10>3.0.CO;2-E; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; DiSanto ME, 1997, AM J PHYSIOL-CELL PH, V272, pC1532, DOI 10.1152/ajpcell.1997.272.5.C1532; FUGLSANG A, 1993, J MUSCLE RES CELL M, V14, P666, DOI 10.1007/BF00141563; GOKINA NL, 1998, AM J PHYSIOL, V274, pG1920; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; Huang QQ, 1999, J BIOL CHEM, V274, P35095, DOI 10.1074/jbc.274.49.35095; Jones R, 1999, CELL TISSUE RES, V295, P453, DOI 10.1007/s004410051251; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; Lauzon AM, 1998, ACTA PHYSIOL SCAND, V164, P357; Loukianov E, 1998, CIRC RES, V83, P889; Loukianov EV, 1997, BIOTECHNIQUES, V23, P376, DOI 10.2144/97233bm05; Matthew JD, 1998, J BIOL CHEM, V273, P31289, DOI 10.1074/jbc.273.47.31289; Morano I, 2000, NAT CELL BIOL, V2, P371, DOI 10.1038/35014065; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; PAUL RJ, 1991, ADV EXP MED BIOL, V304, P139; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; SOBIESZEK A, 1986, ELECTROPHORESIS, V7, P417, DOI 10.1002/elps.1150070906; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Wetzel U, 1998, CIRC RES, V83, P204, DOI 10.1161/01.RES.83.2.204; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; White SL, 1998, AM J PHYSIOL-CELL PH, V275, pC581, DOI 10.1152/ajpcell.1998.275.2.C581	27	76	77	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2001	3	11					1025	1029		10.1038/ncb1101-1025	http://dx.doi.org/10.1038/ncb1101-1025			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	490UJ	11715025				2022-12-25	WOS:000172070300019
J	Hogema, BM; Gupta, M; Senephansiri, H; Burlingame, TG; Taylor, M; Jakobs, C; Schutgens, RBH; Froestl, W; Snead, OC; Diaz-Arrastia, R; Bottiglieri, T; Grompe, M; Gibson, KM				Hogema, BM; Gupta, M; Senephansiri, H; Burlingame, TG; Taylor, M; Jakobs, C; Schutgens, RBH; Froestl, W; Snead, OC; Diaz-Arrastia, R; Bottiglieri, T; Grompe, M; Gibson, KM			Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase	NATURE GENETICS			English	Article							GAMMA-HYDROXYBUTYRIC ACID; GABA(B) RECEPTORS; RAT HIPPOCAMPUS; TAURINE RELEASE; BINDING-SITES; FIRING RATE; BRAIN; ACTIVATION; CELLS; NEURONS	Succinate semialdehyde dehydrogenase (ALDH5A1, encoding SSADH deficiency is a defect of 4-aminobutyric acid (GABA) degradation that manifests in humans as 4-hydroxybutyric (gamma-hydroxybutyric, GHB) aciduria. It is characterized by a non-specific neurological disorder including psychomotor retardation, language delay, seizures, hypotonia and ataxia. The current therapy, vigabatrin (VGB), is not uniformly successful(1). Here we report the development of Aldh5a1-deficient mice. At postnatal day 16-22 Aldh5a1(-/-) mice display ataxia and develop generalized seizures leading to rapid death. We observed increased amounts of GHB and total GABA in urine, brain and liver homogenates and detected significant gliosis in the hippocampus of Aldh5a1(-/-) mice. We found therapeutic intervention with phenobarbital or pherytoin ineffective, whereas intervention with vigabatrin or the GABA(B) receptor antagonist CGP 35348 (ref. 2) prevented tonic-clonic convulsions and significantly enhanced survival of the mutant mice. Because neurologic deterioration coincided with weaning, we hypothesized the presence of a protective compound in breast milk. Indeed, treatment of mutant mice with the amino acid taurine rescued Aldh5a1(-/-) mice. These findings provide insight into pathomechanisms and may have therapeutic relevance for the human SSADH deficiency disease and GHB overdose and toxicity.	Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Metab Unit, Amsterdam, Netherlands; Erasmus Univ, Fac Med, Cardiovasc Res Inst COEUR, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA; Novartis Pharma Inc, CH-4002 Basel, Switzerland; Hosp Sick Children, Fac Med, Dept Pediat, Div Neurol, Toronto, ON, Canada; Hosp Sick Children, Fac Med, Program Brain & Behav, Toronto, ON, Canada; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX USA	Oregon Health & Science University; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Oregon Health & Science University; Novartis; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor University; Baylor University Medical Center	Gibson, KM (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, 2525 SW 3rd Ave, Portland, OR 97201 USA.		Gupta, Maneesh/GSE-3631-2022	Grompe, Markus/0000-0002-6616-4345; Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIA NIH HHS [R03 AG16450, P30 AG12300] Funding Source: Medline; NINDS NIH HHS [NS 40270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG016450, P30AG012300] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENAVIDES J, 1982, LIFE SCI, V30, P953, DOI 10.1016/0024-3205(82)90624-5; CLEMENTS JR, 1989, SYNAPSE, V4, P70, DOI 10.1002/syn.890040108; del Olmo N, 2000, BRAIN RES, V864, P298, DOI 10.1016/S0006-8993(00)02211-3; DIANA M, 1991, BRAIN RES, V566, P208, DOI 10.1016/0006-8993(91)91700-B; ENG LF, 1992, PROG BRAIN RES, V94, P353; Erhardt S, 1998, N-S ARCH PHARMACOL, V357, P611, DOI 10.1007/PL00005215; Fernandes MJD, 1999, J CEREBR BLOOD F MET, V19, P195; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; GIBSON KM, 1990, BIOMED ENVIRON MASS, V19, P89, DOI 10.1002/bms.1200190207; GIBSON KM, 1995, J INHERIT METAB DIS, V18, P143, DOI 10.1007/BF00711750; GIBSON KM, 2001, METABOLIC MOL BASES, P2079; Hardus P, 2001, EPILEPSIA, V42, P262, DOI 10.1046/j.1528-1157.2001.4220262.x; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; Lingenhoehl K, 1999, NEUROPHARMACOLOGY, V38, P1667, DOI 10.1016/S0028-3908(99)00131-8; Mathivet P, 1997, EUR J PHARMACOL, V321, P67, DOI 10.1016/S0014-2999(96)00916-8; MILLER DB, 1995, EXP GERONTOL, V30, P383, DOI 10.1016/0531-5565(94)00064-A; Minn A, 1998, GLIA, V22, P338, DOI 10.1002/(SICI)1098-1136(199804)22:4<338::AID-GLIA3>3.0.CO;2-#; Motalli R, 1999, J NEUROPHYSIOL, V82, P638, DOI 10.1152/jn.1999.82.2.638; NITECKA L, 1984, NEUROSCIENCE, V13, P1073, DOI 10.1016/0306-4522(84)90289-6; Oja SS, 2000, PROG NEUROBIOL, V62, P407, DOI 10.1016/S0301-0082(00)00005-8; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Saransaari P, 2000, AMINO ACIDS, V18, P17, DOI 10.1007/s007260050002; Sarwar G, 1998, BRIT J NUTR, V79, P129, DOI 10.1079/BJN19980023; SMITH SS, 1991, NEUROSCI LETT, V132, P59, DOI 10.1016/0304-3940(91)90433-T; SNEAD OC, 1994, BRAIN RES, V659, P147, DOI 10.1016/0006-8993(94)90874-5; SNEAD OC, 1984, BIOCHEM PHARMACOL, V33, P2587; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Timby N, 2000, AM J MED, V108, P518, DOI 10.1016/S0002-9343(99)00468-4	31	127	137	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2001	29	2					212	216		10.1038/ng727	http://dx.doi.org/10.1038/ng727			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	478XP	11544478				2022-12-25	WOS:000171374100030
J	Ichikawa, K; Liu, WM; Zhao, LM; Wang, Z; Liu, D; Ohtsuka, T; Zhang, HG; Mountz, JD; Koopman, WJ; Kimberly, RP; Zhou, T				Ichikawa, K; Liu, WM; Zhao, LM; Wang, Z; Liu, D; Ohtsuka, T; Zhang, HG; Mountz, JD; Koopman, WJ; Kimberly, RP; Zhou, T			Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity	NATURE MEDICINE			English	Article							NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; DEATH DOMAIN; RECEPTOR; CASPASE-8; FAMILY; MEMBER; ACTIVATE	A novel anti-human DR5 monoclonal antibody, TRA-8, induces apoptosis of most tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-sensitive tumor cells both in vitro and in vivo. In contrast to both the membrane-bound form of human TRAIL, which induced severe hepatitis in mice, and the soluble form of human TRAIL, which induced apoptosis of normal human hepatocytes in vitro, TRA-8 did not induce significant cell death of normal human hepatocytes. However, both primary hepatocellular carcinoma cells and an established liver cancer cell line were highly susceptible to the killing mediated by TRA-8. We show here that elevated levels of cell-surface expression of DRS and increased susceptibility to DRS-mediated apoptosis are characteristics of malignant tumor cells. In contrast, DR5 alone is not sufficient to trigger apoptosis of normal hepatocytes. Therefore, selective, specific targeting of DR5 with an agonistic antibody might be a safe and effective strategy for cancer therapy.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Sankyo Co Ltd, Biomed Res Labs, Tokyo 140, Japan	University of Alabama System; University of Alabama Birmingham; Daiichi Sankyo Company Limited	Zhou, T (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.			Kimberly, Robert/0000-0002-5330-3086	NIAMS NIH HHS [R03-AR44982] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Griffith TS, 1999, J IMMUNOL, V162, P2597; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kagawa S, 2001, CANCER RES, V61, P3330; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641	26	471	576	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2001	7	8					954	960		10.1038/91000	http://dx.doi.org/10.1038/91000			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	485EK	11479629				2022-12-25	WOS:000171740400034
J	Brown, EB; Campbell, RB; Tsuzuki, Y; Xu, L; Carmeliet, P; Fukumura, D; Jain, RK				Brown, EB; Campbell, RB; Tsuzuki, Y; Xu, L; Carmeliet, P; Fukumura, D; Jain, RK			In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy	NATURE MEDICINE			English	Article							IN-VIVO; VASCULAR-PERMEABILITY; BLOOD-FLOW; GROWTH	Intravital microscopy coupled with chronic animal window models has provided stunning insight into tumor pathophysiology, including gene expression, angiogenesis, cell adhesion and migration, vascular, interstitial and lymphatic transport, metabolic microenvironment and drug delivery. However, the findings to date have been limited to the tumor surface (< 150 <mu>m). Here, we show that the multiphoton laser-scanning microscope can provide high three-dimensional resolution of gene expression and function in deeper regions of tumors. These insights could be critical to the development of novel therapeutics that target not only the tumor surface, but also internal regions.	Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.		Xu, Lei/GRR-9174-2022; Jain, Rakesh K/I-1384-2017; Carmeliet, Peter/AAQ-5140-2020	Jain, Rakesh K/0000-0001-7571-3548; Carmeliet, Peter/0000-0001-7961-1821	NATIONAL CANCER INSTITUTE [R35CA056591, R24CA085140, P01CA080124, T32CA073479] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA73479, P01 CA080124, R24 CA85140, R35 CA56591, P01 CA80124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berk DA, 1997, P NATL ACAD SCI USA, V94, P1785, DOI 10.1073/pnas.94.5.1785; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1998, NATURE, V395, P525, DOI 10.1038/26791; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; ENDRICH B, 1979, J NATL CANCER I, V62, P387; Fukumura D, 1997, AM J PATHOL, V150, P713; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; JAIN RK, 2001, TUMOR MODELS CANC; Kim KH, 1999, APPL OPTICS, V38, P6004, DOI 10.1364/AO.38.006004; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; LEUNIG M, 1992, CANCER RES, V52, P6553; Lichtenbeld Hera C., 1996, Microcirculation (Philadelphia), V3, P349, DOI 10.3109/10739689609148307; Naumov GN, 1999, J CELL SCI, V112, P1835; Squirrell JM, 1999, NAT BIOTECHNOL, V17, P763, DOI 10.1038/11698; Wong CW, 2001, CANCER RES, V61, P333; Yu JL, 2001, AM J PATHOL, V158, P1325, DOI 10.1016/S0002-9440(10)64083-7; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	21	472	485	1	34	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2001	7	7					864	868		10.1038/89997	http://dx.doi.org/10.1038/89997			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	451NR	11433354				2022-12-25	WOS:000169808600041
J	Miron, M; Verdu, J; Lachance, PED; Birnbaum, MJ; Lasko, PF; Sonenberg, N				Miron, M; Verdu, J; Lachance, PED; Birnbaum, MJ; Lasko, PF; Sonenberg, N			The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila	NATURE CELL BIOLOGY			English	Article							PHOSPHOINOSITIDE 3-KINASE; SIZE; EXPRESSION; INITIATION; BINDING; PROTEIN; TRANSFORMATION; PROLIFERATION; REGULATOR; WINGLESS	The initiation factor 4E for eukaryotic translation (elF4E) binds the messenger RNA 5'-cap structure and is important in the regulation of protein synthesis'. Mammalian elF4E activity is inhibited when the initiation factor binds to the translational repressors, the 4E-binding proteins (4E-BPS)(1). Here we show that the Drosophila melanogaster 4E-BP (d4E-BP) is a downstream target of the phosphatidylinositol-3-OH kinase (P1(3)K) signal-transduction cascade, which affects the interaction of d4E-BP with elF4E. Ectopic expression of a highly active d4E-BP mutant in wing-imaginal discs causes a reduction of wing size, brought about by a decrease in cell size and number. A marked reduction in cell size was also observed in post-mitotic cells. Expression of d4E-BP in the eye and wing together with P1(3)K or dAkt1, the serine/threonine kinase downstream of P1(3)K, resulted in suppression of the growth phenotype elicited by these kinases. Our results support a role for d4E-BP as an effector of cell growth.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University; McGill University; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	snonen@med.mcgill.ca	Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501; Birnbaum, Morris/0000-0001-9972-8680				Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bernal A, 2000, P NATL ACAD SCI USA, V97, P6019, DOI 10.1073/pnas.100391597; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Britton JS, 1998, DEVELOPMENT, V125, P2149; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Coelho CM, 2000, J CELL SCI, V113, P2927; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; Huang H, 1999, DEVELOPMENT, V126, P5365; Lavoie CA, 1996, J BIOL CHEM, V271, P16393, DOI 10.1074/jbc.271.27.16393; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; MADER S, 1995, MOL CELL BIOL, V15, P4990; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Sigrist SJ, 2000, NATURE, V405, P1062, DOI 10.1038/35016598; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	30	163	169	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2001	3	6					596	601		10.1038/35078571	http://dx.doi.org/10.1038/35078571			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	440VC	11389445				2022-12-25	WOS:000169194400016
J	Mykytyn, K; Braun, T; Carmi, R; Haider, NB; Searby, CC; Shastri, M; Beck, G; Wright, AF; Iannaccone, A; Elbedour, K; Riise, R; Baldi, A; Raas-Rothschild, A; Gorman, SW; Duhl, DM; Jacobson, SG; Casavant, T; Stone, EM; Sheffield, VC				Mykytyn, K; Braun, T; Carmi, R; Haider, NB; Searby, CC; Shastri, M; Beck, G; Wright, AF; Iannaccone, A; Elbedour, K; Riise, R; Baldi, A; Raas-Rothschild, A; Gorman, SW; Duhl, DM; Jacobson, SG; Casavant, T; Stone, EM; Sheffield, VC			Identification of the gene that, when mutated, causes the human obesity syndrome BBS4	NATURE GENETICS			English	Letter							BARDET-BIEDL-SYNDROME; TETRATRICOPEPTIDE REPEAT; CHROMOSOME 16Q; SYNDROME LOCUS; PROTEIN; DNA; MUTATIONS; LINKAGE	Bardet-Biedl syndrome (BBS. MIM 209900) is a heterogeneous autosomal recessive disorder characterized by obesity, pigmentary retinopathy. polydactyly, renal malformations, mental retardation, and hypogenitalism(1-4). The disorder is also associated with diabetes mellitus, hypertension, and congenital heart disease(4-6). Six distinct BBS loci map to 11q13 (BBS1), 16q21 (BBS2). 3p13-p12 (BBS3). 15q22,3-q23 (BBS4), 2q31 (BBS5). and 20p12 (BBS6)(7-13). Although BBS is rare in the general population (<1/100,000). there is considerable interest in identifying the genes causing BBS because components of the phenotype. such as obesity and diabetes, are common. We and others have demonstrated that BBS6 is caused by mutations in the gene MKKS (refs. 12,13). mutation of which also causes McKusick-Kaufman syndrome (hydrometrocolpos. post-axial polydactyly, and congenital heart defects)(14,15). MKKS has sequence homology to the alpha subunit of a prokaryotic chaperonin in the thermosome Thermoplasma acidophilum(15). We recently identified a novel gene that causes BBS2(16). The BBS2 protein has no significant similarity to other chaperonins or known proteins. Here we report the positional cloning and identification of mutations in BBS patients in a novel gene designated BBS4.	Univ Iowa, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Ben Gurion Univ Negev, Soroka Med Ctr, Inst Genet, IL-84105 Beer Sheva, Israel; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38103 USA; Cent Hosp Hedmark, Dept Ophthalmol, Hamar, Norway; Ist Regina Elena, I-00161 Rome, Italy; Hadassah Univ Hosp, Dept Human Genet, IL-91120 Jerusalem, Israel; Chiron Corp, Emeryville, CA 94608 USA; Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; Univ Iowa, Dept Elect Engn, Iowa City, IA 52242 USA; Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA	University of Iowa; Howard Hughes Medical Institute; University of Iowa; Ben Gurion University; Soroka Medical Center; University of Edinburgh; University of Tennessee System; University of Tennessee Health Science Center; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Hebrew University of Jerusalem; Novartis; University of Pennsylvania; Pennsylvania Medicine; University of Iowa; University of Iowa	Sheffield, VC (corresponding author), Univ Iowa, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA.	val-sheffield@uiowa.edu	Mykytyn, Kirk/E-3723-2011; Baldi, Alfonso/ABG-2397-2021	Mykytyn, Kirk/0000-0002-0158-4592; Iannaccone, Alessandro/0000-0001-5737-8424; Baldi, Alfonso/0000-0002-8693-3842; Stone, Edwin M./0000-0003-3343-4414; Jacobson, Samuel/0000-0003-2122-169X; Sheffield, Val/0000-0002-6282-0835	NEI NIH HHS [R01-EY-11298] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011298] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARDET G, 1920, THESIS PARIS; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Biedl A., 1922, DEUT MED WOCHENSCHR, V48, P1630; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; CARMI R, 1995, AM J MED GENET, V59, P199, DOI 10.1002/ajmg.1320590216; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; ELBEDOUR K, 1994, AM J MED GENET, V52, P164, DOI 10.1002/ajmg.1320520208; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; HARNETT JD, 1988, NEW ENGL J MED, V319, P615, DOI 10.1056/NEJM198809083191005; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; IANNACCONE A, 1999, BARDET BIEDL SYNDROM, P187; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; ROBINOW M, 1979, J PEDIATR-US, V94, P776, DOI 10.1016/S0022-3476(79)80155-9; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; SOLISCOHEN S, 1924, T ASSOC AM PHYSICIAN, V39, P356; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301	27	203	211	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2001	28	2					188	191		10.1038/88925	http://dx.doi.org/10.1038/88925			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	437UK	11381270				2022-12-25	WOS:000169011800025
J	Carmeliet, P; Moons, L; Luttun, A; Vincenti, V; Compernolle, V; De Mol, M; Wu, Y; Bon, F; Devy, L; Beck, H; Scholz, D; Acker, T; DiPalma, T; Dewerchin, M; Noel, A; Stalmans, I; Barra, A; Blacher, S; Vandendriessche, T; Ponten, A; Eriksson, U; Plate, KH; Foidart, JM; Schaper, W; Charnock-Jones, DS; Hicklin, DJ; Herbert, JM; Collen, D; Persico, MG				Carmeliet, P; Moons, L; Luttun, A; Vincenti, V; Compernolle, V; De Mol, M; Wu, Y; Bon, F; Devy, L; Beck, H; Scholz, D; Acker, T; DiPalma, T; Dewerchin, M; Noel, A; Stalmans, I; Barra, A; Blacher, S; Vandendriessche, T; Ponten, A; Eriksson, U; Plate, KH; Foidart, JM; Schaper, W; Charnock-Jones, DS; Hicklin, DJ; Herbert, JM; Collen, D; Persico, MG			Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions	NATURE MEDICINE			English	Article							MONOCYTE ACTIVATION; TYROSINE KINASE; FACTOR RECEPTOR; FACTOR VEGF; IN-VIVO; EXPRESSION; FLT-1; HYPOXIA; TUMORS; MICE	Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 (VEGFR-2). The role of its homolog, placental growth factor (PIGF), remains unknown. Both VEGF and PIGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VECFR-1, which exists as a soluble or a membrane-bound type, is an inert decoy or a signaling receptor for PIGF during angiogenesis. Here, we report that embryonic angiogenesis in mice was not affected by deficiency of PIGF (Pgf(-/-)). VEGF-B, another ligand of VEGFR-1, did not rescue development in Pgf(-/-) mice. However, loss of PIGF impaired angiogenesis, plasma extravasation and collateral growth during ischemia, inflammation, wound healing and cancer. Transplantation of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgf(-/-) mice, indicating that PIGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells. The synergism between PIGF and VEGF was specific, as PIGF deficiency impaired the response to VEGF, but not to bFGF or histamine. VECFR-1 was activated by PIGF, given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial response to PIGF or VEGF/PIGF. By upregulating PIGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; ImClone Syst, New York, NY USA; Sanofi Synthelabo, Cardiovasc Thrombosis Res Dept, Toulouse, France; Univ Liege, Lab Tumor & Dev Biol, B-4000 Sart Tilman Par Liege, Belgium; FAU Erlangen Nurnberg, Dept Neuropathol, Erlangen, Germany; Max Planck Inst, Dept Expt Cardiol, Bad Nauheim, Germany; Univ Cambridge, Dept Obstet & Gynaecol, Reprod Mol Res Grp, Cambridge, England; Ludwig Inst Canc Res, S-10401 Stockholm, Sweden	Flanders Institute for Biotechnology (VIB); KU Leuven; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Eli Lilly; Sanofi-Aventis; Sanofi France; University of Liege; University of Erlangen Nuremberg; Max Planck Society; University of Cambridge; Ludwig Institute for Cancer Research	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Luttun, Aernout/AAZ-6540-2020; Carmeliet, Peter/AAQ-5140-2020; Charnock-Jones, D. Stephen/AAE-3391-2020; Di+Palma, Tina/AAN-6853-2021; Charnock-Jones, D. Stephen/B-3743-2009	Luttun, Aernout/0000-0001-7902-9524; Carmeliet, Peter/0000-0001-7961-1821; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Noel, Agnes/0000-0002-7670-6179; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Vandendriessche, Thierry/0000-0003-4230-745X; Acker, Till/0000-0001-6357-7227				AASE K, IN PRESS CIRCULATION; Achen MG, 1997, GROWTH FACTORS, V15, P69, DOI 10.3109/08977199709002113; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clark DE, 1998, BIOL REPROD, V59, P1540, DOI 10.1095/biolreprod59.6.1540; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Hatva E, 1996, AM J PATHOL, V148, P763; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Khaliq A, 1998, LAB INVEST, V78, P109; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Monsky WL, 1999, CANCER RES, V59, P4129; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nicosia RF, 1999, INT REV CYTOL, V185, P1; Nomura M, 1998, J NEURO-ONCOL, V40, P123, DOI 10.1023/A:1006198422718; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; PARK JE, 1994, J BIOL CHEM, V269, P25646; PASSANITI A, 1992, LAB INVEST, V67, P519; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Ryan HE, 2000, CANCER RES, V60, P4010; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Simpson DAC, 1999, BIOCHEM BIOPH RES CO, V262, P333, DOI 10.1006/bbrc.1999.1201; Takahashi A, 1999, BIOCHEM BIOPH RES CO, V257, P855, DOI 10.1006/bbrc.1999.0465; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; VICAUT E, 1990, MICROVASC RES, V39, P120, DOI 10.1016/0026-2862(90)90063-W; Viglietto G, 1996, ONCOGENE, V13, P577; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427	45	1266	1340	4	88	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2001	7	5					575	583		10.1038/87904	http://dx.doi.org/10.1038/87904			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	454FE	11329059	Green Submitted			2022-12-25	WOS:000169961100037
J	Harrington, JJ; Sherf, B; Rundlett, S; Jackson, PD; Perry, R; Cain, S; Leventhal, C; Thornton, M; Ramachandran, R; Whittington, J; Lerner, L; Costanzo, D; McElligott, K; Boozer, S; Mays, R; Smith, E; Veloso, N; Klika, A; Hess, J; Cothren, K; Lo, K; Offenbacher, J; Danzig, J; Ducar, M				Harrington, JJ; Sherf, B; Rundlett, S; Jackson, PD; Perry, R; Cain, S; Leventhal, C; Thornton, M; Ramachandran, R; Whittington, J; Lerner, L; Costanzo, D; McElligott, K; Boozer, S; Mays, R; Smith, E; Veloso, N; Klika, A; Hess, J; Cothren, K; Lo, K; Offenbacher, J; Danzig, J; Ducar, M			Creation of genome-wide protein expression libraries using random activation of gene expression	NATURE BIOTECHNOLOGY			English	Article							EMBRYONIC STEM-CELLS; SUBTRACTIVE HYBRIDIZATION; SEQUENCE IDENTIFICATION; DIFFERENTIAL DISPLAY; DEVELOPMENTAL GENES; SCORING MATRICES; MICE; DROSOPHILA; SCREEN; DNA	Here we report the use of random activation of gene expression (RAGE) to create genome-wide protein expression libraries. RAGE libraries containing only 5 x 10(6) individual clones were found to express every gene tested, including genes that are normally silent in the parent cell line. Furthermore, endogenous genes were activated at similar frequencies and expressed at similar levels within RAGE libraries created from multiple human cell lines, demonstrating that RAGE libraries are inherently normalized. Pools of RAGE clones were used to isolate 19,547 human gene clusters, similar to 53% of which were novel when tested against public databases of expressed sequence tag (EST) and complementary DNA (cDNA). Isolation of individual clones confirmed that the activated endogenous genes can be expressed at high levels to produce biologically active proteins. The properties of RAGE libraries and RAGE expression clones are well suited for a number of biotechnological applications including gene discovery, protein characterization, drug development, and protein manufacturing.	Athersys Inc, Cleveland, OH 44115 USA		Harrington, JJ (corresponding author), Athersys Inc, 3201 Carnegie Ave, Cleveland, OH 44115 USA.	jharrington@athersys.com						Abdelilah-Seyfried S, 2000, GENETICS, V155, P733; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Blumberg B, 1999, METH MOL B, V97, P555, DOI 10.1385/1-59259-270-8:555; Bonaldo P, 1998, EXP CELL RES, V244, P125, DOI 10.1006/excr.1998.4208; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; EALEY PA, 1995, GROWTH REGULAT, V5, P36; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Hardouin N, 2000, GENESIS, V26, P245, DOI 10.1002/(SICI)1526-968X(200004)26:4<245::AID-GENE50>3.0.CO;2-9; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P547; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mural RJ, 1999, TRENDS GENET, V15, P38, DOI 10.1016/S0168-9525(98)01624-2; Neilan EG, 1999, TRANSGENIC RES, V8, P451, DOI 10.1023/A:1008928925142; NIALL HD, 1971, P NATL ACAD SCI USA, V68, P866, DOI 10.1073/pnas.68.4.866; NIWA H, 1993, J BIOCHEM-TOKYO, V113, P343, DOI 10.1093/oxfordjournals.jbchem.a124049; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; ORR SL, 1994, P NATL ACAD SCI USA, V91, P11869, DOI 10.1073/pnas.91.25.11869; Rorth P, 1998, DEVELOPMENT, V125, P1049; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Tanaka T, 1996, GENOMICS, V35, P231, DOI 10.1006/geno.1996.0344; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wan J S, 1997, Methods Mol Biol, V85, P45; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Wu TD, 1999, J COMPUT BIOL, V6, P219, DOI 10.1089/cmb.1999.6.219; Wu TD, 2000, BIOINFORMATICS, V16, P233, DOI 10.1093/bioinformatics/16.3.233; WURST W, 1995, GENETICS, V139, P889; Xu Y, 1997, J COMPUT BIOL, V4, P325, DOI 10.1089/cmb.1997.4.325; Xu Y, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P344; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454	42	60	67	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					440	445		10.1038/88107	http://dx.doi.org/10.1038/88107			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329013				2022-12-25	WOS:000168394800021
J	Muir, SR; Collins, GJ; Robinson, S; Hughes, S; Bovy, A; De Vos, CHR; van Tunen, AJ; Verhoeyen, ME				Muir, SR; Collins, GJ; Robinson, S; Hughes, S; Bovy, A; De Vos, CHR; van Tunen, AJ; Verhoeyen, ME			Overexpression of petunia chalcone isomerase in tomato results in fruit containing increased levels of flavonols	NATURE BIOTECHNOLOGY			English	Article							CORONARY-HEART-DISEASE; PLANTS; GENES; RISK; HPLC	Tomatoes are an excellent source of the carotenoid lycopene, a compound that is thought to be protective against prostate cancer. They also contain small amounts of flavonoids in their peel (similar to5-10 mg/kg fresh weight), mainly naringenin chalcone and the flavonol rutin, a quercetin glycoside. Flavonols are very potent antioxidants, and an increasing body of epidemiological data suggests that high flavonoid intake is correlated with a decreased risk for cardiovascular disease. We have upregulated flavonol biosynthesis in the tomato in order to generate fruit with increased antioxidant capacity and a wider range of potential health benefit properties. This involved transformation of tomato with the Petunia chi-a gene encoding chalcone isomerase. Resulting transgenic tomato lines produced an increase of up to 78 fold in fruit peel flavonols, mainly due to an accumulation of rutin. No gross phenotypical differences were observed between high-flavonol transgenic and control lines. The phenotype segregated with the transgene and demonstrated a stable inheritance pattern over four subsequent generations tested thus far. Whole-fruit flavonol levels in the best of these lines are similar to those found in onions, a crop with naturally high levels of flavonol compounds. Processing of high-flavonol tomatoes demonstrated that 65% of flavonols present in the fresh fruit were retained in the processed paste, supporting their potential as raw materials for tomato-based functional food products.	Unilever Res, Sharnbrook MK44 1LQ, Beds, England; Univ Exeter, Dept Biol, Exeter, Devon, England; Plant Res Int, NL-6700 AA Wageningen, Netherlands	Unilever; University of Exeter	Verhoeyen, ME (corresponding author), Unilever Res, Colworth House, Sharnbrook MK44 1LQ, Beds, England.		De Vos, Ric/F-5012-2017	Bovy, Arnaud/0000-0003-2643-7377				BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; Ewald C, 1999, FOOD CHEM, V64, P231, DOI 10.1016/S0308-8146(98)00136-8; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P1591, DOI 10.1021/jf00021a023; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; KRAUSE M, 1992, Z LEBENSM UNTERS FOR, V194, P29, DOI 10.1007/BF01191036; Middleton E., 1994, FLAVONOIDS ADV RES 1, P619; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; Romer S, 2000, NAT BIOTECHNOL, V18, P666, DOI 10.1038/76523; Sambrook J., 2002, MOL CLONING LAB MANU; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; VANTUNEN AJ, 1988, EMBO J, V7, P1257, DOI 10.1002/j.1460-2075.1988.tb02939.x; Weisshaar B, 1998, CURR OPIN PLANT BIOL, V1, P251, DOI 10.1016/S1369-5266(98)80113-1; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	18	399	469	5	125	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2001	19	5					470	474		10.1038/88150	http://dx.doi.org/10.1038/88150			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	427FU	11329019				2022-12-25	WOS:000168394800027
J	DeFrancesco, L; Cimons, M				DeFrancesco, L; Cimons, M			Stem cell losses and gains in the US	NATURE MEDICINE			English	News Item																			0	18	18	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1076	1076		10.1038/nm1001-1076a	http://dx.doi.org/10.1038/nm1001-1076a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590410	Bronze			2022-12-25	WOS:000171524500005
J	DeFrancesco, L				DeFrancesco, L			Prostate cancer prevention trial launched	NATURE MEDICINE			English	News Item																			0	18	18	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2001	7	10					1076	1076		10.1038/nm1001-1076a	http://dx.doi.org/10.1038/nm1001-1076a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	481NA	11590410	Bronze			2022-12-25	WOS:000171524500006
